FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Saunders, GH Griest, SE AF Saunders, Gabrielle H. Griest, Susan E. TI Hearing loss in veterans and the need for hearing loss prevention programs SO NOISE & HEALTH LA English DT Article DE Veterans; hearing loss prevention; health promotion; multimedia program AB Currently, there are more than 445,000 veterans receiving compensation for hearing loss associated with military service, and 395,000 receiving compensation for service-related tinnitus. In addition to compensation payments, service-related hearing disorders cost the US Department of Veterans Affairs in terms of provision of hearing aids, hearing aid-related services, and clinical services at its 220 facilities nationwide. It is imperative that hearing conservation among military personnel and veterans be addressed. In this paper, we describe the rationale for and the development of a multimedia Hearing Loss Prevention Program aimed at preventing the progression of hearing loss among veterans associated with social, recreational, and nonmilitary occupational noise exposure. The program was developed based on the principles outlined in the Health Belief Model of Rosenstock (1966) and the Health Promotion Model of Pender et al. (2002). C1 [Saunders, Gabrielle H.] Oregon Hlth & Sci Univ, Natl Ctr Rehabilitat Auditory Res, Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA. RP Saunders, GH (reprint author), Oregon Hlth & Sci Univ, Natl Ctr Rehabilitat Auditory Res, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM gabrielle.saunders@va.gov FU RRD VA [I01 RX000192] NR 74 TC 29 Z9 30 U1 3 U2 10 PU MEDKNOW PUBLICATIONS PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1463-1741 J9 NOISE HEALTH JI Noise Health PD JAN-MAR PY 2009 VL 11 IS 42 BP 14 EP 21 DI 10.4103/1463-1741.45308 PG 8 WC Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health SC Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health GA V15SC UT WOS:000207820700004 PM 19265249 ER PT J AU Shannon, J Phoutrides, E Palma, A Farris, P Peters, L Forester, A Tillotson, CJ Garzotto, M AF Shannon, Jackilen Phoutrides, Elena Palma, Amy Farris, Paige Peters, Laura Forester, Anna Tillotson, Carrie J. Garzotto, Mark TI Folate Intake and Prostate Cancer Risk: A Case-Control Study SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID ONE-CARBON METABOLISM; ALCOHOL-CONSUMPTION; PROSPECTIVE COHORT; DNA METHYLATION; DIETARY-FOLATE; BREAST-CANCER; FOLIC-ACID; MEN; MANAGEMENT AB Folate deficiency has been implicated in the carcinogenesis of several tumor types. The role of folate in prostate cancer remains indeterminate. We investigated folate as a risk factor for prostate cancer among 140 biopsy-confirmed prostate cancer patients, 230 age-matched clinic controls, and 250 negative prostate biopsy controls. Dietary folate intake was inversely associated with overall risk of prostate cancer as compared to clinic controls (P for a linear trend = 0.003). When stratified by disease severity, dietary folate and folate from natural sources were associated with reduced risk of high-grade cancer as compared to both clinic controls (P for a linear trend = 0.0009 and 0.02, respectively) and biopsy negative controls (P for a linear trend = 0.03 and 0.05, respectively). There was no interaction between alcohol consumption and folate intake. These analyses support an inverse association between dietary folate intake and prostate cancer risk and primarily risk of high-grade prostate cancer. C1 [Shannon, Jackilen; Phoutrides, Elena; Palma, Amy; Farris, Paige; Forester, Anna; Tillotson, Carrie J.; Garzotto, Mark] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Shannon, Jackilen; Palma, Amy; Farris, Paige; Peters, Laura; Garzotto, Mark] Portland VA Med Ctr, Portland, OR USA. RP Shannon, J (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd L606, Portland, OR 97239 USA. EM shannoja@ohsu.edu FU United States Public Health Service [5 M01 RR000334, 1 UL1 RR024120-01, K22CA94973]; VA Advanced Career Development Award; OHSU Cancer Institute Biostatistics Shared Resource [P30 CA069533-09]; Oregon Clinical and Translational Research Institute [UL1 RR024140] FX This study was supported by United States Public Health Service grants 5 M01 RR000334, 1 UL1 RR024120-01, and K22CA94973 and the resources and facilities of the Portland Veterans Affairs Medical Center. VA Advanced Career Development Award (M. Garzotto) Biostatistics support was provided through the OHSU Cancer Institute Biostatistics Shared Resource (P30 CA069533-09) and the Oregon Clinical and Translational Research Institute (UL1 RR024140). NR 31 TC 21 Z9 22 U1 2 U2 5 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 2009 VL 61 IS 5 BP 617 EP 628 DI 10.1080/01635580902846593 PG 12 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA 502AU UT WOS:000270427100006 PM 19838935 ER PT J AU Katiyar, S Elmets, CA Katiyar, SK AF Katiyar, Suchitra Elmets, Craig A. Katiyar, Santosh K. BE Tabor, A Blair, RM TI Green Tea and Skin Cancer: Immunological Modulation and DNA Repair SO NUTRITIONAL COSMETICS: BEAUTY FROM WITHIN LA English DT Article; Book Chapter ID RADIATION-INDUCED IMMUNOSUPPRESSION; ULTRAVIOLET-B RADIATION; POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE TREATMENT; INDUCED IMMUNE SUPPRESSION; ANTIGEN-PRESENTING CELL; T4 ENDONUCLEASE-V; CONTACT HYPERSENSITIVITY; HAIRLESS MICE; MOUSE SKIN; IN-VIVO C1 [Katiyar, Suchitra; Elmets, Craig A.; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Katiyar, S (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,Box 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu NR 116 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-8155-2030-6 PY 2009 BP 471 EP 499 DI 10.1016/B978-0-8155-2029-0.50031-4 PG 29 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA BFB47 UT WOS:000319112900027 ER PT J AU Martinez, BS Williams, M Fuhr, P AF Martinez, Bethany S. Williams, Michael Fuhr, Patti TI Visually impaired caregivers: Perspectives from patient focus groups SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION LA English DT Article DE Visual impairment; Caregiver; Low vision rehabilitation; Focus groups AB BACKGROUND: With the aging of the population, more persons who are severely visually impaired are now caring for a spouse or significant other. The purpose of this qualitative study is to learn more about this previously unreported, yet vulnerable, population of visually impaired caregivers. METHODS: Focus groups and 1-on-1 interviews were conducted with legally blind U.S. English-speaking adults who served as informal caregivers of adults. Visually impaired caregivers discussed the challenges of caregiving and how their visual impairment affected their caregiving responsibilities. Interview transcripts were analyzed using grounded theory. Standardized questionnaires captured demographic and social characteristics. RESULTS: Fourteen adults participated. Seven major themes emerged from the interviews: (1) impact of lack of transportation, (2) concern over care recipient's quality of life, (3) utilization of support, (4) all encompassing demand, (5) cyclical adaptations, (6) anxieties of the caregivers, and (7) positive aspects of caregiving. CONCLUSIONS: Although visually impaired caregivers experience challenges similar to other caregivers, they differ in their report of added burden because of visual impairment, with extraordinary difficulty in transportation issues and the necessity of cyclical adaptations as their vision worsens. This is, to our knowledge, the first qualitative study of visually impaired caregivers and brings to light the unique problems faced by this special cohort of caregivers. Optometry 2009;80:11-22 C1 [Martinez, Bethany S.; Fuhr, Patti] Univ Alabama, Vet Affairs Med Ctr, Birmingham Dept, Birmingham Sch Optometry, Birmingham, AL 35233 USA. [Williams, Michael] Georgia Inst Technol, Rehabil R&D Ctr Excellence Aging Vet Vis Loss, Vet Affairs Med Ctr, Ctr Assist Technol & Environm Access,Atlanta Dept, Atlanta, GA 30332 USA. [Williams, Michael] Blind Rehabil Serv, US Dept Vet Affairs, Natl Program Off, Washington, DC USA. RP Martinez, BS (reprint author), Univ Alabama, Vet Affairs Med Ctr, Birmingham Dept, Birmingham Sch Optometry, Optometry 112 C,700 S 19th St, Birmingham, AL 35233 USA. EM Bethany.Martinez@va.gov NR 57 TC 0 Z9 0 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-1839 J9 OPTOMETRY JI Optometry PD JAN PY 2009 VL 80 IS 1 BP 11 EP 22 DI 10.1016/j.optm.2008.04.100 PG 12 WC Ophthalmology SC Ophthalmology GA V18QB UT WOS:000208018200004 PM 19111253 ER PT J AU Duszak, RS AF Duszak, Robert S. TI Congenital rubella syndrome major-review SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION LA English DT Review DE Rubella; Congenital rubella syndrome ID 50-YEAR FOLLOW-UP; PRENATAL-DIAGNOSIS; TERATOGEN UPDATE; INFECTION; MANIFESTATIONS; REINFECTION; PREGNANCY; VIRUS; NEOVASCULARIZATION; EPIDEMIOLOGY AB Congenital rubella syndrome is a rare disorder with devastating ocular and systemic consequences. Although efforts to eradicate the disease have been in place for some time, some areas of the world continue to be affected by this disease. The burden of the disease weighs heavily on patients and society; therefore, vaccination and other preventative strategies should continue to be strongly encouraged. Optometry 2009;80:36-43 C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19103 USA. RP Duszak, RS (reprint author), Philadelphia Vet Affairs Med Ctr, 2112 Pine St,Apt 2, Philadelphia, PA 19103 USA. EM bduszak@mac.com NR 77 TC 26 Z9 29 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-1839 J9 OPTOMETRY JI Optometry PD JAN PY 2009 VL 80 IS 1 BP 36 EP 43 DI 10.1016/j.optm.2008.03.006 PG 8 WC Ophthalmology SC Ophthalmology GA V18QB UT WOS:000208018200007 PM 19111256 ER PT J AU Davila, JA Chiao, EY Hasche, JC Petersen, NJ McGlynn, KA Shaib, YH AF Davila, Jessica A. Chiao, Elizabeth Y. Hasche, Jennifer C. Petersen, Nancy J. McGlynn, Katherine A. Shaib, Yasser H. TI Utilization and Determinants of Adjuvant Therapy Among Older Patients Who Receive Curative Surgery for Pancreatic Cancer SO PANCREAS LA English DT Article DE pancreatic cancer; adjuvant therapy; SEER-Medicare ID LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; ELDERLY-PATIENTS; RESECTION; PANCREATICODUODENECTOMY; CHEMORADIOTHERAPY; CHEMOTHERAPY; CARCINOMA; REGION; TRIAL AB Objective: We conducted a population-based study to describe the utilization, determinants, and survival effects of adjuvant therapies after surgery among older patients with pancreatic cancer. Methods: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients older than 65 years who received surgical resection for pancreatic cancer during 1992-2002. We constructed multiple logistic regression models to examine patient, clinical, and hospital factors associated with receiving adjuvant therapy. Cox proportional hazards models were used to examine the effect of therapy on survival. Results: Approximately 49% of patients received adjuvant therapy after surgery. Patient factors associated with increased receipt of adjuvant therapy included more recent diagnosis, younger age, stage II disease, higher income, and geographic location. Hospital factors associated with increased receipt of adjuvant therapy included cooperative group membership and larger size. Adjuvant treatments associated with a significant reduction in 2-year mortality (relative to surgery alone) were chemoradiation or radiation alone but not chemotherapy alone. Conclusions: Our findings suggest that adjuvant chemoradiation and, to a lesser degree, radiation only are associated with a reduction in the risk of mortality among older patients who undergo surgery for pancreatic cancer. However, receipt of adjuvant therapy varied by period and geography as well as by certain patient and hospital factors. C1 [Davila, Jessica A.; Chiao, Elizabeth Y.; Hasche, Jennifer C.; Petersen, Nancy J.; Shaib, Yasser H.] Baylor Coll Med, Sect Hlth Serv Res, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. [Chiao, Elizabeth Y.] Baylor Coll Med, Infect Dis Sect, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. [McGlynn, Katherine A.] NCI DHHS, Div Canc Epidemiol & Genet, Bethesda, MD USA. [Shaib, Yasser H.] Baylor Coll Med, Gastroenterol Sect, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Davila, JA (reprint author), Baylor Coll Med, Sect Hlth Serv Res, Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM jdavila@bcm.tmc.edu FU Dan L. Duncan Cancer Center, Baylor College of Medicine FX This study was supported by pilot funding from the Dan L. Duncan Cancer Center, Baylor College of Medicine. NR 18 TC 20 Z9 21 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD JAN PY 2009 VL 38 IS 1 BP E18 EP E25 DI 10.1097/MPA.0b013e318187eb3f PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 392QP UT WOS:000262317600025 PM 18797424 ER PT J AU Olson, JM Hogan, MT Pogach, LM Rajan, M Raugi, GJ Reiber, GE AF Olson, Jonathan M. Hogan, Molly T. Pogach, Leonard M. Rajan, Mangala Raugi, Gregory J. Reiber, Gayle E. TI Foot care education and self management behaviors in diverse veterans with diabetes SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE diabetes mellitus; diabetic foot; patient self-management; ethnic groups; education AB The objective of this study was to examine differences in self-reported diabetes foot care education, self management behaviors, and barriers to good foot care among veterans with diabetes by race and ethnicity. Data was collected using the Veterans Health Administration Footcare Survey, a validated tool that assessed demographic, general health, diabetes and foot self-care information, barriers to foot self-care, receipt of professional foot care, and satisfaction with current care. We mailed surveys to a random sample of patients with diabetes from eight VA medical centers. Study participants were 81% White; 13% African American; 4% Asian, and 2% American Indian and Pacific Islanders. The majority of respondents felt that they did not know enough about foot self-care. There were large gaps between self-reported knowledge and actual foot care practices, even among those who reported "knowing enough" on a given topic. There were significant differences in self-reported foot care behaviors and education by race and ethnicity. These findings document the need for culturally-specific self-management education to address unique cultural preferences and barriers to care. C1 [Reiber, Gayle E.] VA Puget Sound Healthcare Syst, Res & Dev, Dept Vet Affairs, Seattle, WA USA. [Hogan, Molly T.] Univ Washington, Sch Med, Dept Internal Med, Seattle, WA USA. [Pogach, Leonard M.; Rajan, Mangala] New Jersey Healthcare Syst, Ctr Healthcare Knowledge Management, Dept Vet Affairs, E Orange, NJ USA. [Raugi, Gregory J.] VA Puget Sound Healthcare Syst, Dept Vet Affairs, Div Dermatol, Seattle, WA USA. RP Reiber, GE (reprint author), VA HSR&D, 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA. EM greiber@u.washington.edu FU VA Health Services Research and Development; Rehabilitation Research and Development FX The authors wish to thank VA Health Services Research and Development and Rehabilitation Research and Development for their support. The authors report no conflicts of interest in this work. NR 23 TC 6 Z9 6 U1 1 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2009 VL 3 BP 45 EP 50 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA V21NU UT WOS:000208215100006 PM 19936144 ER PT J AU Shaikh, N Hoberman, A Paradise, JL Wald, ER Switze, GE Kurs-Lasky, M Colborn, DK Kearney, DH Zoffel, LM AF Shaikh, Nader Hoberman, Alejandro Paradise, Jack L. Wald, Ellen R. Switze, Galen E. Kurs-Lasky, Marcia Colborn, D. Kathleen Kearney, Diana H. Zoffel, Lisa M. TI Development and Preliminary Evaluation of a Parent-Reported Outcome Instrument for Clinical Trials in Acute Otitis Media SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE actue otitis media; validation study; patient-reported outcome measure; pediatrics ID QUALITY-OF-LIFE; AMOXICILLIN; CHILDREN AB Background: Acute otitis media (AOM) is the most common childhood diagnosis, leading to prescription of all antibiotic in the United States. Although antibiotics are used in children with AOM, in part, to Shorten the duration of symptoms, no instruments have been developed to track early changes in Symptoms from the parent's point The goal of the present study was to develop and evaluate a parent-reported symptom scale for children with AOM (AOM-SOS) for use as an outcome measure in AOM treatment trials. Methods: From a pool of 28 potential symptoms, we selected 7 on the basis of parent questionnaire, expert interviews, and review of the literature (or inclusion in the AOM-SOS. We administered the AOM-SOS to a primary-care sample of children aged 6-25 months enrolled in a study of nasopharyngeal bacterial colonization. Children were seen for well visits, illness visits, and AOM follow-up visits. At each visit, parents completed the AOM-SOS and their children were examined by trained otoseopists, As part of the evaluation of the AOM-SOS, we examined the association between each item on the questionnaire and the clinical diagnosis of AOM while adjusting for the presence of upper respiratory tract infection. To assess responsiveness, we examined the change in AOM-SOS scores in patients with AOM who were seen for follow-up within 3 weeks of diagnosis. Results: We evaluated 264 children (mean age, 12.5 months at entry) at a total of 642 visits. We diagnosed AOM at 24% of the visits. Each item on the questionnaire was significantly associated with the clinical diagnosis of AOM (P < 0.001 for each), before and after adjusting for the presence or absence of upper respiratory infection. The mean AOM-SOS score at visits when AOM was diagnosed was 3.71, compared with 0.96 at visits when AOM was not diagnosed (P < 0.001). Internal reliability of the scale its measured by Cronbach's alpha was 0.84. AOM-SOS scores in children with AOM who were otoscopically improved decreased by all average of 2.81 points (standardized response mean = 0.73). Conclusions: We have developed a short symptom scale for children with AOM. This study provides preliminary data on the performance of the AOM-SOS in a primary care sample of children. C1 [Shaikh, Nader; Hoberman, Alejandro; Paradise, Jack L.; Colborn, D. Kathleen; Kearney, Diana H.; Zoffel, Lisa M.] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Div Gen Acad Pediat, Pittsburgh, PA 15213 USA. [Wald, Ellen R.] Univ Wisconsin, Sch Med, Dept Pediat, Pittsburgh, PA USA. [Kurs-Lasky, Marcia] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA. [Switze, Galen E.] Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA 15213 USA. [Switze, Galen E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Switze, Galen E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Shaikh, N (reprint author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Div Gen Acad Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA. EM nader.shaikh@chp.edu NR 14 TC 23 Z9 23 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JAN PY 2009 VL 28 IS 1 BP 5 EP 8 DI 10.1097/INF.0b013e318185a387 PG 4 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 391QG UT WOS:000262247200002 PM 19077917 ER PT J AU Shin, JM Munson, K Vagin, O Sachs, G AF Shin, Jai Moo Munson, Keith Vagin, Olga Sachs, George TI The gastric HK-ATPase: structure, function, and inhibition SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY LA English DT Article DE The gastric H,K-ATPase; ATPase structure-function; Proton pump inhibitors; Acid pump antagonists; Gastric acid secretion ID PROTON PUMP INHIBITORS; PLASMA-MEMBRANE DELIVERY; K+-COMPETITIVE INHIBITOR; H,K-ATPASE BETA-SUBUNIT; ACID-SECRETION; ALPHA-SUBUNIT; H+/K+-ATPASE; CDNA CLONING; SARCOPLASMIC-RETICULUM; HEALTHY-VOLUNTEERS AB The gastric H,K-ATPase, a member of the P(2)-type ATPase family, is the integral membrane protein responsible for gastric acid secretion. It is an alpha,beta-heterodimeric enzyme that exchanges cytoplasmic hydronium with extracellular potassium. The catalytic alpha subunit has ten transmembrane segments with a cluster of intramembranal carboxylic amino acids located in the middle of the transmembrane segments TM4, TM5,TM6, and TM8. Comparison to the known structure of the SERCA pump, mutagenesis, and molecular modeling has identified these as constituents of the ion binding domain. The beta subunit has one transmembrane segment with N terminus in cytoplasmic region. The extracellular domain of the beta subunit contains six or seven N-linked glycosylation sites. N-glycosylation is important for the enzyme assembly, maturation, and sorting. The enzyme pumps acid by a series of conformational changes from an E(1) (ion site in) to an E(2) (ion site out) configuration following binding of MgATP and phosphorylation. Several experimental observations support the hypothesis that expulsion of the proton at 160 mM (pH 0.8) results from movement of lysine 791 into the ion binding site in the E(2)P configuration. Potassium access from the lumen depends on activation of a K and Cl conductance via a KCNQ1/KCNE2 complex and Clic6. K movement through the luminal channel in E(2)P is proposed to displace the lysine along with dephosphorylation to return the enzyme to the E(1) configuration. This enzyme is inhibited by the unique proton pump inhibitor class of drug, allowing therapy of acid-related diseases. C1 [Shin, Jai Moo; Munson, Keith; Vagin, Olga; Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Shin, Jai Moo; Munson, Keith; Vagin, Olga; Sachs, George] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Sachs, G (reprint author), Room 324,Bldg 113,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gsachs@ucla.edu FU NIDDK NIH HHS [DK053642, DK58333, R01 DK053642, R01 DK053642-12, R01 DK053642-13, R01 DK058333, R01 DK058333-11, R01 DK077149, R01 DK077149-02, R01 DK077149-03, R56 DK058333, R56 DK058333-12] NR 73 TC 85 Z9 88 U1 2 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0031-6768 J9 PFLUG ARCH EUR J PHY JI Pflugers Arch. PD JAN PY 2009 VL 457 IS 3 BP 609 EP 622 DI 10.1007/s00424-008-0495-4 PG 14 WC Physiology SC Physiology GA 393ZF UT WOS:000262414300006 PM 18536934 ER PT J AU Prela, CM Baumgardner, GA Reiber, GE McFarland, LV Maynard, C Anderson, N Maciejewski, M AF Prela, Cecilia M. Baumgardner, Greg A. Reiber, Gayle E. McFarland, Lynne V. Maynard, Charles Anderson, Nancy Maciejewski, Matthew TI Challenges in Merging Medicaid and Medicare Databases to Obtain Healthcare Costs for Dual-Eligible Beneficiaries Using Diabetes as an Example SO PHARMACOECONOMICS LA English DT Article ID QUALITY; STATE; VETERANS; OUTCOMES; RISK AB Background: Dual-eligible Medicaid-Medicare beneficiaries represent a group of people who are in the lowest income bracket in the US, have numerous co-morbidities and place a heavy financial burden on the US healthcare system. As cost-effectiveness analyses are used to inform national policy decisions and to determine the value of implemented chronic disease control programmes, it is imperative that complete and valid determination of healthcare utilization and costs can be obtained from existing state and federal databases. Differences and inconsistencies between the Medicaid and Medicare databases have presented significant challenges when extracting accurate data for dual-eligible beneficiaries. Objectives: To describe the challenges inherent in merging Medicaid and Medicare claims databases and to present a protocol that would allow successful linkage between these two disparate databases. Methods: Healthcare claims and costs were extracted from both Medicaid and Medicare databases for King County, Seattle, WA, USA. Three Medicaid files were linked to eight Medicare files for unique dual-eligible beneficiaries with type 2 diabetes mellitus. Results: Although major differences were identified in how variables and claims were defined in each database, our method enabled us to link these two different databases to compile a complete and accurate assessment of healthcare use and costs for dual-eligible beneficiaries with a costly chronic condition. For example, of the 1759 dual-eligible beneficiaries with diabetes, the average cost of healthcare was $US15 981 per capita, with an average of 76 claims per person per year. Conclusion: The resulting merged database provides a virtually complete documentation of both utilization and costs of medical care for a population who receives coverage from two different programmes. By identifying differences and implementing our linkage protocol, the merged database serves as a foundation for a broad array of analyses on healthcare use and costs for effectiveness research. C1 [Reiber, Gayle E.; McFarland, Lynne V.; Maynard, Charles] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Prela, Cecilia M.] Ctr Medicare & Medicaid Serv, Medicare Plan Payment Grp, Div Risk Adjustment, Baltimore, MD USA. [Baumgardner, Greg A.] Qualis Hlth, Data Anal Team, Seattle, WA USA. [Anderson, Nancy] Med Assistance Adm, Olympia, WA USA. [Maciejewski, Matthew] Univ N Carolina, Chapel Hill, NC USA. RP McFarland, LV (reprint author), VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev, 1100 Olive Way 1400, Seattle, WA 98101 USA. EM lynne.mcfarland@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU Centers for Medicare & Medicaid Services [500-99-WA02]; US Department of Health and Human Services; Sandy MacColl Foundation, Seattle, Washington; The Robert Wood Johnson Foundation, Princeton, New York; Adventis Pharmaceuticals Inc.; Washington State Department of Health FX The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the Department of Health and Human Services. The authors assume full responsibility for the accuracy and completeness of the ideas presented. NR 31 TC 6 Z9 6 U1 0 U2 3 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-7690 J9 PHARMACOECONOMICS JI Pharmacoeconomics PY 2009 VL 27 IS 2 BP 167 EP 177 PG 11 WC Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Business & Economics; Health Care Sciences & Services; Pharmacology & Pharmacy GA 432IS UT WOS:000265127300007 PM 19254049 ER PT J AU Haynes, K Hennessy, S Localio, AR Cohen, A Leonard, CE Kimmel, SE Feldman, HI Strom, BL Metlay, JP AF Haynes, Kevin Hennessy, Sean Localio, A. Russell Cohen, Abigail Leonard, Charles E. Kimmel, Stephen E. Feldman, Harold I. Strom, Brian L. Metlay, Joshua P. TI Increased risk of digoxin toxicity following hospitalization SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE adverse effects; drug toxicity; physician-patient relationships ID ADVERSE DRUG-REACTIONS; OLDER-ADULTS; EVENTS; CARE; DEPRESSION; IMPAIRMENT; DISCHARGE AB Purpose Adverse drug events (ADEs) are an important cause of preventable hospitalizations among elderly individuals taking high-risk medications. The objective of the study was to identify health care system factors that affect the risk of digoxin toxicity for older adults on digoxin. Methods We conducted a prospective cohort study of older adults within the Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE) program, which provides comprehensive drug benefits for older adults with low income. Subjects were interviewed at the time of enrollment regarding the management and coordination of their health care as well as medication comprehension. Hospitalizations were identified by linking patient identifiers to a state-wide registry. Trained abstractors reviewed discharge summaries of possible digoxin related ADEs. Unadjusted and adjusted incidence rate ratios (IRR) were calculated based on person-months of exposure using Poisson regression models, with variances adjusted for within subject repeated measures. Results We enrolled a total of 2030 adults on digoxin from May 2002 to June 2003. A total of 34 hospitalizations due to digoxin toxicity occurred, equivalent to 1.12 hospitalizations per 1000 person-months of exposure. Adjusting for hospitalization in the past 2 months, age, total number physicians prescribing any medications in past 3 months, total number of pharmacies filling medications in past 3 months, and number of unique prescriptions filled in the past month had a 4.25-fold increased risk of subsequently experiencing digoxin toxicity (IRR 95%CI 1.95, 9.27). Conclusions The risk of digoxin toxicity-related hospitalization, while low, is higher in the post-hospital period. Copyright (C) 2008 John Wiley & Sons, Ltd. C1 [Haynes, Kevin; Hennessy, Sean; Localio, A. Russell; Cohen, Abigail; Leonard, Charles E.; Kimmel, Stephen E.; Feldman, Harold I.; Strom, Brian L.; Metlay, Joshua P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Haynes, Kevin; Hennessy, Sean; Localio, A. Russell; Cohen, Abigail; Leonard, Charles E.; Kimmel, Stephen E.; Feldman, Harold I.; Strom, Brian L.; Metlay, Joshua P.] Univ Penn, Dept Biostat & Epidemiol, Program Reduct Medicat Errors, Philadelphia, PA 19104 USA. [Haynes, Kevin; Hennessy, Sean; Localio, A. Russell; Leonard, Charles E.; Strom, Brian L.; Metlay, Joshua P.] Univ Penn, Dept Biostat & Epidemiol, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. [Haynes, Kevin; Hennessy, Sean; Localio, A. Russell; Cohen, Abigail; Leonard, Charles E.; Kimmel, Stephen E.; Feldman, Harold I.; Strom, Brian L.; Metlay, Joshua P.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Haynes, K (reprint author), Univ Penn, Sch Med, 711 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM khaynes@mail.med.upenn.edu RI Leonard, Charles/K-3447-2012; Cohen, Abigail/K-9180-2013 OI Cohen, Abigail/0000-0002-7425-7218 FU Agency for Healthcare Research and Quality [P01-HS11530]; Health Services Research and Development Service of the Department of Veterans Affairs FX This study was suported by Grant P01-HS11530 from the Agency for Healthcare Research and Quality. Dr Metlay is supported by an Advanced Research Career Development Award from the Health Services Research and Development Service of the Department of Veterans Affairs. NR 21 TC 7 Z9 7 U1 1 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD JAN PY 2009 VL 18 IS 1 BP 28 EP 35 DI 10.1002/pds.1680 PG 8 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 405EX UT WOS:000263206700005 PM 19040200 ER PT J AU Jackevicius, CA Page, RL Chow, S Dunn, SP Lee, CR Ng, TMH Rodgers, JE Vardeny, O Wiggins, BS Munger, MA AF Jackevicius, Cynthia A. Page, Robert L., II Chow, Sheryl Dunn, Steven P. Lee, Craig R. Ng, Tien M. H. Rodgers, Jo E. Vardeny, Orly Wiggins, Barbara S. Munger, Mark A. TI High-Impact Articles Related to the Management of Heart Failure: 2008 Update SO PHARMACOTHERAPY LA English DT Article DE systolic heart failure; decompensated heart failure; left ventricular systolic dysfunction; diastolic heart failure AB This compilation is part of a series of articles identifying important literature in cardiovascular pharmacotherapy. This bibliography focuses on pharmacotherapeutic management of acute decompensated and chronic heart failure and provides an update of the heart failure bibliography published in Pharmacotherapy in 2004. Most of the cited works present the results of landmark clinical studies that have shaped the management of patients with heart failure. Limited primary literature is available for some topics, thus pertinent review articles are also listed. In addition, consensus documents formed by expert panels are reviewed. This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students. C1 [Jackevicius, Cynthia A.; Chow, Sheryl] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA 91766 USA. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Page, Robert L., II] Univ Colorado Denver, Sch Pharm, Aurora, CO USA. [Page, Robert L., II] Univ Colorado Denver, Sch Med, Aurora, CO USA. [Dunn, Steven P.] Univ Kentucky, Coll Pharm, Dept Pharm Serv, Lexington, KY USA. [Dunn, Steven P.] Univ Kentucky, Coll Pharm, Div Cardiovasc Med, Lexington, KY USA. [Lee, Craig R.; Rodgers, Jo E.] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA. [Ng, Tien M. H.] Univ So Calif, Sch Pharm, Los Angeles, CA USA. [Vardeny, Orly] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. [Wiggins, Barbara S.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Wiggins, Barbara S.] Univ Virginia Hlth Syst, Ctr Heart, Charlottesville, VA USA. [Munger, Mark A.] Univ Utah, Sch Pharm, Dept Pharmacotherapy, Salt Lake City, UT USA. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, 309 E 2nd St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu RI Dunn, Steven/I-9480-2012 OI Lee, Craig/0000-0003-3595-5301 NR 1 TC 1 Z9 1 U1 1 U2 1 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JAN PY 2009 VL 29 IS 1 BP 82 EP 120 PG 39 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 392HS UT WOS:000262294400009 PM 19113799 ER PT J AU Grudzen, CR Koenig, WJ Hoffman, JR Boscardin, WJ Lorenz, KA Asch, SM AF Grudzen, Corita R. Koenig, William J. Hoffman, Jerome R. Boscardin, W. John Lorenz, Karl A. Asch, Steven M. TI Potential Impact of a Verbal Prehospital DNR Policy SO PREHOSPITAL EMERGENCY CARE LA English DT Article DE ethics; resuscitation; cardiac arrest; palliative care; prehospital care ID HOSPITAL CARDIAC-ARREST; FATES; WORSE; DEATH AB Background. Forgoing resuscitation in prehospital cardiac arrest has previously required a written prehospital do-not-resuscitate (DNR) order. Some emergency medical services (EMS) agencies, including Los Angeles County (LAC), have implemented policies allowing surrogate decision makers to verbally request to forgo resuscitation. The impact of a verbal DNR policy is unclear, given the absence of information about how often cardiac arrest occurs at home, or in the presence of a family member. Objective. To determine the prevalence of written DNR forms, rate of resuscitation, location of cardiac arrest, and availability of a family member in nontraumatic cardiac arrest prior to implementation of the new policy in LAC. Methods. All prehospital run sheets for nontraumatic cardiac arrest in LAC were reviewed for the first seven days of each month (August 2006-January 2007) for DNR status, location of cardiac arrest, presence of family members, and whether resuscitation was attempted. Results. Of the 897 cardiac arrests, 492 occurred at home, 111 in a public place, and 93 in a nursing home (location was unknown for 201). Fifty-five patients (6%) had a written DNR order, although it was not always available. Of these 55 patients, ten were resuscitated, the majority of the time because the family could not produce the paperwork. A family member was listed as present 29% of the time (261 of 897 cases). A medical history was obtained in an additional 465 cases (52%), indicating that someone familiar with the patient's medical history was present more than half the time, even when a family member was not mentioned. Conclusions. A written DNR order is uncommonly used in the prehospital setting as a reason to forgo resuscitation in LAC. Even when family members state that the patient has a DNR order, patients are often resuscitated. A majority of cardiac arrests occurs at the patient's home, and in many cases in the presence of family members, some of whom may be able to express a patient's preferences regarding end-of-life care. C1 [Grudzen, Corita R.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Koenig, William J.] Los Angeles Cty Emergency Med Serv Agcy, Los Angeles, CA USA. [Hoffman, Jerome R.] Univ Calif Los Angeles, Dept Emergency Med, Los Angeles, CA USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Lorenz, Karl A.; Asch, Steven M.] VA Greater Los Angeles, Los Angeles, CA USA. RP Grudzen, CR (reprint author), Mt Sinai Sch Med, Dept Emergency Med, 1 Gustave L Levy Pl,Box 1620, New York, NY 10029 USA. EM corita.grudzen@mssm.edu OI Grudzen, Corita/0000-0003-3039-8497 FU California Health Care Foundation FX Supported by the California Health Care Foundation. NR 11 TC 6 Z9 6 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1090-3127 J9 PREHOSP EMERG CARE JI Prehosp. Emerg. Care PY 2009 VL 13 IS 2 BP 169 EP 172 AR PII 909573959 DI 10.1080/10903120802471923 PG 4 WC Emergency Medicine; Public, Environmental & Occupational Health SC Emergency Medicine; Public, Environmental & Occupational Health GA 419MT UT WOS:000264224400003 PM 19291552 ER PT B AU Lara-Castro, C Garvey, WT AF Lara-Castro, Cristina Garvey, W. Timothy BE Bendich, A Deckelbaum, RJ TI Role of Nutrition in the Pathophysiology, Prevention, and Treatment of Type 2 Diabetes and the Spectrum of Cardiometabolic Disease SO PREVENTIVE NUTRITION: THE COMPREHENSIVE GUIDE FOR HEALTH PROFESSIONALS, FOURTH EDITION SE Nutrition and Health Series LA English DT Article; Book Chapter DE Cardiometabolic disease; fiber; metabolic syndrome; monounsaturated fatty acids; prediabetes; susceptibility genes; Type 2 diabetes; weight loss ID GENOME-WIDE ASSOCIATION; INSULIN-RESISTANCE ATHEROSCLEROSIS; IMPAIRED GLUCOSE-TOLERANCE; NUCLEAR-MAGNETIC-RESONANCE; LOW-FAT DIET; METABOLIC SYNDROME; LOW-CARBOHYDRATE; WEIGHT-LOSS; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIAL AB Key Points The overlapping syndromes of prediabetes and metabolic syndrome place individuals at increased risk of Type 2 diabetes and cardiovascular disease. and in aggregate, these disorders comprise the spectrum of cardiometabolic disease. Treatment of these prediabetic states is critical for reducing patient suffering and social costs attributable to the increasing prevalence of diabetes worldwide. Insulin resistance is central to the pathophysiology of Type 2 diabetes and metabolic syndrome. While obesity can exacerbate insulin resistance, it is abnormal lipid accumulation in visceral adipose tissue, and in skeletal muscle cells and hepatocytes, that appear to be more potent and independent mediators of cardiometabolic disease. Cardiometabolic disease can be effectively treated or prevented using nutrition as a component of lifestyle therapy, which, given the underlying pathophysiology, will need to augment insulin sensitivity, enhance insulin secretion, and/or ameliorate cardiovascular risk factors. This can be accomplished via hypocaloric feeding or altered macronutrient composition of the diet. Hypocaloric diets resulting in 5-10% weight loss are effective over a wide spectrum of caloric composition ranging from low carbohydrate to low fat. Isocaloric diets can also improve insulin sensitivity and cardiovascular risk factors particularly if enriched in monounsaturated fat or fiber with reduced intake of saturated fat. Genome-wide association studies have confirmed multiple susceptibility loci (i.e., gene-based single nucleotide polymorphisms-SNPs) for Type 2 diabetes and obesity and present a powerful paradigm for the identification and study of nutrient-gene interactions, provided that investigators measure diet as an environmental variable. C1 [Lara-Castro, Cristina; Garvey, W. Timothy] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Lara-Castro, Cristina] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Garvey, W. Timothy] UAB Diabet Res & Training Ctr, Birmingham, AL 35294 USA. RP Lara-Castro, C (reprint author), Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. EM garveyt@uab.edu NR 58 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-541-5 J9 NUTR HEALTH SER JI Nutr. Health Ser. PY 2009 BP 371 EP 387 DI 10.1007/978-1-60327-542-2_15 PG 17 WC Public, Environmental & Occupational Health; Nutrition & Dietetics SC Public, Environmental & Occupational Health; Nutrition & Dietetics GA BLY65 UT WOS:000271457000015 ER PT J AU Agrawal, V Gailey, R O'Toole, C Gaunaurd, I Dowell, T AF Agrawal, Vibhor Gailey, Robert O'Toole, Christopher Gaunaurd, Ignacio Dowell, Tomas TI Symmetry in External Work (SEW): A novel method of quantifying gait differences between prosthetic feet SO PROSTHETICS AND ORTHOTICS INTERNATIONAL LA English DT Article DE Gait symmetry; external mechanical work; prosthetic feet comparison; gait kinetics ID LOWER-LIMB AMPUTATION; TO-STEP TRANSITIONS; MECHANICAL WORK; HUMAN WALKING; AMPUTEES; MOTION; BODY AB Unilateral transtibial amputees (TTAs) show subtle gait variations while using different prosthetic feet. These variations have not been detected consistently with previous experimental measures. We introduce a novel measure called Symmetry in External Work (SEW) for quantifying kinetic gait differences between prosthetic feet. External work is the result of changes in kinetic and potential energy of body center of mass (CoM). SEW is computed by integrating vertical ground reaction forces obtained using F-scan in-sole sensors. Since various prosthetic feet have different designs, we hypothesized that SEW will vary with the type of foot used. This hypothesis was tested with a single unilateral TTA using four prosthetic feet (Proprio, Trias+, Seattle Lite and SACH). The Proprio (mean symmetry 94.5%1.1%) and the Trias+ (92.1%2.5%) feet exhibited higher symmetry between the intact and prosthetic limbs, as compared to the Seattle (67.8%19.3%) and SACH (35.7%11.1%) feet. There was also a good agreement in vertical CoM excursion between the intact foot and prosthetic feet with heel-toe foot plate designs. Results indicate that SEW measure may be a viable method to detect kinetic differences between prosthetic feet and could have clinical applications because of relatively low cost instrumentation and minimal subject intervention. C1 [Agrawal, Vibhor] Miami VA Healthcare Syst, US Dept Vet Affairs, Res Serv 151, Funct Outcomes Res & Evaluat Ctr, Miami, FL 33125 USA. [Agrawal, Vibhor; O'Toole, Christopher] Univ Miami, Coll Engn, Dept Biomed Engn, Coral Gables, FL 33124 USA. [Gailey, Robert; Gaunaurd, Ignacio] Univ Miami, Dept Phys Therapy, Miller Sch Med, Coral Gables, FL 33124 USA. RP Agrawal, V (reprint author), Miami VA Healthcare Syst, US Dept Vet Affairs, Res Serv 151, Funct Outcomes Res & Evaluat Ctr, 1201 NW 16th St, Miami, FL 33125 USA. EM vibhor@umail.miami.edu NR 26 TC 14 Z9 14 U1 3 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0309-3646 J9 PROSTHET ORTHOT INT JI Prosthet. Orthot. Int. PY 2009 VL 33 IS 2 BP 148 EP 156 AR PII 910430308 DI 10.1080/03093640902777254 PG 9 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA 435DM UT WOS:000265323900007 PM 19367518 ER PT J AU Waltman, MA Russell, DC Coyle, CT Enright, RD Holter, AC Swoboda, C AF Waltman, Martina A. Russell, Douglas C. Coyle, Catherine T. Enright, Robert D. Holter, Anthony C. M. Swoboda, Christopher TI The effects of a forgiveness intervention on patients with coronary artery disease SO PSYCHOLOGY & HEALTH LA English DT Article DE forgiveness; anger-recall; mental stress; coronary artery disease; myocardial ischemia; myocardial perfusion imaging ID MYOCARDIAL-ISCHEMIA PIMI; STRESS-INDUCED ISCHEMIA; MENTAL STRESS; CARDIOVASCULAR REACTIVITY; PSYCHOPHYSIOLOGICAL INVESTIGATIONS; GAIN SCORES; ANGER; HOSTILITY; RESPONSES; THERAPY AB This research assesses the effects of a psychology of forgiveness pilot study on anger-recall stress induced changes in myocardial perfusion, forgiveness and related variables. Thirty-two patients were administered baseline rest and anger-recall stress imaging studies, and 17 of these participants who demonstrated anger-recall stress induced myocardial perfusion defects (forgiveness group, n = 9; control group, n = 8) were randomly assigned to a series of 10 weekly interpersonal forgiveness or control therapy sessions with a trained psychologist, and underwent additional anger-recall stress myocardial perfusion nuclear imaging studies post-test and at 10-week follow-up. Patients assigned to the forgiveness group showed significantly fewer anger-recall induced myocardial perfusion defects from pre-test to the 10-week follow-up as well as significantly greater gains in forgiveness from pre-test to post-test and from pre-test to follow-up compared to the control group. Forgiveness intervention may be an effective means of reducing anger-induced myocardial ischemia in patients with coronary artery disease. C1 [Waltman, Martina A.; Coyle, Catherine T.; Enright, Robert D.; M. Swoboda, Christopher] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA. [Waltman, Martina A.; Russell, Douglas C.] William S Middleton Mem Vet Adm Med Ctr, Dept Vet Affairs, Madison, WI USA. [Russell, Douglas C.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Holter, Anthony C.] Univ Notre Dame, South Bend, IN USA. RP Enright, RD (reprint author), Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA. EM rd.enright@yahoo.com NR 72 TC 23 Z9 26 U1 3 U2 15 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0887-0446 EI 1476-8321 J9 PSYCHOL HEALTH JI Psychol. Health PY 2009 VL 24 IS 1 BP 11 EP 27 AR PII 794507871 DI 10.1080/08870440801975127 PG 17 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary SC Public, Environmental & Occupational Health; Psychology GA 400HZ UT WOS:000262859900003 PM 20186637 ER PT J AU Griffin, WC Lopez, MF Yanke, AB Middaugh, LD Becker, HC AF Griffin, William C., III Lopez, Marcelo F. Yanke, Amy B. Middaugh, Lawrence D. Becker, Howard C. TI Repeated cycles of chronic intermittent ethanol exposure in mice increases voluntary ethanol drinking and ethanol concentrations in the nucleus accumbens SO PSYCHOPHARMACOLOGY LA English DT Article DE Ethanol; Dependence; Withdrawal; Self-administration; Mice; Relapse; Microdialysis; Brain ethanol levels ID SUBSEQUENT WITHDRAWAL SEIZURES; C57BL/6J MICE; MICRODIALYSIS PROBES; ALCOHOL-WITHDRAWAL; DRUG-ADDICTION; ANIMAL-MODEL; RAT-BRAIN; ALLOSTASIS; SEVERITY; DOPAMINE AB This study examined the relationship between voluntary ethanol consumption and ethanol concentrations measured in the nucleus accumbens of ethanol dependent and nondependent C57BL/6J mice. Mice were offered ethanol in a two-bottle choice; limited access paradigm and consummatory behavior was monitored with lickometers. After baseline intake stabilized, mice received chronic intermittent ethanol (EtOH group) or air (CTL group) exposure by inhalation (16 h/day for 4 days) and then resumed drinking. Brain ethanol levels during voluntary drinking were measured by microdialysis procedures and compared to brain ethanol concentrations produced during chronic intermittent ethanol vapor exposure. Voluntary ethanol consumption progressively increased over repeated cycles of chronic intermittent ethanol exposure but remained unchanged in CTL mice. Analysis of lick patterns indicated EtOH mice consumed ethanol at a faster rate compared to CTL mice. The greater and faster rate of ethanol intake in EtOH mice produced higher peak brain ethanol concentrations compared to CTL mice, and these levels were similar to levels produced during chronic intermittent ethanol exposure. These results show that in this model of dependence and relapse drinking, dependent mice exhibit enhanced voluntary ethanol consumption relative to nondependent controls, which consequently produces blood and brain ethanol concentrations similar to those experienced during chronic intermittent ethanol exposure. C1 [Griffin, William C., III] Med Univ S Carolina, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA. [Griffin, William C., III; Lopez, Marcelo F.; Yanke, Amy B.; Middaugh, Lawrence D.; Becker, Howard C.] Ctr Drug & Alcohol Programs, Charleston Alcohol Res Ctr, Dept Psychiat & Behav Sci, Charleston, SC USA. [Middaugh, Lawrence D.; Becker, Howard C.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Becker, Howard C.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Griffin, WC (reprint author), Med Univ S Carolina, Ctr Drug & Alcohol Programs, MSC 861, Charleston, SC 29425 USA. EM griffinw@musc.edu FU NIH [AA10716, AA14095, AA13885] FX This work was supported by NIH grants AA10716, AA14095, and AA13885. The authors thank Judi S. Randall and Kay Fernandes for excellent technical assistance in conducting this work. NR 30 TC 75 Z9 75 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD JAN PY 2009 VL 201 IS 4 BP 569 EP 580 DI 10.1007/s00213-008-1324-3 PG 12 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 377PT UT WOS:000261263800011 PM 18791704 ER PT J AU Kim, SG Kim, CM Choi, SW Jae, YM Lee, HG Son, BK Kim, JG Choi, YS Kim, HO Kim, SY Oslin, DW AF Kim, Sung-Gon Kim, Cheol-Min Choi, Sam-Wook Jae, Young-Myo Lee, Hae-Gook Son, Bong-Ki Kim, Jeong-Gee Choi, Young-Sung Kim, Han-Oh Kim, Seong-Yeon Oslin, David W. TI A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients SO PSYCHOPHARMACOLOGY LA English DT Article DE Naltrexone; Mu opioid receptor; Polymorphism; Korean alcohol dependent ID FUNCTIONAL POLYMORPHISM; BETA-ENDORPHIN; OPRM1; ASSOCIATION; MORPHINE; THERAPY; VARIANT; SENSITIVITY; POPULATION; ACTIVATION AB Previous studies have demonstrated an association between genetic polymorphisms of the mu opioid receptor gene (OPRM1) and response to naltrexone treatment. The Asp40 variant genotype previously shown to be associated with naltrexone treatment response is known to be relatively common among Koreans. This study was conducted to prospectively investigate the relationship between genotype and response to open-label naltrexone treatment in Korean alcohol-dependent subjects. Sixty-three alcohol-dependent subjects were prescribed naltrexone for 12 weeks in combination with cognitive behavioral therapy. Thirty-two subjects were adherent, taking the medication at least 80% of the treatment days [16 Asn40 (A/A) patients and 16 Asp40 variant (A/G or G/G) patients]. Subjects adherent to naltrexone treatment with one or two copies of the Asp40 allele took a significantly longer time than the Asn40 group to relapse (p=0.014). Although not significant, the Asn40 group treated with naltrexone had a 10.6 times greater relapse rate than the Asp40 variant group. There was no significant difference between the Asn40 group and the Asp40 variant group treated with naltrexone in rates of abstinence. These results demonstrating a higher therapeutic effect of naltrexone in Korean alcohol-dependent individuals with the Asp40 variant genotype than the Asn40 genotype are consistent with previous study results in individuals of European descent. This is the first study to examine the pharmacogenetics treatment response to naltrexone in non-European subjects. C1 [Kim, Sung-Gon] Pusan Natl Univ, Sch Med, Dept Psychiat, Pusan 602739, South Korea. [Kim, Cheol-Min] Haein Hosp, Yangsan, South Korea. [Choi, Sam-Wook] Univ Ulsan, Coll Med, Dept Psychiat, Ulsan 680749, South Korea. [Jae, Young-Myo] Bongseng Mem Hosp, Dept Psychiat, Pusan, South Korea. [Lee, Hae-Gook] Catholic Univ, Coll Med, Dept Psychiat, Seoul, South Korea. [Son, Bong-Ki] Hallym Univ, Med Ctr, Chuncheon Sacred Heart Hosp, Dept Psychiat, Chunchon, South Korea. [Kim, Jeong-Gee] Maryknoll Gen Hosp, Dept Psychiat, Pusan, South Korea. [Choi, Young-Sung] St Andrews Neuropsychiat Hosp, Icheon, Inchon, South Korea. [Kim, Han-Oh] Keyo Hosp, Keyo Med Fdn, Uiwang, South Korea. [Kim, Seong-Yeon] Dong A Univ, Div Management Informat Sci, Pusan, South Korea. [Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Oslin, David W.] VISN 4 MIRECC, Philadelphia, PA USA. RP Kim, SG (reprint author), Pusan Natl Univ, Sch Med, Dept Psychiat, 1-Ga 10,Ami Dong, Pusan 602739, South Korea. EM sungkim@pusan.ac.kr RI KIM, SEONG YEON/E-4164-2012 FU Je-il Pharmaceutical Co., Seoul, South Korea FX This work was supported by Je-il Pharmaceutical Co., Seoul, South Korea. NR 47 TC 61 Z9 62 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD JAN PY 2009 VL 201 IS 4 BP 611 EP 618 DI 10.1007/s00213-008-1330-5 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 377PT UT WOS:000261263800015 PM 18795264 ER PT J AU Demitrack, MA Thase, ME AF Demitrack, Mark A. Thase, Michael E. TI Clinical Significance of Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Depression: Synthesis of Recent Data SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article DE major depression; treatment resistance; transcranial magnetic stimulation; TMS; antidepressant; efficacy; safety; randomized clinical trial; TMS study group ID STAR-ASTERISK-D; TREATMENT-RESISTANT DEPRESSION; DRUG-ADMINISTRATION DATABASE; FAILED MEDICATION TREATMENTS; DOUBLE-BLIND; MAJOR DEPRESSION; OLANZAPINE/FLUOXETINE COMBINATION; CONTROLLED-TRIAL; ANTIDEPRESSANT THERAPY; ADJUNCTIVE THERAPY AB Transcranial magnetic stimulation (TMS) is a novel treatment for patients with major depressive disorder. Although clearly safer and better tolerated than many other pharmacotherapeutic options or electroconvulsive therapy, questions have persisted about the magnitude of the efficacy of TMS in patients with pharmacoresistant depression, and the clinical significance of these outcomes. Previous studies have explored whether specific patient characteristics are associated with a greater likelihood of clinical benefit. In the largest such analysis conducted to date, the authors confirmed previous observations that the lower the number of prior failed antidepressant treatments, the better the clinical outcome of treatment with TMS. This relationship between prior treatment resistance and subsequent treatment outcome is consistent with previous evidence from antidepressant studies. The authors examined the clinical significance of the treatment effects seen with TMS in pharmacoresistant major depression in their recently completed studies by comparing these outcomes with the results reported in several large, comprehensive published reference datasets of antidepressant medications studied in both treatment-responsive and treatment-resistant patient populations. The efficacy of TMS demonstrated in randomized controlled trials was comparable to that of pharmaceutical antidepressants studied in similarly designed registration trials and to the adjunctive use of atypical antipsychotic medications in controlled trials of antidepressant non-responders. These data may be helpful in treatment-planning decisions when using TMS in clinical practice. Psychopharmacology Bulletin. 2009;42(2):5-38. C1 [Demitrack, Mark A.] Neuronetics Inc, Malvern, PA 19355 USA. [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Demitrack, MA (reprint author), Neuronetics Inc, 31 Gen Warren Blvd, Malvern, PA 19355 USA. EM mdemitrack@neuronetics.com RI Demitrack, Mark/I-7697-2013 FU Eli Lilly and Company; Sepracor, Inc.; Neuronetics Inc. FX Clinical trial posted on www.clinicaltrials.gov. Listing No. NCT 00104611. Supported by a grant from Neuronetics Inc. Dr. Thase has served as an advisor to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc., Eli Lilly & Co., Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, MedAvante, Inc., Neuronetics, Inc., Novartis, Organon International, Sepracor, Inc., Shire US Inc., Supernus Pharmaceuticals and Wyeth Pharmaceuticals. He has received research grant support from Eli Lilly and Company and Sepracor, Inc. He has served on the Speaker's Bureaus for AstraZeneca, Bristol-Myers Squibb Company, Cyberonics, Inc., Eli Lilly & Co., GlaxoSmithKline, Sanofi Aventis, Schering Plough (formerly Organon, Inc.) and Wyeth Pharmaceuticals. He reports having equity holdings in MedAvante, Inc. and receives royalties for work he created and was published by American Psychiatric Publishing, Inc., Guilford Publications, Herald House and W. W. Norton & Company, Inc. NR 45 TC 25 Z9 26 U1 6 U2 10 PU MEDWORKS MEDIA GLOBAL, LLC PI HERMOS BEACH PA 670 FIFTH STREET, STE A, HERMOS BEACH, CA 90254 USA SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 2009 VL 42 IS 2 BP 5 EP 38 PG 34 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 641OH UT WOS:000281137100001 PM 19629020 ER PT J AU Fleurence, R Williamson, R Jing, YH Kim, E Tran, QV Pikalov, A Thase, ME AF Fleurence, Rachael Williamson, Rebecca Jing, Yonghua Kim, Edward Tran, Quynh-Van Pikalov, Andrei Thase, Michael E. TI A Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article DE major depression; treatment resistant; atypical antipsychotics; systematic review ID TREATMENT-RESISTANT DEPRESSION; PLACEBO-CONTROLLED TRIAL; STAR-ASTERISK-D; DOUBLE-BLIND; OLANZAPINE/FLUOXETINE COMBINATION; REFRACTORY DEPRESSION; LITHIUM AUGMENTATION; TRICYCLIC ANTIDEPRESSANTS; MIANSERIN AUGMENTATION; ADJUNCTIVE THERAPY AB Major depressive disorder (MDD) is a leading cause of disability worldwide. Clinicians need to determine the most appropriate and effective interventions for patients who do not benefit from first-line treatment. A systematic review of the literature on augmentation strategies for major depression was conducted. A total of 32 eligible studies were included in the final review. Identified augmentation strategies included lithium, thyroid hormone, buspirone, stimulant drugs (methylphenidate and modafinil), and atypical antipsychotics (olanzapine, quetiapine, aripiprazole, and risperidone). Additional studies used other augmentation strategies (yohimbine, atomoxetine, inositol, testosterone, and lamotrigine), or combinations with a second antidepressant (mianserin, mirtazapine, and desipramine). There was no evidence of clinical efficacy as measured by response in augmentation with buspirone, testosterone, methylphenidate, yohimbine, inositol, and atomoxetine. Although some studies of combined antidepressant therapy and lithium augmentation did show statistically significant clinical effects, results were inconsistent across studies. The only eligible study of thyroid augmentation was positive, though this study evaluated patients treated with tricyclic antidepressants. It is possible due to small sample sizes, that some of the trials failed to detect significant differences versus placebo because of inadequate statistical power. Adjunctive therapy with atypical antipsychotics showed higher response rates compared with antidepressant monotherapy and placebo but also had more withdrawals due to adverse events. Given ongoing concerns with the longer term tolerability and safety of the atypical antipsychotics, future research will need to investigate optimal duration of augmentation therapy in patients with major depressive disorder who do not respond to first line therapy. Psychopharmacology Bulletin. 2009; 42(3): 57-90. C1 [Fleurence, Rachael; Williamson, Rebecca] United BioSource Corp, Ctr Hlth Econ & Sci Policy, Bethesda, MD 20814 USA. [Jing, Yonghua] Bristol Myers Squibb, Plainsboro, NJ USA. [Kim, Edward] Eisai Inc, Woodcliff Lake, NJ USA. [Tran, Quynh-Van; Pikalov, Andrei] Otsuka Amer Pharmaceut, Rockville, MD USA. [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Fleurence, R (reprint author), United BioSource Corp, Ctr Hlth Econ & Sci Policy, 7101 Wisconsin Ave,Suite 600, Bethesda, MD 20814 USA. EM rachael.fleurence@unitedbiosource.com NR 57 TC 37 Z9 37 U1 1 U2 2 PU MEDWORKS MEDIA GLOBAL, LLC PI HERMOS BEACH PA 670 FIFTH STREET, STE A, HERMOS BEACH, CA 90254 USA SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 2009 VL 42 IS 3 BP 57 EP 90 PG 34 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 696QX UT WOS:000285457600004 PM 19752841 ER PT J AU Robert, S Hamner, MB Durkalski, VL Brown, MW Ulmer, HG AF Robert, Sophie Hamner, Mark B. Durkalski, Valerie L. Brown, Mary W. Ulmer, Helen G. TI An Open-Label Assessment of Aripiprazole in the Treatment of PTSD SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article DE posttraumatic stress disorder; psychopharmacology; treatment; second generation antipsychotics; aripiprazole ID POSTTRAUMATIC-STRESS-DISORDER; MAJOR DEPRESSIVE DISORDER; DOUBLE-BLIND; COMBAT VETERANS; ADJUNCTIVE RISPERIDONE; PSYCHOTIC SYMPTOMS; SLEEP QUALITY; RATING-SCALE; OPEN TRIAL; PLACEBO AB Background: Recent studies suggest that atypical antipsychotics effective augmentation strategies for the treatment of posttraumatic stress (PTSD). Limited data were available on the newest agent, aripiprazole, so we aimed to evaluate its efficacy and tolerability in the treatment of PTSD. Methods: A 12-week, prospective, open-label, flexible-dose, adjunctive trial of apripiprazole was conducted in military veterans meeting DSM-IV criteria for PTSD. Concomitant psychiatric medications continued unchanged, except for other neuroleptics which were not allowed. The primary outcome variable was change from baseline in the Clincian Administered PTSD scale (CAPS). Results: All 17 subjects were male with an average age of 57 years. Total CAPS scores decreased from 78.2 (SD = 17.8) at baseline 60.0 (23.5) at study end (p = 0.002). Re-experiencing (CAPS-B) and avoidance/numbing symptoms (CAPS-C) were significantly improved, and trend level reductions were observed in hyperarousal symptoms (CAPS-D). Fifty-three percent (9/17) were considered responders, as defined by a decrease in total CAPS scores of at least 20%. Reductions in the Positive and Negative Symptom Scale (PANS) total score and positive and general psychopathology subscale scores were statistically significant. The final average dose of aripiprazole was 13.06 (SD = 6.45) mg daily. Nine patients discontinued because of side effects. The most common adverse events consisted of gastro-intestinal disturbances, sedation, and psychomotor activation Tolerability was improved with lower starting doses (e.g., 5 mg daily) and slow titration. Conclusions: Addition of aripiprazole to ongoing treatment further reduced PTSD symptoms in military veterans with severe PTSD. These preliminary findings await confirmation in randomized, controlled trials Psychopharmacology Bulletin. 2009;42(1):69-80. C1 [Robert, Sophie] Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Robert, Sophie; Hamner, Mark B.; Durkalski, Valerie L.; Brown, Mary W.; Ulmer, Helen G.] Med Univ S Carolina, Charleston, SC USA. RP Robert, S (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM robertso@musc.edu FU Bristol-Myers Squibb; Abbott Laboratories; AstraZeneca; Forest Laboratories; Janssen Pharmaceutica; Eli Lilly; Organon; Otsuka Pharmaceutical FX This material is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VA Medical Center. The study was funded by Bristol-Myers Squibb as an investigator-initiated grant to Dr. Hamner.; Dr. Robert reports no other significant commercial relationships relevant to the subject matter of this article. Dr. Hamner has been on the speaker's bureau, consultant for, and/or recipient of research grant support from Abbott Laboratories, Bristol-Myers Squibb, AstraZeneca, Forest Laboratories, Janssen Pharmaceutica, Eli Lilly, Organon, and Otsuka Pharmaceutical. He owns stock in Pfizer Inc., and Merck & Co., Other authors report no relevant financial interests or personal affiliations in connection with the content of this paper. NR 77 TC 18 Z9 18 U1 2 U2 4 PU MEDWORKS MEDIA GLOBAL, LLC PI HERMOS BEACH PA 670 FIFTH STREET, STE A, HERMOS BEACH, CA 90254 USA SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 2009 VL 42 IS 1 BP 69 EP 80 PG 12 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 641OG UT WOS:000281137000005 PM 19204652 ER PT J AU Holden, WE Sippel, JM Nelson, B Giraud, GD AF Holden, William E. Sippel, Jeffrey M. Nelson, Bella Giraud, George D. TI Greater nasal nitric oxide output during inhalation: Effects on air temperature and water content SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY LA English DT Article DE Nitric oxide; N(G)-nitro-L-arginine methyl ester (L-NAME); Humidity ID PARANASAL SINUSES; HUMAN NOSE; PHYSIOLOGY; ABILITY; HUMANS; WARM AB The nose conditions the temperature and humidity of nasal air, and the nasal mucosal vasculature Supplies heat and water for these processes. We hypothesize that nitric oxide (NO) modulates these processes through vasoactive effects on nasal mucosal vasculature. We measured the temperature, humidity and NO concentrations of nasal air during inhalation and exhalation across the nose and calculated net heat, water and NO Output before (controls, n = 7) and after inhibition of NO synthase by topical L-NAME (N = 5) in healthy humans. We found that calculated NO output across the nasal passages is approximately threefold greater during inhalation (503 +/- 105 nL/min) compared with exhalation (162 +/- 56 nL/min). Moreover, topical administration Of L-NAME decreased nasal air temperature and humidity conditioning and NO output, but these effects were limited to inhalation. We conclude that nasal NO output is greater during inhalation than exhalation in humans. Our findings also support a role of nasal NO in temperature and humidity conditioning of nasal air. Published by Elsevier B.V C1 [Holden, William E.; Sippel, Jeffrey M.; Nelson, Bella; Giraud, George D.] Portland VA Med Ctr, Dept Hosp & Specialty Med, P3 MED, Portland, OR 97201 USA. RP Holden, WE (reprint author), Portland VA Med Ctr, Dept Hosp & Specialty Med, P3 MED, 3710 SW US Vet Hosp Rd, Portland, OR 97201 USA. EM holdenw@ohsu.edu FU Murdock Foundation Charitable Trust FX We acknowledge the assistance with experiments by Michelle Harris and the support of the Murdock Foundation Charitable Trust. NR 21 TC 3 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1569-9048 J9 RESP PHYSIOL NEUROBI JI Respir. Physiol. Neuro. PD JAN 1 PY 2009 VL 165 IS 1 BP 22 EP 27 DI 10.1016/j.resp.2008.09.009 PG 6 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 399HM UT WOS:000262791000004 PM 18952009 ER PT J AU de Soarez, PC Castelo, A Abrao, P Holmes, WC Ciconelli, RM AF de Soarez, Patricia Coelho Castelo, Adauto Abrao, Paulo Holmes, William C. Ciconelli, Rozana Mesquita TI Brazilian-Portuguese translation and validation of the HIV/AIDS-Targeted Quality of Life Instrument SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA Portuguese DT Article DE Reproducibility of results; validation studies; quality of life; Acquired Immunodeficiency Syndrome; Brazil ID CROSS-CULTURAL ADAPTATION; HAT-QOL INSTRUMENT; HEALTH SURVEY; ANTIRETROVIRAL THERAPY; HIV DISEASE; MOS-HIV; RELIABILITY; GUIDELINES; INFECTION; VALIDITY AB Objectives. To translate the HIV/AIDS-Targeted Quality of Life Instrument (HAT-QoL) into Brazilian Portuguese, culturally adapt it, and evaluate its psychometric properties (validity and reliability) as a Brazilian version. Methods. This cross-sectional study was carried out at the laboratory of infectious diseases at Escola Paulista de Medicina (Universidade Federal de Sao Paulo). Data were collected on clinical and sociodemographic characteristics of 106 HIV-infected individuals who answered the HAT-QoL and the SF-36 (R). Pearson's correlation coefficient was used to measure construct validity. Reliability was assessed using Cronbach's alpha and intraclass correlation coefficients. Results. The sample was 70.8% male. The mean age was 39.9 years, with 40.5% of the participants being homosexual or bisexual. Eleven (10.4%) patients had a CD4 cell count <= 200 cells/mm(3). A substantial ceiling effect was observed in 7 of 9 HAT-QoL domains (overall function, life satisfaction, health worries, medication worries, HIV acceptance, provider trust, and sexual function). Sexual function was the domain with the highest ceiling effect (63.2%). A substantial floor effect (30.2%) was observed for financial worries. Statistically significant associations were observed between the HAT-QoL domains and clinical and sociodemographic characteristics, as well as with SF-36 domains. Internal consistency was satisfactory (Cronbach's alpha = 0.73-0.90). Inter- and intra-observer reproducibility was very high (0.87-0.98 and 0.82-0.97, respectively). Conclusion. The Brazilian Portuguese version of the HAT-QoL is valid, reliable, and may contribute to evaluating the impact of HIV infection on the quality of life of patients in Brazil. C1 [de Soarez, Patricia Coelho; Ciconelli, Rozana Mesquita] Univ Fed Sao Paulo, Ctr Paulista Econ Saude, Sao Paulo, Brazil. [Castelo, Adauto; Abrao, Paulo; Ciconelli, Rozana Mesquita] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil. [Holmes, William C.] Univ Penn, Sch Med, Ctr Hlth Equ Res & Promot, Filadelfia, PA USA. [Holmes, William C.] Ctr Clin Epidemiol & Biostat, Filadelfia, PA USA. RP de Soarez, PC (reprint author), Rua Botucatu 685, BR-04023062 Sao Paulo, Brazil. EM patricia.soarez@cpes.org.br RI Ciconelli, Rozana /G-4549-2013; Abrao Ferreira, Paulo Roberto/A-5703-2016; SOAREZ, PATRICIA/D-9710-2012 OI Abrao Ferreira, Paulo Roberto/0000-0003-4858-2778; SOAREZ, PATRICIA/0000-0001-8383-0728 NR 21 TC 6 Z9 14 U1 2 U2 12 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD JAN PY 2009 VL 25 IS 1 BP 69 EP 76 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 423YD UT WOS:000264531800011 PM 19341527 ER PT J AU Jang, JS Choi, SR Qureshi, W Kim, MC Kim, SJ Jeung, JS Han, SY Noh, MH Lee, JH Lee, SW Baek, YH Kim, SH Choi, PJ AF Jang, Jin Seok Choi, Seok Reyol Qureshi, Waqar Kim, Min Chan Kim, Su Jin Jeung, Jin Sook Han, Sang Young Noh, Myung Hwan Lee, Jong Hoon Lee, Seung Wook Baek, Yang Hyun Kim, Sung Hyun Choi, Phil Jo TI Long-term outcomes of endoscopic submucosal dissection in gastric neoplastic lesions at a single institution in South Korea SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Curability; disease-free survival rate; endoscopic submucosal dissection; local recurrence; resectability ID LYMPH-NODE METASTASIS; MUCOSAL RESECTION; DIATHERMIC KNIFE; CANCER; STOMACH; TUMORS AB Objective. Although endoscopic treatment for early gastric cancer (EGC) is an accepted therapy in South Korea and Japan, long-term outcomes remain unknown. We evaluated the clinical outcome of endoscopic submucosal dissection (ESD) for gastric dysplasia and EGC. Material and methods. A total of 402 patients with gastric dysplasia and EGC were treated with ESD at a single hospital from January 2004 to December 2007. The patients underwent ESD and then received periodic endoscopic follow-up and metastatic surveys for 9-49 months (median 30 months). Resectability (en bloc or piecemeal resection), curability (complete or incomplete), local recurrence, and disease-free survival rates were estimated. Results. There were 107 patients with low-grade dysplasia (LGD), 97 with high-grade dysplasia (HGD) and 198 with EGC. In EGC patients, en bloc resection was achieved in 89.7% (177/198), the complete resection rate was 87.9% (174/198), and the local recurrence rate was 5.1% (10/198). Tumor size > 20 mm was significantly associated with local recurrence (odds ratio 6.45; 95% CI 1.20-20.11; p=0.001). There were significant correlations between the incidences of a piecemeal or incomplete resection and that of local recurrence (odds ratio 5.23; 95% CI 1.02-18.34; p=0.001; and odds ratio 6.99; 95% CI 1.22-21.65; p=0.002, respectively). The 3-year cancer-free survival rate was 94.9%. Conclusions. Curative treatment with successful en bloc resection can reduce the local recurrence of gastric neoplastic lesions after ESD. Clinical outcome may be excellent, although longer follow-up studies are warranted. C1 [Kim, Min Chan] Univ Coll Med, Dong A Med Ctr, Dept Gen Surg, Pusan, South Korea. [Kim, Su Jin; Jeung, Jin Sook] Univ Coll Med, Dong A Med Ctr, Dept Pathol, Pusan, South Korea. [Choi, Phil Jo] Univ Coll Med, Dong A Med Ctr, Dept Cardiac Surg, Pusan, South Korea. [Qureshi, Waqar] Baylor Coll Med, Houston, TX 77030 USA. [Qureshi, Waqar] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. [Jang, Jin Seok; Choi, Seok Reyol; Han, Sang Young; Noh, Myung Hwan; Lee, Jong Hoon; Lee, Seung Wook; Baek, Yang Hyun; Kim, Sung Hyun] Univ Coll Med, Dong A Med Ctr, Dept Internal Med, Pusan, South Korea. RP Choi, SR (reprint author), Univ Coll Med Busan, Dong A Med Ctr, Pusan, South Korea. EM sychoi@dau.ac.kr FU Dong-A University FX This study was supported by research funds from Dong-A University. NR 25 TC 25 Z9 27 U1 0 U2 0 PU TAYLOR & FRANCIS AS PI OSLO PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PY 2009 VL 44 IS 11 BP 1315 EP 1322 DI 10.3109/00365520903254304 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 528YX UT WOS:000272484000007 PM 19891582 ER PT J AU Jang, JS Choi, SR Graham, DY Kwon, HC Kim, MC Jeong, JS Won, JJ Han, SY Noh, MH Lee, JH Lee, SW Baek, YH Kim, MJ Jeong, DS Kim, SK AF Jang, Jin Seok Choi, Seok Reyol Graham, David Y. Kwon, Hyuk-Chan Kim, Min Chan Jeong, Jin Sook Won, Jong Jin Han, Sang Young Noh, Myung Hwan Lee, Jong Hoon Lee, Seung Wook Baek, Yang Hyun Kim, Min Ji Jeong, Dong Seong Kim, Seul Ki TI Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Endoscopic submucosal dissection; gastric neoplastic lesion; immediate and delayed bleeding; risk factors ID MUCOSAL RESECTION; CANCER; ULCER; TUMORS AB Objective. Endoscopic submucosal dissection (ESD) of gastric neoplasia has been reported to have a higher bleeding rate than conventional endoscopic mucosal resection (EMR). The aim of this study was to identify the risk factors for bleeding associated with ESD. Material and methods. The records of consecutive patients who underwent ESD for gastric adenoma/early gastric cancer were reviewed. Potential risk factors included patient age, lesion size, gross findings, location, and histology of the tumor. The primary end-point was the incidence of immediate or delayed bleeding related to ESD. Results. A total of 144 patients were studied; bleeding occurred in 32 cases (22.2%) with immediate bleeding in 29 cases. Delayed bleeding (3 cases) occurred at day 2 (2 patients) and at day 7 in 1 patient. In all cases of immediate bleeding, immediate hemostatic therapy was successful. The histology of tumor was the only factor that was statistically significantly associated with bleeding (adjusted hazard ratio 6.770, 95% confidence interval 1.830-25.048, p=0.004). Conclusions. The only factor that correlated with an increased risk of bleeding with ESD was the presence of gastric malignancy. We found no factor that would, prospectively, be amenable to prevention of bleeding. C1 [Jang, Jin Seok; Choi, Seok Reyol; Won, Jong Jin; Han, Sang Young; Noh, Myung Hwan; Lee, Jong Hoon; Lee, Seung Wook; Baek, Yang Hyun; Kim, Min Ji; Jeong, Dong Seong; Kim, Seul Ki] Univ Coll Med, Dong A Med Ctr, Dept Internal Med, Pusan, South Korea. [Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. [Graham, David Y.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. [Kwon, Hyuk-Chan] Univ Coll Med, Dong A Med Ctr, Dept Hematooncol, Pusan, South Korea. [Kim, Min Chan] Univ Coll Med, Dong A Med Ctr, Dept Gen Surg, Pusan, South Korea. [Jeong, Jin Sook] Univ Coll Med, Dong A Med Ctr, Dept Pathol, Pusan, South Korea. RP Choi, SR (reprint author), Univ Coll Med Busan, Dong A Med Ctr, Pusan, South Korea. EM sychoi@dau.ac.kr NR 20 TC 23 Z9 25 U1 0 U2 0 PU TAYLOR & FRANCIS AS PI OSLO PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PY 2009 VL 44 IS 11 BP 1370 EP 1376 DI 10.3109/00365520903194609 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 528YX UT WOS:000272484000014 PM 19891589 ER PT J AU Jespersen, S Sogaard, OS Fine, MJ Ostergaard, L AF Jespersen, Sanne Sogaard, Ole Schmeltz Fine, Michael J. Ostergaard, Lars TI The relationship between diagnostic tests and case characteristics in Legionnaires' disease SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID URINARY ANTIGEN TEST; LEGIONELLA INFECTION; CLINICAL SEVERITY; LARGE OUTBREAK; SENSITIVITY; PNEUMONIA AB In this retrospective study of 332 cases of Legionnaires' disease (LD) in 4 Danish counties between 1995 and 2005 we aimed to compare the sensitivity of culture, PCR, 'urinary antigen testing, and serology to the mode of acquisition, serogroup, and severity of disease. Furthermore, we analyzed time to diagnosis. Laboratory confirmed cases of LD were found through the national Danish surveillance system and departments of clinical microbiology. In our study PCR was more sensitive (79.2%) than urinary antigen testing (70.4%), serology (54.8%), and culture (39.9%) (p<0.001). The sensitivity of Legionella urinary antigen test was higher among travel-associated cases (90.2%) compared to non-travel-associated cases (65.8%) and hospital acquired cases (45.7%) (p <0.001). Overall, the most common species and serogroup identified was L. pneumophila serogroup 1 (64.3% (110/171)). Community acquired cases with serogroup 1 were diagnosed earlier (mean 5 cl, IQR: 4-9 d) than community acquired cases with other species or serogroups (mean 10.5 d, IQR: 5-19.5) (p < 0. 00 1). In conclusion, the urinary antigen test, PCR, and culture were conducive to the diagnosis of Legionella infection, and ordering of all 3 tests is recommended to ensure a definite and rapid diagnosis of Legionella. C1 [Jespersen, Sanne; Sogaard, Ole Schmeltz; Ostergaard, Lars] Aarhus Univ Hosp, Dept Infect Dis, Skejby, Denmark. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Fine, Michael J.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Med, Div Gen Med, Philadelphia, PA USA. RP Jespersen, S (reprint author), Aarhus Univ Hosp, Dept Infect Dis, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark. EM sannejespersen@hotmail.com RI Sogaard, Ole/P-6058-2016 FU Beckettforiden FX We acknowledge Statens Serum Institute and especially Soren Anker Uldum for making the microbiological data available to us. We thank Henrik C. Schonheyder for suggestions with the manuscript. The study was financially supported by Beckettforiden. NR 14 TC 7 Z9 9 U1 1 U2 3 PU TAYLOR & FRANCIS AS PI OSLO PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY SN 0036-5548 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PY 2009 VL 41 IS 6-7 BP 425 EP 432 DI 10.1080/00365540902946536 PG 8 WC Infectious Diseases SC Infectious Diseases GA 478JF UT WOS:000268583000005 PM 19424933 ER PT J AU Corrales-Medina, VE Fatemi, O Serpa, J Valayam, J Bozkurt, B Madjid, M Musher, DM AF Corrales-Medina, Vicente E. Fatemi, Omid Serpa, Jose Valayam, Josemon Bozkurt, Biykem Madjid, Mohammad Musher, Daniel M. TI The association between Staphylococcus aureus bacteremia and acute myocardial infarction SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID RECENT RESPIRATORY-INFECTION; ACUTE CORONARY SYNDROME; CARDIOVASCULAR-DISEASE; HEART-DISEASE; RISK; PREVENTION; INFLUENZA; VACCINATION; PNEUMONIA AB We evaluated a possible association between S. aureus bacteremia (SAB) and the occurrence of myocardial infarction (MI) in 588 patients using the self-controlled case series method. SAB increased the risk for MI 35-fold in the 2 d after recognition of this infection (IRR = 35.3; CI 16.7-74.7). C1 [Corrales-Medina, Vicente E.; Valayam, Josemon; Musher, Daniel M.] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Bozkurt, Biykem] Michael E DeBakey Vet Affairs Med Ctr, Cardiol Sect, Houston, TX 77030 USA. [Corrales-Medina, Vicente E.; Fatemi, Omid; Serpa, Jose; Bozkurt, Biykem; Madjid, Mohammad; Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Madjid, Mohammad] Univ Texas Hlth Sci Ctr, Texas Heart Inst, Houston, TX USA. RP Corrales-Medina, VE (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Room 4B-370, Houston, TX 77030 USA. EM vfmedina@bcm.edu OI Corrales-Medina, Vicente/0000-0002-9691-491X FU VA Menit Review Program FX This study was funded in part by the VA Menit Review Program (D.M.M). NR 23 TC 12 Z9 12 U1 0 U2 0 PU TAYLOR & FRANCIS AS PI OSLO PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY SN 0036-5548 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PY 2009 VL 41 IS 6-7 BP 511 EP 514 DI 10.1080/00365540902913460 PG 4 WC Infectious Diseases SC Infectious Diseases GA 478JF UT WOS:000268583000018 PM 19396667 ER PT J AU Minces, LR Ho, KS Veldkamp, PJ Clancy, CJ AF Minces, Lucio R. Ho, Ken S. Veldkamp, Peter J. Clancy, Cornelius J. TI Candida rugosa: a distinctive emerging cause of candidaemia. A case report and review of the literature SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID BLOOD-STREAM INFECTIONS; UNITED-STATES; FUNGEMIA; SURVEILLANCE; RESISTANCE; HOSPITALS; MASTITIS; PATHOGEN; OUTBREAK; ALBICANS AB Candida rugosa is a rare cause of candidaemia, but important to recognize because of frequent azole-resistance and its association with catheters and total parenteral nutrition. Recommended therapy is an echinocandin or amphotericin, and catheter discontinuation. Fluconazole might be substituted based on susceptibility testing and a clinical response to initial therapy. C1 [Minces, Lucio R.; Ho, Ken S.; Veldkamp, Peter J.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Med Ctr, Div Infect Dis, Pittsburgh, PA 15213 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Minces, LR (reprint author), Univ Pittsburgh, Dept Internal Med, Med Ctr, Div Infect Dis, 3601 5th Ave,Suite 3A, Pittsburgh, PA 15213 USA. EM mincesL2@upmc.edu NR 18 TC 12 Z9 12 U1 1 U2 1 PU TAYLOR & FRANCIS AS PI OSLO PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY SN 0036-5548 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PY 2009 VL 41 IS 11-12 BP 892 EP 897 DI 10.3109/00365540903161531 PG 6 WC Infectious Diseases SC Infectious Diseases GA 535MZ UT WOS:000272974600017 PM 19922077 ER PT J AU Barch, DM Carter, CS Arnsten, A Buchanan, RW Cohen, JD Geyer, M Green, MF Krystal, JH Nuechterlein, K Robbins, T Silverstein, S Smith, EE Strauss, M Wykes, T Heinssen, R AF Barch, Deanna M. Carter, Cameron S. Arnsten, Amy Buchanan, Robert W. Cohen, Jonathan D. Geyer, Mark Green, Michael F. Krystal, John H. Nuechterlein, Keith Robbins, Trevor Silverstein, Steven Smith, Edward E. Strauss, Milton Wykes, Til Heinssen, Robert TI Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting SO SCHIZOPHRENIA BULLETIN LA English DT Article ID IMPROVE COGNITION; SCHIZOPHRENIA; TARGETS; ENHANCEMENT; RECEPTORS; DEFICITS; AGONISTS; TASKS; SIZE AB This overview describes the goals and objectives of the third conference conducted as part of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. This third conference was focused on selecting specific paradigms from cognitive neuroscience that measured the constructs identified in the first CNTRICS meeting, with the goal of facilitating the translation of these paradigms into use in clinical trials contexts. To identify such paradigms, we had an open nomination process in which the field was asked to nominate potentially relevant paradigms and to provide information on several domains relevant to selecting the most promising tasks for each construct (eg, construct validity, neural bases, psychometrics, availability of animal models). Our goal was to identify 1-2 promising tasks for each of the 11 constructs identified at the first CNTRICS meeting. In this overview article, we describe the on-line survey used to generate nominations for promising tasks, the criteria that were used to select the tasks, the rationale behind the criteria, and the ways in which breakout groups worked together to identify the most promising tasks from among those nominated. This article serves as an introduction to the set of 6 articles included in this special issue that provide information about the specific tasks discussed and selected for the constructs from each of 6 broad domains (working memory, executive control, attention, long-term memory, perception, and social cognition). C1 [Barch, Deanna M.] Washington Univ, St Louis, MO 63130 USA. [Carter, Cameron S.] Univ Calif Davis, Davis, CA 95616 USA. [Arnsten, Amy; Krystal, John H.] Yale Univ, New Haven, CT USA. [Buchanan, Robert W.] Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA. [Cohen, Jonathan D.] Princeton Univ, Princeton, NJ 08544 USA. [Geyer, Mark] Univ Calif San Diego, San Diego, CA 92103 USA. [Green, Michael F.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Nuechterlein, Keith] Univ Calif Los Angeles, Los Angeles, CA USA. [Robbins, Trevor] Univ Cambridge, Cambridge, England. [Silverstein, Steven] Univ Med & Dent New Jersey, Rutgers, NJ USA. [Smith, Edward E.] Columbia Univ, New York, NY USA. [Strauss, Milton] Univ New Mexico, Albuquerque, NM USA. [Wykes, Til] Kings Coll London, Inst Psychiat, London, England. [Heinssen, Robert] NIMH, Bethesda, MD 20892 USA. RP Barch, DM (reprint author), Washington Univ, St Louis, MO 63130 USA. EM dbarch@artsci.wustl.edu RI Wykes, Til/B-7894-2008; Wykes, Til/B-3812-2011; Barch, Deanna/G-8638-2013 OI Wykes, Til/0000-0002-5881-8003; FU National Institute of Mental Health (NIMH); Robert Wood Johnson Foundation; National Alliance for Research on Schizophrenia and Depression (NARSAD); McDonnell Foundation; National Institute of Drugs and Alcohol; US Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center; Janssen; Pfizer; GSK Inc FX We would also like to thank Jody Conrad, Carol Cox, and Deb Tussing, whose efforts have been invaluable in the CNTRICS process. Financial Disclosures: Carter receives funding from the National Institute of Mental Health (NIMH), the Robert Wood Johnson Foundation, and National Alliance for Research on Schizophrenia and Depression (NARSAD). Dr Carter has served as a consultant for Pfizer, Eli Lilly, and Roche. Barch receives funding from the NIMH, the McDonnell Foundation, and NARSAD. Dr Buchanan is currently a Data Safety and Management Board (DSMB) member for Pfizer and in the past has served as a DSMB member for Wyeth. He has served as a consultant for: Pfizer, Roche, Memory, GlaxoSmithKline, Astra-Zeneca, Solvay, Sanofi-Aventis, and Organon and has received study medications from Janssen and Ortho-McNeil Neurologics. Dr Geyer has received consulting compensation from Abbott, Acadia, Addex, Amgen, AstraZeneca, Bristol-Myers Squibb, Jazz, Organon, Nura, San Diego Instruments, Serono, and Wyeth-Ayerst. Dr Geyer also has research grant support from National Institute of Drugs and Alcohol, NIMH, and the US Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center. Dr Green received funding form the NIMH and serves as a consultant to Amgen, Acadia, Astellas, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Eli Lilly, Lundbeck, Memory Pharmaceuticals, Otsuka Pharmaceutical, Sanofi-Aventis Pharmaceuticals, and Solvay. Dr Krystal receives research funding from the NIMH and has served as an advisor or consultant for AstraZeneca Pharmaceuticals; LP Bristol-Myers Squibb; Cypress Bioscience, Inc; Eli Lilly and Co; Forest Laboratories; GlaxoSmithKline; HoustonPharma; Lohocla Research Corporation; Merz Pharmaceuticals; Organon Pharmaceuticals; Pfizer Pharmaceuticals; Tetragenex Pharmaceuticals; and Transcept Pharmaceuticals, Inc. Dr Nuechterlein has received research funding from the NIMH and from Janssen, L. P., and has served as a consultant for Janssen, L. P. Dr Robbins is a stockholder in CeNeS and has share options in Cambridge Cognition. He has served as a consultant to Eli Lilly, GSK, Wyeth, and Allon and has received research funding from Pfizer, GSK Inc and received speaking honoraria from Merck, Sharp and Dohme, Lundbeck, Cephalon, and Cortex. Dr Silverstein Medical Research Institute, Janssen, and AstraZeneca. Dr Strauss, Dr Heinssen, Dr Smith, and Dr Wykes reported no biomedical financial interests or conflicts of interest. Dr Cohen receives research funding from the NIMH. NR 17 TC 73 Z9 74 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2009 VL 35 IS 1 BP 109 EP 114 DI 10.1093/schbul/sbn163 PG 6 WC Psychiatry SC Psychiatry GA 383OK UT WOS:000261682700014 PM 19023126 ER PT J AU Green, MF Butler, PD Chen, Y Geyer, MA Silverstein, S Wynn, JK Yoon, JH Zemon, V AF Green, Michael F. Butler, Pamela D. Chen, Yue Geyer, Mark A. Silverstein, Steven Wynn, Jonathan K. Yoon, Jong H. Zemon, Vance TI Perception Measurement in Clinical Trials of Schizophrenia: Promising Paradigms From CNTRICS SO SCHIZOPHRENIA BULLETIN LA English DT Review ID LATERAL GENICULATE-NUCLEUS; EVENT-RELATED POTENTIALS; PRIMARY VISUAL-CORTEX; MACAQUE V1 NEURONS; MISMATCH NEGATIVITY GENERATION; PREPULSE INHIBITION DEFICITS; SENSORIMOTOR GATING DEFICITS; CONTOUR INTEGRATION DEFICITS; AUDITORY SENSORY MEMORY; RETINAL GANGLION-CELLS AB The third meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) focused on selecting promising measures for each of the cognitive constructs selected in the first CNTRICS meeting. In the domain of perception, the 2 constructs of interest were gain control and visual integration. CNTRICS received 5 task nominations for gain control and three task nominations for visual integration. The breakout group for perception evaluated the degree to which each of these tasks met prespecified criteria. For gain control, the breakout group for perception believed that 2 of the tasks (prepulse inhibition of startle and mismatch negativity) were already mature and in the process of being incorporated into multisite clinical trials. However, the breakout group recommended that steady-state visual-evoked potentials be combined with contrast sensitivity to magnocellular vs parvocellular biased stimuli and that this combined task and the contrast-contrast effect task be recommended for translation for use in clinical trial contexts in schizophrenia research. For visual integration, the breakout group recommended the Contour Integration and Coherent Motion tasks for translation for use in clinical trials. This manuscript describes the ways in which each of these tasks met the criteria used by the breakout group to evaluate and recommend tasks for further development. C1 [Green, Michael F.; Wynn, Jonathan K.] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA 90095 USA. [Green, Michael F.; Wynn, Jonathan K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Butler, Pamela D.] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA. [Butler, Pamela D.] NYU, Sch Med, Dept Psychiat, New York, NY USA. [Butler, Pamela D.] NYU, Cognit Neurosci Program, New York, NY USA. [Chen, Yue] Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, Belmont, MA 02178 USA. [Geyer, Mark A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Silverstein, Steven] Univ Behav HealthCare, Piscataway, NJ USA. [Silverstein, Steven] Robert Wood Johnson Med Sch, Piscataway, NJ USA. [Yoon, Jong H.] Univ Calif Davis, Dept Psychiat, Davis, CA 95616 USA. [Zemon, Vance] Yeshiva Univ, Ferkauf Grad Sch Psychol, Bronx, NY USA. RP Green, MF (reprint author), Univ Calif Los Angeles, Semel Inst, Los Angeles, CA 90095 USA. EM mgreen@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU National Institute of Mental Health (NIMH); Department of Veterans Affairs (VA) [MH43292, MH66374, MH61824]; National Institute of Drug Abuse (NIDA) [DA02925]; US Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center; Stanley Medical Research Institute; Janssen; AstraZeneca FX National Institute of Mental Health (NIMH) and the Department of Veterans Affairs (VA) to M. F. G. MH43292 and J.K.W.; NIMH to P. D. B., MH66374 Y.C., MH61824 and J.H.Y.; consulting compensation from Abbott, Acadia, Addex, Amgen, AstraZeneca, Bristol-Myers Squibb, Jazz, Organon, Nura, San Diego Instruments, Serono, and Wyeth-Ayerst to M. A. G.; MH52885 research grant support from National Institute of Drug Abuse (NIDA DA02925, NIMH, and the US Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center to M. A. G.; NIMH, NARSAD, Stanley Medical Research Institute, Janssen, and AstraZeneca to S. S. M. F. G. serves as a consultant to Amgen, Acadia, Astellas, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Eli Lilly, Lundbeck, Memory Pharmaceuticals, Otsuka Pharmaceutical, Sanofi-Aventis Pharmaceuticals, and Solvay. NR 172 TC 62 Z9 62 U1 2 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2009 VL 35 IS 1 BP 163 EP 181 DI 10.1093/schbul/sbn156 PG 19 WC Psychiatry SC Psychiatry GA 383OK UT WOS:000261682700018 PM 19023123 ER PT J AU Kee, KS Horan, WR Salovey, P Kern, RS Sergi, MJ Fiske, AP Lee, JH Subotnik, KL Nuechterlein, K Sugar, CA Green, MF AF Kee, Kimmy S. Horan, William R. Salovey, Peter Kern, Robert S. Sergi, Mark J. Fiske, Alan P. Lee, Junghee Subotnik, Kenneth L. Nuechterlein, Keith Sugar, Catherine A. Green, Michael F. TI Emotional intelligence in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Emotional intelligence; Emotion processing; Social cognition ID FACIAL-AFFECT RECOGNITION; SOCIAL COGNITION; BEHAVIOR; PERFORMANCE; MEDIATOR; PSYCHOPATHOLOGY; SYMPTOMATOLOGY; NEUROSCIENCE; PERSONALITY; PERCEPTION AB Background: Deficits in emotion perception have been extensively documented in schizophrenia and are associated with poor psychosocial functioning. However, little is known about other aspects of emotion processing that are critical for adaptive functioning. The current study assessed schizophrenia patients' performance on a theoretically-based, well-validated, multidimensional measure of emotional intelligence, the Mayer-Salovey-Caruso Emotional Intelligence Test (Mayer, J.D., Salovey, P., Caruso, D.R., 2002. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT): User's Manual. Multi-Health Systems, Inc., Toronto, Ontario). Methods: 50 schizophrenia outpatients and 39 non-psychiatric controls completed the MSCEIT, a performance measure comprised of subtests that assess four components (branches) of emotional intelligence: Identifying, Using, Understanding, and Managing Emotions. Among patients, associations between MSCEIT scores and measures of clinical symptoms as well as functional outcome were evaluated. Results: The MSCEIT demonstrated good psychometric properties in both groups. Schizophrenia patients performed significantly worse than controls on the total MSCEIT score, and on three of the four subtests: Identifying, Understanding, and Managing Emotions. Among patients, lower MSCEIT scores significantly correlated with higher negative and disorganized symptoms, as well as worse community functioning. Conclusions: The MSCEIT is a useful tool for investigating emotion processing in schizophrenia. Individuals with schizophrenia demonstrate deficits across multiple domains of emotion processing. These deficits have significant links with clinical symptoms of schizophrenia and with how patients function in their daily lives. Further research is required to understand the links between emotional intelligence, clinical symptoms, and functional outcome in schizophrenia. (c) 2008 Elsevier B.V. All rights reserved. C1 [Kee, Kimmy S.; Horan, William R.; Kern, Robert S.; Sergi, Mark J.; Lee, Junghee; Green, Michael F.] VA Greater Angeles Healthcare Syst, VISN22, MIRECC, Los Angeles, CA 90073 USA. [Kee, Kimmy S.] Calif State Univ Channel Islands, Psychol Program, Camarillo, CA USA. [Kee, Kimmy S.; Horan, William R.; Kern, Robert S.; Lee, Junghee; Subotnik, Kenneth L.; Nuechterlein, Keith; Green, Michael F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Salovey, Peter] Yale Univ, Yale Coll Deans Off, New Haven, CT 06520 USA. [Salovey, Peter] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Sergi, Mark J.] Calif State Univ Northridge, Dept Psychol, Northridge, CA 91330 USA. [Fiske, Alan P.] Univ Calif Los Angeles, Dept Anthropol, Ctr Culture Brain & Dev, Los Angeles, CA 90024 USA. [Fiske, Alan P.] Univ Calif Los Angeles, Ctr Behav Evolut & Culture, Los Angeles, CA 90024 USA. [Nuechterlein, Keith] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. RP Kee, KS (reprint author), VA Greater Angeles Healthcare Syst, VISN22, MIRECC, 11301 Wilshire Blvd,MIRECC 210A,Bldg 210, Los Angeles, CA 90073 USA. EM kee@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU National Institute of Mental Health Center [P50 MH 66586] FX Funding for this project was supported by the National Institute of Mental Health Center Grant P50 MH 66586 (K. Nuechterlein, P.I.) The authors wish to thank Mike DeGroot, Robin Kite, Jeff Nishii, and Samantha Swain for their assistance in data collection and data management. NR 67 TC 45 Z9 49 U1 3 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 2009 VL 107 IS 1 BP 61 EP 68 DI 10.1016/j.schres.2008.08.016 PG 8 WC Psychiatry SC Psychiatry GA 404KW UT WOS:000263151500008 PM 18805674 ER PT J AU Gutierrez, PM Osman, A AF Gutierrez, Peter M. Osman, Augustine TI Getting the Best Return on Your Screening Investment: An Analysis of the Suicidal Ideation Questionnaire and Reynolds Adolescent Depression Scale SO SCHOOL PSYCHOLOGY REVIEW LA English DT Article ID PREVENTION PROGRAMS; BEHAVIOR; SCHOOL; YOUTH; ISSUES; RECOMMENDATIONS; INTERVIEW; VALIDITY; CHILDREN AB Data from 64 adolescent inpatients admitted for serious suicidal ideation, 50 adolescent inpatients admitted following a suicide attempt, and 56 randomly selected high school control participants were used to evaluate the sensitivity, specificity, positive predictive value, and negative predictive value of the Suicidal Ideation Questionnaire (SIQ) and the Reynolds Adolescent Depression Scale-2nd Edition (RADS-2). The purpose of the study was to provide information necessary for selecting assessment tools to use in large-scale screenings of high school students for suicide risk. The hypothesis that a combination of mean scores on the two measures and critical item scores would provide the best clinical utility was partially supported. The SIQ was found to be very useful in discriminating between the study groups, whereas the RADS-2 did not perform as expected. The fewest false negatives would result from relying on RADS-2 scale scores >= 63 and SIQ scale scores >= 14. However, the parsimonious and hence most cost-effective approach would be to rely on SIQ scale scores >= 14 in combination with SIQ critical Items 2, 3, and 4 for screening purposes. C1 [Gutierrez, Peter M.] Denver VA Med Ctr, MIRECC, Denver, CO 80220 USA. [Osman, Augustine] Univ Texas San Antonio, San Antonio, TX USA. RP Gutierrez, PM (reprint author), Denver VA Med Ctr, MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM peter.gutierrez@va.gov OI Gutierrez, Peter/0000-0001-8981-8404 NR 39 TC 12 Z9 12 U1 2 U2 6 PU NATL ASSOC SCHOOL PSYCHOLOGISTS PI BETHESDA PA 4340 EAST WEST HWY, STE 402, BETHESDA, MD 20814 USA SN 0279-6015 J9 SCHOOL PSYCHOL REV JI Sch. Psychol. Rev. PY 2009 VL 38 IS 2 BP 200 EP 217 PG 18 WC Psychology, Educational SC Psychology GA 462MV UT WOS:000267358400004 ER PT J AU Kutner, NG Johansen, KL AF Kutner, Nancy G. Johansen, Kirsten L. TI Targeting Inactivity, Falls and Mobility Deficits SO SEMINARS IN DIALYSIS LA English DT Editorial Material ID HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; WOMENS HEALTH; FRAILTY; OLDER; INTERVENTIONS; PHENOTYPE; MORTALITY; EXERCISE; TIME C1 [Kutner, Nancy G.] Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. RP Kutner, NG (reprint author), Emory Univ, Dept Rehabil Med, 1441 Clifton Rd NE, Atlanta, GA 30322 USA. EM nkutner@emory.edu NR 20 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD JAN-FEB PY 2009 VL 22 IS 1 BP 34 EP 36 DI 10.1111/j.1525-139X.2008.00509.x PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 408WT UT WOS:000263467000010 ER PT J AU Li, YH Xiang, M Vodovotz, Y Billiar, TR Wilson, MA Fan, J AF Li, Yuehua Xiang, Meng Vodovotz, Yoram Billiar, Timothy R. Wilson, Mark A. Fan, Jie TI ROLE OF HMGB1-TLR2 SIGNALING IN HEMORRHAGIC SHOCK-AUGMENTED ICAM-1 EXPRESSION IN LUNG ENDOTHELIAL CELLS SO SHOCK LA English DT Meeting Abstract CT 13th Congress of the European-Shock-Society CY SEP 24-26, 2009 CL Lisbon, PORTUGAL SP European Shock Soc C1 [Li, Yuehua; Xiang, Meng; Vodovotz, Yoram; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15240 USA. [Wilson, Mark A.; Fan, Jie] VA Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1073-2322 J9 SHOCK JI Shock PY 2009 VL 32 BP 10 EP 10 PG 1 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA 486UV UT WOS:000269226200041 ER PT J AU Chakravorty, S Oslin, D Witte, LM Cardillo, C Kuna, ST AF Chakravorty, S. Oslin, D. Witte, L. M. Cardillo, C. Kuna, S. T. TI SLEEP QUALITY IN RECENTLY SOBER ALCOHOLICS SO SLEEP LA English DT Meeting Abstract CT 23rd Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 06-11, 2009 CL Seattle, WA SP Associated Profess Sleep Soc C1 [Chakravorty, S.; Oslin, D.; Witte, L. M.; Cardillo, C.; Kuna, S. T.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chakravorty, S.; Oslin, D.; Kuna, S. T.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2009 VL 32 MA 1119 BP A365 EP A365 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FT UT WOS:000265542001466 ER PT J AU DaSilva, JK Madan, V Lei, Y Laitman, BM Mann, GL Gehrman, PR Tejani-Butt, S Ross, RJ Morrison, AR AF DaSilva, J. K. Madan, V Lei, Y. Laitman, B. M. Mann, G. L. Gehrman, P. R. Tejani-Butt, S. Ross, R. J. Morrison, A. R. TI FEAR-CONDITIONED ALTERATIONS IN REM PHASIC ACTIVITY MEASURED BY MUSCLE TWITCHES IN STRESS-SENSITIVE WISTAR-KYOTO (WKY) VERSUS WISTAR (WIS) RATS SO SLEEP LA English DT Meeting Abstract CT 23rd Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 06-11, 2009 CL Seattle, WA SP Associated Profess Sleep Soc C1 [DaSilva, J. K.; Lei, Y.; Tejani-Butt, S.] Univ Sci Philadelphia, Dept Pharmaceut Sci, Philadelphia, PA USA. [Madan, V; Laitman, B. M.; Mann, G. L.; Ross, R. J.; Morrison, A. R.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA. [Gehrman, P. R.; Ross, R. J.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Ross, R. J.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2009 VL 32 MA 0068 BP A22 EP A22 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FT UT WOS:000265542000070 ER PT J AU Fiorentino, L Martin, JL Josephson, K Jouldjian, S Alessi, CA AF Fiorentino, L. Martin, J. L. Josephson, K. Jouldjian, S. Alessi, C. A. TI SLEEP DISTURBANCE AMONG OLDER ADULTS RESIDING IN ASSISTED LIVING FACILITIES SO SLEEP LA English DT Meeting Abstract CT 23rd Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 06-11, 2009 CL Seattle, WA SP Associated Profess Sleep Soc C1 [Fiorentino, L.] Univ Calif Los Angeles, Semel Inst Neurosci & Behav, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. [Fiorentino, L.; Martin, J. L.; Josephson, K.; Jouldjian, S.; Alessi, C. A.] Vet Adm Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, North Hills, CA USA. [Martin, J. L.; Alessi, C. A.] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2009 VL 32 MA 0359 BP A119 EP A119 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FT UT WOS:000265542000361 ER PT J AU Fiorentino, L Martin, JL Josephson, K Jouldjian, S Alessi, CA AF Fiorentino, L. Martin, J. L. Josephson, K. Jouldjian, S. Alessi, C. A. TI SLEEP DISTURBANCE PREDICTS DEPRESSIVE SYMPTOMS AND FUNCTIONAL DECLINE AMONG OLDER RESIDENTS IN ASSISTED LIVING FACILITIES SO SLEEP LA English DT Meeting Abstract CT 23rd Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 06-11, 2009 CL Seattle, WA SP Associated Profess Sleep Soc C1 [Fiorentino, L.] Univ Calif Los Angeles, Semel Inst Neurosci & Behav, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. [Fiorentino, L.; Martin, J. L.; Josephson, K.; Jouldjian, S.; Alessi, C. A.] Vet Adm Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA. [Martin, J. L.; Alessi, C. A.] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2009 VL 32 MA 345 BP A114 EP A115 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FT UT WOS:000265542000347 ER PT J AU Kosenko, P Lyamin, O Belyaev, E Kibalnikov, A Lapierre, J Mukhametov, L Siegel, J AF Kosenko, P. Lyamin, O. Belyaev, E. Kibalnikov, A. Lapierre, J. Mukhametov, L. Siegel, J. TI SELECTIVE REM SLEEP DEPRIVATION OF THE NORTHERN FUR SEAL ON LAND SO SLEEP LA English DT Meeting Abstract CT 23rd Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 06-11, 2009 CL Seattle, WA SP Associated Profess Sleep Soc C1 [Kosenko, P.; Lyamin, O.; Belyaev, E.; Mukhametov, L.] Utrish Dolphinarium Ltd, Moscow, Russia. [Lyamin, O.; Lapierre, J.; Siegel, J.] Dept Psychiat, North Hills, CA USA. [Lyamin, O.; Lapierre, J.; Siegel, J.] VA GLAHS Sepulveda, North Hills, CA USA. [Lyamin, O.; Kibalnikov, A.] Russian Acad Sci, So Sci Ctr, Rostov Na Donu, Russia. NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2009 VL 32 MA 04 BP A2 EP A2 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FT UT WOS:000265542000006 ER PT J AU Laitman, BM DaSilva, JK Tejani-Butt, S Ross, RJ Morrison, AR AF Laitman, B. M. DaSilva, J. K. Tejani-Butt, S. Ross, R. J. Morrison, A. R. TI REM HEART RATE CHANGES IN WISTAR-KYOTO (WKY) VERSUS WISTAR (WIS) RATS SUGGEST NOREPINEPHRINE (NE) SURGES AS A POSSIBLE CAUSE OF REM FRAGMENTATION SO SLEEP LA English DT Meeting Abstract CT 23rd Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 06-11, 2009 CL Seattle, WA SP Associated Profess Sleep Soc C1 [Laitman, B. M.; Ross, R. J.; Morrison, A. R.] Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA. [DaSilva, J. K.; Tejani-Butt, S.] Univ Sci Philadelphia, Philadelphia, PA USA. [Ross, R. J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Ross, R. J.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2009 VL 32 MA 0036 BP A12 EP A12 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FT UT WOS:000265542000038 ER PT J AU Martin, J Fiorentino, L Jouldjian, S Josephson, KR Alessi, CA AF Martin, J. Fiorentino, L. Jouldjian, S. Josephson, K. R. Alessi, C. A. TI DOES POOR SLEEP AMONG OLDER ADULTS DURING INPATIENT POST-ACUTE REHABILITATION PREDICT PERSISTENT SLEEP DISTURBANCE? SO SLEEP LA English DT Meeting Abstract CT 23rd Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 06-11, 2009 CL Seattle, WA SP Associated Profess Sleep Soc C1 [Martin, J.; Jouldjian, S.; Alessi, C. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, J.; Fiorentino, L.; Josephson, K. R.; Alessi, C. A.] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2009 VL 32 MA 0366 BP A121 EP A122 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FT UT WOS:000265542000368 ER PT J AU Ross, RJ Gehrman, P Cook, JM Harb, GC Gamble, GM AF Ross, R. J. Gehrman, P. Cook, J. M. Harb, G. C. Gamble, G. M. TI RANDOMIZED CONTROLLED TRIAL OF IMAGERY REHEARSAL FOR POSTTRAUMATIC NIGHTMARES IN VIETNAM VETERANS SO SLEEP LA English DT Meeting Abstract CT 23rd Annual Meeting of the Associated-Professional-Sleep-Societies CY JUN 06-11, 2009 CL Seattle, WA SP Associated Profess Sleep Soc C1 [Ross, R. J.; Gehrman, P.; Harb, G. C.; Gamble, G. M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Ross, R. J.; Gehrman, P.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Cook, J. M.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2009 VL 32 MA 1066 BP A348 EP A348 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 438FT UT WOS:000265542001413 ER PT J AU Alexander, MS Biering-Sorensen, F Bodner, D Brackett, NL Cardenas, D Charlifue, S Creasey, G Dietz, V Ditunno, J Donovan, W Elliott, SL Estores, I Graves, DE Green, B Gousse, A Jackson, AB Kennelly, M Karlsson, AK Krassioukov, A Krogh, K Linsenmeyer, T Marino, R Mathias, CJ Perkash, I Sheel, AW Shilero, G Schurch, B Sonksen, J Stiens, S Wecht, J Wuermser, LA Wyndaele, JJ AF Alexander, M. S. Biering-Sorensen, F. Bodner, D. Brackett, N. L. Cardenas, D. Charlifue, S. Creasey, G. Dietz, V. Ditunno, J. Donovan, W. Elliott, S. L. Estores, I. Graves, D. E. Green, B. Gousse, A. Jackson, A. B. Kennelly, M. Karlsson, A-K Krassioukov, A. Krogh, K. Linsenmeyer, T. Marino, R. Mathias, C. J. Perkash, I. Sheel, A. W. Shilero, G. Schurch, B. Sonksen, J. Stiens, S. Wecht, J. Wuermser, L. A. Wyndaele, J-J TI International standards to document remaining autonomic function after spinal cord injury SO SPINAL CORD LA English DT Review DE autonomic nervous system; spinal cord injury; human; international standards ID URINARY-TRACT FUNCTION; FEMALE SEXUAL FUNCTION; DATA SET; BRAIN ACTIVATION; NERVOUS-SYSTEM; DYSFUNCTION; PATHWAYS; HYPERRESPONSIVENESS; DYSREFLEXIA; AROUSAL AB Study design: Experts opinions consensus. Objective: To develop a common strategy to document remaining autonomic neurologic function following spinal cord injury (SCI). Background and Rationale: The impact of a specific SCI on a person's neurologic function is generally described through use of the International Standards for the Neurological Classification of SCI. These standards document the remaining motor and sensory function that a person may have; however, they do not provide information about the status of a person's autonomic function. Methods: Based on this deficiency, the American Spinal Injury Association (ASIA) and the International Spinal Cord Society (ISCoS) commissioned a group of international experts to develop a common strategy to document the remaining autonomic neurologic function. Results: Four subgroups were commissioned: bladder, bowel, sexual function and general autonomic function. On-line communication was followed by numerous face to face meetings. The information was then presented in a summary format at a course on Measurement in Spinal Cord Injury, held on June 24, 2006. Subsequent to this it was revised online by the committee members, posted on the websites of both ASIA and ISCoS for comment and re-revised through webcasts. Topics include an overview of autonomic anatomy, classification of cardiovascular, respiratory, sudomotor and thermoregulatory function, bladder, bowel and sexual function. Conclusion: This document describes a new system to document the impact of SCI on autonomic function. Based upon current knowledge of the neuroanatomy of autonomic function this paper provides a framework with which to communicate the effects of specific spinal cord injuries on cardiovascular, broncho-pulmonary, sudomotor, bladder, bowel and sexual function. C1 [Krassioukov, A.] Univ British Columbia, Dept Med, ICORD, Vancouver, BC V6T 1Z4, Canada. [Alexander, M. S.; Jackson, A. B.] Univ Alabama, Birmingham, AL USA. [Biering-Sorensen, F.] Rigshosp, DK-2100 Copenhagen, Denmark. [Biering-Sorensen, F.] Univ Copenhagen, Copenhagen, Denmark. [Bodner, D.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Brackett, N. L.; Cardenas, D.; Gousse, A.] Univ Miami, Miami, FL USA. [Charlifue, S.] Craig Hosp, Englewood, CO USA. [Creasey, G.; Perkash, I.] Stanford Univ, Palo Alto, CA 94304 USA. [Dietz, V.; Schurch, B.] Univ Hosp Balgrist, Zurich, Switzerland. [Ditunno, J.; Marino, R.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Estores, I.] James A Haley VA Hosp, Tampa, FL USA. [Donovan, W.; Graves, D. E.] Baylor Coll Med, Houston, TX 77030 USA. [Green, B.] Shepherd Ctr, Atlanta, GA USA. [Kennelly, M.] Carolinas Healthcare, McKay Urol, Charlotte, NC USA. [Karlsson, A-K] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden. [Krogh, K.] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark. [Linsenmeyer, T.] Kessler Inst Rehabil, W Orange, NJ USA. [Mathias, C. J.] Imperial Coll Sch Med, St Marys Hosp, London, England. [Shilero, G.; Wecht, J.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Sonksen, J.] Univ Copenhagen, Herlev Hosp, Copenhagen, Denmark. [Stiens, S.] Vet Affairs Puget Sound Hlth Care, Seattle, WA USA. [Wuermser, L. A.] Mayo Clin, Rochester, MS USA. [Wyndaele, J-J] Univ Antwerp, Univ Antwerp Hosp, B-2020 Antwerp, Belgium. RP Krassioukov, A (reprint author), Univ British Columbia, Dept Med, ICORD, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada. EM krassioukov@icord.org OI Marino, Ralph/0000-0003-2670-4113 NR 42 TC 84 Z9 93 U1 1 U2 15 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 J9 SPINAL CORD JI Spinal Cord PD JAN PY 2009 VL 47 IS 1 BP 36 EP 43 DI 10.1038/sc.2008.121 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 392IS UT WOS:000262297000003 PM 18957962 ER PT J AU Paxinos, O Ghanayem, AJ Zindrick, MR Voronov, LI Havey, RM Carandang, G Hadjipavlou, A Patwardhan, AG AF Paxinos, Odysseas Ghanayem, Alexander J. Zindrick, Michael R. Voronov, Leonard I. Havey, Robert M. Carandang, Gerard Hadjipavlou, Alexander Patwardhan, Avinash G. TI Anterior Cervical Discectomy and Fusion With a Locked Plate and Wedged Graft Effectively Stabilizes Flexion-Distraction Stage-3 Injury in the Lower Cervical Spine A Biomechanical Study SO SPINE LA English DT Article DE cervical spine; flexion-distraction injury; trauma; facet dislocation; ACDF; preload; follower load ID BONE-MINERAL DENSITY; HUMAN CADAVERIC MODEL; FACET DISLOCATION; FRACTURE-DISLOCATIONS; FIXATION; REDUCTION; MANAGEMENT; CASPAR; SCREWS; LOAD AB Study Design. An in vitro three-dimensional (3D) flexibility test of human C3-C7 cervical spine specimens. Objective. To test the hypothesis that anterior cervical fusion with a wedged graft and a locked plate can effectively stabilize the cervical spine after complete anterior and posterior segmental ligamentous release. Summary of Background Data. Distraction-flexion Stage 3 injuries of the lower cervical spine (bilateral facet dislocations) are usually reduced under awake cranial traction. When the magnetic resonance imaging reveals a traumatic disc prolapse, anterior cervical discectomy and fusion (ACDF) is usually recommended. Most authors advise combining ACDF with posterior instrumentation to address the insufficiency of the posterior elements. However, there is clinical evidence that ACDF with a locked plate alone suffices for the treatment of these injuries, especially in young patients. Still, there are no biomechanical studies on the effect of a locked plate on the complete anterior and posterior ligamentous-deficient young cervical spine under physiologic preload. Methods. Eight fresh frozen human lower cervical spines (C3-C7) from young donors (age, 44.5 years; range, 21-63 years) were used. A 3D flexibility test was conducted using a moment of 0.8 Nm without preload. Flexion-extension was additionally tested using a moment of 1.5 Nm under 0 and 150 N follower preload. Spines were tested first intact, then after complete C5-C6 discectomy with posterior longitudinal ligament resection and ACDF with a wedged bone graft and a rigid locked plate, and finally after complete release of the supraspinous, interspinous, and intertransverse ligaments; the facet capsules; and ligamentum flavum. Results. When tested under 0.8 Nm moment without preload, complete posterior and anterior ligamentous release did not significantly increase the ROM of the ACDF construct in flexion-extension (P > 0.025), lateral bending (P > 0.025), and axial rotation (P > 0.025). When tested under 1.5 Nm moment with or without a compressive preload, the complete posterior and anterior ligamentous release did not significantly affect the ROM of the ACDF construct (P > 0.01). The application of preload significantly reduced the motion at the C5-C6 ACDF construct with ligamentous disruption in comparison with the motion in the absence of a preload (P < 0.01). Conclusion. Anterior cervical fusion with a wedged graft and a rigid constrained (locked) plate can effectively stabilize the nonosteoporotic cervical spine after complete posterior element injury when excessive ROM is prevented (for example, by the use of postoperative external immobilization). Even when the construct is subjected to higher moments, adequate stability can be achieved when physiologic preload is present. Osteoporosis and lack of sufficient preload due to poor neuromuscular control may affect long-term screw stability, and additional external immobilization may be needed until fusion matures. C1 [Paxinos, Odysseas; Ghanayem, Alexander J.; Zindrick, Michael R.; Voronov, Leonard I.; Havey, Robert M.; Patwardhan, Avinash G.] Loyola Univ, Dept Orthopaed Surg & Rehabil, Med Ctr, Maywood, IL 60153 USA. [Paxinos, Odysseas; Voronov, Leonard I.; Havey, Robert M.; Carandang, Gerard; Patwardhan, Avinash G.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Zindrick, Michael R.] Hinsdale Orthopaed Associates, Hinsdale, IL USA. [Hadjipavlou, Alexander] Univ Crete, Iraklion, Greece. RP Patwardhan, AG (reprint author), Loyola Univ, Dept Orthopaed Surg & Rehabil, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA. EM apatwar@lumc.edu NR 46 TC 10 Z9 15 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD JAN 1 PY 2009 VL 34 IS 1 BP E9 EP E15 DI 10.1097/BRS.0b013e318188386a PG 7 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 405YV UT WOS:000263261000019 PM 19127153 ER PT J AU Phillips, FM Tzermiadianos, MN Voronov, LI Havey, RM Carandang, G Renner, SM Rosler, DM Ochoa, JA Patwardhan, AG AF Phillips, Frank M. Tzermiadianos, Michael N. Voronov, Leonard I. Havey, Robert M. Carandang, Gerard Renner, Susan M. Rosler, David M. Ochoa, Jorge A. Patwardhan, Avinash G. TI Effect of the Total Facet Arthroplasty System after complete laminectomy-facetectomy on the biomechanics of implanted and adjacent segments SO SPINE JOURNAL LA English DT Review DE Lumbar spine; Facetectomy; Facet arthroplasty; ROM; Quality of motion ID LUMBAR SPINE; HYPOTHESIS; KINEMATICS; FUSION AB BACKGROUND CONTEXT: Lumbar fusion is traditionally used to restore stability after wide surgical decompression for spinal stenosis. The Total Facet Arthroplasty System (TFAS) is a motion-restoring implant suggested as an alternative to rigid fixation after complete facetectomy. PURPOSE: To investigate the effect of TFAS on the kinematics of the implanted and adjacent lumbar segments. STUDY DESIGN: Biomechanical in vitro study. METHODS: Nine human lumbar spines (L1 to sacrum) were tested in flexion-extension (+8 to -6 Nm), lateral bending (+/- 6 Nm), and axial rotation (+/- 5 Nm). Flexion-extension was tested under 400 N follower preload. Specimens were tested intact, after complete L3 laminectomy with L3-L4 facetectomy, after L3-L4 pedicle screw fixation, and after L3-L4 TFAS implantation. Range of motion (ROM) was assessed in all tested directions. Neutral zone and stiffness in flexion and extension were calculated to assess quality of motion. RESULTS: Complete laminectomy-facetectomy increased L3-L4 ROM compared with intact in flexion-extension (8.7 +/- 2.0 degrees to 12.2 +/- 3.2 degrees, p<.05) lateral bending (9.0 +/- 2.5 degrees to 12.6 +/- 3.2 degrees, p=.09), and axial rotation (3.8 +/- 2.7 degrees to 7.8 +/- 4.5 degrees p<.05). Pedicle screw fixation decreased ROM compared with intact, resulting in 1.7 +/- 0.5 degrees flexion-extension (p<.05), 3.3 +/- 1.4 degrees lateral bending (p<.05), and 1.8 +/- 0.6 degrees axial rotation (p=.09). TFAS restored intact ROM (p>.05) resulting in 7.9 +/- 2.1 degrees flexion-extension, 10.1 +/- 3.0 degrees lateral bending, and 4.7 +/- 1.6 degrees axial rotation. Fusion significantly increased the normalized ROM at all remaining lumbar segments, whereas TFAS implantation resulted in near-normal distribution of normalized ROM at the implanted and remaining lumbar segments. Flexion and extension stiffness in the high-flexibility zone decreased after facetectomy (p<.05) and increased after simulated fusion (p<.05). TFAS restored quality of motion parameters (load-displacement curves) to intact (p>.05). The quality of motion parameters for the whole lumbar spine mimicked L3-L4 segmental results. CONCLUSIONS: TEAS restored range and quality of motion at the operated segment to intact values and restored near-normal motion at the adjacent segments. (C) 2009 Elsevier Inc. All rights reserved. C1 [Patwardhan, Avinash G.] Loyola Univ, Med Ctr, Dept Orthoped Surg, Maywood, IL 60153 USA. [Phillips, Frank M.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Carandang, Gerard; Renner, Susan M.; Patwardhan, Avinash G.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Rosler, David M.; Ochoa, Jorge A.] Archus Orthoped Inc, Redmond, WA USA. RP Patwardhan, AG (reprint author), Loyola Univ, Med Ctr, Dept Orthoped Surg, 2160 S 1st Ave, Maywood, IL 60153 USA. EM apatwar@lumc.edu OI Ochoa, Jorge/0000-0003-1992-8143 FU Archus Orthopedics Inc. FX This study was funded by Archus Orthopedics Inc., a commercial entity. NR 13 TC 20 Z9 22 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 J9 SPINE J JI Spine Journal PD JAN PY 2009 VL 9 IS 1 BP 96 EP 102 DI 10.1016/j.spinee.2008.01.010 PG 7 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 393MX UT WOS:000262378500012 PM 18440280 ER PT J AU Primack, BA Kraemer, KL Fine, MJ Dalton, MA AF Primack, Brian A. Kraemer, Kevin L. Fine, Michael J. Dalton, Madeline A. TI Media Exposure and Marijuana and Alcohol Use Among Adolescents SO SUBSTANCE USE & MISUSE LA English DT Article DE alcohol; marijuana; mass media; entertainment media; adolescence; music; movies; television; video games; books ID RATED VIDEO GAMES; CANNABIS USE; SMOKING INITIATION; CIGARETTE-SMOKING; RISK; ASSOCIATION; TELEVISION; DRINKING; HEALTH; MUSIC AB We aimed to determine which media exposures are most strongly associated with marijuana and alcohol use among adolescents. In 2004, we surveyed 1,211 students at a large high school in suburban Pittsburgh regarding substance use, exposure to entertainment media, and covariates. Of the respondents, 52% were female, 8% were non-White, 27% reported smoking marijuana, and 60% reported using alcohol. They reported average exposure to 8.6 hr of media daily. In adjusted models, exposure to music was independently associated with marijuana use, but exposure to movies was independently associated with alcohol use. Implications, limitations, and suggestions for further research are discussed. C1 [Primack, Brian A.; Kraemer, Kevin L.; Fine, Michael J.] Univ Pittsburgh, Ctr Res Hlth Care, Sch Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.; Kraemer, Kevin L.; Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Dept Med, Sch Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Div Adolescent Med, Dept Pediat, Sch Med, Pittsburgh, PA 15213 USA. [Fine, Michael J.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Fine, Michael J.] VA Hlth Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Dalton, Madeline A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat, Hanover, NH 03756 USA. [Dalton, Madeline A.] Dartmouth Med Sch, Community Hlth Res Program, Hood Ctr Children & Families, Hanover, NH USA. RP Primack, BA (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, Sch Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu FU NCI NIH HHS [K07 CA114315, K07 CA114315-03]; NIAID NIH HHS [K24 AI001769] NR 58 TC 13 Z9 13 U1 3 U2 24 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1082-6084 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2009 VL 44 IS 5 BP 722 EP 739 AR PII 909746983 DI 10.1080/10826080802490097 PG 18 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA 434WK UT WOS:000265304600009 PM 19306219 ER PT J AU Harris, AHS Bryson, CL Sun, HL Blough, D Bradley, KA AF Harris, Alex H. S. Bryson, Chris L. Sun, Haili Blough, David Bradley, Katharine A. TI Alcohol Screening Scores Predict Risk of Subsequent Fractures SO SUBSTANCE USE & MISUSE LA English DT Article DE alcohol misuse; alcohol screening; fractures; risk factors; clinical markers ID PRIMARY-CARE PATIENTS; BONE-MINERAL DENSITY; HIP FRACTURE; HEALTH-STATUS; SELF-REPORTS; MEN; CONSUMPTION; OSTEOPOROSIS; MORTALITY; WOMEN AB The Alcohol Use Disorders Identification Test-Consumption (AUDIT-C; 0-12 points) was included on health surveys in a cohort (if 32,622 general medicine outpatients from seven US Department of Veterans Affairs (VA) hospitals. Cox proportional hazards models were used to estimate the risk of fracture (mean follow-up = 1.6 years) by AUDIT-C category After adjusting for confounders, AUDIT-C scores of 8-9 and 10-12 were associated with significantly increased risks for subsequent fractures, HR (95% CI) = 1.37 (1.03 to 1.83) and 1.79 (1.38 to 2.33) respectively. These results can be used to provide feedback to patients linking their alcohol screening scores to medical outcomes-a critical component of evidence-based brief counseling for alcohol misuse. The study's limitations are noted. C1 [Harris, Alex H. S.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat MC152, Menlo Pk, CA 94025 USA. [Bryson, Chris L.; Sun, Haili; Blough, David; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Harris, AHS (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat MC152, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Alexander.Harris2@va.gov NR 39 TC 20 Z9 20 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1082-6084 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2009 VL 44 IS 8 BP 1055 EP 1069 DI 10.1080/10826080802485972 PG 15 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA 478JA UT WOS:000268582500001 PM 19544147 ER PT J AU Miller, CS Woodson, J Howell, RT Shields, AL AF Miller, Christopher S. Woodson, Joshua Howell, Ryan T. Shields, Alan L. TI Assessing the Reliability of Scores Produced by the Substance Abuse Subtle Screening Inventory SO SUBSTANCE USE & MISUSE LA English DT Article DE The Substance Abuse Subtle Screening Inventory (SASSI); substance abuse scales; reliability induction; reliability generalization; meta-analysis ID PSYCHOMETRIC PROPERTIES; PSYCHOLOGY; ALCOHOL; SCALES; DISORDERS; JOURNALS AB The Substance Abuse Subtle Screening Inventory (SASSI) is a 10 scale indirect screening instrument used to detect substance use disorders. The current meta-analytic study described reliability reporting practices across 48 studies involving the SASSI. Reliability generalization methods were then employed to evaluate typical score reliability for the screening measure. Results showed approximately 73% of studies did not report reliability estimates. Analysis of data from the remaining studies revealed adequate reliability for the total scale (alpha = .87) and face valid, scales (FVA alpha = .88 and FVOD alpha = .92), but substantially lower reliability estimates for the indirect scales (range of alpha = .23-65). The study's findings underscore the need for improved reliability reporting for the SASSI and suggest cautious use of the measure, especially its indirect scales, as an indicator of problematic substance use/abuse in clinical settings. C1 [Miller, Christopher S.] VA Puget Sound Hlth Care Syst, Ctr Polytrauma Care, Seattle, WA 98101 USA. [Woodson, Joshua] E Tennessee State Univ, Johnson City, TN 37614 USA. [Howell, Ryan T.] San Francisco State Univ, San Francisco, CA 94132 USA. [Shields, Alan L.] Harvard Univ, E Tennessee State Univ, McLean Hosp, Sch Med, Belmont, MA 02178 USA. [Miller, Christopher S.; Shields, Alan L.] PRO Consulting, Pittsburgh, PA USA. RP Miller, CS (reprint author), VA Puget Sound Hlth Care Syst, Ctr Polytrauma Care, 1600 S Columbian Way, Seattle, WA 98101 USA. EM Christopher.Miller7@va.gov NR 40 TC 3 Z9 3 U1 3 U2 10 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1082-6084 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2009 VL 44 IS 8 BP 1090 EP 1100 DI 10.1080/10826080802486772 PG 11 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA 478JA UT WOS:000268582500003 PM 19544146 ER PT J AU Katzburg, JR Yano, EM Washington, DL Farmer, MM Yee, EFT Fu, S Trowell-Harris, I Sherman, SE AF Katzburg, Judith R. Yano, Elizabeth M. Washington, Donna L. Farmer, Melissa M. Yee, Ellen F. T. Fu, Steven Trowell-Harris, Irene Sherman, Scott E. TI Combining Women's Preferences and Expert Advice to Design a Tailored Smoking Cessation Program SO SUBSTANCE USE & MISUSE LA English DT Article DE women veterans; smoking cessation; tailored; consumer focus; expert panel ID VA HEALTH-CARE; GENDER-DIFFERENCES; FEMALE VETERANS; QUIT-SMOKING; TOBACCO; PREDICTORS; THERAPY; INTERVENTION; PREVENTION; DEPENDENCE AB We designed a patient-centered smoking cessation program for women in 2004/2005, incorporating women's preferences and expert opinion. Our four-step process included: (1) concept-development focus groups; (2) an expert panel; (3) concept-testing focus groups, and (4) a pilot study. Data analyses occurred in 2004-2007. The new program offered options: the traditional Veterans Health Administration (VA) male-dominated program was the least selected option in the pilot study. Patients can be effectively involved in program development. The study's implications and limitations are noted. This research (conducted in Los Angeles, California) was funded by the American Legacy Foundation with additional VA support. C1 [Katzburg, Judith R.; Sherman, Scott E.] Vet Affairs Greater Los Angeles HSR & D Ctr Excel, Sepulveda, CA USA. [Katzburg, Judith R.] Univ Calif Los Angeles, Johnson & Johnson Hlth Care Inst, Anderson Sch Management, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Yano, Elizabeth M.] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, VA HSR&D, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Yee, Ellen F. T.] New Mexico Vet Affairs Healthcare Syst, Womens Hlth Clin Albuquerque, Albuquerque, NM USA. [Yee, Ellen F. T.] Univ New Mexico, Albuquerque, NM 87131 USA. [Fu, Steven] Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Fu, Steven] Univ Minnesota, Sch Med, TTURC, Minneapolis, MN 55455 USA. [Trowell-Harris, Irene] Ctr Women Vet, Dept VA, Washington, DC USA. [Sherman, Scott E.] NYU, Sch Med, Geriatr Med Sect, New York, NY USA. [Sherman, Scott E.] Vet Affairs New York Harbor Healthcare Sys, New York, NY USA. RP Katzburg, JR (reprint author), Vet Affairs Greater Los Angeles HSR & D Ctr Excel, Sepulveda, CA USA. EM jkatzbur@ucla.edu OI Sherman, Scott/0000-0003-1752-7303 FU Veterans Affairs Greater Los Angeles Healthcare System; VA HSRD Center [012]; American Legacy Foundation; Agency for Healthcare Research FX We gratefully acknowledge the contributions of the following agencies: Veterans Affairs Greater Los Angeles Healthcare System and the VA HSR&D Center for the Study of Healthcare Provider Behavior for additional resources and support (Project # 012), American Legacy Foundation for funding this research project, and the Agency for Healthcare Research and Quality for funding Dr. Katzburg's postdoctoral fellowship which provided support during part of this project. NR 35 TC 6 Z9 6 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1082-6084 J9 SUBST USE MISUSE JI Subst. Use Misuse PY 2009 VL 44 IS 14 BP 2114 EP 2127 DI 10.3109/10826080902858433 PG 14 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA 545PO UT WOS:000273748500010 PM 20001698 ER PT J AU Tohamy, AE Eid, GM AF Tohamy, Aley Eldin Eid, George M. TI Laparoscopic reduction of small bowel intussusception in a 33-week pregnant gastric bypass patient: surgical technique and review of literature SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Intussusception; Gastric bypass; Pregnancy; Laparoscopy ID RETROGRADE INTUSSUSCEPTION; PREOPERATIVE DIAGNOSIS; ADULT INTUSSUSCEPTION; OBSTRUCTION; MANAGEMENT; PAIN C1 [Tohamy, Aley Eldin; Eid, George M.] Univ Pittsburgh, Med Ctr, Div Minimally Invas Surg, Pittsburgh, PA USA. [Eid, George M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Eid, GM (reprint author), Magee Womens Hosp, 300 Halket St, Pittsburgh, PA 15213 USA. EM eidgm@upmc.edu NR 22 TC 8 Z9 8 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD JAN-FEB PY 2009 VL 5 IS 1 BP 111 EP 115 DI 10.1016/j.soard.2008.09.008 PG 5 WC Surgery SC Surgery GA 400UW UT WOS:000262895700023 PM 19161938 ER PT B AU Marvizon, JC AF Marvizon, Juan Carlos BE Malcangio, M TI Opioidergic Transmission in the Dorsal Horn SO SYNAPTIC PLASTICITY IN PAIN LA English DT Article; Book Chapter ID RAT SPINAL-CORD; ENKEPHALIN-LIKE MATERIAL; FOOTSHOCK-INDUCED ANALGESIA; PRIMARY AFFERENT-FIBERS; PROTEIN-COUPLED RECEPTOR; CENTRAL-NERVOUS-SYSTEM; ROOT GANGLION NEURONS; SUBSTANCE-P RELEASE; METHYL-D-ASPARTATE; ANGIOTENSIN CONVERTING ENZYME AB The potent analgesia produced by opiate drugs is induced, at least in part, in the spinal cord. The three "classical" opioid receptors, mu, delta and kappa, are found in dorsal horn neurons and primary afferent terminals. Dorsal horn neurons expressing opioid receptors are mostly excitatory, and their inhibition by opioids decreases pain intensity. In primary afferents, opioid receptors inhibit the release of the pro-nociceptive neuropeptides substance P and CGRP. The spinal cord also contains "atypical" opioid receptors: the nociceptin receptor, the opioid growth factor receptor and toll-like receptors, which modulate pain in ways still not well understood. Enkephalins and dynorphins are the main opioid peptides in the dorsal horn, and are expressed by different neuronal Populations. Endorphins are not found in the dorsal horn, and recent Studies question whether endomorphins are indeed endogenous. Enkephalins and dynorphins are highly susceptible to peptidase degradation, which has prompted the use of peptidase inhibitors as analgesics. Endogenous peptidase inhibitors with analgesic properties have also been found. Opioid release in the spinal cord is inhibited by several neurotransmitter receptors, including adrenergic alpha(2C) receptors, serotonin 5-HT1A receptors and NMDA receptors. Spinal opioid release appears to be driven by signals originating in both in primary afferents and supraspinally. Pain modality appears to determine whether pain induces spinal opioid release through local or supraspinal circuits. Some forms of stress-induced analgesia are also mediated by spinal opioid release. This involves a circuit originating in the dorsal raphe nucleus involved in the fear/anxiety response. Spinal opioids also mediate the analgesia induced by acupuncture. C1 [Marvizon, Juan Carlos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis,Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Marvizon, Juan Carlos] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Marvizon, JC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis,Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. EM marvizon@ucla.edu NR 232 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0225-2 PY 2009 BP 139 EP 173 DI 10.1007/978-1-4419-0226-9_7 D2 10.1007/978-1-4419-0226-9 PG 35 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA BKW58 UT WOS:000269476100007 ER PT J AU Younker, TD Conlay, LA Searle, NS Khan, M Raty, SR Afifi, S Martin, D Zimmerman, B Epps, JL Rinehardt, P Stock, MC Zell, C AF Younker, T. Dirk Conlay, Lydia A. Searle, Nancy S. Khan, Myrna Raty, Sally R. Afifi, Sheriff Martin, Donna Zimmerman, Brian Epps, Jerry L. Rinehardt, Paige Stock, M. Christine Zell, Christopher TI Performance Outcomes in Anesthesiology Residents Completing Categorical (Anesthesia) or Advanced (Nonspecific) Internship Training SO TEACHING AND LEARNING IN MEDICINE LA English DT Article AB Background: The internship or first year (PGY 1) of anesthesiology training may be categorical (within anesthesiology), or obtained in more diverse settings. Revisions recently proposed in the training requirements incorporated the PGY 1 into the existing curriculum. Purposes: We studied whether this change improved measurable outcomes. Methods: There were 518 residents studied retrospectively from four institutions that offered entry following both "Categorical" and "Other" internships. Thus the training in clinical anesthesia was identical. Results: No differences were observed in percentile scores on the Anesthesiology In-Service Training Examination during clinical anesthesia training, the receipt of awards, board certification or time to certification, or in reports of unsatisfactory performance to the American Board of Anesthesiology. "Categorical" residents were more frequently appointed chief resident. Conclusions: Easily accessible performance measures may function as valuable aids in decision making, particularly when significant changes in curricula are contemplated. Data do not support the proposed changes in anesthesiology. C1 [Conlay, Lydia A.] Baylor Coll Med, Michael E Debakey Vet Affairs Med Ctr, Dept Anesthesiol, Houston, TX 77030 USA. [Searle, Nancy S.] Baylor Coll Med, Off Curriculum, Houston, TX 77030 USA. [Khan, Myrna] Houston Ctr Stat Anal, Houston, TX USA. [Afifi, Sheriff; Stock, M. Christine] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA. [Martin, Donna; Zimmerman, Brian] Advocate Illinois Mason Med Ctr, Dept Anesthesiol, Chicago, IL USA. [Epps, Jerry L.; Rinehardt, Paige] Univ Tennessee, Med Ctr, Dept Anesthesiol, Knoxville, TN USA. [Zell, Christopher] NW Med Fac Fdn, Chicago, IL USA. RP Conlay, LA (reprint author), Baylor Coll Med, Michael E Debakey Vet Affairs Med Ctr, Dept Anesthesiol, 2002 Holcombe Blvd 145, Houston, TX 77030 USA. EM lconlay@bcm.edu NR 7 TC 0 Z9 0 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1040-1334 J9 TEACH LEARN MED JI Teach. Learn. Med. PY 2009 VL 21 IS 1 BP 20 EP 23 DI 10.1080/10401330802573878 PG 4 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 425OB UT WOS:000264645900004 PM 19130382 ER PT J AU Yehuda, R Sarapas, C AF Yehuda, Rachel Sarapas, Casey BE Stein, DJ Hollander, E Rothbaum, BO TI Pathogenesis of Posttraumatic Stress Disorder and Acute Stress Disorder SO TEXTBOOK OF ANXIETY DISORDERS, 2ND EDITION LA English DT Article; Book Chapter ID CHILDHOOD SEXUAL-ABUSE; CORTICOTROPIN-RELEASING-FACTOR; NEUROPEPTIDE-Y CONCENTRATIONS; NATIONAL COMORBIDITY SURVEY; MAJOR DEPRESSIVE DISORDER; VEHICLE ACCIDENT VICTIMS; VIETNAM COMBAT VETERANS; URINARY CORTISOL-LEVELS; DELAYED-ONSET PTSD; TRAUMA EXPOSURE C1 James J Peters Vet Affairs Med Ctr, Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY USA. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY USA. NR 147 TC 0 Z9 0 U1 1 U2 2 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA BN 978-1-58562-254-2 PY 2009 BP 567 EP 581 PG 15 WC Psychiatry; Psychology SC Psychiatry; Psychology GA BCF28 UT WOS:000310050600033 ER PT J AU Back, SE Waldrop, AE Brady, KT AF Back, Sudie E. Waldrop, Angela E. Brady, Kathleen T. BE Stein, DJ Hollander, E Rothbaum, BO TI Anxiety in the Context of Substance Abuse SO TEXTBOOK OF ANXIETY DISORDERS, 2ND EDITION LA English DT Article; Book Chapter ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-COMORBIDITY-SURVEY; PLACEBO-CONTROLLED TRIAL; COCAINE-DEPENDENT INDIVIDUALS; ALCOHOL-USE DISORDERS; PROSPECTIVE FOLLOW-UP; DSM-IV DISORDERS; PSYCHIATRIC-DISORDERS; PANIC DISORDER; GENERALIZED ANXIETY C1 [Back, Sudie E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [Waldrop, Angela E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Waldrop, Angela E.] San Francisco VA Med Ctr, PTSD Clin Team, San Francisco, CA USA. RP Back, SE (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 171 Ashley Ave, Charleston, SC 29425 USA. NR 105 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 USA BN 978-1-58562-254-2 PY 2009 BP 665 EP 679 PG 15 WC Psychiatry; Psychology SC Psychiatry; Psychology GA BCF28 UT WOS:000310050600038 ER PT B AU Kraut, JA Nagami, GT AF Kraut, Jeffrey A. Nagami, Glenn T. BE Singh, AK Williams, GH TI Metabolic Acidosis of Chronic Kidney Disease SO TEXTBOOK OF NEPHRO-ENDOCRINOLOGY LA English DT Article; Book Chapter ID CHRONIC-RENAL-FAILURE; NA+-H+ EXCHANGE; SODIUM-BICARBONATE TREATMENT; NUTRITION EXAMINATION SURVEY; SERUM ELECTROLYTE PATTERNS; PROXIMAL TUBULE SEGMENTS; 3RD NATIONAL-HEALTH; HEMODIALYSIS-PATIENTS; ANGIOTENSIN-II; GROWTH-HORMONE C1 [Kraut, Jeffrey A.; Nagami, Glenn T.] VA Greater Los Angeles Hlth Care Syst, UCLA Membrane Biol Lab, Div Nephrol Med & Res Serv, Los Angeles, CA 90073 USA. [Kraut, Jeffrey A.; Nagami, Glenn T.] UCLA David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Kraut, JA (reprint author), VA Greater Los Angeles Hlth Care Syst, UCLA Membrane Biol Lab, Div Nephrol Med & Res Serv, Los Angeles, CA 90073 USA. NR 210 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-092046-7; 978-0-12-373870-7 PY 2009 BP 457 EP 481 DI 10.1016/B978-0-12-373870-7.00029-6 PG 25 WC Endocrinology & Metabolism; Gastroenterology & Hepatology SC Endocrinology & Metabolism; Gastroenterology & Hepatology GA BA4PI UT WOS:000336096500030 ER PT J AU Pan, Y Sawalha, AH AF Pan, Yujun Sawalha, Amr H. TI Epigenetic regulation and the pathogenesis of systemic lupus erythematosus SO TRANSLATIONAL RESEARCH LA English DT Article ID DRUG-INDUCED LUPUS; CD4(+) T-CELLS; DNA METHYLATION INHIBITORS; MRL-LPR/LPR MOUSE; GENE-EXPRESSION; IN-VITRO; HISTONE MODIFICATIONS; AUTOIMMUNE-DISEASE; SYNGENEIC MICE; RENAL-DISEASE AB The pathogenesis of systemic lupus erythematosus (SLE) is incompletely understood. Studies in both lupus animal models and human disease indicate a clear role for epigenetic defects, particularly DNA methylation, in the pathogenesis of lupus. T-cell DNA from active lupus patients is hypomethylated, which results in overexpression of methylation-regulated genes, T-cell autoreactivity, and autoimmunity in vivo. Inducing an extracellular signal-regulated kinase (ERK) signaling defect in T cells using a transgenic mouse model resulted in reduced DNA methyltransferase 1 (DNMT1) expression, overexpression of methylation-sensitive genes, and anti-double-stranded DNA (anti-dsDNA) antibody production. ERK signaling is known to be defective in lupus T cells, and this defect is now explained by impaired T-cell protein kinase C (PKC) delta activation. Herein, we discuss how defective epigenetic regulation is involved in the pathogenesis of lupus, which includes both DNA methylation and histone modification changes. (Translational Research 2009;153:4-10) C1 Univ Oklahoma, Hlth Sci Ctr, Oklahoma Med Res Fdn, Arthrit & Immunol Program,Dept Med, Oklahoma City, OK USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Sawalha, AH (reprint author), 825 NE 13th St,MS 24, Oklahoma City, OK 73104 USA. EM amr-sawalha@omrf.ouhsc.edu FU National Center for Research Resources [P20-RR015577]; National Institute of Allergy and Infectious Diseases [R03AI076729]; Arthritis National Research Foundation; University of Oklahoma College of Medicine FX Supported by NIH Grant P20-RR015577 from the National Center for Research Resources and NIH Grant R03AI076729 from the National Institute of Allergy and Infectious Diseases, as well as by funding from the Arthritis National Research Foundation and the University of Oklahoma College of Medicine. NR 56 TC 58 Z9 64 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-5244 J9 TRANSL RES JI Transl. Res. PD JAN PY 2009 VL 153 IS 1 BP 4 EP 10 DI 10.1016/j.trsl.2008.10.007 PG 7 WC Medical Laboratory Technology; Medicine, General & Internal; Medicine, Research & Experimental SC Medical Laboratory Technology; General & Internal Medicine; Research & Experimental Medicine GA 392TU UT WOS:000262325900002 PM 19100952 ER PT J AU Cowart, LA AF Cowart, L. Ashley TI Sphingolipids: players in the pathology of metabolic disease SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID INDUCED INSULIN-RESISTANCE; CYTOSOLIC PHOSPHOLIPASE A(2); TANDEM MASS-SPECTROMETRY; SATURATED FATTY-ACIDS; HUMAN SKELETAL-MUSCLE; PROTEIN-KINASE-C; CERAMIDE SYNTHESIS; SPHINGOSINE 1-PHOSPHATE; TNF-ALPHA; SERINE PALMITOYLTRANSFERASE AB The contribution of aberrant production of bioactive lipids to pathophysiological changes associated with obesity has risen to the forefront of lipid research. Increased diacylglycerol has been appreciated as a cause of insulin resistance, but emerging data support a role for sphingolipids in other metabolic diseases including obesity, diabetes, atherosclerosis and metabolic syndrome. Recent data demonstrate that elevation of plasma free fatty acids promotes aberrant sphingolipid production and composition in various tissues including skeletal muscle, pancreas and adipocytes. Moreover, rectifying these aberrant sphingolipid profiles often attenuates pathologies associated with their production. Although data thus far generate more questions than they answer, they indicate a major contribution of sphingolipids to pathologies associated with obesity. This review summarizes recent work in these areas. C1 [Cowart, L. Ashley] Med Univ S Carolina, Charleston, SC 29401 USA. [Cowart, L. Ashley] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Cowart, LA (reprint author), Med Univ S Carolina, 114 Doughty St Rm 423, Charleston, SC 29401 USA. EM cowartl@musc.edu NR 89 TC 52 Z9 53 U1 2 U2 8 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD JAN PY 2009 VL 20 IS 1 BP 34 EP 42 DI 10.1016/j.tem.2008.09.004 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 400VX UT WOS:000262898600005 PM 19008117 ER PT J AU Lee, SWH Liong, ML Yuen, KH Leong, WS Khan, N Cheah, PY Krieger, JN AF Lee, Shaun Wen Huey Liong, Men Long Yuen, Kah Hay Leong, Wing Seng Khan, Nurzalina Cheah, Phaik Yeong Krieger, John N. TI Prostatitis-Like Symptoms: Diagnosis and Management in a Malaysian Primary Care Population SO UROLOGIA INTERNATIONALIS LA English DT Article; Proceedings Paper CT Annual Meeting of the Society-of-Infection-and-Inflammation CY MAY, 2005 CL San Antonio, TX SP Soc Infect Inflammat DE Chronic pelvic pain; Prostatitis syndromes; Primary care management ID PELVIC PAIN SYNDROME; QUESTIONNAIRE SURVEY; UROLOGISTS; MEN; TRIAL AB Background: Little is known about how primary care physicians (PCPs) in Asia diagnose and manage prostatitis-like symptoms. This study investigated the clinical diagnosis of and care provided for prostatitis-like symptoms by PCPs in a Malaysian population, and compared these findings to reports from other areas. Methods: All members of the Penang Private Medical Practitioners' Society were asked to complete a self-administered survey. Nonresponders were contacted after 3 weeks and received a telephone request after 6 weeks. Results: Of the 786 practitioners contacted, 669 considered themselves to be PCPs, including 279 (42%) who responded to the survey. Adult males with prostatitis-like symptoms typically constitute <1% of the patients seen by PCPs. Most PCPs (72%) believe that prostatitis-like symptoms are caused by bacterial infection. 61% of PCPs base their diagnosis of prostatitis-like symptoms on clinical history, a physical examination and dipstick urinalysis. Standard management was to prescribe 1 or 2 courses of antimicrobials. Conclusions: Despite the 8.7% prevalence found in a previous survey in this population, prostatitis remains underdiagnosed in Malaysia. In contrast to many other clinical settings, urologists in Malaysia see a large proportion of newly diagnosed and treatment-naive prostatitis patients, providing an opportunity for clinical diagnostic and treatment studies. Copyright (C) 2009 S. Karger AG, Basel C1 [Liong, Men Long; Leong, Wing Seng] Lam Wah Ee Hosp, Dept Urol, George Town, Malaysia. [Lee, Shaun Wen Huey; Yuen, Kah Hay; Khan, Nurzalina; Cheah, Phaik Yeong] Univ Sci Malaysia, Sch Pharmaceut Sci, George Town, Malaysia. [Krieger, John N.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Dept Urol Surg,Dept Urol, Seattle, WA 98108 USA. RP Krieger, JN (reprint author), Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Dept Urol Surg,Dept Urol, 1660 S Columbian Way, Seattle, WA 98108 USA. EM jkrieger@u.washington.edu RI Yuen, Kah Hay /F-9059-2010; Khan, Nurzalina/E-3875-2012 OI Lee, Shaun/0000-0001-7361-6576 NR 19 TC 1 Z9 1 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0042-1138 J9 UROL INT JI Urol.Int. PY 2009 VL 82 IS 1 BP 32 EP 37 DI 10.1159/000176022 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 395UR UT WOS:000262549500008 PM 19172094 ER PT S AU El-Shewy, HM Luttrell, LM AF El-Shewy, Hesham M. Luttrell, Louis M. BE Litwack, G TI INSULIN-LIKE GROWTH FACTOR-2/MANNOSE-6 PHOSPHATE RECEPTORS SO VITAMINS AND HORMONES INSULIN AND IGFS SE Vitamins and Hormones LA English DT Review; Book Chapter ID FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE RECEPTOR; TUMOR-SUPPRESSOR GENE; GRANULE-MEDIATED APOPTOSIS; AMINO-ACID-SEQUENCE; TYPE-2 IGF RECEPTOR; CASEIN KINASE-II; G-PROTEIN; GRANZYME-B; HUMAN-SERUM AB The insulin-like growth factor type 2/mannose-6-phosphate (IGF-2/M6P) receptor is a multifunctional single transmembrane glycoprotein that is known to regulate diverse biological functions. It is composed of a large extracytoplasmic domain, a single transmembrane region and a short cytoplasmic tail that lacks intrinsic catalytic activity. The receptor cycles continuously between intracellular compartments and the plasma membrane, and at steady state is predominantly localized in the trans-Golgi network and endosomal compartments, and to a lesser extent on the cell surface. The receptor binds IGF-2 with higher affinity than IGF-1 and does not bind insulin. It interacts, via distinct sites, with lysosomal enzymes and a variety of other M6P-containing ligands. IGF-2/M6P receptors perform diverse cellular functions related to lysosome biogenesis and the regulation of growth and development. It regulates extracellular IGF-2 concentrations, modulating signaling through the growth-stimulatory IGF-1 receptor pathway. It appears to mediate the uptake and processing of M6P-containing cytokines and peptide hormones, such as transforming growth factor-beta, leukemia inhibitory factor, and proliferin. Some data suggest that the IGF-2/M6P receptor also functions in signal transduction by transactivating G protein-coupled sphingosine 1-phosphate receptors. Genetic evidence clearly supports a role for IGF-2/M6P receptors in organ development and growth, and recent data indicate that it may play an important role in tumor progression. (C) 2009 Elsevier Inc. C1 [El-Shewy, Hesham M.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP El-Shewy, HM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. NR 199 TC 40 Z9 41 U1 1 U2 9 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0083-6729 BN 978-0-12-374408-1 J9 VITAM HORM JI Vitam. Horm. PY 2009 VL 80 BP 667 EP 697 DI 10.1016/S0083-6729(08)00624-9 PG 31 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA BJB99 UT WOS:000264638200024 PM 19251055 ER PT J AU Ketchen, B Armistead, L Cook, S AF Ketchen, Bethany Armistead, Lisa Cook, Sarah TI HIV Infection, Stressful Life Events, and Intimate Relationship Power: The Moderating Role of Community Resources for Black South African Women SO WOMEN & HEALTH LA English DT Article DE South African women; HIV; relationship power; community-based resources ID GENDER-BASED VIOLENCE; RISK-FACTORS; SEXUAL RISK; EMPOWERMENT; HIV/AIDS; PREDICTORS; EDUCATION; PARTNERS; HEALTH AB Background: Black women in South Africa are vulnerable with limited power in intimate relationships. This study explored whether stressful life events and/or HIV infection were associated with relationship power and whether the impact was moderated by community resources. Method: One hundred four women living with HIV and 152 women not living with HIV participated in individual interviews. Results: Undesirable life changes were negatively associated with relationship control. HIV infection and women's knowledge of community resources were associated with mutual decision-making, while frequency of family use of community resources was negatively related to female dominated decisions. Women living with HIV perceived their male partners as less dominant when they perceived their community resources to be more helpful. Conclusions: Power in intimate relationships may enhance the quality and length of life for black South African women living with HIV. Knowledge of and perceived helpfulness of community resources are avenues for promoting relationship power. C1 [Armistead, Lisa; Cook, Sarah] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [Ketchen, Bethany] San Francisco VA Med Ctr, San Francisco, CA USA. RP Armistead, L (reprint author), Georgia State Univ, Dept Psychol, POB 5010, Atlanta, GA 30303 USA. EM lparmistead@gsu.edu FU NICHD NIH HHS [R03 HD046371, R03 HD046371-01A1, R03HD046371] NR 45 TC 13 Z9 13 U1 2 U2 6 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 0363-0242 J9 WOMEN HEALTH JI Women Health PY 2009 VL 49 IS 2-3 BP 197 EP 214 AR PII 912434829 DI 10.1080/03630240902963648 PG 18 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 459KN UT WOS:000267101100006 PM 19533510 ER PT S AU Giampietro, PF Dunwoodie, SL Kusumi, K Pourquie, O Tassy, O Offiah, AC Cornier, AS Alman, BA Blank, RD Raggio, CL Glurich, I Turnpenny, PD AF Giampietro, Philip F. Dunwoodie, Sally L. Kusumi, Kenro Pourquie, Olivier Tassy, Olivier Offiah, Amaka C. Cornier, Alberto S. Alman, Benjamin A. Blank, Robert D. Raggio, Cathleen L. Glurich, Ingrid Turnpenny, Peter D. BE Smith, M TI Progress in the Understanding of the Genetic Etiology of Vertebral Segmentation Disorders in Humans SO YEAR IN HUMAN AND MEDICAL GENETICS 2009 SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article DE congenital vertebral malformation; spondylothoracic dysostosis; Agagille syndrome; congenital scoliosis; Klippel-Feil syndrome; VACTERL; CHARGE syndrome; teratogens; Jarcho-Levin syndrome; ICVAS; array-based CGH; DLL3; Wnt3A; T(Brachyury); Tbx6; SLC35A3; MESP2 LFNG; PAX1 JAG1; NOTCH2; CHD7 ID JARCHO-LEVIN-SYNDROME; KLIPPEL-FEIL-SYNDROME; NOTCH SIGNALING PATHWAY; RECESSIVE SPONDYLOCOSTAL DYSOSTOSIS; NEURAL-TUBE DEFECTS; LUNATIC-FRINGE GENE; CONGENITAL SCOLIOSIS; HUMAN T; IDIOPATHIC SCOLIOSIS; ALAGILLE-SYNDROME AB Vertebral malformations contribute substantially to the pathophysiology of kyphosis and scoliosis, common health problems associated with back and neck pain, disability, cosmetic disfigurement, and functional distress. This review explores (1) recent advances in the understanding of the molecular embryology underlying vertebral development and relevance to elucidation of etiologies of several known human vertebral malformation syndromes; (2) outcomes of molecular studies elucidating genetic contributions to congenital and sporadic vertebral malformation; and (3) complex interrelationships between genetic and environmental factors that contribute to the pathogenesis of isolated syndromic and non-syndromic congenital vertebral malformation. Discussion includes exploration of the importance of establishing improved classification systems for vertebral malformation, future directions in molecular and genetic research approaches to vertebral malformation, and translational value of research efforts to clinical management and genetic counseling of affected individuals and their families. C1 [Giampietro, Philip F.] Marshfield Clin Fdn Med Res & Educ, Dept Med Genet Serv, Marshfield, WI 54449 USA. [Dunwoodie, Sally L.] Univ New S Wales, Victor Chang Cardiac Res Inst, Darlinghurst, NSW, Australia. [Kusumi, Kenro] Arizona State Univ, Sch Life Sci, Tempe, AZ USA. [Pourquie, Olivier] Howard Hughes Med Inst, Kansas City, MO USA. [Pourquie, Olivier; Tassy, Olivier] Stowers Inst Med Res, Kansas City, MO USA. [Offiah, Amaka C.] Great Ormond St Hosp Sick Children, Dept Radiol, London WC1N 3JH, England. [Cornier, Alberto S.] Ponce Sch Med, Dept Biochem, Div Genet, Ponce, PR USA. [Cornier, Alberto S.] La Concepcion Hosp, Dept Mol Med, San German, PR USA. [Alman, Benjamin A.] Univ Toronto, Hosp Sick Children, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada. [Alman, Benjamin A.] Univ Toronto, Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada. [Blank, Robert D.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. [Raggio, Cathleen L.] Hosp Special Surg, Dept Pediat Orthoped, New York, NY 10021 USA. [Glurich, Ingrid] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA. [Turnpenny, Peter D.] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England. [Turnpenny, Peter D.] Peninsula Med Sch, Exeter, Devon, England. RP Giampietro, PF (reprint author), Marshfield Clin Fdn Med Res & Educ, Dept Med Genet Serv, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM giampietro.philip@marshfieldclinic.org RI Kusumi, Kenro/J-2626-2012; Offiah, Amaka/G-2911-2010 OI Kusumi, Kenro/0000-0002-1458-4540; Offiah, Amaka/0000-0001-8991-5036; Pourquie, Olivier/0000-0001-5189-1227; Dunwoodie, Sally/0000-0002-2069-7349; Blank, Robert Daniel/0000-0003-2950-1944 FU Marshfield Clinic Research Foundation FX The authors thank Marshfield Clinic Research Foundation for its support through the assistance of Marie Flelsner and Alice Stargardt. NR 149 TC 17 Z9 17 U1 1 U2 5 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-731-3 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2009 VL 1151 BP 38 EP 67 DI 10.1111/j.1749-6632.2008.03452.x PG 30 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BIW37 UT WOS:000263365700004 PM 19154516 ER PT J AU Smith, JL Williams, JW Owen, RR Rubenstein, LV Chaney, E AF Smith, Jeffrey L. Williams, John W., Jr. Owen, Richard R. Rubenstein, Lisa V. Chaney, Edmund TI Developing a national dissemination plan for collaborative care for depression: QUERI Series SO IMPLEMENTATION SCIENCE LA English DT Article ID IMPLEMENTATION RESEARCH; QUALITY; STRATEGIES; MANAGEMENT; PHARMACOTHERAPY; INTERVENTIONS; OUTCOMES; IMPROVE; SYSTEM AB Background: Little is known about effective strategies for disseminating and implementing complex clinical innovations across large healthcare systems. This paper describes processes undertaken and tools developed by the U. S. Department of Veterans Affairs (VA) Mental Health Quality Enhancement Research Initiative (MH-QUERI) to guide its efforts to partner with clinical leaders to prepare for national dissemination and implementation of collaborative care for depression. Methods: An evidence-based quality improvement (EBQI) process was used to develop an initial set of goals to prepare the VA for national dissemination and implementation of collaborative care. The resulting product of the EBQI process is referred to herein as a "National Dissemination Plan" (NDP). EBQI participants included: a) researchers with expertise on the collaborative care model for depression, clinical quality improvement, and implementation science, and b) VA clinical and administrative leaders with experience and expertise on how to adapt research evidence to organizational needs, resources and capacity. Based on EBQI participant feedback, drafts of the NDP were revised and refined over multiple iterations before a final version was approved by MH-QUERI leadership. 'Action Teams' were created to address each goal. A formative evaluation framework and related tools were developed to document processes, monitor progress, and identify and act upon barriers and facilitators in addressing NDP goals. Results: The National Dissemination Plan suggests that effectively disseminating collaborative care for depression in the VA will likely require attention to: Guidelines and Quality Indicators (4 goals), Training in Clinical Processes and Evidence-based Quality Improvement (6 goals), Marketing (7 goals), and Informatics Support (1 goal). Action Teams are using the NDP as a blueprint for developing infrastructure to support system-wide adoption and sustained implementation of collaborative care for depression. To date, accomplishments include but are not limited to: conduct of a systematic review of the literature to update VA depression treatment guidelines to include the latest evidence on collaborative care for depression; training for clinical staff on TIDES (Translating Initiatives for Depression into Effective Solutions project) care; spread of TIDES care to new VA facilities; and integration of TIDES depression assessment tools into a planned update of software used in delivery of VA mental health services. Thus far, common barriers encountered by Action Teams in addressing NDP goals include: a) limited time to address goals due to competing tasks/priorities, b) frequent turnover of key organizational leaders/stakeholders, c) limited skills and training among team members for addressing NDP goals, and d) difficulty coordinating activities across Action Teams on related goals. Conclusion: MH-QUERI has partnered with VA organizational leaders to develop a focused yet flexible plan to address key factors to prepare for national dissemination and implementation of collaborative care for depression. Early indications suggest that the plan is laying an important foundation that will enhance the likelihood of successful implementation and spread across the VA healthcare system. C1 [Smith, Jeffrey L.; Owen, Richard R.] Cent Arkansas Vet Healthcare Syst, VA Mental Hlth Qual Enhancement Res Initiat, N Little Rock, AR 72114 USA. [Williams, John W., Jr.] Durham VA Med Ctr HSR&D, Durham, NC 27705 USA. [Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Provider Behav, Sepulveda, CA 91343 USA. [Chaney, Edmund] VA Puget Sound Healthcare Syst, VA HSR&D Ctr Excellence, Seattle, WA 98101 USA. RP Smith, JL (reprint author), Cent Arkansas Vet Healthcare Syst, VA Mental Hlth Qual Enhancement Res Initiat, 2200 Ft Roots Dr,Bldg 58 152 NLR, N Little Rock, AR 72114 USA. EM Jeffrey.Smith6@va.gov; willi007@mc.duke.edu; Richard.Owen2@va.gov; lisar@rand.org; chaney@u.washington.edu FU VA HSRD Service [MNH 98-001, MNT 03-215] FX The study was funded by VA HSR&D Service, MNH 98-001, MNT 03-215. NR 51 TC 30 Z9 31 U1 1 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD DEC 31 PY 2008 VL 3 AR 59 DI 10.1186/1748-5908-3-59 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 432TI UT WOS:000265156700003 PM 19117524 ER PT J AU Shi, LH Ko, S Kim, S Echchgadda, I Oh, TS Song, CS Chatterjee, B AF Shi, Liheng Ko, Soyoung Kim, Soyoung Echchgadda, Ibtissam Oh, Tae-Sung Song, Chung S. Chatterjee, Bandana TI Loss of Androgen Receptor in Aging and Oxidative Stress through Myb Protooncoprotein-regulated Reciprocal Chromatin Dynamics of p53 and Poly(ADP-ribose) Polymerase PARP-1 SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FACTOR-KAPPA-B; TRANSCRIPTIONAL REPRESSION; HEPATOCELLULAR-CARCINOMA; CALORIE RESTRICTION; PROSTATE-CANCER; RAT-LIVER; GENE; COREPRESSOR; EXPRESSION; ALPHA AB Poly(ADP-ribosyl)ation of transcription factors and coregulators, mediated by the poly(ADP-ribose) polymerase PARP-1, has been emerging as an important epigenetic mechanism that controls transcriptional dynamics in response to diverse intra- and extracellular signals. PARP-1 activity is also implicated in the regulation of mammalian lifespan. Herein we show that transcriptional down-regulation of androgen receptor (AR) in the aging rat liver and in oxidatively stressed hepatoma cells involves exchange of a PARP-1-associated, p/CAF-containing coactivator assembly for a p53-interacting, Groucho/TLE1-, and mSin3A-induded corepressor complex at an age- and oxidant-responsive DNA element (age- dependent factor (ADF) element) in the AR promoter. The coregulator switch is mediated by B-Myb and c-Myb, which bind to the ADF element and physically associate with PARP-1 and the tumor suppressor p53. Heterogeneous nuclear ribonucleoprotein K, residing at the ADF element in association with PARP-1, may serve a platform role in stabilizing the activating complex. PARP-1 coactivated B-Myb- and c-Myb-mediated transactivation of the AR promoter, and p53 antagonized the B-Myb/c-Myb-induced AR promoter activation. PARP-1, heterogeneous nuclear ribonucleoprotein K, B-Myb, and c-Myb each serves as a positive regulator of cellular AR content, whereas p53 negatively regulates AR expression. Our results identify a shared, PARP-1-regulated sensing mechanism that coordinates transcriptional repression of AR during aging and in response to oxidative stress. This study may provide insights as to how advancing age and intracellular redox balance might influence androgen-regulated physiology. C1 [Shi, Liheng; Ko, Soyoung; Kim, Soyoung; Echchgadda, Ibtissam; Oh, Tae-Sung; Song, Chung S.; Chatterjee, Bandana] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA. [Chatterjee, Bandana] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM chatterjee@uthscsa.edu FU National Institutes of Health [AG-10486, AG-19660] FX This work was supported, in whole or in part, by National Institutes of Health Grants AG-10486 and AG-19660. This work was also supported by a merit review grant from Veterans Affairs. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 53 TC 18 Z9 19 U1 1 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 26 PY 2008 VL 283 IS 52 BP 36474 EP 36485 DI 10.1074/jbc.M805980200 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 385VA UT WOS:000261840500045 PM 18945670 ER PT J AU Volpp, KG Loewenstein, G Troxel, AB Doshi, J Price, M Laskin, M Kimmel, SE AF Volpp, Kevin G. Loewenstein, George Troxel, Andrea B. Doshi, Jalpa Price, Maureen Laskin, Mitchell Kimmel, Stephen E. TI A test of financial incentives to improve warfarin adherence SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID ACUTE ISCHEMIC-STROKE; ATRIAL-FIBRILLATION; BLEEDING COMPLICATIONS; ANTITHROMBOTIC THERAPY; RANDOMIZED-TRIAL; RISK-FACTORS; ANTICOAGULATION; PREVENTION; BEHAVIOR; ASPIRIN AB Background: Sub-optimal adherence to warfarin places millions of patients at risk for stroke and bleeding complications each year. Novel methods are needed to improve adherence for warfarin. We conducted two pilot studies to determine whether a lottery-based daily financial incentive is feasible and improves warfarin adherence and anticoagulation control. Methods: Volunteers from the University of Pennsylvania Anticoagulation Management Center who had taken warfarin for at least 3 months participated in either a pilot study with a lottery with a daily expected value of $5 (N = 10) or a daily expected value of $3 (N = 10). All subjects received use of an Informedix Med-eMonitor (TM) System with a daily reminder feature. If subjects opened up their pill compartments appropriately, they were entered into a daily lottery with a 1 in 5 chance of winning $10 and a 1 in 100 chance of winning $100 (pilot 1) or a 1 in 10 chance of winning $10 and a 1 in 100 chance of winning $100 (pilot 2). The primary study outcome was proportion of incorrect warfarin doses. The secondary outcome was proportion of INR measurements not within therapeutic range. Within-subject pre-post comparisons were done of INR measurements with comparisons with either historic means or within-subject comparisons of incorrect warfarin doses. Results: In the first pilot, the percent of out-of-range INRs decreased from 35.0% to 12.2% during the intervention, before increasing to 42% post-intervention. The mean proportion of incorrect pills taken during the intervention was 2.3% incorrect pills, compared with a historic mean of 22% incorrect pill taking in this clinic population. Among the five subjects who also had MEMS cap adherence data from warfarin use in our prior study, mean incorrect pill taking decreased from 26% pre-pilot to 2.8% in the pilot. In the second pilot, the time out of INR range decreased from 65.0% to 40.4%, with the proportion of mean incorrect pill taking dropping to 1.6%. Conclusion: A daily lottery-based financial incentive demonstrated the potential for significant improvements in missed doses of warfarin and time out of INR range. Further testing should be done of this approach to determine its effectiveness and potential application to both warfarin and other chronic medications. C1 [Volpp, Kevin G.; Doshi, Jalpa] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.; Loewenstein, George; Troxel, Andrea B.; Doshi, Jalpa; Kimmel, Stephen E.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Doshi, Jalpa; Kimmel, Stephen E.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Doshi, Jalpa] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. [Troxel, Andrea B.; Price, Maureen; Kimmel, Stephen E.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Price, Maureen; Kimmel, Stephen E.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Laskin, Mitchell] Univ Penn, Hosp Univ Penn, Dept Pharm Serv, Philadelphia, PA 19104 USA. RP Volpp, KG (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. EM volpp70@mail.med.upenn.edu; gl20@andrew.cmu.edu; atroxel@mail.med.upenn.edu; jdoshi@mail.med.upenn.edu; maureenpprice@hotmail.com; mitchell.laskin@uphs.upenn.edu; stevek@mail.med.upenn.edu OI Troxel, Andrea/0000-0002-1393-3075 FU NHLBI [R01HL066176]; AHRQ [P01-HS11530]; VA HSRD; [P20RR020741] FX This work was supported by NHLBI R01HL066176 and AHRQ P01-HS11530. Dr. Kimmel is also supported by P20RR020741. Dr. Volpp was also supported by a Research Career Transition Award from VA HSR&D. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Dr. Kimmel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 36 TC 91 Z9 92 U1 4 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD DEC 23 PY 2008 VL 8 AR 272 DI 10.1186/1472-6963-8-272 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 404WT UT WOS:000263184400001 PM 19102784 ER PT J AU McMillan, P Korvatska, E Poorkaj, P Evstafjeva, Z Robinson, L Greenup, L Leverenz, J Schellenberg, GD D'Souza, I AF McMillan, Pamela Korvatska, Elena Poorkaj, Parvoneh Evstafjeva, Zana Robinson, Linda Greenup, Lynne Leverenz, James Schellenberg, Gerard D. D'Souza, Ian TI Tau Isoform Regulation Is Region- and Cell-Specific in Mouse Brain SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE splicing; phosphorylation; Alzheimer's disease; frontotemporal dementia; 3-repeat and 4-repeat tau; tauopathy ID PROGRESSIVE SUPRANUCLEAR PALSY; PAIRED HELICAL FILAMENTS; PARKINSONISM-DEMENTIA COMPLEX; ALZHEIMERS-DISEASE; MICROTUBULE-BINDING; PROTEIN-TAU; NEURODEGENERATIVE DISORDERS; CORTICOBASAL DEGENERATION; NEUROFIBRILLARY TANGLES; WHITE-MATTER AB Tau is a microtubule-associated protein implicated in neurodegenerative tauopathies. Alternative splicing of the tau gene (MAPT) generates six tau isoforms, distinguishable by the exclusion or inclusion of a repeat region of exon 10, which are referred to as 3-repeat (311) and 4-repeat (4R) tau, respectively. We developed transgenic mouse models that express the entire human MAPT gene in the presence and absence of the mouse Mapt gene and compared the expression and regulation of mouse and human tau isoforms during development and in the young adult. We found differences between mouse and human tau in the regulation of exon 10 inclusion. Despite these differences, the isoform splicing pattern seen in normal human brain is replicated in our mouse models. In addition, we found that all tau, both in the neonate and young adult, is phosphorylated. We also examined the normal anatomic distribution of mouse and human tau isoforms in mouse brain. We observed developmental and species-specific variations in the expression of 3R- and 4R-tau within the frontal cortex and hippocampus. In addition, there were differences in the cellular distribution of the isoforms. Mice transgenic for the human MAPT gene exhibited higher levels of neuronal cell body expression of tau compared to wildtype mice. This neuronal cell body expression of tau was limited to the 3R isoform, whereas expression of 4R-tau was more "synaptic like," with granular staining of neuropil rather than in neuronal cell bodies. These developmental and species-specific differences in the regulation and distribution of tau isoforms may be important to the understanding of normal and pathologic tau isoform expression. J. Comp. Neurol. 511:788-803, 2008. (C) 2008 Wiley-Liss, Inc. C1 [McMillan, Pamela; Korvatska, Elena; Evstafjeva, Zana; Robinson, Linda; Schellenberg, Gerard D.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Geriatr Ctr, Seattle, WA 98108 USA. [McMillan, Pamela; Poorkaj, Parvoneh; Greenup, Lynne; Leverenz, James] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [McMillan, Pamela; Greenup, Lynne; Leverenz, James] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Leverenz, James; Schellenberg, Gerard D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [D'Souza, Ian] Forest Res Inst, Seattle, WA 98103 USA. RP Schellenberg, GD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Geriatr Ctr, 1660 S Columbian Ave, Seattle, WA 98108 USA. EM zachdad@u.washington.edu FU National Institute on Aging (NIA) [POI AG17586, R37 AG 11762-10]; American Health Assistance Foundatiom; Department of Veteran's Affairs FX Grant sponsor: National Institute on Aging (NIA); Grant numbers: POI AG17586 and R37 AG 11762-10; Grant sponsor: American Health Assistance Foundatiom Grant sponsor: Department of Veteran's Affairs. NR 86 TC 54 Z9 54 U1 1 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD DEC 20 PY 2008 VL 511 IS 6 BP 788 EP 803 DI 10.1002/cne.21867 PG 16 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA 371PB UT WOS:000260842300006 PM 18925637 ER PT J AU Shaw, LJ Veledar, E Berman, DS Hayes, SW Friedman, J Slomka, P Germano, G Maron, DJ Mancini, GBJ Hartigan, PM Weintraub, WS O'Rourke, RA Heller, GV Dada, M Spertus, JA McCallister, B Chaitman, BR Gosselin, G Berger, P Kostuk, WJ Schwartz, RG Knudtson, M Bates, ER Teo, KK Boden, WE AF Shaw, Leslee J. Veledar, Emir Berman, Daniel S. Hayes, Sean W. Friedman, John Slomka, Piotr Germano, Guido Maron, David J. Mancini, G. B. John Hartigan, Pamela M. Weintraub, William S. O'Rourke, Robert A. Heller, Gary V. Dada, Marcin Spertus, John A. McCallister, Benjamin Chaitman, Bernard R. Gosselin, Gilbert Berger, Peter Kostuk, William J. Schwartz, Ronald G. Knudtson, Merill Bates, Eric R. Teo, Koon K. Boden, William E. CA COURAGE Investigators TI Response to Letters Regarding Article, "Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy" SO CIRCULATION LA English DT Letter ID EMISSION COMPUTED-TOMOGRAPHY; MYOCARDIAL-INFARCTION; PROGNOSTIC VALUE; RISK C1 [Shaw, Leslee J.; Veledar, Emir] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Berman, Daniel S.; Hayes, Sean W.; Friedman, John; Slomka, Piotr; Germano, Guido] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Mancini, G. B. John] Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada. [Hartigan, Pamela M.] Vet Affairs Connecticut Healthcare Syst, Vet Affairs Cooperat Studies Program Coordinating, West Haven, CT USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [O'Rourke, Robert A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Heller, Gary V.; Dada, Marcin] Hartford Hosp, Hartford, CT 06115 USA. [Spertus, John A.; McCallister, Benjamin] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Chaitman, Bernard R.] St Louis Univ, St Louis, MO 63103 USA. [Gosselin, Gilbert] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Berger, Peter] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA. [Kostuk, William J.] London Hlth Sci Ctr, London, ON, Canada. [Schwartz, Ronald G.] Univ Rochester, Rochester, NY USA. [Knudtson, Merill] Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada. [Bates, Eric R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Teo, Koon K.] McMaster Univ, Hamilton, ON, Canada. [Boden, William E.] SUNY Buffalo, Buffalo Gen Hosp, Western New York Vet Affairs Healthcare Network, Buffalo, NY 14260 USA. RP Shaw, LJ (reprint author), Emory Univ, Sch Med, Atlanta, GA 30322 USA. RI Veledar, Emir/K-2808-2012 OI Veledar, Emir/0000-0002-3831-5433 NR 6 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD DEC 16 PY 2008 VL 118 IS 25 BP E840 EP E841 DI 10.1161/CIRCULATIONAHA.108.791129 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 387JO UT WOS:000261948700032 ER PT J AU Caplan, L Prochazka, AV Hoffecker, L AF Caplan, Liron Prochazka, Allan V. Hoffecker, Lilian TI Absence of ethical discourse in the rheumatology literature: comment on the article by Caplan et al Reply SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Letter C1 [Caplan, Liron; Prochazka, Allan V.; Hoffecker, Lilian] Univ Colorado, Denver, CO 80202 USA. [Caplan, Liron; Prochazka, Allan V.] Denver VAMC, Denver, CO USA. RP Caplan, L (reprint author), Univ Colorado, Denver, CO 80202 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD DEC 15 PY 2008 VL 59 IS 12 BP 1835 EP 1836 DI 10.1002/art.24094 PG 2 WC Rheumatology SC Rheumatology GA 382DW UT WOS:000261586300023 ER PT J AU Turetsky, BI Greenwood, TA Olincy, A Radant, AD Braff, DL Cadenhead, KS Dobie, DJ Freedman, R Green, MF Gur, RE Gur, RC Light, GA Mintz, J Nuechterlein, KH Schork, NJ Seidman, LJ Siever, LJ Silverman, JM Stone, WS Swerdlow, NR Tsuang, DW Tsuang, MT Calkins, ME AF Turetsky, Bruce I. Greenwood, Tiffany A. Olincy, Ann Radant, Allen D. Braff, David L. Cadenhead, Kristin S. Dobie, Dorcas J. Freedman, Robert Green, Michael F. Gur, Raquel E. Gur, Ruben C. Light, Gregory A. Mintz, James Nuechterlein, Keith H. Schork, Nicholas J. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Swerdlow, Neal R. Tsuang, Debby W. Tsuang, Ming T. Calkins, Monica E. TI Abnormal Auditory N100 Amplitude: A Heritable Endophenotype in First-Degree Relatives of Schizophrenia Probands SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Endophenotype; evoked potential; gating; heritability; N100; schizophrenia ID EVENT-RELATED POTENTIALS; EVOKED RESPONSE SUPPRESSION; TRAIT LINKAGE ANALYSIS; CORTICAL DYSFUNCTION; GENETICS; RISK; RELIABILITY; DISCORDANT; DISORDERS; INTERVIEW AB Background: N100 evoked potential amplitude and gating abnormalities have been widely observed in schizophrenia patients. However, previous studies have been inconclusive as to whether similar deficits are present in unaffected family members. The Consortium on the Genetics of Schizophrenia (COGS) is a multisite National Institute of Mental Health (NIMH) initiative examining neurocognitive and neurophysiological measures as endophenotypes for genetic studies of schizophrenia. We report initial results from the COGS dataset of auditory N100 amplitude and gating as candidate endophenotypes. Methods: Evoked potential data were acquired from 142 schizophrenia probands, 373 unaffected first-degree relatives, and 221 community comparison subjects (CCS), using an auditory paired-click stimulation paradigm. Amplitude of the N100 response to each click and the click 2/click 1 ratio were dependent variables. Heritability was estimated based on kinships using Solar v.2.1.2. Group differences were examined after subjects were categorized as either "broad" or "narrow," based on the presence (broad) or absence (narrow) of nonpsychotic psychiatric comorbidity. Results: Heritability estimates were.40 and.29 for click1 and click2 amplitudes and.22 for the ratio. Broad and narrow patients both had impaired click 1 amplitudes. Broad relatives, but not narrow relatives, exhibited similar impairments. There were no group differences for either click 2 amplitude or the gating ratio. Conclusions: N100 amplitude is a heritable measure that is abnormal in patients and a subset of relatives for whom psychiatric comorbidity may be a genetically associated phenotype. Auditory N100 gating, although heritable, is less viable as a schizophrenia endophenotype. C1 [Turetsky, Bruce I.; Gur, Raquel E.; Gur, Ruben C.; Calkins, Monica E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Greenwood, Tiffany A.; Braff, David L.; Cadenhead, Kristin S.; Light, Gregory A.; Swerdlow, Neal R.; Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Olincy, Ann; Freedman, Robert] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Radant, Allen D.; Dobie, Dorcas J.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Radant, Allen D.; Dobie, Dorcas J.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Green, Michael F.; Mintz, James; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Schork, Nicholas J.] Scripps Genom Med, La Jolla, CA USA. [Schork, Nicholas J.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA. [Seidman, Larry J.; Stone, William S.; Tsuang, Ming T.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Sch Med,Publ Psychiat Div, Boston, MA 02215 USA. Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.] James J Peters VA Med Ctr, Bronx, NY USA. [Siever, Larry J.] Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network 3, Bronx, NY USA. RP Turetsky, BI (reprint author), Univ Penn, Dept Psychiat, 10th Floor Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM turetsky@upenn.edu RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016 OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang, Debby/0000-0002-4716-1894 FU National Institute of Mental Health; Harvard University [RO1-MH06556]; Mount Sinai School of Medicine [RO1-MH065554]; University of California Los Angeles [RO1-MH65707]; University of California San Diego [R01-MH065571]; University of Colorado [RO1-MH65588]; University of Pennsylvania [RO1-MH65578]; University of Washington [RO1-MH65558]; [MH064045]; [MH43292]; [MH79777] FX This research conducted by the Consortium on the Genetics of Schizophrenia (COGS) and supported by collaborative RO1 Grants from the National Institute of Mental Health to the following institutions: Harvard University RO1-MH06556; Mount Sinai School of Medicine RO1-MH065554; University of California Los Angeles RO1-MH65707; University of California San Diego R01-MH065571; University of Colorado RO1-MH65588; University of Pennsylvania RO1-MH65578; and University of Washington RO1-MH65558. Additional grant support for this study was provided by MH064045 (BIT), MH43292 (MFG), and MH79777 (GAL). NR 53 TC 63 Z9 64 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 15 PY 2008 VL 64 IS 12 BP 1051 EP 1059 DI 10.1016/j.biopsych.2008.06.018 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 382HA UT WOS:000261595400007 PM 18701089 ER PT J AU Shi, YJ Frost, PJ Hoang, BQ Benavides, A Sharma, S Gera, JF Lichtenstein, AK AF Shi, Yijiang Frost, Patrick J. Hoang, Bao Q. Benavides, Angelica Sharma, Sanjai Gera, Joseph F. Lichtenstein, Alan K. TI IL-6-Induced Stimulation of c-Myc Translation in Multiple Myeloma Cells Is Mediated by Myc Internal Ribosome Entry Site Function and the RNA-Binding Protein, hnRNP A1 SO CANCER RESEARCH LA English DT Article ID TRANS-ACTING FACTOR; MESSENGER-RNA; AKT ACTIVITY; CYCLIN D1; MTOR INHIBITORS; EXPRESSION; RAPAMYCIN; ONCOGENE; PATHWAY; GROWTH AB Prior work indicates that c-myc translation is up-regulated in multiple myeloma cells. To test a role for interleukin (IL)-6 in myc translation, we studied the IL-6-responsive ANBL-6 and IL-6-autocrine U266 cell lines as well as primary patient samples. IL-6 increased c-myc translation, which was resistant to rapamycin, indicating a mechanism independent of mammalian target of rapamycin (mTOR) and cap-dependent translation. In contrast, the cytokine enhanced cap-independent translation via a stimulatory effect on the myc internal ribosome entry site (IRES). As known IRES-trans-activating factors (ITAF) were unaffected by IL-6, we used a yeast-three-hybrid screen to identify novel ITAFs and identified hnRNP A1 (A1) as a mediator of the IL-6 effect. At specifically interacted with the myc IRES in filter binding assays as well as EMSAs. Treatment of myeloma cells with IL-6 induced serine phosphorylation of A1 and increased its binding to the myc IRES in vivo in myeloma cells. Primary patient samples also showed binding between A1 and the IRES. RNA interference to knock down hnRNP A1 prevented an IL-6 increase in myc protein expression, myc IRES activity, and cell growth. These data point to hnRNP A1 as a critical regulator of c-myc translation and a potential therapeutic target in multiple myeloma. [Cancer Res 2008;68(24):10215-22] C1 [Shi, Yijiang; Frost, Patrick J.; Hoang, Bao Q.; Benavides, Angelica; Sharma, Sanjai; Gera, Joseph F.; Lichtenstein, Alan K.] Greater Los Angeles VA Healthcare Syst, Dept Med, Los Angeles, CA USA. [Shi, Yijiang; Frost, Patrick J.; Hoang, Bao Q.; Benavides, Angelica; Sharma, Sanjai; Gera, Joseph F.; Lichtenstein, Alan K.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Lichtenstein, AK (reprint author), VA W LA Hosp, W111H,Bldg 500,Room 4237,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM alan.lichtenstein@med.va.gov OI Frost, Patrick/0000-0003-3348-5983 FU Veteran's Administration; Multiple Myeloma Research Foundation; NIH [RO1CA111448, RO1CA109312] FX Veteran's Administration, the Multiple Myeloma Research Foundation, and NIH grants RO1CA111448 (A.K. Lichtenstein) and RO1CA109312 (J. Gera). NR 37 TC 34 Z9 34 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD DEC 15 PY 2008 VL 68 IS 24 BP 10215 EP 10222 DI 10.1158/0008-5472.CAN-08-1066 PG 8 WC Oncology SC Oncology GA 386FD UT WOS:000261866800027 PM 19074889 ER PT J AU Lipsky, BA Holroyd, KJ Zasloff, M AF Lipsky, Benjamin A. Holroyd, Kenneth J. Zasloff, Michael TI Topical versus Systemic Antimicrobial Therapy for Treating Mildly Infected Diabetic Foot Ulcers: A Randomized, Controlled, Double-Blinded, Multicenter Trial of Pexiganan Cream SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SAMPLE-SIZE REQUIREMENTS; PEPTIDES; SKIN; CLASSIFICATION; CLAVULANATE; DISEASE AB Background. Topical antimicrobial therapy of infected diabetic foot ulcers can focus on the wound and avoid the adverse effects of systemic anti-infective agents. We compared the efficacy of outpatient treatment using an investigational topical antimicrobial peptide, pexiganan acetate cream, with the efficacy of systemic therapy using an oral fluoroquinolone antibiotic, ofloxacin, for mildly infected diabetic foot ulcers. Methods. In 2 consecutive, double-blind, controlled trials (study 303 and study 304), we randomized diabetic patients with a mildly infected diabetic foot ulcer to receive the active topical agent or active oral antibiotic, plus a respective inactive placebo. The primary outcome of interest was clinical cure or improvement of the infection. Secondary outcomes included eradication of wound pathogens and wound healing, which was documented by a semiquantitative scoring system. Results. Overall, 835 patients were randomized; those in each treatment arm were similar with regard to demographic and clinical characteristics. Although study 303 failed to demonstrate equivalence, study 304 and the combined data for the 2 trials demonstrated equivalent results (within the 95% confidence interval) for topical pexiganan and oral ofloxacin in clinical improvement rates (85%-90%), overall microbiological eradication rates (42%-47%), and wound healing rates. The incidence of worsening cellulitis (2%-4%) and amputation (2%-3%) did not differ significantly between treatment arms. Bacterial resistance to ofloxacin emerged in some patients who received ofloxacin, but no significant resistance to pexiganan emerged among patients who received pexiganan. Conclusions. Topical pexiganan might be an effective alternative to oral antibiotic therapy in treating diabetic patients with a mildly infected foot ulcer, and might reduce the risk of selecting antimicrobial-resistant bacteria. Clinical trials registration. NCT00563394 and NCT00563433. C1 [Lipsky, Benjamin A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98116 USA. [Lipsky, Benjamin A.] Univ Washington, Sch Med, Seattle, WA USA. [Holroyd, Kenneth J.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Zasloff, Michael] Georgetown Univ, Sch Med, Washington, DC USA. RP Lipsky, BA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, S-111-PCC,1660 S Columbian Way, Seattle, WA 98116 USA. EM Benjamin.Lipsky@med.va.gov RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114 FU MacroChem FX At the time these studies were conducted, K.J.H. and M. Z. were employees of, and B. A. L. was a consultant to, Magainin Pharmaceuticals. B. A. L., K. J. H., and M. Z. have served as consultants to MacroChem. B. A. L. has received research grants from and been a consultant and speaker for Ortho McNeil. NR 30 TC 113 Z9 118 U1 0 U2 24 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2008 VL 47 IS 12 BP 1537 EP 1545 DI 10.1086/593185 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 376DO UT WOS:000261163600011 PM 18990064 ER PT J AU Taylor, TN Dolezal, C Tross, S Holmes, WC AF Taylor, Tonya N. Dolezal, Curtis Tross, Susan Holmes, William C. TI Comparison of HIV/AIDS-Specific Quality of Life Change in Zimbabwean Patients at Western Medicine Versus Traditional African Medicine Care Sites SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE AIDS; health care delivery; HIV; sub-Saharan Africa; quality of life; Zimbabwe ID CLINICAL CASE-DEFINITION; HAT-QOL INSTRUMENT; HIV; UGANDA; HEALERS; QUESTIONNAIRE; RELIABILITY; VALIDITY; OUTCOMES; AIDS AB Context: The rollout of antiretroviral treatment (ART) for the 25 million sub-Saharan Africans living with HIV/AIDS has been hampered by the lack of a western medical infrastructure. Given limited infrastructure, many Africans seek and receive HIV care from traditional African healers. This reality calls for culturally sensitive approaches to ART rollout that make use of local alternative health care providers, and an assessment of the potential quality of life (QOL) benefits of traditional African care (TAC) is imperative. Objective: To examine changes in self-reported health status resulting from TAC and western medical care (WC). Design, Setting, and Patients: QOL in 254 consecutively sampled Zimbabwean patients seeking care at TAC and WC sites was assessed over I month. Main Outcome Measures: Shona translations of the HIV/AID-Stargeted QOL instrument and Medical Outcomes Study HIV Health Survey. Results: After adjustment for baseline QOL scores and variables that differed across care sites, all dimensions of both instruments revealed QOL improvements only in the 155 (61%) patients from TAC sites when compared with the 99 (39%) patients from WC sites. These improvements were significant (P <= 0.01) for the HIV/AIDS-targeted QOL instrument dimensions of overall function, health worries, illness mastery; medication worries, and provider trust, and for the Medical Outcomes Study HIV Health Survey dimensions of general health perceptions, physical function, role function, pain, health distress, and energy/fatigue (range of regression coefficients, 10.0-18.3). Conclusions: Patients from TAC versus WC sites demonstrated significantly greater health status improvement across the majority of QOL dimensions assessed over I month. Though these data are from I rural Community and capture only I month of disease progression, they strongly suggest that the potential benefit of integrating TAC sites in ART rollout programs-particularly in resource-poor settings-may go well beyond cultural sensitivity to impact on health itself and the likely related issues of ART adherence. C1 [Taylor, Tonya N.; Dolezal, Curtis; Tross, Susan] New York State Psychiat Inst & Hosp, HIV Ctr Clin & Behav Studies, Dept Psychiat, New York, NY 10032 USA. [Tross, Susan] Columbia Univ, Dept Psychiat, New York, NY USA. [Tross, Susan] Columbia Univ, Dept Pediat, New York, NY 10027 USA. [Holmes, William C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Holmes, William C.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Taylor, TN (reprint author), New York State Psychiat Inst & Hosp, HIV Ctr Clin & Behav Studies, Dept Psychiat, 1051 Riverside Drive,Unit 15, New York, NY 10032 USA. EM tnt2109@columbia.edu FU National Institute of Mental Health [1-R03-MH62250-01, T32 MH19139]; Social Science Research Council; The University of Pennsylvania; Zimbabwe National Traditional Healers Association; Zimbabwean Medical Research Council; HIV Center for Clinical and Behavioral Studies [P30-MH43520]; Veterans Affairs Health Services Research; Development Research Career Development Award [RCD 03-029] FX Dr. T.N.T and research were supported by funding from the National Institute of Mental Health (1-R03-MH62250-01) and the Social Science Research Council. The University of Pennsylvania, the Zimbabwe National Traditional Healers Association, and the Zimbabwean Medical Research Council provided institutional support for this research. Dr. T.N.T. is currently supported by a training grant from the National Institute of Mental Health (T32 MH19139) at the HIV Center for Clinical and Behavioral Studies (P30-MH43520; Principal Investigator Anke A. Ehrhardt, PhD.). Dr. WC.H.s involvement was supported by a Veterans Affairs Health Services Research and Development Research Career Development Award (grant no. RCD 03-029). NR 29 TC 10 Z9 10 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 15 PY 2008 VL 49 IS 5 BP 552 EP 556 DI 10.1097/QAI.0b013e31818d5be0 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 376YN UT WOS:000261219000014 PM 18989225 ER PT J AU Simeon, D Yehuda, R Knutelska, M Schmeidler, J AF Simeon, Daphne Yehuda, Rachel Knutelska, Margaret Schmeidler, James TI Dissociation versus posttraumatic stress: Cortisol and physiological correlates in adults highly exposed to the World Trade Center attack on 9/11 SO PSYCHIATRY RESEARCH LA English DT Article DE Disaster; Cortisol; Heart rate; Dissociation; Posttraumatic stress; Trier Social Stress Test ID PERITRAUMATIC DISSOCIATION; DEPERSONALIZATION DISORDER; CENTER DISASTER; NOREPINEPHRINE; EARTHQUAKE; SURVIVORS; SEVERITY AB Nine months on average after the World Trade Center (WTC) attack, 21 highly exposed adults and 10 healthy controls without major exposure did not differ in cortisol and physiologic measures. Dissociation and posttraumatic stress symptoms were quantified in the exposed group. Dissociation was associated with greater peritraumatic dissociation and, marginally, childhood trauma, lower plasma cortisol levels at 08.00h, and blunted heart rate reactivity to psychosocial stress. Posttraumatic stress was associated with exposure, peritraumatic distress, and early posttraumatic stress, and marginally associated with peritraumatic dissociation; it was not associated with cortisol or physiologic measures. Urinary cortisol differed significantly in its relationship to dissociation versus posttraumatic stress. This small study emphasizes the importance of dissecting the neurobiology of posttraumatic stress versus dissociative traumatic responses. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Simeon, Daphne; Yehuda, Rachel; Knutelska, Margaret; Schmeidler, James] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Yehuda, Rachel] Bronx Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. RP Simeon, D (reprint author), Mt Sinai Sch Med, Dept Psychiat, Psychiat Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA. EM daphne.simeon@mssm.edu FU [NIH RO1 MH62414]; [NIH MO1 RR0071] FX The research reported was supported in part by NIH RO1 MH62414 supplement to Dr. Simeon and NIH MO1 RR0071 to the Mount Sinai General Clinical Research Center. NR 26 TC 14 Z9 16 U1 2 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD DEC 15 PY 2008 VL 161 IS 3 BP 325 EP 329 DI 10.1016/j.psychres.2008.04.021 PG 5 WC Psychiatry SC Psychiatry GA 384BN UT WOS:000261718700008 PM 18930323 ER PT J AU Volpp, KG John, LK Troxel, AB Norton, L Fassbender, J Loewenstein, G AF Volpp, Kevin G. John, Leslie K. Troxel, Andrea B. Norton, Laurie Fassbender, Jennifer Loewenstein, George TI Financial Incentive-Based Approaches for Weight Loss A Randomized Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID LOSS AVERSION; MONETARY CONTRACTS; OBESITY; HEALTH; OVERWEIGHT; CHOICE; RISK; PREVALENCE; REDUCTION; BEHAVIOR AB Context Identifying effective obesity treatment is both a clinical challenge and a public health priority due to the health consequences of obesity. Objective To determine whether common decision errors identified by behavioral economists such as prospect theory, loss aversion, and regret could be used to design an effective weight loss intervention. Design, Setting, and Participants Fifty- seven healthy participants aged 30- 70 years with a body mass index of 30- 40 were randomized to 3 weight loss plans: monthly weigh- ins, a lottery incentive program, or a deposit contract that allowed for participant matching, with a weight loss goal of 1 lb ( 0.45 kg) a week for 16 weeks. Participants were recruited May- August 2007 at the Philadelphia VA Medical Center in Pennsylvania and were followed up through June 2008. Main Outcome Measures Weight loss after 16 weeks. Results The incentive groups lost significantly more weight than the control group ( mean, 3.9 lb). Compared with the control group, the lottery group lost a mean of 13.1 lb ( 95% confidence interval [ CI] of the difference in means, 1.95- 16.40; P=. 02) and the deposit contract group lost a mean of 14.0 lb ( 95% CI of the difference in means, 3.69- 16.43; P =. 006). About half of those in both incentive groups met the 16- lb target weight loss: 47.4% ( 95% CI, 24.5%- 71.1%) in the deposit contract group and 52.6% ( 95% CI, 28.9%- 75.6%) in the lottery group, whereas 10.5% ( 95% CI, 1.3%- 33.1%; P=. 01) in the control group met the 16- lb target. Although the net weight loss between enrollment in the study and at the end of 7 months was larger in the incentive groups ( 9.2 lb; t= 1.21; 95% CI, - 3.20 to 12.66; P=. 23, in the lottery group and 6.2 lb; t= 0.52; 95% CI, - 5.17 to 8.75; P=. 61 in the deposit contract group) than in the control group ( 4.4 lb), these differences were not statistically significant. However, incentive participants weighed significantly less at 7 months than at the study start ( P=. 01 for the lottery group; P=. 03 for the deposit contract group) whereas controls did not. Conclusions The use of economic incentives produced significant weight loss during the 16 weeks of intervention that was not fully sustained. The longer- term use of incentives should be evaluated. Trial Registration clinicaltrials. gov Identifier: NCT00520611. C1 [Volpp, Kevin G.; Troxel, Andrea B.; Norton, Laurie; Loewenstein, George] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Norton, Laurie] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Wharton Sch, Philadelphia, PA USA. [Volpp, Kevin G.; Norton, Laurie] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Sch Med, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Fassbender, Jennifer] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Troxel, Andrea B.; Fassbender, Jennifer] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [John, Leslie K.; Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. RP Volpp, KG (reprint author), Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, 1232 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM volpp70@wharton.upenn.edu FU National Institute on Aging [P30 AG12836]; Boettner Center for Pensions and Retirement Security at the University of Pennsylvania; National Institute of Child Health and Development Population Research Infrastructure Program [R24 HD-044964]; University of Pennsylvania [58-4000-70058]; S Department of Agriculture; Economic Research Service; Hewlett Foundation FX This work was supported by grant P30 AG12836 from the National Institute on Aging, the Boettner Center for Pensions and Retirement Security at the University of Pennsylvania, grant R24 HD-044964 from National Institute of Child Health and Development Population Research Infrastructure Program, all at the University of Pennsylvania, and grant 58-4000-70058 from the US Department of Agriculture, Economic Research Service, and the Hewlett Foundation. NR 39 TC 270 Z9 271 U1 5 U2 48 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 10 PY 2008 VL 300 IS 22 BP 2631 EP 2637 DI 10.1001/jama.2008.804 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 380YW UT WOS:000261503000022 PM 19066383 ER PT J AU Lorenz, KA AF Lorenz, Karl A. TI Promoting Efficiency and Quality of Care in the Hummer Health Care System SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID MEDICARE C1 [Lorenz, Karl A.] Univ Calif Los Angeles, Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA. RP Lorenz, KA (reprint author), Univ Calif Los Angeles, Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA 90024 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 10 PY 2008 VL 26 IS 35 BP 5664 EP 5665 DI 10.1200/JCO.2008.18.2162 PG 2 WC Oncology SC Oncology GA 381IC UT WOS:000261528200002 PM 19001319 ER PT J AU Hakeem, A Bhatti, S Dillie, KS Cook, JR Samad, Z Roth-Cline, MD Chang, SM AF Hakeem, Abdul Bhatti, Sabha Dillie, Kathryn Sullivan Cook, Jeffrey R. Samad, Zainab Roth-Cline, Michelle D. Chang, Su Min TI Predictive Value of Myocardial Perfusion Single-Photon Emission Computed Tomography and the Impact of Renal Function on Cardiac Death SO CIRCULATION LA English DT Article DE prognosis; imaging; kidney disease; scintigraphy; mortality ID CHRONIC KIDNEY-DISEASE; CORONARY-ARTERY-DISEASE; GLOMERULAR-FILTRATION-RATE; INCREMENTAL PROGNOSTIC VALUE; RISK STRATIFICATION; CARDIOVASCULAR OUTCOMES; DIAGNOSTIC-ACCURACY; SERUM CREATININE; BYPASS SURGERY; HEART-FAILURE AB Background-Patients with chronic kidney disease CKD) have worse cardiovascular outcomes than those without CKD. The prognostic utility of myocardial perfusion single-photon emission CT MPS) in patients with varying degrees of renal dysfunction and the impact of CKD on cardiac death prediction in patients undergoing MPS have not been investigated. Methods and Results-We followed up 1652 consecutive patients who underwent stress MPS 32% exercise, 95% gated) for cardiac death for a mean of 2.15 +/- 0.8 years. MPS defects were defined with a summed stress score normal summed stress score < 4, abnormal summed stress score >= 4). Ischemia was defined as a summed stress score >= 4 plus a summed difference score >= 2, and scar was defined as a summed difference score < 2 plus a summed stress score >= 4. Renal function was calculated with the Modified Diet in Renal Disease equation. CKD estimated glomerular filtration rate < 60 mL center dot min(-1) center dot 1.73 m(-2)) was present in 36%. Cardiac death increased with worsening levels of perfusion defects across the entire spectrum of renal function. Presence of ischemia was independently predictive of cardiac death, all-cause mortality, and nonfatal myocardial infarction. Patients with normal MPS and CKD had higher unadjusted cardiac death event rates than those with no CKD and normal MPS 2.7% versus 0.8%, P = 0.001). Multivariate Cox proportional hazards models revealed that both perfusion defects hazard ratio 1.90, 95% CI 1.47 to 2.46) and CKD hazard ratio 1.96, 95% CI 1.29 to 2.95) were independent predictors of cardiac death after accounting for risk factors, left ventricular dysfunction, pharmacological stress, and symptom status. Both MPS and CKD had incremental power for cardiac death prediction over baseline risk factors and left ventricular dysfunction global chi(2) 207.5 versus 169.3, P < 0.0001). Conclusions-MPS provides effective risk stratification across the entire spectrum of renal function. Renal dysfunction is also an important independent predictor of cardiac death in patients undergoing MPS. Renal function and MPS have additive value in risk stratisfying patients with suspected coronary artery disease. Patients with CKD appear to have a relatively less benign prognosis than those without CKD, even in the presence of a normal scan. Circulation. 2008; 118: 2540-2549.) C1 [Hakeem, Abdul; Bhatti, Sabha] Univ Cincinnati, Coll Med, Div Cardiovasc Med, Cincinnati, OH USA. [Dillie, Kathryn Sullivan; Cook, Jeffrey R.; Roth-Cline, Michelle D.] Univ Wisconsin Hosp, Dept Internal Med, Madison, WI USA. Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA. [Samad, Zainab] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. [Chang, Su Min] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA. RP Hakeem, A (reprint author), Univ Cincinnati Hosp, Acad Hlth Ctr, 231 Albert Sabin Way,POB 670542, Cincinnati, OH 45257 USA. EM ahakeem@gmail.com NR 40 TC 60 Z9 60 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD DEC 9 PY 2008 VL 118 IS 24 BP 2540 EP 2549 DI 10.1161/CIRCULATIONAHA.108.788109 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 381CJ UT WOS:000261512400009 PM 19047585 ER PT J AU Massie, BM Carson, PE McMurray, JJ Komajda, M McKelvie, R Zile, MR Anderson, S Donovan, M Iverson, E Staiger, C Ptaszynska, A AF Massie, Barry M. Carson, Peter E. McMurray, John J. Komajda, Michel McKelvie, Robert Zile, Michael R. Anderson, Susan Donovan, Mark Iverson, Erik Staiger, Christoph Ptaszynska, Agata CA I-PRESERVE Investigators TI Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID VENTRICULAR SYSTOLIC FUNCTION; BRAIN NATRIURETIC PEPTIDE; DIASTOLIC DYSFUNCTION; CLINICAL CHARACTERISTICS; CARDIOVASCULAR OUTCOMES; RANDOMIZED TRIAL; MECHANISMS; PROGNOSIS; MORBIDITY; MORTALITY AB Background: Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. Methods: We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. Results: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. Conclusions: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.). C1 [Massie, Barry M.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Carson, Peter E.] Vet Affairs Med Ctr, Washington, DC 20422 USA. [McMurray, John J.] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Komajda, Michel] Univ Paris 06, Paris, France. [Komajda, Michel] Grp Hosp Pitie Salpetriere, F-75634 Paris, France. [McKelvie, Robert] McMaster Univ, Hamilton, ON, Canada. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Anderson, Susan; Iverson, Erik] Univ Wisconsin, Madison, WI USA. [Donovan, Mark; Ptaszynska, Agata] Bristol Myers Squibb Co, Princeton, NJ USA. [Staiger, Christoph] Sanofi Aventis, Bridgewater, NJ USA. RP Massie, BM (reprint author), Vet Affairs Med Ctr, 111C,4150 Clement St, San Francisco, CA 94121 USA. EM barry.massie@va.gov RI van Veldhuisen, Dirk Jan/E-8967-2014; Casademont, Jordi/A-6828-2010; Colquhoun, David/F-9078-2013; Ponikowski, Piotr/O-6454-2015; Hradec, Jaromir/S-2388-2016; Brito, Dulce/G-9650-2016 OI Casademont, Jordi/0000-0002-8100-1827; Ponikowski, Piotr/0000-0002-3391-7064; Hradec, Jaromir/0000-0001-7597-8239; Brito, Dulce/0000-0003-1278-1847; mcmurray, john/0000-0002-6317-3975 FU Bristol-Myers Squibb; Sanofi-Aventis; Merck; Duke Clinical Research Institute; Momentum Research; Novartis; GlaxoSmithKline; Scios-Johnson Johnson; Corthera; Niles Therapeutics; AstraZeneca; Servier; Pfizer FX Supported by Bristol-Myers Squibb and Sanofi-Aventis.; Dr. Massie reports receiving grant support from Bristol-Myers Squibb, Sanofi-Aventis, and Merck, consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, Merck, Duke Clinical Research Institute, Momentum Research, Novartis, GlaxoSmithKline, Scios-Johnson & Johnson, Corthera, and Niles Therapeutics, and lecture fees from Merck; Dr. Carson, receiving consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, and Merck and lecture fees from AstraZeneca and Novartis; Dr. McMurray, receiving support from Bristol-Myers Squibb (to Glasgow University) for his work on this trial; Dr. Komajda, receiving consulting fees from Bristol-Myers Squibb and Servier and lecture fees from Servier, Sanofi-Aventis, and AstraZeneca; Dr. McKelvie, receiving consulting fees from Bristol-Myers Squibb and Sanofi-Aventis and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Pfizer, Merck, and AstraZeneca; Dr. Zile, receiving consulting fees from Bristol-Myers Squibb and Sanofi-Aventis; Ms. Anderson, being employed by the Statistical Data Analysis Center at the University of Wisconsin - Madison, which conducted statistical analysis for this trial, supported by Bristol- Myers Squibb and Sanofi-Aventis; Drs. Donovan and Ptaszynska, being employees of and having an equity interest in Bristol- Myers Squibb; and Dr. Staiger, being an employee of and having an equity interest in Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.; We thank clinical scientists Jean-Michel Bocquet and Magalie Thuault for their care in handling the logistics of the trial. NR 36 TC 645 Z9 680 U1 2 U2 25 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 4 PY 2008 VL 359 IS 23 BP 2456 EP 2467 DI 10.1056/NEJMoa0805450 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 378MT UT WOS:000261325900006 PM 19001508 ER PT J AU Al-Noori, S Sanders, NM Taborsky, GJ Wilkinson, CW Figlewicz, DP AF Al-Noori, Salwa Sanders, Nicole M. Taborsky, Gerald J. Wilkinson, Charles W. Figlewicz, Dianne P. TI Acute THPVP inactivation decreases the glucagon and sympathoadrenal responses to recurrent hypoglycemia (vol 1194, pg 65, 2008) SO BRAIN RESEARCH LA English DT Correction C1 [Al-Noori, Salwa; Wilkinson, Charles W.; Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Sanders, Nicole M.; Taborsky, Gerald J.; Figlewicz, Dianne P.] Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab & Geriatr Res, Seattle, WA USA. [Taborsky, Gerald J.; Figlewicz, Dianne P.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Wilkinson, Charles W.] Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle, WA USA. RP Al-Noori, S (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM saan@u.washington.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 3 PY 2008 VL 1243 BP 175 EP 175 DI 10.1016/j.brainres.2008.08.035 PG 1 WC Neurosciences SC Neurosciences & Neurology GA 384YL UT WOS:000261780000021 ER PT J AU Stetler, RA Cao, GD Gao, YQ Zhang, F Wang, SP Weng, ZF Vosler, P Zhang, LL Signore, A Graham, SH Chen, J AF Stetler, R. Anne Cao, Guodong Gao, Yanqin Zhang, Feng Wang, Suping Weng, Zhongfang Vosler, Peter Zhang, Lili Signore, Armando Graham, Steven H. Chen, Jun TI Hsp27 Protects against Ischemic Brain Injury via Attenuation of a Novel Stress-Response Cascade Upstream of Mitochondrial Cell Death Signaling SO JOURNAL OF NEUROSCIENCE LA English DT Article DE cerebral ischemia; neuroprotection; heat shock proteins; apoptosis signaling kinase-1; JNK; mitochondria ID FOCAL CEREBRAL-ISCHEMIA; HEAT-SHOCK-PROTEIN; APOPTOSIS-INDUCING FACTOR; CYTOCHROME-C; REGULATING KINASE-1; GLUCOSE DEPRIVATION; NEURONAL CULTURES; AKT ACTIVATION; UP-REGULATION; MAP KINASE AB Heat shock protein 27 (Hsp27), a recently discovered member of the heat shock protein family, is markedly induced in the brain after cerebral ischemia and other injury states. In non-neuronal systems, Hsp27 has potent cell death-suppressing functions. However, the mechanism of Hsp27-mediated neuroprotection has not yet been elucidated. Using transgenic and viral overexpression of Hsp27, we investigated the molecular mechanism by which Hsp27 exerts its neuroprotective effect. Overexpression of Hsp27 conferred long-lasting tissue preservation and neurobehavioral recovery, as measured by infarct volume, sensorimotor function, and cognitive tasks up to 3 weeks following focal cerebral ischemia. Examination of signaling pathways critical to neuronal death demonstrated that Hsp27 overexpression led to the suppression of the MKK4/JNK kinase cascade. While Hsp27 overexpression did not suppress activation of an upstream regulatory kinase of the MKK/JNK cascade, ASK1, Hsp27 effectively inhibited ASK1 activity via a physical association through its N-terminal domain and the kinase domain of ASK1. The N-terminal region of Hsp27 was required for neuroprotective function against in vitro ischemia. Moreover, knockdown of ASK1 or inhibition of the ASK1/MKK4 cascade effectively inhibited cell death following neuronal ischemia. This underscores the importance of this kinase cascade in the progression of ischemic neuronal death. Inhibition of PI3K had no effect on Hsp27-mediated neuroprotection, suggesting that Hsp27 does not promote cell survival via activation of PI3K/Akt. Based on these findings, we conclude that overexpression of Hsp27 confers long-lasting neuroprotection against ischemic brain injury via a previously unexplored association and inhibition of ASK1 kinase signaling. C1 [Stetler, R. Anne; Cao, Guodong; Zhang, Feng; Wang, Suping; Weng, Zhongfang; Vosler, Peter; Zhang, Lili; Signore, Armando; Graham, Steven H.; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Stetler, R. Anne; Cao, Guodong; Zhang, Feng; Wang, Suping; Weng, Zhongfang; Vosler, Peter; Zhang, Lili; Signore, Armando; Graham, Steven H.; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Stetler, R. Anne; Cao, Guodong; Gao, Yanqin; Chen, Jun] Fudan Univ, Sch Med, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Stetler, R. Anne; Cao, Guodong; Zhang, Feng; Wang, Suping; Signore, Armando; Graham, Steven H.; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst Pittsburgh, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, 507 S Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA. EM chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU National Institutes of Health-National Institute of Neurological Disorders and Stroke [NS43802, NS45048, NS36736, NS 56118]; VA Merit Review; American Heart Association [0725503U, 0715254U]; Chinese Natural Science Foundation [30470592, 30670642] FX This work was supported by National Institutes of Health-National Institute of Neurological Disorders and Stroke Grants NS43802, NS45048, NS36736, and NS 56118 and VA Merit Review Grant ( to J. C.). Additional support was provided by the American Heart Association to R. A. S. (0725503U) and P. V. (0715254U), and by the Chinese Natural Science Foundation ( Grants 30470592 and 30670642 to Y.G.). We thank Drs. Lin Zhang and Jian Yu ( Pittsburgh Cancer Institute) for providing adenovirus vectors expressing Bax and PUMA. We thank Carol Culver for editorial assistance and Pat Strickler for secretarial support. NR 77 TC 72 Z9 76 U1 2 U2 6 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD DEC 3 PY 2008 VL 28 IS 49 BP 13038 EP 13055 DI 10.1523/JNEUROSCI.4407-08.2008 PG 18 WC Neurosciences SC Neurosciences & Neurology GA 379DZ UT WOS:000261378100003 PM 19052195 ER PT J AU Kerlikowske, K Walker, R Miglioretti, DL Desai, A Ballard-Barbash, R Buist, DSM AF Kerlikowske, Karla Walker, Rod Miglioretti, Diana L. Desai, Arati Ballard-Barbash, Rachel Buist, Diana S. M. TI Obesity, Mammography Use and Accuracy, and Advanced Breast Cancer Risk SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID BODY-MASS INDEX; ADULT WEIGHT CHANGE; CARCINOMA IN-SITU; SCREENING MAMMOGRAPHY; UNITED-STATES; POSTMENOPAUSAL WOMEN; COHORT; POPULATION; OVERWEIGHT; GROWTH AB Being overweight or obese is associated with increased breast cancer risk and disease severity among postmenopausal women, but whether extent of mammography use and accuracy modify this association and further contribute to increases in disease severity at diagnosis among overweight and obese women is unclear. We prospectively collected data during 1996-2005 on 287 115 postmenopausal women not using hormone therapy (HT) who underwent 614 562 mammography examinations; 4446 women were diagnosed with breast cancer within 12 months of a mammography examination. We calculated rates per 1000 mammography examinations of large (> 15 mm), advanced-stage (IIb, III, or IV), high-grade (3 or 4), estrogen receptor (ER)-positive and -negative, and screen-detected and non-screen-detected breast cancer across body mass index (BMI, kg/m(2)) groups defined as normal (18.5-24.9), overweight (25.0-29.9), obese class I (30.0-34.9), and obese class II/III (>= 35.0), adjusting for age, race/ethnicity, and mammography registry and use. All statistical tests were two-sided. Adjusted rates per 1000 mammography examinations of overall breast cancer increased across BMI groups (6.6 normal, 7.4 overweight, 7.9 obese I, 8.5 obese II/III; P(trend) < .001), as did rates of advanced disease, including large invasive (2.3 normal, 2.6 overweight, 2.9 obese I, 3.2 obese II/III; P(trend) < .001), advanced-stage (0.8 normal, 0.9 overweight, 1.3 obese I, 1.5 obese II/III; P(trend) < .001), and high nuclear grade (1.5 normal, 1.7 overweight, 1.7 obese I, 1.9 obese II/III; P(trend) = .10) tumors. Rates of ER-positive tumors increased across BMI groups (P(trend) < .001); rates of ER-negative tumors did not. Rates of screen-detected cancers were higher among overweight and obese women than normal and underweight women, but rates of non-screen-detected (false-negative) cancers were similar. Rates of advanced breast cancer increased across BMI groups regardless of extent of mammography use. Patterns of mammography use and mammography accuracy are not the primary reasons for higher rates of advanced breast cancer among overweight and obese postmenopausal women not using HT; thus, biologic differences in breast tumor development and/or progression may be important. C1 [Kerlikowske, Karla] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco Vet Affairs Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA. [Walker, Rod; Miglioretti, Diana L.; Buist, Diana S. M.] Grp Hlth Ctr Hlth Studies, Seattle, WA USA. [Miglioretti, Diana L.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Desai, Arati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA. [Ballard-Barbash, Rachel] NCI, Appl Res Program, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. RP Kerlikowske, K (reprint author), Univ Calif San Francisco, Gen Internal Med Sect, San Francisco Vet Affairs Med Ctr, Dept Vet Affairs, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM karla.kerlikowske@ucsf.edu FU NCI [U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040] FX NCI-funded Breast Cancer Surveillance Consortium cooperative agreement (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040). The collection of cancer incidence data used in this study was supported in part by several state public health departments and cancer registries throughout the United States. For a full description of these sources, please see: http://breastscreening.cancer.gov/work/acknowledgement.html. NR 46 TC 41 Z9 43 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD DEC 3 PY 2008 VL 100 IS 23 BP 1724 EP 1733 DI 10.1093/jnci/djn388 PG 10 WC Oncology SC Oncology GA 380JQ UT WOS:000261462400012 PM 19033562 ER PT J AU Bryson, CL Au, DH Sun, HL Williams, EC Kivlahan, DR Bradley, KA AF Bryson, Chris L. Au, David H. Sun, Haili Williams, Emily C. Kivlahan, Daniel R. Bradley, Katharine A. TI Alcohol Screening Scores and Medication Nonadherence SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; ANTIRETROVIRAL THERAPY ADHERENCE; TYPE-2 DIABETES-MELLITUS; PRIMARY-CARE PATIENTS; CONSUMPTION QUESTIONS; OBJECTIVE ASSESSMENT; PREVENTIVE-SERVICES; PROBLEM DRINKING; HIV-INFECTION; MENTAL-HEALTH AB Background: Medication nonadherence is common and is associated with adverse outcomes. Alcohol misuse may be a risk factor for nonadherence; however, evidence is limited. Objective: To identify whether alcohol misuse, as identified by a simple screening tool, is associated in a dose-response manner with increased risk for medication nonadherence in veterans attending primary care clinics. Design: Secondary analysis of cohort data collected prospectively from 1997 to 2000 as part of a randomized, controlled trial. Setting: 7 Veterans Affairs primary care clinics. Participants: 5473 patients taking a statin, 3468 patients taking oral hypoglycemic agents, and 13 729 patients taking antihypertensive medications. Measurements: Patients completed the Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) questionnaire, a validated 3-question alcohol misuse screening test. Their scores were categorized into nondrinkers; low-level alcohol use; and mild, moderate, and severe alcohol misuse. Medication adherence, defined as having medications available for at least 80% of the observation days, was measured from pharmacy records for either 90 days or 1 year after the alcohol screening date. Logistic regression was used to estimate the predicted proportions of adherent patients in each AUDIT-C group and adjusted for demographic and clinical covariates. Results: The proportion of patients treated for hypertension and hyperlipidemia who were nonadherent increased with higher AUDIT-C scores. For 1-year adherence to statins, the percentage of adherent patients was lower in the 2 highest alcohol misuse groups ( adjusted percentage of adherent patients, 58% [95% CI, 52% to 65%] and 55% [ CI, 47% to 63%]) than in the nondrinker group (66% [ CI, 64% to 68%]). For 1-year adherence to antihypertensive regimens, the percentage of adherent patients was lower in the 3 highest alcohol misuse groups ( adjusted percentage of adherent patients, 61% [ CI, 58% to 64%]; 60% [ CI, 56% to 63%]; and 56% [ CI, 52% to 60%]) than in the nondrinker group ( 64% [ CI, 63% to 65%]). No statistically significant differences were observed for oral hypoglycemics in adjusted analyses. Limitation: This observational study cannot address whether changes in drinking lead to changes in adherence and may not be generalizable to other populations. Conclusion: Alcohol misuse, as measured by a brief screening questionnaire, was associated with increased risk for medication nonadherence. C1 [Bryson, Chris L.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev Serv, Hlth Serv Res & Dev NW Ctr Excellence, Seattle, WA 98101 USA. Univ Washington, Seattle, WA 98195 USA. RP Bryson, CL (reprint author), Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev Serv, Hlth Serv Res & Dev NW Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM christopher.bryson@va.gov; haili.sun@va.gov FU Department of Veterans Affairs [SDR 96-002, IIR 99-376]; Veterans Health Administration; Health Services Research & Development Service; AUDIT-C as a Scaled Marker for Health Risks in VA Medical Outpatients [IAC 05-206]; Development Service Career Development Awards [RCD 03-177, RCD 00-018] FX By the Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service (AUDIT-C as a Scaled Marker for Health Risks in VA Medical Outpatients; IAC 05-206). The ACQUIP was funded by Department of Veterans Affairs grants SDR 96-002 and IIR 99-376. Drs. Bryson and Au were supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service Career Development Awards (RCD 03-177 and RCD 00-018). NR 44 TC 61 Z9 62 U1 2 U2 7 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 2 PY 2008 VL 149 IS 11 BP 795 EP W165 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 383AA UT WOS:000261645300003 PM 19047026 ER PT J AU Hwang, U Richardson, L Livote, E Harris, B Spencer, N Morrison, RS AF Hwang, Ula Richardson, Lynne Livote, Elayne Harris, Ben Spencer, Natasha Morrison, R. Sean TI Emergency Department Crowding and Decreased Quality of Pain Care SO ACADEMIC EMERGENCY MEDICINE LA English DT Article DE emergency department; quality of care; pain ID MYOCARDIAL-INFARCTION; MEDICINE RESEARCH; CANCER PAIN; REAL-TIME; MANAGEMENT; VALIDATION; ETHNICITY; ANALGESIA; FRACTURE; TRAUMA AB The objective of this study was to evaluate the association of emergency department (ED) crowding factors with the quality of pain care. This was a retrospective observational study of all adult patients (>= 18 years) with conditions warranting pain care seen at an academic, urban, tertiary care ED from July 1 to July 31, 2005, and December 1 to December 31, 2005. Patients were included if they presented with a chief complaint of pain and a final ED diagnosis of a painful condition. Predictor ED crowding variables studied were 1) census, 2) number of admitted patients waiting for inpatient beds (boarders), and 3) number of boarders divided by ED census (boarding burden). The outcomes of interest were process of pain care measures: documentation of clinician pain assessment, medications ordered, and times of activities (e.g., arrival, assessment, ordering of medications). A total of 1,068 patient visits were reviewed. Fewer patients received analgesic medication during periods of high census (> 50th percentile; parameter estimate = -0.47; 95% confidence interval [CI] = -0.80 to -0.07). There was a direct correlation with total ED census and increased time to pain assessment (Spearman r = 0.33, p < 0.0001), time to analgesic medication ordering (r = 0.22, p < 0.0001), and time to analgesic medication administration (r = 0.25, p < 0.0001). There were significant delays (> 1 hour) for pain assessment and the ordering and administration of analgesic medication during periods of high ED census and number of boarders, but not with boarding burden. ED crowding as measured by patient volume negatively impacts patient care. Greater numbers of patients in the ED, whether as total census or number of boarders, were associated with worse pain care. C1 [Hwang, Ula; Richardson, Lynne; Harris, Ben] Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. [Hwang, Ula; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY USA. [Morrison, R. Sean] Mt Sinai Sch Med, Lillian & Benjamin Hertzberg Palliat Care Inst, New York, NY USA. [Hwang, Ula; Livote, Elayne; Morrison, R. Sean] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Hwang, U (reprint author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY 10029 USA. EM ula.hwang@mountsinai.org FU Jahnigen Career Development Award; American Geriatrics Society (UH); Mid-Career Investigator Award in Patient-Oriented Research [K24 AG022345]; National Institute on Aging (RSM) FX This study was supported by a Jahnigen Career Development Award administered by the American Geriatrics Society (UH) and a Mid-Career Investigator Award in Patient-Oriented Research (K24 AG022345) from the National Institute on Aging (RSM). NR 43 TC 62 Z9 64 U1 2 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD DEC PY 2008 VL 15 IS 12 BP 1248 EP 1255 DI 10.1111/j.1553-2712.2008.00267.x PG 8 WC Emergency Medicine SC Emergency Medicine GA 379KI UT WOS:000261394700004 PM 18945239 ER PT J AU Caldeiro, RM Malte, CA Calsyn, DA Baer, JS Nichol, P Kivlahan, DR Saxon, AJ AF Caldeiro, Ryan M. Malte, Carol A. Calsyn, Donald A. Baer, John S. Nichol, Paul Kivlahan, Daniel R. Saxon, Andrew J. TI The association of persistent pain with out-patient addiction treatment outcomes and service utilization SO ADDICTION LA English DT Article DE Addiction; co-morbidity; pain; out-patient treatment; outcomes; prospective data; service utilization ID POSTTRAUMATIC-STRESS-DISORDER; HEPATITIS-C; METHADONE-MAINTENANCE; DEPENDENT PATIENTS; SUBSTANCE-ABUSE; PREVALENCE; CHEMOKINES; VETERANS; BARRIERS; COSTS AB To estimate the prevalence of persistent pain among veterans in out-patient addiction treatment and examine associated addiction treatment outcomes and medical and psychiatric service use. Analysis of data from a prospective randomized controlled trial comparing on-site versus referral primary care of veterans with substance dependence (n = 582), excluding opioid dependence who had at least one follow-up interview during the 12-month study period in a Veterans Affairs (VA) out-patient addiction treatment center. Pain status was classified as persistent (pain was rated moderate to very severe at all time-points), low (pain was rated none to mild at all time-points) or intermittent (all others). Main outcome measures were addiction treatment retention, addiction severity index (ASI) alcohol and drug composite scores, VA service utilization and treatment costs. A total of 33.2% of veterans reported persistent pain and 47.3% reported intermittent pain. All groups benefited from addiction treatment, but veterans with persistent pain were in treatment for an estimated 35.1 fewer days [95% confidence interval (CI) = -64.1, -6.1, P = 0.018], less likely to be abstinent from alcohol or drugs at 12 months [odds ratio (OR)(adj) = 0.52; 95% CI = 0.30,0.89; P = 0.018], had worse ASI alcohol composite scores at 12 months (beta(adj) = 0.09; 95% CI = 0.02,0.15; P = 0.007), were more likely to be medically hospitalized (OR(adj) = 2.70; 95% CI = 1.02,7.13; P = 0.046) and had higher total service costs compared to those with low pain ($17 766 versus $13 261, P = 0.012). Persistent pain is common among veterans in out-patient addiction treatment and is associated with poorer rates of abstinence, worse alcohol use severity and greater service utilization and costs than those with low pain. C1 [Caldeiro, Ryan M.; Calsyn, Donald A.; Kivlahan, Daniel R.; Saxon, Andrew J.] Univ Washington, Med Ctr, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Malte, Carol A.; Calsyn, Donald A.; Baer, John S.; Nichol, Paul; Kivlahan, Daniel R.; Saxon, Andrew J.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Malte, Carol A.; Calsyn, Donald A.; Baer, John S.; Kivlahan, Daniel R.; Saxon, Andrew J.] Univ Washington, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA 98195 USA. [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Nichol, Paul] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Caldeiro, RM (reprint author), Univ Washington, Med Ctr, Dept Psychiat & Behav Sci, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA. EM caldeiro@u.washington.edu FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service [SUI 99-109-1]; Center of Excellence in Substance Abuse Treatment and Education at VA Puget Sound Health Care System FX The research reported here was supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, grant no. SUI 99-109-1, and by the Center of Excellence in Substance Abuse Treatment and Education at VA Puget Sound Health Care System. Dr Saxon is currently the Director of Addiction Patient Care Line VA Puget Sound Health Care System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. Carol A. Malte had full access to all the data inthe study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 26 TC 33 Z9 33 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0965-2140 J9 ADDICTION JI Addiction PD DEC PY 2008 VL 103 IS 12 BP 1996 EP 2005 DI 10.1111/j.1360-0443.2008.02358.x PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 369ZF UT WOS:000260731700021 PM 18855809 ER PT J AU Nadon, NL Strong, R Miller, RA Nelson, J Javors, M Sharp, ZD Peralba, JM Harrison, DE AF Nadon, N. L. Strong, R. Miller, R. A. Nelson, J. Javors, M. Sharp, Z. D. Peralba, J. M. Harrison, D. E. TI Design of aging intervention studies: the NIA interventions testing program SO AGE LA English DT Article DE Anti-aging; Lifespan; Longevity; Mice ID GENETICALLY HETEROGENEOUS MICE; CONVERTING ENZYME-INHIBITORS; TERT-BUTYL NITRONE; QUANTITATIVE TRAIT LOCI; ACID PHENETHYL ESTER; LIFE-SPAN; BODY-WEIGHT; SPIN-TRAP; ANTIOXIDANT PROPERTIES; CALORIC RESTRICTION AB The field of biogerontology has made great strides towards understanding the biological processes underlying aging, and the time is ripe to look towards applying this knowledge to the pursuit of aging interventions. Identification of safe, inexpensive, and non-invasive interventions that slow the aging process and promote healthy aging could have a significant impact on quality of life and health care expenditures for the aged. While there is a plethora of supplements and interventions on the market that purport to slow aging, the evidence to validate such claims is generally lacking. Here we describe the development of an aging interventions testing program funded by the National Institute on Aging (NIA) to test candidate interventions in a model system. The development of this program highlights the challenges of long-term intervention studies and provides approaches to cope with the stringent requirements of a multi-site testing program. C1 [Nadon, N. L.] NIA, Biol Aging Program, Bethesda, MD 20892 USA. [Strong, R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Nelson, J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Strong, R.; Nelson, J.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Aging Inst, San Antonio, TX 78229 USA. [Miller, R. A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Miller, R. A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA. [Miller, R. A.] VA Med Ctr, Ann Arbor, MI USA. [Javors, M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Sharp, Z. D.; Peralba, J. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Harrison, D. E.] Jackson Labs, Bar Harbor, ME USA. [Strong, R.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Nadon, NL (reprint author), NIA, Biol Aging Program, 7201 Wisconsin Ave GW 2C231, Bethesda, MD 20892 USA. EM nadonn@nia.nih.gov FU National Institutes of Health [U01-AG-022307, U01-AG-022303, U01-AG-022308] FX This work was support by grants from the National Institutes of Health U01-AG-022307 ( R. S.), U01-AG-022303 ( R. A. M.) and U01-AG-022308 ( D. E. H.). NR 82 TC 58 Z9 60 U1 1 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0161-9152 J9 AGE JI Age PD DEC PY 2008 VL 30 IS 4 BP 187 EP 199 DI 10.1007/s11357-008-9048-1 PG 13 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 413LJ UT WOS:000263794300001 PM 19424842 ER PT J AU Chen, LJ Na, R Gu, MJ Salmon, AB Liu, YH Liang, HY Qi, WB Van Remmen, H Richardson, A Ran, QT AF Chen, Liuji Na, Ren Gu, Mingjun Salmon, Adam B. Liu, Yuhong Liang, Hanyu Qi, Wenbo Van Remmen, Holly Richardson, Arlan Ran, Qitao TI Reduction of mitochondrial H(2)O(2) by overexpressing peroxiredoxin 3 improves glucose tolerance in mice SO AGING CELL LA English DT Article DE aging; diabetes; mitochondria; oxidative stress; peroxiredoxin 3; reactive oxygen species ID CELLULAR GLUTATHIONE-PEROXIDASE; PROTEIN-TYROSINE PHOSPHATASES; INSULIN-RESISTANCE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; INCREASED SENSITIVITY; ANTIOXIDANT DEFENSE; MULTIPLE FORMS; ROS PRODUCTION; LIFE-SPAN AB H(2)O(2) is a major reactive oxygen species produced by mitochondria that is implicated to be important in aging and pathogenesis of diseases such as diabetes; however, the cellular and physiological roles of mitochondrial H(2)O(2) remain poorly understood. Peroxiredoxin 3 (Prdx3/Prx3) is a thioredoxin peroxidase localized in mitochondria. To understand the cellular and physiological roles of mitochondrial H(2)O(2) in aging and pathogenesis of age-associated diseases, we generated transgenic mice overexpressing Prdx3 (Tg(PRDX3) mice). Tg(PRDX3) mice overexpress Prdx3 in a broad range of tissues, and the Prdx3 overexpression occurs exclusively in the mitochondria. As a result of increased Prdx3 expression, mitochondria from Tg(PRDX3) mice produce significantly reduced amount of H(2)O(2), and cells from Tg(PRDX3) mice have increased resistance to stress-induced cell death and apoptosis. Interestingly, Tg(PRDX3) mice show improved glucose homeostasis, as evidenced by their reduced levels of blood glucose and increased glucose clearance. Tg(PRDX3) mice are also protected against hyperglycemia and glucose intolerance induced by high-fat diet feeding. Our results further show that the inhibition of GSK3 may play a role in mediating the improved glucose tolerance phenotype in Tg(PRDX3) mice. Thus, our results indicate that reduction of mitochondrial H(2)O(2) by overexpressing Prdx3 improves glucose tolerance. C1 [Chen, Liuji; Gu, Mingjun; Liu, Yuhong; Liang, Hanyu; Qi, Wenbo; Van Remmen, Holly; Richardson, Arlan; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA. [Chen, Liuji; Na, Ren; Gu, Mingjun; Salmon, Adam B.; Liu, Yuhong; Liang, Hanyu; Qi, Wenbo; Van Remmen, Holly; Richardson, Arlan; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Van Remmen, Holly; Richardson, Arlan; Ran, Qitao] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Ran, QT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Texas Res Pk Campus,15355 Lambda Dr, San Antonio, TX 78245 USA. EM ran@uthscsa.edu RI Liang, Hanyu/A-1066-2010 FU Department of Veteran Affairs; NIA/NIH FX The study was supported by a Merit Review Award (Q. R.) from the Department of Veteran Affairs and a Nathan Shock Center award (A. R.) from NIA/NIH. NR 62 TC 59 Z9 61 U1 0 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1474-9718 J9 AGING CELL JI Aging Cell PD DEC PY 2008 VL 7 IS 6 BP 866 EP 878 DI 10.1111/j.1474-9726.2008.00432.x PG 13 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 376LF UT WOS:000261184400009 PM 18778410 ER PT J AU Kao, J Vicuna, R House, JA Rumsfeld, JS Ting, HH Spertus, JA AF Kao, John Vicuna, Ricardo House, John A. Rumsfeld, John S. Ting, Henry H. Spertus, John A. CA Natl Cardiovasc Data CathPCI Regis TI Disparity in drug-eluting stent utilization by insurance type SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; INVASIVE CARDIAC PROCEDURES; COMPLEX CORONARY STENOSES; COLLEGE-OF-CARDIOLOGY; BARE-METAL STENTS; COST-EFFECTIVENESS; HEALTH-CARE; PREMATURE DISCONTINUATION; AMERICAN-COLLEGE; ARTERY LESIONS AB Background Because of the expense of drug-eluting stents (DES) and associated adjuvant therapy, nonclinical, socioeconomic factors may be associated with DES use in clinical practice. Methods Data on 112,588 patients from the National Cardiovascular Data CathPCI Registry (NCDR) between 2004 and 2005 with "on-label" indications for DES were analyzed. Insurance status was categorized as No Insurance, Governmental, and Private Insurance. Hierarchical multivariable logistic regression analyses were used to evaluate the association between insurance status and DES use, after adjusting for patient and procedural characteristics. Results Drug-eluting stent use was >96% during the study period, with utilization significantly associated with insurance status. Compared with patients with Private Insurance, patients with No Insurance (odds ratio 0.44, 95% confidence interval 0.37-0.53) and Government Insurance (odds ratio 0.73, 95% confidence interval 0.67-0.80) were significantly less likely to receive a DES than a bare metal stent. Repeat analysis of patients <65 years of age demonstrated virtually identical results. Conclusions Despite the high penetration of DES, significant associations between insurance status and DES utilization were identified. This indicates that disparities in health care based on socioeconomic factors extend to DES utilization and highlights the need to address such disparities as novel therapies emerge. (Am Heart J 2008; 156:1133-40.) C1 [Kao, John] Univ Illinois, Div Cardiol, Chicago, IL 60612 USA. [House, John A.; Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [House, John A.; Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA. [House, John A.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Rumsfeld, John S.] Univ Colorado, Denver, CO 80202 USA. [Ting, Henry H.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA. RP Kao, J (reprint author), Univ Illinois, Div Cardiol, 840 S Wood St,Suite 926,M-C 715, Chicago, IL 60612 USA. EM jokao@uic.edu NR 45 TC 10 Z9 11 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD DEC PY 2008 VL 156 IS 6 BP 1133 EP 1140 DI 10.1016/j.ahj.2008.07.012 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 380SC UT WOS:000261484500017 PM 19033009 ER PT J AU Spiegel, BMR Chey, WD Chang, L AF Spiegel, Brennan M. R. Chey, William D. Chang, Lin TI Bacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID GASTROESOPHAGEAL-REFLUX DISEASE; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; PSYCHOLOGICAL TREATMENT; BREATH TESTS; SYMPTOMS; OMEPRAZOLE; PLACEBO; IBS AB Some studies indicate that small intestinal bacterial overgrowth (SIBO), as measured by hydrogen breath tests (HBT), is more prevalent in patients with irritable bowel syndrome (IBS) vs. matched controls without IBS. Although the data are conflicting, this observation has led to the hypothesis that SIBO may be a primary cause of IBS. Yet, it remains unclear whether SIBO is truly fundamental to the pathophysiology of IBS, or is instead a mere epiphenomenon or bystander of something else altogether. We hypothesize that SIBO might be a byproduct of the disproportionate use of proton pump inhibitors (PPIs) in IBS, as follows: (1) IBS patients are more likely than controls to receive PPI therapy; (2) PPI therapy may promote varying forms of SIBO by eliminating gastric acid; and (3) existing studies linking SIBO to IBS have not adjusted for or excluded the use of PPI therapy. When linked together, these premises form the basis for a simple and testable hypothesis: the relationship between SIBO and IBS may be confounded by PPIs. Our article explores these premises, lays out the argument supporting this "PPI hypothesis," discusses potential implications, and outlines next steps to further investigate this possibility. (Am J Gastroenterol 2008;103:2972-2976). C1 [Spiegel, Brennan M. R.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Spiegel, Brennan M. R.; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Chey, William D.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Spiegel, Brennan M. R.; Chang, Lin] Ctr Neurobiol Stress CNS, Los Angeles, CA USA. [Spiegel, Brennan M. R.; Chang, Lin] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. FU NCCIH NIH HHS [1 R24 AT002681, R24 AT002681-01, R24 AT002681]; NIAMS NIH HHS [AR46122-01, R01 AR046122, R01 AR046122-01]; NIDDK NIH HHS [P50 DK064539, 2P30DK 041301-17, P30 DK041301-17, P50 DK064539-019001, P30 DK041301, P50 DK64539] NR 40 TC 40 Z9 41 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2008 VL 103 IS 12 BP 2972 EP 2976 DI 10.1111/j.1572-0241.2008.01992.x PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 378YN UT WOS:000261361200004 PM 19086951 ER PT J AU George, CJ Korc, B Ross, JS AF George, Claudene J. Korc, Beatriz Ross, Joseph S. TI Appropriate Proton Pump Inhibitor Use Among Older Adults: A Retrospective Chart Review SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY LA English DT Article DE proton pump inhibitors; polypharmacy; outpatient ID DIFFICILE-ASSOCIATED DISEASE; ACID-SUPPRESSIVE THERAPY; PRIMARY-CARE; HOSPITALIZED-PATIENTS; GENERAL-PRACTICE; RISK; MEDICATION; OVERUSE; DRUGS; QUALITY AB Background: Proton pump inhibitors (PPIs) arc widely used, but not always with a clear indication. Nonindicated use is of particular concern among older adults, who may have multiple comorbidities and take more medications, increasing their risk for adverse drug reactions. Objective: This study examined the appropriateness Of PPI use at an outpatient geriatric practice and the association between particular patient characteristics and appropriate use of these medications. Methods: This was a retrospective chart review of a group of randomly identified community-dwelling adults aged >= 65 years with a current prescription for a PPI (as of August 2006) from a geriatric ambulatory care practice within all urban academic medical center. The main outcome was appropriateness Of PPI use, categorized as indicated, possibly indicated, or not indicated, based on US Food and Drug Administration-approved indications and national gastroenterology guidelines. Results: Out of similar to 2500 patients in the geriatric practice, 702 (similar to 28%) were identified as having a current prescription for a PPI. From these, 110 charts were randomly selected for review, of which 10 were excluded based on predefined criteria. The sample was 79% female and 46% white, with a mean age of 82.8 years (range, 66-99 years). PPI use was indicated in 64% of these patients, possibly indicated in 7%, and not indicated in 29%. Compared with indicated PPI use, nonindicated use was significantly associated with use for <1 year (relative risk = 2.20; 95% CI, 1.00-4.86; P = 0.05). Nonindicated PPI use was not significantly associated with age, female sex, nonwhite race, or PPI initiation in the inpatient setting. Conclusion: Almost 30% of patients receiving a PPI in this academic geriatric practice had no documented indication for PPI use. (Am J Geriatr Pharmacother. 2008;6:249-254) (C) 2008 Excerpta Medica Inc. C1 [George, Claudene J.] Albert Einstein Coll Med, Montefiore Med Ctr, Div Geriatr, Dept Med, Bronx, NY 10467 USA. [Korc, Beatriz; Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, HSR&D Targeted Res Enhancement Program, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP George, CJ (reprint author), Albert Einstein Coll Med, Montefiore Med Ctr, Div Geriatr, Dept Med, 111 E 210th St, Bronx, NY 10467 USA. EM clgeorge@montefiore.org FU Department of Veterans Affairs Health Services Research and Development Service [TRP-02-149]; Hartford Foundation FX This project was not directly supported by any external grants or funds. Dr. Ross is currently supported by Department of Veterans Affairs Health Services Research and Development Service project no. TRP-02-149 and the Hartford Foundation. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Neither the Department of Veterans Affairs nor the Hartford Foundation had any role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. Dr. Ross was a consultant at the request of plaintiffs in litigation against Merck and Co., Inc., in relation to rofecoxib. NR 25 TC 24 Z9 26 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 1543-5946 J9 AM J GERIATR PHARMAC JI Am. J. Geriatr. Pharmacother. PD DEC PY 2008 VL 6 IS 5 BP 249 EP 254 DI 10.1016/j.amjopharm.2008.12.001 PG 6 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 391FS UT WOS:000262219800003 PM 19161927 ER PT J AU Fried, L Hebah, N Finkelstein, F Piraino, B AF Fried, Linda Hebah, Nasser Finkelstein, Fredric Piraino, Beth TI Association of Kt/V and Creatinine Clearance With Outcomes in Anuric Peritoneal Dialysis Patients SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Peritoneal dialysis; adequacy; mortality; hospitalization ID SURVIVAL; ADEQUACY; MORTALITY; TARGETS; EAPOS AB Background: The 2006 Kidney Disease Outcomes Quality Initiative recommended a minimum total Kt/V of 1.7, eliminated creatinine clearance (Ccr) as a target, and recommended the use of ideal body weight to calculate Kt/V. We assessed these recommendations as predictors of outcomes in anuric peritoneal dialysis patients. Study Design: Retrospective observational study using administrative data. Setting & Participants: 1,432 peritoneal dialysis patients with anuria from January 1, 1994, to January 31, 2005, in a national sample (1,428 with Kt/V, 1,416 with Ccr). Predictors: Kt/V and Ccr at anuria; Kt/V based on actual body weight and ideal body weight. Outcomes & Measurements: Association of dialysis adequacy with mortality and time to first hospitalization after anuria assessed by using accelerated failure time models. Results: 293 anuric patients had Kt/V less than 1.7, 366 had Kt/V of 1.7 to 2.0, and 769 had Kt/V greater than 2.0, using actual body weight for calculation. In unadjusted analyses, Kt/V calculated using actual body weight both less than 1.7 (-41.3%; 95% confidence interval [Cl], -55.5 to -22.6) and 1.7 to 2.0 (-26.1 %; 95% Cl, -42.6 to -4.6) were associated with shorter time to mortality. Kt/V calculated using actual body weight less than 1.7 was associated with shorter time to hospitalization (-38.1 %; 95% Cl, -50.0 to -23.4), but Kt/V calculated using actual body weight of 1.7 to 2.0 was not a significant predictor (-3.3%; 95% Cl, -21.1 to 18.6). After adjustment, Kt/V calculated using actual body weight less than 1.7 remained associated with mortality (-25.3%; 95% Cl, -41.1 to -4.8) and hospitalization (-33.4%; 95% Cl, -47.1 to -16.0). Ccr did not predict mortality. In unadjusted analysis, Ccr was not associated with hospitalization, but after adjustment, Ccr less than 50 L/wk/1.73 m(2) was significantly associated with shorter time to hospitalization (-19.9%; 95% Cl, -35.0 to -1.3). Kt/V using ideal body weight was not a significant predictor in adjusted models. Limitations: This study was nonrandomized, with few malnourished patients. In addition, there is a potential for informative censoring for transfer to hemodialysis therapy before anuria. Conclusions: Kt/V calculated using actual body weight less than 1.7 in anuric peritoneal dialysis patients is associated with increased mortality and hospitalization. Use of ideal body weight to calculate Kt/V weakened the associations with outcomes and therefore cannot be recommended. C1 [Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Fried, Linda; Piraino, Beth] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Hebah, Nasser] Dialysis Clin Inc, Nashville, TN USA. [Finkelstein, Fredric] Yale Univ, Hosp St Raphael, Renal Res Inst, New Haven, CT USA. RP Fried, L (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Univ Dr,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM linda.fried@va.gov OI Piraino, Beth/0000-0001-5061-0841 NR 25 TC 7 Z9 8 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD DEC PY 2008 VL 52 IS 6 BP 1122 EP 1130 DI 10.1053/j.ajkd.2008.05.013 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 380UD UT WOS:000261489800013 PM 18617306 ER PT J AU Aujesky, D Fine, MJ AF Aujesky, Drahomir Fine, Michael J. TI Community-Acquired Pneumonia: Treatment at Home or in the Hospital? SO AMERICAN JOURNAL OF MEDICINE LA English DT Editorial Material ID LOW-RISK PATIENTS; GUIDELINES; CARE C1 [Aujesky, Drahomir] Univ Lausanne, Div Gen Internal Med, Lausanne, Switzerland. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. RP Aujesky, D (reprint author), CHU Vaudois, Serv Med Interne, BH 10-622, CH-1011 Lausanne, Switzerland. EM drahomir.aujesky@chuv.ch NR 7 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD DEC PY 2008 VL 121 IS 12 BP 1038 EP 1040 DI 10.1016/j.amjmed.2008.08.016 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 387XO UT WOS:000261985100018 PM 19028194 ER PT J AU Limsukon, A Barack, BM Hoo, GWS AF Limsukon, Atikun Barack, Bruce M. Hoo, Guy W. Soo TI Can't Take a Deep Breath SO AMERICAN JOURNAL OF MEDICINE LA English DT Editorial Material ID DIAPHRAGMATIC-HERNIA C1 [Limsukon, Atikun] Cedars Sinai Med Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90048 USA. [Limsukon, Atikun; Hoo, Guy W. Soo] W Los Angeles VA Healthcare Ctr, Pulm & Crit Care Sect, Los Angeles, CA USA. [Limsukon, Atikun; Barack, Bruce M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Barack, Bruce M.; Hoo, Guy W. Soo] W Los Angeles VA Healthcare Ctr, Dept Thorac Radiol, Los Angeles, CA USA. RP Limsukon, A (reprint author), 11301 Wilshire Blvd,111Q, Los Angeles, CA 90073 USA. EM atikun.limsukon@cshs.org NR 17 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD DEC PY 2008 VL 121 IS 12 BP 1055 EP 1057 DI 10.1016/j.amjmed.2008.09.004 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 387XO UT WOS:000261985100024 PM 19028200 ER PT J AU Carr, D Utzschneider, K Tong, J Gaba, K Brunzell, J Easterling, T Kahn, S AF Carr, Darcy Utzschneider, Kristina Tong, Jenny Gaba, Kersten Brunzell, John Easterling, Thomas Kahn, Steven TI WOMEN WITH A HISTORY OF PREECLAMPSIA HAVE AN ATHEROGENIC LIPID PROFILE AND ENDOTHELIAL DYSFUNCTION BUT NO DIFFERENCE IN ADIPOSITY OR INSULIN SENSITIVITY SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Meeting Abstract CT 29th Annual Meeting of the Society-for-Maternal-Fetal-Medicine CY JAN 26-31, 2009 CL San Diego, CA SP Soc Mat Fetal Med C1 [Utzschneider, Kristina; Kahn, Steven] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Tong, Jenny] Univ Cincinnati, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD DEC PY 2008 VL 199 IS 6 MA 240 BP S78 EP S78 DI 10.1016/j.ajog.2008.09.268 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 391AV UT WOS:000262205700240 ER PT J AU Kempen, JH Gangaputra, S Daniel, E Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Suhler, EB Thorne, JE Foster, CS Jabs, DA Helzlsouer, KJ AF Kempen, John H. Gangaputra, Sapna Daniel, Ebenezer Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Helzlsouer, Kathy J. TI Long-term Risk of Malignancy Among Patients Treated With Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the Evidence SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Editorial Material ID POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; RENAL-TRANSPLANT RECIPIENTS; NECROSIS-FACTOR ANTAGONISTS; NON-HODGKINS-LYMPHOMA; RHEUMATOID-ARTHRITIS; MYCOPHENOLATE-MOFETIL; SKIN-CANCER; FOLLOW-UP; LIVER-TRANSPLANTATION; ORGAN-TRANSPLANTATION C1 [Kempen, John H.] Univ Penn, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, Scheie Eye Inst,Ocular Inflammat Serv, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Gangaputra, Sapna; Daniel, Ebenezer; Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.; Jabs, Douglas A.; Helzlsouer, Kathy J.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Levy-Clarke, Grace A.] St Lukes Cataract & Laser Inst, Tarpon Springs, FL USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA. [Helzlsouer, Kathy J.] St Johns Mercy Med Ctr, Ctr Prevent & Res, Baltimore, MD USA. RP Kempen, JH (reprint author), Univ Penn, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, Scheie Eye Inst,Ocular Inflammat Serv, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Daniel, Ebenezer/0000-0002-2027-2316 FU NEI NIH HHS [R01 EY014943-05, EY014943, R01 EY014943, R56 EY014943] NR 96 TC 50 Z9 51 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD DEC PY 2008 VL 146 IS 6 BP 802 EP 812 DI 10.1016/j.ajo.2008.04.035 PG 11 WC Ophthalmology SC Ophthalmology GA 378UH UT WOS:000261349200003 PM 18579112 ER PT J AU Kacmaz, RO Kempen, JH Newcomb, C Gangaputra, S Daniel, E Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Suhler, EB Thorne, JE Jabs, DA Foster, CS AF Kacmaz, R. Oktay Kempen, John H. Newcomb, Craig Gangaputra, Sapna Daniel, Ebenezer Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Thorne, Jennifer E. Jabs, Douglas A. Foster, C. Stephen CA Systemic Immunosuppressive Therapy TI Ocular Inflammation in Behcet Disease: Incidence of Ocular Complications and of Loss of Visual Acuity SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID INFLIXIMAB TREATMENT; PROGNOSTIC-FACTORS; RISK; EPIDEMIOLOGY; INVOLVEMENT; UVEITIS; VISION; TRIAL AB PURPOSE: To estimate the risk of structural ocular complications and loss of visual acuity (VA) in cases of Behcet disease (BD) and to evaluate potential risk and protective factors for these events. 0 DESIGN: Retrospective cohort study. METHODS: A total of 168 consecutive patients with 1313,associated ocular inflammation treated at five academic center ocular inflammation subspecialty practices were included. Clinical data for these patients were ascertained by standardized chart review. Main outcome measures included VA, structural ocular complications of inflammation, and intraocular pressure (lop). RESULTS: Over a median follow-up of 1.05 years, the incidence of specific structural complications and IOP disturbances were common: the incidence rate of any ocular complication was 0.45 per eye-year (EY). Rates of loss of VA to 20/50 or worse and to 20/200 or worse were 0.12 per EY and 0.09 per EY, respectively. Risk factors for loss of VA during follow-up were persistent inflammatory activity, presence of posterior synechiae, presence of hypotony, and presence of elevated IOP. In a time-dependent analysis, current activity of ocular in, flammation was associated with an increased risk of loss of VA to 20/50 or worse (relative risk [RR], 2.45; 95% confidence interval [CI], 1.1 to 5.5; P =.03) and to 20/200 or worse (RR, 2.67; 95% CI, 1.2 to 5.8; P= .01). CONCLUSIONS: Loss of VA and occurrence of ocular complications were common in patients with ocular inflammation associated with BD, even with aggressive therapy. Ongoing inflammation during follow-up, presence or occurrence of posterior synechiae, hypotony, and elevated IOP were associated with an increased risk of loss of VA. (Am J Ophthalmol 2008;146:828-836. (C) 2008 by Elsevier Inc. All rights reserved.) C1 [Kacmaz, R. Oktay; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA 02142 USA. [Kempen, John H.; Newcomb, Craig] Univ Penn, Ocular Inflammat Serv, Scheie Eye Inst, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, Philadelphia, PA 19104 USA. [Kempen, John H.; Newcomb, Craig] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Gangaputra, Sapna; Daniel, Ebenezer; Rosenbaum, James T.; Jabs, Douglas A.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Foster, CS (reprint author), Massachusetts Eye Res & Surg Inst, 5 Cambridge Ctr,8th Floor, Cambridge, MA 02142 USA. EM sfoster@mersi.us OI Daniel, Ebenezer/0000-0002-2027-2316 FU NATIONAL EYE INSTITUTE, NATIONAL INSTITUTES of Health, Bethesda, Maryland [EY014943]; Paul and Evanina Mackall Foundation, Philadelphia, Pennsylvania; Research to Prevent Blindness Inc (RPB), New York, New York FX THIS STUDY WAS SUPPORTED PRIMARILY BY GRANT EY014943 FROM THE NATIONAL EYE INSTITUTE, NATIONAL INSTITUTES of Health, Bethesda, Maryland (Dr Kempen). Additional support was provided by the Paul and Evanina Mackall Foundation, Philadelphia, Pennsylvania, and Research to Prevent Blindness Inc (RPB), New York, New York. Dr Kempen is a Research to Prevent Blindness James S. Adams Special Scholar Award recipient. Dr Thorne is a Research to Prevent Blindness Harrington Special Scholar Award recipient. Drs Jabs and Rosenbaum are a Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr Levy-Clarke was previously and Dr Nussenblatt continues to be supported by intramural funds of the National Eye Institute. The authors indicate no financial conflict of interest. Involved in conception and design (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.); analysis and interpretation (R.O.K., J.H.K., C.W.N.); writing the article (R.O.K., J.H.K.); critical review of the article (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.); final approval of the article (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.,C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.); data collection (R.O.K., J.H.K., S.G., E.D.); provision of resources (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.); statistical expertise (J.H.K., C.W.N.); obtaining funding (J.H.K.); literature search (R.O.K., J.H.K.); and administrative, technical, or logistic support (R.O.K., J.H.K., C.N., S.G., E.D., G.A.L.-C., R.B.N., J.T.R., E.B.S., J.E.T., D.A.J., C.S.F.). The SITE Cohort Study was conducted with the approval of the following institutional review boards: University of Pennsylvania Office of Regulatory Affairs (PENN); Johns Hopkins School of Medicine Institutional Review Board no. 3 (Wilmer/JHU); New England Institutional Review Board (MERSI); Massachusetts Eye & Ear Infirmary Institutional Review Board (MEEI); Oregon Health & Sciences University Institutional Review Board (Casey/OHSU); Combined Neurosciences (CNS) Institutional Review Board of the Clinical Center (CC), National Eye Institute. The study was conducted in accordance with the precepts of the Declaration of Helsinki. NR 28 TC 43 Z9 44 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD DEC PY 2008 VL 146 IS 6 BP 828 EP 836 DI 10.1016/j.ajo.2008.06.019 PG 9 WC Ophthalmology SC Ophthalmology GA 378UH UT WOS:000261349200006 PM 18708181 ER PT J AU Suhler, EB Lloyd, MJ Choi, D Rosenbaum, JT Austin, DF AF Suhler, Eric B. Lloyd, Michael J. Choi, Dongseok Rosenbaum, James T. Austin, Donald F. TI Incidence and Prevalence of Uveitis in Veterans Affairs Medical Centers of the Pacific Northwest SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID EPIDEMIOLOGY; BLINDNESS; FINLAND AB PURPOSE: To ascertain the frequency of uveitis in Veterans Affairs (VA) patients in the Pacific Northwest and to compare disease rates with those in previously published epidemiologic studies. DESIGN: Cross-sectional, population based-study. METHODS: The medical records of 152,267 patients seen at six VA Medical Centers in Oregon and Washington during fiscal year 2004 were searched for uveitis-related Internation Classification of Diseases 9th edition codes. Cases were reviewed and classified anatomically, by associated systemic disease, and as incident or prevalent. Only definite cases were used for disease rate calculations. RESULTS: This study found a crude incidence of 25.6 cases/100,000 person-years and a crude prevalence of 69 cases/100,000 persons. The most common anatomic location for uveitis was anterior. Approximately half of cases were idiopathic, with human leukocyte antigen, B27-related diseases being the most common identified cause. There was no statistical evidence of increased or decreased incidence with age, although uveitis seemed to be more prevalent in the younger age groups. CONCLUSIONS: Our data are consistent with those of most published population based studies on the epidemiologic features of uveitis, but we detected significantly lower incidence and prevalence than those reported in a recently published study from Kaiser Permanente. The significance of and possible explanations for the differences between our data and that published by the Kaiser group are discussed. (Am J Ophthalmol 2008;146: 890-896. Published by Elsevier Inc.) C1 [Suhler, Eric B.; Lloyd, Michael J.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Choi, Dongseok; Austin, Donald F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. RP Suhler, EB (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA. EM suhlere@ohsu.edu FU RESEARCH TO PREVENT BLINDNESS, NEW YORK, NEW YORK FX THIS STUDY WAS SUPPORTED BY A GRANT FROM RESEARCH TO PREVENT BLINDNESS, NEW YORK, NEW YORK (UNRESTRICTED Grant to the Casey Eye Institute, Senior Scholar Award to Dr Rosenbaum); and the Rosenfeld Family Trust, Portland, Oregon (Dr Rosenbaum). The authors indicate no financial conflict of interest. Involved in design of study (E.B.S., M.J.L., J.T.R., D.F.A.); data analysis and interpretation (E.B.S., M.J.L., D.C., J.T.R., D.F.A.); writing and critical revision of the article (E.B.S., M.J.L., J.T.R., D.F.A.); statistical expertise (E.B.S., D.C., D.F.A.); and preparation, review, and approval of the manuscript (E.B.S., M.J.L., D.C., J.T.R., D.F.A.). This Study was approved by the Institutional Review Boards (IRBs) and Research and Development Committees of the Portland Veterans Affairs Medical Center, the Puget Sound Veterans Affairs Medical Center, and the Veterans Integrated Service Network 20 IRB, which has jurisdiction over research studies performed on patients seen at the White City, Oregon, Roseburg, Oregon, Walla Walla, Washington, and Spokane, Washington, VA facilities. All IRBs waived the requirement for informed consent in this noninterventional chart review Study. NR 17 TC 49 Z9 52 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD DEC PY 2008 VL 146 IS 6 BP 890 EP 896 DI 10.1016/j.ajo.2008.09.014 PG 7 WC Ophthalmology SC Ophthalmology GA 378UH UT WOS:000261349200014 PM 19027424 ER PT J AU Cooper, RA Tolerico, M Kaminski, BA Spaeth, D Ding, D Cooper, R AF Cooper, Rory A. Tolerico, Michelle Kaminski, Beth Ann Spaeth, Donald Ding, Dan Cooper, Rosemarie TI Quantifying Wheelchair Activity of Children A Pilot Study SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Child; Wheelchairs; Rehabilitation; Activity ID PHYSICAL-ACTIVITY; POWERED MOBILITY; ACTIVITY MONITOR; ENERGY-COST; USERS; MYELOMENINGOCELE; PROPULSION; BEHAVIORS; VALIDITY; STRAIN AB Objective: The purpose of this study was to investigate mobility-related wheelchair activity of children in their community setting. Design: Mobility-related wheelchair activity data from 18 community-dwelling children (9 manual and 9 electric powered) were collected using custom-designed data logging devices. The children were between 8 and 17 yrs of age and independently used a wheelchair as their primary means of mobility. A data logging device was installed on their wheelchair for 7 days. However, because the device was attached and removed at different times of the day, the first and last days of the study period were not analyzed. Therefore, a total of 5 days of data were used to investigate wheelchair activity. Results: Overall, the children who used manual wheelchairs traveled on an average of 1602.31 m/day (SD, 976.78) at a speed of 0.67 m/sec (SID, 0.12), and the children who used electric-powered wheelchairs drove 1752.42 m/day (SD, 835.14) at a speed of 0.75 m/sec (SID, 0.35). It was also calculated that the average daily number of starts/stops per thousand meters the manual and electric-powered wheelchair users completed were 166.77 (SD, 64.32) and 112.53 (SD, 62.27), respectively. A comparison of mobility-related wheelchair activity revealed a significant (P = 0.008) difference in the average daily distance traveled between genders, with the boys traveling further than the girls. Conclusions: The mobility data obtained from the children wheelchair users suggest that one possible factor of variability among wheelchair activity is between genders. The data collected provide us with direction for future research in this area. C1 [Cooper, Rory A.; Tolerico, Michelle; Spaeth, Donald; Ding, Dan; Cooper, Rosemarie] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Cooper, Rory A.; Spaeth, Donald; Cooper, Rosemarie] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.; Tolerico, Michelle] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Kaminski, Beth Ann] Childrens Inst, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,Bldg 4,2nd Floor E,151R1 H, Pittsburgh, PA 15206 USA. RI Schmoelz, Camilie/D-1707-2012 OI Schmoelz, Camilie/0000-0003-2221-9954 FU U.S. Department of Education; National Institute for Disability and Rehabilitation Research (NIDRR); Rehabilitation Service Administration [H129E990004]; Spinal Cord Injury Model System Center [H133N000019] FX Part of the material presented in this manuscript was published as an abstract in the Proceedings of the 28th Annual RESNA Conference, 2005. The material is based upon work supported by the U.S. Department of Education, National Institute for Disability and Rehabilitation Research (NIDRR), Rehabilitation Service Administration Training Grant (H129E990004) and NIDRR, Spinal Cord Injury Model System Center (H133N000019). NR 20 TC 13 Z9 13 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD DEC PY 2008 VL 87 IS 12 BP 977 EP 983 DI 10.1097/PHM.0b013e31818dfe74 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 376QR UT WOS:000261198600002 PM 19033759 ER PT J AU Dicianno, BE Kurowski, BG Yang, JMJ Chancellor, MB Bejjani, GK Fairman, AD Lewis, N Sotirake, J AF Dicianno, Brad E. Kurowski, Brad G. Yang, Jennifer Marie J. Chancellor, Michael B. Bejjani, Ghassan K. Fairman, Andrea D. Lewis, Nancy Sotirake, Jennifer TI Rehabilitation and Medical Management of the Adult with Spina Bifida SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Review DE Adult; Myelomeningocele; Hydrocephalus; Rehabilitation; Review; Tethered Cord Syndrome; Transitional Care ID TETHERED CORD SYNDROME; QUALITY-OF-LIFE; CLEAN INTERMITTENT CATHETERIZATION; NEUROGENIC BLADDER DYSFUNCTION; ANTEGRADE CONTINENCE ENEMA; EVERYDAY PHYSICAL-ACTIVITY; BEARING UPPER EXTREMITY; DEEP VENOUS THROMBOSIS; BONE-MINERAL DENSITY; LONG-TERM OUTCOMES AB As the life expectancy of individuals with spina bifida increases, a lifelong need for management of many health issues in a rehabilitation setting has emerged in recent years. Physiatrists, in consultation with a variety of adult specialists, are particularly well suited to manage the common musculoskeletal, skin, bowel, bladder, renal, neurological, and other issues that arise in the adult population. This article reviews the last 20 yrs of literature pertinent to the rehabilitative care of this population, summarizes current evidence-based practice, and identifies key areas in which scientific evidence is lacking and future research is needed. C1 [Dicianno, Brad E.; Yang, Jennifer Marie J.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Lewis, Nancy; Sotirake, Jennifer] Univ Pittsburgh, Med Ctr, Adult Outpatient Spina Bifida Clin, Pittsburgh, PA USA. [Dicianno, Brad E.; Kurowski, Brad G.; Yang, Jennifer Marie J.; Lewis, Nancy] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Chancellor, Michael B.] William Beaumont Hosp, Dept Urol, Royal Oak, MI 48072 USA. [Bejjani, Ghassan K.] UPMC Presybterian Shadyside, Dept Neurosurg, Pittsburgh, PA USA. [Fairman, Andrea D.] Spina Bifida Assoc Western PA, Pittsburgh, PA USA. [Dicianno, Brad E.; Fairman, Andrea D.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Sotirake, Jennifer] UPMC, Dept Nutr, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,Bldg 4,2nd Floor E,151R1-H, Pittsburgh, PA 15206 USA. OI Dicianno, Brad/0000-0003-0738-0192 NR 360 TC 17 Z9 17 U1 5 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD DEC PY 2008 VL 87 IS 12 BP 1026 EP 1050 DI 10.1097/PHM.0b013e31818de070 PG 25 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 376QR UT WOS:000261198600009 PM 18923330 ER PT J AU Yuan, JZ Lugea, A Zheng, L Gukovsky, I Edderkaoui, M Rozengurt, E Pandol, SJ AF Yuan, Jingzhen Lugea, Aurelia Zheng, Ling Gukovsky, Ilya Edderkaoui, Mouad Rozengurt, Enrique Pandol, Stephen J. TI Protein kinase D1 mediates NF-kappa B activation induced by cholecystokinin and cholinergic signaling in pancreatic acinar cells SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE PKC delta; PKC epsilon; pancreatitis; carbachol; cerulein ID COLONIC EPITHELIAL-CELLS; D-DEPENDENT ACTIVATION; C-DELTA; INTERLEUKIN-8 EXPRESSION; LYSOPHOSPHATIDIC ACID; INFLAMMATORY RESPONSE; LOOP PHOSPHORYLATION; CATALYTIC ACTIVATION; TRANSDUCTION PATHWAY; OXIDATIVE STRESS AB The transcription factor NF-kappa B plays a critical role in inflammatory and cell death responses during acute pancreatitis. Previous studies in our laboratory demonstrated that protein kinase C (PKC) isoforms PKC delta and epsilon are key regulators of NF-kappa B activation induced by cholecystokinin-8 (CCK-8), tumor necrosis factor-alpha, and ethanol. However, the downstream participants in regulating NF-kappa B activation in exocrine pancreas remain poorly understood. Here, we demonstrate that protein kinase D1 (PKD1) is a key downstream target of PKC delta and PKC epsilon in pancreatic acinar cells stimulated by two major secretagogues, CCK-8 and the cholinergic agonist carbachol (CCh), and that PKD1 is necessary for NF-kappa B activation induced by CCK-8 and CCh. Both CCK-8 and CCh dose dependently induced a rapid and striking activation of PKD1 in rat pancreatic acinar cells, as measured by in vitro kinase assay and by phosphorylation at PKD1 activation loop (Ser744/748) or autophosphorylation site (Ser916). The phosphorylation and activation of PKD1 correlated with NF-kappa B activity stimulated by CCK-8 or CCh, as measured by NF-kappa B DNA binding. Either inhibition of PKC delta or epsilon by isoform-specific inhibitory peptides, genetic deletion of PKC delta and epsilon in pancreatic acinar cells, or knockdown of PKD1 by using small interfering RNAs in AR42J cells resulted in a marked decrease in PKD1 and NF-kappa B activation stimulated by CCK-8 or CCh. Conversely, overexpression of PKD1 resulted in augmentation of CCK-8 and CCh-stimulated NF-kappa B activation. Finally, the kinetics of PKD1 and NF-kappa B activation during cerulein-induced rat pancreatitis showed that both PKD1 and NF-kappa B activation were early events during acute pancreatitis and that their time courses of response were similar. Our results identify PKD1 as a novel early convergent point for PKC delta and epsilon in the signaling pathways mediating NF-kappa B activation in pancreatitis. C1 [Yuan, Jingzhen] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA. [Yuan, Jingzhen; Lugea, Aurelia; Gukovsky, Ilya; Pandol, Stephen J.] Univ Calif Los Angeles, USC, Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90024 USA. [Yuan, Jingzhen; Lugea, Aurelia; Gukovsky, Ilya; Edderkaoui, Mouad; Rozengurt, Enrique; Pandol, Stephen J.] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. RP Yuan, JZ (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, W Los Angeles VA Healthcare Ctr, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jzyuan@ucla.edu FU Department of Veterans Affairs Merit; National Institute on Alcohol Abuse and Alcoholism [P50-A11999]; National Institute of Diabetes and Digestive and Kidney Diseases [DK-55003] FX This study was supported by the Department of Veterans Affairs Merit Grant and National Institute on Alcohol Abuse and Alcoholism Grant P50-A11999 (to USC-UCLA Research Center for Alcoholic Liver and Pancreatic Diseases). E. Rozengurt is supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-55003. NR 59 TC 24 Z9 25 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD DEC PY 2008 VL 295 IS 6 BP G1190 EP G1201 DI 10.1152/ajpgi.90452.2008 PG 12 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 379GP UT WOS:000261385000006 PM 18845574 ER PT J AU Wang, XW Chai, H Wang, ZH Lin, PH Yao, QZ Chen, CY AF Wang, Xinwen Chai, Hong Wang, Zehao Lin, Peter H. Yao, Qizhi Chen, Changyi TI Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE endothelial nitric oxide synthase; reactive oxygen species; antioxidant; mitogen-activated protein kinase; nuclear factor-kappa B ID C-REACTIVE PROTEIN; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ACUTE-PHASE; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; CARDIOVASCULAR-DISEASE; HUMAN NEUTROPHILS; OXIDATIVE STRESS; HEART-DISEASE AB Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 295: H2399-H2408, 2008. First published October 17, 2008; doi: 10.1152/ajpheart. 00238.2008.-The objective of this study was to determine the effects and mechanisms of serum amyloid A (SAA) on coronary endothelial function. Porcine coronary arteries and human coronary arterial endothelial cells (HCAECs) were treated with SAA (0, 1, 10, or 25 mu g/ml). Vasomotor reactivity was studied using a myograph tension system. SAA significantly reduced endothelium-dependent vasorelaxation of porcine coronary arteries in response to bradykinin in a concentration-dependent manner. SAA significantly decreased endothelial nitric oxide (NO) synthase (eNOS) mRNA and protein levels as well as NO bioavailability, whereas it increased ROS in both artery rings and HCAECs. In addition, the activities of internal antioxidant enzymes catalase and SOD were decreased in SAA-treated HCAECs. Bio-plex immunoassay analysis showed the activation of JNK, ERK2, and I kappa B-alpha after SAA treatment. Consequently, the antioxidants seleno-L-methionine and Mn(III) tetrakis( 4-benzoic acid) porphyrin and specific inhibitors for JNK and ERK1/2 effectively blocked the SAA-induced eNOS mRNA decrease and SAA-induced decrease in endothelium-dependent vasorelaxation in porcine coronary arteries. Thus, SAA at clinically relevant concentrations causes endothelial dysfunction in both porcine coronary arteries and HCAECs through molecular mechanisms involving eNOS downregulation, oxidative stress, and activation of JNK and ERK1/2 as well as NF-kappa B. These findings suggest that SAA may contribute to the progress of coronary artery disease. C1 [Chen, Changyi] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. Baylor Coll Med, Mol Surgeon Res Ctr, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Chen, CY (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, 1 Baylor Pl,Mail Stop BCM390, Houston, TX 77030 USA. EM jchen@bcm.tmc.edu RI Chai, Hong/H-5438-2011 FU National Institutes of Health Research [HL-076345, DE-15543, AT-003094, EB-002436, HL-083471]; Michael E. DeBakey Department of Surgery; Baylor College of Medicine; Michael E. DeBakey Veterans Affairs Medical Center FX This work was partially supported by National Institutes of Health Research Grants HL-076345 (to P. H. Lin), DE-15543 (to Q. Yao), AT-003094 (to Q. Yao), EB-002436 (to C. Chen), and HL-083471 (to C. Chen) as well as by the Michael E. DeBakey Department of Surgery, Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center (Houston, TX). NR 55 TC 28 Z9 31 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD DEC PY 2008 VL 295 IS 6 BP H2399 EP H2408 DI 10.1152/ajpheart.00238.2008 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 379MH UT WOS:000261399900023 PM 18931033 ER PT J AU John, J Ramanathan, L Siegel, JM AF John, Joshi Ramanathan, Lalini Siegel, Jerome M. TI Rapid changes in glutamate levels in the posterior hypothalamus across sleep-wake states in freely behaving rats SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE rapid eye movement sleep; histamine; microdialysis; biosensor; cortex ID HISTAMINERGIC TUBEROMAMMILLARY NEURONS; IN-VIVO MICRODIALYSIS; CEREBRAL-CORTEX; OREXIN-A; HYPOCRETIN NEURONS; LOCUS-COERULEUS; GABA RELEASE; MOUSE-BRAIN; CELL GROUPS; REM-SLEEP AB John J, Ramanathan L, Siegel JM. Rapid changes in glutamate levels in the posterior hypothalamus across sleep-wake states in freely behaving rats. Am J Physiol Regul Integr Comp Physiol 295: R2041-R2049, 2008. First published September 24, 2008; doi:10.1152/ajpregu.90541.2008. The histamine-containing posterior hypothalamic region (PH-TMN) plays a key role in sleep-wake regulation. We investigated rapid changes in glutamate release in the PH-TMN across the sleep-wake cycle with a glutamate biosensor that allows the measurement of glutamate levels at 1- to 4-s resolution. In the PH-TMN, glutamate levels increased in active waking (AW) and rapid eye movement (REM) sleep compared with quiet waking and nonrapid eye movement (NREM) sleep. There was a rapid (0.6 +/- 1.8 s) and progressive increase in glutamate levels at REM sleep onset. A reduction in glutamate levels consistently preceded the offset of REM sleep by 8 +/- 3 s. Short-duration sleep deprivation resulted in a progressive increase in glutamate levels in the PH-TMN, perifornical-lateral hypothalamus (PF-LH), and cortex. We found that in the PF-LH, glutamate levels took a longer time to return to basal values compared with the time it took for glutamate levels to increase to peak values during AW onset. This is in contrast to other regions we studied in which the return to baseline values after AW was quicker than their rise with waking onset. In summary, we demonstrated an increase in glutamate levels in the PH-TMN with REM/AW onset and a drop in glutamate levels before the offset of REM. High temporal resolution measurement of glutamate levels reveals dynamic changes in release linked to the initiation and termination of REM sleep. C1 Vet Affairs Greater Los Angeles Hlth Care Syst, North Hills, CA USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Neurobiol Res 151A3,16111 Plummer St,Sepulveda VA, North Hills, CA 91343 USA. EM JSiegel@UCLA.edu FU Medical Research Services of Department of Veterans Affairs [HL-41370, MH-64109] FX Funding for this study was provided by Grants HL-41370 and MH-64109 and by the Medical Research Services of Department of Veterans Affairs. NR 51 TC 24 Z9 24 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD DEC PY 2008 VL 295 IS 6 BP R2041 EP R2049 DI 10.1152/ajpregu.90541.2008 PG 9 WC Physiology SC Physiology GA 381TV UT WOS:000261559700038 PM 18815208 ER PT J AU Lee, DBN Jamgotchian, N Allen, SG Abeles, MB Ward, HJ AF Lee, David B. N. Jamgotchian, Nora Allen, Suni G. Abeles, Michael B. Ward, Harry J. TI A lipid-protein hybrid model for tight junction SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Review DE lipid rafts; lipid leaflets; claudins; hemifusion ID TRANSEPITHELIAL ELECTRICAL-RESISTANCE; MEMBRANE MICRODOMAIN LOCALIZATION; CLOSTRIDIUM-DIFFICILE TOXINS; POLYUNSATURATED FATTY-ACIDS; EPITHELIAL BARRIER FUNCTION; CACO-2 CELL MONOLAYERS; ANNEXIN II TETRAMER; CANINE KIDNEY-CELLS; BASIC-AMINO-ACIDS; MDCK-CELLS AB The epithelial tight junction (TJ) was first described ultrastructurally as a fusion of the outer lipid leaflets of the adjoining cell membrane bilayers (hemifusion). The discovery of an increasing number of integral TJ and TJ-associated proteins has eclipsed the original lipid-based model with the wide acceptance of a protein-centric model for the TJ. In this review, we stress the importance of lipids in TJ structure and function. A lipid-protein hybrid model accommodates a large body of information supporting the lipidic characteristics of the TJ, harmonizes with the accumulating evidence supporting the TJ as an assembly of lipid rafts, and focuses on an important, but relatively unexplored, field of lipid-protein interactions in the morphology, physiology, and pathophysiology of the TJ. C1 [Lee, David B. N.; Jamgotchian, Nora; Allen, Suni G.; Abeles, Michael B.] Vet Affairs Greater Los Angeles Healthcare Syst, Vet Integrated Serv Network 22, Nephrol Sect, Los Angeles, CA USA. [Lee, David B. N.; Jamgotchian, Nora; Allen, Suni G.; Abeles, Michael B.] Vet Affairs Greater Los Angeles Healthcare Syst, Vet Integrated Serv Network 22, Epithelial Biol Lab, Los Angeles, CA USA. [Ward, Harry J.] Rancho Los Amigos Med Ctr, Div Nephrol, Los Angeles, CA USA. [Lee, David B. N.; Ward, Harry J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Lee, DBN (reprint author), Vet Adm Med Ctr, Dept Med 111, 16111 Plummer St, North Hills, CA 91343 USA. EM dbnlee@ucla.edu FU National Institutes of Health [1RO1 DK/HD-51948]; Department of Veterans Affairs Merit Review Board; UCLA Council on Research/Faculty Research Grant Program FX This work was supported in part by National Institutes of Health Grant 1RO1 DK/HD-51948, the Department of Veterans Affairs Merit Review Board, and the UCLA Council on Research/Faculty Research Grant Program (2006-2007). NR 118 TC 12 Z9 13 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD DEC PY 2008 VL 295 IS 6 BP F1601 EP F1612 DI 10.1152/ajprenal.00097.2008 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 379GQ UT WOS:000261385100002 PM 18701633 ER PT J AU Nagami, GT Chang, JA Plato, ME Santamaria, R AF Nagami, Glenn T. Chang, Jenny A. Plato, Megan E. Santamaria, Rafael TI Acid loading in vivo and low pH in culture increase angiotensin receptor expression: enhanced ammoniagenic response to angiotensin II SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE ammoniagenesis; angiotensin type receptor; cell surface; acidosis; colchicine ID PROXIMAL TUBULE SEGMENTS; HUMAN AT(1) RECEPTOR; METABOLIC-ACIDOSIS; N-GLYCOSYLATION; SECRETION; CELLS; RAT; ALDOSTERONE; INHIBITION; MEMBRANES AB The proximal tubule defends the body against acid challenges by enhancing its production and secretion of ammonia. Our previous studies demonstrated an enhanced ammoniagenic response of the proximal tubule to ANG II added to the lumen in vitro after an in vivo acid challenge. The present study examined the effect of NH(4)Cl acid loading in vivo on renal cortical type 1 ANG II (AT(1)) receptor expression, the effect of low pH on AT(1) receptor expression in a proximal tubule cells in culture, and their response to ANG II. A short-term (18 h) NH(4)Cl load in vivo resulted in increased renal cortical AT(1) receptor mRNA expression and increased brush-border membrane AT(1) receptor protein expression levels. Changing the cell culture pH from 7.4 to 7.0 for at least 2 h increased cell surface expression of AT1 receptors and enhanced the stimulatory effect of ANG II on ammonia production rates. This increased ammoniagenic response to ANG II and the early enhancement of cell surface expression induced by exposure of the cultured proximal tubule cells to pH 7.0 were prevented by treatment with colchicine. These results suggest that, after acid challenges, the enhanced ammoniagenic response of the proximal tubule to ANG II is, in part, mediated by increased AT(1) receptor cell surface expression and that the enhancement of receptor expression plays an important role in the early response of the proximal tubule to acid challenges. C1 [Nagami, Glenn T.] VA Greater Los Angeles Healthcare Syst, Nephrol Sect, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Nagami, GT (reprint author), VA Greater Los Angeles Healthcare Syst, Nephrol Sect, Dept Med, Mail Code 111L,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM glenn.nagami@va.gov NR 33 TC 7 Z9 7 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD DEC PY 2008 VL 295 IS 6 BP F1864 EP F1870 DI 10.1152/ajprenal.90410.2008 PG 7 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 379GQ UT WOS:000261385100029 PM 18945827 ER PT J AU Mortensen, EM Restrepo, MI Copeland, LA Pugh, JA Anzueto, A AF Mortensen, Eric M. Restrepo, Marcos I. Copeland, Laurel A. Pugh, Jacqueline A. Anzueto, Antonio TI Association of Hydrophilic Versus Lipophilic Angiotensin-Converting Enzyme Inhibitor Use on Pneumonia-Related Mortality SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Angiotensin-converting enzyme; Pneumonia; Mortality ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-DISTRESS-SYNDROME; CHRONIC HEART-FAILURE; ANTIMICROBIAL THERAPY; RECEPTOR BLOCKERS; RISK; POLYMORPHISM; REDUCTION; STATINS; SYSTEM AB Background: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for patients with or at risk for pneumonia. However, other studies have not found a survival benefit. Other research suggests that ACE inhibitors that are lipophilic may be superior to hydrophilic ACE inhibitors in terms of tissue penetration and inhibition of ACF. Our aim was to examine the associations of prior outpatient use of lipophilic and hydrophilic ACE inhibitors on mortality for patients hospitalized with community-acquired pneumonia. Methods: A retrospective cohort study of subjects hospitalized with pneumonia at 2 tertiary teaching hospitals. We examined whether the prior outpatient use of hydrophilic or lipophilic ACE inhibitors was associated with 30-day mortality in a logistic regression analysis that adjusted for potential confounders using a propensity score. Results: Data were abstracted on 787 subjects at the 2 hospitals. In our cohort, 240% (n = 186) were on ACE inhibitors at presentation: I I I lipophilic and 74 hydrophilic. Mortality was 9.21% at 30 days. In the multivariable model, lipophilic ACE inhibitor use (odds ratio 0.3, 95% confidence interval 0.1-0.8), but not hydrophilic ACE inhibitor use (0.7, 0.3-1.7), was significantly associated with 30-day mortality. Conclusions: Our study suggests that future research of ACE inhibitors in pneumonia must describe the specific medications received. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect. C1 [Mortensen, Eric M.; Restrepo, Marcos I.; Copeland, Laurel A.] S Texas Vet Healthcare Syst, VERDICT Res Ctr, San Antonio, TX 78284 USA. [Mortensen, Eric M.; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Div Gen Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Univ Texas Hlth Sci Ctr San Antonio, Div Psychiat, San Antonio, TX 78229 USA. RP Mortensen, EM (reprint author), S Texas Vet Healthcare Syst, VERDICT Res Ctr, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78284 USA. EM mortensene@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Pugh, Jacqueline/0000-0003-4933-141X; Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 FU Howard Hughes Medical Institute [00378-001] NR 27 TC 7 Z9 7 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-9629 J9 AM J MED SCI JI Am. J. Med. Sci. PD DEC PY 2008 VL 336 IS 6 BP 462 EP 466 DI 10.1097/MAJ.0b013e31817149ed PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 384VR UT WOS:000261772800003 PM 19092318 ER PT J AU Croda, J Medeiros, MA Greenwald, R Sun, J Mcbride, A Peacock, SJ Choy, HA Haake, DA Homma, A Reis, MG Esfandiari, J Lyashchenko, KP Ko, AI AF Croda, Julio Medeiros, Marco A. Greenwald, Rena Sun, Jenny Mcbride, Alan Peacock, Sharon J. Choy, Henry A. Haake, David A. Homma, Akira Reis, Mitermayer G. Esfandiari, Javan Lyashchenko, Konstantin P. Ko, Albert I. TI IDENTIFICATION OF IMUNODOMINANT REGIONS OF LEPTOSPIRAL IMMUNOGLOBUILIN-LIKE PROTEINS FOR USE IN THE DIAGNOSIS OF LEPTOSPIROSIS SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene CY DEC 07-11, 2008 CL New Orleans, LA SP Amer Soc Trop Med & Hyg C1 [Croda, Julio; Mcbride, Alan; Reis, Mitermayer G.; Ko, Albert I.] Brazilian Minist Hlth, Goncalo Moniz Inst, Oswaldo Cruz Fdn, Salvador, BA, Brazil. [Medeiros, Marco A.; Homma, Akira] Brazilian Minist Hlth, Oswaldo Cruz Fdn, Rio De Janeiro, Brazil. [Greenwald, Rena; Sun, Jenny; Esfandiari, Javan; Lyashchenko, Konstantin P.] Chembio Diagnost Syst Inc, Medford, NY USA. [Peacock, Sharon J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. [Choy, Henry A.; Haake, David A.] Univ Calif Los Angeles, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Choy, Henry A.; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Ko, Albert I.] Cornell Univ, Weill Med Coll, Div Int Med & Infect Dis, Ithaca, NY USA. RI Ko, Albert/P-2343-2015 OI Ko, Albert/0000-0001-9023-2339 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2008 VL 79 IS 6 MA 68 BP 20 EP 21 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 382ZT UT WOS:000261644600069 ER PT J AU Kelly, JX Smilkstein, M Melendez, V Cooper, R Winter, R Hinrichs, D Riscoe, M AF Kelly, Jane X. Smilkstein, Martin Melendez, Victor Cooper, Roland Winter, Rolf Hinrichs, Dave Riscoe, Mike TI OPTIMIZATION OF DUAL-FUNCTION ACRIDONE ANTIMALARIALS: IMPROVED EFFICACY AND SYNERGY WITH PIPERAQUINE SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Meeting Abstract CT 57th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene CY DEC 07-11, 2008 CL New Orleans, LA SP Amer Soc Trop Med & Hyg C1 [Kelly, Jane X.; Smilkstein, Martin; Winter, Rolf; Hinrichs, Dave; Riscoe, Mike] Portland VA Med Ctr, Portland, OR USA. [Melendez, Victor] Walter Reed Army Inst Res, Silver Spring, MD USA. [Cooper, Roland] Old Dominion Univ, Norfolk, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2008 VL 79 IS 6 MA 760 BP 224 EP 224 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 382ZT UT WOS:000261644601125 ER PT J AU Radulovic, M Schilero, GJ Wecht, JM Weir, JP Spungen, AM Bauman, WA Lesser, M AF Radulovic, Miroslav Schilero, Gregory J. Wecht, Jill M. Weir, Joseph P. Spungen, Ann M. Bauman, William A. Lesser, Marvin TI Airflow Obstruction and Reversibility in Spinal Cord Injury: Evidence for Functional Sympathetic Innervation SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Anticholinergic agents; Plethysmography; whole body; Pulmonary function tests; Rehabilitation; Spinal cord injuries; Spirometry ID FORCED OSCILLATION TECHNIQUE; HEALTHY NONSMOKING ADULTS; LOWER RESPIRATORY-TRACT; PULMONARY-FUNCTION; ESSENTIAL HYPERHIDROSIS; AIRWAYS OBSTRUCTION; SMOOTH-MUSCLE; SPIROMETRY; NERVES; PLETHYSMOGRAPHY AB Objectives: The first objective was to assess group differences for specific airway conductance (sGaw) among subjects with tetraplegia, high paraplegia (HP: T2-T6), and low paraplegia (LP: T10-L4). The second objective was to determine the significance of responsiveness to ipratropium bromide (IB) by the assessment of the inherent variability of baseline measurements for impulse oscillation (IOS), body plethysmography, and spirometry. Design: Prospective cross-sectional intervention study. Setting: James J. Peters Veterans Administration Medical Center. Participants: Subjects (N=43): 12 with tetraplegia (C4-8), 11 with HP, 11 with LP, and 9 controls. Interventions: Not applicable. Main Outcome Measures: Measurement of IOS, body plethysmography, and spirometry parameters at baseline and 30 minutes after IB. Results: Baseline sGaw was significantly lower in tetraplegia (0.14 +/- 0.03) compared with HP (0.19 +/- 0.05) and LP (0.19 +/- 0.04) patients. By use of minimal difference to evaluate IB responsiveness in tetraplegia, 4 of 12 and 12 of 12 subjects had significant increases in forced expiratory volume in I second and sGaw, respectively, whereas I I of 12 and 10 of 12 subjects had significant decreases in respiratory resistances measured at 5 and 20Hz (R5 and R20), respectively. Conclusions: The finding of group differences for baseline sGaw supports the hypothesis that human lung contains functional sympathetic innervation. Body plethysmography and IOS were comparable in detecting IB-induced bronchodilation in tetraplegia and significantly more sensitive than spirometry. C1 [Radulovic, Miroslav; Schilero, Gregory J.; Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.; Lesser, Marvin] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Radulovic, Miroslav; Schilero, Gregory J.; Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Vet Affairs Rehabil Res & Dev Serv, Bronx, NY 10468 USA. [Radulovic, Miroslav; Schilero, Gregory J.; Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Dept Med, Bronx, NY 10468 USA. [Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Spinal Cord Injury Serv, Bronx, NY 10468 USA. [Schilero, Gregory J.; Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Weir, Joseph P.] Des Moines Univ, Osteopath Med Ctr, Des Moines, IA USA. RP Radulovic, M (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Miroslav.Radulovic@va.gov FU Veterans Administration Rehabilitation Research and Development Center of Excellence [B4162C] FX Supported by the Veterans Administration Rehabilitation Research and Development Center of Excellence (grant no. B4162C). NR 35 TC 13 Z9 13 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD DEC PY 2008 VL 89 IS 12 BP 2349 EP 2353 DI 10.1016/j.apmr.2008.06.011 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 385GY UT WOS:000261803900017 PM 19061747 ER PT J AU Andersen, B Colburn, K Richard, W Green, L AF Andersen, Bradley Colburn, Keith Richard, Weisbart Green, Lora TI Cellular Penetration and Localization of the Anti-guanosine Antibody 4h2 SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 24-29, 2008 CL San Francisco, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Andersen, Bradley; Colburn, Keith; Green, Lora] LLUMC, Redlands, CA USA. [Richard, Weisbart] Vet Affairs Greater Los Angeles Hlth Syst, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD DEC PY 2008 VL 58 IS 12 BP 3983 EP 3984 PG 2 WC Rheumatology SC Rheumatology GA 382EI UT WOS:000261587500070 ER PT J AU Hingorani, SR Seidel, K Lindner, A Aneia, T Schoch, G McDonald, G AF Hingorani, Sangeeta R. Seidel, Kristy Lindner, Armando Aneia, Tia Schoch, Gary McDonald, George TI Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE chronic kidney disease; graft-versus-host disease; albuminuria; proteinuria; mortality; hematopoietic cell transplant ID VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; CARDIOVASCULAR RISK-FACTORS; URINARY ALBUMIN; NEPHROTIC SYNDROME; RENAL-FUNCTION; FAILURE; MICROALBUMINURIA; POPULATION; EXCRETION AB Chronic kidney disease (CKD) is common after hematopoietic cell transplantation (HCT). We prospectively measured the urinary albumin:creatinine ratio (ACR) in 142 patients. Total (intact) monomeric albumin was determined by liquid chromatography of untreated urine samples collected weekly to day 100 after HCT Albuminuria was defined as ACR (mg/g creatinine) > 30; proteinuria, as ACR > 300. Cox and logistic regression analyses evaluated ACR as a risk factor for clinical events. The prevalence of albuminuria was 37% at baseline, 64% at day 100, and 50% at 1 year. Proteinuria occurred in 4% of patients at baseline, in 15% at day 100, and in 4% at 1 year. Characteristics associated with albuminuria include age, sex, donor type, hypertension, and sinusoidal obstruction syndrome (SOS). Albuminuria was associated with an increased risk of acute graft-versus-host disease (aGVHD) and bacteremia, but not acute kidney injury (AKI). Albuminuria at day 100 was associated with CKD at 1 year (odds ratio = 4.0; 95% confidence interval [CI] = 1.1 to 14.6). Nonrelapse mortality (NRM) risk was elevated (hazard ratio = 6.8; 95% CI = 1.1 to 41.5) in patients with overt proteinuria at day 100. Albuminuria occurs frequently after HCT and is correlated with aGVHD, bacteremia, hypertension, and progression of renal disease. Proteinuria at day 100 is associated with an 6-fold increased risk of NRM by 1 year after HCT. C1 [Hingorani, Sangeeta R.; Seidel, Kristy; Aneia, Tia] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Lindner, Armando; McDonald, George] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Schoch, Gary; McDonald, George] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Lindner, Armando] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Hingorani, SR (reprint author), Childrens Hosp & Reg Med Ctr, 4800 Sand Point Way NE,A-7931, Seattle, WA 98105 USA. EM sangeeta.hingorani@seattlechildrens.org FU National Institutes of Health (NIH) [M01-RR-00037, CA18029]; National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK63038]; American Society of Nephrology/Renal Physicians Association Health Scholars; National Kidney Foundation Young Investigators FX This research was supported by National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases Grant K23 DK63038, an American Society of Nephrology/Renal Physicians Association Health Scholars Grant, and a National Kidney Foundation Young Investigators Grant (to S.H.) and NIH Grants M01-RR-00037 (to the University of V Washington General Clinical Research Center) and CA18029 (to G.B.M.). NR 30 TC 27 Z9 27 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD DEC PY 2008 VL 14 IS 12 BP 1365 EP 1372 DI 10.1016/j.bbmt.2008.09.015 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 384OR UT WOS:000261754600006 PM 19041058 ER PT J AU Mani, G Johnson, DM Marton, D Feldman, MD Patel, D Ayon, AA Agrawal, CM AF Mani, Gopinath Johnson, Dave M. Marton, Denes Feldman, Marc D. Patel, Devang Ayon, Arturo A. Agrawal, C. Mauli TI Drug delivery from gold and titanium surfaces using self-assembled monolayers SO BIOMATERIALS LA English DT Article DE Drug-eluting stents; Drug delivery; Self-assembled monolayers; Surface modification ID CORONARY-ARTERY-DISEASE; SIROLIMUS-ELUTING STENT; NATIVE-OXIDE SURFACE; BALLOON ANGIOPLASTY; AQUEOUS-SOLUTION; PHOSPHONIC ACID; THROMBOSIS; METAL; FLUORESCENCE; BINDING AB Currently available drug-eluting stents (DES) use polymers for coating and releasing drugs. increasing evidence suggests that inflammatory and hypersensitive reactions are caused by such polymer coatings. This study focused on developing new techniques for delivering drugs directly from metal implant surfaces. Hydroxyl-terminated self-assembled monolayers (SAMs) were coated on Au and Ti surfaces. Therapeutic self-assembled monolayers (TSAMs) were prepared by chemically attaching the model drug, flufenamic acid, to SAM coated metal surfaces. Three different methods of esterification (acid chloride esterification, dry heat esterification, and direct esterification) were explored to attach flufenamic acid to SAMs. TSAMs were characterized using X-ray photoelectron spectroscopy, fluorescence microscopy, atomic force microscopy, and contact angle goniometry. These techniques collectively confirmed the attachment of drug onto SAM coated metal surfaces. In vitro drug release was investigated by immersing TSAM coated metal specimens in tris-buffered saline (TBS) at 37 degrees C for 28 days. TBS was analyzed at 1, 3, 7,14, 21, and 28 days for the amount of drug eluted using high performance liquid chromatography. Large data scatter was observed for the release profiles of TSAMs prepared by acid chloride esterification. TSAMs prepared by dry heat and direct esterification methods showed an initial burst release of the drug followed by a sustained slow release for up to 2 weeks. Thus, this study suggests the potential for using self-assembled monolayers as an alternate system for delivering drugs from coronary stents and other metal implants. C1 [Mani, Gopinath; Johnson, Dave M.; Marton, Denes; Feldman, Marc D.; Ayon, Arturo A.; Agrawal, C. Mauli] Univ Texas San Antonio, Dept Biomed Engn, Coll Engn, San Antonio, TX 78249 USA. [Johnson, Dave M.] Univ Texas San Antonio, Coll Sci, Dept Chem, San Antonio, TX 78249 USA. [Marton, Denes] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Radiol, San Antonio, TX 78229 USA. [Feldman, Marc D.; Patel, Devang] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, San Antonio, TX 78229 USA. [Feldman, Marc D.] Dept Vet Affairs S Texas Hlth Care Syst, San Antonio, TX 78229 USA. RP Agrawal, CM (reprint author), Univ Texas San Antonio, Dept Biomed Engn, Coll Engn, 1 UTSA Circle, San Antonio, TX 78249 USA. EM mauli.agrawal@utsa.edu RI Ayon, Arturo/C-7544-2009; Marton, Denes/E-7759-2010 NR 59 TC 58 Z9 58 U1 1 U2 30 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 J9 BIOMATERIALS JI Biomaterials PD DEC PY 2008 VL 29 IS 34 BP 4561 EP 4573 DI 10.1016/j.biomaterials.2008.08.014 PG 13 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 368KH UT WOS:000260619500011 PM 18790530 ER PT J AU Castillo, DL Abraham, NS AF Castillo, Diana L. Abraham, Neena S. TI Knowledge Management: How to Keep up With the Literature SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Review ID OPTIMAL SEARCH STRATEGIES; EVIDENCE-BASED MEDICINE; USERS GUIDES; MEDLINE; READ; CARE AB With the increasing medical literature, staying current with medical information is becoming a major challenge for clinicians. To ensure best practice and treatment for patients, clinicians must access medical information, acquire new knowledge, and achieve information mastery in their field. Without a systematic approach to identify and critically appraise clinical research, they might become dependent on inappropriate or outdated information. In this review, we present a brief synopsis of the multitude of resources available to clinicians for knowledge management, our best-practice suggestions for selecting an evidence-based medicine resource, and a convenient overview and easily adaptable strategy to successfully identify relevant medical literature and evaluate its validity. For rapid retrieval, review, and synthesis of the medical literature, we recommend the systematic approach of retrieve, review, reject, and read. This strategy allows clinicians to more efficiently stay abreast of the medical literature and more effectively translate the best evidence from peer-reviewed publication to patient. C1 [Castillo, Diana L.; Abraham, Neena S.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Castillo, Diana L.; Abraham, Neena S.] Michael E DeBakey VA Med Ctr, GO GERI Unit, Houston, TX USA. [Abraham, Neena S.] Michael E DeBakey VA Med Ctr, Dept Gastroenterol, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Abraham, NS (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM nabraham@bcm.tmc.edu FU American Gastroenterological Association Foundation; Department of Veterans Affairs (VA) [IIR 115-05] FX The authors disclose the following: Or Abraham is supported by an American Gastroenterological Association Foundation-Sucampo-ASP Designated Research Award in Geriatric Gastroenterology and a Merit Review Award from the Department of Veterans Affairs (VA) (IIR 115-05). NR 37 TC 3 Z9 3 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2008 VL 6 IS 12 BP 1294 EP 1300 DI 10.1016/j.cgh.2008.06.019 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 384DK UT WOS:000261724300006 PM 18986844 ER PT J AU Aujesky, D Fine, MJ AF Aujesky, Drahomir Fine, Michael J. TI The Pneumonia Severity Index: A Decade after the Initial Derivation and Validation SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Workshop on Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community-Acquired Pneumonia CY JAN 17-18, 2008 CL Silver Spring, MD SP FDA, Infect Dis Soc Amer ID COMMUNITY-ACQUIRED PNEUMONIA; CLINICAL-PREDICTION RULES; LOW-RISK PATIENTS; METHODOLOGICAL STANDARDS; CONTROLLED-TRIAL; GUIDELINES; MANAGEMENT; HOSPITALIZATION; ADULTS AB The prognosis of community-acquired pneumonia ranges from rapid resolution of symptoms and full recovery of functional status to the development of severe medical complications and death. The pneumonia severity index is a rigorously studied prediction rule for prognosis that objectively stratifies patients into quintiles of risk for short-term mortality on the basis of 20 demographic and clinical variables routinely available at presentation. The pneumonia severity index was derived and validated with data on >50,000 patients with community-acquired pneumonia by use of well-accepted methodological standards and is the only pneumonia decision aid that has been empirically shown to safely increase the proportion of patients given treatment in the outpatient setting. Because of its prognostic accuracy, methodological rigor, and effectiveness and safety as a decision aid, the pneumonia severity index has become the reference standard for risk stratification of community-acquired pneumonia. C1 [Aujesky, Drahomir] Univ Lausanne, Div Gen Internal Med, Lausanne, Switzerland. [Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Vet Affairs Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Aujesky, D (reprint author), CHU Vaudois, Serv Med Interne, BH 10-622, CH-1011 Lausanne, Switzerland. EM drahomir.aujesky@chuv.ch NR 26 TC 34 Z9 34 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2008 VL 47 SU 3 BP S133 EP S139 DI 10.1086/591394 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 368XI UT WOS:000260655900006 PM 18986279 ER PT J AU Musher, DM AF Musher, Daniel M. TI Clinical and Microbiological End Points in the Treatment of Pneumonia SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Workshop on Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community-Acquired Pneumonia CY JAN 17-18, 2008 CL Silver Spring, MD SP FDA, Infect Dis Soc Amer ID BACTEREMIC PNEUMOCOCCAL PNEUMONIA; COMMUNITY-ACQUIRED PNEUMONIA; BRONCHITIS AB The US Food and Drug Administration is reviewing its criteria for evaluating new antibiotics for the treatment of bacterial pneumonia. Although there are descriptions of hundreds of comparative studies of various antimicrobials, there is surprisingly little scientific literature on how the evaluations should be done. This brief contribution outlines areas for further consideration as new drugs are evaluated. C1 [Musher, Daniel M.] Michael E DeBakey Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, Houston, TX USA. [Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Musher, DM (reprint author), 2002 Holcombe Blvd,Rm 4B-370, Houston, TX 77030 USA. NR 15 TC 4 Z9 4 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2008 VL 47 SU 3 BP S207 EP S209 DI 10.1086/591406 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 368XI UT WOS:000260655900018 PM 18986291 ER PT J AU Joo, MJ Lee, TA Au, DH Fitzgibbon, ML Weiss, KB AF Joo, Min J. Lee, Todd A. Au, David H. Fitzgibbon, Marian L. Weiss, Kevin B. TI Medication Use Patterns Associated with Spirometry in Diagnosing COPD SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE Chronic Obstructive Pulmonary Disease; Diagnosis; Drug Therapy; Professional Practice; Health Services ID OBSTRUCTIVE PULMONARY-DISEASE; INHALED CORTICOSTEROID USE; AIR-FLOW OBSTRUCTION; FLUTICASONE PROPIONATE; LUNG-FUNCTION; SALMETEROL; METAANALYSIS; MANAGEMENT; RISK; TIOTROPIUM AB Spirometry is necessary to diagnose and assess severity of COPD, but is used infrequently. Therapy with inhaled medications can improve COPD outcomes, but are not without risks. The use of spirometry may help mitigate the therapy risks if treatment is appropriate based on spirometry results. Before determining benefits of spirometry use, it is important to examine use of medications and the use of spirometry. Our objective was to characterize the association between the use of spirometry and respiratory medications in newly diagnosed COPD. This is a retrospective, longitudinal study using data from the Department of Veterans Affairs. We identified patients with a new diagnosis of COPD (index date). Spirometry use was measured two years before to six months after the index date. Respiratory medications were measured within one year following the index date. The association between spirometry and medication use was evaluated using logistic regressions and stratified by quintiles of the propensity scores for the probability of having had spirometry performed. A total of 81,162 patients were included and 30.8% had a spirometry performed. Patients with spirometry were more likely to have been dispensed an inhaled corticosteroid (AOR=1.22 (95% CI, 1.11-1.36) to 1.61 (1.45-1.79)), long-acting beta-agonists (AOR = 1.41(1.25-1.58) to 1.63(1.45-1.83)), and ipratropium bromide C1 [Joo, Min J.; Lee, Todd A.] Hines VA Hosp, Ctr Management Complex Chron Care CMC3, Hines, IL USA. [Joo, Min J.; Fitzgibbon, Marian L.] Jesse Brown VA Hosp, CMC3, Chicago, IL USA. [Joo, Min J.] Univ Illinois, Dept Med, Sect Pulm Crit Care & Sleep Med, Chicago, IL 60612 USA. [Lee, Todd A.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. [Lee, Todd A.] Northwestern Univ, Div Gen Internal Med, Dept Med, Chicago, IL 60611 USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Weiss, Kevin B.] Amer Board Med Specialties, Evanston, IL USA. RP Joo, MJ (reprint author), Univ Illinois, Jesse Brown VA Hosp, Hines VA Hosp, 840 S Wood St,M-C 719, Chicago, IL 60612 USA. EM joo@uic.edu; Todd.lee@va.gov; dau@u.washington.edu FU HSRD Service; Center for Management of Complex Chronic Care COE, Hines VA Hospital; ALTANA; Aventis; AstraZeneca; Boehringer-Ingelheim; Chiesi; GlacoSmith Kline; Merck; Novartis; Pfizer; Schering-Plough; Sepracor and Univeristy of Kentucky FX This material is based upon work supported by the HSR&D Service, Center for Management of Complex Chronic Care COE, Hines VA Hospital. The funding agency did not participate in the design and conduct of the study, collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript Research for this paper was done in part while Min Joo was a National Research Service Award postdoctoral fellow at the Institute for Healthcare Studies, Feinberg School of Medicine at Northwestern University (Chicago, Illinois) under an institutional award from the Agency for Healthcare Research and Quality. Kevin Weiss was the Director for the Management of Complex Chronic Care, Hines VA Hospital, Hines, IL and the Institute for Healthcare Studies at Northwestern University Feinberg School of Medicine, Chicago, IL when this work was performed. Dr. Lee has received funding for his contribution to the Burden of Obstructive Lung Disease (BOLD) Initiative, which has been funded inpart by uinrestricted educational grants to the Operations Center (www.boldcopd.org) from ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi, GlacoSmith Kline, Merck, Novartis, Pfizer, Schering-Plough, Sepracor and Univeristy of Kentucky. Dr. Lee has received past research grants from Astra-Zeneca, Pfizer, GlaxoSmithKiine, and Boehringer-Ingelheim. Dr. Au received a one time consultant fee from GlaxoSmithKline in the past three years. Min Joo, Todd Lee, David Au, Marian Fitzgibbon, and Kevin Weiss have no other potential conflicts of interests to disclose. NR 39 TC 7 Z9 8 U1 0 U2 0 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1541-2555 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD DEC PY 2008 VL 5 IS 6 BP 360 EP 368 DI 10.1080/15412550802522346 PG 9 WC Respiratory System SC Respiratory System GA 428HA UT WOS:000264837400005 PM 19353350 ER PT J AU Bradesi, S Herman, J Mayer, EA AF Bradesi, Sylvie Herman, Jeremy Mayer, Emeran A. TI Visceral analgesics: drugs with a great potential in functional disorders? SO CURRENT OPINION IN PHARMACOLOGY LA English DT Review ID IRRITABLE-BOWEL-SYNDROME; LONG-EVANS RATS; DOUBLE-BLIND; COLORECTAL DISTENSION; RECEPTOR SUBTYPE-1; CONTROLLED-TRIAL; NERVOUS-SYSTEM; CLINICAL-TRIAL; MEDIATES ACUTE; GI-DISORDERS AB Irritable bowel syndrome remains an incompletely understood, common syndrome with significant unmet medical needs. In IBS patients, abdominal pain is a primary factor related to quality of life impairment, symptom severity and health care utilization, and chronic visceral hyperalgesia has been identified as an important aspect of IBS pathophysiology. However, the development of therapies aimed at reducing this hyperalgesia (visceral analgesics) has been only partially successful despite preclinical evidence supporting the potential usefulness of several preclinical compounds aimed at peripheral as well as central targets. C1 [Bradesi, Sylvie; Herman, Jeremy; Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis,Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. [Bradesi, Sylvie] VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. RP Bradesi, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis,Ctr Neurobiol Stress, Los Angeles, CA 90073 USA. EM sbradesi@ucla.edu FU NIH [P50 DK64539, R24 AT00281, R21 DK071767] FX Supported by NIH grants P50 DK64539 (EAM), R24 AT00281 (EAM), and R21 DK071767 (SB). NR 68 TC 17 Z9 18 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4892 J9 CURR OPIN PHARMACOL JI Curr. Opin. Pharmacol. PD DEC PY 2008 VL 8 IS 6 BP 697 EP 703 DI 10.1016/j.coph.2008.08.009 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 381VP UT WOS:000261564300006 PM 18786654 ER PT J AU Minzenberg, MJ Poole, JH Vinogradov, S AF Minzenberg, Michael J. Poole, John H. Vinogradov, Sophia TI A neurocognitive model of borderline personality disorder: Effects of childhood sexual abuse and relationship to adult social attachment disturbance SO DEVELOPMENT AND PSYCHOPATHOLOGY LA English DT Review ID POSTTRAUMATIC-STRESS-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; EXECUTIVE FUNCTION DEFICITS; MOTHER-INFANT INTERACTIONS; VERBAL-LEARNING TEST; CEREBRAL-BLOOD-FLOW; AXIS-II COMORBIDITY; PREFRONTAL CORTEX; DECISION-MAKING; ORBITOFRONTAL CORTEX AB Borderline personality disorder (BPD) is a paradigmatic disorder of adult attachment, with high rates of antecedent childhood maltreatment. The neurocognitive correlates of both attachment disturbance and maltreatment are both presently unknown in BPD. This study evaluated whether dimensional adult attachment disturbance in BPD is related to specific neurocognitive deficits, and whether childhood maltreatment is related to these dysfunctions. An outpatient BPD group (n = 43) performed nearly 1 SD below a control group (n = 26) on short-term recall, executive, and intelligence functions. These deficits were not affected by emotionally charged stimuli. In the BPD group, impaired recall was related to attachment-anxiety, whereas executive dysfunction was related to attachment-avoidance. Abuse history was correlated significantly with executive dysfunction and at a trend level with impaired recall. Neurocognitive deficits and abuse history exhibited both independent and interactive effects on adult attachment disturbance. These results suggest that (a) BPD patients' reactivity in attachment relationships is related to temporal-limbic dysfunction, irrespective of the emotional content of stimuli, (b) BPD patients' avoidance within attachment relationships may be a relational strategy to compensate for the emotional consequences of frontal-executive dysregulation, and (c) childhood abuse may contribute to these neurocognitive deficits but may also exert effects on adult attachment disturbance that is both independent and interacting with neurocognitive dysfunction. C1 [Minzenberg, Michael J.] Univ Calif Davis, Imaging Res Ctr, Sch Med, Sacramento, CA 95817 USA. [Poole, John H.; Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Poole, John H.; Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. RP Minzenberg, MJ (reprint author), Univ Calif Davis, Imaging Res Ctr, Sch Med, 4701 10 St, Sacramento, CA 95817 USA. EM michael.minzenberg@udcmc.ucdavis.edu NR 212 TC 38 Z9 39 U1 7 U2 34 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0954-5794 J9 DEV PSYCHOPATHOL JI Dev. Psychopathol. PD WIN PY 2008 VL 20 IS 1 BP 341 EP 368 DI 10.1017/S0954579408000163 PG 28 WC Psychology, Developmental SC Psychology GA 255WQ UT WOS:000252689300016 PM 18211741 ER PT J AU Jeffcoate, WJ Lipsky, BA Berendt, AR Cavanagh, PR Bus, SA Peters, EJG van Houtum, WH Valk, GD Bakker, K AF Jeffcoate, W. J. Lipsky, B. A. Berendt, A. R. Cavanagh, P. R. Bus, S. A. Peters, E. J. G. van Houtum, W. H. Valk, G. D. Bakker, K. CA Three Systematic Review Working Pa TI Unresolved issues in the management of ulcers of the foot in diabetes SO DIABETIC MEDICINE LA English DT Review DE diabetic foot; infection; osteomyelitis; systematic review; wound healing ID RANDOMIZED-CONTROLLED-TRIAL; PRESSURE WOUND THERAPY; STAGE RENAL-DISEASE; VACUUM-ASSISTED CLOSURE; TO-BONE TEST; CLINICAL-TRIAL; NONSURGICAL MANAGEMENT; CLASSIFICATION-SYSTEM; HYPERBARIC-OXYGEN; PLANTAR PRESSURE AB Management of diabetic foot ulcers presents a major clinical challenge. The response to treatment is often poor and the outcome disappointing, while the costs are high for both healthcare providers and the patient. In such circumstances, it is essential that management should be based on firm evidence and follow consensus. In the case of the diabetic foot, however, clinical practice can vary widely. It is for these reasons that the International Working Group on the Diabetic Foot has published guidelines for adoption worldwide. The Group has now also completed a series of non-systematic and systematic reviews on the subjects of soft tissue infection, osteomyelitis, offloading and other interventions designed to promote ulcer healing. The current article collates the results of this work in order to demonstrate the extent and quality of the evidence which is available in these areas. In general, the available scientific evidence is thin, leaving many issues unresolved. Although the complex nature of diabetic foot disease presents particular difficulties in the design of robust clinical trials, and the absence of published evidence to support the use of an intervention does not always mean that the intervention is ineffective, there is a clear need for more research in the area. Evidence from sound clinical studies is urgently needed to guide consensus and to underpin clinical practice. It is only in this way that patients suffering with these frequently neglected complications of diabetes can be offered the best hope for a favourable outcome, at the least cost. Diabet. Med. 25, 1380-1389 (2008). C1 [Jeffcoate, W. J.] Nottingham Univ Hosp Trust, Foot Ulcer Trials Unit, Dept Endocrinol & Diabet, Nottingham NG5 1PB, England. [Lipsky, B. A.] VA Puget Sound HCS, Seattle, WA USA. [Berendt, A. R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Berendt, A. R.] Nuffield Orthopaed Ctr NHS Turst, Bone Infect Unit, Oxford, England. [Bus, S. A.] Univ Amsterdam, Acad Med Ctr, Dept Rehabil, NL-1105 AZ Amsterdam, Netherlands. [Peters, E. J. G.] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands. [Valk, G. D.] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands. [van Houtum, W. H.] Spaarne Hosp, Dept Internal Med, Hoofddorp, Netherlands. [Bakker, K.] IWGDF, Heemstede, Netherlands. RP Jeffcoate, WJ (reprint author), Nottingham Univ Hosp Trust, Foot Ulcer Trials Unit, Dept Endocrinol & Diabet, City Hosp Campus, Nottingham NG5 1PB, England. EM wjeffcoate@futu.co.uk RI Lipsky, Benjamin/B-4645-2013; Peters, Edgar /B-7790-2014 OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 93 TC 39 Z9 42 U1 2 U2 16 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0742-3071 J9 DIABETIC MED JI Diabetic Med. PD DEC PY 2008 VL 25 IS 12 BP 1380 EP 1389 DI 10.1111/j.1464-5491.2008.02573.x PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 377KD UT WOS:000261249200002 PM 19046235 ER PT J AU Silveira, EB Artifon, EL AF da Silveira, Eduardo B. Artifon, Everson L. TI Cost-Effectiveness of Palliation of Unresectable Esophageal Cancer SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Cost-effective analysis; Dysphagia; Esophageal cancer; Decision modeling ID EXPANDABLE METAL STENTS; RATE INTRALUMINAL BRACHYTHERAPY; SINGLE-DOSE BRACHYTHERAPY; MALIGNANT DYSPHAGIA; GASTROESOPHAGEAL JUNCTION; RANDOMIZED-TRIAL; GASTRIC CARDIA; CLINICAL-TRIAL; CARCINOMA; PLACEMENT AB Introduction Different modalities of palliation for obstructive symptoms in patients with unresectable esophageal cancer (EC) exist. However, these therapeutic alternatives have significant differences in costs and effectiveness. Methods A Markov model was designed to compare the cost-effectiveness (CE) of self-expandable stent (SES), brachytherapy and laser in the palliation of unresectable EC. Patients were assigned to one of the strategies, and the improvement in swallowing function was compared given the treatment efficacy, probability of survival, and risks of complications associated to each strategy. Probabilities and parameters for distribution were based on a 9-month time frame. Results Under the base-case scenario, laser has the lowest CE ratio, followed by brachytherapy at an incremental cost-effectiveness ratio (ICER) of $4,400.00, and SES is a dominated strategy. In the probabilistic analysis, laser is the strategy with the highest probability of cost-effectiveness for willingness to pay (WTP) values lower than $3,201 and brachytherapy for all WTP yielding a positive net health benefit (NHB) (threshold $4,440). The highest probability of cost-effectiveness for brachytherapy is 96%, and consequently, selection of suboptimal strategies can lead to opportunity losses for the US health system, ranging from US$ 4.32 to US$ 38.09 million dollars over the next 5-20 years. Conclusion Conditional to the WTP and current US Medicare costs, palliation of unresectable esophageal cancers with brachytherapy provides the largest amount of NHB and is the strategy with the highest probability of CE. However, some level of uncertainly remains, and wrong decisions will be made until further knowledge is acquired. C1 [da Silveira, Eduardo B.] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97239 USA. [Artifon, Everson L.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil. RP Silveira, EB (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,P3GI, Portland, OR 97239 USA. EM eduardo.dasilveira@va.gov NR 44 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD DEC PY 2008 VL 53 IS 12 BP 3103 EP 3111 DI 10.1007/s10620-008-0302-2 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 371NC UT WOS:000260837000008 ER PT J AU Reavis, KM Phillips, DS Fausti, SA Gordon, JS Helt, WJ Wilmington, D Bratt, GW Konrad-Martin, D AF Reavis, Kelly M. Phillips, David S. Fausti, Stephen A. Gordon, Jane S. Helt, Wendy J. Wilmington, Debra Bratt, Gene W. Konrad-Martin, Dawn TI Factors Affecting Sensitivity of Distortion-Product Otoacoustic Emissions to Ototoxic Hearing Loss SO EAR AND HEARING LA English DT Article; Proceedings Paper CT Annual Convention of the American-Speech-Language-Hearing-Association CY NOV 15-17, 2007 CL Boston, MA SP Amer Speech Language Hearing Assoc ID CISPLATIN-INDUCED OTOTOXICITY; HIGH-FREQUENCY AUDIOMETRY; CANAL STANDING WAVES; HIGH-DOSE CISPLATIN; HUMAN TEMPORAL BONE; HAIR CELL LOSS; CIS-DIAMMINEDICHLOROPLATINUM; AMINOGLYCOSIDE OTOTOXICITY; GUINEA-PIG; TONE AUDIOMETRY AB Objectives: (1) To determine the ototoxicity detection rate (sensitivity) for distortion-product otoacoustic emissions (DPOAEs) testing in adults who received ototoxic medications and experienced pure-tone threshold changes during the course of treatment; (2) to determine the extent to which DPOAE sensitivity to ototoxicity depends on the type of drug administered (platinum or antibiotic), magnitude of ototoxic threshold shifts, pre-exposure pure-tone threshold, and DPOAE data; and (3) to build a model to predict DPOAE sensitivity. Design: DPOAE and audiometric data were obtained as part of a prospective Veterans Affairs study investigating methods of ototoxicity monitoring. Data were analyzed from 90 ears of 53 subjects receiving ototoxic medications and showing significant hearing changes in at least one ear. Pure-tone threshold data were obtained at frequencies from 0.5 to 20 kHz, using 1/6-octave precision near the upper frequency limit of hearing. DPOAE data are reported for f(2)'s from 0.8 to 8.0 kHz in 1/6-octave increments using primary levels (L(1)/L(2)) of 65/59 dB SPL and a primary frequency ratio (f(2)/f(1)) of 1.2. Test results were evaluated at various times during drug treatment to determine whether DPOAE level changes were associated with behavioral hearing changes. Univariate and multivariate analysis techniques were used to determine factors that affected DPOAE sensitivity to ototoxic damage. Results: Of the 90 ears examined, 82 (91%) had DPOAEs that could be monitored for changes. Sixty-four of these 82 ears (78%) had DPOAEs that were reduced or absent following drug treatment. DPOAE sensitivity to ototoxicity was unrelated to the type of ototoxic drug administered. Rather, DPOAE sensitivity depended on the magnitude of postexposure hearing changes and on variables related to pre-exposure audiogram and DPOAE measurements. Behavioral hearing changes not detected by DPOAEs were small on average (<7 dB). DPOAE sensitivity was reduced in cars with poorer pre-exposure hearing, and in ears with measurable DPOAE frequencies limited to f(2)'s below 2.5 kHz or more than one octave from the frequency region where hearing change occurred. Results of logistic regression modeling showed that DPOAEs present at f(2)'s greater than 2.5 kHz were associated with the eventual success of ototoxicity monitoring with DPOAEs. However, independent variables examined could not explain differences in the relative timing of behavioral and DPOAE changes. A roughly equivalent proportion of ears experienced DPOAE changes before, during, or after behavioral hearing changes. Conclusions: DPOAEs are a useful screening tool for ototoxicity in adults with pre-exposure hearing loss, but are less sensitive compared with a behavioral test method that targets thresholds near the upper limit of a subject's audible frequency range. Ears successfully monitored for ototoxicity with DPOAEs are those with better pre-exposure hearing, greater postexposure hearing changes, and baseline DPOAEs near the highest behavioral test frequencies and present at high f(2)'s. Results suggest that successful monitoring of ototoxicity with DPOAEs may be predicted clinically by assessing the measurable DPOAE f(2) frequency range and its relation to the highest behavioral test frequencies. C1 [Reavis, Kelly M.; Phillips, David S.; Fausti, Stephen A.; Gordon, Jane S.; Helt, Wendy J.; Wilmington, Debra; Konrad-Martin, Dawn] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Fausti, Stephen A.; Konrad-Martin, Dawn] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [Bratt, Gene W.] VA Tennessee Valley Hlth Care Syst, Nashville, TN USA. [Bratt, Gene W.] Vanderbilt Univ, Sch Med, Dept Otolaryngol, Nashville, TN 37212 USA. RP Reavis, KM (reprint author), Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kelly.reavis@va.gov NR 76 TC 23 Z9 25 U1 3 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD DEC PY 2008 VL 29 IS 6 BP 875 EP 893 DI 10.1097/AUD.0b013e318181ad99 PG 19 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 371DY UT WOS:000260813200006 PM 18753950 ER PT J AU Lara-Castro, C Garvey, WT AF Lara-Castro, Cristina Garvey, W. Timothy TI Intracellular Lipid Accumulation in Liver and Muscle and the Insulin Resistance Syndrome SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA LA English DT Article DE Insulin resistance; Muscle fat; Intramyocellular fat; Hepatic steatosis; Inflammation ID DEPENDENT DIABETES-MELLITUS; FREE FATTY-ACIDS; ADIPOSE-TISSUE INFLAMMATION; SKELETAL-MUSCLE; WEIGHT-LOSS; METABOLIC SYNDROME; MITOCHONDRIAL DYSFUNCTION; HEPATIC STEATOSIS; GENE-EXPRESSION; CLINICAL-COURSE AB This article emphasizes intrahepatocellular and intramyocellular lipid accumulation as components of the insulin resistance syndrome. It examines the mechanisms responsible for the interrelationships among ectopic fat deposition, insulin resistance, and associated metabolic traits. These relationships are complex and vary according to diet, exercise, weight loss, and racial identity. Overall, there is a high degree of association of both intrahepatocellular and intramyocellular lipids with insulin resistance and associated cardiometabolic risk factors. It concludes that further research is necessary to determine the orchestrated roles of adipose and nonadipose tissue compartments in the regulation of insulin sensitivity, and mechanisms explaining racial differences in the insulin resistance syndrome-trait cluster. C1 [Lara-Castro, Cristina; Garvey, W. Timothy] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Garvey, WT (reprint author), Univ Alabama, Dept Nutr Sci, 1675 Univ Blvd,Webb Bldg 232, Birmingham, AL 35294 USA. EM garveyt@uab.edu FU National Institutes of Health [DK-381764, P01 HL-55, 782]; Mechanisms of Hypertension and Cardiovascular Diseases [HL-007, 457]; UAB General Clinical Research Center [M01-RR00032]; Clinical Nutrition Research Unit [P30 DK56336]; Diabetes Research and Training Center [P60 DK079626] FX This work was supported from grants from the National Institutes of Health DK-381764 (WTG), P01 HL-55, 782(WTG), and the T32 training grant (HL-007, 457) entitled 'Mechanisms of Hypertension and Cardiovascular Diseases (PI: S. Oparil), and by the Merit Review program of the Department of Veterans Affairs (WTG). We also acknowledge support from the UAB General Clinical Research Center M01-RR00032, and the research core facilities of the Clinical Nutrition Research Unit (P30 DK56336) and the Diabetes Research and Training Center (P60 DK079626) at UAB. NR 91 TC 60 Z9 64 U1 3 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8529 J9 ENDOCRIN METAB CLIN JI Endocrinol. Metabol. Clin. North Amer. PD DEC PY 2008 VL 37 IS 4 BP 841 EP + DI 10.1016/j.ecl.2008.09.002 PG 17 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 390PL UT WOS:000262176100005 PM 19026935 ER PT J AU Leung, JW Lee, W Wilson, R Lim, BS Leung, FW AF Leung, J. W. Lee, W. Wilson, R. Lim, B. S. Leung, F. W. TI Comparison of accessory performance using a novel ERCP mechanical simulator SO ENDOSCOPY LA English DT Article ID BILE-DUCT STRICTURES; FOLLOW-UP; STENTS AB Background and study aims: There is a paucity of in vitro methods for evaluating ERCP accessories. We hypothesize that the time taken to perform a simulated single stent or multiple stents placement is different for stenting systems with or without the capability of intraductal ductal release (IDR) of the guide wire. Patients and methods: We conducted an un-blinded in vitro comparison of ERCP accessories using a mechanical simulator during hands-on ERCP practice workshops. A total of 21 U.S. participants and 20 Chinese participants with various level of ERCP experience took part in the different practice workshops. Accessories with and without the capability of intraductal release of guide wire were compared. Total time required for completing a simulated stenting procedure with single or multiple stents and the respective simulated fluoroscopy time were recorded. Results: There was no significant difference in the time taken for placement of a single stent using either stenting systems. Stenting system capable of intraductal release of the guide wire required significantly shorter time to complete placement of three stents. Conclusions: Using time required to complete a specific task, i.e. biliary stenting, the mechanical simulator permits the performance of different accessories by the same group of operators to be evaluated objectively. C1 [Leung, J. W.] Sacramento VA Med Ctr, Gastroenterol Sect, Mather, CA 95655 USA. [Leung, J. W.; Wilson, R.; Lim, B. S.] Univ Calif, Davis Med Ctr, Sacramento, CA USA. [Lee, W.] Tianjian Union Med Ctr, Endoscopy Ctr, Tianjin, Peoples R China. [Leung, F. W.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Med Serv, Sepulveda Ambulatory Care Ctr & Nursing Home, Los Angeles, CA USA. [Leung, F. W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Leung, JW (reprint author), Sacramento VA Med Ctr, Gastroenterol Sect, 10535 Hosp Way, Mather, CA 95655 USA. EM jwleung@ucdavis.edu FU Veterans Affairs Medical Research Funds; Outcome Research Award of the American College of Gastroenterology FX This study was supported in part by Veterans Affairs Medical Research Funds and an Outcome Research Award of the American College of Gastroenterology. The authors are indebted to the trainees and attending staff who participated in the described assessments. NR 15 TC 6 Z9 6 U1 0 U2 1 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PD DEC PY 2008 VL 40 IS 12 BP 983 EP 988 DI 10.1055/s-2008-1077777 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 393HP UT WOS:000262364700004 PM 19065479 ER PT J AU Albertini, MR Macklin, MD Zuleger, CL Newton, MA Judice, SA Albertini, RJ AF Albertini, Mark R. Macklin, Michael D. Zuleger, Cindy L. Newton, Michael A. Judice, Stephen A. Albertini, Richard J. TI Clonal Expansions of 6-Thioguanine Resistant T Lymphocytes in the Blood and Tumor of Melanoma Patients SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CELL-RECEPTOR REPERTOIRE; IN-VIVO; V-BETA; GENETIC INSTABILITY; INCREASED FREQUENCY; MULTIPLE EPITOPES; PERIPHERAL-BLOOD; MUTANT FREQUENCY; METASTASES AB The identification of specific lymphocyte populations that mediate tumor immune responses is required for elucidating the mechanisms underlying these responses and facilitating therapeutic interventions in humans with cancer. To this end, mutant hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficient (HPRT-) T-cells were used as probes to detect T-cell clonal amplifications and trafficking in vivo in patients with advanced melanoma. Mutant T-cells from peripheral blood were obtained as clonal isolates or in mass cultures in the presence of 6-thioguanine (TG) selection and from tumor-bearing lymph nodes (LNs) or metastatic melanoma tissues by TG-selected mass cultures. Nonmutant (wildtype) cells were obtained from all sites by analogous means, but without TG selection. cDNA sequences of the T-cell receptor (TCR) beta chains (TCR-beta), determined directly (clonal isolates) or following insertion into plasmids (mass cultures), were used as unambiguous biomarkers of in vivo clonality of mature T-cell clones. Clonal amplifications, identified as repetitive TCR-beta V-region, complementarity determining region 3 (CDR3), and J-region gene sequences, were demonstrated at all sites studied, that is, peripheral blood, LNs, and metastatic tumors. Amplifications were significantly enriched among the mutant compared with the wild-type T-cell fractions. Importantly, T-cell trafficking was manifested by identical TCR-beta cDNA sequences, including the hypervariable CDR3 motifs, being found in both blood and tissues in individual patients. The findings described herein indicate that the mutant T-cell fractions from melanoma patients are enriched for proliferating T-cells that infiltrate the tumor, making them candidates for investigations of potentially protective immunological responses. Environ. Mal. Mutagen. 49:676-687, 2008. Published 2008 Wiley-Liss, Inc. C1 [Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI 53705 USA. [Albertini, Mark R.; Macklin, Michael D.; Zuleger, Cindy L.; Newton, Michael A.] Univ Wisconsin, Sch Med & Publ Hlth, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA. [Albertini, Mark R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA. [Newton, Michael A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Stat, Madison, WI USA. [Judice, Stephen A.] Whatman Inc, Sanford, MA USA. [Albertini, Richard J.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. RP Albertini, MR (reprint author), William S Middleton Mem Vet Adm Med Ctr, Med Serv, Room B-5055B,2500 Overlook Terrace, Madison, WI 53705 USA. EM rnralbert@wisc.edu FU Office of Research and Development; Biomedical Laboratory Research and Development Service; Department of Veterans Affairs; U.S. Department of Energy; Gretchen and Andrew Dawes Melanoma Research Fund Ann's Hope Foundation; Jay Van Sloan Memorial from the Steve Leuthold Family; Tint Eagle Memorial FX Grant sponsors: Office of Research and Development, Biomedical Laboratory Research and Development Service. Department of Veterans Affairs: U.S. Department of Energy: Gretchen and Andrew Dawes Melanoma Research Fund Ann's Hope Foundation: Jay Van Sloan Memorial from the Steve Leuthold Family: Tint Eagle Memorial. NR 39 TC 3 Z9 3 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD DEC PY 2008 VL 49 IS 9 BP 676 EP 687 DI 10.1002/em.20417 PG 12 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA 384EA UT WOS:000261725900002 PM 18712786 ER PT J AU Paintlia, AS Paindia, MK Singh, I Singh, AK AF Paintlia, Ajaib S. Paindia, Manjeet K. Singh, Inderjit Singh, Avtar K. TI Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Combination therapy; EAE; Lovastatin; Rolipram; Inflammation; Demyelination; Neuroprotection ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; REMITTING MULTIPLE-SCLEROSIS; COA REDUCTASE INHIBITOR; BLOOD-BRAIN-BARRIER; GLATIRAMER ACETATE; COMBINATION THERAPY; PHOSPHODIESTERASE INHIBITORS; INTERFERON-BETA; T-CELLS AB Combinations of new medications or existing therapies are gaining momentum over monotherapy to treat central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS). Recent Studies established that statins (HMG-CoA reductase inhibitors) are effective in experimental autoimmune encephalomyelitis (EAE), an MS model and are promising candidates for future MS medication. Another drug, rolipram (phosphodiesterase-4 inhibitor) ameliorates the clinical severity of EAE via induction of various anti-inflammatory and neuroprotective activities. In this study, we tested whether combining the suboptimal doses of these drugs can suppress the severity of EAE. Prophylactic studies revealed that combined treatment with Suboptimal doses of statins perform better than their individually administered optimal doses in EAE as evidenced by delayed clinical scores, reduced disease severity, and rapid recovery. Importantly, combination therapy suppressed the progression of disease in an established EAE case via attenuation of inflammation, axonal loss and demyelination. Combination treatment attenuated inflammatory T(H)1 and T(H)17 immune responses and induced T(H)2-biased immunity in the peripheral and CNS as revealed by serological, quantitative, and immunosorbant assay-based analyses. Moreover, the expansion of T regulatory (CD25(+)/Foxp3(+)) cells and self-immune tolerance was apparent in the CNS. These effects of combined drugs were reduced or minimal with either drug alone in this setting. In conclusion, our findings demonstrate that the combination of these drugs suppresses EAE severity and provides neuroprotection thereby suggesting that this pharmacological approach could be a better future therapeutic strategy to treat MS patients. Published by Elsevier Inc. C1 [Paintlia, Ajaib S.] Med Univ S Carolina, Darby Childrens Res Inst, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pediat, Charleston, SC USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Paintlia, AS (reprint author), Med Univ S Carolina, Darby Childrens Res Inst, Charleston, SC 29425 USA. EM paintlia@musc.edu; singhi@musc.edu OI Paintlia, Ajaib/0000-0003-4525-5333 FU NIH [NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455, C06-RR018823]; Merck and Company FX This study was supported by grants from the NIH (NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455, and C06-RR018823 and support from Merck and Company. NR 62 TC 27 Z9 28 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD DEC PY 2008 VL 214 IS 2 BP 168 EP 180 DI 10.1016/j.expneurol.2008.07.024 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 380RW UT WOS:000261483900003 PM 18775426 ER PT J AU Ioannou, GN AF Ioannou, George N. TI Implications of Elevated Serum Alanine Aminotransferase Levels: Think Outside the Liver SO GASTROENTEROLOGY LA English DT Editorial Material ID INSULIN-RESISTANCE ATHEROSCLEROSIS; NONALCOHOLIC HEPATIC STEATOSIS; METABOLIC SYNDROME; DISEASE; RISK; ENZYMES; MEN; PREDICTS; MARKERS C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA 98108 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. [Ioannou, George N.] Univ Washington, Div Gastroenterol, Dept Med, Seattle, WA USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu NR 18 TC 16 Z9 17 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2008 VL 135 IS 6 BP 1851 EP 1854 DI 10.1053/j.gastro.2008.11.005 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 384RP UT WOS:000261762200043 PM 19007778 ER PT J AU Whall, AL Colling, KB Kolanowski, A Kim, HJ Hong, GRS DeCicco, B Ronis, DL Richards, KC Algase, D Beck, C AF Whall, Ann L. Colling, Kathleen B. Kolanowski, Ann Kim, Hyo Jeong Hong, Gwi-Ryung Son DeCicco, Barry Ronis, David L. Richards, Kathy C. Algase, Donna Beck, Cornelia TI Factors Associated With Aggressive Behavior Among Nursing Home Residents With Dementia SO GERONTOLOGIST LA English DT Article DE Aggression in dementia; Need-Driven Dementia-Compromised Behavior (NDB) model of; dementia care; Nursing home care ID MINIMUM DATA SET; ALZHEIMERS-DISEASE; PREMORBID PERSONALITY; PSYCHOLOGICAL SYMPTOMS; PSYCHOMETRIC CHARACTERISTICS; VERBAL AGGRESSION; MENTAL-STATE; AGITATION; INTERVENTION; POPULATION AB Purpose: In an attempt to more thoroughly describe aggressive behavior in nursing home residents with dementia, we examined background and proximal factors as guided by the Need-Driven Dementia-Compromised Behavior model. Design and Methods: We used a multivariate cross-sectional survey with repeated measures; participants resided in nine randomly selected nursing homes within four midwestern counties. The Minimum Data Set (with verification by caregivers) identified participants. We used a disproportionate probability sample of 107 participants (51% with a history of aggressive behavior) to ensure variability. Videotaped care events included four of direct care (shower baths, meals, dressing, and undressing) and two of non-direct care (two randomly selected 20-minute time periods in the afternoon and evening). The majority of participants (75%) received three shower. baths, for a total of 282 videotaped baths. Results: Because the shower bath was the only care event significantly related to aggressive behavior (F = 6.9, p <.001), only those data are presented. Multilevel statistical modeling identified background factors (gender, mental status score, and lifelong history of less agreeableness) and a proximal factor (amount of nighttime sleep) as significant predictors (p < .05) of aggressive behavior during the shower bath. We found significant correlations between aggressive behavior and negative subject affect (r = .27) during the bath, and aggressive behavior and lifetime agreeableness level (r = - .192). We also found significant correlations between mental status and the amount of education (r = .212), and between negative care-giver affect and negative participant affect (r = .321). Implications: We identified three background and one proximal factor as significant risk factors for aggressive behavior in dementia. Data identify not only those persons most at risk for aggressive behavior during care, but also the care event most associated with aggressive behavior. Together these data inform both caregiving for persons with dementia as well as the design of intervention studies for aggressive behavior in dementia. C1 [Whall, Ann L.; Colling, Kathleen B.; Ronis, David L.; Algase, Donna] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Whall, Ann L.] Oakland Univ, Sch Nursing, Rochester, MI 48063 USA. [Kolanowski, Ann] Penn State Univ, Sch Nursing, University Pk, PA 16802 USA. [Kim, Hyo Jeong] Ewha Womans Univ, Coll Nursing Sci, Seoul, South Korea. [Hong, Gwi-Ryung Son] Hanyang Univ, Coll Med, Seoul 133791, South Korea. [DeCicco, Barry] Univ Michigan, Hosp & Hlth Ctr, Ann Arbor, MI 48109 USA. [Ronis, David L.] US Dept Vet Affairs, Ann Arbor, MI USA. [Richards, Kathy C.] Univ Penn, Polisher Res Inst, Philadelphia, PA 19104 USA. [Beck, Cornelia] Univ Arkansas, Med Sci Coll Med, Fayetteville, AR 72701 USA. RP Whall, AL (reprint author), Univ Michigan, Sch Nursing, 400 N Ingalls St,Room 2160, Ann Arbor, MI 48109 USA. EM annwhall@umich.edu FU NINR NIH HHS [R01 NR004568, R01 NR004568-01A1, R01 NR004568-02, R01 NR004568-03, R01 NR004568-04, R01 NR004568-05, R01 NR004569, R01 NR004570, R01-NR04569, R01-NR04570]; PHS HHS [R01-NRO4568] NR 69 TC 29 Z9 30 U1 4 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 2008 VL 48 IS 6 BP 721 EP 731 PG 11 WC Gerontology SC Geriatrics & Gerontology GA 396NQ UT WOS:000262598800002 PM 19139246 ER PT J AU Akiba, Y Mizumori, M Kuo, M Ham, M Guth, PH Engel, E Kaunitz, JD AF Akiba, Y. Mizumori, M. Kuo, M. Ham, M. Guth, P. H. Engel, E. Kaunitz, J. D. TI CO2 chemosensing in rat oesophagus SO GUT LA English DT Article ID MUCOSAL BLOOD-FLOW; CARBONIC-ANHYDRASE; EPITHELIAL-CELLS; CAPSAICIN RECEPTOR; RABBIT ESOPHAGUS; DUODENAL MUCOSA; HCO3-SECRETION; PH REGULATION; LUMINAL CO2; IN-VIVO AB Background: Acid in the oesophageal lumen is often sensed as heartburn. It was hypothesised that luminal CO2, a permeant gas, rather than H+, permeates through the epithelium, and is converted to H+, producing an afferent neural signal by activating chemosensors. Methods: The rat lower oesophageal mucosa was superfused with pH 7.0 buffer, and pH 1.0 or pH 6.4 high CO2 (P-CO2 = 260 Torr) solutions with or without the cell-permeant carbonic anhydrase (CA) inhibitor methazolamide (MTZ, 1 mM), the cell-impermeant CA inhibitor benzolamide (BNZ, 0.1 mM), the transient receptor potential vanilloid 1 (TRPV1) antagonist capsazepine (CPZ, 0.5 mM) or the acid-sensing ion channel (ASIC) inhibitor amiloride (0.1 mM). Interstitial pH (pH(int)) was measured with 5',6'-carboxyfluorescein (5 mg/kg intravenously) loaded into the interstitial space, and blood flow was measured with laser-Doppler. Results: Perfusion of a high CO2 solution induced hyperaemia without changing pH(int), mimicking the effect of pH 1.0 perfusion. Perfused MTZ, BNZ, CPZ and amiloride all inhibited CO2-induced hyperaemia. CA XIV was expressed in the prickle cells, with CA XII in the basal cells. TRPV1 was expressed in the stratum granulosum and in the muscularis mucosa, whereas all ASICs were expressed in the prickle cells, with ASIC3 additionally in the muscularis mucosa. Conclusions: The response to CO2 perfusion suggests that CO2 diffuses through the stratum epithelium, interacting with TRPV1 and ASICs in the epithelium or in the submucosa. Inhibition of the hyperaemic response to luminal CO2 by CA, TRPV1 and ASIC inhibitors implicates CA and these chemosensors in transduction of the luminal acid signal. Transepithelial CO2 permeation may explain how luminal H+ equivalents can rapidly be transduced into hyperaemia, and the sensation of heartburn. C1 [Akiba, Y.; Mizumori, M.; Ham, M.; Kaunitz, J. D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Akiba, Y.; Mizumori, M.] Brentwood Biomed Res Inst, Los Angeles, CA USA. [Kuo, M.; Guth, P. H.; Kaunitz, J. D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Engel, E.] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), W Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU Investigator-Sponsored Study Program of AstraZeneca [IRUSESOM0424]; Veterans Affairs Merit Review Award; NIH-NIDDK [RO1 DK54221] FX We thank Rebecca Cho and Jenifer Kugler for their assistance with manuscript preparation. Supported by Investigator-Sponsored Study Program of AstraZeneca IRUSESOM0424 (YA), Veterans Affairs Merit Review Award and NIH-NIDDK RO1 DK54221 (JK). NR 53 TC 26 Z9 27 U1 1 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD DEC PY 2008 VL 57 IS 12 BP 1654 EP 1664 DI 10.1136/gut.2007.144378 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 375YI UT WOS:000261149300008 PM 18682519 ER PT J AU Keyhani, S Siu, AL AF Keyhani, Salomeh Siu, Albert L. TI The Underuse of Overuse Research SO HEALTH SERVICES RESEARCH LA English DT Editorial Material ID HOSPITAL RESOURCE USE; HEALTH-CARE SERVICES; CORONARY-ANGIOGRAPHY; GUIDELINES; QUALITY; APPROPRIATENESS; MEDICARE; ANGINA C1 [Keyhani, Salomeh] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA. [Keyhani, Salomeh; Siu, Albert L.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Keyhani, Salomeh; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA. RP Keyhani, S (reprint author), Mt Sinai Sch Med, Dept Hlth Policy, Box 1077,1 Gustave L Levy Pl, New York, NY 10029 USA. EM salomeh.keyhani@mountsinai.org NR 19 TC 13 Z9 13 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD DEC PY 2008 VL 43 IS 6 BP 1923 EP 1930 DI 10.1111/j.1475-6773.2008.00920.x PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 372BZ UT WOS:000260877700002 PM 19166411 ER PT J AU Shiomi, S Toriie, A Imamura, S Konishi, H Mitsufuji, S Iwakura, Y Yamaoka, Y Ota, H Yamamoto, T Imanishi, J Kita, M AF Shiomi, Satoshi Toriie, Akihiro Imamura, Shigeyoshi Konishi, Hideyuki Mitsufuji, Shoji Iwakura, Yoichiro Yamaoka, Yoshio Ota, Hiroyoshi Yamamoto, Toshiro Imanishi, Jiro Kita, Masakazu TI IL-17 is Involved in Helicobacter pylori-Induced Gastric Inflammatory Responses in a Mouse Model SO HELICOBACTER LA English DT Article DE Helicobacter; interleukin 17; inflammation; neutrophil; mice ID COLLAGEN-INDUCED ARTHRITIS; COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; IFN-GAMMA; NEUTROPHIL RECRUITMENT; IL-17-DEFICIENT MICE; EPITHELIAL-CELLS; DEFICIENT MICE; HOST-DEFENSE; CAGA GENE AB Helicobacter pylori (H. pylori) is the major cause of chronic active gastritis and peptic ulcer disease. Recent studies have shown that H. pylori produces various cytokines that are related to neutrophil or mononuclear cell accumulation. Interleukin-17 (IL-17) is the founding member of an emerging family of inflammatory cytokines whose biological activities remain incompletely defined. In this study, the contributions of IL-17 to the induction of gastric inflammation and to the protection from H. pylori infection were investigated using IL-17 gene-knockout (IL-17(-/-)) mice. IL-17(-/-) and wild-type C57BL/6 mice were challenged with H. pylori CPY2052 (2 x 10(8) CFU/mL) and the histological and microbiological evaluation were carried out at specified times. IL-17 and myeloperoxidase (MPO) protein levels in tissues were assayed in duplicate using ELISA kits. In wild-type mice, IL-17 was undetected at baseline; however, the protein expression of IL-17 was induced after infection with H. pylori. A severe infiltration of neutrophils appeared in the submucosa and the lamina propria in wild-type mice. In contrast, the degree of neutrophil infiltration in IL-17(-/-) mice was significantly lower than that in wild-type mice. Although wild-type mice infected with H. pylori showed drastically higher MPO activity compared with uninfected wild-type mice, any significant increase in the enzyme activity was not revealed in infected IL-17(-/-) mice. The number of H. pylori colonized in the stomach of IL-17(-/-) mice was significantly lower than that of wild-type mice from 1 to 6 months after infection. These results suggest that IL-17 may play an important role in the inflammatory response to the H. pylori infection and ultimately influence the outcome of the H. pylori-associated disease. C1 [Kita, Masakazu] Kyoto Prefectural Univ Med, Dept Microbiol, Kamigyo Ku, Kyoto 6028566, Japan. [Shiomi, Satoshi; Toriie, Akihiro; Imamura, Shigeyoshi; Konishi, Hideyuki; Mitsufuji, Shoji] Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6028566, Japan. [Iwakura, Yoichiro] Univ Tokyo, Inst Med Sci, Ctr Med Expt, Tokyo 1088639, Japan. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. [Ota, Hiroyoshi] Shinshu Univ, Sch Med, Sch Hlth Sci, Dept Biomed Lab Sci, Nagano 3908621, Japan. RP Kita, M (reprint author), Kyoto Prefectural Univ Med, Dept Microbiol, Kamigyo Ku, Kyoto 6028566, Japan. EM kita@koto.kpu-m.ac.jp RI Iwakura, Yoichiro/E-5457-2011 OI Iwakura, Yoichiro/0000-0002-9934-5775 FU Japan Society for the Promotion of Science (JSPS) [19590696]; National Institutes of Health [DK 62813] FX This work was supported by Grant-in-Aid for Scientific Research(C) 19590696 from Japan Society for the Promotion of Science (JSPS) and also supported in part by National Institutes of Health grant through DK 62813 (to Y. Y.). The authors have no competing interests. NR 35 TC 52 Z9 57 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD DEC PY 2008 VL 13 IS 6 BP 518 EP 524 DI 10.1111/j.1523-5378.2008.00629.x PG 7 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 371HV UT WOS:000260823300005 PM 19166417 ER PT J AU Hiruma, Y Kurihara, N Subler, MA Zhou, H Boykin, CS Zhang, HJ Ishizuka, S Dempster, DW Roodman, GD Windle, JJ AF Hiruma, Yuko Kurihara, Noriyoshi Subler, Mark A. Zhou, Hua Boykin, Christina S. Zhang, Heju Ishizuka, Seiichi Dempster, David W. Roodman, G. David Windle, Jolene J. TI A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment SO HUMAN MOLECULAR GENETICS LA English DT Article ID 1,25-DIHYDROXYVITAMIN D-3; FAMILIAL AGGREGATION; CELLS; HISTOMORPHOMETRY; PRECURSORS; EXPRESSION; P62; NOMENCLATURE; GENETICS; SEQUENCE AB Paget's disease of bone (PDB) is the second most common bone disease and is characterized by focal bone lesions which contain large numbers of abnormal osteoclasts (OCLs) and very active normal osteoblasts in a highly osteoclastogenic marrow microenvironment. The etiology of PDB is not well understood and both environmental and genetic causes have been implicated in its pathogenesis. Mutations in the SQSTM1/p62 gene have been identified in up to 30% of Paget's patients. To determine if p62 mutation is sufficient to induce PDB, we generated mice harboring a mutation causing a P-to-L (proline-to-leucine) substitution at residue 394 (the murine equivalent of human p62(P392L), the most common PDB-associated mutation). Bone marrow cultures from p62(P394L) mice formed increased numbers of OCLs in response to receptor activator of NF-kappa B ligand (RANKL), tumor necrosis factor alpha (TNF-alpha) or 1 alpha,25-(OH)(2)D-3, similar to PDB patients. However, purified p62(P394L) OCL precursors depleted of stromal cells were no longer hyper-responsive to 1 alpha,25-(OH)(2)D-3, suggesting effects of the p62(P394L) mutation on the marrow microenvironment in addition to direct effects on OCLs. Co-cultures of purified p62(P394L) stromal cells with either wild-type (WT) or p62(P394L) OCL precursors formed more OCLs than co-cultures containing WT stromal cells due to increased RANKL production by the mutant stromal cells. However, despite the enhanced osteoclastogenic potential of both OCL precursors and marrow stromal cells, the p62(P394L) mice had histologically normal bones. These results indicate that this PDB-associated p62 mutation is not sufficient to induce PDB and suggest that additional factors acting together with p62 mutation are necessary for the development of PDB in vivo. C1 [Subler, Mark A.; Boykin, Christina S.; Windle, Jolene J.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA 23298 USA. [Zhang, Heju; Windle, Jolene J.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA. [Hiruma, Yuko; Kurihara, Noriyoshi; Roodman, G. David] Univ Pittsburgh, Med Ctr, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. [Zhou, Hua; Dempster, David W.] Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA. [Ishizuka, Seiichi] Teijin Biomed Res, Tokyo 1918512, Japan. [Dempster, David W.] Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. RP Windle, JJ (reprint author), Virginia Commonwealth Univ, Dept Human & Mol Genet, POB 980033, Richmond, VA 23298 USA. EM jjwindle@vcu.edu OI Windle, Jolene/0000-0001-6690-385X FU National Institutes of Health [R01 AR053537, PO1 AR049363, P30 CA16059]; Paget Foundation; National Institutes of Health/NCRR/CTRC [1 UL1 RR024153-01] FX This work was supported by research funds from the National Institutes of Health (R01 AR053537 to J. J. W. and PO1 AR049363 to G. D. R.), the Paget Foundation, funds received from National Institutes of Health/NCRR/CTRC Grant # 1 UL1 RR024153-01, and the VCU/Massey Cancer Center Transgenic/Knock-out Mouse Core, which is supported by National Institutes of Health Grant P30 CA16059. NR 37 TC 40 Z9 41 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD DEC 1 PY 2008 VL 17 IS 23 BP 3708 EP 3719 DI 10.1093/hmg/ddn266 PG 12 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 373OG UT WOS:000260980800009 PM 18765443 ER PT J AU Sobo, EJ Bowman, C Aarons, GA Asch, S Gifford, AL AF Sobo, Elisa J. Bowman, Candice Aarons, Gregory A. Asch, Steven Gifford, Allen L. TI Enhancing Organizational Change and Improvement Prospects: Lessons from an HIV Testing Intervention for Veterans SO HUMAN ORGANIZATION LA English DT Article DE implementation science; quality improvement; organizational culture; health services research and delivery; collaboration; HIV/AIDS ID HEALTH-CARE; EXCHANGE; QUALITY; SCIENCE AB Most research on why health care quality improvement implementation succeeds or fails focuses on front-line or provider-based factors. However, background factors related to the structures and processes of projects themselves also pose challenges. Using a focused ethnographic assessment approach, we undertook a case study to characterize particularly challenging background factors in an ongoing implementation effort. We found that the organizational structure of the project under study sustained several key "cultural" differences in stakeholder agendas. Moreover, it fostered the emergence of strategic communication processes that, despite their immediate utility, sometimes undermined progress and threatened long-term relations by distorting information flow in particularly patterned ways. These included a "focus on the local" and "information reconfigurations" or "partiality" that sometimes led to miscommunication or interpretive disjunctions between various stakeholders. Successful cross-organizational communication is in certain ways a cross-cultural achievement, and several guidelines were devised to facilitate this. Our experience with other health care systems and with health services research in general suggests that our findings and recommendations are broadly applicable. Because the main barriers identified were generated by complex organizational arrangements, lessons learned may also be transferable to other complex organizational contexts. C1 [Sobo, Elisa J.] San Diego State Univ, San Diego, CA 92182 USA. [Bowman, Candice] Greater Los Angeles VA Healthcare Syst, Ctr Study Healthcare Provider, Los Angeles, CA USA. [Aarons, Gregory A.] Univ Calif San Diego, San Diego, CA 92103 USA. [Aarons, Gregory A.] Rady Childrens Hosp, Child & Adolescent Serv Res Ctr, San Diego, CA USA. [Asch, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gifford, Allen L.] Boston Univ, Boston, MA 02215 USA. RP Sobo, EJ (reprint author), San Diego State Univ, San Diego, CA 92182 USA. NR 34 TC 5 Z9 5 U1 0 U2 7 PU SOC APPLIED ANTHROPOLOGY PI OKLAHOMA CITY PA 3000 UNITED FOUNDERS BLVD, STE 148, OKLAHOMA CITY, OK 73112 USA SN 0018-7259 J9 HUM ORGAN JI Hum. Organ. PD WIN PY 2008 VL 67 IS 4 BP 443 EP 453 PG 11 WC Anthropology; Social Sciences, Interdisciplinary SC Anthropology; Social Sciences - Other Topics GA 376YJ UT WOS:000261218600009 ER PT J AU Chirinos, JA David, R Bralley, JA Zea-Diaz, H Munoz-Atahualpa, E Corrales-Medina, F Cuba-Bustinza, C Chirinos-Pacheco, J Medina-Lezama, J AF Chirinos, Julio A. David, Robert Bralley, J. Alexander Zea-Diaz, Humberto Munoz-Atahualpa, Edgar Corrales-Medina, Fernando Cuba-Bustinza, Carolina Chirinos-Pacheco, Julio Medina-Lezama, Josefina TI Endogenous Nitric Oxide Synthase Inhibitors, Arterial Hemodynamics, and Subclinical Vascular Disease The PREVENCION Study SO HYPERTENSION LA English DT Article DE asymmetrical dimethylarginine; hypertension; atherosclerosis; arterial stiffness; hemodynamics ID INTIMA-MEDIA THICKNESS; ASYMMETRIC DIMETHYLARGININE ADMA; L-ARGININE; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR EVENTS; PLASMA-CONCENTRATIONS; DIABETES-MELLITUS; RENAL-FUNCTION; HYPERTENSION; RISK AB Endogenous NO synthase inhibitors (end-NOSIs) have been associated with cardiovascular risk factors and atherosclerosis. In addition, end-NOSIs may directly cause hypertension through hemodynamic effects. We aimed to examine the association between end-NOSI asymmetrical dimethylarginine (ADMA) and N-guanidino-monomethylarginine (NMMA), subclinical atherosclerosis, and arterial hemodynamics. We studied 922 adults participating in a population-based study (PREVENCION Study) and examined the correlation between end-NOSI/L-arginine and arterial hemodynamics, carotid-femoral pulse wave velocity, and carotid intima-media thickness using linear regression. ADMA, NMMA, and L-arginine were found to be differentially associated with various classic cardiovascular risk factors. ADMA and NMMA (but not L-arginine) were significant predictors of carotid intima-media thickness, even after adjustment for cardiovascular risk factors, C-reactive protein, and renal function. In contrast, ADMA and NMMA did not predict carotid-femoral pulse wave velocity, blood pressure, or hemodynamic abnormalities. Higher L-arginine independently predicted systolic hypertension, higher central pulse pressure, incident wave amplitude, central augmented pressure, and lower total arterial compliance but not systemic vascular resistance or cardiac output. We conclude that ADMA and NMMA are differentially associated with cardiovascular risk factors, but both end-NOSIs are independent predictors of carotid atherosclerosis. In contrast, they are not associated with large artery stiffness, hypertension, or hemodynamic abnormalities. Our findings are consistent with a role for asymmetrical arginine methylation in atherosclerosis but not in large artery stiffening, hypertension, or long-term hemodynamic regulation. L-Arginine is independently associated with abnormal pulsatile (but not resistive) arterial hemodynamic indices, which may reflect abnormal L-arginine transport, leading to decreased intracellular bioavailability for NO synthesis. (Hypertension. 2008; 52: 1051-1059.) C1 [David, Robert; Bralley, J. Alexander] Metametrix Clin Lab, Duluth, GA USA. [Zea-Diaz, Humberto; Munoz-Atahualpa, Edgar; Corrales-Medina, Fernando; Cuba-Bustinza, Carolina; Chirinos-Pacheco, Julio; Medina-Lezama, Josefina] Santa Maria Catholic Univ, Sch Med, Aqp, Peru. [Chirinos, Julio A.] Univ Penn, Philadelphia, PA 19104 USA. RP Chirinos, JA (reprint author), Philadelphia VA Med Ctr, Div Cardiol, 8B111,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Julio.chirinos@uphs.upenn.edu FU Santa Maria Research Institute; American Heart Association National Research [0885031N]; National Institutes of Health [RO1-HL080076-02] FX This work was supported by the Santa Maria Research Institute. J.A.C. is supported by American Heart Association National Research Award 0885031N and National Institutes of Health grant RO1-HL080076-02. NR 43 TC 32 Z9 33 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD DEC PY 2008 VL 52 IS 6 BP 1051 EP 1059 DI 10.1161/HYPERTENSIONAHA.108.120352 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 374GI UT WOS:000261031400014 PM 18852383 ER PT J AU Young, EJ AF Young, E. J. TI Family Studies in Brucellosis SO INFECTION LA English DT Editorial Material ID INFECTION; TESTS C1 [Young, E. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Young, E. J.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Young, E. J.] VA Med Ctr, Infect Dis Sect, Houston, TX USA. RP Young, EJ (reprint author), VA Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX USA. EM eyoung@bcm.tmc.edu NR 18 TC 3 Z9 3 U1 0 U2 0 PU URBAN & VOGEL PI MUNICH PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY SN 0300-8126 J9 INFECTION JI Infection PD DEC PY 2008 VL 36 IS 6 BP 578 EP 579 DI 10.1007/s15010-008-8090-3 PG 2 WC Infectious Diseases SC Infectious Diseases GA 397YI UT WOS:000262697900013 PM 19020802 ER PT J AU Waters, AM Craske, MG Bergman, RL Naliboff, BD Negoro, H Ornitz, EM AF Waters, Allison M. Craske, Michelle G. Bergman, R. Lindsey Naliboff, Bruce D. Negoro, Hideki Ornitz, Edward M. TI Developmental changes in startle reactivity in school-age children at risk for and with actual anxiety disorder SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Article DE Startle reactivity; Children; Anxiety disorders; EMG ID FEAR-POTENTIATED STARTLE; POSTTRAUMATIC-STRESS-DISORDER; INTERVIEW SCHEDULE; PARENT VERSIONS; SOCIAL PHOBIA; BASE-LINE; DSM-IV; CHILDHOOD; MODULATION; DEPRESSION AB The present study examined the development of elevated startle reactivity in anticipation of mild anxiogenic procedures in school-age children with current anxiety disorders and in those at-risk for their development due to parental anxiety. Startle blink reflexes and skin conductance responses were assessed in 7 to 12 year old anxious children (N = 21). non-anxious children at-risk for anxiety by virtue of parental anxiety disorder status (N = 16) and non-anxious control children of non-anxious parents (N = 13). Responses were elicited by 28 auditory startle stimuli presented prior to undertaking mild anxiogenic laboratory procedures. Results showed that group differences in startle reactivity differed as a function of children's age. Relative to control children for whom age had no effect, startle reflex magnitude in anticipation of anxiogenic procedures increased across the 7 to 12 years age range in children at-risk for anxiety disorders, whereas elevations in startle reactivity were already manifest from a younger age in children with anxiety disorders. These findings may suggest an underlying vulnerability that becomes manifest with development in offspring of anxious parents as the risk for anxiety disorders increases. (c) 2008 Elsevier B.V. All rights reserved. C1 [Waters, Allison M.] Griffith Univ, Sch Psychol, Gold Coast, Qld, Australia. [Craske, Michelle G.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Naliboff, Bruce D.; Ornitz, Edward M.] Univ Calif Los Angeles, CNS, Los Angeles, CA USA. [Ornitz, Edward M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA USA. [Naliboff, Bruce D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Negoro, Hideki] Nara Med Univ, Dept Psychiat, Nara, Japan. RP Waters, AM (reprint author), Griffith Univ, Sch Psychol, Gold Coast, Qld, Australia. EM a.waters@griffith.edu.au OI Waters, Allison/0000-0003-2453-793X FU NIMH [1 R03 MH64815-01]; Virginia Friedhofer Charitable Trust; CNS Psychophysiology Core [R24 AT002681]; VA Medical Research FX This research was supported by NIMH grant 1 R03 MH64815-01 (Michelle G. Craske), the Virginia Friedhofer Charitable Trust (Edward M. Ornitz), and the CNS Psychophysiology Core (R24 AT002681) and VA Medical Research (Bruce D. Naliboff). NR 42 TC 15 Z9 15 U1 3 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD DEC PY 2008 VL 70 IS 3 BP 158 EP 164 DI 10.1016/j.ijpsycho.2008.07.014 PG 7 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 383IS UT WOS:000261667900002 PM 18718853 ER PT J AU Tien, PC Schneider, MF Cole, SR Levine, AM Cohen, M DeHovitz, J Young, M Justman, JE AF Tien, Phyllis C. Schneider, Michael F. Cole, Stephen R. Levine, Alexandra M. Cohen, Mardge DeHovitz, Jack Young, Mary Justman, Jessica E. TI Antiretroviral Therapy Exposure and Insulin Resistance in the Women's Interagency HIV Study SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE antiretroviral therapy; HIV; HOMA; insulin resistance; nucleoside reverse transcriptase inhibitor; protease inhibitor ID CORONARY-HEART-DISEASE; BETA-CELL FUNCTION; REVERSE-TRANSCRIPTASE INHIBITORS; HOMEOSTASIS MODEL ASSESSMENT; IMPAIRED GLUCOSE-TOLERANCE; PROTEASE INHIBITORS; INFECTED PATIENTS; BODY-COMPOSITION; CLAMP TECHNIQUE; SENSITIVITY AB Background: Evidence suggesting an increased risk of cardiovascular disease in HIV-infected individuals has heightened the need to understand the relation of HIV infection, antiretroviral therapy use, and non-HIV-related factors with insulin resistance (IR). Methods: Prospective study of 1614 HIV-infected and 604 HIV-uninfected participants from the Women's Interagency HIV Study between October 2000 and March 2007. Homeostasis model assessment (HOMA)-estimated IR at 11,019 semiannual visits. Results: HIV-infected women reporting highly active antiretroviral therapy (HAART) had higher median HOMA than HIV-uninfected women {1.20 [95% confidence interval (CI): 1.11 to 1.30] times higher for those reporting protease inhibitor-containing HAART; 1.10 (95% CI: 1.01 to 1.20) times higher for those reporting non-protease inhibitor-containing HAART}. Among HIV-infected, cumulative exposure to nucleoside reverse transcriptase inhibitors (NRTIs) of >3 years was associated with HOMA 1.13 (95% CI: 1.02 to 1.25) times higher than the HOMA without any cumulative NRTI exposure. Cumulative exposure to the NRTI stavudine of >1 year was associated with HOMA 1.15 (95'% CI: 1.05 to 1.27) times higher than the HOMA without any cumulative stavudine use. Family history of diabetes, hepatitis C virus seropositivity. higher body mass index, or reporting menopause was associated with higher HOMA. Conclusions: Longer cumulative exposure to NRTI; in particular, stavudine is associated with greater IR in HIV infected women. C1 [Tien, Phyllis C.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Infect Dis Sect, Dept Med, San Francisco, CA 94121 USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Schneider, Michael F.; Cole, Stephen R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Levine, Alexandra M.] Univ So Calif, Dept Med, Los Angeles, CA USA. [Cohen, Mardge] CORE Ctr Stroger Hosp Cook Cty, Chicago, IL USA. [DeHovitz, Jack] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Justman, Jessica E.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Justman, Jessica E.] Columbia Univ, Dept Med, New York, NY USA. RP Tien, PC (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Infect Dis Sect, Dept Med, 111W 4150 Clement St, San Francisco, CA 94121 USA. EM ptien@ucsf.edu FU National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development; National Institute oft Drug Abuse; Agency for Health Care Policy and Research; National Center for Research Resources; Centers for Disease Control and Prevention [U01-AI-35004, DO1-AI-3183, U01-AI-34994, U01-AI-34989]; National Institute of Child Health and Human Development [U01-HD-32632]; National Institute of Allergy and Infectious Diseases [U01-AI-34993, U01-AI-42590, M01-RR00079, M01RR00083]; [K23 AI 66943-01] FX The Women's Interagency HIV Study is funded by the National Institute of Allergy and Infectious Diseases. with additional supplemental funding from the National Cancer Institute. the National Institute of Child Health and Human Development, the National Institute oft Drug Abuse, the Agency for Health Care Policy and Research, the National Center for Research Resources. and the Centers for Disease Control and Prevention. U01-AI-35004. DO1-AI-3183, U01-AI-34994, U01-AI-34994, U01-AI-34989. U01-HD-32632 (National Institute of Child Health and Human Development). U01-AI-34993, U01-AI-42590, M01-RR00079, and M01RR00083. Dr. PCT. is supported by the National Institute of Allergy and Infectious Diseases through K23 AI 66943-01 and currently has a research grant from Gilead. NR 39 TC 29 Z9 29 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 1 PY 2008 VL 49 IS 4 BP 369 EP 376 DI 10.1097/QAI.0b013e318189a780 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 371PV UT WOS:000260844300004 PM 19186350 ER PT J AU Cunningham, ET Suhler, EB AF Cunningham, Emmett T., Jr. Suhler, Eric B. TI Childhood uveitis - young patients, old problems, new perspectives SO JOURNAL OF AAPOS LA English DT Editorial Material ID JUVENILE IDIOPATHIC ARTHRITIS; TERM-FOLLOW-UP; INFLIXIMAB; CHILDREN; ETANERCEPT C1 [Cunningham, Emmett T., Jr.] Calif Pacific Med Ctr, Dept Ophthalmol, San Francisco, CA USA. [Cunningham, Emmett T., Jr.] Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA. [Suhler, Eric B.] Portland VA Med Ctr, Dept Ophthalmol, Portland, OR USA. [Suhler, Eric B.] Oregon Hlth & Sci Univ, Casey Eye Inst, Uveitis Div, Portland, OR 97201 USA. RP Cunningham, ET (reprint author), W Coast Retina Med Grp Inc, 185 Berry St,Lobby 5,Suite 130, San Francisco, CA 94107 USA. EM emmett_cumingham@yahoo.com NR 20 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1091-8531 J9 J AAPOS JI J. AAPOS PD DEC PY 2008 VL 12 IS 6 BP 537 EP 538 DI 10.1016/j.jaapos.2008.10.004 PG 2 WC Ophthalmology; Pediatrics SC Ophthalmology; Pediatrics GA 388GX UT WOS:000262009400001 PM 19101497 ER PT J AU Naifeh, JA Elhai, JD Kashdan, TB Grubaugh, AL AF Naifeh, James A. Elhai, Jon D. Kashdan, Todd B. Grubaugh, Anouk L. TI The PTSD Symptom Scale's latent structure: An examination of trauma-exposed medical patients SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Confirmatory factor analysis; Posttraumatic Stress Disorder Symptom Scale; Posttraumatic stress disorder; Medical patients ID POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSIS; WORLD-TRADE-CENTER; PSYCHOMETRIC PROPERTIES; ANXIETY DISORDERS; COMBAT VETERANS; EVENT SCALE; 2 SAMPLES; CHECKLIST; VALIDITY AB Several studies have employed confirmatory factor analysis (CFA) to evaluate the latent structure of posuraumatic stress disorder (PTSD) assessment measures among various trauma-exposed populations. Findings have generally failed to support the current three-factor DSM-IV PTSD conceptualization, demonstrating the need to consider alternative models. The present study used CFA to evaluate seven models, including intercorrelated and hierarchical versions of two models with the most empirical support. Data were utilized from a heterogeneous trauma-exposed sample of general medical patients (n = 252). Based on several indices, the three-factor DSM-IV PTSD model was shown to be inferior to alternative models. The strongest support was found for an intercoffelated four-factor model, separating avoidance and numbing symptoms into distinct factors. Validity for this model was partially supported by divergent relations between factors and external variables. Implications of the results are discussed, and a framework is proposed for resolving discrepant findings in the PTSD CFA literature. (c) 2008 Elsevier Ltd. All rights reserved. C1 [Naifeh, James A.; Elhai, Jon D.] Univ S Dakota, Disaster Mental Hlth Inst, Vermillion, SD 57069 USA. [Kashdan, Todd B.] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA. [Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Elhai, JD (reprint author), Univ S Dakota, Disaster Mental Hlth Inst, 414 E Clark St,SDU 114, Vermillion, SD 57069 USA. EM jonelhai@fastmail.fm NR 64 TC 44 Z9 44 U1 7 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD DEC PY 2008 VL 22 IS 8 BP 1355 EP 1368 DI 10.1016/j.janxdis.2008.01.016 PG 14 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 361TV UT WOS:000260150900009 PM 18337058 ER PT J AU Kota, B Prasad, AS Economides, C Singh, BN AF Kota, Bindu Prasad, Aditya S. Economides, Christina Singh, Bramah N. TI Levosimendan and Calcium Sensitization of the Contractile Proteins in Cardiac Muscle: Impact on Heart Failure SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS LA English DT Review DE levosimendan; calcium sensitivity; inotrope; QTc; heart failure; diuretics ID DOBUTAMINE; PHARMACOKINETICS; TRIAL; METABOLITES; ACTIVATION; EFFICACY; SURVIVE; SAFETY; LIDO AB Levosimendan increases the sensitivity of the cardiac fibrils to calcium, favorably affects hemodynamics in patients with heart failure. It is a positive inotrope and a peripheral vasodilator. The elimination half-life of the compound is about 1 hour. The drug decreases pulmonary capillary wedge pressure, increases cardiac output with the improvement in left ventricular ejection fraction leading to symptomatic improvement which includes decreased dyspnea and fatigue. Levosimendan can be used safely with diuretics, nitrates, beta-blockers, digoxin, and angiotensin-converting enzyme inhibitors. The most common adverse effects of levosimendan are headache and hypotension. Prolongation of the QTc interval does not appear to increase the incidence of arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes. Levosimendan is a novel agent in the treatment of decompensated heart failure, representing a newer class of medications aimed at increasing calcium sensitivity. Its properties holds promise for the treatment of heart failure but further large-scale studies will be needed to determine its precise efficacy, safety, as well as the compound's long-term impact on mortality. C1 [Kota, Bindu; Prasad, Aditya S.; Economides, Christina; Singh, Bramah N.] Univ Calif Los Angeles, David Geffen Sch Med, W LA VA Med Ctr, Los Angeles, CA 90095 USA. [Singh, Bramah N.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA. [Prasad, Aditya S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Singh, BN (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Cardiol, 111E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM bsingh@ucla.edu NR 26 TC 10 Z9 11 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1074-2484 J9 J CARDIOVASC PHARM T JI J. Cardiovasc. Pharmacol. Ther. PD DEC PY 2008 VL 13 IS 4 BP 269 EP 278 DI 10.1177/1074248408324550 PG 10 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 376ZU UT WOS:000261222300004 PM 19087950 ER PT J AU Ratner, RE Christophi, CA Metzger, BE Dabelea, D Bennett, PH Pi-Sunyer, X Fowler, S Kahn, SE AF Ratner, Robert E. Christophi, Costas A. Metzger, Boyd E. Dabelea, Dana Bennett, Peter H. Pi-Sunyer, Xavier Fowler, Sarah Kahn, Steven E. CA Diabet Prevention Program Res Grp TI Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GLUCOSE-TOLERANCE; MELLITUS; PREGNANCY; PROGRAM; MODELS AB Context: A past history of gestational diabetes mellitus (GDM) confers a very high risk of postpartum development of diabetes, particularly type 2 diabetes. Objective: The Diabetes Prevention Program (DPP) sought to identify individuals with impaired glucose tolerance (IGT) and intervene in an effort to prevent or delay their progression to diabetes. This analysis examined the differences between women enrolled in DPP with and without a reported history of GDM. Design: The DPP was a randomized, controlled clinical trial. Setting: The study was a multicenter, National Institutes of Health-sponsored trial carried out at 27 centers including academic and Indian Health Services sites. Patients: A total of 2190 women were randomized into the DPP and provided information for past history of GDM. This analysis addressed the differences between those 350 women providing a past history of GDM and those 1416 women with a previous live birth but no history of GDM. Interventions: Subjects were randomized to either standard lifestyle and placebo or metformin therapy or to an intensive lifestyle intervention. Main Outcomes: The primary outcome was the time to development of diabetes ascertained by semiannual fasting plasma glucose and annual oral glucose tolerance testing. Assessments of insulin secretion and insulin sensitivity were also performed. Results: Whereas entering the study with similar glucose levels, women with a history of GDM randomized to placebo had a crude incidence rate of diabetes 71% higher than that of women without such a history. Among women reporting a history of GDM, both intensive lifestyle and metformin therapy reduced the incidence of diabetes by approximately 50% compared with the placebo group, whereas this reduction was 49 and 14%, respectively in parous women without GDM. These data suggest that metformin may be more effective in women with a GDM history as compared with those without. Conclusions: Progression to diabetes is more common in women with a history of GDM compared with those without GDM history despite equivalent degrees of IGT at baseline. Both intensive lifestyle and metformin are highly effective in delaying or preventing diabetes in women with IGT and a history of GDM. (J Clin Endocrinol Metab 93: 4774-4779, 2008) C1 [Christophi, Costas A.; Fowler, Sarah] George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, Rockville, MD 20852 USA. [Ratner, Robert E.] Medstar Res Inst, Hyattsville, MD 20783 USA. [Metzger, Boyd E.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Dabelea, Dana] Univ Colorado, Dept Prevent Med & Biometr, Denver, CO 80262 USA. [Bennett, Peter H.] NIDDKD, Phoenix, AZ 85016 USA. [Pi-Sunyer, Xavier] Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY 10019 USA. [Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98108 USA. RP Ratner, RE (reprint author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA. OI Kahn, Steven/0000-0001-7307-9002 FU Intramural NIH HHS NR 15 TC 249 Z9 261 U1 4 U2 24 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD DEC PY 2008 VL 93 IS 12 BP 4774 EP 4779 DI 10.1210/jc.2008-0772 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 379LE UT WOS:000261396900028 PM 18826999 ER PT J AU Tabibian, JH Gornbein, J Heidari, A Dien, SL Lau, VH Chahal, P Churchill, BM Haake, DA AF Tabibian, James H. Gornbein, Jeffrey Heidari, Arash Dien, Sarah L. Lau, Valerie H. Chahal, Puneet Churchill, Bernard M. Haake, David A. TI Uropathogens and Host Characteristics SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID URINARY-TRACT-INFECTIONS; URETHRAL CATHETERS; BACTERIURIA; EPIDEMIOLOGY; PATHOGENS AB Uropathogens other than Escherichia coli occur with greater frequency in patients with risk factors for urinary tract infection (UTI). However, little is known about associations between uropathogen species and host characteristics. Three hundred nineteen urine specimens containing a balanced distribution of uropathogen species were selected from inpatients and outpatients at a university hospital clinical microbiology laboratory. Information on host characteristics was retrospectively collected by chart review. Differences in the frequencies of host characteristics in UTI groups, as defined by the causative uropathogen, were compared by chi-square/Fisher analysis. Multivariate classification and regression tree analysis were used to identify host characteristic subsets that distinguish among uropathogen groups. In this exploratory study, several uropathogen species were found to be strongly linked to host characteristics relevant to UTI. Patients with Pseudomonas aeruginosa UTIs were more likely to have undergone urinary tract procedures (43% versus 15% overall), to have a neurogenic bladder (29% versus 12% overall), to have received recent antibiotic therapy (52% versus 24% overall), and to be male (76% versus 28% overall). Patients with Proteus mirabilis UTIs were more likely to have a foreign body in the lower urinary tract (48% versus 30% overall). The classification tree identified males over the age of 27 years who had undergone a prior urinary tract procedure as belonging to a host characteristic profile associated with P. aeruginosa UTI: 38% of patients with P. aeruginosa UTIs fit this profile. These data may be useful for planning future targeted prophylaxis studies. C1 [Tabibian, James H.; Heidari, Arash; Chahal, Puneet; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Gornbein, Jeffrey] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90095 USA. [Lau, Valerie H.; Churchill, Bernard M.; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Heidari, Arash; Dien, Sarah L.; Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. RP Haake, DA (reprint author), VA Greater LA Healthcare Syst, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu FU National Institute of Biomedical Imaging and Bioengineering [EB00127]; National Institute of Allergy and Infectious Diseases [AI075565]; Wendy and Ken Ruby Fund FX This study was supported by Bioengineering Research Partnership grant EB00127 (to B. M. C.) from the National Institute of Biomedical Imaging and Bioengineering, by Cooperative Agreement Award AI075565 (to D. A. H.) from the National Institute of Allergy and Infectious Diseases, and by the Wendy and Ken Ruby Fund for Excellence in Pediatric Urology Research. B. M. Churchill holds the Judith and Robert Winston Chair in Pediatric Urology. NR 14 TC 24 Z9 26 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2008 VL 46 IS 12 BP 3980 EP 3986 DI 10.1128/JCM.00339-08 PG 7 WC Microbiology SC Microbiology GA 377JQ UT WOS:000261247900018 PM 18842936 ER PT J AU Satterthwaite, TD Wolf, DH Rosenheck, RA Gur, RE Caroff, SN AF Satterthwaite, Theodore D. Wolf, Daniel H. Rosenheck, Robert A. Gur, Raquel E. Caroff, Stanley N. TI A Meta-Analysis of the Risk of Acute Extrapyramidal Symptoms With Intramuscular Antipsychotics for the Treatment of Agitation SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID HALOPERIDOL PLUS PROMETHAZINE; BORDERLINE PERSONALITY-DISORDER; RANDOMIZED CONTROLLED-TRIAL; DRUG-INDUCED DYSTONIA; DOUBLE-BLIND; RAPID TRANQUILIZATION; 2ND-GENERATION ANTIPSYCHOTICS; SCHIZOAFFECTIVE DISORDER; TARDIVE-DYSKINESIA; PSYCHOTIC PATIENT AB Objective: We examined the evidence for a decreased risk of extrapyramidal symptoms (EPS) with intramuscular second-generation antipsychotics (SGAs) versus intramuscular haloperidol alone or in combination with an anticholinergic agent. Data Sources: We searched MEDLINE (1950 to the present), and EMBASE and the Cochrane Database through January 16, 2008, for studies published in English of intramuscular SGAs and intramuscular haloperidol alone or in combination with an anticholinergic agent using the following drug names: ziprasidone, Geodon, olanzapine, Zyprexa, aripiprazole, Ability, haloperidol, and Haldol. We then searched this pool of studies for trials with the terms intramuscular, IM, or injectable. Initially, we included only randomized controlled trials (RCTs). To obtain more data comparing SGAs to the combination of haloperidol and an anticholinergic, we conducted a second analysis including studies of any methodology. Study Selection: Seven RCTs that compared intramuscular SGAs to intramuscular haloperidol alone were identified. However, we found only one RCT of haloperidol plus an anticholinergic. In the second analysis, we identified 18 studies, including 4 using haloperidol combined with promethazine (an antihistamine with anticholinergic properties). Data Extraction: The primary outcome measure was acute dystonia; secondary outcome measures included akathisia, parkinsonism, or the need for additional anticholinergic medication. For RCTs, risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for each outcome. When all studies were included in the second analysis, we calculated the risk of acute dystonia. Data Synthesis: Among RCTs (N = 2032), SGAs were associated with a significantly lower risk of acute dystonia (RR = 0.19, 95% CI = 0.10 to 0.39), akathisia (RR = 0.25, 95% CI = 0.14 to 0.44), and anticholinergic use (RR = 0.19, 95% Cl = 0.09 to 0.43) compared with haloperidol alone. When all trials were considered (N = 3425), rates of acute dystonia were higher for haloperidol alone (4.7%) than for SGAs (0.6%) or for haloperidol plus promethazine (0.0%). Conclusions: Intramuscular SGAs have a significantly lower risk of acute EPS compared to haloperidol alone. However, intramuscular haloperidol plus promethazine has a risk of acute dystonia comparable to intramuscular SGAs. The decision to use SGAs should consider other factors in addition to the reduction of EPS, which can be prevented by the use of an anticholinergic agent. C1 [Satterthwaite, Theodore D.; Wolf, Daniel H.; Gur, Raquel E.; Caroff, Stanley N.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Rosenheck, Robert A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Rosenheck, Robert A.] Connecticut Vet Affairs Hlth Care Syst, West Haven, CT USA. [Gur, Raquel E.; Caroff, Stanley N.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Satterthwaite, TD (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,2nd Floor, Philadelphia, PA 19104 USA. EM Ted.Satterthwaite@uphs.upenn.edu RI Wolf, Daniel/H-2581-2013 FU Eli Lilly; Janssen; AstraZeneca; Wyeth; Pfizer; Bristol-Myers Squibb FX Dr. Rosenheck has received grant/research support from Eli Lilly, Janssen, AstraZeneca, and Wyeth and is a consultant for NR 97 TC 25 Z9 27 U1 2 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD DEC PY 2008 VL 69 IS 12 BP 1869 EP 1879 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 388ZQ UT WOS:000262059700004 PM 19192477 ER PT J AU Heimer, R Grau, LE Singer, M Scott, G Marshall, PA Hu, YQ Seal, KH AF Heimer, Robert Grau, Lauretta E. Singer, Merrill Scott, Greg Marshall, Patricia A. Hu, Yiqing Seal, Karen H. TI Hepatitis B virus prevalence and vaccination rates among hispanic injection drug users participating in a vaccination campaign SO JOURNAL OF DRUG ISSUES LA English DT Article ID SYRINGE EXCHANGE; UNITED-STATES; YOUNG INJECTION; HARM REDUCTION; SAN-FRANCISCO; RISK-FACTORS; US CITIES; INFECTION; IMMUNIZATION; HIV AB Injection drug users are at high risk for hepatitis B virus infections. Nevertheless, few concerted efforts have been made to provide injectors with access to an available, safe, and effective vaccine. A campaign to screen and vaccinate injectors was conducted at syringe exchange programs in Chicago, Illinois, and Hartford and Bridgeport, Connecticut. Injectors with no evidence of past hepatitis B infection were eligible for vaccination. Eligible injectors were offered the three doses of vaccine and questioned about their past and current drug use, their sociodemographics, their understanding of hepatitis infections, and their motivation for participating in the study. Disease prevalence, vaccination rates, and the answers to study questions were analyzed comparing the sample of Hispanic to non-Hispanic injectors. We screened 1970 injectors, 860 of whom were eligible for vaccination. Of those, 591 received at least one dose of the vaccine. Hispanics comprised 30.9% of those screened, 24.9% of those eligible, and 25.2% of those receiving at least one dose. Hispanics were more likely than non-Hispanic Whites or non-Hispanic Blacks to have already been infected with hepatitis B-55.6% for Hispanics versus 46.5% for non-Hispanics. Although it is impossible to generalize from our study population to Hispanic injectors as a whole, it seems apparent that if greater efforts are made to promote hepatitis B vaccination among Hispanics, high rates of vaccination can be achieved. C1 [Heimer, Robert; Grau, Lauretta E.; Hu, Yiqing] Yale Univ, Sch Med, Ctr Interdisciplinary Res AIDS, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA. [Singer, Merrill] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT 06269 USA. [Singer, Merrill] Univ Connecticut, Ctr Hlth Commun & Mkt, Storrs, CT 06269 USA. [Scott, Greg] Depaul Univ, Chicago, IL 60604 USA. Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH 44106 USA. Case Western Reserve Univ, Sch Med, Chair Eth Program, Ctr AIDS Res, Cleveland, OH 44106 USA. [Seal, Karen H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Seal, Karen H.] San Francisco VA Med Ctr, Integrated Clin Vet Iraq & Afghanistan, San Francisco, CA USA. RP Heimer, R (reprint author), Yale Univ, Sch Med, Ctr Interdisciplinary Res AIDS, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA. NR 38 TC 2 Z9 2 U1 1 U2 1 PU J DRUG ISSUES INC PI TALLAHASSEE PA FLORIDA STATE UNIV, SCHOOL CRIMINOLOGY CRIMINAL JUSTICE, PO BOX 66696, TALLAHASSEE, FL 32313-6696 USA SN 0022-0426 J9 J DRUG ISSUES JI J. Drug Issues PD WIN PY 2008 VL 38 IS 1 BP 335 EP 350 PG 16 WC Substance Abuse SC Substance Abuse GA 290GL UT WOS:000255111200016 ER PT J AU Kogai, T Sajid-Crockett, S Newmarch, LS Liu, YY Brent, GA AF Kogai, Takahiko Sajid-Crockett, Saima Newmarch, Lynell S. Liu, Yan-Yun Brent, Gregory A. TI Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells (vol 199, pg 249, 2008) SO JOURNAL OF ENDOCRINOLOGY LA English DT Correction C1 [Kogai, Takahiko; Sajid-Crockett, Saima; Newmarch, Lynell S.; Liu, Yan-Yun; Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Endocrinol & Diabet Div, VA Greater Los Angeles Healthcare Syst,Dept Med, Los Angeles, CA 90073 USA. [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Endocrinol & Diabet Div, VA Greater Los Angeles Healthcare Syst,Dept Physi, Los Angeles, CA 90073 USA. RP Kogai, T (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Endocrinol & Diabet Div, VA Greater Los Angeles Healthcare Syst,Dept Med, 11301 Wilshire Blvd,Bldg 114,Room 230, Los Angeles, CA 90073 USA. EM tkogai@ucla.edu NR 1 TC 1 Z9 1 U1 0 U2 2 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0022-0795 J9 J ENDOCRINOL JI J. Endocrinol. PD DEC PY 2008 VL 199 IS 3 BP 500 EP 500 DI 10.1677/JOE-08-0333e PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 380YX UT WOS:000261503100017 ER PT J AU Ganz, DA Fung, CH Sinsky, CA Wu, SY Reuben, DB AF Ganz, David A. Fung, Constance H. Sinsky, Christine A. Wu, Shinyi Reuben, David B. TI Key Elements of High-Quality Primary Care for Vulnerable Elders SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE primary care; practice redesign; quality of care; quality improvement; older adults ID RANDOMIZED CONTROLLED-TRIAL; GERIATRIC SYNDROMES; HEALTH INFORMATION; MEDICAL HOME; OLDER-PEOPLE; MANAGEMENT; INTERVENTION; PHYSICIANS; COMMUNITY; ACCESS AB With the impending surge in the number of older adults, primary care clinicians will increasingly need to manage the care of vulnerable elders. Caring for vulnerable elders is complex because of their wide range of health goals and the interdependence of medical care and community supports needed to achieve those goals. In this article, we identify ways a primary care practice can reorganize to improve the care of vulnerable elders. We begin by identifying important outcomes for vulnerable elders and three key processes of care (communication, developing a personal care plan for each patient, and care coordination) needed to achieve these outcomes. We then describe two delivery models of primary care for vulnerable elders - co-management, and augmented primary care. Finally, we discuss how the physical plant, people, workflow management, and community linkages in a primary care practice can be restructured to better serve these patients. C1 [Ganz, David A.] VA Greater Los Angeles Healthcare Syst 11G, Los Angeles, CA 90073 USA. [Ganz, David A.; Reuben, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA. [Fung, Constance H.] Zynx Hlth Inc, Los Angeles, CA USA. [Sinsky, Christine A.] Med Associates Clin, Dubuque, IA USA. [Wu, Shinyi] Univ So Calif, Daniel J Epstein Dept Ind & Syst Engn, Los Angeles, CA USA. [Wu, Shinyi] RAND Corp, Santa Monica, CA USA. RP Ganz, DA (reprint author), VA Greater Los Angeles Healthcare Syst 11G, Bldg 220,Room 313, Los Angeles, CA 90073 USA. EM dganz@mednet.ucla.edu FU National Institute on Aging [5P30AG028748, 5P30AG024968-02]; Veterans Affairs Health Services Research and Development Service [VA CD2 08-012-1] FX Support: David Ganz was supported by the UCLA Claude Pepper Older Americans Independence Center funded by the National Institute on Aging (5P30AG028748) and the Veterans Affairs Health Services Research and Development Service (VA CD2 08-012-1). Shinyi Wu is supported by the Roybal Center for Health Policy Simulation funded by the National Institute on Aging (5P30AG024968-02). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or Zynx Health Incorporated. NR 48 TC 8 Z9 8 U1 2 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2008 VL 23 IS 12 BP 2018 EP 2023 DI 10.1007/s11606-008-0808-5 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 379VJ UT WOS:000261424000014 PM 18839261 ER PT J AU Korthuis, PT Saha, S Fleishman, JA McGrath, MM Josephs, JS Moore, RD Gebo, KA Hellinger, J Beach, MC AF Korthuis, P. Todd Saha, Somnath Fleishman, John A. McGrath, Moriah McSharry Josephs, Joshua S. Moore, Richard D. Gebo, Kelly A. Hellinger, James Beach, Mary Catherine CA HIV Res Network TI Impact of Patient Race on Patient Experiences of Access and Communication in HIV Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE physician-patient relations; communication; HIV/AIDS treatment; health services accessibility; blacks; HIV Research Network ID HEALTH-CARE; RACIAL DISPARITIES; INFECTED ADULTS; UNITED-STATES; ANTIRETROVIRAL THERAPY; SERVICES UTILIZATION; ETHNIC-DIFFERENCES; QUALITY; CONCORDANCE; MULTISTATE AB BACKGROUND: Patient-centered care-including the domains of access and communication-is an important determinant of positive clinical outcomes. OBJECTIVE: To explore associations between race and HIV-infected patients' experiences of access and communication. DESIGN: This was a cross-sectional survey. PARTICIPANTS: Nine hundred and fifteen HIV-infected adults receiving care at 14 U.S. HIV clinics. MEASUREMENTS: Dependent variables included patients' reports of travel time to their HIV care site and waiting time to see their HIV provider (access) and ratings of their HIV providers on always listening, explaining, showing respect, and spending enough time with them (communication). We used multivariate logistic regression to estimate associations between patient race and dependent variables, and random effects models to estimate site-level contributions. RESULTS: Patients traveled a median 30 minutes (range 1 - 180) and waited a median 20 minutes (range 0 - 210) to see their provider. On average, blacks and Hispanics reported longer travel and wait times compared with whites. Adjusting for HIV care site attenuated this association. HIV care sites that provide services to a greater proportion of blacks and Hispanics may be more difficult to access for all patients. The majority of patients rated provider communication favorably. Compared to whites, blacks reported more positive experiences with provider communication. CONCLUSIONS: We observed racial disparities in patients' experience of access to care but not in patient - provider communication. Disparities were explained by poor access at minority-serving clinics. Efforts to make care more patient-centered for minority HIV-infected patients should focus more on improving access to HIV care in minority communities than on improving cross-cultural patient - provider interactions. C1 [Korthuis, P. Todd; Saha, Somnath; McGrath, Moriah McSharry] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. [Fleishman, John A.] Agcy Healthcare Res & Qual, Rockville, MD USA. [Josephs, Joshua S.; Moore, Richard D.; Gebo, Kelly A.; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Hellinger, James] Community Med Alliance, Boston, MA USA. RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA. EM korthuis@ohsu.edu FU Agency for Healthcare Research and Quality, Rockville, Maryland; Health Resources and Services Administration, Rockville, Maryland FX Agency for Healthcare Research and Quality, Rockville, Maryland (Fred Hellinger, Ph. D., John Fleishman, Ph. D., Irene Fraser, Ph. D.); Health Resources and Services Administration, Rockville, Maryland (Alice Kroliczak, Ph. D., Robert Mills, Ph. D.) NR 38 TC 11 Z9 11 U1 2 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2008 VL 23 IS 12 BP 2046 EP 2052 DI 10.1007/s11606-008-0788-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 379VJ UT WOS:000261424000017 PM 18830770 ER PT J AU Gordon, A Fiellin, D Friedmann, P Gourevitch, M Kraemer, K Arnsten, J Saitz, R AF Gordon, Adam J. Fiellin, David A. Friedmann, Peter D. Gourevitch, Marc N. Kraemer, Kevin L. Arnsten, Julia H. Saitz, Richard CA Soc Gen Internal Med Subst Abuse TI Update in Addiction Medicine for the Primary Care Clinician SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE substance-related disorders; primary health care; review literature ID RANDOMIZED CONTROLLED-TRIAL; ALCOHOL-USE DISORDERS; SELF-HELP GROUPS; OUTCOMES; BUPRENORPHINE; TOPIRAMATE; DEPENDENCE; ADULTS; AUDIT; ABUSE C1 [Gordon, Adam J.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Gordon, Adam J.; Kraemer, Kevin L.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. [Fiellin, David A.] Yale Univ, Sch Med, New Haven, CT USA. [Friedmann, Peter D.] Brown Univ, Alpert Med Sch, Rhode Isl Hosp,Div Gen Internal Med, Providence VA Med Ctr,Ctr Syst Outcomes & Qual Ch, Providence, RI 02912 USA. [Gourevitch, Marc N.] NYU, Sch Med, New York, NY USA. [Arnsten, Julia H.] Albert Einstein Coll Med, New York, NY USA. [Arnsten, Julia H.] Montefiore Med Ctr, New York, NY USA. [Saitz, Richard] Boston Med Ctr, Gen Internal Med Sect, CARE Unit, Boston, MA USA. [Saitz, Richard] Boston Univ, Sch Med, Boston, MA 02118 USA. [Saitz, Richard] Boston Univ, Sch Publ Hlth, Youth Alcohol Prevent Ctr, Boston, MA 02215 USA. [Saitz, Richard] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. RP Gordon, A (reprint author), Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Mailcode 151-C-H,7180 Highland Dr 151 C-H, Pittsburgh, PA 15206 USA. EM adam.gordon@va.gov OI Fiellin, David/0000-0002-4006-010X; Gourevitch, Marc/0000-0001-6865-2126; /0000-0002-2535-1427 FU Society of General Internal Medicine's Substance Abuse Interest Group FX All authors are members of the Society of General Internal Medicine's Substance Abuse Interest Group to which we are deeply indebted for its support. The authors also wish to thank Margaret Krumm for her contributions of coordinating the review and editing this paper. NR 27 TC 8 Z9 8 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2008 VL 23 IS 12 BP 2112 EP 2116 DI 10.1007/s11606-008-0806-7 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 379VJ UT WOS:000261424000026 PM 18830761 ER PT J AU Jackonis, MJ Deyton, L Hess, WJ AF Jackonis, Michael J. Deyton, Lawrence Hess, William J. TI War, Its Aftermath, and US Health Policy: Toward a Comprehensive Health Program for America's Military Personnel, Veterans, and Their Families SO JOURNAL OF LAW MEDICINE & ETHICS LA English DT Article AB This essay discusses the challenges faced by veterans returning to society in light of the current organization and structure of the military, veterans', and overall U.S. health care systems. It also addresses the need for an integrated health care financing and delivery system to ensure a continuum of care for service members, veterans, dependents, and other family members. The health care systems of both the Department of Defense and the Department of Veterans Affairs execute their responsibilities to active duty service members, while their families and retirees/veterans are under separate legal authorities. Although they perform their mandates with extraordinary commitment and demonstrably high quality, both systems need to explore improved communication, coordination, and sharing, as well as increased collaboration with the Department of Health and Human Services programs serving the same populations, far beyond current efforts. The health care-related missions and the locus of health care delivery of each agency are admittedly unique, but their distinctions must not be permitted to impede system integration and coordination of a continuum of care provided to the men and women who serve the nation, and their families. C1 [Deyton, Lawrence] US Dept Vet Affairs, Washington, DC USA. [Deyton, Lawrence] George Washington Univ, Med Ctr, Sch Publ Hlth & Hlth Sci, Washington, DC 20052 USA. [Hess, William J.] Natl Naval Med Ctr, Bethesda, MD USA. NR 39 TC 10 Z9 10 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1073-1105 J9 J LAW MED ETHICS JI J. Law Med. Ethics PD WIN PY 2008 VL 36 IS 4 BP 677 EP 689 DI 10.1111/j.1748-720X.2008.00322.x PG 13 WC Ethics; Law; Medical Ethics; Medicine, Legal SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine GA 378ZR UT WOS:000261364300008 PM 19093991 ER PT J AU McCaslin, SE Inslicht, SS Metzler, TJ Henn-Haase, C Maguen, S Neylan, TC Choucroun, G Marmar, CR AF McCaslin, Shannon E. Inslicht, Sabra S. Metzler, Thomas J. Henn-Haase, Clare Maguen, Shira Neylan, Thomas C. Choucroun, Gerard Marmar, Charles R. TI Trait Dissociation Predicts Posttraumatic Stress Disorder Symptoms in a Prospective Study of Urban Police Officers SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Dissociation; traumatic stress; police officers ID EMERGENCY SERVICES PERSONNEL; CIVILIAN MISSISSIPPI SCALE; SEXUAL-ABUSE; PERITRAUMATIC DISSOCIATION; VIETNAM VETERANS; NEUROPEPTIDE-Y; PTSD SYMPTOMS; RISK-FACTORS; TRAUMA; RELIABILITY AB The current study prospectively examines the predictive relationship of trait dissociation, assessed during academy training, to PTSD symptoms assessed at 12 months of active police duty in relatively young and healthy police academy recruits (N = 180). The roles of pre-academy trauma exposure, exposure to life-threatening critical incidents during police duty, and peritraumatic dissociation at the time of the officer's worst critical incident were also examined. Utilizing path analytic techniques, greater trait dissociation, assessed during academy training, was predictive of both peritraumatic dissociation, and PTSD symptoms assessed at 12 months of police service. Moreover, after accounting for trait dissociation and peritraumatic dissociation, the relationship of previous trauma to later PTSD symptoms was no longer significant, demonstrating that the effect of previous trauma on later vulnerability to PTSD symptoms in this sample may be mediated by both trait and peritraumatic dissociation. C1 [McCaslin, Shannon E.; Inslicht, Sabra S.; Metzler, Thomas J.; Henn-Haase, Clare; Maguen, Shira; Neylan, Thomas C.; Marmar, Charles R.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [McCaslin, Shannon E.; Inslicht, Sabra S.; Metzler, Thomas J.; Henn-Haase, Clare; Maguen, Shira; Neylan, Thomas C.; Marmar, Charles R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Choucroun, Gerard] No Calif Inst Res & Educ, San Francisco, CA USA. RP McCaslin, SE (reprint author), Vet Affairs Med Ctr, PTSD Res Program, 4150 Clement St 116P, San Francisco, CA 94121 USA. EM Shannon.McCaslin@ucsf.edu FU NIMH NIH HHS [R01 MH056350] NR 54 TC 22 Z9 22 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD DEC PY 2008 VL 196 IS 12 BP 912 EP 918 DI 10.1097/NMD.0b013e31818ec95d PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 383DE UT WOS:000261653500008 PM 19077859 ER PT J AU McMurtray, AM Sultzer, DL Monserratt, L Yeo, T Mendez, MF AF McMurtray, Aaron M. Sultzer, David L. Monserratt, Lorena Yeo, Tuty Mendez, Mario F. TI Content-specific delusions from right caudate lacunar stroke: Association with prefrontal hypometabolism SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID NEURO-BEHAVIORAL CHANGES; BASAL GANGLIA; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; LESIONS; INFARCTS; DEMENTIA; CIRCUITS; NUCLEUS; CORTEX AB Patients with caudate lesions can present with content-specific delusions, possibly due to disruption of frontosubcortical circuits connecting the frontal lobes with the basal ganglia. This study included eight patients who presented with content-specific delusions after right caudate stroke and an equal number of matched controls, without stroke or delusions. Compared to controls, patients with caudate lesions performed less well on tests of memory, abstract reasoning, and frontal executive functions, and had significantly reduced metabolism in the inferior prefrontal cortex. These patients suggest an etiological relationship between alterations in inferior prefrontal functions and the development of content-specific delusions. C1 [McMurtray, Aaron M.; Sultzer, David L.; Monserratt, Lorena; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, Neurol Serv, Los Angeles, CA 90073 USA. [McMurtray, Aaron M.; Sultzer, David L.; Monserratt, Lorena; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, Psychiat & Mental Hlth Serv, Los Angeles, CA 90073 USA. [McMurtray, Aaron M.; Sultzer, David L.; Monserratt, Lorena; Yeo, Tuty; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [McMurtray, Aaron M.; Sultzer, David L.; Monserratt, Lorena; Yeo, Tuty; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurobehav Unit 116AF, Neurol Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu FU PHS HHS [R01 56031] NR 31 TC 11 Z9 11 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD WIN PY 2008 VL 20 IS 1 BP 62 EP 67 DI 10.1176/appi.neuropsych.20.1.62 PG 6 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 264SP UT WOS:000253311000006 PM 18305285 ER PT J AU Ahmad, M Rose, ME Vagni, V Griffith, RP Dixon, CE Kochanek, PM Hickey, RW Graham, SH AF Ahmad, Muzamil Rose, Marie E. Vagni, Vincent Griffith, Raymond P. Dixon, C. Edward Kochanek, Patrick M. Hickey, Robert W. Graham, Steven H. TI Genetic Disruption of Cyclooxygenase-2 Does Not Improve Histological or Behavioral Outcome After Traumatic Brain Injury in Mice SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE cyclooxygenase; prostaglandin E(2); TUNEL staining; behavior; Morris water maze ID CELL-DEATH; INHIBITOR ROFECOXIB; COX-2 INHIBITORS; IN-SITU; RATS; EXPRESSION; CELECOXIB; INFLAMMATION; NEURONS; EDEMA AB Increasing evidence suggests a role for cyclooxygenase-2 (COX-2) in traumatic brain injury (TBI). In the present study, the role of COX-2 in TBI was investigated using COX-2 gene-disrupted (COX-2 null) mice and wild-type (WT) controls that were subjected to the controlled cortical impact (CCI) model of TBI. There was increased expression of COX-2 in ipsilateral hippocampus in WT mice subjected to CCI. CCI resulted in a significant increase in prostaglandin E(2) concentrations in WT compared with COX-2 null hippocampi. There was a significant increase in TUNEL staining of CA1 neurons 24 hr after CCI in WT, but not in COX-2 null mice, compared with sham-operated controls, which is consistent with a protective role for COX-2 in the early phase of injury after TBI. However, there was no difference in lesion volume 21 days after CCI in COX-2 null and WT mice. COX-2 gene disruption did not alter Morris water maze performance. Taken together, these results suggest only a minor role for COX-2 activity in determining outcome after TBI in mouse. (c) 2008 Wiley-Liss, Inc. C1 [Ahmad, Muzamil; Rose, Marie E.; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA. [Ahmad, Muzamil; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Vagni, Vincent; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA. [Griffith, Raymond P.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA. [Kochanek, Patrick M.; Hickey, Robert W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA. RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, 151-UH,7108 Highland Dr, Pittsburgh, PA 15206 USA. EM sgra@pitt.edu RI Kochanek, Patrick/D-2371-2015 OI Kochanek, Patrick/0000-0002-2627-913X FU Department of Veterans Affairs/Department of Defense; Traumatic Brain Injury Initiative Merit Review Program; NIH [R01 NS37459] FX Contract grant sponsor: Department of Veterans Affairs/Department of Defense, Traumatic Brain Injury Initiative Merit Review Program (to S.H.G.); Contract grant sponsor: NIH; Contract grant number: R01 NS37459 (to S.H.G.). NR 48 TC 18 Z9 18 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD DEC PY 2008 VL 86 IS 16 BP 3605 EP 3612 DI 10.1002/jnr.21809 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 383CO UT WOS:000261651900012 PM 18711748 ER PT J AU Cole, CM Sundararaj, KP Leite, RS Nareika, A Slate, EH Sanders, JJ Lopes-Virella, MF Huang, Y AF Cole, C. M. Sundararaj, K. P. Leite, R. S. Nareika, A. Slate, E. H. Sanders, J. J. Lopes-Virella, M. F. Huang, Y. TI A trend of increase in periodontal interleukin-6 expression across patients with neither diabetes nor periodontal disease, patients with periodontal disease alone, and patients with both diseases SO JOURNAL OF PERIODONTAL RESEARCH LA English DT Article DE periodontal diseases; diabetes mellitus; interleukin-6; gene expression ID INFLAMMATION; MEDIATOR AB Epidemiological studies have established that patients with diabetes have increased prevalence and severity of periodontal disease. However, the periodontal expression of inflammatory cytokines and matrix metalloproteinases (MMPs) in diabetic patients has not been well characterized. The objective of this study was to determine the difference in the periodontal expression of MMP-1, MMP-8, interleukin-6, tumor necrosis factor-alpha and interleukin-1 beta between diabetic and nondiabetic patients. Periodontal tissue specimens were collected from nine nondiabetic patients without periodontal disease (group 1), from 11 nondiabetic patients with periodontal disease (group 2) and from seven diabetic patients with periodontal disease (group 3). The expression of MMP-1, MMP-8, interleukin-6, tumor necrosis factor-alpha and interleukin-1 beta was quantified using real-time polymerase chain reaction. The nonparametric Kruskal-Wallis test showed that the difference in interleukin-6 expression among the groups was statistically significant (p = 0.04). Furthermore, the generalized Kruskal-Wallis nonparametric linear-by-linear association test showed a statistically significant trend of increase in the expression of interleukin-6 from group 1 to group 2 to group 3 (p = 0.02) and a suggestion of such a trend for MMP-1 (p = 0.05). No increase in MMP-8 expression was observed in patients in group 3 compared to patients in groups 1 and 2. Although the average expression levels of MMP-1, interleukin-1 beta and tumor necrosis factor-alpha were increased from group 1 to group 3, the differences were not statistically significant. A trend of increased interleukin-6 expression in periodontal tissues was observed across patients with neither diabetes nor periodontal disease, patients with periodontal disease alone, and patients with both diseases. C1 [Cole, C. M.; Leite, R. S.; Sanders, J. J.] Med Univ S Carolina, Div Periodont, Dept Stomatol, Coll Dent Med, Charleston, SC 29403 USA. [Sundararaj, K. P.; Nareika, A.; Lopes-Virella, M. F.; Huang, Y.] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29403 USA. [Slate, E. H.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29403 USA. [Lopes-Virella, M. F.; Huang, Y.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Huang, Y (reprint author), Med Univ S Carolina, Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU NIH [DE16353]; NIH/NCRR COBRE [P20 RR017696] FX This work was supported by NIH grant DE16353 and a Merit Review Grant from the Department of Veterans Affairs (to YH). EHS, JJS, SDL and MFL-V additionally acknowledge partial support from the NIH/NCRR COBRE project P20 RR017696. NR 28 TC 15 Z9 15 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3484 J9 J PERIODONTAL RES JI J. Periodont. Res. PD DEC PY 2008 VL 43 IS 6 BP 717 EP 722 DI 10.1111/j.1600-0765.2008.01082.x PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 374TZ UT WOS:000261067900016 PM 18627438 ER PT J AU Pumbwe, L Curzon, M Wexler, HM AF Pumbwe, Lilian Curzon, Matthew Wexler, Hannah M. TI RAPID MULTIPLEX PCR ASSAY FOR SIMULTANEOUS DETECTION OF MAJOR ANTIBIOTIC RESISTANCE DETERMINANTS IN CLINICAL ISOLATES OF BACTEROIDES FRAGILIS SO JOURNAL OF RAPID METHODS AND AUTOMATION IN MICROBIOLOGY LA English DT Article ID INDUCIBLE METRONIDAZOLE RESISTANCE; ANAEROBIC-BACTERIA; CONJUGATIVE TRANSPOSON; NIM GENES; SUSCEPTIBILITY; CLINDAMYCIN; PREVALENCE; SPP.; ERMF; CFIA AB This study developed a rapid and cost-effective multiplex polymerase chain reaction assay (M-PCR) for simultaneous detection of major clinically relevant antibiotic resistance genes in Bacteroides fragilis. The M-PCR optimized amplification conditions with primers designed for detection of five resistance genes: carbapenems (cfiA) and cephalosporins (cepA), clindamycin (ermF), metronidazole (nimA-F) and tetracycline (tetQ), plus a set of primers for the B. fragilis 16S rRNA gene (positive control). An initial single PCR was performed for each gene, followed by a gradient PCR to determine the optimal PCR conditions for each primer set. This was followed by several test M-PCRs using the Qiagen multiplex PCR kit (Valencia, CA) with 60 ng of a template DNA mastermix containing all genes of interest and 0.2 mu M of each primer set. Multiplex PCR products were detectable at annealing temperatures ranging from 53-57C for 30-35 cycles. The final optimized M-PCR was then used to evaluate 21 different B. fragilis isolates from various patients. Eleven different M-PCR genotypes were obtained, which correlated with phenotypic antibiograms and nitrocefin beta-lactamase production assays. This M-PCR provides an accurate, rapid, sensitive and cost-effective tool for detecting clinically relevant antibiotic resistance genes in B. fragilis, and owing to its high sensitivity, it could also be used to investigate the prevalence of such genetic determinants in mixed bacterial specimens. C1 [Pumbwe, Lilian; Wexler, Hannah M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Pumbwe, Lilian; Curzon, Matthew; Wexler, Hannah M.] Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. RP Pumbwe, L (reprint author), Wadsworth Anaerobe Lab, Bldg 304,Room E3-226, Los Angeles, CA 90073 USA. EM lilskil@ucla.edu FU Department of Veterans Affairs FX This study was supported by Merit Review Funds from the Department of Veterans Affairs. NR 28 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1060-3999 J9 J RAPID METH AUT MIC JI J Rapid Methods Autom. Microbiol. PD DEC PY 2008 VL 16 IS 4 BP 381 EP 393 DI 10.1111/j.1745-4581.2008.00143.x PG 13 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 378ZZ UT WOS:000261365100010 ER PT J AU Petri, M Naqibuddin, M Carson, KA Wallace, DJ Weisman, MH Holliday, SL Sampedro, M Narayana, S Fox, PT Franklin, C Padilla, PA Brey, RL AF Petri, Michelle Naqibuddin, Mohammad Carson, Kathryn A. Wallace, Daniel J. Weisman, Michael H. Holliday, Stephen L. Sampedro, Margaret Narayana, Shalini Fox, Peter T. Franklin, Crystal Padilla, Patricia A. Brey, Robin L. TI Brain Magnetic Resonance Imaging in Newly Diagnosed Systemic Lupus Erythematosus SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE SYSTEMIC LUPUS ERYTHEMATOSUS; MAGNETIC RESONANCE IMAGING; CEREBRALATROPHY ID OVERT NEUROPSYCHIATRIC MANIFESTATIONS; MULTIPLE-SCLEROSIS; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; REVISED CRITERIA; CEREBRAL ATROPHY; DISEASE-ACTIVITY; RATING-SCALE; MRI; CLASSIFICATION AB Objective. We wished to determine the prevalence of cerebral atrophy and focal lesions in a cohort of patients with newly diagnosed systemic lupus erythematosus (SLE) and the association of these brain abnormalities with clinical characteristics. Methods. A total of 97 patients with SLE, within 9 months of diagnosis, with 4 or more American College of Rheumatology classification criteria, were enrolled. Brain magnetic resonance imaging was performed. Results. The patients were 97% female. mean age 38.1 (SD 12.2) years, education 15.1 (2.8) years; 59 Caucasian, I I African American, 19 Hispanic, 5 Asian, and 3 other ethnicity. Cerebral atrophy was prevalent in 18% (95% Cl 11%-27%): mild in 12%, moderate in 5%. Focal lesions were prevalent in 8% (95% Cl 4%-16%): mild in 2%, moderate in 5%. severe in 1%. Patients with cerebral atrophy were more likely to have anxiety disorder (p = 0.04). Patients with focal lesions were more likely to be African American (p = 0.045) and had higher Safety of Estrogens in Lupus Erythematosus National Assessment SLEDAI scores (p = 0.02) and anti-dsDNA (p = 0.05). Conclusion. In this population with newly diagnosed SLE, brain abnormalities were prevalent in 25% of patients. These findings suggest that the brain may be affected extremely early in the course of SLE, even before the clinical diagnosis of SLE is made. Followup of these patients is planned. to determine the reversibility or progression of these abnormalities and their association with and potential predictive value for subsequent neuropsychiatric SLE manifestations. (First Release Sept 15 2008 J Rheumatol 200835:2348-54: doi: 10.3899/jrheum.071010) C1 [Petri, Michelle; Naqibuddin, Mohammad; Sampedro, Margaret] Johns Hopkins Univ, Baltimore, MD 21205 USA. [Carson, Kathryn A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Wallace, Daniel J.; Weisman, Michael H.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Los Angeles, CA 90095 USA. [Holliday, Stephen L.] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Narayana, Shalini; Fox, Peter T.; Franklin, Crystal] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Narayana, Shalini] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Padilla, Patricia A.; Brey, Robin L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. RP Petri, M (reprint author), Johns Hopkins Univ, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA. EM mpetri@jhmi.edu RI Fox, Peter/B-4725-2010; Narayana, Shalini/F-3031-2010 OI Fox, Peter/0000-0002-0465-2028; FU NIH [RO1-AR049125, AR043727]; Johns Hopkins University General Clinical Research Center [M01-RR00052]; University of Texas Health Science Center at San Antonio Frederic C. Bartter General Clinical Research Center [MOI-RR01346] FX The Brain CONECTIONS study is supported by NIH RO1-AR049125. AR043727. and the Johns Hopkins University General Clinical Research Center (K. Carson is supported by M01-RR00052) and the University of Texas Health Science Center at San Antonio Frederic C. Bartter General Clinical Research Center (MOI-RR01346). NR 53 TC 34 Z9 36 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD DEC PY 2008 VL 35 IS 12 BP 2348 EP 2354 DI 10.3899/jrehum.071010 PG 7 WC Rheumatology SC Rheumatology GA 379XA UT WOS:000261428400013 PM 18793003 ER PT J AU Partinen, M Leger, D Hirshkowitz, M Chokroverty, S Hedner, J AF Partinen, M. Leger, D. Hirshkowitz, M. Chokroverty, S. Hedner, J. TI Frequency of insomnia symptoms in PCPS patients: results of the EQUINOX international survey SO JOURNAL OF SLEEP RESEARCH LA English DT Meeting Abstract CT 19th Congress of the European-Sleep-Research-Society CY SEP 09-13, 2008 CL Glasgow, SCOTLAND SP European Sleep Res Soc C1 [Leger, D.] Physiol Explorat Fonct Ctr Sommeil, Hotel Dieu, Paris, France. [Hirshkowitz, M.] VA Med Ctr, Sleep Disorders & Res Ctr, Houston, TX USA. [Chokroverty, S.] New Jersey Neurosci Inst, JFK Med Ctr, Edison, NJ USA. [Hedner, J.] Sahlgrens Univ Hosp, Sleep Lab Unit, Dept Resp Med & Allergol, Gothenburg, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0962-1105 J9 J SLEEP RES JI J. Sleep Res. PD DEC PY 2008 VL 17 BP 196 EP 197 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 400EH UT WOS:000262850300550 ER PT J AU Horn, JH Pratt, SR Durrant, JD AF Horn, Jennifer H. Pratt, Sheila R. Durrant, John D. TI Parameters to Maximize 2f2-f1 Distortion Product Otoacoustic Emission Levels SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article DE distortion product otoacoustic emissions (DPOAEs); parameters; 2f2-f1; input-output functions ID NORMALLY HEARING SUBJECTS; PRIMARY FREQUENCIES RATIO; HUMAN NEWBORNS; HUMAN EARS; AMPLITUDE; HUMANS; 2F1-F2; ADULTS; PHASE; INTERRELATIONS AB Purpose: Past research has established parameters for the 2f1-f2 distortion product otoacoustic emissions (DPOAEs) that enhance response levels ( e. g., L1-L2 = 10 dB; f2/f1 = 1.22; L1, L2 = 65, 55 dB SPL). These same parameters do not optimize 2f2-f1 DPOAEs. Therefore, this study was conducted to evaluate more completely those parameters that produce the most robust 2f2-f1 output. Method: Input-output functions of the 2f2-f1 component were obtained from 20 normal-hearing adults ( with f2 = 2000 Hz and 4000 Hz). Frequency ratios, level differences, and overall sound levels were manipulated with parameter combinations chosen to expand on information established in previous studies. The DPOAE signal-to-noise ratio (SNR), response presence, and output levels were measured. Results: In general, mean SNRs and 2f2-f1 levels were greater, and DPOAEs were present more often for 2000 than for 4000 Hz across all parameter combinations. No single parameter combination resulted in pronounced maxima for 2f2-f1, which is consistent with past studies but is in sharp contrast to results for the more familiar 2f1-f2. Conclusions: Overall, the results suggest that to maximize the 2f2-f1 level, lower test frequencies, low frequency ratio, essentially equal levels of primary tones, and moderate stimulus levels are best, and such parameters might be important for applying DPOAE measurement to assessment of normal and impaired auditory function. C1 [Horn, Jennifer H.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. [Horn, Jennifer H.; Pratt, Sheila R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Horn, JH (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. EM jhhst15@pitt.edu RI Pratt, Sheila/H-7139-2013 NR 35 TC 3 Z9 4 U1 0 U2 2 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD DEC 1 PY 2008 VL 51 IS 6 BP 1620 EP 1629 DI 10.1044/1092-4388(2008/07-0179) PG 10 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 376PS UT WOS:000261196100019 PM 18664689 ER PT J AU Boyd, CM Landefeld, CS Counsell, SR Palmer, RM Fortinsky, RH Kresevic, D Burant, C Covinsky, KE AF Boyd, Cynthia M. Landefeld, C. Seth Counsell, Steven R. Palmer, Robert M. Fortinsky, Richard H. Kresevic, Denise Burant, Christopher Covinsky, Kenneth E. TI Recovery of Activities of Daily Living in Older Adults After Hospitalization for Acute Medical Illness SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hospitalization; functional decline; recovery ID HOME HEALTH-CARE; PROSPECTIVE-PAYMENT SYSTEM; HIP FRACTURE PATIENTS; POST-ACUTE CARE; FUNCTIONAL OUTCOMES; THERAPY INTENSITY; REHABILITATION; DISABILITY; COMMUNITY; INDEPENDENCE AB To compare functional outcomes in the year after discharge for older adults discharged from the hospital after an acute medical illness with a new or additional disability in their basic self-care activities of daily living (ADL) (compared with preadmission baseline 2 weeks before admission) with those of older adults discharged with baseline ADL function and identify predictors of failure to recover to baseline function 1 year after discharge. Observational. Tertiary care hospital, community teaching hospital. Older (aged >= 70) patients nonelectively admitted to general medical services (1993-1998). Number of ADL disabilities at preadmission baseline and 1, 3, 6, and 12 months after discharge. Outcomes were death, sustained decline in ADL function, and recovery to baseline ADL function at each time point. By 12 months after discharge, of those discharged with new or additional ADL disability, 41.3% died, 28.6% were alive but had not recovered to baseline function, and 30.1% were at baseline function. Of those discharged at baseline function, 17.8% died, 15.2% were alive but with worse than baseline function, and 67% were at their baseline function (P <.001). Of those discharged with new or additional ADL disability, the presence or absence of recovery by 1 month was associated with long-term outcomes. Age, cardiovascular disease, dementia, cancer, low albumin, and greater number of dependencies in instrumental ADLs independently predicted failure to recover. For older adults discharged with new or additional disability in ADL after hospitalization for medical illness, prognosis for functional recovery is poor. Rehabilitation interventions of longer duration and timing than current reimbursement allows, caregiver support, and palliative care should be evaluated. C1 [Boyd, Cynthia M.] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA. [Boyd, Cynthia M.] Johns Hopkins Univ, Sch Med, Dept Med, Ctr Aging & Hlth, Baltimore, MD 21224 USA. [Boyd, Cynthia M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Ctr Aging & Hlth, Baltimore, MD 21224 USA. [Boyd, Cynthia M.] Johns Hopkins Univ, Roger C Lipitz Ctr Integrated Hlth Care, Bloomberg Sch Publ Hlth, Baltimore, MD 21224 USA. [Landefeld, C. Seth; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Landefeld, C. Seth; Covinsky, Kenneth E.] San Francisco VA Med Ctr, Interdisciplinary Res Program Improve Care Older, San Francisco, CA USA. [Landefeld, C. Seth; Covinsky, Kenneth E.] San Francisco VA Med Ctr, Qual Scholars Program, San Francisco, CA USA. [Counsell, Steven R.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA. [Palmer, Robert M.] Univ Pittsburgh, Sch Med Ctr, Div Geriatr Med, Pittsburgh, PA USA. [Fortinsky, Richard H.] Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA. [Fortinsky, Richard H.] Univ Connecticut, Ctr Hlth, Div Geriatr, Farmington, CT USA. [Kresevic, Denise] Case Western Reserve Univ, Sch Nursing, Dept Sociol & Bioeth,Univ Hosp Case Med Ctr, Louis Stokes Cleveland Vet Affairs Med Ctr,GRE, Cleveland, OH 44106 USA. RP Boyd, CM (reprint author), Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Mason F Lord Bldg,Ctr Tower,7th Floor,5200 Easter, Baltimore, MD 21224 USA. EM cboyd1@jhmi.edu FU National Institute on Aging [AG029233, AG00912, AG10418, K24AG029812]; Johns Hopkins University (CMB); Summa Health System Foundation to Akron City Hospital; John A. Hartford Foundation, Inc. [2003-0455] FX Conflict of Interest: Drs. Landefeld, Covinsky, Palmer, Counsell Fortinsky, Burant, and Kresevic have all received funding from the NIA. Dr Kresevic has received funding from the Department of Veterans Affairs. Drs. Landefeld and Boyd have received funding from the John A. Hartford Foundation. Dr. Boyd was a Pfizer/American Geriatrics Society Junior Faculty Scholar for Research on Health Outcomes during the conduct of this study. Dr. Boyd is a Johns Hopkins Bayview Scholar in the Center for Innovative Medicine. This work was supported by grants from the National Institute on Aging to the Claude Pepper Older Americans Independence Center at Case Western Reserve University and Johns Hopkins University (CMB), National Institute on Aging Grants AG029233, AG00912, AG10418, and K24AG029812. The Summa Health System Foundation to Akron City Hospital, and the John A. Hartford Foundation, Inc. 2003-0455 to the University of California, San Francisco.; Author Contributions: Dr. Boyd conceptualized the manuscript, obtained funding, developed the design of the analysis with Dr. Covinsky and wrote the manuscript. Dr. Landefeld and Dr. Counsell were responsible for collaborating in study design and implementation, obtaining funding, analysis and interpretation of data and critical revision of the manuscript for important intellectual content. Dr. Palmer was a co-investigator responsible for collaborating in design and implementation, interpretation of data, and critical revision of the manuscript for important intellectual content. Dr. Fortinsky was a co-investigator responsible for collaborating in the analysis and interpretation of data and critical revision of the manuscript for important intellectual content. Dr. Kresevic was a co-investigator responsible for collaborating in design and implementation, interpretation of data, and critical revision of the manuscript for important intellectual content. Dr. Covinsky was responsible for supervision of the entire project and manuscript and collaborated on the design and implementation and analysis and interpretation of data and undertook critical revision of this manuscript for important intellectual content.; Sponsors' Role: The funding sources had no role in the design and conduct of the study; collection, management, analysis or interpretation of the data; or the preparation, review, or approval of the manuscript. NR 50 TC 169 Z9 174 U1 1 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2008 VL 56 IS 12 BP 2171 EP 2179 DI 10.1111/j.1532-5415.2008.02023.x PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 378ZP UT WOS:000261364100001 PM 19093915 ER PT J AU Sarkisian, CA Gruenewald, TL Boscardin, WJ Seeman, TE AF Sarkisian, Catherine A. Gruenewald, Tara L. Boscardin, W. John Seeman, Teresa E. TI Preliminary Evidence for Subdimensions of Geriatric Frailty: The MacArthur Study of Successful Aging SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE frailty; disability; aged; comorbidity ID OLDER-ADULTS; FUNCTIONAL DECLINE; PHYSICAL-ACTIVITY; ELDERLY-PEOPLE; WOMENS HEALTH; DISABILITY; MORTALITY; COAGULATION; ACTIVATION; PHENOTYPE AB To identify frailty subdimensions. Longitudinal cohort (MacArthur Study). Three U.S. urban centers. One thousand one hundred eighteen high-functioning subjects aged 70 to 79 in 1988. Participants with three or more of five Cardiovascular Health Study (CHS) frailty criteria (weight loss, weak grip, exhaustion, slow gait, and low physical activity) in 1991 were classified as having the CHS frailty phenotype. To identify frailty subdimensions, factor analysis was conducted using the CHS variables and an expanded set including the CHS variables, cognitive impairment, interleukin-6 (IL-6), C-reactive protein (CRP), subjective weakness, and anorexia. Participants with four or more of 10 criteria were classified as having an expanded frailty phenotype. Predictive validity of each identified frailty subdimension was assessed using regression models for 4-year disability and 9-year mortality. Two subdimensions of the CHS phenotype and four subdimensions of the expanded frailty phenotype were identified. Cognitive function was consistently part of a subdimension including slower gait, weaker grip, and lower physical activity. The CHS subdimension of slower gait, weaker grip, and lower physical activity predicted disability (adjusted odds ratio (AOR)=1.7, 95% confidence interval (CI)=1.3-2.2) and mortality (AOR=1.5, 95% CI=1.3-1.8). Subdimensions of the expanded model with predictive validity were higher IL-6 and CRP (AOR=1.2 for mortality); slower gait, weaker grip, lower physical activity, and lower cognitive function (AOR=1.8 for disability; AOR=1.5 for mortality), and anorexia and weight loss (AOR=1.2 for disability). This study provides preliminary empirical support for subdimensions of geriatric frailty, suggesting that pathways to frailty differ and that subdimension-adapted care might enhance care of frail seniors. C1 [Sarkisian, Catherine A.] GRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Sarkisian, Catherine A.; Gruenewald, Tara L.; Seeman, Teresa E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Sarkisian, CA (reprint author), GRECC, VA Greater Los Angeles Healthcare Syst, Bldg 220,Room 315 11G,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM csarkisian@mednet.ucla.edu FU Paul B. Beeson Career Development Award in Aging; National Institute on Aging [1K23AG0 24811-03, R21, 5 R21 AG025764-02, 5 P30 AG017265-08]; University of Southern California/University of California at Los Angeles Center for the Study of Biodemography and Population Health; MacArthur Research Network on Successful Aging; John D. and Catherine T. MacArthur Foundation FX The authors want to express their appreciation to Ms. Constance Gewa, Ms. Sungjin Kim, and Ms. Diana Liao for carefully carrying out the computer programming necessary for this manuscript.; Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this manuscript. This work was supported by a Paul B. Beeson Career Development Award in Aging, National Institute on Aging (1K23AG0 24811-03), an R21 from the National Institute on Aging (5 R21 AG025764-02), the University of Southern California/University of California at Los Angeles Center for the Study of Biodemography and Population Health, National Institute on Aging (5 P30 AG017265-08), and by the MacArthur Research Network on Successful Aging and the MacArthur Research Network on SES and Health through grants from the John D. and Catherine T. MacArthur Foundation.; Author Contributions: All four authors contributed to the study concept and design, analysis and interpretation of data, and preparation of the manuscript. Dr. Seeman also contributed to subject enrollment and data collection. Sponsor's Role: The funders had no role in this investigation's design, conduct, or reporting. NR 29 TC 50 Z9 51 U1 4 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2008 VL 56 IS 12 BP 2292 EP 2297 DI 10.1111/j.1532-5415.2008.02041.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 378ZP UT WOS:000261364100017 PM 19016933 ER PT J AU Shay, K Burris, JF AF Shay, Kenneth Burris, James F. CA State Art Planning Comm TI Setting the Stage for a New Strategic Plan for Geriatrics and Extended Care in the Veterans Health Administration: Summary of the 2008 VA State of the Art Conference, "The Changing Faces of Geriatrics and Extended Care: Meeting the Needs of Veterans in the Next Decade" SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; INTEGRATED CARE; PRISM-E; DEPRESSION; OUTCOMES; PARTICIPATE; MANAGEMENT; PROGRAM; MODELS AB The Department of Veterans Affairs (VA) assumed an early leadership role in focusing on care of elderly adults. In 1998, the Federal Advisory Committee on the Future of VA Long-Term Care, appointed by the VA Undersecretary for Health, recommended redirection of VA's extended care programs toward noninstitutional forms. A decade later, VA's Office of Geriatrics and Extended Care (GEC) initiated a strategic planning process by convening experts in geriatrics and health care, policy, and finance in Virginia on March 25 to 27, 2008, to present to VA clinicians and clinical managers the "State of the Art" of VA GEC. Recurring clinical themes included rising numbers and complexity of aging veterans, recent addition of younger veterans to VA's extended care mix, challenges that dementia and mental illness exert throughout GEC, and need for seamlessness in delivery of care across multiple venues. Ongoing research efforts quantifying demand and resources and validating models of care will remain indispensible for meeting clinical challenges. Serious undersupply of clinicians of all disciplines with general or specialty geriatrics knowledge persists. Much of VA's healthcare workforce and leadership are approaching retirement age, driving the need for new educational approaches, recruitment and retention strategies, and innovative delivery systems. Growing dependence on informal caregivers highlights the need for supporting these partners. VA's healthcare budget allocation illustrates how national policy dictates systemic, regional, and local clinical decisions. Rehabilitation of the newest veterans is resulting in systemwide efficiencies. Educating and empowering patients and families results in optimized utilization of health resources. C1 [Shay, Kenneth; Burris, James F.] US Dept Vet Affairs, Off Geriatr & Extended Care, Washington, DC USA. RP Shay, K (reprint author), VA Cent Off 114, 810 Vermont Ave NW, Washington, DC 20420 USA. EM Kenneth.shay@va.gov NR 20 TC 12 Z9 12 U1 1 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2008 VL 56 IS 12 BP 2330 EP 2339 DI 10.1111/j.1532-5415.2008.02079.x PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 378ZP UT WOS:000261364100023 PM 19093933 ER PT J AU Casarett, D Chen, Z AF Casarett, David Chen, Zhen TI PROPENSITY SCORING RESPONSE SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Casarett, David] Univ Penn, Div Geriatr, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Chen, Zhen] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Casarett, D (reprint author), Univ Penn, Div Geriatr, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2008 VL 56 IS 12 DI 10.1111/j.1532-5415.2008.02042.x PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 378ZP UT WOS:000261364100029 ER PT J AU Luks, AM Johnson, RJ Swenson, ER AF Luks, Andrew M. Johnson, Richard J. Swenson, Erik R. TI Chronic Kidney Disease at High Altitude SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID ENDOTHELIAL GROWTH-FACTOR; MODERATELY HIGH-ALTITUDE; RIGHT PULMONARY-ARTERY; STAGE RENAL-DISEASE; CHRONIC HYPOXIA; RAT-KIDNEY; SEA-LEVEL; TUBULOINTERSTITIAL INJURY; RESPIRATORY ALKALOSIS; IMPAIRED ANGIOGENESIS AB With a prevalence of 10 to 11% in the general population, it is likely that many patients with chronic kidney disease will visit or reside in mountainous areas. Little is known, however, about whether short- or long-duration, high-altitude exposure poses a risk in this patient population. Given that many areas of the kidney are marginally oxygenated even at sea level and that kidney disease may result in further renal hypoxia and hypoxia-associated renal injury, there is concern that high altitude may accelerate the progression of chronic kidney disease. In this review, we address how chronic kidney disease and its management is affected at high altitude. We postulate that arterial hypoxemia at high altitude poses a risk of faster disease progression in those with preexisting kidney disease. In addition, we consider the risks of developing acute altitude illness in patients with chronic kidney disease and the appropriate use of medications for the prevention and treatment of these problems. C1 [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA 98108 USA. [Johnson, Richard J.] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA. RP Swenson, ER (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM eswenson@u.washington.edu FU NHLBI NIH HHS [R01 HL068607, R01 HL068607-07A2]; NIDDK NIH HHS [R01 DK052121, R01 DK052121-12] NR 105 TC 21 Z9 22 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2008 VL 19 IS 12 BP 2262 EP 2271 DI 10.1681/ASN.2007111199 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 381MC UT WOS:000261539300007 PM 18842990 ER PT J AU Bartels, C Goetz, S Ward, E Carnes, M AF Bartels, Christie Goetz, Sarah Ward, Earlise Carnes, Molly TI Internal Medicine Residents' Perceived Ability to Direct Patient Care: Impact of Gender and Experience SO JOURNAL OF WOMENS HEALTH LA English DT Article ID SEX-ROLE INVENTORY; WOMEN; STEREOTYPES; LEADERSHIP; METAANALYSIS AB Background: Physicians are expected to effect patient care by giving orders to members of a healthcare team. Because women are socialized to be less directive than men, the assertive behavior required of new physicians may be experienced differently by male and female residents. We sought to explore the effects of gender and year of training on residents' experiences and perceived ability to direct patient care. Methods: This was a mixed-methods, cross-sectional, descriptive study employing a quantitative written survey and qualitative interviews among internal medicine residents at an academic health center. Measurements included questionnaires and interviews about stress, assertiveness, and personal factors that influence their effectiveness in directing patient care. Analyses examined differences by gender and year of training. Results: One hundred residents were invited to participate; 65 returned questionnaires, and 16 of these residents were interviewed. Compared with male residents, female residents selected less assertive behaviors for clinical scenarios ( p = 0.047) and were more likely to perceive gender as inhibiting their ability to influence patient care ( p = 0.01). Stress associated with being assertive varied more with experience than gender. Interviews corroborated these findings and supported the complexity of gender norms for behavior for female residents in a directive leadership position. Conclusions: When compared with male peers, female residents reported more gender issues in residency and chose less assertive behaviors in clinical scenarios. Experience mitigated some gender differences. Our findings suggest that discussion of the existing research on prescriptive gender norms for behavior and leadership may be warranted in resident orientation. C1 [Bartels, Christie; Carnes, Molly] Univ Wisconsin, Dept Med, Madison, WI 53715 USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. RP Carnes, M (reprint author), Univ Wisconsin, Dept Med Psychiat & Ind & Syst Engn, Ctr Womens Hlth Res, 700 Regent St,Suite 101, Madison, WI 53715 USA. EM mlcarnes@wisc.edu FU University of Wisconsin-Madison School of Medicine and Public Health; Jean Manchester Biddick-Bascom Endowed Professorship; Meriter Hospital FX This work was supported by a Shapiro Grant from the University of Wisconsin-Madison School of Medicine and Public Health, the Jean Manchester Biddick-Bascom Endowed Professorship, and Meriter Hospital. We thank Tim Hess for statistical support and Linda Baier for reviewing the manuscript. NR 27 TC 16 Z9 16 U1 1 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD DEC PY 2008 VL 17 IS 10 BP 1615 EP 1621 DI 10.1089/jwh.2008.0798 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 378OG UT WOS:000261331500012 PM 19049356 ER PT J AU Martin, JL Alam, T Harker, JO Josephson, KR Alessi, CA AF Martin, Jennifer L. Alam, Tarannum Harker, Judith O. Josephson, Karen R. Alessi, Cathy A. TI Sleep in Assisted Living Facility Residents Versus Home-Dwelling Older Adults SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Sleep; Aging; Circadian rhythms; Assisted living ID ACTIVITY RHYTHMS; INDEX; WAKE AB Background. Sleep problems among assisted living facility (ALF) residents are not well understood, and sleep-related differences between ALF residents and home-dwelling older adults have not been examined. Methods. We compared sleep patterns in 19 ALF residents to sleep patterns in 19 matched home-dwelling older people (age >= 65 years). All were participating in the follow-up portion of a longitudinal study of sleep and functional outcomes following post-acute rehabilitation. Sleep was assessed with the Pittsburgh Sleep Quality Index and l week of wrist actigraphy. Results. By actigraphy, ALF residents awoke earlier in the morning and exhibited more nighttime awakenings compared to home-dwelling participants (06:50 hours +/- 1:29 hours vs 07:51 hours +/- 1:19 hours and 19.5 +/- 8.5 vs 12.9 +/- 11.4 awakenings, respectively). Conclusions. Larger studies are needed to confirm these initial findings that ALF residents have more disrupted sleep than do home-dwelling older persons, and to examine the functional and health consequences of poor sleep among ALF residents. C1 [Martin, Jennifer L.; Alam, Tarannum; Harker, Judith O.; Josephson, Karen R.; Alessi, Cathy A.] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. [Martin, Jennifer L.; Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Martin, JL (reprint author), VA Sepulveda GRECC 11E, 16111 Plummer St, North Hills, CA 91343 USA. EM jennifer.martin@va.gov FU National Institute on Aging (NIA) [K23AG028452]; VA Special Fellowship Program in Advanced Geriatrics; VA Health Services Research and Development Service [IIR01-053-1, AlA03-047]; UCLA Older Americans Independence Center (OAIC) [5-P60-AG010415]; VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center FX This work was supported by National Institute on Aging (NIA) grant K23AG028452, the VA Special Fellowship Program in Advanced Geriatrics, VA Health Services Research and Development Service grants IIR01-053-1 and AlA03-047. UCLA Older Americans Independence Center (OAIC) grant 5-P60-AG010415, and by the VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center.; Portions of this article were presented at the 2005 American Geriatrics Society meeting, Orlando, Florida. NR 17 TC 6 Z9 6 U1 0 U2 1 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2008 VL 63 IS 12 BP 1407 EP 1409 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 395PG UT WOS:000262535400018 PM 19126856 ER PT J AU Agarwal, A Eide, CA Harlow, A Corbin, AS Mauro, MJ Druker, BJ Corless, CL Heinrich, MC Deininger, MW AF Agarwal, A. Eide, C. A. Harlow, A. Corbin, A. S. Mauro, M. J. Druker, B. J. Corless, C. L. Heinrich, M. C. Deininger, M. W. TI An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia SO LEUKEMIA LA English DT Letter ID CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL; CELLS; MECHANISMS; STI571; CML C1 [Agarwal, A.; Eide, C. A.; Harlow, A.; Corbin, A. S.; Mauro, M. J.; Druker, B. J.; Corless, C. L.; Heinrich, M. C.; Deininger, M. W.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Agarwal, A.; Eide, C. A.; Corbin, A. S.; Druker, B. J.] Howard Hughes Med Inst, Div Hematol & Med Oncol, Portland, OR USA. [Harlow, A.; Corless, C. L.; Heinrich, M. C.] Portland VA Med Ctr, Portland, OR USA. [Harlow, A.; Corless, C. L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. RP Agarwal, A (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA. EM deininge@ohsu.edu FU NHLBI NIH HHS [HL082978-01] NR 12 TC 17 Z9 17 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD DEC PY 2008 VL 22 IS 12 BP 2269 EP 2272 DI 10.1038/leu.2008.124 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 386DJ UT WOS:000261862200022 PM 18509354 ER PT J AU Bailey, FA AF Bailey, F. Amos TI "I Am Not Afraid of Dying. I Just Don't Want To Be There When it Happens" SO MEDICAL CARE LA English DT Editorial Material ID PHYSICIAN-ASSISTED SUICIDE; OF-LIFE DECISIONS; PALLIATIVE CARE; MEDICAL-PRACTICE; END; EUTHANASIA; OUTCOMES; CANCER; DEATH C1 Birmingham VAMC, Birmingham, AL 35233 USA. RP Bailey, FA (reprint author), Birmingham VAMC, 700 S 19th St, Birmingham, AL 35233 USA. EM amos-bailey@va.gov NR 23 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2008 VL 46 IS 12 BP 1195 EP 1197 DI 10.1097/MLR.0b013e3181904fd8 PG 3 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 379UC UT WOS:000261420700001 PM 19300307 ER PT J AU Keyhani, S Hebert, PL Ross, JS Federman, A Zhu, CW Siu, AL AF Keyhani, Salomeh Hebert, Paul L. Ross, Joseph S. Federman, Alex Zhu, Carolyn W. Siu, Albert L. TI Electronic Health Record Components and the Quality of Care SO MEDICAL CARE LA English DT Article DE quality of health care; personal health record; hypertension; ambulatory care ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL REMINDERS; MEDICAL-RECORD; UNITED-STATES; ORDER ENTRY; ERRORS; SYSTEM; IMPACT; TRANSFORMATION; PRESCRIPTION AB Background: Electronic health records (EHRs) have been promoted as an important tool to improve quality of care. We examined the association between EHR components, a complete EHR, and the quality of care. Methods: Using data from the 2005 National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, we conducted a cross-sectional analysis of all visits with an established primary care provider and examined the association between presence of EHR components and: (1) blood pressure control; and (2) receipt of appropriate therapy for chronic conditions. We examined similar associations for complete EHRs which we defined as one that includes physician and nursing notes, electronic reminder system, computerized prescription order entry, test results, and computerized test order entry. We constructed multivariate models to examine the association between EHR components and each outcome controlling for patient sociodemographic, health, physician practice, and geographic factors. Results: We found no association between electronic physician notes and blood pressure control or receipt of appropriate therapies, with the exception of inhaled steroids among asthmatics (adjusted odds ratio 2.86; 95% confidence interval, 1.12-7.32). We found no association between electronic reminder systems and blood pressure control or receipt of appropriate therapies, with the exception of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in patients with diabetes with hypertension (odds ratio 2.58; 95% confidence interval, 1.22-5.42). We found no association between electronic physician notes and any measure of quality. We found no relationship between having a complete EHR and any of the quality measures investigated. Conclusions: We found no consistent association between blood pressure control, management of chronic conditions, and specific EHR components. Future research focusing on how an EHR is implemented and used and how care is integrated through an EHR will improve our understanding of the impact of EHRs on the quality of care. C1 [Keyhani, Salomeh; Hebert, Paul L.] Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA. [Keyhani, Salomeh; Ross, Joseph S.; Zhu, Carolyn W.; Siu, Albert L.] James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Ross, Joseph S.; Zhu, Carolyn W.; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Federman, Alex] Mt Sinai Sch Med, Dept Gen Internal Med, New York, NY 10029 USA. RP Keyhani, S (reprint author), Mt Sinai Sch Med, Dept Hlth Policy, Box 1077,1 Gustave L Levy Pl, New York, NY 10029 USA. EM salomeh.keyhani@mountsinai.org FU Department of Veterans Affairs Health Services Research and Development Service [TRP-02-149]; Hartford Foundation; Robert Wood Johnson Foundation FX Supported by Department of Veterans Affairs Health Services Research and Development Service project #TRP-02-149 (to S.K., J.S.R., and A.L.S.); the Hartford Foundation (to J.S.R.); and the Robert Wood Johnson Foundation (to A.R). NR 33 TC 50 Z9 51 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2008 VL 46 IS 12 BP 1267 EP 1272 DI 10.1097/MLR.0b013e31817e18ae PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 379UC UT WOS:000261420700011 PM 19300317 ER PT J AU Cooper, RA Dicianno, BE Brewer, B LoPresti, E Ding, D Simpson, R Grindle, G Wang, HW AF Cooper, Rory A. Dicianno, Brad E. Brewer, Bambi LoPresti, Edmund Ding, Dan Simpson, Richard Grindle, Garrett Wang, Hongwu TI A perspective on intelligent devices and environments in medical rehabilitation SO MEDICAL ENGINEERING & PHYSICS LA English DT Review DE Rehabilitation; Intelligent systems; Machine learning; Physical impairment; Wheelchairs; Cognitive impairment ID INDUCED MOVEMENT THERAPY; TRAUMATIC BRAIN-INJURY; UPPER-LIMB FUNCTION; OF-THE-ART; UPPER EXTREMITY; STROKE REHABILITATION; RANDOMIZED CROSSOVER; ASSISTIVE-TECHNOLOGY; INTERFACE PRESSURE; CARE COORDINATION AB Globally, the number of people older than 65 years is anticipated to double between 1997 and 2025, while at the same time the number of people with disabilities is growing at it similar rate, which makes technical advances and social policies critical to attain, prolong, and preserve quality of life. Recent advancements in technology, including computation, robotics, machine learning, communication, and miniaturization of sensors have been used primarily in manufacturing, military, space exploration, and entertainment. However, few efforts have been made to utilize these technologies to enhance the quality of life of people with disabilities. This article offers a perspective of future development in seven emerging areas: translation of research into clinical practice, pervasive assistive technology, cognitive assistive technologies, rehabilitation monitoring and coaching technologies, robotic assisted therapy, and personal mobility and manipulation technology. Published by Elsevier Ltd on behalf of IPEM C1 [Cooper, Rory A.; Dicianno, Brad E.; Brewer, Bambi; Ding, Dan; Simpson, Richard; Grindle, Garrett; Wang, Hongwu] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Rehabil Res & Dev Serv, Pittsburgh, PA 15206 USA. [Cooper, Rory A.; Dicianno, Brad E.; Brewer, Bambi; LoPresti, Edmund; Ding, Dan; Simpson, Richard; Grindle, Garrett; Wang, Hongwu] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Cooper, Rory A.; Dicianno, Brad E.; Brewer, Bambi; LoPresti, Edmund; Ding, Dan; Simpson, Richard; Grindle, Garrett; Wang, Hongwu] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA. [Cooper, Rory A.; Dicianno, Brad E.; Brewer, Bambi; LoPresti, Edmund; Ding, Dan; Simpson, Richard; Grindle, Garrett; Wang, Hongwu] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Dicianno, Brad E.; Simpson, Richard] Univ Pittsburgh, Med Ctr, Ctr Assist Technol, Pittsburgh, PA 15260 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs, Rehabil Res & Dev Serv, 151-R1,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Wang, Hongwu/J-6133-2013; Simpson, Richard/G-5683-2015 OI Wang, Hongwu/0000-0002-6567-9144; Simpson, Richard/0000-0002-6306-9393; Dicianno, Brad/0000-0003-0738-0192 FU National Science Foundation [EEC-0540865]; Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs [B3142C] FX This material is based upon work supported by the National Science Foundation under Cooperative Agreement EEC-0540865. This material is also based upon work supported by the Office of Research and Development, Rehabilitation Research & Development Service, Department of Veterans Affairs, Grant# B3142C. NR 122 TC 21 Z9 21 U1 1 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1350-4533 J9 MED ENG PHYS JI Med. Eng. Phys. PD DEC PY 2008 VL 30 IS 10 BP 1387 EP 1398 DI 10.1016/j.medengphy.2008.09.003 PG 12 WC Engineering, Biomedical SC Engineering GA 386WX UT WOS:000261914400014 PM 18993108 ER PT J AU Pfeiffer, D Sutlief, S Feng, WZ Pierce, HM Kofler, J AF Pfeiffer, Douglas Sutlief, Steven Feng, Wenzheng Pierce, Heather M. Kofler, Jim TI AAPM Task Group 128: Quality assurance tests for prostate brachytherapy ultrasound systems SO MEDICAL PHYSICS LA English DT Article DE biological organs; biomedical ultrasonics; brachytherapy; cancer; dosimetry; image resolution; quality assurance; tumours ID CANCER; SPEED; SOUND AB While ultrasound guided prostate brachytherapy has gained wide acceptance as a primary treatment tool for prostate cancer, quality assurance of the ultrasound guidance system has received very little attention. Task Group 128 of the American Association of Physicists in Medicine was created to address quality assurance requirements specific to transrectal ultrasound used for guidance of prostate brachytherapy. Accurate imaging guidance and dosimetry calculation depend upon the quality and accuracy of the ultrasound image. Therefore, a robust quality assurance program for the ultrasound system is essential. A brief review of prostate brachytherapy and ultrasound physics is provided, followed by a recommendation for elements to be included in a comprehensive test phantom. Specific test recommendations are presented, covering grayscale visibility, depth of penetration, axial and lateral resolution, distance measurement, area measurement, volume measurement, needle template/electronic grid alignment, and geometric consistency with the treatment planning computer. C1 [Pfeiffer, Douglas] Boulder Community Foothills Hosp, Dept Imaging, Boulder, CO 80301 USA. [Sutlief, Steven] VA Puget Sound Hlth Care Syst, VA Med Ctr, Seattle, WA 98108 USA. [Feng, Wenzheng] William Beaumont Hosp, Royal Oak, MI 48073 USA. [Pierce, Heather M.] CIRS Inc, Norfolk, VA 23513 USA. [Kofler, Jim] Mayo Clin, Rochester, MN 55905 USA. RP Pfeiffer, D (reprint author), Boulder Community Foothills Hosp, Dept Imaging, Boulder, CO 80301 USA. EM dpfeiffer@bch.org NR 19 TC 19 Z9 20 U1 0 U2 3 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD DEC PY 2008 VL 35 IS 12 BP 5471 EP 5489 DI 10.1118/1.3006337 PG 19 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 376VB UT WOS:000261210000029 PM 19175107 ER PT J AU Chen, G Jingbo, A Wang, M Farley, S Lee, LY Lee, LC Sawicki, MP AF Chen, Gao Jingbo, A. Wang, Min Farley, Steven Lee, Lung-Yi Lee, Lung-Ching Sawicki, Mark P. TI Menin Promotes the Wnt Signaling Pathway in Pancreatic Endocrine Cells SO MOLECULAR CANCER RESEARCH LA English DT Article ID HISTONE METHYLTRANSFERASE COMPLEX; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; NEOPLASIA TYPE-1; WNT/BETA-CATENIN; GENE-EXPRESSION; STEM-CELLS; TRANSCRIPTION; OSTEOBLAST; GROWTH AB Menin is a tumor suppressor protein mutated in patients with multiple endocrine neoplasia type 1. We show that menin is essential for canonical Wnt/beta-catenin signaling in cultured rodent islet tumor cells. In these cells, overexpression of menin significantly enhances TCF gene assay reporter activity in response to beta-catenin activation. Contrastingly, inhibition of menin expression with Men1 siRNA decreases TCF reporter gene activity. Likewise, multiple endocrine neoplasia type 1 disease associated missense mutations of menin abrogate the ability to increase TCF reporter gene activity. We show that menin physically interacts with proteins involved in the canonical Wnt signaling pathway, including beta-catenin, TCF3 (TCFL1), and weakly with TCF4 (TCFL2). Menin overexpression increases expression of the Wnt/beta-catenin downstream target gene Axing, which is associated with increased H3K4 trimethylation of the Axing gene promoter. Moreover, inhibition of menin expression by siRNA abrogates H3K4 trimethylation and Axing gene expression. Based on these studies, we hypothesized that Wnt signaling could inhibit islet cell proliferation because loss of menin function is thought to increase endocrine tumor cell proliferation. TGP61 rodent islet tumor cells treated with a glycogen synthase kinase 3 beta inhibitor that increases Writ pathway signaling had decreased cell proliferation compared with vehicle-treated cells. Collectively, these data suggest that menin has an essential role in Wnt/beta-catenin signaling through a mechanism that eventually affects histone trimethylation of the downstream target gene Axing, and activation of Wnt/beta-catenin signaling inhibits islet tumor cell proliferation. (Mol Cancer Res 2008;6(12):1894-907) C1 [Sawicki, Mark P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Sawicki, MP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CHS 72-215, Los Angeles, CA 90095 USA. EM msawicki@ucla.edu FU NIH [R01CA095148]; VA Merit FX Grant support: NIH grant R01CA095148 and VA Merit grants (M.P. Sawicki). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. NR 49 TC 23 Z9 25 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 J9 MOL CANCER RES JI Mol. Cancer Res. PD DEC PY 2008 VL 6 IS 12 BP 1894 EP 1907 DI 10.1158/1541-7786.MCR-07-2206 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 385OZ UT WOS:000261824800010 PM 19074834 ER PT J AU Parra, LA Baust, T El Mestikawy, S Quiroz, M Hoffman, B Haflett, JM Yao, JK Torres, GE AF Parra, Leonardo A. Baust, Tracy El Mestikawy, Salah Quiroz, Marisol Hoffman, Beth Haflett, Jack M. Yao, Jeffrey K. Torres, Gonzalo E. TI The Orphan Transporter Rxt1/NTT4 (SLC6A17) Functions as a Synaptic Vesicle Amino Acid Transporter Selective for Proline, Glycine, Leucine, and Alanine SO MOLECULAR PHARMACOLOGY LA English DT Article ID VESICULAR GLUTAMATE TRANSPORTER; CENTRAL-NERVOUS-SYSTEM; INORGANIC-PHOSPHATE COTRANSPORTER; NEUROTRANSMITTER TRANSPORTER; MOLECULAR-CLONING; NMDA RECEPTOR; RAT-BRAIN; ACETYLCHOLINE TRANSPORTER; DEPENDENT TRANSPORTER; EXPRESSION PATTERN AB Rxt1/NTT4 (SLC6A17) belongs to a gene family of "orphan transporters" whose substrates and consequently functions remain unidentified. Although Rxt1/NTT4 was previously thought to function as a sodium-dependent plasma membrane transporter, recent studies localized the protein to synaptic vesicles of glutamatergic and GABAergic neurons. Here, we provide evidence indicating that Rxt1/NTT4 functions as a vesicular transporter selective for proline, glycine, leucine, and alanine. Using Western blot, immunoprecipitation, immunocytochemistry, and polymerase chain reaction approaches, we demonstrate that PC12 cells express the Rxt1/NTT4 gene and protein. Small interfering RNA (siRNA)- mediated knockdown of Rxt1/NTT4 in PC12 cells resulted in selective reductions in uptake levels for proline, glycine, leucine, and alanine. Likewise, gas chromatography analysis of amino acid content in an enriched synaptic vesicle fraction from wild-type and siRNA-Rxt1/NTT4 PC12 cells revealed that proline, glycine, leucine, and alanine levels were decreased in siRNA-treated cells compared with wild-type cells. Furthermore, Rxt1/NTT4-transfected Chinese hamster ovary (CHO) cells exhibited significant uptake increases of these amino acids compared with mock-transfected CHO cells. Finally, proline uptake in both PC12 cells and Rxt1/NTT4-transfected CHO cells was dependent on the electrochemical gradient maintained by the vacuolar-type H+-ATPase. These data indicate that the orphan Rxt1/NTT4 protein functions as a vesicular transporter for proline, glycine, leucine, and alanine, further suggesting its important role in synaptic transmission. C1 [Parra, Leonardo A.; Baust, Tracy; Quiroz, Marisol; Torres, Gonzalo E.] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA. [Parra, Leonardo A.; Baust, Tracy; Quiroz, Marisol; Torres, Gonzalo E.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. [El Mestikawy, Salah] Univ Paris 06, INSERM, U513, Paris, France. [El Mestikawy, Salah] McGill Univ, Dept Psychiat, Douglas Hosp, Res Ctr, Montreal, PQ, Canada. [Hoffman, Beth] Amgen Inc, Dept Neurosci, Thousand Oaks, CA 91320 USA. [Haflett, Jack M.; Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15261 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. RP Torres, GE (reprint author), Univ Pittsburgh, Sch Med, Dept Neurobiol, Room 6061,BST3,3501 5th Ave, Pittsburgh, PA 15261 USA. EM gtorres@pitt.edu FU Amgen research [200620123] FX This work was funded in part by Amgen research agreement 200620123. NR 66 TC 18 Z9 19 U1 0 U2 3 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD DEC PY 2008 VL 74 IS 6 BP 1521 EP 1532 DI 10.1124/mol.108.050005 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 373WG UT WOS:000261003600004 PM 18768736 ER PT J AU Owens, MJ Krulewicz, S Simon, JS Sheehan, DV Thase, ME Carpenter, DJ Plott, SJ Nemeroff, CB AF Owens, Michael J. Krulewicz, Stan Simon, Jeffrey S. Sheehan, David V. Thase, Michael E. Carpenter, David J. Plott, Susan J. Nemeroff, Charles B. TI Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE antidepressant; transporters; reuptake; occupancy; depression; SSRI ID REUPTAKE INHIBITORS; CEREBROSPINAL-FLUID; DOUBLE-BLIND; RESISTANT DEPRESSION; CLINICAL-RESPONSE; MAJOR DEPRESSION; BINDING PROFILE; PLASMA-LEVELS; ANTIDEPRESSANTS; METABOLITES AB Paroxetine and venlafaxine are potent serotonin transporter (SERT) antagonists and weaker norepinephrine transporter ( NET) antagonists. However, the relative magnitude of effect at each of these sites during treatment is unknown. Using a novel blood assay that estimates CNS transporter occupancy we estimated the relative SERT and NET occupancy of paroxetine and venlafaxine in human subjects to assess the relative magnitude of SERT and NET inhibition. Outpatient subjects (N = 86) meeting criteria for major depression were enrolled in a multicenter, 8 week, randomized, double-blind, parallel group, antidepressant treatment study. Subjects were treated by forced-titration of paroxetine CR (12.5-75 mg/day) or venlafaxine XR (75-375 mg/day) over 8 weeks. Blood samples were collected weekly to estimate transporter inhibition. Both medications produced dose-dependent inhibition of the SERT and NET. Maximal SERT inhibition at week 8 for paroxetine and venlafaxine was 90% (SD 7) and 85% ( SD 10), respectively. Maximal NET inhibition for paroxetine and venlafaxine at week 8 was 36% ( SD 19) and 60% ( SD 13), respectively. The adjusted mean change from baseline ( mean 28.6) at week 8 LOCF in MADRS total score was -16.7 ( SE 8.59) and -17.3 ( SE 8.99) for the paroxetine and venlafaxine-treated patients, respectively. The magnitudes of the antidepressant effects were not significantly different from each other (95% CI - 3.42, 4.54, p = 0.784). The results clearly demonstrate that paroxetine and venlafaxine are potent SERT antagonists and less potent NET antagonists in vivo. NET antagonism has been posited to contribute to the antidepressant effects of these compounds. The clinical significance of the magnitude of NET antagonism by both medications remains unclear at present. C1 [Owens, Michael J.; Plott, Susan J.; Nemeroff, Charles B.] Emory Univ, Dept Psychiat & Behav Sci, Sch Med, Lab Neuropsychopharmacol, Atlanta, GA 30322 USA. [Krulewicz, Stan; Carpenter, David J.] GlaxoSmithKline Inc, Neurosci Med Dev Ctr, Clin Psychiat N Amer, King Of Prussia, PA USA. [Simon, Jeffrey S.] Northbrooke Res Ctr, Brown Deer, WI USA. [Sheehan, David V.] Univ S Florida, Dept Psychiat, Tampa, FL USA. [Thase, Michael E.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. RP Owens, MJ (reprint author), Emory Univ, Dept Psychiat & Behav Sci, Sch Med, Lab Neuropsychopharmacol, 101 Woodruff Circle,Suite 4000, Atlanta, GA 30322 USA. EM mowens@emory.edu RI Owens, Michael/G-5191-2012 FU GlaxoSmithKline; NIH [MH-77083, MH-69056, MH-58922, MH-42088, MH-39415, MH-68036] FX We thank Drs Raj Rajani, Murray Rosenthal, and Nicholas Vatakis for their contribution to this study. We also acknowledge Peter Gething, B. S. at INC Research and Mary Kelley, Ph. D ( Departments of Psychiatry and Behavioral Sciences and Biostatistics, Emory University) for performing the statistical analyses and Kathy Sheehan, Ph. D. ( Department of Psychiatry, University of South Florida) for the post hoc MADRS response and remission analyses. This work was supported by a collaborative research grant to MJO from GlaxoSmithKline. The authors are also supported by NIH MH-77083, MH-69056, MH-58922, MH-42088, MH-39415, and MH-68036. NR 43 TC 32 Z9 33 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2008 VL 33 IS 13 BP 3201 EP 3212 DI 10.1038/npp.2008.47 PG 12 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 370GP UT WOS:000260751000021 PM 18418363 ER PT J AU Lara-Castro, C Doud, EC Tapia, PC Munoz, AJ Fernandez, JR Hunter, GR Gower, BA Garvey, WT AF Lara-Castro, Cristina Doud, Erin C. Tapia, Patrick C. Munoz, Andres J. Fernandez, Jose R. Hunter, Gary R. Gower, Barbara A. Garvey, W. Timothy TI Adiponectin Multimers and Metabolic Syndrome Traits: Relative Adiponectin Resistance in African Americans SO OBESITY LA English DT Article ID HIGH-MOLECULAR-WEIGHT; INSULIN SENSITIVITY; GENETIC ADMIXTURE; WAIST CIRCUMFERENCE; SERUM ADIPONECTIN; FAT DISTRIBUTION; RISK-FACTORS; PLASMA; PIOGLITAZONE; ASSOCIATIONS AB African Americans (AAs) tend to have lower total adiponectin levels compared to European Americans (EA); however, it is not known whether race affects adiponectin multimer distribution and their relationships to metabolic traits. We measured total adiponectin, high molecular weight (HMW), low molecular weight (LMW) (i.e., hexamer), and trimer adiponectin in 132 normoglycemic premenopausal women (75 AAs, 57 EAs), together with measures of total and abdominal fat, plasma lipids, insulin sensitivity (S(i)), and genetic admixture estimates. We found that lower total adiponectin in AAs was explained by reduced LMW, and trimer forms because levels of HMW did not differ between races. In EAs, HMW was highly correlated with multiple metabolic syndrome traits. In contrast, the LMW and trimer forms were most highly correlated with metabolic traits in AAs, including abdominal adiposity, lipids, and S(i). At similar levels of visceral adiposity, AAs exhibited significantly lower LMW adiponectin than EAs. Similarly, at comparable levels of HMW and LMW adiponectin, AAs were more insulin resistant than their EA counterparts. In conclusion, (i) serum adiponectin is lower in AAs predominantly as a result of reduced concentrations of LMW and trimers multimeric forms; (ii) LMW and trimer, not HMW, are most broadly correlated with metabolic traits in AAs. Thus, HMW adiponectin may exert less bioactivity in explaining the metabolic syndrome trait cluster in populations of predominant African genetic background. C1 [Lara-Castro, Cristina; Doud, Erin C.; Tapia, Patrick C.; Munoz, Andres J.; Fernandez, Jose R.; Hunter, Gary R.; Gower, Barbara A.; Garvey, W. Timothy] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Lara-Castro, C (reprint author), Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA. EM larac@uab.edu FU NIH [DK 49779, DK51684, DK-38764, PO1 HL-55782]; UAB GCRC [M01-RR00032]; CNRU [P30-DK56336]; T32 grant [HL-007457]; Merit Review program of the Department of Veterans Affairs; Nestle Food Co FX We thank our sources of support: the NIH grants DK 49779, DK51684, DK-38764, and PO1 HL-55782, the UAB GCRC M01-RR00032, the CNRU (P30-DK56336), the T32 grant (HL-007457) (PI: S. Oparil), and the Merit Review program of the Department of Veterans Affairs. We also acknowledge support from Nestle Food Co. for providing Stouffer's Lean Cuisine entrees. NR 44 TC 23 Z9 24 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD DEC PY 2008 VL 16 IS 12 BP 2616 EP 2623 DI 10.1038/oby.2008.411 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 379OJ UT WOS:000261405800008 PM 18820653 ER PT J AU Strack, S AF Strack, Stephen TI The Millon Behavioral Medicine Diagnostic (MBMD) Is a Valid, Reliable, and Relevant Choice for Bariatric Surgery Candidates SO OBESITY SURGERY LA English DT Letter C1 [Strack, Stephen] VA LAACC, Psychol Serv 116B, Los Angeles, CA 90012 USA. [Strack, Stephen] US Dept Vet Affairs, Ctr Ambulatory Care, Los Angeles, CA USA. RP Strack, S (reprint author), VA LAACC, Psychol Serv 116B, 351 E Temple St, Los Angeles, CA 90012 USA. EM snstrack@aol.com NR 8 TC 1 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0960-8923 J9 OBES SURG JI Obes. Surg. PD DEC PY 2008 VL 18 IS 12 BP 1657 EP 1659 DI 10.1007/s11695-008-9689-2 PG 3 WC Surgery SC Surgery GA 392CX UT WOS:000262281600031 PM 18797975 ER PT J AU Inhoff, T Monnikes, H Noetzel, S Stengel, A Goebel, M Dinh, QT Riedl, A Bannert, N Wisser, AS Wiedenmann, B Klapp, BF Tache, Y Kobelt, P AF Inhoff, Tobias Moennikes, Hubert Noetzel, Steffen Stengel, Andreas Goebel, Miriam Dinh, Q. Thai Riedl, Andrea Bannert, Norbert Wisser, Anna-Sophia Wiedenmann, Bertram Klapp, Burghard F. Tache, Yvette Kobelt, Peter TI Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats SO PEPTIDES LA English DT Article DE Rat; Desacyl ghrelin; Ghrelin; Food intake; c-Fos; ARC ID DES-ACYL GHRELIN; HYPOTHALAMIC ARCUATE NUCLEUS; STIMULATES FOOD-INTAKE; FOS EXPRESSION; PARAVENTRICULAR NUCLEUS; CONSCIOUS RATS; PEPTIDE; BRAIN; STOMACH; NEURONS AB Studies showed that the metabolic unlike the neuroendocrine effects of ghrelin could be abrogated by co-administered unacylated ghrelin. The aim was to investigate the interaction between ghrelin and desacyl ghrelin administered intraperitoneally on food intake and neuronal activity (c-Fos) in the arcuate nucleus in non-fasted rats. Ghrelin (13 mu g/kg) significantly increased food intake within the first 30 min post-injection. Desacyl ghrelin at 64 and 127 mu g/kg injected simultaneously with ghrelin abolished the stimulatory effect of ghrelin on food intake. Desacyl ghrelin alone at both doses did not alter food intake. Both doses of desacyl ghrelin injected separately in the light phase had no effects on food intake when rats were fasted for 12 h. Ghrelin and desacyl ghrelin (64 mu g/kg) injected alone increased the number of Fos positive neurons in the arcuate nucleus compared to vehicle. The effect on neuronal activity induced by ghrelin was significantly reduced when injected simultaneously with desacyl ghrelin. Double labeling revealed that nesfatin-1 immunoreactive neurons in the arcuate nucleus are activated by simultaneous injection of ghrelin and desacyl ghrelin. These results suggest that desacyl ghrelin suppresses ghrelin-induced food intake by curbing ghrelin-induced increased neuronal activity in the arcuate nucleus and recruiting nesfatin-1 immunopositive neurons. (c) 2008 Elsevier Inc. All rights reserved. C1 [Dinh, Q. Thai; Riedl, Andrea; Klapp, Burghard F.; Kobelt, Peter] Charite, Div Psychosomat Med & Psychotherapy, Dept Med, D-10117 Berlin, Germany. [Inhoff, Tobias; Noetzel, Steffen; Wisser, Anna-Sophia; Wiedenmann, Bertram; Kobelt, Peter] Charite, Div Hepatol Gastroenterol & Endocrinol, Dept Med, D-10117 Berlin, Germany. [Stengel, Andreas; Goebel, Miriam] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress,Digest Dis Div, Los Angeles, CA 90024 USA. [Stengel, Andreas; Goebel, Miriam; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Moennikes, Hubert] Martin Luther Hosp, Dept Med, Berlin, Germany. [Moennikes, Hubert] Martin Luther Hosp, Inst Neurogastroenterol, Berlin, Germany. [Bannert, Norbert] Robert Koch Inst, D-1000 Berlin, Germany. RP Kobelt, P (reprint author), Charite, Div Psychosomat Med & Psychotherapy, Dept Med, Campus Mitte,Luisenstr 13A, D-10117 Berlin, Germany. EM peter.kobelt@charite.de FU Charite Universitatsmedizin Berlin [UFF 2008-251]; Research Career Scientist Award; Department of Veterans Affairs; NIHDK [R01 33061] FX This work was supported by grants from the Charite Universitatsmedizin Berlin (UFF 2008-251), and grants to Y.T. (Research Career Scientist Award, Department of Veterans Affairs and NIHDK R01 33061). NR 38 TC 103 Z9 109 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD DEC PY 2008 VL 29 IS 12 BP 2159 EP 2168 DI 10.1016/j.peptides.2008.09.014 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 384BG UT WOS:000261718000010 PM 18938204 ER PT J AU Heitjan, DF Asch, DA Ray, R Rukstalis, M Patterson, F Lerman, C AF Heitjan, D. F. Asch, D. A. Ray, Riju Rukstalis, Margaret Patterson, Freda Lerman, C. TI Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment SO PHARMACOGENOMICS JOURNAL LA English DT Article DE addiction; genetic testing; Monte Carlo simulation; tobacco dependence ID NICOTINE REPLACEMENT THERAPY; RECEPTOR PARTIAL AGONIST; SHORT-TERM RESPONSE; TOBACCO DEPENDENCE; TRANSDERMAL NICOTINE; CIGARETTE-SMOKING; SUSTAINED-RELEASE; CONTROLLED-TRIAL; FOLLOW-UP; BUPROPION AB We evaluated the cost-effectiveness of a range of smoking cessation drug treatments, including varenicline, transdermal nicotine (TN), bupropion and the use of a genetic test to choose between TN and bupropion. We performed Monte Carlo simulation with sensitivity analysis, informing analyses with published estimates of model parameters and current prices for genetic testing and smoking-cessation therapy. The primary outcomes were discounted life-years (LY) and lifetime tobacco-cessation treatment costs. In the base case, varenicline treatment was optimal with an ICER, compared to bupropion, of $2985/LY saved. In sensitivity analyses, varenicline was in all cases (and bupropion in most cases) admissible; only under favorable assumptions was the genetically tailored approach competitive. Our data suggest that an untailored approach of treatment with either bupropion or varenicline is a cost-effective form of tobacco dependence treatment, but a tailored approach for selecting between TN and bupropion can be cost-effective under plausible assumptions. C1 [Heitjan, D. F.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Heitjan, D. F.; Asch, D. A.; Lerman, C.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Heitjan, D. F.; Asch, D. A.; Ray, Riju; Rukstalis, Margaret; Patterson, Freda; Lerman, C.] Philadelphia Vet Adm Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Asch, D. A.; Lerman, C.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, D. A.] Univ Penn, Transdisciplinary Tobacco Use Res Ctr, Philadelphia, PA 19104 USA. [Ray, Riju] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Rukstalis, Margaret; Patterson, Freda; Lerman, C.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA. RP Heitjan, DF (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, 622 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM dheitjan@mail.med.upenn.edu RI Ray, Riju/D-1113-2009; Heitjan, Daniel/D-1116-2009 OI Asch, David/0000-0002-7970-286X FU National Cancer Institute [P50 CA084718, R01 CA063562]; National Institutes on Drug Abuse FX We acknowledge the contributions of the following investigators to the pharmacogenetic studies on which this analysis was based: Wade H Berrettini, Susan Crystal-Mansour, Leonard Epstein, Larry Hawk, Vyga Kaufmann, David Main, Ray Niaura, Angela Pinto, Peter Shields, Susan Ware and E Paul Wileyto. We also thank Steven Siegel for helpful comments on an earlier draft.; Sources of funding: This study was supported by Grants P50 CA084718 from the National Cancer Institute and National Institutes on Drug Abuse and R01 CA063562 from the National Cancer Institute, which had no role in its design, conduct or reporting. NR 62 TC 21 Z9 23 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1470-269X J9 PHARMACOGENOMICS J JI Pharmacogenomics J. PD DEC PY 2008 VL 8 IS 6 BP 391 EP 399 DI 10.1038/sj.tpj.6500492 PG 9 WC Genetics & Heredity; Pharmacology & Pharmacy SC Genetics & Heredity; Pharmacology & Pharmacy GA 372CC UT WOS:000260878100004 PM 18347612 ER PT J AU Hill, AS Nishino, A Nakajo, K Zhang, GX Fineman, JR Selzer, ME Okamura, Y Cooper, EC AF Hill, Alexis S. Nishino, Atsuo Nakajo, Koichi Zhang, Giuxin Fineman, Jaime R. Selzer, Michael E. Okamura, Yasushi Cooper, Edward C. TI Ion Channel Clustering at the Axon Initial Segment and Node of Ranvier Evolved Sequentially in Early Chordates SO PLOS GENETICS LA English DT Article ID KCNQ POTASSIUM CHANNELS; K+ CHANNEL; ANKYRIN-G; NEURAL CREST; ANTICONVULSANT RETIGABINE; MOLECULAR EVOLUTION; ANTIEPILEPTIC DRUGS; SPIKE INITIATION; VOLTAGE SENSOR; MOTOR-NEURON AB In many mammalian neurons, dense clusters of ion channels at the axonal initial segment and nodes of Ranvier underlie action potential generation and rapid conduction. Axonal clustering of mammalian voltage-gated sodium and KCNQ (Kv7) potassium channels is based on linkage to the actin-spectrin cytoskeleton, which is mediated by the adaptor protein ankyrin-G. We identified key steps in the evolution of this axonal channel clustering. The anchor motif for sodium channel clustering evolved early in the chordate lineage before the divergence of the wormlike cephalochordate, amphioxus. Axons of the lamprey, a very primitive vertebrate, exhibited some invertebrate features ( lack of myelin, use of giant diameter to hasten conduction), but possessed narrow initial segments bearing sodium channel clusters like in more recently evolved vertebrates. The KCNQ potassium channel anchor motif evolved after the divergence of lampreys from other vertebrates, in a common ancestor of shark and humans. Thus, clustering of voltage-gated sodium channels was a pivotal early innovation of the chordates. Sodium channel clusters at the axon initial segment serving the generation of action potentials evolved long before the node of Ranvier. KCNQ channels acquired anchors allowing their integration into pre-existing sodium channel complexes at about the same time that ancient vertebrates acquired myelin, saltatory conduction, and hinged jaws. The early chordate refinements in action potential mechanisms we have elucidated appear essential to the complex neural signaling, active behavior, and evolutionary success of vertebrates. C1 [Hill, Alexis S.; Zhang, Giuxin; Fineman, Jaime R.; Selzer, Michael E.; Cooper, Edward C.] Univ Penn, Dept Neurol, Penn Epilepsy Ctr, Philadelphia, PA 19104 USA. [Hill, Alexis S.; Zhang, Giuxin; Fineman, Jaime R.; Selzer, Michael E.; Cooper, Edward C.] David Mahoney Inst Neurol Sci, Philadelphia, PA 19104 USA. [Nishino, Atsuo] Osaka Univ, Grad Sch Sci, Dept Biol, Dev Biol Lab, Osaka, Japan. [Nakajo, Koichi] Natl Inst Physiol Sci, Okazaki, Aichi 444, Japan. [Selzer, Michael E.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA. [Okamura, Yasushi] Osaka Univ, Grad Sch Med, Dept Integrat Physiol, Osaka, Japan. RP Cooper, EC (reprint author), Univ Penn, Dept Neurol, Penn Epilepsy Ctr, Philadelphia, PA 19104 USA. EM edc@mail.med.upenn.edu RI Nakajo, Koichi/H-4104-2011; Nishino, Atsuo/F-5393-2013 FU NIH [R01-NS14837, R01NS38537, R24-HD050838]; US-Japan Brain Research Cooperative Program [R01 NS49119] FX This work was supported by the Roy and Diana Vagelos Scholars Program in the Molecular Life Sciences ( AH), NIH Grants R01-NS14837( MES), R01NS38537 ( MES), R24-HD050838 ( MES), the Craig H. Neilsen Foundation ( MES), a Japan- U. S. Brain Research Cooperative Program Grant ( YO), a Human Frontiers Science Program Short Term Fellowship ( ECC), a US-Japan Brain Research Cooperative Program Supplement ( R01 NS49119, ECC), and the Miles Family Fund ( ECC). The funders had no role in study design, conduct, data interpretation, or manuscript preparation. NR 107 TC 62 Z9 64 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD DEC PY 2008 VL 4 IS 12 AR e1000317 DI 10.1371/journal.pgen.1000317 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 411RO UT WOS:000263667900032 PM 19112491 ER PT J AU Gray, KM LaRowe, SD Upadhyaya, HP AF Gray, Kevin M. LaRowe, Steven D. Upadhyaya, Himanshu P. TI Cue Reactivity in Young Marijuana Smokers: A Preliminary Investigation SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS LA English DT Article DE marijuana; cannabis; craving; cue reactivity; adolescent ID ADOLESCENT CIGARETTE SMOKERS; CRAVING QUESTIONNAIRE; CANNABIS WITHDRAWAL; SMOKING CUES; IN-VIVO; ALCOHOL; DEPENDENCE; USERS AB To develop and evaluate the feasibility of a cue reactivity paradigm for young marijuana smokers, the authors set up a laboratory procedure involving neutral and marijuana-related imagery, video, and in vivo cues. Fifteen adolescents and young adults with cannabis use disorders completed the procedure, which included continuous measurement of skin conductance and heart rate. Participants also completed questionnaires regarding marijuana craving before, during, and after cue presentations. Higher levels of craving and skin conductance were observed during marijuana cue presentations. The procedure appears to elicit cue reactivity among adolescents and young adults with cannabis use disorders and should be further evaluated and refined with a larger sample. Implications for future studies are discussed. C1 [Gray, Kevin M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Youth Div, Charleston, SC 29425 USA. [LaRowe, Steven D.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA. [LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Subst Abuse Treatment Ctr, Charleston, SC USA. [Upadhyaya, Himanshu P.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Div Clin Neurosci, Charleston, SC 29425 USA. RP Gray, KM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Youth Div, 67 President St,POB 250861, Charleston, SC 29425 USA. EM graykm@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU NCRR NIH HHS [M01 RR 01070, M01 RR001070, M01 RR001070-29]; NIDA NIH HHS [5K12 DA 000357, K12 DA000357, K12 DA000357-07] NR 28 TC 26 Z9 26 U1 3 U2 3 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0893-164X J9 PSYCHOL ADDICT BEHAV JI Psychol. Addict. Behav. PD DEC PY 2008 VL 22 IS 4 BP 582 EP 586 DI 10.1037/a0012985 PG 5 WC Substance Abuse; Psychology, Multidisciplinary SC Substance Abuse; Psychology GA 380JO UT WOS:000261462200015 PM 19071985 ER PT J AU Zhang, XY Cao, LY Song, C Wu, GY Chen, DC Qi, LY Wang, F Xiu, MH Chen, S Zhang, YY Lu, L Kosten, TA Kosten, TR AF Zhang, Xiang Yang Cao, Lian Yuan Song, Cai Wu, Gui Ying Chen, Da Chun Qi, Ling Yan Wang, Fan Xiu, Mei Hong Chen, Song Zhang, Yingyang Lu, Lin Kosten, Therese A. Kosten, Thomas R. TI Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics SO PSYCHOPHARMACOLOGY LA English DT Article DE Schizophrenia; Smoking; Nicotine; Cytokine; Immune ID NICOTINE DEPENDENCE; CIGARETTE-SMOKING; NEUROLEPTIC TREATMENT; INTERLEUKIN-2; PSYCHOPATHOLOGY; ASSOCIATION; RECEPTORS; IL-2; RESISTANT; CELLS AB Schizophrenia is associated with various abnormalities in the immune system. Suppression of inflammatory cytokines by cigarette smoke is well-established. The purpose of this study was to determine any differences in cytokine profiles in smokers and nonsmokers with schizophrenia and whether there were any relationships among altered cytokine profiles and psychopathological symptoms. Serum interleukin (IL)-2, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha levels were measured in 96 male inpatients with DSM-IV schizophrenia: 66 smokers and 30 nonsmokers. Symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). The positive PANSS symptoms were lower in smokers than nonsmokers, while the negative symptoms were lower in those who smoked more cigarettes. Cytokine levels were positively correlated: IL-2 level with IL-6 and IL-6 with both IL-8 and TNF-alpha. Both IL-2 and IL-6, but not IL-8 or TNF-alpha, were significantly lower in smokers than nonsmokers (p < 0.002; p < 0.01). Lower IL-2 levels correlated with fewer negative symptoms and with smoking more cigarettes. The fewer positive symptoms in smokers and fewer negative symptoms in those who smoked more cigarettes may be associated with nicotine-induced suppression of some inflammatory cytokines. C1 [Zhang, Xiang Yang; Wu, Gui Ying; Zhang, Yingyang; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang; Cao, Lian Yuan; Chen, Da Chun; Qi, Ling Yan; Wang, Fan; Xiu, Mei Hong; Chen, Song; Zhang, Yingyang] Beijing Hui Long Guan Hosp, Ctr Biol Psychiat, Beijing, Peoples R China. [Song, Cai] Univ Prince Edward Isl, Atlantic Vet Coll, Dept Biomed Sci, Charlottetown, PE C1A 4P3, Canada. [Song, Cai] NRC Inst Nutrisci & Hlth, Charlottetown, PE, Canada. [Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100871, Peoples R China. RP Kosten, TR (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 110,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu; kosten@bcm.edu FU NIDA NIH HHS [K05-DA0454, P50-DA18827] NR 51 TC 19 Z9 19 U1 3 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD DEC PY 2008 VL 201 IS 3 BP 383 EP 389 DI 10.1007/s00213-008-1295-4 PG 7 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 374IP UT WOS:000261037300007 PM 18719893 ER PT J AU Rubenstein, LV Hempel, S Farmer, MM Asch, SM Yano, EM Dougherty, D Shekelle, PW AF Rubenstein, L. V. Hempel, S. Farmer, M. M. Asch, S. M. Yano, E. M. Dougherty, D. Shekelle, P. W. TI Finding order in heterogeneity: types of quality-improvement intervention publications SO QUALITY & SAFETY IN HEALTH CARE LA English DT Article ID PATIENT-OUTCOMES-RESEARCH; RANDOMIZED CLINICAL-TRIALS; HEALTH-CARE; ORGANIZATIONAL-CHANGE; TRANSLATING RESEARCH; SYSTEMATIC REVIEWS; ASTHMA-CARE; DESIGN; IMPLEMENTATION; POLICY AB Background: Stakeholders in quality improvement agree on the need for augmenting and synthesising the scientific literature supporting it. The diversity of perspectives, approaches, and contexts critical to advancing quality improvement science, however, creates challenges. The paper explores the heterogeneity in clinical quality improvement intervention (QII) publications. Methods: A preliminary classification framework was developed for QII articles, aiming for categories homogeneous enough to support coherent scientific discussion on QII reporting standards and facilitate systematic review. QII experts were asked to identify articles important to QII science. The framework was tested and revised by applying it to the article set. The final framework screened articles into (1) empirical literature on development and testing of QIIs; (2) QII stories, theories, and frameworks; (3) QII literature syntheses and meta-analyses; or (4) development and testing of QII-related tools. To achieve homogeneity, category (1) required division into (1a) development of QIIs; 1(b) history, documentation, or description of QIIs; or (1c) success, effectiveness or impact of QIIs. Results: By discussing unique issues and established standards relevant to each category, QII stakeholders can advance QII practice and science, including the scope and conduct of systematic literature reviews. C1 [Rubenstein, L. V.; Farmer, M. M.; Asch, S. M.; Yano, E. M.; Shekelle, P. W.] Vet Affairs Greater Los Angeles Healthcare Syst S, North Hills, CA 91343 USA. [Rubenstein, L. V.; Hempel, S.; Asch, S. M.; Shekelle, P. W.] RAND Corp, Santa Monica, CA USA. [Rubenstein, L. V.; Yano, E. M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Rubenstein, L. V.; Asch, S. M.; Shekelle, P. W.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Dougherty, D.] Agcy Healthcare Res & Qual, Rockville, MD USA. RP Rubenstein, LV (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst S, 16111 Plummer St 152, North Hills, CA 91343 USA. EM lisa_rubenstein@rand.org FU Agency for Healthcare Research and Quality (AHRQ) [HHSP233200400717P]; Centers for Disease Control and Prevention FX Agency for Healthcare Research and Quality (AHRQ) under a contract to LVR ( contract no HHSP233200400717P) funded by an Interagency Agreement between AHRQ and the Centers for Disease Control and Prevention. NR 98 TC 31 Z9 31 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1475-3898 J9 QUAL SAF HEALTH CARE JI Qual. Saf. Health Care PD DEC PY 2008 VL 17 IS 6 BP 403 EP 408 DI 10.1136/qshc.2008.028423 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 380YK UT WOS:000261501800004 PM 19064654 ER PT J AU Siegel, RE AF Siegel, Robert E. TI Emerging Gram-Negative Antibiotic Resistance: Daunting Challenges, Declining Sensitivities, and Dire Consequences Response SO RESPIRATORY CARE LA English DT Letter C1 James J Peters Vet Affairs Med Ctr, Intens Care Unit, Bronx, NY USA. RP Siegel, RE (reprint author), James J Peters Vet Affairs Med Ctr, Intens Care Unit, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD DEC PY 2008 VL 53 IS 12 BP 1750 EP 1750 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 381BZ UT WOS:000261511100020 ER PT J AU Kasinath, BS Mariappan, MM Sataranatarajan, K Lee, MJ Choudhury, GG Feliers, D AF Kasinath, B. S. Mariappan, M. M. Sataranatarajan, K. Lee, M. J. Choudhury, G. Ghosh Feliers, D. TI Novel mechanisms of protein synthesis in diabetic nephropathy-role of mRNA translation SO REVIEWS IN ENDOCRINE & METABOLIC DISORDERS LA English DT Article DE Protein synthesis; MicroRNA; Signaling reactions; Insulin; Glucose; Angiotensin II; Vascular endothelial growth factor ID RENAL EPITHELIAL-CELLS; GLYCOGEN-SYNTHASE KINASE-3; ANGIOTENSIN-II; INITIATION-FACTOR; SIGNALING PATHWAYS; MAMMALIAN TARGET; GENE-EXPRESSION; LET-7 MICRORNA; HIGH GLUCOSE; HNRNP-K AB Ambient protein levels are affected by both synthesis and degradation. Synthesis of a protein is regulated by transcription and messenger RNA (mRNA) translation. Translation has emerged as an important site of regulation of protein expression during development and disease. It is under the control of distinct factors that regulate initiation, elongation and termination phases. Regulation of translation occurs via signaling reactions, guanosine diphosphate-guanosine triphosphate binding and by participation of non-coding RNA species such as microRNA. Recent work has revealed an important role for translation in hypertrophy, matrix protein synthesis, elaboration of growth factors in in vivo and in vitro models of diabetic nephropathy. Studies of translation dysregulation in diabetic nephropathy have enabled identification of novel therapeutic targets. Translation of mRNA is a fertile field for exploration in investigation of kidney disease. C1 [Kasinath, B. S.; Mariappan, M. M.; Sataranatarajan, K.; Lee, M. J.; Choudhury, G. Ghosh; Feliers, D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, OBrien Kidney Res Ctr, San Antonio, TX 78229 USA. [Kasinath, B. S.; Mariappan, M. M.; Sataranatarajan, K.; Lee, M. J.; Choudhury, G. Ghosh; Feliers, D.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kasinath, BS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, OBrien Kidney Res Ctr, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kasinath@uthscsa.edu FU O'Brien Kidney Research Center, BSK, JLB [NIH-DK061597]; BSK [NIH-DK077295]; American Diabetes Association [7-05-RA-60]; VA Research Service; Juvenile Diabetes Research Foundation [3-2007-245]; American Heart Association [SDG 0630283N]; VA Research Career Scientist Award; [NIH-DK050190] FX Studies were supported by grants from the NIH-DK061597 (O'Brien Kidney Research Center, BSK, JLB), NIH-DK077295 (BSK), American Diabetes Association-7-05-RA-60 (BSK), VA Research Service (BSK, GGC, JLB), Juvenile Diabetes Research Foundation-3-2007-245 (MMM/BSK), NIH-DK050190 (GGC), American Heart Association SDG 0630283N (DF). GGC is a recipient of the VA Research Career Scientist Award. NR 83 TC 7 Z9 8 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1389-9155 J9 REV ENDOCR METAB DIS JI Rev. Endocr. Metab. Disord. PD DEC PY 2008 VL 9 IS 4 BP 255 EP 266 DI 10.1007/s11154-008-9091-3 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 365BB UT WOS:000260379800002 PM 18654857 ER PT J AU Byne, W Tatusov, A Yiannoulos, G Vong, GS Marcus, S AF Byne, William Tatusov, Alex Yiannoulos, Georgia Vong, Ghe S. Marcus, Sue TI Effects of mental illness and aging in two thalamic nuclei SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Bipolar disorder; Psychosis; Aging; Oligodendrocyte; Myelin ID ANTERIOR CINGULATE CORTEX; MAJOR DEPRESSIVE DISORDER; EFFERENT CONNECTIONS; NEURON NUMBER; OLIGODENDROCYTE DYSFUNCTION; NEUROPATHOLOGY CONSORTIUM; HIPPOCAMPAL-FORMATION; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; BIPOLAR DISORDER AB We previously reported a schizophrenia associated reduction of neuronal and oligodendrocyte number in the anterior principal thalamic nucleus (APN) in a cohort of severely impaired elderly subjects with schizophrenia (SZ) relative to age matched nonpsychiatric controls (NCs). The present study was undertaken to determine 1) if those findings could be replicated in an independent sample of less chronically impaired subjects with SZ and NCs stratified across a broader age range; 2) if the findings are specific to SZ or are also seen in unipolar major depressive (MDD) or bipolar disorder (BPD); and 3) if the findings are specific to the APN or also seen in another thalamic nucleus. Computer assisted stereological methods were employed to determine the number of neurons and oligodendrocytes in the APN and centromedian nucleus (CMN) of the Nissl-stained thalamic sections maintained by the Stanley Foundation Brain Bank. This collection includes specimens from NCs and age matched subjects with diagnoses of SZ, MDD, or BPD who died between the ages of 25 and 68. Data were analyzed by mixed-effects linear regressions adjusting for demographic variables and known history of exposure to psychotropic medications. Oligodendrocyte number was decreased in both nuclei relative to NCs in subjects with SZ and in that subset of subjects with BPD who had experienced psychotic episodes. Compared to NCs both of these patient groups also exhibited an attenuation of an age-related increase in the number of oligodendrocytes. Contrary to our previous report, we did not detect a SZ-associated deficit in neuronal number in the APN. A history of exposure to neuroleptics, however, was associated with a decrease in neuronal number in both nuclei, but this decrease did not vary in relation to cumulative lifetime neuroleptic exposure in fluphenazine equivalents. Among subjects with psychiatric diagnoses, exposure to lithium was associated with an increase in the number of oligodendrocytes. No effects were detected for exposure to anticonvulsants or for abuse of alcohol or other substances. Published by Elsevier B.V. C1 [Byne, William; Tatusov, Alex; Yiannoulos, Georgia; Vong, Ghe S.] Bronx Vet Affairs Med Ctr, Div Basic & Lab Res, Bronx, NY 10468 USA. [Byne, William; Tatusov, Alex; Vong, Ghe S.; Marcus, Sue] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. RP Byne, W (reprint author), Bronx Vet Affairs Med Ctr, Div Basic & Lab Res, Res Bldg Rm 2F37,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM william.byne@mssm.edu FU NIH [MH66998, MH45212]; Veterans Merit Review Award FX Supported by the Veterans Integrated Services Network-3 Mental Illness Research, Education and Clinical Center, NIH grants MH66998, MH45212 and a Veterans Merit Review Award. NR 57 TC 17 Z9 18 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2008 VL 106 IS 2-3 BP 172 EP 181 DI 10.1016/j.schres.2008.08.023 PG 10 WC Psychiatry SC Psychiatry GA 385YU UT WOS:000261850300010 PM 18835520 ER PT J AU Escamilla, M Lee, BD Ontiveros, A Raventos, H Nicolini, H Mendoza, R Jerez, A Munoz, R Medina, R Figueroa, A Walss-Bass, C Armas, R Contreras, S Ramirez, ME Dassori, A AF Escamilla, Michael Lee, Byung Dae Ontiveros, Alfonso Raventos, Henriette Nicolini, Humberto Mendoza, Ricardo Jerez, Alvaro Munoz, Rodrigo Medina, Rolando Figueroa, Andres Walss-Bass, Consuelo Armas, Regina Contreras, Salvador Ramirez, Mercedes E. Dassori, Albana TI The epsin 4 gene is associated with psychotic disorders in families of Latin American origin SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Epsin 4 gene; Schizophrenia; Phenotype; Biobehavioral Science; Single nucleotide polymorphisms (SNPs) ID LINKAGE DISEQUILIBRIUM; SCHIZOPHRENIA; SUSCEPTIBILITY; CLATHRIN; ENTHOPROTIN; SUPPORT; LOCUS AB This study attempted to replicate evidence for association of the Epsin 4 gene (which encodes enthoprotin, a protein involved in vesicular transport) to schizophrenia in a new sample of families segregating schizophrenia drawn from the Latin American population. 1423 subjects (767 with a history of psychosis) from 337 Latino families were genotyped using three single nucleotide polymorphisms (SNPs) spanning the Epsin 4 gene. A family based association test was utilized to test for association of these SNPs to the phenotypes of psychosis and schizophrenia. Haplotypes defined by these three SNPs showed significant association to the phenotype of psychosis in this sample (global p value=0.014, bi-allelic p value=0.047). Variation in the Epsin 4 gene is significantly associated with psychotic disorder in this Latino population. This provides additional support for the involvement of enthoprotin in the pathogenesis of schizophrenia and other psychotic disorders. (C) 2008 Elsevier B.V. All rights reserved. C1 [Escamilla, Michael; Lee, Byung Dae; Medina, Rolando; Walss-Bass, Consuelo; Contreras, Salvador; Ramirez, Mercedes E.; Dassori, Albana] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Psychiat Genet Res Center, San Antonio, TX 78229 USA. [Ontiveros, Alfonso] Inst Informac & Invest Salud Mental, Monterrey, Mexico. [Raventos, Henriette] Univ Costa Rica, Ctr Invest Biol & Mol, San Jose, Costa Rica. [Medina, Rolando; Dassori, Albana] S Texas Vet Hlth Syst, Dept Psychiat, San Antonio, TX USA. [Nicolini, Humberto] Gep Estudios Med & Familiares Carracci SC, Mexico City, DF, Mexico. [Mendoza, Ricardo] Univ Calif Los Angeles, Harbor Med Ctr, Dept Psychiat & Biobehav Sci, Torrance, CA 90509 USA. [Jerez, Alvaro] Ctr Invest Biomed, Guatemala City, Guatemala. [Munoz, Rodrigo] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Escamilla, Michael; Figueroa, Andres] Univ Texas Hlth Sci Ctr San Antonio, Reg Acad Hlth Ctr, S Texas Med Genet Res Group, Edinburg, TX USA. [Armas, Regina] Univ Calif San Francisco, Langley Porter Psychiat Inst, San Francisco, CA 94143 USA. [Figueroa, Andres] Univ Texas Pan Amer, Dept Comp Sci, Edinburg, TX 78541 USA. RP Escamilla, M (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, Psychiat Genet Res Center, 7703 Floyd Curl Dr MC 7789, San Antonio, TX 78229 USA. EM escamillam@uthscsa.edu OI Nicolini, Humberto/0000-0003-2494-0067; Raventos, Henriette/0000-0001-9423-8308; Jerez Magana, Alvaro Antonio/0000-0002-1208-3769 FU International Neuro-Genetics Association of Spanish America and the United States (INGASU); NIMH; University of Texas Health Science Center at San Antonio [MH60881]; University of California at Los Angeles-Harbor [MH60875] FX Additional principal investigators who participated in these grants were Dr. Henriette Raventos (University of Costa Rica, San Jose, Costa Rica), Dr. Alfonso Ontiveros (Instituto de Informacion de Investigacion en Salud Mental. Monterrey, Mexico), Dr. Humberto Nicolini (Medical and Family Research Group. Carracci S.C., Mexico City. Mexico). Dr. Rodrigo Munoz (Family Health Centers of San Diego, California), and Dr. Alvaro Jerez (Centro Internacional de Trastornos Afectivos y de la Conducta Adictiva-CITACA, Guatemala). Additional investigators from the University ofTexas Health Science Center at San Antonio included Dr. Albana Dassori and Dr. Rolando Medina. NR 19 TC 8 Z9 9 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2008 VL 106 IS 2-3 BP 253 EP 257 DI 10.1016/j.schres.2008.09.005 PG 5 WC Psychiatry SC Psychiatry GA 385YU UT WOS:000261850300020 PM 18929466 ER PT J AU Chen, DC Qi, LY Xiu, MH Cao, LY Wang, F Chen, S Wu, GY Kosten, TA Kosten, TR Zhang, XY AF Chen, Da Chun Qi, Ling Yan Xiu, Mei Hong Cao, Lian Yuan Wang, Fan Chen, Song Wu, Gui Ying Kosten, Therese A. Kosten, Thomas R. Zhang, Xiang Yang TI Elevated serum levels of tumor necrosis factor-alpha in clozapine-associated obesity in chronic schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Letter ID WEIGHT-GAIN; CACHEXIA; MICE; TNF C1 [Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Chen, Da Chun; Qi, Ling Yan; Xiu, Mei Hong; Cao, Lian Yuan; Wang, Fan; Chen, Song] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. RP Kosten, TR (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA. FU NIDA NIH HHS [K05-DA0454, P50-DA18827] NR 9 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2008 VL 106 IS 2-3 BP 367 EP 368 DI 10.1016/j.schres.2008.08.030 PG 2 WC Psychiatry SC Psychiatry GA 385YU UT WOS:000261850300037 PM 18835132 ER PT J AU Xiu, MH Chen, S Wang, F Cao, LY Qi, LY Chen, DC Lu, L Wu, GY Kosten, TA Kosten, TR Zhang, XY AF Xiu, Mei Hong Chen, Song Wang, Fan Cao, Lian Yuan Qi, Ling Yan Chen, Da Chun Lu, Lin Wu, Gui Ying Kosten, Therese A. Kosten, Thomas R. Zhang, Xiang Yang TI Altered interleukin-3 serum levels in drug-naive and neuroleptic-treated schizophrenic patients SO SCHIZOPHRENIA RESEARCH LA English DT Letter C1 [Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100083, Peoples R China. [Xiu, Mei Hong; Chen, Song; Wang, Fan; Cao, Lian Yuan; Qi, Ling Yan; Chen, Da Chun] Beijing HuiLongGuan Hosp, Ctr Biol Psychiat, Beijing 100096, Peoples R China. RP Kosten, TR (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM kosten@bcm.edu; xyzhang@bcm.edu FU NIDA NIH HHS [P50-DA18827, K05-DA0454] NR 8 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2008 VL 106 IS 2-3 BP 369 EP 370 DI 10.1016/j.schres.2008.09.001 PG 2 WC Psychiatry SC Psychiatry GA 385YU UT WOS:000261850300038 PM 18838250 ER PT J AU Burgess, DJ Crowley-Matoka, M Phelan, S Dovidio, JF Kerns, R Roth, C Saha, S van Ryn, M AF Burgess, Diana Jill Crowley-Matoka, Megan Phelan, Sean Dovidio, John F. Kerns, Robert Roth, Craig Saha, Somnath van Ryn, Michelle TI Patient race and physicians' decisions to prescribe opioids for chronic low back pain SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE USA; Health disparities; Chronic pain; Medical decision-making; Race; Men; Prescribing ID PRIMARY-CARE PHYSICIANS; CORONARY-HEART-DISEASE; CHRONIC NONCANCER PAIN; PROVIDERS CONTRIBUTE; ETHNIC DISPARITIES; RACIAL-DIFFERENCES; RACE/ETHNICITY; GENDER; HEALTH; COMMUNICATION AB Nonwhite patients are less likely than white patients to have their pain adequately treated. This study examined the influence of patient race and patient verbal and nonverbal behavior on primary care physicians' treatment decisions for chronic low back pain in men. We randomly assigned physicians to receive a paper-based, clinical vignette of a chronic pain patient that differed in terms of patient race (white vs. black), verbal behavior ("challenging" vs. "non-challenging"), and nonverbal behavior (confident vs. dejected vs. angry). We employed a between-subjects factorial design and surveyed primary care physicians (N = 382), randomly selected from the American Medical Association Physician Masterfile. The primary dependent measure was the physician's decision as to whether (s)he would switch the patient to a higher dose or stronger type of opioid. Logistic regression was used to determine the effects of patient characteristics on physicians' prescribing decisions. There was a significant interaction between patient verbal behavior and patient race on physicians' decisions to prescribe opioids. Among black patients, physicians were significantly more likely to state that they would switch to a higher dose or stronger opioid for patients exhibiting "challenging" behaviors (e.g., demanding a specific narcotic, exhibiting anger) compared to those exhibiting "non-challenging" behaviors (55.1%). For white patients there was an opposite pattern of results in which physicians were slightly more likely to escalate treatment for patients exhibiting "non-challenging" (64.3%) vs. "challenging" (54.5%) verbal behaviors. Results point to the need for better understanding of the way a complex interplay of non-clinical characteristics affects physician behavior in order to improve quality of pain management and other clinical decision-making. Published by Elsevier Ltd. C1 [Burgess, Diana Jill] VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55419 USA. [Burgess, Diana Jill; Roth, Craig] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Crowley-Matoka, Megan] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Crowley-Matoka, Megan] Pittsburgh Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Crowley-Matoka, Megan] Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA 15260 USA. [Phelan, Sean] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA. [Dovidio, John F.] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. [Kerns, Robert; Saha, Somnath] Yale Univ, Dept Psychiat, VA Connecticut Healthcare Syst, New Haven, CT 06520 USA. [Kerns, Robert; Saha, Somnath] Yale Univ, Dept Neurol, VA Connecticut Healthcare Syst, New Haven, CT 06520 USA. [Kerns, Robert; Saha, Somnath] Yale Univ, Dept Psychol, VA Connecticut Healthcare Syst, New Haven, CT 06520 USA. [Roth, Craig] Univ Minnesota, Minneapolis Vet Affairs Med Ctr, Minneapolis, MN 55455 USA. [van Ryn, Michelle] Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA. [van Ryn, Michelle] Univ Minnesota, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA. [Saha, Somnath] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. [Saha, Somnath] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. RP Burgess, DJ (reprint author), VA Med Ctr, Ctr Chron Dis Outcomes Res, 1 Vet Dr, Minneapolis, MN 55419 USA. EM diana.burgess@med.va.gov; mcm29@imap.pitt.edu; phel0085@umn.edu; john.dovidio@yale.edu; robert.kerns@va.gov; craig.roth@va.gov; sahas@ohsu.edu; vanry001@umn.edu RI VAN RYN, MICHELLE/B-1664-2010; Burgess, Diana/A-1946-2016 NR 62 TC 43 Z9 43 U1 3 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD DEC PY 2008 VL 67 IS 11 BP 1852 EP 1860 DI 10.1016/j.socscimed.2008.09.009 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 383EZ UT WOS:000261658200025 PM 18926612 ER PT J AU Bryce, CL Zickmund, S Hess, R McTigue, KM Olshansky, E Fitzgerald, K Fischer, G AF Bryce, Cindy L. Zickmund, Susan Hess, Rachel McTigue, Kathleen M. Olshansky, Ellen Fitzgerald, Katharine Fischer, Gary TI Value Versus User Fees: Perspectives of Patients Before and After Using a Web-Based Portal for Management of Diabetes SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Article DE diabetes; user fee; access fee; patient portal; quantitative and qualitative methods ID SELF-MANAGEMENT; HEALTH RECORDS; COMMUNICATION; IMPLEMENTATION; INFORMATION AB The objective of this work was to rate the potential or actual usefulness of 15 features of a Web-based portal for diabetes management and assess whether patients would be willing to pay user fees for portal access. We used a combination of qualitative methods (focus group discussions) and quantitative methods (survey responses) to examine patients' perspectives. We enrolled 21 patients before the diabetes-specific portal was released ("preportal" group) and 18 patients after it was released ("portal-users" group). The two groups were similar except that 67% of preportal patients and 100% of portal users were Internet users. Overall, portal features that were rated most favorably were the online calculator to estimate blood glucose control (characterized as "very useful" by 74% of patients), appointment reminder systems (74%), e-mail access to health team (74%), personal tracking logs (69%), and online scheduling (69%). More patients from the preportal group than the portal-users group favored personal logs (86% versus 50%; p = 0.015) and opportunities to form interest groups (62% versus 28%; p = 0.034). Of the 30 patients who assigned a dollar amount for 1 month of portal access, 20 assigned zero dollars. Discussions about payment focused on equity and access. Because fees are expected to discourage portal usage, many patients believed that the potential benefits associated with self-management would not be realized. Others felt that the health system would benefit financially from a portal and should therefore absorb the costs. Even if portals are valued, patients may be resistant to paying for them. This opposition stems from concerns about fairness and from the recognition that health systems may experience cost savings if patients manage their diabetes successfully. C1 [Bryce, Cindy L.; Zickmund, Susan; Hess, Rachel; McTigue, Kathleen M.; Fitzgerald, Katharine; Fischer, Gary] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Bryce, Cindy L.; Zickmund, Susan; Hess, Rachel; McTigue, Kathleen M.; Olshansky, Ellen; Fitzgerald, Katharine; Fischer, Gary] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Bryce, Cindy L.] Univ Pittsburgh, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA 15213 USA. [Bryce, Cindy L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA. [Zickmund, Susan] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Olshansky, Ellen] Univ Calif Irvine, Coll Hlth Sci, Program Nursing Sci, Irvine, CA USA. RP Bryce, CL (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM brycecl@upmc.edu OI Bryce, Cindy/0000-0001-6356-6675 FU United States Air Force [W81XWH-04-2-003]; VA Health Services Research and Development Merit Review FX Portions of this research were sponsored by funding from the United States Air Force, administered by the U. S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland, Award Number W81XWH-04-2-003. Review of material does not imply Department of the Air Force endorsement of factual accuracy or opinion. Dr. Zickmund is supported by a VA Health Services Research and Development Merit Review Grant. NR 17 TC 13 Z9 13 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD DEC PY 2008 VL 14 IS 10 BP 1035 EP 1043 DI 10.1089/tmj.2008.0005 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 394UD UT WOS:000262473600004 PM 19119825 ER PT J AU Armstrong, D Lipsky, B Boulton, A AF Armstrong, David Lipsky, Benjamin Boulton, Andrew TI A Closer Look At The Prevalence Of MRSA And Its Impact On Empiric Therapy SO WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE LA English DT Article C1 [Armstrong, David] Univ Arizona, Coll Med, SALSA, Tucson, AZ 85721 USA. [Boulton, Andrew] Univ Manchester, Manchester M13 9PL, Lancs, England. Coatesville Vet Affairs Med Ctr, Coatesville, PA USA. Roxborough Mem Hosp, Philadelphia, PA USA. [Lipsky, Benjamin] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Lipsky, Benjamin] Gen Internal Med Clin, Seattle, WA USA. [Lipsky, Benjamin] Vet Affairs Puget Sound Hlth Care Syst, Antibiot Res Clin, Seattle, WA USA. RP Armstrong, D (reprint author), Univ Arizona, Coll Med, SALSA, Tucson, AZ 85721 USA. RI Lipsky, Benjamin/B-4645-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1044-7946 J9 WOUNDS JI Wounds-Compend. Clin. Res. Pract. PD DEC PY 2008 BP 5 EP 10 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA 393EI UT WOS:000262353300001 ER PT J AU Armstrong Boulton Rogers Lipsky AF Dr Armstrong Dr Boulton Dr Rogers Dr Lipsky TI A Guide To Current MRSA Treatment Options SO WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE LA English DT Article C1 [Dr Armstrong] Univ Arizona, Coll Med, SALSA, Tucson, AZ 85721 USA. [Dr Boulton] Univ Manchester, Manchester M13 9PL, Lancs, England. Roxborough Mem Hosp, Philadelphia, PA USA. Coatesville Vet Affairs Med Ctr, Coatesville, PA USA. [Dr Lipsky] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Dr Lipsky] Gen Internal Med Clin, Seattle, WA USA. [Dr Lipsky] Vet Affairs Puget Sound Hlth Care Syst, Antibiot Res Clin, Seattle, WA USA. [Dr Rogers] Broadlawns Med Ctr, Amputat Prevent Ctr, Des Moines, IA USA. RP Armstrong (reprint author), Univ Arizona, Coll Med, SALSA, Tucson, AZ 85721 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1044-7946 J9 WOUNDS JI Wounds-Compend. Clin. Res. Pract. PD DEC PY 2008 BP 11 EP 17 PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA 393EI UT WOS:000262353300002 ER PT J AU Weiner, DK Perera, S Rudy, TE Glick, RM Shenoy, S Delitto, A AF Weiner, Debra K. Perera, Subashan Rudy, Thomas E. Glick, Ronald M. Shenoy, Sonali Delitto, Anthony TI Efficacy of percutaneous electrical nerve stimulation and therapeutic exercise for older adults with chronic low back pain: A randomized controlled trial SO PAIN LA English DT Article DE Chronic low back pain; Older adults; Percutaneous electrical nerve stimulation; Exercise ID SELF-RATED HEALTH; LOWER-EXTREMITY FUNCTION; PHYSICAL PERFORMANCE BATTERY; FOLLOW-UP; NEUROPSYCHOLOGICAL PERFORMANCE; SUBSEQUENT DISABILITY; BODY-COMPOSITION; FITNESS PROGRAM; ACUPUNCTURE; SCALE AB Chronic low back pain (CLBP) in older adults may be disabling and therapeutically challenging, largely because of the inefficacy and/or morbidity associated with traditional pain treatment. We conducted a randomized controlled trial in 200 men and women >= age 65 with CLBP to evaluate the efficacy of percutaneous electrical nerve stimulation (PENS) with and without general conditioning and aerobic exercise (GCAE), for reducing pain and improving physical function. Participants were randomized to receive (1) PENS, (2) control-PENS (brief electrical stimulation to control for treatment expectancy), (3) PENS + GCAE, or (4) control-PENS + GCAE, twice a week for 6 weeks. All (Our groups experienced significantly reduced pain (range -2.3 to -4.1 on the McGill Pain Questionnaire short form), improved self-reported disability (range -2.1 to -3.0 on Roland scale) and improved gait velocity (0.04-0.07 m/s), Sustained at 6 months. The GCAE groups experienced significantly fewer fear avoidance beliefs immediately post-intervention and at 6 months than non-GCAE groups. There were no significant side effects. Since brief electrical stimulation (i.e., control-PENS) facilitated comparably reduced pain and improved function at 6 months as compared with PENS, the exact dose of electrical stimulation required for analgesia cannot be determined. GCAE was more effective than PENS alone in reducing fear avoidance beliefs, but not in reducing pain or in improving physical function. Published by Elsevier B.V. on behalf of International Association For the Study of Pain. C1 [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15213 USA. [Weiner, Debra K.; Perera, Subashan] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Weiner, Debra K.; Rudy, Thomas E.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15260 USA. [Weiner, Debra K.; Rudy, Thomas E.; Glick, Ronald M.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. [Perera, Subashan; Rudy, Thomas E.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA. [Glick, Ronald M.] Univ Pittsburgh, Ctr Integrat Med, Pittsburgh, PA 15260 USA. [Shenoy, Sonali; Delitto, Anthony] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA 15260 USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, 3471 5th Ave,Suite 500, Pittsburgh, PA 15213 USA. EM dweiner@pitt.edu RI Perera, Subashan/D-7603-2014 FU National Center [R01 AT000985]; National Institute on Aging; National Institutes of Health; Older Americans Independence Center [NIA P30 AG-024827] FX This work was supported in by Grant R01 AT000985 from the National Center for Complementary and Alternative Medicine and the National Institute on Aging, National Institutes of Health. Dr. Percra was also supported by the Pittsburgh Claude D. Pepper Older Americans Independence Center (NIA P30 AG-024827). NR 71 TC 16 Z9 20 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD NOV 30 PY 2008 VL 140 IS 2 BP 344 EP 357 DI 10.1016/j.pain.2008.09.005 PG 14 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 381QT UT WOS:000261551700011 PM 18930352 ER PT J AU Wynn, JK Green, MF Engel, S Korb, A Lee, J Glahn, D Nuechterlein, KH Cohen, MS AF Wynn, Jonathan K. Green, Michael F. Engel, Stephen Korb, Alex Lee, Junghee Glahn, David Nuechterlein, Keith H. Cohen, Mark S. TI Increased extent of object-selective cortex in schizophrenia SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Schizophrenia; visual processing; functional MRI; object processing ID HUMAN VISUAL-CORTEX; BRAIN; RECOGNITION; AREAS; FMRI; REGISTRATION; DYSFUNCTION; ACTIVATION; RELATIVES; ACCURATE AB Schizophrenia patients exhibit deficits in various stages of visual information processing. Despite recent informative efforts to examine visual processing in schizophrenia with functional magnetic resonance imaging (fMRI), much remains unknown about the basic function, structure, and organization of key early visual processing areas in schizophrenia. This study examined magnitude and topography of regional brain activity in three early visual processing areas: early retinotopically organized areas (V1-V4), motion-sensitive areas (human area MT, hMT+), and object-recognition areas (lateral occipital complex, LO). Using visual stimuli that are known to preferentially activate each respective region, we compared responses in these areas in 22 schizophrenia patients and 19 normal controls. Activity in all three regions was of similar amplitude in schizophrenia patients and normal controls. Activity in retinotopically organized areas and hMT+ showed good spatial overlap between groups. However, activation of LO was more widely distributed in patients compared with normal controls. The findings of abnormal spatial organization of LO in schizophrenia patients may converge with behavioral evidence of deficits in schizophrenia patients for object-recognition tasks that are believed to be mediated by LO activity. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Wynn, Jonathan K.; Green, Michael F.; Lee, Junghee] VA Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA 90073 USA. [Wynn, Jonathan K.; Green, Michael F.; Korb, Alex; Lee, Junghee; Nuechterlein, Keith H.; Cohen, Mark S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Engel, Stephen; Nuechterlein, Keith H.; Cohen, Mark S.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Glahn, David] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Wynn, JK (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC, Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkwynn@ucla.edu RI Lee, Junghee/C-5226-2014; Wynn, Jonathan/H-3749-2014; Cohen, Mark/C-6610-2011 OI Lee, Junghee/0000-0001-9567-8700; Wynn, Jonathan/0000-0002-1763-8540; Cohen, Mark/0000-0001-6731-4053 FU NIMH [MH43292, MH065707]; Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; Northstar Fund FX Support for this study came from NIMH Grant MH43292 (PI: Michael F. Green, Ph.D) and NIMH Grant MH065707 (PI: Michael F. Green, Ph.D.). For generous support, we also thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, and Northstar Fund. The authors thank Poorang Nori and Alisa Malin for assistance in data collection. NR 39 TC 18 Z9 18 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD NOV 30 PY 2008 VL 164 IS 2 BP 97 EP 105 DI 10.1016/j.pscychresns.2008.01.005 PG 9 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 381QS UT WOS:000261551600001 PM 18938066 ER PT J AU Lyamin, OI Kosenko, PO Lapierre, JL Mukhametov, LM Siegel, JM AF Lyamin, Oleg I. Kosenko, Peter O. Lapierre, Jennifer L. Mukhametov, Lev M. Siegel, Jerome M. TI Fur Seals Display a Strong Drive for Bilateral Slow-Wave Sleep While on Land SO JOURNAL OF NEUROSCIENCE LA English DT Article DE EEG asymmetry; bilateral slow-wave sleep; slow-wave activity; sleep deprivation; sleep-wake cycle; Callorhinus ursinus ID UNIHEMISPHERIC SLEEP; SPECTRAL POWER; DEPRIVATION; EEG; ASYMMETRY; STIMULATION; DOLPHINS; RAT AB Fur seals (pinnipeds of the family Otariidae) display two fundamentally different patterns of sleep: bilaterally symmetrical slow-wave sleep (BSWS) as seen in terrestrial mammals and slow-wave sleep (SWS) with a striking interhemispheric EEG asymmetry (asymmetrical SWS or ASWS) as observed in cetaceans. We examined the effect of preventing fur seals from sleeping in BSWS on their pattern of sleep. Four northern fur seals (Callorhinus ursinus) kept on land were sleep deprived (SD) of BSWS for 3 consecutive days, followed by 1 recovery day. EEG asymmetry was evaluated both visually and by EEG spectral analysis. SD significantly reduced the percentage of high-voltage BSWS (on average to 14% of baseline) and REM sleep (to 60% of baseline) whereas the percentage of low-voltage BSWS was not affected. During the SD period, all seals repeatedly tried to enter BSWS (109-411 attempts per day). SD significantly increased the amount of ASWS in each seal when scored visually (to 116-235% of baseline) and the difference in the EEG slow-wave activity (spectral power in the range of 1.2-4.0 Hz) between the two hemispheres (117-197%) as measured by the asymmetry index. High-voltage BSWS and the amount of SWS in each hemisphere were significantly elevated during the first 4 h of recovery. These data indicate that fur seals display a homeostatic response to the loss of SWS and that alternating SWS in the two hemispheres does not adequately compensate for the absence of BSWS. C1 [Lyamin, Oleg I.; Lapierre, Jennifer L.; Siegel, Jerome M.] Vet Affairs Greater Los Angeles Healthcare Syst, Neurobiol Res 151A3, North Hills, CA 91343 USA. [Lyamin, Oleg I.; Lapierre, Jennifer L.; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat, Sch Med, North Hills, CA 91343 USA. [Lyamin, Oleg I.; Kosenko, Peter O.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow 119071, Russia. RP Lyamin, OI (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Neurobiol Res 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM olyamin@ucla.edu FU National Science Foundation [0234687]; Defense Advanced Research Projects Agency [BAA0412F8034]; Department of Veterans Affairs; Utrish Dolphinarium, Ltd FX This work was supported by the National Science Foundation (Grant 0234687), the Defense Advanced Research Projects Agency (Grant BAA0412F8034), the Medical Research Service of the Department of Veterans Affairs, and the Utrish Dolphinarium, Ltd. We thank E. Belyaev, A. Kibalnikov, E. Nazarenko, J. Pryaslova, and O. Shpak for their assistance during the experiments. NR 28 TC 11 Z9 11 U1 3 U2 10 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 26 PY 2008 VL 28 IS 48 BP 12614 EP 12621 DI 10.1523/JNEUROSCI.2306-08.2008 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 376OA UT WOS:000261191700003 PM 19036955 ER PT J AU Davis, BR Kostis, JB Simpson, LM Black, HR Cushman, WC Einhorn, PT Farber, MA Ford, CE Levy, D Massie, BM Nawaz, S AF Davis, Barry R. Kostis, John B. Simpson, Lara M. Black, Henry R. Cushman, William C. Einhorn, Paula T. Farber, Michael A. Ford, Charles E. Levy, Daniel Massie, Barry M. Nawaz, Shah CA ALLHAT Collaborative Res Grp TI Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial SO CIRCULATION LA English DT Article DE angiotensin-converting enzyme inhibitors; antihypertensive agents; calcium channel blockers; diuretics; heart failure; hypertension; ventricular ejection fraction ID SYSTOLIC FUNCTION; DIASTOLIC DYSFUNCTION; CARDIOVASCULAR HEALTH; OLMSTED COUNTY; PREVALENCE; COMMUNITY; POPULATION; PROGNOSIS; ALLHAT; MECHANISMS AB Background-Heart failure (HF) developing in hypertensive patients may occur with preserved or reduced left ventricular ejection fraction (PEF [>= 50%] or REF [<50%]). In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 42 418 high-risk hypertensive patients were randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin, providing an opportunity to compare these treatments with regard to occurrence of hospitalized HFPEF or HFREF. Methods and Results-HF diagnostic criteria were prespecified in the ALLHAT protocol. EF estimated by contrast ventriculography, echocardiography, or radionuclide study was available in 910 of 1367 patients (66.6%) with hospitalized events meeting ALLHAT criteria. Cox regression models adjusted for baseline characteristics were used to examine treatment differences for HF (overall and by PEF and REF). HF case fatality rates were examined. Of those with EF data, 44.4% had HFPEF and 55.6% had HFREF. Chlorthalidone reduced the risk of HFPEF compared with amlodipine, lisinopril, or doxazosin; the hazard ratios were 0.69 (95% confidence interval [CI], 0.53 to 0.91; P=0.009), 0.74 (95% CI, 0.56 to 0.97; P=0.032), and 0.53 (95% CI, 0.38 to 0.73; P<0.001), respectively. Chlorthalidone reduced the risk of HFREF compared with amlodipine or doxazosin; the hazard ratios were 0.74 (95% CI, 0.59 to 0.94; P=0.013) and 0.61 (95% CI, 0.47 to 0.79; P<0.001), respectively. Chlorthalidone was similar to lisinopril with regard to incidence of HFREF (hazard ratio, 1.07; 95% CI, 0.82 to 1.40; P=0.596). After HF onset, death occurred in 29.2% of participants (chlorthalidone/amlodipine/lisinopril) with new-onset HFPEF versus 41.9% in those with HFREF (P<0.001; median follow-up, 1.74 years); and in the chlorthalidone/doxazosin comparison that was terminated early, 20.0% of HFPEF and 26.0% of HFREF patients died (P=0.185; median follow-up, 1.55 years). Conclusions-In ALLHAT, with adjudicated outcomes, chlorthalidone significantly reduced the occurrence of new-onset hospitalized HFPEF and HFREF compared with amlodipine and doxazosin. Chlorthalidone also reduced the incidence of new-onset HFPEF compared with lisinopril. Among high-risk hypertensive men and women, HFPEF has a better prognosis than HFREF. (Circulation. 2008; 118: 2259-2267.) C1 [Davis, Barry R.; Simpson, Lara M.; Ford, Charles E.] Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77030 USA. [Kostis, John B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Black, Henry R.] NYU, Sch Med, New York, NY USA. [Cushman, William C.] Memphis Vet Affairs Med Ctr, Memphis, TN USA. [Einhorn, Paula T.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA. [Farber, Michael A.] Crozer Keystone Hlth Network, Upland, PA USA. [Levy, Daniel] NHLBI, Framingham Heart Study, Framingham, MA USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Davis, BR (reprint author), Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, 1200 Herman Pressler,Suite E801, Houston, TX 77030 USA. EM barry.r.davis@uth.tmc.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services Bethesda, Md [N01-HC-35130] FX This research was supported by Health and Human Services contract N01-HC-35130 from the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, Md. The ALLHAT investigators acknowledge contributions of study medications supplied by Pfizer Inc (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support provided by Pfizer Inc. NR 45 TC 73 Z9 77 U1 2 U2 31 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 25 PY 2008 VL 118 IS 22 BP 2259 EP 2267 DI 10.1161/CIRCULATIONAHA.107.762229 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 377AO UT WOS:000261224300007 PM 19001024 ER PT J AU Ono, K Condron, MM Ho, L Wang, J Zhao, W Pasinetti, GM Teplow, DB AF Ono, Kenjiro Condron, Margaret M. Ho, Lap Wang, Jun Zhao, Wei Pasinetti, Giulio M. Teplow, David B. TI Effects of Grape Seed-derived Polyphenols on Amyloid beta-Protein Self-assembly and Cytotoxicity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FIBRILS IN-VITRO; ALZHEIMERS-DISEASE; CROSS-LINKING; SYNAPTIC PLASTICITY; WINE CONSUMPTION; APOLIPOPROTEIN-E; TRANSGENIC MICE; ALPHA-SYNUCLEIN; FRENCH PARADOX; MOUSE MODEL AB Epidemiological evidence suggests that moderate consumption of red wine reduces the incidence of Alzheimer disease (AD). To study the protective effects of red wine, experiments recently were executed in the Tg2576 mouse model of AD. These studies showed that a commercially available grape seed polyphenolic extract, MegaNatural-AZ (MN), significantly attenuated AD-type cognitive deterioration and reduced cerebral amyloid deposition (Wang, J., Ho, L., Zhao, W., Ono, K., Rosensweig, C., Chen, L., Humala, N., Teplow, D. B., and Pasinetti, G. M. (2008) J. Neurosci. 28, 6388-6392). To elucidate the mechanistic bases for these observations, here we used CD spectroscopy, photo-induced cross-linking of unmodified proteins, thioflavin T fluorescence, size exclusion chromatography, and electron microscopy to examine the effects of MN on the assembly of the two predominant disease-related amyloid beta-protein alloforms, A beta 40 and A beta 42. We also examined the effects of MN on A beta-induced cytotoxicity by assaying 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide metabolism and lactate dehydrogenase activity in A beta-treated, differentiated pheochromocytoma (PC12) cells. Initial studies revealed that MN blocked A beta fibril formation. Subsequent evaluation of the assembly stage specificity of the effect showed thatMNwas able to inhibit protofibril formation, pre-protofibrillar oligomerization, and initial coil -> alpha-helix/beta-sheet secondary structure transitions. Importantly, MN had protective effects in assays of cytotoxicity in which MN was mixed with A beta prior to peptide assembly or following assembly and just prior to peptide addition to cells. These data suggest that MN is worthy of consideration as a therapeutic agent for AD. C1 [Ho, Lap; Wang, Jun; Zhao, Wei; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ono, Kenjiro; Condron, Margaret M.; Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Condron, Margaret M.; Teplow, David B.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Condron, Margaret M.; Teplow, David B.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. [Ono, Kenjiro] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol, Kanazawa, Ishikawa 9208640, Japan. [Ho, Lap; Wang, Jun; Zhao, Wei; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA. [Ho, Lap; Pasinetti, Giulio M.] Bronx Vet Adm Med Ctr, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1468 Madison Ave,Rm 14-94C, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu; dteplow@ucla.edu RI Zhao, Wei/B-3220-2010; Zhao, Wei/A-2206-2010 FU National Institutes of Health [PO1 AT004511]; NCCAM; Department of Veterans Affairs Merit Review; James J. Peters Veterans Affairs Medical Center Geriatric Research Education Clinical Center Program, and Polyphenolics; Japan Human Science Foundation and the Mochida Memorial Foundation for Medical and Pharmaceutical Research; Alzheimer's Association; Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at UCLA; [AG027818] FX This work was supported, in whole or in part, by National Institutes of Health Grant PO1 AT004511 through the NCCAM (to L. H., G. M. P., and D. B. T.) and Grant AG027818(to (D. B. T.). This work also was supported by the Department of Veterans Affairs Merit Review grant and a grant from the James J. Peters Veterans Affairs Medical Center Geriatric Research Education Clinical Center Program, and Polyphenolics (to G. M. P.); grants from the Japan Human Science Foundation and the Mochida Memorial Foundation for Medical and Pharmaceutical Research (to K. O.); and grants from the Alzheimer's Association, and the Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at UCLA (to D. B. T.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 53 TC 104 Z9 110 U1 1 U2 27 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 21 PY 2008 VL 283 IS 47 BP 32176 EP 32187 DI 10.1074/jbc.M806154200 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 372HW UT WOS:000260893700004 PM 18815129 ER PT J AU Heinrich, MC Owzar, K Corless, CL Hollis, D Borden, EC Fletcher, CDM Ryan, CW von Mehren, M Blanke, CD Rankin, C Benjamin, RS Bramwell, VH Demetri, GD Bertagnolli, MM Fletcher, JA AF Heinrich, Michael C. Owzar, Kouros Corless, Christopher L. Hollis, Donna Borden, Ernest C. Fletcher, Christopher D. M. Ryan, Christopher W. von Mehren, Margaret Blanke, Charles D. Rankin, Cathryn Benjamin, Robert S. Bramwell, Vivien H. Demetri, George D. Bertagnolli, Monica M. Fletcher, Jonathan A. TI Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID RECEPTOR TYROSINE KINASE; OF-FUNCTION MUTATIONS; TERM-FOLLOW-UP; C-KIT; DOSE IMATINIB; SARCOMA-GROUP; GENE; INHIBITOR; EFFICACY; SAFETY AB Purpose Imatinib mesylate is standard treatment for patients who have advanced gastrointestinal stromal tumor (GIST), but not all patients benefit equally. In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing. Patients and Methods We examined the relationship between kinase genotype and treatment outcome for 428 patients enrolled on the North American phase III study SWOG S0033/CALGB 150105 and treated with either 400 mg or 800 mg daily doses of imatinib. Results The presence of KIT exon 11-mutant genotype (n = 283) correlated with improved treatment outcome when compared with KIT exon 9-mutant (n = 32) and wild-type (WT; n = 67) genotypes for objective response (complete response [CR]/ partial response [PR], 71.7% v 44.4% [P = .007]; and 44.6% [P = .0002], respectively); time to tumor progression (TTP; median 24.7 months v 16.7 and 12.8 months, respectively); and overall survival (OS; median 60.0 months v 38.4 and 49.0 months, respectively). The survival outcomes for patients with exon 9-mutant, exon 11-mutant or WT GIST were not affected by imatinib dose. However, there was evidence of improved response rates for patients with exon 9-mutant tumors treated with imatinib 800 mg versus 400 mg (CR/PR, 67% v 17%; P = .02). Patients who had CD117-negative GIST had similar TTP but inferior OS compared with patients who had CD117-positive disease, which suggests that patients who have CD117-negative GIST may benefit from imatinib treatment. In addition, we identified novel but rare mutations of the KIT extracellular domain (exons 8 and 9). Conclusion We confirmed the favorable impact of KIT exon 11 genotype when compared with KIT exon 9 and wild-type genotype for patients with advanced GIST who are treated with imatinib. C1 [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Div Hematol Oncol, Portland, OR 97239 USA. Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. SW Oncol Grp, Ctr Stat, Seattle, WA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Tom Baker Canc Clin, Calgary, AB, Canada. RP Heinrich, MC (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,R&D 19, Portland, OR 97239 USA. EM heinrich@ohsu.edu FU National Cancer Institute (NCI) [CA33601, CA04919, CA32291, CA27525, CA31946, CA32102, CA77202, U01-CA70172-01, N01-CM-17003]; Veterans Affairs Merit Review; Novartis Pharmaceuticals FX Supported in part by Grants No. CA33601, CA04919, CA32291, CA27525, CA31946, CA32102, and CA77202 from the National Cancer Institute (NCI); by Grants No. U01-CA70172-01 and N01-CM-17003 from the NCI; by a Veterans Affairs Merit Review Grant (M. H.); and by research funding from Novartis Pharmaceuticals. NR 28 TC 278 Z9 301 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2008 VL 26 IS 33 BP 5360 EP 5367 DI 10.1200/JCO.2008.17.4284 PG 8 WC Oncology SC Oncology GA 376RA UT WOS:000261199500010 PM 18955451 ER PT J AU Peterson, ED Rumsfeld, JS AF Peterson, Eric D. Rumsfeld, John S. TI Quality of Life with PCI versus Medical Therapy in Stable Coronary Disease Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Peterson, Eric D.] Duke Clin Res Inst, Durham, NC 27715 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Peterson, ED (reprint author), Duke Clin Res Inst, Durham, NC 27715 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 20 PY 2008 VL 359 IS 21 BP 2292 EP 2293 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 373SW UT WOS:000260994000028 ER PT J AU Wang, TY Xiao, L Alexander, KP Rao, SV Kosiborod, MN Rumsfeld, JS Spertus, JA Peterson, ED AF Wang, Tracy Y. Xiao, Lan Alexander, Karen P. Rao, Sunil V. Kosiborod, Mikhail N. Rumsfeld, John S. Spertus, John A. Peterson, Eric D. TI Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding SO CIRCULATION LA English DT Article DE anticoagulants; antiplatelet therapy; bleeding; myocardial infarction ID ACUTE CORONARY SYNDROMES; ST-SEGMENT ELEVATION; HIGH-RISK PATIENTS; CLINICAL-OUTCOMES; COLLABORATIVE METAANALYSIS; RANDOMIZED-TRIALS; BLOOD-TRANSFUSION; IMPACT; PREDICTORS; REGISTRY AB Background-Bleeding among patients with acute myocardial infarction (AMI) is associated with worse long-term outcomes. Although the mechanism underlying this association is unclear, a potential explanation is that withholding antiplatelet therapies long beyond resolution of the bleeding event may contribute to recurrent events. Methods and Results-We examined medication use at discharge, 1, 6, and 12 months after AMI among 2498 patients in the Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER) registry. Bleeding was defined as non-coronary artery bypass graft-related Thrombolysis of Myocardial Infarction major/minor bleeding or transfusion among patients with baseline hematocrit >= 28%. Logistic regression was used to evaluate the association between bleeding during the index AMI hospitalization and medication use. In-hospital bleeding occurred in 301 patients (12%) with AMI. Patients with in-hospital bleeding were less likely to be discharged on aspirin or thienopyridine (adjusted odds ratio = 0.45; 95% CI, 0.31 to 0.64; and odds ratio = 0.62; 95% CI, 0.42 to 0.91, respectively). At 1 month after discharge, although patients with in-hospital bleeding remained significantly less likely to receive aspirin (odds ratio = 0.68; 95% CI, 0.50 to 0.92), use of thienopyridines in the 2 groups started to become similar. By 1 year, antiplatelet therapy use was similar among patients with and without bleeding. Postdischarge cardiology follow-up was associated with greater antiplatelet therapy use than either primary care or no clinical follow-up. Conclusions-Patients whose index AMI is complicated by bleeding are less likely to be treated with antiplatelet therapies during the first 6 months after discharge. Early reassessment of antiplatelet eligibility may represent an opportunity to reduce the long-term risk of adverse outcomes associated with bleeding. (Circulation. 2008; 118: 2139-2145.) C1 [Wang, Tracy Y.; Alexander, Karen P.; Rao, Sunil V.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC 27705 USA. [Wang, Tracy Y.; Alexander, Karen P.; Rao, Sunil V.; Peterson, Eric D.] Duke Univ, Med Ctr, Durham, NC 27705 USA. [Xiao, Lan; Kosiborod, Mikhail N.; Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA. [Xiao, Lan; Kosiborod, Mikhail N.; Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Wang, TY (reprint author), Duke Clin Res Inst, 2400 Pratt St,Room 0311,Terrace Level, Durham, NC 27705 USA. EM wang0085@mc.duke.edu FU Cardiovascular Outcomes, Inc; Cardiovascular Therapeutics, Inc, Palo Alto, Calif; Duke Clinical Research Institute, Durham, NC; CV Therapeutics, Inc, Palo Alto, Calif FX The PREMIER Quality Improvement Registry was organized by Cardiovascular Outcomes, Inc, a nonprofit 501( c)( 3) organization dedicated to the advancement of outcomes research and improvement of cardiovascular healthcare quality, and is funded by Cardiovascular Therapeutics, Inc, Palo Alto, Calif. More information on the PREMIER Quality Improvement Registry can be found at http://www.cvoutcomes.org. Funding and support for this publication were provided by the Duke Clinical Research Institute, Durham, NC. Funding for statistical analysis was provided by CV Therapeutics, Inc, Palo Alto, Calif. NR 27 TC 70 Z9 73 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 18 PY 2008 VL 118 IS 21 BP 2139 EP 2145 DI 10.1161/CIRCULATIONAHA.108.787143 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 373FB UT WOS:000260955300005 PM 18981304 ER PT J AU Greyson, CR AF Greyson, Clifford R. TI Letter by Greyson Regarding Article, "High-Dose Folic Acid Pretreatment Blunts Cardiac Dysfunction During Ischemia Coupled to Maintenance of High-Energy Phosphates and Reduces Postreperfusion Injury" SO CIRCULATION LA English DT Letter ID HEART; FLOW C1 [Greyson, Clifford R.] Denver VAMC, Denver, CO USA. [Greyson, Clifford R.] Univ Colorado, Denver, CO 80202 USA. RP Greyson, CR (reprint author), Denver VAMC, Denver, CO USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD NOV 18 PY 2008 VL 118 IS 21 BP E703 EP E703 DI 10.1161/CIRCULATIONAHA.108.789529 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 373FB UT WOS:000260955300018 PM 19015409 ER PT J AU Kahn, JM Asch, RJ Iwashyna, TJ Rubenfeld, GD Angus, DC Asch, DA AF Kahn, Jeremy M. Asch, Rebecca J. Iwashyna, Theodore J. Rubenfeld, Gordon D. Angus, Derek C. Asch, David A. TI Perceived barriers to the regionalization of adult critical care in the United States: a qualitative preliminary study SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID HOSPITAL VOLUME; DELIVERY; ILL; ORGANIZATION; MORTALITY; MEDICINE; SERVICES; OUTCOMES; IMPACT AB Background: Regionalization of adult critical care services may improve outcomes for critically ill patients. We sought to develop a framework for understanding clinician attitudes toward regionalization and potential barriers to developing a tiered, regionalized system of care in the United States. Methods: We performed a qualitative study using semi-structured interviews of critical care stakeholders in the United States, including physicians, nurses and hospital administrators. Stakeholders were identified from a stratified-random sample of United States general medical and surgical hospitals. Key barriers and potential solutions were identified by performing content analysis of the interview transcriptions. Results: We interviewed 30 stakeholders from 24 different hospitals, representing a broad range of hospital locations and sizes. Key barriers to regionalization included personal and economic strain on families, loss of autonomy on the part of referring physicians and hospitals, loss of revenue on the part of referring physicians and hospitals, the potential to worsen outcomes at small hospitals by limiting services, and the potential to overwhelm large hospitals. Improving communication between destination and source hospitals, provider education, instituting voluntary objective criteria to become a designated referral center, and mechanisms to feed back patients and revenue to source hospitals were identified as potential solutions to some of these barriers. Conclusion: Regionalization efforts will be met with significant conceptual and structural barriers. These data provide a foundation for future research and can be used to inform policy decisions regarding the design and implementation of a regionalized system of critical care. C1 [Kahn, Jeremy M.; Asch, Rebecca J.] Univ Penn, Div Pulm Allergy & Crit Care, Sch Med, Philadelphia, PA 19104 USA. [Kahn, Jeremy M.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Kahn, Jeremy M.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Iwashyna, Theodore J.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA. [Rubenfeld, Gordon D.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Program Trauma Emergency & Crit Care, Toronto, ON M4N 3M5, Canada. [Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, CRISMA Lab, Pittsburgh, PA USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Kahn, JM (reprint author), Univ Penn, Div Pulm Allergy & Crit Care, Sch Med, 3400 Spruce St, Philadelphia, PA 19104 USA. EM jmkahn@mail.med.upenn.edu; aschrj@mail.med.upenn.edu; tiwashyn@umich.edu; gordon.rubenfeld@sunnybrook.ca; angusdc@ccm.upmc.edu; asch@wharton.upenn.edu RI Angus, Derek/E-9671-2012 OI Asch, David/0000-0002-7970-286X; Iwashyna, Theodore/0000-0002-4226-9310 FU United States National Institutes of Health [K23 HL082650] FX This work was supported by the University of Pennsylvania Leschly Fund. Dr. Kahn is supported by a career development award from the United States National Institutes of Health (K23 HL082650). The funding source had no role in the design, implementation, analysis or decision to publish this research. NR 28 TC 11 Z9 11 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD NOV 17 PY 2008 VL 8 AR 239 DI 10.1186/1472-6963-8-239 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 391LA UT WOS:000262233600002 PM 19014704 ER PT J AU Gyurkocza, B Storb, RF Storer, B Chauncey, T Niederwieser, D Shizuru, J Langston, A Pulsipher, M Bredeson, C Maziarz, RT Bruno, B Petersen, F Maris, M Agura, E Yeager, AM Bethge, WA Sahebi, F Vindelov, L McSweeney, PA Appelbaum, FR Maloney, DG Sandmaier, BM AF Gyurkocza, Boglarka Storb, Rainer F. Storer, Barry Chauncey, Thomas Niederwieser, Dietger Shizuru, Judith Langston, Amelia Pulsipher, Michael Bredeson, Christopher Maziarz, Richard T. Bruno, Benedetto Petersen, Finn Maris, Michael Agura, Edward Yeager, Andrew M. Bethge, Wolfgang A. Sahebi, Firoozeh Vindelov, Lars McSweeney, Peter A. Appelbaum, Frederick R. Maloney, David G. Sandmaier, Brenda M. TI Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-of-Hematology CY DEC 06-09, 2008 CL San Francisco, CA SP Amer Soc Hematol C1 [Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Niederwieser, Dietger] Univ Leipzig, Leipzig, Germany. [Shizuru, Judith] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Langston, Amelia] Emory Univ, Atlanta, GA 30322 USA. [Pulsipher, Michael] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Bredeson, Christopher] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Petersen, Finn] LDS Hosp, Salt Lake City, UT USA. [Maris, Michael; McSweeney, Peter A.] Rocky Mt Canc Ctr, Denver, CO USA. [Agura, Edward] Baylor Univ, Med Ctr, Dallas, TX USA. [Yeager, Andrew M.] Univ Arizona, Tucson, AZ USA. [Bethge, Wolfgang A.] Univ Tubingen, Med Ctr, Tubingen, Germany. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA USA. [Vindelov, Lars] Univ Copenhagen, Rigshosp, DK-2100 Copenhagen, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2008 VL 112 IS 11 BP 61 EP 61 PG 1 WC Hematology SC Hematology GA 389OP UT WOS:000262104700150 ER PT J AU Toro, JJ Haile, DJ Chao, JH Jewell, PS Lee, S Freytes, CO AF Toro, Juan J. Haile, David J. Chao, Ju-Hsien Jewell, Pamela S. Lee, Shuko Freytes, Cesar O. TI The Department of Veterans Affairs Nutritional Status Classification Scheme Allows for Rapid Assessment of Nutritional Status Before Autologous Peripheral Blood Stem Cell Transplantation and Identifies Patients at High-Risk of Transplant-Related Complications SO BLOOD LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-of-Hematology CY DEC 06-09, 2008 CL San Francisco, CA SP Amer Soc Hematol C1 [Toro, Juan J.; Haile, David J.; Chao, Ju-Hsien; Jewell, Pamela S.; Lee, Shuko; Freytes, Cesar O.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2008 VL 112 IS 11 BP 274 EP 274 PG 1 WC Hematology SC Hematology GA 389OP UT WOS:000262104700740 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Maris, M Chauncey, T Maziarz, RT Pulsipher, M Shizuru, J Niederwieser, D Agura, E Wade, JC Langston, AA Storb, RF Maloney, DG AF Sorror, Mohamed L. Storer, Barry Sandmaier, Brenda M. Maris, Michael Chauncey, Thomas Maziarz, Richard T. Pulsipher, Michael Shizuru, Judith Niederwieser, Dietger Agura, Edward Wade, James C. Langston, Amelia A. Storb, Rainer F. Maloney, David G. TI Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative, Allogeneic Hematopoictic Cell Transplantation (HCT). SO BLOOD LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-of-Hematology CY DEC 06-09, 2008 CL San Francisco, CA SP Amer Soc Hematol C1 [Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Pulsipher, Michael] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Shizuru, Judith] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Niederwieser, Dietger] Univ Leipzig, Leipzig, Germany. [Agura, Edward] Baylor Univ, Med Ctr, Dallas, TX USA. [Wade, James C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Langston, Amelia A.] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2008 VL 112 IS 11 BP 747 EP 748 PG 2 WC Hematology SC Hematology GA 389OP UT WOS:000262104702480 ER PT J AU Sorror, ML Storer, B Sandmaier, BM Maloney, DG Franke, G Shizuru, J Chauncey, T Agura, E Maziarz, RT Sahebi, F Langston, AA Wade, JC Maris, M Bruno, B Yeager, AM Pulsipher, M Petersen, F Bethge, WA McSweeney, PA Niederwieser, D Blume, KG Storb, RF AF Sorror, Mohamed L. Storer, Barry Sandmaier, Brenda M. Maloney, David G. Franke, Georg Shizuru, Judith Chauncey, Thomas Agura, Edward Maziarz, Richard T. Sahebi, Firoozeh Langston, Amelia A. Wade, James C. Maris, Michael Bruno, Benedetto Yeager, Andrew M. Pulsipher, Michael Petersen, Finn Bethge, Wolfgang A. McSweeney, Peter A. Niederwieser, Dietger Blume, Karl G. Storb, Rainer F. TI Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged >= 60 Years SO BLOOD LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-of-Hematology CY DEC 06-09, 2008 CL San Francisco, CA SP Amer Soc Hematol C1 [Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Agura, Edward] Baylor Univ, Med Ctr, Dallas, TX USA. [Franke, Georg] Univ Leipzig, Laipzig, Germany. [Shizuru, Judith; Blume, Karl G.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Sahebi, Firoozeh] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Langston, Amelia A.] Emory Univ, Sch Med, Atlanta, GA USA. [Wade, James C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Maris, Michael; McSweeney, Peter A.] Rocky Mt Canc Ctr, Denver, CO USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [Yeager, Andrew M.] Univ Arizona, Tucson, AZ USA. [Pulsipher, Michael] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Petersen, Finn] LDS Hosp, Salt Lake City, UT USA. [Bethge, Wolfgang A.] Univ Tubingen, Med Ctr, Tubingen, Germany. [Niederwieser, Dietger] Univ Leipzig, Leipzig, Germany. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2008 VL 112 IS 11 BP 753 EP 754 PG 2 WC Hematology SC Hematology GA 389OP UT WOS:000262104702495 ER PT J AU Zakai, NA French, B Arnold, A Newman, A Fried, LF Robbins, J Chaves, P Cushman, M AF Zakai, Neil A. French, Benjamin Arnold, Alice Newman, Anne Fried, Linda F. Robbins, John Chaves, Paolo Cushman, Mary TI Hemoglobin Decline and Health Outcomes in the Elderly: the Cardiovascular Health Study SO BLOOD LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-of-Hematology CY DEC 06-09, 2008 CL San Francisco, CA SP Amer Soc Hematol C1 [Zakai, Neil A.; Cushman, Mary] Univ Vermont, Colchester, VT USA. [French, Benjamin] Univ Penn, Philadelphia, PA 19104 USA. [Arnold, Alice] Univ Washington, Seattle, WA 98195 USA. [Fried, Linda F.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Robbins, John] Univ Calif, David, CA USA. [Chaves, Paolo] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2008 VL 112 IS 11 BP 1183 EP 1183 PG 1 WC Hematology SC Hematology GA 389OP UT WOS:000262104704066 ER PT J AU Kwiatkowski, BA Dong, Z Richard, RE AF Kwiatkowski, Boguslaw A. Dong, ZhaoMing Richard, Robert E. TI The Identification of Genes Cooperating with Mpl Signaling Using Insertional Mutagenesis SO BLOOD LA English DT Meeting Abstract CT 50th Annual Meeting of the American-Society-of-Hematology CY DEC 06-09, 2008 CL San Francisco, CA SP Amer Soc Hematol C1 [Kwiatkowski, Boguslaw A.] VA Puget Sound Hlth Care Syst, Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Richard, Robert E.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2008 VL 112 IS 11 BP 1314 EP 1314 PG 1 WC Hematology SC Hematology GA 389OP UT WOS:000262104704467 ER PT J AU Esrailian, E Gralnek, IM Jensen, D Laine, L Dulai, GS Eisen, G Spiegel, BMR AF Esrailian, E. Gralnek, I. M. Jensen, D. Laine, L. Dulai, G. S. Eisen, G. Spiegel, B. M. R. TI Evaluating the process of care in nonvariceal upper gastrointestinal haemorrhage: a survey of expert vs. non-expert gastroenterologists SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ENDOSCOPY; QUALITY; METAANALYSIS; VIGNETTES; TRIAL AB Background When faced with the same facts, physicians often make different decisions. Aim To perform a survey to measure the process of care and variations in decision-making in nonvariceal upper gastrointestinal tract haemorrhage (NVUGIH) and compare results between experts and non-experts. Methods We administered a vignette survey to elicit knowledge and beliefs about NVUGIH, including 13 'best practice' guidelines. We compared guideline compliance between experts and non-experts. Results One hundred and eighty-eight gastroenterologists responded (46%). Experts endorsed more 'best practices' than non-experts (93% vs. 85%; P = 0.002). Non-experts were more likely to endorse incorrectly bolus dosing vs. continuous infusion of intravenous proton pump inhibitors (PPIs; 92% vs. 64%; P = 0.005) and to select standard-channel vs. large-channel endoscopes in high-risk bleeding (100% vs. 85%; P = 0.04). There were wide variations within groups regarding the timing of nasogastric lavage, use of promotility agents, use of hemoclips and appropriateness of snaring clots overlying ulcers. Conclusions Experts are more likely to comply with NVUGIH guidelines. Non-experts diverge from experts in the dosing of PPIs and choice of endoscope in high-risk bleeding. Moreover, there are wide variations in key practices even within groups. This suggests that best practices have been generally well disseminated, but that persistent disconnects exist that should be further investigated. C1 [Jensen, D.; Spiegel, B. M. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Esrailian, E.; Jensen, D.; Spiegel, B. M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Esrailian, E.; Spiegel, B. M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA 90095 USA. [Laine, L.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Dulai, G. S.] Kaiser So Calif, Portland, OR USA. [Eisen, G.] Oregon Hlth & Sci Univ, Portland, OR USA. [Spiegel, B. M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Gralnek, I. M.] Ramban Med Ctr, Haifa, Israel. RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition [RCD03-179-2]; CURE Digestive Disease Research Center [NIH 2P30 DK 041301-17]; NIH K24 [NIH-NIDDK 1K24DK02650]; NIH-NIDDK [AM41301]; AstraZeneca [ESOM0396] FX Declaration of personal interests: Dr Spiegel is supported by a Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition Award (RCD03-179-2). Drs. Esrailian, Jensen and Spiegel are supported by the CURE Digestive Disease Research Center (NIH 2P30 DK 041301-17). Dr Jensen is supported by an NIH K24 grant (NIH-NIDDK 1K24DK02650), and NIH-NIDDK AM41301. This study was supported by an investigator-initiated research grant by AstraZeneca. The authors had complete authority over all aspects of the study, including development of the hypotheses and analysis plan, development of data collection instruments, collection of data, analysis and interpretation of data and writing of the manuscript. Declaration of funding interests: This investigator-iniated study was funded in full by AstraZeneca, grant number ESOM0396. All aspects of the study conduct, interpretation, and writing were performed by the study authors without influence by the sponsor. NR 17 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD NOV 15 PY 2008 VL 28 IS 10 BP 1199 EP 1208 DI 10.1111/j.1365-2036.2008.03838.x PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 361MK UT WOS:000260131600003 PM 18729846 ER PT J AU Mergenhagen, KA Sherman, O AF Mergenhagen, Kari A. Sherman, Olga TI Elevated International Normalized Ratio after concurrent ingestion of cranberry sauce and warfarin SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article DE Anticoagulants; Drug interactions; Geriatrics; International normalized ratio; Vaccinium macrocarpon; Warfarin sodium ID JUICE AB Purpose. A case of increased International Normalized Ratio (INR) values in a patient receiving warfarin who consumed a large amount of cranberry sauce is reported. Summary. A 75-year-old Caucasian man with atrial fibrillation was taking 22.5 mg of warfarin weekly for 10 months and had maintained stable INR values between 2 and 3. During a clinic visit one week after Thanksgiving, the patient's INR was 4.8. The patient was extensively questioned about any changes in his diet, medications, and health. The patient reported consuming approximately 113 g of cranberry sauce for seven consecutive days before the clinic visit. He reported no other diet or health changes. The patient denied alcohol consumption, had not taken nutritional supplements, and did not miss or double any medication doses during this time period. There were no dosing changes or discernible compliance issues in the 10 months preceding the change in INR. The patient's complete blood cell count and results of a chemistry panel and liver function tests were within normal limits. He did not have any bleeding or bruising. The only identifiable change was the addition of store-bought cranberry sauce to his diet. The patient's warfarin dose was held for two days. Subsequently, the patient resumed warfarin at a dosage of 20 mg per week. Seven days after the patient discontinued the cranberry sauce, his INR returned to 2.2 and remained stable over the next month. Conclusion. Consumption of cranberry sauce led to an increase in INR values in a patient receiving warfarin. C1 [Mergenhagen, Kari A.; Sherman, Olga] James J Peters Vet Affairs Med Ctr, Coagulat Warfarin Lipid Clin, Bronx, NY 10468 USA. RP Mergenhagen, KA (reprint author), James J Peters Vet Affairs Med Ctr, Coagulat Warfarin Lipid Clin, 130 W Kingsbridge Rd 119, Bronx, NY 10468 USA. EM kari.mergenhagen2@va.gov NR 23 TC 4 Z9 6 U1 0 U2 1 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD NOV 15 PY 2008 VL 65 IS 22 BP 2113 EP 2116 DI 10.2146/ajhp080135 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 372LG UT WOS:000260902500012 PM 18997138 ER PT J AU Kozora, E Arciniegas, DB Filley, CM West, SG Brown, M Miller, D Grimm, A Devore, MD Wingrove, C Zhang, LN AF Kozora, Elizabeth Arciniegas, David B. Filley, Christopher M. West, Sterling G. Brown, Mark Miller, David Grimm, Alex Devore, Maria D. Wingrove, Christy Zhang, Lening TI Cognitive and Neurologic Status in Patients With Systemic Lupus Erythematosus Without Major Neuropsychiatric Syndromes SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article ID MULTIPLE-SCLEROSIS; RATING-SCALE; IMPAIRMENT; PREVALENCE; DYSFUNCTION; MANIFESTATIONS; DEFINITIONS; ANTIBODIES; DEFICITS; FLUENCY AB Objective. To examine neuropsychological and neurologic functioning in systemic lupus erythematosus (SLE) patients without histories of overt neuropsychiatric disorders (non-NPSLE patients). Methods. Sixty-seven non-NPSLE patients and 29 healthy controls were administered a standardized neurologic examination and measures of cognition, depression, and self-reported cognitive functioning. Results. Non-NPSLE patients scored lower than controls on the total score of the neurologic examination (P < 0.0001). Item analysis indicated that the physician's description of mentation and mood was the only item that differed significantly between patients with SLE and controls (P = 0.004). Compared with controls, non-NPSLE patients had significantly higher rates of impairment on logical reasoning (P = 0.012) and verbal memory (P = 0.03), and trends toward greater impairment on visual attention (P = 0.06) and working memory (P = 0.098). There were no significant differences between non-NPSLE patients and controls on a cognitive impairment index (CII): 20.9% of non-NPSLE patients and 13.8% of controls were impaired. Patients with SLE scored higher on depressive symptoms (P < 0.0001) and perceived cognitive difficulties (P = 0.001) compared with controls. Conclusion. The utility of a standardized neurologic examination in SLE for excluding overt neurologic dysfunction and assuring a non-NPSLE group selection was demonstrated. In contrast to our earlier study, we did not find differences between non-NPSLE patients and controls on the CII Slightly lower CII scores in non-NPSLE patients and higher CII scores in controls may have reduced cognitive differences between these groups. Non-NPSLE patients demonstrate specific decline in the areas of attention, memory, and reasoning; continued studies of associated brain regions are warranted. C1 [Kozora, Elizabeth; Devore, Maria D.; Wingrove, Christy; Zhang, Lening] Natl Jewish Med & Res Ctr, Denver, CO 80206 USA. [Kozora, Elizabeth; Arciniegas, David B.; Filley, Christopher M.; West, Sterling G.; Brown, Mark; Miller, David; Grimm, Alex; Zhang, Lening] Univ Colorado Denver, Hlth Sci Ctr, Denver, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kozora, E (reprint author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA. EM Kozorae@njc.org RI Arciniegas, David/A-3792-2009 FU National Institute of Musculoskeletal and Skin Diseases; NIH [R01-AR04915202] FX Supported by a grant from National Institute of Musculoskeletal and Skin Diseases, NIH (R01-AR04915202). NR 47 TC 29 Z9 31 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD NOV 15 PY 2008 VL 59 IS 11 BP 1639 EP 1646 DI 10.1002/art.24189 PG 8 WC Rheumatology SC Rheumatology GA 371TC UT WOS:000260853200015 PM 18975359 ER PT J AU Shimazaki, K Lepin, EJ Wei, B Nagy, AK Coulam, CP Mareninov, S Fu, MY Wu, AM Marks, JD Braun, J Gordon, LK Wadehra, M AF Shimazaki, Kaori Lepin, Eric J. Wei, Bo Nagy, Agnes K. Coulam, Catherine P. Mareninov, Sergey Fu, Maoyong Wu, Anna M. Marks, James D. Braun, Jonathan Gordon, Lynn K. Wadehra, Madhuri TI Diabodies Targeting Epithelial Membrane Protein 2 Reduce Tumorigenicity of Human Endometrial Cancer Cell Lines SO CLINICAL CANCER RESEARCH LA English DT Article ID SINGLE-CHAIN FV; FOCAL ADHESION KINASE; ANTIBODY FRAGMENTS; SURFACE EXPRESSION; GYNECOLOGIC MALIGNANCIES; INTEGRIN FUNCTION; LIPID RAFTS; EMP2; GENE; CARCINOGENESIS AB Purpose: Endometrial cancer is the most common gynecologic malignancy. One promising biomarker is epithelial membrane protein 2 (EMP2), and its expression is an independent prognostic indicator for tumors with poor clinical outcome expression. The present study assesses the suitability of EMP2 as a therapeutic target. Experimental Design: Human monovalent anti-EMP2 antibody fragments were isolated from a human phage display library and engineered as bivalent antibody fragments (diabodies) with specificity and avidity to both EMP2 peptides and native cell-surface EMP2 protein. Diabodies were assessed using cell death and apoptosis assays. In addition, the efficacy of EMP2 diabodies on endometrial cancer tumors was determined using mouse xenograft models. Results: Treatment of human endometrial adenocarcinoma cell lines with anti-EMP2 diabodies induced significant cell death and caspase-3 cleavage in vitro. These responses correlated with cellular EMP2 expression and were augmented by progesterone, which physiologically induces EMP2 expression. In vivo, treatment of subcutaneous human xenografts of HEC-1A cell lines with anti-EMP2 diabodies suppressed tumor growth and induced cell death in the xenograft. Conclusions: These findings suggest that EMP2 may be a potential pharmacologic target for human endometrial cancer. C1 [Wei, Bo; Nagy, Agnes K.; Coulam, Catherine P.; Mareninov, Sergey; Fu, Maoyong; Braun, Jonathan; Wadehra, Madhuri] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab, Los Angeles, CA 90095 USA. [Shimazaki, Kaori; Braun, Jonathan] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Gordon, Lynn K.] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Gordon, Lynn K.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Marks, James D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Wadehra, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab, 14-127 Ctr Hlth Sci, Los Angeles, CA 90095 USA. EM mwadehra@mednet.ucla.edu RI Fu, Maoyong/E-9201-2010 OI Braun, Jonathan/0000-0003-1646-2974 FU NIH [HD48540, CA86306, CA009120, 2-T32-Al-07323]; University of California at Los Angeles Jonsson Comprehensive Cancer Center flow cytometry core [CA016042]; Iris Cantor Seed Grant, Giannini Family Foundation [U54 CA119367]; Oppenheimer Family Foundation; Center for the Prevention of Eye Disease FX NIH grants HD48540 (J. Braun), CA86306 (A.M. Wu and J. Braun), CA009120 (M. Wadehra), 2-T32-Al-07323 (K. Shimazaki), and CA016042 (University of California at Los Angeles Jonsson Comprehensive Cancer Center flow cytometry core); Iris Cantor Seed Grant, Giannini Family Foundation, and U54 CA119367 (M.Wadehra), unrestricted gift of Dr. Richard and Barbara Braun (J. Braun); and Oppenheimer Family Foundation Grant Center for the Prevention of Eye Disease (L.K. Gordon). NR 50 TC 15 Z9 16 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD NOV 15 PY 2008 VL 14 IS 22 BP 7367 EP 7377 DI 10.1158/1078-0432.CCR-08-1016 PG 11 WC Oncology SC Oncology GA 374AL UT WOS:000261014500025 PM 19010852 ER PT J AU Jackson, LA Janoff, EN AF Jackson, Lisa A. Janoff, Edward N. TI Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; POLYSACCHARIDE VACCINE; CONJUGATE VACCINE; HIGH-RISK; UNITED-STATES; OLDER-ADULTS; CLINICAL-EFFICACY; PHASE-1 TRIAL; DISEASE; POPULATION AB Pneumococcal polysaccharide vaccine has been licensed for use in the United States for 130 years, and two-thirds of the elderly population in the United States have received this vaccine. Observational studies have demonstrated that pneumococcal polysaccharide vaccine reduces the risk of invasive pneumococcal disease in immunocompetent elderly individuals, but neither observational studies nor clinical trials have demonstrated consistent evidence for a reduction in the incidence of pneumonia in vaccinated older adults. The introduction of pneumococcal protein conjugate vaccine among children has led to a herd immunity effect that has resulted in a 38% decrease in the rate of invasive pneumococcal disease among elderly adults. The high efficacy of pneumococcal protein conjugate vaccine in children has renewed interest in evaluating pneumococcal protein conjugate vaccines in adults for prevention of invasive pneumococcal disease and pneumonia. Moreover, the recognition of the presence and function of noncapsular pneumococcal protein antigens and the increasing availability of adjuvants highlight the promise of new vaccination strategies to decrease the burden of pneumococcal infection in this high-risk population. C1 [Jackson, Lisa A.] Grp Hlth Ctr Hlth Studies, Seattle, WA 98101 USA. [Janoff, Edward N.] Univ Colorado, Denver Sch Med, Mucosal & Vaccine Res Program Colorado, Div Infect Dis,Denver Vet Affairs Med Ctr, Denver, CO USA. RP Jackson, LA (reprint author), Grp Hlth Ctr Hlth Studies, 1730 Minor Ave,Ste 1600, Seattle, WA 98101 USA. EM Jackson.L@ghc.org FU Veterans Affairs Research Service; Mucosal and Vaccine Research Program Colorado; National Institutes of Health [R21-AI077069, R01-AI48796] FX Financial support. Veterans Affairs Research Service, Mucosal and Vaccine Research Program Colorado ( to E.N.J.), and the National Institutes of Health (R21-AI077069 and R01-AI48796 to E.N.J.). NR 63 TC 74 Z9 75 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2008 VL 47 IS 10 BP 1328 EP 1338 DI 10.1086/592691 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 360ST UT WOS:000260078800014 PM 18844484 ER PT J AU Rodrigues, GGR Walker, RH Brice, A Cazeneuve, C Russaouen, O Teive, HAG Munhoz, RP Becker, N Raskin, S Werneck, LC Marques, W Tumas, V AF Rodrigues, Guilherme G. Riccioppo Walker, Ruth H. Brice, Alexis Cazeneuve, Cecile Russaouen, Odile Teive, Helio A. G. Munhoz, Renato Puppi Becker, Nilson Raskin, Salino Werneck, Lineu Cesar Marques, Wilson Junior Tumas, Vitor TI Huntington's Disease-Like 2 in Brazil-Report of 4 Patients SO MOVEMENT DISORDERS LA English DT Article DE Huntington's disease; junctophilin 3; Huntington's disease like ID REPEAT EXPANSION; CAG EXPANSION; HUNTINGTON-DISEASE-LIKE-2; FEATURES; HUNTINGTONS-DISEASE-LIKE-2; PHENOCOPIES; ANCESTRY; FAMILY AB Huntington's disease-like 2 (HDL2) is a neurodegenerative disorder found in people of African ancestry with clinical, radiological, and neuropathological manifestations similar to Huntington's disease (HD). HDL2 is caused by a pathological expansion of CAG/CTG triplets in exon 2A of the JPH3 gene. We describe four cases of HDL2 from four unrelated families, and discuss their clinical findings. HDL2 should be considered in every patient with an HD-like phenotype who tests negative for the HD mutation, even if African ancestry is not immediately apparent. (C) 2008 Movement Disorder Society C1 [Rodrigues, Guilherme G. Riccioppo; Marques, Wilson Junior; Tumas, Vitor] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Neurol, Ribeirao Preto, SP, Brazil. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Brice, Alexis; Cazeneuve, Cecile; Russaouen, Odile] Grp Hosp Pitie Salpetriere, Neurogenet Unit, Dept Genet & Cytogenet, AP HP, F-75634 Paris, France. [Teive, Helio A. G.; Munhoz, Renato Puppi; Becker, Nilson; Raskin, Salino; Werneck, Lineu Cesar] Univ Fed Parana, Hosp Clin, Neurol Serv, Movement Disorders Unit, BR-80060000 Curitiba, Parana, Brazil. RP Tumas, V (reprint author), Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Neurol, Ribeirao Preto, SP, Brazil. EM tumasv@rnp.fmrp.usp.br RI Rodrigues, Guilherme/D-3547-2009; Marques, Wilson/G-4240-2012; Tumas, Vitor/C-9949-2014 OI Rodrigues, Guilherme/0000-0002-4296-1016; Marques, Wilson/0000-0002-4589-2749; NR 17 TC 12 Z9 12 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV 15 PY 2008 VL 23 IS 15 BP 2244 EP 2247 DI 10.1002/mds.22223 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 380CF UT WOS:000261442600015 PM 18816802 ER PT J AU Fish, KN Sweet, RA Deo, AJ Lewis, DA AF Fish, Kenneth N. Sweet, Robert A. Deo, Anthony J. Lewis, David A. TI An automated segmentation methodology for quantifying immunoreactive puncta number and fluorescence intensity in tissue sections SO BRAIN RESEARCH LA English DT Article DE Quantitative fluorescence microscopy; Immunoreactive puncta; Segmentation; Synaptic structure; Fluorescent immunohistochemistry ID MONKEY PREFRONTAL CORTEX; GAD(67) MESSENGER-RNAS; POSTNATAL-DEVELOPMENT; AXON TERMINALS; LOCALIZATION; MICROSCOPY; PERFORMANCE; SYNAPSES; PROTEINS; SUPPORTS AB A number of human brain diseases have been associated with disturbances in the structure and function of cortical synapses. Answering fundamental questions about the synaptic machinery in these disease states requires the ability to image and quantify small synaptic structures in tissue sections and to evaluate protein levels at these major sites of function. We developed a new automated segmentation imaging method specifically to answer such fundamental questions. The method takes advantage of advances in spinning disk confocal microscopy, and combines information from multiple iterations of a fluorescence intensity/morphological segmentation protocol to construct three-dimensional object masks of immunoreactive (IR) puncta. This new methodology is unique in that high- and low-fluorescing IR puncta are equally masked, allowing for quantification of the number of fluorescently-labeled puncta in tissue sections. In addition, the shape of the final object masks highly represents their corresponding original data. Thus, the object masks can be used to extract information about the IR puncta (e.g., average fluorescence intensity of proteins of interest). Importantly, the segmentation method presented can be easily adapted for use with most existing microscopy analysis packages. (C) 2008 Elsevier B.V. All rights reserved. C1 [Fish, Kenneth N.] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. [Lewis, David A.] Univ Pittsburgh, Sch Med, Dept Neurosci, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Deo, Anthony J.] Univ Pittsburgh, Sch Med, Phys Sci Training Program, Pittsburgh, PA 15213 USA. RP Fish, KN (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Biomed Sci Tower,Room W165, Pittsburgh, PA 15213 USA. EM fishkn@upmc.edu RI Lewis, David/G-4053-2014 OI Lewis, David/0000-0002-3225-6778 FU NIH [MHOS1234, MH071533]; University of Pittsburgh FX Supported by NIH grant MHOS1234 (DAL), MH071533 (RAS), and University of Pittsburgh CMRF award (KNF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. We are extremely grateful to Mrs. Kelly Rogers and Heidi Scriven for their technical assistance. We are also grateful to Olympus American and B and B Microscopes for their advice. NR 25 TC 20 Z9 20 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD NOV 13 PY 2008 VL 1240 BP 62 EP 72 DI 10.1016/j.brainres.2008.08.060 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 379SD UT WOS:000261415600008 PM 18793619 ER PT J AU Ford, AC Talley, NJ Spiegel, BMR Foxx-Orenstein, AE Schiller, L Quigley, EMM Moayyedi, P AF Ford, Alexander C. Talley, Nicholas J. Spiegel, Brennan M. R. Foxx-Orenstein, Amy E. Schiller, Lawrence Quigley, Eamonn M. M. Moayyedi, Paul TI Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis SO BRITISH MEDICAL JOURNAL LA English DT Review ID CLINICAL-TRIALS; VISCERAL SENSATION; NATURAL-HISTORY; SMOOTH-MUSCLE; PREVALENCE; DISORDERS; QUALITY; POPULATION; MANAGEMENT; TRANSIT AB Objective To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome. Design Systematic review and meta- analysis of randomised controlled trials. Data sources Medline, Embase, and the Cochrane controlled trials register up to April 2008. Review methods Randomised controlled trials comparing fibre, antispasmodics, and peppermint oil with placebo or no treatment in adults with irritable bowel syndrome were eligible for inclusion. The minimum duration of therapy considered was one week, and studies had to report either a global assessment of cure or improvement in symptoms, or cure of or improvement in abdominal pain, after treatment. A random effects model was used to pool data on symptoms, and the effect of therapy compared with placebo or no treatment was reported as the relative risk (95% confidence interval) of symptoms persisting. Results 12 studies compared fibre with placebo or no treatment in 591 patients (relative risk of persistent symptoms 0.87, 95% confidence interval 0.76 to 1.00). This effect was limited to ispaghula (0.78, 0.63 to 0.96). Twenty two trials compared antispasmodics with placebo in 1778 patients (0.68, 0.57 to 0.81). Various antispasmodics were studied, but otilonium (four trials, 435 patients, relative risk of persistent symptoms 0.55, 0.31 to 0.97) and hyoscine (three trials, 426 patients, 0.63, 0.51 to 0.78) showed consistent evidence of efficacy. Four trials compared peppermint oil with placebo in 392 patients ( 0.43, 0.32 to 0.59). Conclusion Fibre, antispasmodics, and peppermint oil were all more effective than placebo in the treatment of irritable bowel syndrome. C1 [Ford, Alexander C.; Moayyedi, Paul] McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, Hamilton, ON L8N 3Z5, Canada. [Talley, Nicholas J.] Mayo Clin, Dept Med, Jacksonville, FL 32224 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Foxx-Orenstein, Amy E.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. [Schiller, Lawrence] Baylor Univ, Med Ctr, Digest Hlth Assoc Texas, Dallas, TX USA. [Quigley, Eamonn M. M.] Cork Univ Hosp, Dept Med, Cork, Ireland. RP Ford, AC (reprint author), McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada. EM alexf12399@yahoo.com RI Ford, Alexander/K-5491-2012; Talley, nicholas/D-5399-2013; Moayyedi, Paul/M-6178-2014 OI Ford, Alexander/0000-0001-6371-4359; Talley, nicholas/0000-0003-2537-3092; Moayyedi, Paul/0000-0002-3616-9292 FU American College of Gastroenterology FX This study was funded by the American College of Gastroenterology. The authors' work was independent of the funders. NR 32 TC 169 Z9 172 U1 4 U2 25 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD NOV 13 PY 2008 VL 337 AR a2313 DI 10.1136/bmj.a2313 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 385AE UT WOS:000261784500003 PM 19008265 ER PT J AU Kuznetsova, MS Higgs, MH Spain, WJ AF Kuznetsova, Marina S. Higgs, Matthew H. Spain, William J. TI Adaptation of Firing Rate and Spike-Timing Precision in the Avian Cochlear Nucleus SO JOURNAL OF NEUROSCIENCE LA English DT Article DE sound localization; nucleus magnocellularis; potassium channel; phase-locking; spike-timing precision; coincidence detection ID INTERAURAL TIME DIFFERENCES; STEM AUDITORY NUCLEI; INACTIVATING POTASSIUM CURRENT; NEOCORTICAL PYRAMIDAL NEURONS; BRAIN-STEM; COINCIDENCE DETECTION; TEMPORAL INTEGRATION; MEMBRANE-PROPERTIES; BARN OWL; FEEDFORWARD INHIBITION AB Adaptation is commonly defined as a decrease in response to a constant stimulus. In the auditory system such adaptation is seen at multiple levels. However, the first-order central neurons of the interaural time difference detection circuit encode information in the timing of spikes rather than the overall firing rate. We investigated adaptation during in vitro whole-cell recordings from chick nucleus magnocellularis neurons. Injection of noisy, depolarizing current caused an increase in firing rate and a decrease in spike time precision that developed over similar to 20 s. This adaptation depends on sustained depolarization, is independent of firing, and is eliminated by alpha-dendrotoxin (0.1 mu M), implicating slow inactivation of low-threshold voltage-activated K+ channels as its mechanism. This process may alter both firing rate and spike-timing precision of phase-locked inputs to coincidence detector neurons in nucleus laminaris and thereby adjust the precision of sound localization. C1 [Kuznetsova, Marina S.; Higgs, Matthew H.; Spain, William J.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98105 USA. [Kuznetsova, Marina S.] Univ Washington, Interdisciplinary Grad Program Neurobiol & Behav, Seattle, WA 98105 USA. [Spain, William J.] Univ Washington, Dept Neurol, Seattle, WA 98105 USA. [Spain, William J.] Vet Affairs Puget Sound Hlth Care Syst, Neurol Sect, Seattle, WA 98108 USA. RP Spain, WJ (reprint author), Neurol 127,1660 S Columbian Way, Seattle, WA 98108 USA. EM spain@u.washington.edu FU Veterans Affairs Merit Review; National Institute on Deafness and Other Communication Disorders [5F31DC009176] FX This work was supported by a Veterans Affairs Merit Review (W.J.S.) and by National Research Service Award 5F31DC009176 from the National Institute on Deafness and Other Communication Disorders (M.S.K.). We thank Sean Slee, Adrienne Fairhall, Marc Binder, David Perkel, and Ed Rubel for helpful discussions, Carol Robbins, and Sue Usher for excellent technical assistance. NR 79 TC 17 Z9 17 U1 1 U2 3 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 12 PY 2008 VL 28 IS 46 BP 11906 EP 11915 DI 10.1523/JNEUROSCI.3827-08.2008 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 371JM UT WOS:000260827600023 PM 19005056 ER PT J AU Kim, MS Wang, TY Dai, D Klein, AJ Peterson, ED Rumsfeld, JS Messenger, JC AF Kim, Michael S. Wang, Tracy Y. Dai, David Klein, Andrew J. Peterson, Eric D. Rumsfeld, John S. Messenger, John C. TI Association of Previous Coronary Artery Bypass Graft Surgery With Door-to-Balloon Time and In-Hospital Outcomes: A Report From the National Cardiovascular Data Registry (NCDR) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT News Item DE door-to-balloon time; primary PCI; CABG; mortality; performance measurement ID ACUTE MYOCARDIAL-INFARCTION; PRIMARY ANGIOPLASTY; MORTALITY; DELAY C1 [Kim, Michael S.; Klein, Andrew J.; Rumsfeld, John S.; Messenger, John C.] Univ Colorado Denver, Aurora, CO 80045 USA. [Wang, Tracy Y.; Dai, David; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. RP Messenger, JC (reprint author), Univ Colorado Denver, Anschutz Med Campus,12401 E 17th Ave,Campus Mail, Aurora, CO 80045 USA. EM John.Messenger@UCHSC.edu NR 13 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 11 PY 2008 VL 52 IS 20 BP 1665 EP 1670 DI 10.1016/j.jacc.2008.08.017 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 372LV UT WOS:000260904000010 PM 18992658 ER PT J AU Rifkin, DE Shlipak, MG Katz, R Fried, LF Siscovick, D Chonchol, M Newman, AB Sarnak, MJ AF Rifkin, Dena E. Shlipak, Michael G. Katz, Ronit Fried, Linda F. Siscovick, David Chonchol, Michel Newman, Anne B. Sarnak, Mark J. TI Rapid Kidney Function Decline and Mortality Risk in Older Adults SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; BODY-COMPOSITION; ELDERLY PERSONS; CARDIOVASCULAR-DISEASE; RENAL-INSUFFICIENCY; POOLED ANALYSIS; CREATININE; INDIVIDUALS; PROGNOSIS AB Background: Impaired kidney function is associated with increased mortality risk in older adults. It remains unknown, however, whether longitudinal declines in kidney function are independently associated with increased cardiovascular and all-cause mortality in older adults. Methods: The Cardiovascular Health Study evaluated a cohort of community-dwelling older adults enrolled from 1989 to 1993 in 4 US communities with follow-up through 2005. Among 4380 participants, the slope of annual decline in estimated glomerular filtration rate (eGFR) was estimated using both serum creatinine (eGFR(creat)) and cystatin C (eGFR(cys)) rates, which were measured at baseline, year 3, and year 7 of follow-up. Rapid decline in eGFR was defined as a loss greater than 3 mL/min/1.73 m(2) per year, and cardiovascular and all-cause mortality were assessed over a mean of 9.9 years of follow-up. Results: Mean (SD) levels of creatinine and cystatin C were 0.93 (0.30) mg/dL and 1.03 (0.25) mg/L, respectively; mean (SD) eGFR(creat) and eGFR(cys) were 79 (23) mL/min/1.73 m(2) and 79 (19) mL/min/1.73m(2), respectively. Individuals with rapid decline measured by eGFR(creat) (n = 714; 16%) had increased risk of cardiovascular (adjusted hazard ratio [AHR], 1.70; 95% confidence interval [CI], 1.40-2.06) and all-cause (AHR, 1.73; 95% CI, 1.54-1.94) mortality. Individuals with rapid decline measured by eGFR(cys) (n = 1083; 25%) also had increased risk of cardiovascular (AHR, 1.53; 95% CI, 1.29-1.80) and all-cause (AHR, 1.53; 95% CI, 1.38-1.69) mortality. The association of rapid decline in eGFR with elevated mortality risk did not differ across subgroups based on baseline kidney function, age, sex, race, or prevalent coronary heart disease. Conclusion: Rapid decline in eGFR is associated with an increased risk of cardiovascular and all-cause mortality in older adults, independent of baseline eGFR and other demographic variables. C1 [Rifkin, Dena E.; Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA 02111 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Med Serv, Pittsburgh, PA USA. [Fried, Linda F.; Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Fried, Linda F.; Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Med, Pittsburgh, PA USA. [Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Chonchol, Michel] Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Denver, CO USA. RP Rifkin, DE (reprint author), Tufts Med Ctr, Div Nephrol, 750 Washington St,Box 391, Boston, MA 02111 USA. EM drifkin@tuftsmedicalcenter.org RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Maryland [R01-AG-027002, K24DK078204, N01-HC-35129, N01-HC-45133, N01HC-75150, N01-HC-85079, N01-HC-85086, N01-HC-15103, N01-HC-55222, U01 HL080295]; National Institute of Neurological Disorders and Stroke, Bethesda FX The research reported in this article was supported by contracts R01-AG-027002, K24DK078204, N01-HC-35129, N01-HC-45133, N01HC-75150, N01-HC-85079 through N01-HC-85086, N01-HC-15103, N01-HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Maryland, with additional contribution from the National Institute of Neurological Disorders and Stroke, Bethesda. NR 25 TC 170 Z9 171 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 10 PY 2008 VL 168 IS 20 BP 2212 EP 2218 DI 10.1001/archinte.168.20.2212 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 370XS UT WOS:000260797000005 PM 19001197 ER PT J AU Zhou, XH Lin, HZ AF Zhou, Xiao-Hua Lin, Huazhen TI Semi-parametric maximum likelihood estimates for ROC curves of continuous-scale tests SO STATISTICS IN MEDICINE LA English DT Article DE ROC curves; sensitivity and specificity; semi-parametric maximum likelihood estimators ID COMPARING DIAGNOSTIC MARKERS; TRANSFORMATION MODELS AB In this paper, we propose a new semi-parametric maximum likelihood (ML) estimate of a receiver operating characteristic (ROC) curve that satisfies the property of invariance of the ROC curve and is easy to compute. We show that our new estimator is root n-consistent and has an asymptotically normal distribution. Our extensive Simulation studies show that the proposed method is efficient and robust. Finally, we illustrate the application of the proposed estimator in a real data set. Copyright (C) 2008 John Wiley & Sons, Ltd. C1 [Zhou, Xiao-Hua; Lin, Huazhen] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA. [Lin, Huazhen] Sichuan Univ, Sch Math, Chengdu 610064, Sichuan, Peoples R China. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA. EM azhou@u.washington.edu FU NIH [R01EB005829]; NSF [DMS 0603913]; Fund of National Natural Science [10771148] FX Contract/grant sponsor: NIH; contract/grant number: R01EB005829; Contract/grant sponsor: NSF; contract/grant number: DMS 0603913; Contract/grant sponsor: Fund of National Natural Science; contract/grant number: 10771148 NR 17 TC 5 Z9 5 U1 0 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD NOV 10 PY 2008 VL 27 IS 25 BP 5271 EP 5290 DI 10.1002/sim.3349 PG 20 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 368RS UT WOS:000260640800010 PM 18613272 ER PT J AU Mariappan, MM Shetty, M Sataranatarajan, K Choudhury, GG Kasinath, BS AF Mariappan, Meenalakshmi M. Shetty, Megan Sataranatarajan, Kavithalakshmi Choudhury, Goutam Ghosh Kasinath, Balakuntalam S. TI Glycogen Synthase Kinase 3 beta Is a Novel Regulator of High Glucose- and High Insulin-induced Extracellular Matrix Protein Synthesis in Renal Proximal Tubular Epithelial Cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MESSENGER-RNA TRANSLATION; SIGNAL-TRANSDUCTION PATHWAYS; SKELETAL-MUSCLE; GROWTH-FACTOR; CARDIAC-HYPERTROPHY; DIABETIC-NEPHROPATHY; GENE-EXPRESSION; POTENTIAL ROLE; PHOSPHORYLATION; KINASE-3-BETA AB High glucose (30 mM) and high insulin (1 nM), pathogenic factors of type 2 diabetes, increased mRNA expression and synthesis of laminin beta 1 and fibronectin after 24 h of incubation in kidney proximal tubular epithelial (MCT) cells. We tested the hypothesis that inactivation of glycogen synthase kinase 3 beta(GSK3 beta) by high glucose and high insulin induces increase in synthesis of laminin beta 1 via activation of eIF2B epsilon. Both high glucose and high insulin induced Ser-9 phosphorylation and inactivation of GSK3 beta at 2 h that lasted for up to 48 h. This was associated with dephosphorylation of eIF2B epsilon and eEF2, and increase in phosphorylation of 4E-BP1 and eIF4E. Expression of the kinase-dead mutant of GSK3 beta or constitutively active kinase led to increased and diminished laminin beta 1 synthesis, respectively. Incubation with selective kinase inhibitors showed that high glucose- and high insulin-induced laminin beta 1 synthesis and phosphorylation of GSK3 beta were dependent on PI 3-kinase, Erk, and mTOR. High glucose and high insulin augmented activation of Akt, Erk, and p70S6 kinase. Dominant negative Akt, but not dominant negative p70S6 kinase, inhibited GSK3 beta phosphorylation induced by high glucose and high insulin, suggesting Akt but not p70S6 kinase was upstream of GSK3 beta. Status of GSK3 beta was examined in vivo in renal cortex of db/db mice with type 2 diabetes at 2 weeks and 2 months of diabetes. Diabetic mice showed increased phosphorylation of renal cortical GSK3 beta and decreased phosphorylation of eIF2B epsilon, which correlated with renal hypertrophy at 2 weeks, and increased laminin beta 1 and fibronectin protein content at 2 months. GSK3 beta and eIF2B epsilon play a role in augmented protein synthesis associated with high glucose- and high insulin-stimulated hypertrophy and matrix accumulation in renal disease in type 2 diabetes. C1 [Mariappan, Meenalakshmi M.; Shetty, Megan; Sataranatarajan, Kavithalakshmi; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, OBrien Kidney Res Ctr, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Kasinath, BS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC7882, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Kasinath@uthscsa.edu FU National Institutes of Health [DK061597, DK077295, DK050190]; Juvenile Diabetes Research Foundation [3-2007-245, 1-2008-185]; American Diabetes Association [7-05-RA-60]; Veterans Administration Research Service; American Heart Association [SDG 0630283N] FX This work was supported, in whole or in part, by National Institutes of Health Grants DK061597 and DK077295 (to B. S. K.) and DK050190 (to G. G. C.). These studies were also supported by Juvenile Diabetes Research Foundation Grants 3-2007-245 (to M. M. M. and B. S. K.) and 1-2008-185 (to G. G. C.), American Diabetes Association Grant 7-05-RA-60 (to B. S. K.), the Veterans Administration Research Service (to B. S. K. and G. G. C.), and American Heart Association Grant SDG 0630283N (to D. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact. NR 58 TC 36 Z9 39 U1 1 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 7 PY 2008 VL 283 IS 45 BP 30566 EP 30575 DI 10.1074/jbc.M801756200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 367ID UT WOS:000260544800015 PM 18701453 ER PT J AU Kulkarni, H Marconi, VC Agan, BK McArthur, C Crawford, G Clark, RA Dolan, MJ Ahuja, SK AF Kulkarni, Hemant Marconi, Vincent C. Agan, Brian K. McArthur, Carole Crawford, George Clark, Robert A. Dolan, Matthew J. Ahuja, Sunil K. TI Role of CCL3L1-CCR5 Genotypes in the Epidemic Spread of HIV-1 and Evaluation of Vaccine Efficacy SO PLOS ONE LA English DT Article AB Background: Polymorphisms in CCR5, the major coreceptor for HIV, and CCL3L1, a potent CCR5 ligand and HIV-suppressive chemokine, are determinants of HIV-AIDS susceptibility. Here, we mathematically modeled the potential impact of these genetic factors on the epidemic spread of HIV, as well as on its prevention. Methods and Results: Ro, the basic reproductive number, is a fundamental concept in explaining the emergence and persistence of epidemics. By modeling sexual transmission among HIV+/HIV- partner pairs, we find that Ro estimates, and concordantly, the temporal and spatial patterns of HIV outgrowth are highly dependent on the infecting partners' CCL3L1-CCR5 genotype. Ro was least and highest when the infected partner possessed protective and detrimental CCL3L1-CCR5 genotypes, respectively. The modeling data indicate that in populations such as Pygmies with a high CCL3L1 gene dose and protective CCR5 genotypes, the spread of HIV might be minimal. Additionally, Pc, the critical vaccination proportion, an estimate of the fraction of the population that must be vaccinated successfully to eradicate an epidemic was <1 only when the infected partner had a protective CCL3L1-CCR5 genotype. Since in practice Pc cannot be >1, to prevent epidemic spread, population groups defined by specific CCL3L1-CCR5 genotypes might require repeated vaccination, or as our models suggest, a vaccine with an efficacy of >70%. Further, failure to account for CCL3L1-CCR5-based genetic risk might confound estimates of vaccine efficacy. For example, in a modeled trial of 500 subjects, misallocation of CCL3L1-CCR5 genotype of only 25 (5%) subjects between placebo and vaccine arms results in a relative error of similar to 12% from the true vaccine efficacy. Conclusions: CCL3L1-CCR5 genotypes may impact on the dynamics of the HIV epidemic and, consequently, the observed heterogeneous global distribution of HIV infection. As Ro is lowest when the infecting partner has beneficial CCL3L1-CCR5 genotypes, we infer that therapeutic vaccines directed towards reducing the infectivity of the host may play a role in halting epidemic spread. Further, CCL3L1-CCR5 genotype may provide critical guidance for optimizing the design and evaluation of HIV-1 vaccine trials and prevention programs. C1 [Kulkarni, Hemant; Crawford, George; Clark, Robert A.; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. [Marconi, Vincent C.; Agan, Brian K.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD USA. [Marconi, Vincent C.; Dolan, Matthew J.] Wilford Hall US Air Force Med Ctr, Infect Dis Serv, Lackland AFB, TX USA. [Marconi, Vincent C.; Dolan, Matthew J.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA. [McArthur, Carole] Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO USA. [Dolan, Matthew J.] Wilford Hall US Air Force Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr, Dept Med, Microbiol & Immunol & Biochem, San Antonio, TX USA. RP Kulkarni, H (reprint author), S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. EM kulkarnih@uthscsa.edu; ahujas@uthscsa.edu RI Marconi, Vincent/N-3210-2014 OI Marconi, Vincent/0000-0001-8409-4689; Agan, Brian/0000-0002-5114-1669 FU Veterans Administration (VA) Center on AIDS and HIV infection of the South Texas Veterans Health Care System; MERIT [R37046326]; NIH [AI043279, MH069270]; Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical Scientist Award in Translational Research; Infectious Disease Clinical Research Program (IDCRP) of the Uniformed Services University of the Health Sciences (USUHS); Henry M. Jackson Foundation for the Advancement of Military Medicine; HHS/NIH/NIAID/DCR [HU0001-05-2-0011] FX This work was supported by the Veterans Administration (VA) Center on AIDS and HIV infection of the South Texas Veterans Health Care System, and a MERIT (R37046326) and other awards (AI043279 and MH069270) from the NIH to S.K.A. S.K.A. is also supported by a VA MERIT award and is a recipient of the Elizabeth Glaser Scientist Award and the Burroughs Wellcome Clinical Scientist Award in Translational Research. Support for the DoD HIV Natural History Study cohort and staff involved in this work was provided by the Infectious Disease Clinical Research Program (IDCRP) of the Uniformed Services University of the Health Sciences (USUHS), of which the Tri-Service AIDS Clinical Consortium (TACC) is a component. The IDCRP is a Department of Defense tri-service program executed through USUHS and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), in collaboration with HHS/NIH/NIAID/DCR through Interagency Agreement HU0001-05-2-0011. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting the views of the Departments of the Army, Navy, Air Force, or the Department of Defense. NR 96 TC 15 Z9 16 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 7 PY 2008 VL 3 IS 11 AR e3671 DI 10.1371/journal.pone.0003671 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 432LM UT WOS:000265134600007 PM 18989363 ER PT J AU Woody, GE Poole, SA Subramaniam, G Dugosh, K Bogenschutz, M Abbott, P Patkar, A Publicker, M McCain, K Potter, JS Forman, R Vetter, V McNicholas, L Blaine, J Lynch, KG Fudala, P AF Woody, George E. Poole, Sabrina A. Subramaniam, Geetha Dugosh, Karen Bogenschutz, Michael Abbott, Patrick Patkar, Ashwin Publicker, Mark McCain, Karen Potter, Jennifer Sharpe Forman, Robert Vetter, Victoria McNicholas, Laura Blaine, Jack Lynch, Kevin G. Fudala, Paul TI Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth A Randomized Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID METHADONE-MAINTENANCE TREATMENT; DRUG-USERS; DEPENDENCE; ABUSE; PHARMACOLOGY; NALTREXONE; INJECTION; RELAPSE AB Context The usual treatment for opioid- addicted youth is detoxification and counseling. Extended medication- assisted therapy may be more helpful. Objective To evaluate the efficacy of continuing buprenorphine- naloxone for 12 weeks vs detoxification for opioid- addicted youth. Design, Setting, and Patients Clinical trial at 6 community programs from July 2003 to December 2006 including 152 patients aged 15 to 21 years who were randomized to 12 weeks of buprenorphine- naloxone or a 14- day taper (detox). Interventions Patients in the 12- week buprenorphine- naloxone group were prescribed up to 24 mg per day for 9 weeks and then tapered to week 12; patients in the detox group were prescribed up to 14 mg per day and then tapered to day 14. All were offered weekly individual and group counseling. Main Outcome Measure Opioid- positive urine test result at weeks 4, 8, and 12. Results The number of patients younger than 18 years was too small to analyze separately, but overall, patients in the detox group had higher proportions of opioidpositive urine test results at weeks 4 and 8 but not at week 12 (chi(2)(2) = 4.93, P =. 09). At week 4, 59 detox patients had positive results ( 61%; 95% confidence interval [CI]= 47%-75%) vs 58 12- week buprenorphine- naloxone patients (26%; 95% CI= 14%- 38%). At week 8, 53 detox patients had positive results ( 54%; 95% CI= 38%- 70%) vs 52 12- week buprenorphine- naloxone patients ( 23%; 95% CI= 11%- 35%). At week 12, 53 detox patients had positive results (51%; 95% CI= 35%- 67%) vs 49 12- week buprenorphine-naloxone patients (43%; 95% CI= 29%-57%). By week 12, 16 of 78 detox patients ( 20.5%) remained in treatment vs 52 of 74 12- week buprenorphine-naloxone patients ( 70%; chi(2)(1) = 32.90, P <. 001). During weeks 1 through 12, patients in the 12- week buprenorphine- naloxone group reported less opioid use (chi(2)(1) = 18.45, P <. 001), less injecting (chi(2)(1) = 6.00, P =. 01), and less nonstudy addiction treatment (chi(2)(1) = 25.82, P <. 001). High levels of opioid use occurred in both groups at follow-up. Four of 83 patients who tested negative for hepatitis C at baseline were positive for hepatitis C at week 12. Conclusions Continuing treatment with buprenorphine- naloxone improved outcome compared with short-term detoxification. Further research is necessary to assess the efficacy and safety of longer- term treatment with buprenorphine for young individuals with opioid dependence. Trial Registration clinicaltrials. gov Identifier: NCT00078130. C1 [Woody, George E.; Poole, Sabrina A.; Dugosh, Karen; Forman, Robert; McNicholas, Laura; Lynch, Kevin G.; Fudala, Paul] Univ Penn, Dept Psychiat, Treatment Res Inst, Philadelphia, PA 19106 USA. [Subramaniam, Geetha] Johns Hopkins Univ, Div Child & Adolescent Psychiat, Baltimore, MD USA. [Bogenschutz, Michael; Abbott, Patrick] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. [Bogenschutz, Michael] Univ New Mexico, Ctr Alcoholism Substance Abuse & Addict, Albuquerque, NM 87131 USA. [Abbott, Patrick] Univ New Mexico, Hlth Sci Ctr, Addict Program, Albuquerque, NM 87131 USA. [Abbott, Patrick] Univ New Mexico, Hlth Sci Ctr, Substance Abuse Program, Albuquerque, NM 87131 USA. [Patkar, Ashwin] Duke Univ, Med Ctr, Durham, NC USA. [Publicker, Mark] Mercy Recovery Ctr, Westbrook, ME USA. [McCain, Karen] Duke Univ, Duke Addict Program, Durham, NC USA. [Potter, Jennifer Sharpe] Harvard Univ, Sch Med, Boston, MA USA. [Potter, Jennifer Sharpe] McLean Hosp, Belmont, MA 02178 USA. [Vetter, Victoria] Childrens Hosp Philadelphia, Div Pediat Cardiol, Philadelphia, PA 19104 USA. [Woody, George E.; McNicholas, Laura; Fudala, Paul] Vet Affairs Med Ctr, Philadelphia, PA USA. [Blaine, Jack] NIDA, Ctr Clin Trials Network, Bethesda, MD 20892 USA. RP Woody, GE (reprint author), Univ Penn, Dept Psychiat, Treatment Res Inst, 150 S Independence Mall W,Ste 600, Philadelphia, PA 19106 USA. EM woody@tresearch.org RI Potter, Jennifer/C-6720-2008 OI Potter, Jennifer/0000-0002-7250-4422 FU National Institute on Drug Abuse [U10-DA013711, U10-DA015831, U10-DA13034, K12-DA000357, U10-DA1533, U10DA13043, KO5-DA17009] FX This study was supported by the following grants from the National Institute on Drug Abuse: U10-DA013711 to Duke University (Dr Patkar); U10-DA015831 to Harvard University (Dr Weiss); U10-DA13034 to Johns Hopkins University (Dr Stitzer); K12-DA000357 (Dr Subramaniam); U10-DA1533 to the University of New Mexico (Dr Miller); and U10DA13043 and KO5-DA17009 (Dr Woody). Reckitt Benckiser provided medication for the study. NR 35 TC 139 Z9 140 U1 2 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 5 PY 2008 VL 300 IS 17 BP 2003 EP 2011 DI 10.1001/jama.2008.574 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 368EX UT WOS:000260605400020 PM 18984887 ER PT J AU Lee, MH Klein, RL El-Shewy, HM Luttrell, DK Luttrell, LM AF Lee, Mi-Hye Klein, Richard L. El-Shewy, Hesham M. Luttrell, Deirdre K. Luttrell, Louis M. TI The Adiponectin Receptors AdipoR1 and AdipoR2 Activate ERK1/2 through a Src/Ras-Dependent Pathway and Stimulate Cell Growth SO BIOCHEMISTRY LA English DT Article ID PROTEIN-COUPLED RECEPTORS; COMPLEMENT-RELATED PROTEIN; FATTY-ACID OXIDATION; ENDOTHELIAL-CELLS; INSULIN-RESISTANCE; NITRIC-OXIDE; MAP KINASE; KAPPA-B; ACRP30/ADIPONECTIN; ACRP30 AB Adiponectin is an adipocyte-derived cytokine that has attracted much attention because of its insulin-sensitizing effects in liver and skeletal muscle. Two adiponectin receptors, AdipoR1/R2, have been cloned, but relatively little is known about their intracellular signaling mechanisms. We found that full-length adiponectin rapidly and robustly activates the ERK1/2 mitogen-activated protein kinase pathway in primary vascular smooth muscle, vascular endothelial cells, and hepatocytes. In a HEK293 cell model, we found that downregulating AdipoR1/R2 simultaneously, but not individually, by RNA interference attenuated adiponectin-induced ERK1/2 activation, suggesting that either receptor was sufficient to mediate the response. Downregulation of T-cadherin, another adiponectin binding protein, enhanced. the response. Downregulation of APPL1, an adapter protein and putative mediator of AdipoR1/R2 signaling, impaired adiponectin-stimulated ERK1/2 activation. Inhibiting PKA modestly attenutated ERK1/2 activation, while inhibition of Src family tyrosine kinases with PP2 abolished the response. The small GTPase inhibitor Clostridium difficile toxin B also produced complete inhibition. Adiponectin caused rapid, PP2-sensitive activation of Ras, but not the cAMP-regulated small GTPase, Rap1, suggesting that Src-dependent Ras activation is the dominant mechanism of adiponectin-stimulated ERK1/2 activation. To test whether Ras-ERK1/2 signaling by adiponectin was physiologically relevant, we determined the effects of overexpressing AdipoR1, adiponectin, or both on the rate of HEK293 cell growth. Overexpression of adiponectin alone, but not AdipoR1 alone, supported growth under serum-free conditions, while simultaneous expression of both led to further enhancement. These results suggest that adiponectin can exert proliferative effects by activating Ras signaling pathways. C1 [Lee, Mi-Hye; Klein, Richard L.; El-Shewy, Hesham M.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Lee, Mi-Hye; Klein, Richard L.; El-Shewy, Hesham M.; Luttrell, Deirdre K.; Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Klein, Richard L.; Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St 816 CSB,MSC6ZY, Charleston, SC 29425 USA. EM luttrell@musc.edu FU National Institutes of Health [DK58283]; Department of Veterans Affairs Merit; Research Enhancement Award Program FX This work was supported by National Institutes of Health Grant DK58283 (L.M.L.) and Department of Veterans Affairs Merit (R.L.K.) and Research Enhancement Award Program (L.M.L.) awards. NR 39 TC 63 Z9 66 U1 1 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD NOV 4 PY 2008 VL 47 IS 44 BP 11682 EP 11692 DI 10.1021/bi801451f PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 366TU UT WOS:000260507100033 PM 18842004 ER PT J AU An, J Mo, D Liu, H Veena, MS Srivatsan, ES Massoumi, R Rettig, MB AF An, Jiabin Mo, Deqiong Liu, Huiren Veena, Mysore S. Srivatsan, Eri S. Massoumi, Ramin Rettig, Matthew B. TI Inactivation of the CYLD Deubiquitinase by HPV E6 Mediates Hypoxia-Induced NF-kappa B Activation SO CANCER CELL LA English DT Article ID HUMAN-PAPILLOMAVIRUS TYPE-16; GENE-EXPRESSION; ASPARAGINYL HYDROXYLASE; TUMOR MICROENVIRONMENT; EPITHELIAL-CELLS; INDUCIBLE FACTOR; CERVICAL-CANCER; KINASE PATHWAYS; P53; PROTEIN AB The biochemical mechanisms that underlie hypoxia-induced NF-kappa B activity have remained largely undefined. Here, we find that prolonged hypoxia-induced NF-kappa B activation is restricted to cancer cell lines infected with high-risk human papillomavirus (HPV) serotypes. The HPV-encoded E6 protein is necessary and sufficient for prolonged hypoxia-induced NF-kappa B activation in these systems. The molecular target of E6 in the NF-kappa B pathway is the CYLD lysine 63 (K63) deubiquitinase, a negative regulator of the NF-kappa B pathway. Specifically, hypoxia stimulates E6-mediated ubiquitination and proteasomal degradation of CYLD. Given the established role of NF-kappa B in human carcinogenesis, these findings provide a potential molecular/viral link between hypoxia and the adverse clinical outcomes observed in HPV-associated malignancies. C1 [An, Jiabin; Mo, Deqiong; Liu, Huiren; Rettig, Matthew B.] VA Greater Los Angeles Healthcare Syst W Los Ange, Dept Med, Los Angeles, CA 90095 USA. [Veena, Mysore S.; Srivatsan, Eri S.] VA Greater Los Angeles Healthcare Syst W Los Ange, Dept Surg, Los Angeles, CA 90095 USA. [Massoumi, Ramin] Lund Univ, Malmo Univ Hosp, Dept Lab Med Cell & Expt Pathol, SE-20502 Malmo, Sweden. [Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA. [Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. RP Rettig, MB (reprint author), VA Greater Los Angeles Healthcare Syst W Los Ange, Dept Med, Los Angeles, CA 90095 USA. EM mrettig@mednet.ucla.edu OI Massoumi, Ramin/0000-0001-8875-6440 FU NIH and the US Department of Veterans Affairs; NIH [2P30DK041301] FX This work was supported by the NIH and the US Department of Veterans Affairs (to M.B.R.). We thank C. Logg and N. Kasahara (UCLA) for helpful advice, the UCLA Vector Core (NIH grant 2P30DK041301) for production of viral vectors, and G. Cheng and A. Lichtenstein for helpful NR 53 TC 52 Z9 56 U1 0 U2 6 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 J9 CANCER CELL JI Cancer Cell PD NOV 4 PY 2008 VL 14 IS 5 BP 394 EP 407 DI 10.1016/j.ccr.2008.10.007 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 369OC UT WOS:000260702800008 PM 18977328 ER PT J AU Yang, T Knowles, JK Lu, Q Zhang, H Arancio, O Moore, LA Chang, T Wang, Q Andreasson, K Rajadas, J Fuller, GG Xie, YM Massa, SM Longo, FM AF Yang, Tao Knowles, Juliet K. Lu, Qun Zhang, Hong Arancio, Ottavio Moore, Laura A. Chang, Timothy Wang, Qian Andreasson, Katrin Rajadas, Jayakumar Fuller, Gerald G. Xie, Youmei Massa, Stephen M. Longo, Frank M. TI Small Molecule, Non-Peptide p75(NTR) Ligands Inhibit A beta-Induced Neurodegeneration and Synaptic Impairment SO PLOS ONE LA English DT Article AB The p75 neurotrophin receptor (p75(NTR)) is expressed by neurons particularly vulnerable in Alzheimer's disease (AD). We tested the hypothesis that non-peptide, small molecule p75(NTR) ligands found to promote survival signaling might prevent A beta-induced degeneration and synaptic dysfunction. These ligands inhibited Ab-induced neuritic dystrophy, death of cultured neurons and A beta-induced death of pyramidal neurons in hippocampal slice cultures. Moreover, ligands inhibited A beta-induced activation of molecules involved in AD pathology including calpain/cdk5, GSK3b and c-Jun, and tau phosphorylation, and prevented A beta-induced inactivation of AKT and CREB. Finally, a p75(NTR) ligand blocked A beta-induced hippocampal LTP impairment. These studies support an extensive intersection between p75(NTR) signaling and A beta pathogenic mechanisms, and introduce a class of specific small molecule ligands with the unique ability to block multiple fundamental AD-related signaling pathways, reverse synaptic impairment and inhibit Ab-induced neuronal dystrophy and death. C1 [Yang, Tao; Knowles, Juliet K.; Chang, Timothy; Wang, Qian; Andreasson, Katrin; Rajadas, Jayakumar; Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Yang, Tao; Knowles, Juliet K.; Moore, Laura A.; Xie, Youmei; Longo, Frank M.] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA. [Lu, Qun] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC USA. [Zhang, Hong; Arancio, Ottavio] Columbia Univ, Taub Inst, Dept Pathol, New York, NY 10027 USA. [Rajadas, Jayakumar; Fuller, Gerald G.] Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA. [Massa, Stephen M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Dept Neurol, Lab Computat Neurochem & Drug Discovery, San Francisco, CA USA. RP Yang, T (reprint author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. EM longo@stanford.edu FU Institute for the Study of Aging; Alzheimer's Association; Eastern Chapter of the North Carolina Alzheimer's Association; NINDS [F30 NA051971]; NIA [AG026630]; NCI [CA111891, NS049442]; Veterans Administration FX This project was supported by the Institute for the Study of Aging (FL), Alzheimer's Association (FL), the Eastern Chapter of the North Carolina Alzheimer's Association (FL), NINDS F30 NA051971 (JK), NIA AG026630 (QL), NCI CA111891 (QL), NS049442 (OA) and the Veterans Administration (SM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 58 Z9 60 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 3 PY 2008 VL 3 IS 11 AR e3604 DI 10.1371/journal.pone.0003604 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 432LI UT WOS:000265134200003 PM 18978948 ER PT J AU Hardy, DJ Castellon, SA Hinkin, CH Levine, AJ Lam, MN AF Hardy, David J. Castellon, Steven A. Hinkin, Charles H. Levine, Andrew J. Lam, Mona N. TI Sensation Seeking and Visual Selective Attention in Adults with HIV/AIDS SO AIDS AND BEHAVIOR LA English DT Article DE HIV; AIDS; Cognition; Personality; Performance; Individual differences ID INTRAVENOUS-DRUG-USERS; HIV-INFECTED ADULTS AB The association between sensation seeking and visual selective attention was examined in 31 adults with the Human Immunodeficiency Virus (HIV). Sensation seeking was measured with Zuckerman's Sensation Seeking Scale Form V (SSS-V). Selective attention was assessed with a perceptual span task, where a target letter-character must be identified in a quickly presented array of nontarget letter-characters. As predicted, sensation seeking was strongly associated (R-2 = .229) with perceptual span performance in the array size 12 condition, where selective attention demands were greatest, but not in the easier conditions. The Disinhibition, Boredom Susceptibility, and Experience Seeking subscales of the SSS-V were associated with span performance. It is argued that personality factors such as sensation seeking may play a significant role in selective attention and related cognitive abilities in HIV positive adults. Furthermore, sensation seeking differences might explain certain inconsistencies in the HIV neuropsychology literature. C1 [Hardy, David J.] Loyola Marymount Univ, Dept Psychol, Los Angeles, CA 90045 USA. [Hardy, David J.; Castellon, Steven A.; Hinkin, Charles H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Castellon, Steven A.; Hinkin, Charles H.; Lam, Mona N.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Levine, Andrew J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Lam, Mona N.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. RP Hardy, DJ (reprint author), Loyola Marymount Univ, Dept Psychol, Suite 4700, Los Angeles, CA 90045 USA. EM dhardy@lmu.edu FU NIA NIH HHS [R03 AG-18549, R03 AG018549-01]; NIMH NIH HHS [R01 MH-58552, R01 MH058552, R01 MH058552-05, T32 MH-19535, T32 MH019535, T32 MH019535-18] NR 12 TC 5 Z9 5 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD NOV PY 2008 VL 12 IS 6 BP 930 EP 934 DI 10.1007/s10461-007-9288-6 PG 5 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 359CC UT WOS:000259962800012 PM 17701336 ER PT J AU Korthuis, PT Zephyrin, LC Fleishman, JA Saha, S Josephs, JS McGrath, MM Hellinger, J Gebo, KA AF Korthuis, P. Todd Zephyrin, Laurie C. Fleishman, John A. Saha, Somnath Josephs, Joshua S. McGrath, Moriah M. Hellinger, James Gebo, Kelly A. CA HIV Res Network TI Health-Related Quality of Life in HIV-Infected Patients: The Role of Substance Use SO AIDS PATIENT CARE AND STDS LA English DT Article ID MULTICENTER AIDS COHORT; UNITED-STATES; SERVICES UTILIZATION; PSYCHIATRIC-DISORDERS; ANTIRETROVIRAL THERAPY; ABUSE TREATMENT; MENTAL-HEALTH; OPIATE USERS; DRUG-USE; ADULTS AB HIV infection and substance use disorders are chronic diseases with complex contributions to health-related quality of life (HRQOL). We conducted a cross-sectional survey of 951 HIV-infected adults receiving care at 14 HIV Research Network sites in 2003 to estimate associations between HRQOL and specific substance use among HIV-infected patients. HRQOL was assessed by multi-item measures of physical and role functioning, general health, pain, energy, positive affect, anxiety, and depression. Mental and physical summary scales were developed by factor analysis. We used linear regression to estimate adjusted associations between HRQOL and current illicit use of marijuana, analgesics, heroin, amphetamines, cocaine, sedatives, inhalants, hazardous/binge alcohol, and drug use severity. Current illicit drug use was reported by 37% of subjects. Mental HRQOL was reduced for current users [adjusted beta coefficient -9.66, 95% confidence interval [(CI]) -13.4, -5.94] but not former users compared with never users. Amphetamines and sedatives were associated with large decreases in mental (amphetamines: beta = -22.8 [95% CI -33.5, -12.0], sedatives: beta = -18.6 [95% CI -26.2, -11.0]), and physical HRQOL (amphetamines: beta = -11.5 [95% CI -22.6, -0.43], sedatives: beta = -13.2 [95% CI -21.0, -5.36]). All illicit drugs were associated with decreased mental HRQOL: marijuana (beta = -7.72 [95% CI -12.0, -3.48]), non-prescription analgesics (beta = -13.4 [95% CI -20.8, -6.07]), cocaine (beta = -10.5 [95% CI -16.4, -4.67]), and inhalants (beta = -14.0 [95% CI -24.1, -3.83]). Facilitating sobriety for patients with attention to specific illicit drugs represents an important avenue for elevating HRQOL in patients living with HIV. C1 [Korthuis, P. Todd; Saha, Somnath; McGrath, Moriah M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Zephyrin, Laurie C.] Columbia Univ, Dept Obstet & Gynecol, New York, NY USA. [Fleishman, John A.] Agcy Healthcare Res & Qual, Rockville, MD USA. [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. [Josephs, Joshua S.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Hellinger, James] Community Med Alliance, Boston, MA USA. RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA. EM korthuis@ohsu.edu FU Agency for Healthcare Research and Quality [290-01-0012]; National Institutes of Aging [R01 AG026250, K23 AA015313, K23-DA00523, K-23-DA019820]; Department of Veterans Affairs Health Services Research & Development Service; Robert Wood Johnson Foundation; Johns Hopkins Clinician Scientist FX Participating Sites: Alameda County Medical Center, Oakland, California (Silver Sisneros, D. O.); Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (Richard Rutstein, M. D.); Community Health Network, Rochester, New York (Roberto Corales, D. O.); Community Medical Alliance, Boston, Massachusetts (James Hellinger, M. D.); Drexel University, Philadelphia, Pennsylvania (Peter Sklar, M. D.); Henry Ford Hospital Detroit, Michigan (Norman Markowitz, M. D.); Johns Hopkins University, Baltimore, Maryland (Kelly Gebo, M. D., Richard Moore, M. D); Montefiore Medical Group, Bronx, New York (Robert Beil, M. D.); Montefiore Medical Center, Bronx, New York (Lawrence Hanau, M. D.); Nemechek Health Renewal, Kansas City, Missouri (Patrick Nemechek, D. O.); Oregon Health and Science University, Portland, Oregon (P. Todd Korthuis, M. D.); Parkland Health and Hospital System, Dallas, Texas (Philip Keiser, M. D.); St. Jude's Children's Hospital and University of Tennessee, Memphis, Tennessee (Aditya Gaur, M. D.); St. Luke's Roosevelt Hospital Center, New York, New York (Victoria Sharp, M. D.); Tampa General Health Care, Tampa, Florida (Charurut Somboonwit, M. D., Jeffrey Nadler, M. D.); University of California, San Diego, La Jolla, California (Stephen Spector, M. D.); University of California, San Diego, California (W. Christopher Mathews, M. D.); Wayne State University, Detroit, Michigan (Lawrence Crane, M. D.).; Sponsoring Agencies: Agency for Healthcare Research and Quality, Rockville, Maryland (Fred Hellinger, Ph. D., John Fleishman, Ph. D., Irene Fraser, Ph. D.); Health Resources and Services Administration, Rockville, Maryland (Alice Kroliczak, Ph. D., Robert Mills, Ph. D., Richard Conviser, Ph. D.); Substance Abuse and Mental Health Services Administration, Rockville, Maryland (Laura House, Ph. D., Joan Dilonardo, Ph. D.); Office of AIDS Research, NIH, Bethesda, Maryland (Paul Gaist, Ph. D, M. P. H.).; Supported by the Agency for Healthcare Research and Quality (290-01-0012) and the National Institutes of Aging (R01 AG026250) Alcohol (K23 AA015313) and Drug Abuse (K23-DA00523 and K-23-DA019820). Dr. Saha is supported by an Advanced Research Career Development Award from the Department of Veterans Affairs Health Services Research & Development Service, and a Generalist Physician Faculty Scholar Award from The Robert Wood Johnson Foundation. Dr. Gebo also received support from a Johns Hopkins Clinician Scientist Award.; The views expressed in this paper are those of the authors. No official endorsement by DHHS, the National Institutes of Health, the Agency for Healthcare Research and Quality, the Robert Wood Johnson Foundation, or the Department of Veterans Affairs is intended or should be inferred. NR 48 TC 36 Z9 37 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD NOV PY 2008 VL 22 IS 11 BP 859 EP 867 DI 10.1089/apc.2008.0005 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 378SM UT WOS:000261344200004 PM 19025480 ER PT J AU Durazzo, TC Gazdzinski, S Yeh, PH Meyerhoff, DJ AF Durazzo, Timothy C. Gazdzinski, Stefan Yeh, Ping-Hong Meyerhoff, Dieter J. TI Combined Neuroimaging, Neurocognitive and Psychiatric Factors to Predict Alcohol Consumption Following Treatment for Alcohol Dependence SO ALCOHOL AND ALCOHOLISM LA English DT Article ID MAGNETIC-RESONANCE-SPECTROSCOPY; MAJOR DEPRESSIVE DISORDER; POSTTREATMENT ALCOHOLICS; CLINICAL-IMPLICATIONS; COGNITIVE EFFICIENCY; ABSTINENT ALCOHOLICS; N-ACETYLASPARTATE; FEMALE ALCOHOLICS; PREFRONTAL CORTEX; BIPOLAR DISORDER AB Aims: Resumption of hazardous drinking after treatment is common in alcohol use disorders (AUD). This study examined the ability of multimodality magnetic resonance, neurocognitive, psychiatric and demographic, to predict alcohol consumption after treatment for AUD. Methods: Seventy treatment-seeking participants completed 1.5T magnetic resonance studies, yielding regional gray matter (GM) and white matter (WM) surrogate markers of neuronal integrity (N-acetylaspartate: NAA) and cell membrane turnover/synthesis (choline: Cho), assessment of major psychiatric disorders and comprehensive neurocognitive assessment after similar to 1 month of abstinence. Participants were followed up 6-12 months after treatment and classified as Abstainers (no alcohol consumption; n = 26) and Resumers (any alcohol consumption; n = 44). Abstainers and Resumers were contrasted on various outcome measures, and those that significantly differed between groups were entered as factors in a logistical regression model to predict drinking status at follow-up. Results: The following variables were independent predictors of resumption of drinking: temporal GM NAA, frontal WM NAA, frontal GM Cho, processing speed and comorbid unipolar mood disorder. With each standard deviation unit decrease in temporal GM NAA, frontal WM NAA, frontal GM Cho and processing speed, the odds of resumption of drinking were increased 3.1, 3.3, 6.4 and 14.2 times, respectively. Diagnosis of a unipolar mood disorder was associated with 14.5-fold increased odds of resumed drinking. Conclusions: The findings suggest that Resumers, relative to Abstainers, demonstrated greater abnormalities in anterior frontal-subcortical circuits involved in mood and behavioral regulation, and development and maintenance of alcohol use disorders, The magnetic resonance-derived variables used in this study may provide additional information regarding the prediction and neurobiological correlates of resumption of hazardous drinking. C1 [Durazzo, Timothy C.; Yeh, Ping-Hong; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Durazzo, Timothy C.; Gazdzinski, Stefan; Yeh, Ping-Hong; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. RP Durazzo, TC (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu FU NIH [AA10788] FX This project was supported by NIH AA10788 (D. J. M.). We thank Mary RebeccaYoung and Bill Clift of the VA Substance Abuse Day Hospital and Dr David Pating, Karen Moise and their colleagues at the Kaiser Permanente Chemical Dependency Recovery Program for their valuable assistance in recruiting participants. We also wish to extend our gratitude to the study participants, who made this research possible. NR 95 TC 39 Z9 39 U1 0 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0735-0414 J9 ALCOHOL ALCOHOLISM JI Alcohol Alcohol. PD NOV-DEC PY 2008 VL 43 IS 6 BP 683 EP 691 DI 10.1093/alcalc/agn078 PG 9 WC Substance Abuse SC Substance Abuse GA 365BN UT WOS:000260381000015 PM 18818189 ER PT J AU Voronin, K Randall, P Myrick, H Anton, R AF Voronin, Konstantin Randall, Patrick Myrick, Hugh Anton, Raymond TI Aripiprazole Effects on Alcohol Consumption and Subjective Reports in a Clinical Laboratory Paradigm-Possible Influence of Self-Control SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol; Aripiprazole; Laboratory; Treatment ID CUE-INDUCED ACTIVATION; EXTRACELLULAR DOPAMINE; ABSTINENT ALCOHOLICS; ETHANOL-CONSUMPTION; PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS; IMAGING EVIDENCE; SOCIAL DRINKERS; DRUG-ADDICTION; C57BL/6 MICE AB Introduction: There has been increasing interest in the use of medications that affect the dopamine receptor in the treatment of alcoholism. Aripiprazole has the unique pharmacology of being a partial dopamine agonist serving to stabilize brain dopamine systems in both frontal cortical and subcortical areas. As such, it might act to dampen alcohol reinforcement and craving and/or alter control over alcohol use. The current clinical laboratory study was conducted to evaluate the safety and efficacy of aripiprazole as a potential agent to alter drinking and objective effects of alcohol. Methods: Thirty nontreatment seeking alcoholics were enrolled in a subacute human laboratory study and received double-blind treatment with up to 15 mg of aripiprazole (n = 15) or identical placebo (n = 15) for 8 days. Tolerability and utility of aripiprazole was monitored during natural drinking over the first 6 days of medication treatment and also during a free choice limited access alcohol consumption paradigm following an initial drink of alcohol in a bar-lab setting on Day 8. Results: Aripiprazole was well tolerated and reduced drinking in nontreatment seeking alcoholics over 6 days of natural drinking-especially in those with lower self control (more impulsive). It also reduced drinks in the bar-lab after a priming drink and broke the link between priming drink induced stimulation and further drinking. During the bar-lab drinking session, there were no differences in subjective high, intoxication, or craving between subjects treated with aripiprazole or placebo. Discussion: This study joins several others in demonstrating the utility of subacute dosing laboratory paradigms for evaluating medication effects in alcoholics. Aripiprazole was well tolerated and lowered alcohol use, especially in those with lower impulse control. Further study is needed to determine the safety and utility of aripiprazole in the treatment of alcoholism and if subgroups of alcoholics are more likely to respond. C1 [Voronin, Konstantin; Randall, Patrick; Myrick, Hugh; Anton, Raymond] Med Univ S Carolina, Dept Psychiat & Behav Sci, Alcohol Res Ctr, Charleston, SC 29425 USA. [Myrick, Hugh] Res & Dev Serv, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Voronin, K (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Alcohol Res Ctr, IOP 4N,67 President St, Charleston, SC 29425 USA. EM voronin@musc.edu FU Alcohol Research Center [P50 AA010761] FX Abraham Tiffany assisted in collection of data. Nancy White and Mary Evelyn Boyd assisted in preparation of this manuscript. Supported was granted by Alcohol Research Center Grant P50 AA010761. NR 57 TC 31 Z9 32 U1 5 U2 8 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0145-6008 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD NOV PY 2008 VL 32 IS 11 BP 1954 EP 1961 DI 10.1111/j.1530-0277.2008.00783.x PG 8 WC Substance Abuse SC Substance Abuse GA 362FK UT WOS:000260183400012 PM 18782344 ER PT J AU Hachem, CY Kramer, JR Kanwal, F El-Serag, HB AF Hachem, C. Y. Kramer, J. R. Kanwal, F. El-Serag, H. B. TI Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large veterans administration medical centre SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID CHRONIC LIVER-DISEASE; VIRUS SUPERINFECTION; B VACCINATION; QUALITY; CARE; IMMUNOGENICITY; INFECTION; AGREEMENT; CIRRHOSIS AB Background Hepatitis vaccination is recommended in patients with chronic liver disease. Aim To validate Current Procedural Terminology (CPT) codes and drug codes for hepatitis vaccination in administrative databases and determine vaccination rates in hepatitis C virus (HCV)-infected patients in a single large Veterans Administration Medical Center. Methods We calculated predictive values for hepatitis vaccination codes in a validation set of 168 patients. We then conducted a retrospective cohort study of 243 HCV-infected patients to determine rates of hepatitis vaccination and serological testing. Results The presence of CPT or drug codes for hepatitis A vaccine yielded a positive predictive value (PPV) and negative predictive value (NPV) of 93.2% and 94.0%. The presence of hepatitis B vaccine codes yielded a PPV of 98.0% and an NPV of 94.0%. Among patients diagnosed with HCV between 2000 and 2005, receipt of hepatitis vaccination was documented in approximately 8% overall and 7% in patients with cirrhosis. Half of the patients without hepatitis vaccinations were either not tested for immunity or had negative serology. Conclusions Current Procedural Terminology or drug codes for hepatitis vaccinations in administrative data are highly predictive of the presence of vaccinations in medical records. Our data suggest that there is significant under-utilization of vaccination in patients with HCV. C1 [Hachem, C. Y.; Kramer, J. R.; El-Serag, H. B.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Hachem, C. Y.; Kramer, J. R.; El-Serag, H. B.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Hachem, C. Y.; El-Serag, H. B.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [Hachem, C. Y.; Kanwal, F.] St Louis Univ, Dept Med, St Louis, MO 63103 USA. RP Hachem, CY (reprint author), 3635 Vista Ave, St Louis, MO 63130 USA. EM chachem@slu.edu FU Health Services Research and Development Service; Office of Research and Development; Department of Veterans Affairs [MRP05-315, RCD00-013-2]; NIH [NCI R01 125487] FX Declaration of personal interests: None. Declaration of funding interests: This material is based on work supported in part by Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs, grant MRP05-315 to Dr Kramer and grant RCD00-013-2 to Dr El-Serag as well as funding (NIH NCI R01 125487) to Dr El-Serag and a grant to Dr Hachem from Bristol-Meyers Squibb as a part of the Virology Fellows Research Training Programme. NR 30 TC 15 Z9 15 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD NOV 1 PY 2008 VL 28 IS 9 BP 1078 EP 1087 DI 10.1111/j.1365-2036.2008.03827.x PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 357QX UT WOS:000259862300004 PM 18691350 ER PT J AU Kanwal, F Spiegel, BMR Hays, RD Durazo, F Han, SB Saab, S Bolus, R Kim, SJ Gralnek, IM AF Kanwal, F. Spiegel, B. M. R. Hays, R. D. Durazo, F. Han, S. B. Saab, S. Bolus, R. Kim, S. J. Gralnek, I. M. TI Prospective validation of the short form liver disease quality of life instrument SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID UNITED-STATES; TRANSPLANTATION; IMPACT; RELIABILITY; MEANINGFUL; CARCINOMA; CIRRHOSIS; SEVERITY; VALIDITY; INDEXES AB Background Despite the realization that health-related quality of life (HRQOL) is an important outcome in patients with liver disease, there is scarcity of disease-targeted HRQOL measures that have undergone prospective evaluation. Aim To validate prospectively the short form of liver disease quality of life instrument (the SF-LDQOL) in patients with advanced liver disease. Methods The SF-LDQOL includes 36 disease-targeted items representing nine domains: symptoms of liver disease, effects of liver disease, memory/concentration, sleep, hopelessness, distress, loneliness, stigma of liver disease and sexual problems. We administered the SF-LDQOL to 156 advanced liver disease patients at baseline and at 6-month follow-up. We estimated internal consistency reliability for multi-item scales, item discrimination across scale and evaluated construct validity by estimating the associations of SF-LDQOL scores with SF-36 scores, symptom severity and disability days. To evaluate the SF-LDQOL's responsiveness, we compared HRQOL changes for patients who received with those who did not receive liver transplantation (LT). Results The internal consistency reliability coefficients were >= 0.70 for seven of nine scales in baseline and for all scales in follow-up administration. The SF-LDQOL correlated highly with SF-36 scores, symptom severity, disability days and global health. Patients undergoing LT reported improved HRQOL compared with patients without LT and the responsiveness indices were excellent. Conclusions This study provides support for the reliability and validity of the SF-LDQOL in patients with advanced chronic liver disease. This instrument may be useful in everyday clinical practice and in future clinical trials. C1 [Gralnek, I. M.] Technion Israel Inst Technol, Rappaport Fac Med, Dept Gastroenterol, Rambam Med Ctr, IL-31096 Haifa, Israel. [Hays, R. D.] RAND Corp, Santa Monica, CA USA. [Kanwal, F.] St Louis Univ, Div Gastroenterol, St Louis, MO 63103 USA. [Kanwal, F.] John Cochran VA Med Ctr, St Louis, MO USA. [Kanwal, F.; Spiegel, B. M. R.; Bolus, R.; Kim, S. J.] Univ Calif Los Angeles, Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Spiegel, B. M. R.; Hays, R. D.; Durazo, F.; Han, S. B.; Saab, S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA 90095 USA. [Han, S. B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Gralnek, IM (reprint author), Technion Israel Inst Technol, Rappaport Fac Med, Dept Gastroenterol, Rambam Med Ctr, Rambam Hlth Care Campus, IL-31096 Haifa, Israel. EM i_gralnek@rambam.health.gov.il RI Hays, Ronald/D-5629-2013 FU American College of Gastroenterology Clinical Research Award 2003-2004 FX Declaration of funding interests: This study was funded by the American College of Gastroenterology Clinical Research Award 2003-2004. NR 43 TC 14 Z9 14 U1 13 U2 17 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD NOV 1 PY 2008 VL 28 IS 9 BP 1088 EP 1101 DI 10.1111/j.1365-2036.2008.03817.x PG 14 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 357QX UT WOS:000259862300005 PM 18671776 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Medical Groundhog Days SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material C1 Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Div Gastroenterol, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2008 VL 103 IS 11 BP 2681 EP 2682 DI 10.1111/j.1572-0241.2008.02143.x PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 367HU UT WOS:000260543900002 PM 19032463 ER PT J AU Chan, FKL Abraham, NS Scheiman, JM Laine, L AF Chan, Francis K. L. Abraham, Neena S. Scheiman, James M. Laine, Loren CA First Int Working Party Gastrointe TI Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID LOW-DOSE ASPIRIN; SELECTIVE CYCLO-OXYGENASE-2 INHIBITORS; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; HIGH-RISK; COX-2 INHIBITORS; PREVENTION; TRIAL; COMPLICATIONS; GUIDELINES AB BACKGROUND: Prescribing nonsteroidal antiinflammatory drugs (NSAIDs) is challenging because physicians have to consider gastrointestinal (GI) and cardiovascular (CV) safety issues. OBJECTIVE: The purpose of the study was to determine appropriate NSAID treatment strategies based on different combinations of GI and CV risks. METHODS: The working party comprised a multidisciplinary international panel of 19 experts. Two hundred eighty-eight vignettes were evaluated for the appropriateness of each of six options: naproxen, non-naproxen nonselective NSAIDs, naproxen plus proton pump inhibitor (PPI)/misoprostol, non-naproxen nonselective NSAID plus PPI/misoprostol, cyclooxygenase-2 selective NSAID (coxib), or coxib plus PPI/misoprostol. Using a two-stage modified Delphi process, the panel anonymously ranked the appropriateness of each option from 1 (extremely inappropriate) to 9 (extremely appropriate). Vignettes were considered appropriate if >= 80% of all panelists' scores were 7-9 and inappropriate if >= 80% of all panelists' scores were 1-3. RESULTS: The panel rated nonselective NSAIDs as appropriate when the patient had average GI risk (< 70 yr of age; no prior upper GI event; no corticosteroids, antithrombotic agents, anticoagulants). In patients with GI risk factors, cotherapy with a PPI/misoprostol was appropriate. Either a nonselective NSAID or a coxib was rated appropriate in patients with average CV risk; naproxen was preferred in patients with high CV risk. None of the options was considered appropriate in patients with multiple GI risk factors and high CV risk. CONCLUSIONS: The initial choice of an NSAID (naproxen vs. others) relates to a patient's CV risk, and the need for therapy to decrease GI complications (PPI/misoprostol or coxibs) is determined by severity and number of GI risk factors. C1 [Chan, Francis K. L.] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China. [Abraham, Neena S.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Abraham, Neena S.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [Abraham, Neena S.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Scheiman, James M.] Univ Michigan, Sch Med, Div Gastroenterol, Ann Arbor, MI USA. [Laine, Loren] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. RP Chan, FKL (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China. RI Hossain, Sarah /C-7332-2009; Chan, Francis K. L./F-4851-2010 OI Hossain, Sarah /0000-0003-1355-0979; Chan, Francis K. L./0000-0001-7388-2436 FU Institute of Digestive Disease, Chinese University of Hong Kong; Asia Pacific offices of AstraZeneca; Pfizer; Eisai; Altana Pharma and Takeda FX This work was funded by an educational grant from the Institute of Digestive Disease, Chinese University of Hong Kong, and supplemented by unrestricted educational funding from the Asia Pacific offices of AstraZeneca, Pfizer, Eisai, Altana Pharma and Takeda. The funders were not involved in the initiation or planning of this consensus meeting, selection of panel members, or drafting, editing or reviewing the manuscript. NR 45 TC 88 Z9 94 U1 1 U2 6 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD NOV PY 2008 VL 103 IS 11 BP 2908 EP 2918 DI 10.1111/j.1572-0241.2008.02200.x PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 367HU UT WOS:000260543900030 PM 18853980 ER PT J AU Rosenberg, PB Mielke, MM Tschanz, J Cook, L Corcoran, C Hayden, KM Norton, M Rabins, PV Green, RC Welsh-Bohmer, KA Breitner, JCS Munger, R Lyketsos, CG AF Rosenberg, P. B. Mielke, M. M. Tschanz, J. Cook, L. Corcoran, Chris Hayden, K. M. Norton, M. Rabins, P. V. Green, R. C. Welsh-Bohmer, K. A. Breitner, J. C. S. Munger, R. Lyketsos, C. G. TI Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 45th Annual Meeting of the American-College-of-Neuropsychopharmacology CY DEC 03-07, 2006 CL Hollywood, FL SP Amer Coll Neuropsychopharmacol DE Alzheimer disease; risk factors in epidemiology; medications; prognosis ID MILD COGNITIVE IMPAIRMENT; CACHE COUNTY; INCIDENT DEMENTIA; VASCULAR-DISEASE; STATIN THERAPY; BLOOD-PRESSURE; RISK-FACTORS; CHOLESTEROL; PROGRESSION; PREVALENCE AB Background: Evidence suggests that cardiovascular medications, including statins and antihypertensive medications, may delay cognitive decline in patients with Alzheimer dementia (AD). We examined the association of cardiovascular medication use and rate of functional decline in a population-based cohort of individuals with incident AD. Methods: In the Dementia Progression Study of the Cache County Study on Memory, Health, and Aging, 216 individuals with incident AD were identified and followed longitudinally with in-home visits for a mean of 3.0 years and 2.1 follow-up visits. The Clinical Dementia Rating (CDR) was completed at each follow-up. Medication use was inventoried during in-home visits. Generalized least-squares random-effects regression was performed with CDR Sum of Boxes (CDR-Sum) as the outcome and cardiovascular medication use as the major predictors. Results: CDR-Sum increased an average of 1.69 points annually, indicating a steady decline in functioning. After adjustment for demographic variables and the baseline presence of cardiovascular conditions, use of statins (p = 0.03) and beta-blockers (p = 0.04) was associated with a slower annual rate of increase in CDR-Sum (slower rate of functional decline) of 0.75 and 0.68 points respectively, while diuretic use was associated with a faster rate of increase in CDR-Sum (p = 0.01; 0.96 points annually). Use of calcium-channel blockers, angiotensin-converting enzyme inhibitors, digoxin, or nitrates did not affect the rate of functional decline. Conclusions: In this population-based study of individuals with incident AD, use of statins and beta-blockers was associated with delay of functional decline. Further studies are needed to confirm these results and to determine whether treatment with these medications may help delay AD progression. C1 [Rosenberg, P. B.] Johns Hopkins Univ, Sch Med, Div Geriatr Psychiat & Neuropsychiat, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA. [Tschanz, J.; Cook, L.; Corcoran, Chris; Norton, M.; Munger, R.] Utah State Univ, Logan, UT 84322 USA. [Hayden, K. M.; Welsh-Bohmer, K. A.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Green, R. C.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Breitner, J. C. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Breitner, J. C. S.] Univ Washington, Sch Med, Seattle, WA USA. RP Rosenberg, PB (reprint author), Johns Hopkins Univ, Sch Med, Div Geriatr Psychiat & Neuropsychiat, Johns Hopkins Bayview Med Ctr, 5300 Alpha Commons Dr,AC4, Baltimore, MD 21224 USA. EM prosenb9@jhmi.edu RI Corcoran, Chris/F-2155-2010; Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013; Hayden, Kathleen/B-6442-2012 OI Hayden, Kathleen/0000-0002-7745-3513 FU NIA NIH HHS [R01 AG018712-03, R01 AG021136, K08 AG029157, R01 AG011380-08, R01 AG018712, R01 AG021136-05] NR 43 TC 61 Z9 64 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD NOV PY 2008 VL 16 IS 11 BP 883 EP 892 DI 10.1097/JGP.0b013e318181276a PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 367FS UT WOS:000260538500005 PM 18978249 ER PT J AU Moran, A Katz, R Jenny, NS Astor, B Bluemke, DA Lima, JAC Siscovick, D Bertoni, AG Shlipak, MG AF Moran, Andrew Katz, Ronit Jenny, Nancy Swords Astor, Brad Bluemke, David A. Lima, Joao A. C. Siscovick, David Bertoni, Alain G. Shlipak, Michael G. TI Left Ventricular Hypertrophy in Mild and Moderate Reduction in Kidney Function Determined Using Cardiac Magnetic Resonance Imaging and Cystatin C: The Multi-Ethnic Study of Atherosclerosis (MESA) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Kidney disease; cystatin C; glomerular filtration rate; left ventricular hypertrophy; left ventricular mass; magnetic resonance imaging (MRI) ID NUTRITION EXAMINATION SURVEY; GLOMERULAR-FILTRATION-RATE; 3RD NATIONAL-HEALTH; STAGE RENAL-DISEASE; ELDERLY PERSONS; HEART-FAILURE; CARDIOVASCULAR HEALTH; SERUM CREATININE; MORTALITY RISK; UNITED-STATES AB Background: Left ventricular (LV) hypertrophy (LVH) is associated with chronic kidney disease, but the association of LVH with a mild decrease in kidney function is not known. We hypothesized that mild and moderate decreases in kidney function, reflected in greater serum cystatin C concentrations, would be linearly associated with a greater prevalence of LVH. Study Design: Cross-sectional observational study. Settings & Participants: Participants in baseline examinations in the Multi-Ethnic Study of Atherosclerosis (MESA), a population-based study with several sites in the United States. Predictors: Cystatin C-based estimated glomerular filtration rate (eGFR(cysC)) and creatinine-based eGFR. Outcomes: LVH and LV mass index. Measurements: Serum cystatin C and creatinine, LV mass obtained by using magnetic resonance imaging. LVH cutoff values for men and women were defined by the upper 95th percentile of LV mass index of all MESA participants without hypertension. Results: Of the 4,971 participants analyzed, mean creatinine-based eGFR was 81 +/- 17 (SD) mL/min/ 1.73 m(2) and mean eGFR(cysC) was 94 +/- 32 mL/min/1.73 m(2). LVH was distinctly more prevalent (> 12%) in only the lowest 2 deciles of eGFR(cysC) (<75 mL/min/1.73 m(2)). When 435 participants (9%) with stage 3 or higher chronic kidney disease (creatinine-based eGFR < 60 mL/min/1.73 m(2)) were excluded, the odds for LVH increased for each lower category of eGFR(cysC) less than 75 mL/min/1.73 m(2): odds ratio 1.6 for LVH with eGFR(cysC) of 60 to 75 mL/min/1.73 m(2) (95% confidence interval, 1.20 to 2.07; P = 0.001), and odds ratio 2.0 for eGFR(cysC) less than 60 mL/min/1.73 m(2) (95% confidence interval, 1.03 to 3.75; P = 0.04) after adjustment for demographic factors, study site, diabetes, and smoking. The association of lower eGFR(cysC); with LVH was attenuated after further adjustment for hypertension. Limitations: Cross-sectional rather than longitudinal design, lack of participants with more advanced kidney disease, lack of a direct measurement of glomerular filtration rate. Conclusions: In participants without chronic kidney disease, eGFRcy c of 75 mL/min/1.73 m(2) or less was associated with a greater odds of LVH. Am J Kidney Dis 52:839-848. (C) 2008 by the National Kidney Foundation, Inc. C1 [Moran, Andrew] Columbia Univ, Dept Med, Div Gen Internal Med, New York, NY USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Jenny, Nancy Swords] Univ Vermont, Dept Pathol, Colchester, VT USA. [Astor, Brad] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Bluemke, David A.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA. [Lima, Joao A. C.] Johns Hopkins Univ, Dept Cardiol, Baltimore, MD USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Bertoni, Alain G.; Shlipak, Michael G.] Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. RP Shlipak, MG (reprint author), VA Med Ctr 111A1, Gen Internal Med Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM shlip@itsa.ucsf.edu OI Bluemke, David/0000-0002-8323-8086 FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-95159, N01-HC-95165, N01-HC-95166] FX This research was supported by contracts N01-HC-95159 through N01-HC-95165 and N01-HC-95166 from the National Heart, Lung, and Blood Institute (NHLBI). Dade Behring Inc donated the reagents used to measure cystatin C to MESA and the NHLBI. NR 41 TC 37 Z9 39 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2008 VL 52 IS 5 BP 839 EP 848 DI 10.1053/j.ajkd.2008.06.012 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 367ML UT WOS:000260556000006 PM 18845370 ER PT J AU Gaffo, AL Saag, KG AF Gaffo, Angelo L. Saag, Kenneth G. TI Management of Hyperuricemia and Gout in CKD SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Review DE Management; hyperuricemia; gout; chronic kidney disease ID SERUM URIC-ACID; KIDNEY-TRANSPLANT RECIPIENTS; ALLOPURINOL HYPERSENSITIVITY SYNDROME; NUTRITION EXAMINATION SURVEY; XANTHINE-OXIDASE INHIBITOR; RECOMBINANT URATE OXIDASE; STAGE RENAL-DISEASE; 3RD NATIONAL-HEALTH; PURINE-RICH FOODS; DOUBLE-BLIND C1 [Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. RP Saag, KG (reprint author), FOT 820,1530 3rd Ave S, Birmingham, AL 35294 USA. EM ksaag@uab.edu NR 135 TC 12 Z9 15 U1 1 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2008 VL 52 IS 5 BP 994 EP 1009 DI 10.1053/j.ajkd.2008.07.035 PG 16 WC Urology & Nephrology SC Urology & Nephrology GA 367ML UT WOS:000260556000023 PM 18971014 ER PT J AU Madaras-Kelly, KJ Remington, RE Oliphant, CM Sloan, KL Bearden, DT AF Madaras-Kelly, Karl J. Remington, Richard E. Oliphant, Catherine M. Sloan, Kevin L. Bearden, David T. TI Cephalexin Remains Preferred Oral Antibiotic Therapy for Uncomplicated Cellulitis Reply SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter ID RESISTANT STAPHYLOCOCCUS-AUREUS; SOFT-TISSUE INFECTIONS; EFFICACY; SKIN C1 [Madaras-Kelly, Karl J.; Oliphant, Catherine M.] Idaho State Univ, Coll Pharm, Dept Vet Affairs Med Ctr, Boise, ID 83209 USA. [Remington, Richard E.] Quantified Inc, Boise, ID USA. [Sloan, Kevin L.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Bearden, David T.] Oregon State Univ, Coll Pharm, Dept Vet Affairs Med Ctr, Portland, OR USA. RP Madaras-Kelly, KJ (reprint author), Idaho State Univ, Coll Pharm, Dept Vet Affairs Med Ctr, Boise, ID 83209 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD NOV PY 2008 VL 121 IS 11 BP E15 EP E16 DI 10.1016/j.amjmed.2008.08.001 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 364XV UT WOS:000260369900026 ER PT J AU Gee, RE Shacter, HE Kaufman, EJ Long, JA AF Gee, Rebekah E. Shacter, Hannah E. Kaufman, Elinore J. Long, Judith A. TI Behind-the-counter status and availability of emergency contraception SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE behind-the-counter status; contraception availability; emergency contraception ID RANDOMIZED CONTROLLED-TRIAL; CONSCIENTIOUS OBJECTION; ADVANCED PROVISION; ABORTION RATES; ACCESS; PHARMACIES; PREGNANCY; WOMEN AB OBJECTIVE: The objective of the study was to determine whether the 2006 Food and Drug Administration approval of Plan B for behind-the-counter status increased availability. STUDY DESIGN: We conducted a survey in 2005 and 2007 of pharmacies listed in Atlanta, GA, Boston, MA, and Philadelphia, PA. We measured ability to dispense Plan B within 24 hours. Also measured were reasons for lack of availability and cost of Plan B. RESULTS: Pharmacists were interviewed at 1087 pharmacies (75% response rate) in 2005 and 795 pharmacies (82% response rate) in 2007. In 2007, 8% of pharmacies were unable to provide Plan B within 24 hours, compared with 23% of pharmacies in 2005 (P < .001). The total refusal rate in 2007 was half the rate of 2005 (2% vs 4%, P = .004). The average cost of Plan B was $43. CONCLUSION: Availability of Plan B in Atlanta and Philadelphia increased after it was awarded behind-the-counter status. C1 [Gee, Rebekah E.] Univ Penn, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. [Gee, Rebekah E.; Long, Judith A.] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Long, Judith A.] Univ Penn, Sch Med, Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA 19104 USA. [Long, Judith A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Shacter, Hannah E.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Kaufman, Elinore J.] Harvard Univ, Sch Med, Boston, MA USA. RP Gee, RE (reprint author), 13th Floor Blockley Hall 1303A,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rebe@mail.med.upenn.edu OI Kaufman, Elinore/0000-0001-7550-0024 FU Robert Wood Johnson Clinical Scholars Program FX The authors gratefully acknowledge Zoe Chace and Erica Crane for their help with data collection. The authors thank the Robert Wood Johnson Clinical Scholars Program for funding support. NR 29 TC 5 Z9 5 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD NOV PY 2008 VL 199 IS 5 AR 478.e1 DI 10.1016/j.ajog.2008.04.032 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 367XL UT WOS:000260585800011 PM 18554568 ER PT J AU Rodriquez, AA Burns, SP AF Rodriquez, Arthur A. Burns, Stephen P. TI Assessment of Chronic Neck Pain and a Brief Trial of Cervical Strengthening SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Neck Pain; Neck Muscles; Range of Motion; Hyperalgesia ID RANDOMIZED CONTROLLED-TRIAL; WHIPLASH-ASSOCIATED DISORDERS; RESTING HEAD POSTURE; BACK-PAIN; RELIABILITY; DISABILITY; WOMEN; REPEATABILITY; EXCURSION; VALIDITY AB Objective: To determine the relationship among pain, disability, range of motion, isometric strength, and muscle tenderness in persons with chronic nonradicular neck pain and to compare them with healthy controls without neck pain. Design: Cross-sectional study of 30 subjects with and 14 without chronic neck pain. All subjects were administered pain scales, the neck disability index, isometric cervical strength, cervical range of motion, and a quantitated muscle tenderness measure. In addition, an uncontrolled trial of neck strengthening was performed on a subset of 14 subjects with the same outcome variables. Results: Tenderness correlated with pain, neck disability index, and headache in the pain group, and statistically, significantly differed from the subjects without neck pain. Males were stronger than females. Strength was less in the group with neck pain, but did not reach statistical significance. Range of motion was less in the group with pain. Neither range of motion nor strength correlated with neck disability index or pain scores in the neck pain group. in the strengthening trial, strength in left and right rotation significantly improved. Range of motion, pain, and neck disability index changed in a positive direction, but did not reach statistical significance. Muscle tenderness did not change. Conclusions: Muscle tenderness and disability (but not range of motion or muscle strength) is closely related to average pain in the previous week in neck pain subjects. Neck flexor muscle strengthening resulted in positive changes in pain, neck disability index, range of motion, and strength, but not tenderness. C1 [Rodriquez, Arthur A.; Burns, Stephen P.] Univ Washington, Sch Med, Dept Rehabil Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Rodriquez, AA (reprint author), Univ Washington, Sch Med, Dept Rehabil Med, Vet Affairs Puget Sound Hlth Care Syst, C-O Gail Wise Mail Stop 117,1660 S Columbian Way, Seattle, WA 98108 USA. FU Department of Veterans Affairs and the Harborview Injury Prevention and Research Center FX This work was supported by the Department of Veterans Affairs and the Harborview Injury Prevention and Research Center. This article represents the opinion of the authors and does not necessarily represent the Department of Veterans Affairs. NR 30 TC 3 Z9 3 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD NOV PY 2008 VL 87 IS 11 BP 903 EP 909 DI 10.1097/PHM.0b013e318186b05c PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 364MX UT WOS:000260340900005 PM 18787498 ER PT J AU Suri, P Burns, SP Bach, JR AF Suri, Pradeep Burns, Stephen P. Bach, John R. TI Pneumothorax Associated with Mechanical Insufflation-Exsufflation and Related Factors SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Paraplegia-Society CY SEP 06-08, 2005 CL Las Vegas, NV SP Amer Paraplegia Soc DE Insufflation; Pneumothorax; Cough; Adverse Effects; Spinal Cord Injuries ID DUCHENNE MUSCULAR-DYSTROPHY; NEUROMUSCULAR DISEASE; VENTILATION; PROLONGATION; OUTCOMES; LIFE AB Impaired cough that results in ineffective airway secretion clearance is an important contributor to pulmonary complications in patients with neuromuscular weakness including spinal cord injury. Mechanical insufflation-exsufflation (MI-E) is a respiratory aid used by patients with weak respiratory muscles to increase cough peak flows and improve cough effectiveness. Relative contraindications to MI-E are said to include susceptibility to pneumothorax, but the association of pneumothorax with MI-E use has never before been described. We report two cases of pneumothorax in patients with respiratory muscle weakness associated with daily use of MI-E: one was a 58-yr-old male with C4 ASIA C tetraplegia, and the other was a 26-yr-old male with Duchenne muscular dystrophy. Both patients also used positive-pressure ventilatory assistance. Although seemingly rare in this patient population, ventilator users also using MI-E who have increasing dyspnea or who require increasing positive inspiratory pressures when using noninvasive ventilation should be evaluated for pneumothorax. C1 [Suri, Pradeep; Burns, Stephen P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Burns, Stephen P.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA. [Bach, John R.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP Suri, P (reprint author), New England Baptist Hosp, Spine Ctr, 125 Parker Hill Ave, Boston, MA 02120 USA. NR 21 TC 15 Z9 18 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD NOV PY 2008 VL 87 IS 11 BP 951 EP 955 DI 10.1097/PHM.0b013e31817c181e PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 364MX UT WOS:000260340900010 PM 18617862 ER PT J AU Al-Noori, S Sanders, NM Taborsky, GJ Wilkinson, CW Zavosh, A West, C Sanders, CM Figlewicz, DP AF Al-Noori, Salwa Sanders, Nicole M. Taborsky, Gerald J., Jr. Wilkinson, Charles W. Zavosh, Aryana West, Connie Sanders, Colleen M. Figlewicz, Dianne P. TI Recurrent hypoglycemia alters hypothalamic expression of the regulatory proteins FosB and synaptophysin SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE FosB; recurrent hypoglycemia; paraventricular nucleus; corticotropinreleasing factor; synaptophysin ID CORTICOTROPIN-RELEASING-FACTOR; PITUITARY-ADRENOCORTICAL AXIS; NEUROPEPTIDE GENE-EXPRESSION; PARAVENTRICULAR NUCLEUS; RAT HYPOTHALAMUS; DIFFERENTIAL REGULATION; NEURONAL PLASTICITY; STRESS INTEGRATION; REPEATED RESTRAINT; AUTONOMIC FAILURE AB A limiting factor to the clinical management of diabetes is iatrogenic hypoglycemia. With multiple hypoglycemic episodes, the collective neuroendocrine response that restores euglycemia is impaired. In our animal model of recurrent hypoglycemia (RH), neuroendocrine deficits are accompanied by a decrease in medial hypothalamic activation. Here we tested the hypothesis that the medial hypothalamus may exhibit unique changes in the expression of regulatory proteins in response to RH. We report that expression of the immediate early gene FosB is increased in medial hypothalamic nuclei, anterior hypothalamus, and posterior paraventricular nucleus of the thalamus (THPVN) of the thalamus following RH. We identified the hypothalamic PVN, a key autonomic output site, among the regions expressing FosB. To identify the subtype(s) of neuronal populations that express FosB, we screened candidate neuropeptides of the PVN for coexpression using dual fluorescence immunohistochemistry. Among the neuropeptides analyzed [including oxytocin, vasopressin, thyrotropin-releasing hormone, and corticotropin-releasing factor (CRF)], FosB was only identified in CRF-positive neurons. Inhibitory gamma-aminobutyric acidpositive processes appear to impinge on these FosB-expressing neurons. Finally, we observed a significant decrease in the presynaptic marker synaptophysin within the PVN of RH-treated vs. saline-treated rats, suggesting that rapid alterations of synaptic morphology may occur in association with RH. Collectively, these data suggest that RH stress triggers cellular changes that support synaptic plasticity, in specific neuroanatomical sites, which may contribute to the development of hypoglycemia-associated autonomic failure. C1 [Al-Noori, Salwa; Sanders, Nicole M.; Wilkinson, Charles W.; Zavosh, Aryana; Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Taborsky, Gerald J., Jr.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Sanders, Nicole M.; Taborsky, Gerald J., Jr.; West, Connie; Figlewicz, Dianne P.] Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. [Wilkinson, Charles W.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Al-Noori, S (reprint author), VA Puget Sound Hlth Care Syst, Metab Endocrinol 151,1660 So Columbian Way, Seattle, WA 98108 USA. EM saan@u.washington.edu FU Department of Veterans Affairs (VA); National Institute of Diabetes and Digestive and Kidney Diseases [R21-062446, DK-40963, 2 R01 DK-050154-09A1] FX These studies were supported by the Department of Veterans Affairs (VA) Merit Review Program and Research Career Scientist (D. P. Figlewicz Lattemann), the VA Merit Review Entry Program (N. Sanders), and VA support to G. J. Taborsky and C. Wilkinson and by National Institute of Diabetes and Digestive and Kidney Diseases Grants R21-062446 and DK-40963 (S. Al-Noori) and 2 R01 DK-050154-09A1. NR 61 TC 9 Z9 9 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD NOV PY 2008 VL 295 IS 5 BP R1446 EP R1454 DI 10.1152/ajpregu.90511.2008 PG 9 WC Physiology SC Physiology GA 368DB UT WOS:000260600400011 PM 18753263 ER PT J AU Miller, YE AF Miller, York E. TI Minimizing Unintended Consequences of Detecting Lung Nodules by Computed Tomography SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID CANCER; GUIDELINES; PROJECT; ASSAY; CT C1 [Miller, York E.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Miller, York E.] Univ Colorado, Denver, CO 80202 USA. RP Miller, YE (reprint author), Denver Vet Affairs Med Ctr, Denver, CO USA. NR 16 TC 3 Z9 3 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2008 VL 178 IS 9 BP 891 EP 892 DI 10.1164/rccm.200808-1257ED PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 368HG UT WOS:000260611600003 PM 18945870 ER PT J AU Chu, D Bakaeen, FG Wang, XL LeMaire, SA Coselli, JS Huh, J AF Chu, Danny Bakaeen, Faisal G. Wang, Xing Li LeMaire, Scott A. Coselli, Joseph S. Huh, Joseph TI Does the duration of surgery affect outcomes in patients undergoing coronary artery bypass grafting? SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 32nd Annual Surgical Symposium CY MAY 04-06, 2008 CL Dallas, TX DE Coronary artery bypass grafting; Duration of surgery; Outcomes ID CARDIAC-SURGERY; DETERMINANTS; MORTALITY; STAY; CARE AB BACKGROUND: Numerous predictors of coronary artery bypass grafting (CABG) outcomes have been identified. We aimed to determine whether the duration of surgery independently predicts outcome in patients undergoing CABG. METHODS: We retrospectively reviewed data from 337 patients (mean age 62 +/- 7 years) who underwent CABG consecutively at our institution between January 2005 and December 2006. RESULTS: Duration of surgery correlated positively with length of both surgical intensive care unit (SICU) stay (r = .147, P = .004) and ventilator support (r = .097, P = .038) in univariate analysis, but only with length of SICU stay (P = .01) in a multivariate logistic regression after confounding factors were controlled for in the model. The regression coefficient was .006; every additional 30 minutes of surgery time was associated with 4.32 more hours of SICU stay. Duration of surgery was not associated with survival (P > .05). CONCLUSIONS: Although duration of surgery did not affect short-term survival after CABG, surgical duration independently predicted length of SICU stays. Efforts to reduce the length of operations may promote more efficient use of hospital resources. Published by Elsevier Inc. C1 [Chu, Danny; Bakaeen, Faisal G.; Wang, Xing Li; LeMaire, Scott A.; Coselli, Joseph S.; Huh, Joseph] Baylor Coll Med, Div Cardiothorac Surg, Houston, TX 77030 USA. [Chu, Danny; Bakaeen, Faisal G.; Huh, Joseph] Michael E DeBakey Vet Affairs Med Ctr, Operat Care Line, Houston, TX USA. [Wang, Xing Li; LeMaire, Scott A.; Coselli, Joseph S.] St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiac Surg, Houston, TX USA. RP Chu, D (reprint author), Baylor Coll Med, Div Cardiothorac Surg, Houston, TX 77030 USA. EM dchumd@gmail.com NR 14 TC 6 Z9 6 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2008 VL 196 IS 5 BP 652 EP 656 DI 10.1016/j.amjsurg.2008.07.003 PG 5 WC Surgery SC Surgery GA 368WK UT WOS:000260653200007 PM 18778805 ER PT J AU Robinson, TN Raeburn, CD Angles, EM Moss, M AF Robinson, Thomas N. Raeburn, Christopher D. Angles, Erik M. Moss, Marc TI Low tryptophan levels are associated with postoperative delirium in the elderly SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 32nd Annual Surgical Symposium CY MAY 04-06, 2008 CL Dallas, TX DE Tryptophan; Delirium; Surgery; Postoperative; Geriatric ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL; AMINO-ACIDS; PLASMA; VALIDATION; DEMENTIA; SURGERY AB BACKGROUND: Postoperative delirium is a common complication in geriatric patients. Tryptophan is an amino acid precursor to the mood-stabilizing neurotransmitters serotonin and melatonin. We hypothesized that tryptophan levels are lower in elderly subjects who develop postoperative delirium. METHODS: A prospective observational study was performed. Subjects older than 50 years undergoing surgery with an anticipated postoperative intensive care unit admission were recruited. Postoperative delirium assessment occurred daily using the Confusion Assessment Method-intensive care unit. Peripheral serum tryptophan levels were measured 2 days after surgery. RESULTS: Forty-nine subjects (46 men) were enrolled, with an average age of 64 7 years. The incidence of delirium was 43% (21 of 49). The average duration of delirium was 2.9 +/- 3.0 days. Tryptophan levels were lower in the subjects who developed delirium (29.9 +/- 13.3 vs 48.5 +/- 19.8 mu g/mL; P = .001). CONCLUSIONS: Lower levels of tryptophan postoperatively were associated with the development of delirium in the elderly. Published by Elsevier Inc. C1 [Robinson, Thomas N.; Raeburn, Christopher D.; Angles, Erik M.] Univ Colorado, Hlth Sci Ctr, Dept Surg, Aurora, CO 80045 USA. [Moss, Marc] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO 80045 USA. [Robinson, Thomas N.; Raeburn, Christopher D.; Angles, Erik M.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA. RP Robinson, TN (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Surg, 12631 E 17th Ave,Mail Stop C313,POB 6511, Aurora, CO 80045 USA. EM thomas.robinson@uchsc.edu FU NHLBI NIH HHS [K24 HL089223, K24 HL089223-02, K24-HL-089,223] NR 18 TC 22 Z9 23 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2008 VL 196 IS 5 BP 670 EP 674 DI 10.1016/j.amjsurg.2008.07.007 PG 5 WC Surgery SC Surgery GA 368WK UT WOS:000260653200010 PM 18789427 ER PT J AU Dhaliwal, AS Chu, D Deswal, A Bozkurt, B Coselli, JS LeMaire, SA Huh, J Bakaeen, FG AF Dhaliwal, Arnandeep S. Chu, Danny Deswal, Anita Bozkurt, Biykern Coselli, Joseph S. LeMaire, Scott A. Huh, Joseph Bakaeen, FaisaL G. TI The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes SO AMERICAN JOURNAL OF SURGERY LA English DT Article; Proceedings Paper CT 32nd Annual Surgical Symposium CY MAY 04-06, 2008 CL Dallas, TX DE Cardiac surgery; July effect; Morbidity; Mortality; Outcomes; Seasonal effects ID SEASONAL-VARIATION; TEACHING HOSPITALS; HEART-DISEASE; MORTALITY; CORONARY; IMPACT; RISK; TEMPERATURE; IMPROVEMENT; RESIDENT AB BACKGROUND: The effect of the time of the academic year on cardiac surgical outcomes is unknown. METHODS: Using prospectively collected data, we identified all (n = 1,673) cardiac surgical procedures performed at our institution between October 1997 and April 2007. Morbidity and mortality rates were compared between 2 periods of the academic year, one early (July I-August 31, n = 242) and one later in the year (September 1-June 30, n = 1,431). A prediction model was constructed by using stepwise logistic regression modeling. RESULTS: Morbidity rates did not differ significantly between the early (12.8%) and later periods (15.4%) (odds ratio [OR], 0.83; 95% confidence interval [CI], 0.54-1.28; P = 0.3). Additionally, there was no significant difference in operative mortality between the early (1.2%) and later periods (3.5%) (OR, 0.28; 95% CI, 0.07-1.19; P = 0.06). CONCLUSIONS: The early and later parts of the academic year were associated with similar risk-adjusted outcomes. Further studies are needed to determine whether our findings are applicable to other academic cardiac centers. Published by Elsevier Inc. C1 [Chu, Danny; Coselli, Joseph S.; LeMaire, Scott A.; Huh, Joseph; Bakaeen, FaisaL G.] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX 77030 USA. [Dhaliwal, Arnandeep S.; Deswal, Anita; Bozkurt, Biykern] Baylor Coll Med, Dept Med, Div Cardiol, Houston, TX 77030 USA. [Chu, Danny; Deswal, Anita; Bozkurt, Biykern; Huh, Joseph; Bakaeen, FaisaL G.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Coselli, Joseph S.; LeMaire, Scott A.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA. RP Bakaeen, FG (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX 77030 USA. EM fbakaeen@bcm.edu NR 23 TC 23 Z9 23 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9610 J9 AM J SURG JI Am. J. Surg. PD NOV PY 2008 VL 196 IS 5 BP 720 EP 725 DI 10.1016/j.amjsurg.2008.07.005 PG 6 WC Surgery SC Surgery GA 368WK UT WOS:000260653200018 PM 18789415 ER PT J AU Halla, YN O'Harea, AM Younga, BA Boyko, EJ Chertow, GM AF Halla, Y. N. O'Harea, A. M. Younga, B. A. Boyko, E. J. Chertow, G. M. TI Neighborhood poverty and kidney transplantation among US Asians and Pacific Islanders with end-stage renal disease SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Asian; end-stage renal disease; kidney transplant; Pacific Islander; poverty; racial disparities ID DISPARITIES GEOCODING PROJECT; RACIAL-DIFFERENCES; RESIDENTIAL SEGREGATION; HEALTH LITERACY; NATIONAL-SURVEY; UNITED-STATES; ACCESS; ORGANIZATION; MORTALITY; AMERICANS AB The degree to which low transplant rates among Asians and Pacific Islanders in the United States are confounded by poverty and reduced access to care is unknown. We examined the relationship between neighborhood poverty and kidney transplant rates among 22152 patients initiating dialysis during 1995-2003 within 1800 ZIP codes in California, Hawaii and the US-Pacific Islands. Asians and whites on dialysis were distributed across the spectrum of poverty, while Pacific Islanders were clustered in the poorest areas. Overall, worsening neighborhood poverty was associated with lower relative rates of transplant (adjusted HR [95% CI] for areas with >= 20% vs. < 5% residents living in poverty, 0.41 [0.32-0.53], p < 0.001). At every level of poverty, Asians and Pacific Islanders experienced lower transplant rates compared with whites. The degree of disparity increased with worsening neighborhood poverty (adjusted HR [95% CI] for Asians-Pacific Islanders vs. whites, 0.64 [0.51-0.80], p < 0.001 for areas with < 5% and 0.30 [0.21-0.44], p < 0.001 for areas with >= 20% residents living in poverty; race-poverty level interaction, p = 0.039). High levels of neighborhood poverty are associated with lower transplant rates among Asians and Pacific Islanders compared with whites. Our findings call for studies to identify cultural and local barriers to transplant among Asians and Pacific Islanders, particularly those residing in resource-poor neighborhoods. C1 [Halla, Y. N.; O'Harea, A. M.; Younga, B. A.; Boyko, E. J.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Halla, Y. N.; O'Harea, A. M.; Younga, B. A.; Boyko, E. J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Chertow, G. M.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA. RP Halla, YN (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. EM ynhall@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU Satellite Healthcare's Norman S. Coplon Extramural Grant Program; [K23 AG 028980-02]; [R01 DK079745-01]; [P30 DK 17407]; [R33 DK 067645-04]; [N01 DK 002498]; [U01 DK 066481-05] FX The authors are indebted to Su-Chun Cheng, DSc, MS, for her biostatistical guidance and support. Y.N.H. received support from Satellite Healthcare's Norman S. Coplon Extramural Grant Program. A. M.O. received support from K23 AG 028980-02. B.A.Y. received support from R01 DK079745-01. E.J.B. received support from P30 DK 17407. G. M. C. received support from R33 DK 067645-04, N01 DK 002498 and U01 DK 066481-05. The interpretation and reporting of the study data are the responsibility of the authors and NR 42 TC 30 Z9 30 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD NOV PY 2008 VL 8 IS 11 BP 2402 EP 2409 DI 10.1111/j.1600-6143.2008.02413.x PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA 358SE UT WOS:000259937000029 PM 18808403 ER PT J AU Belperio, PS Mole, LA Halloran, J Boothroyd, DB Thomas, IC Backus, LI AF Belperio, Pamela S. Mole, Larry A. Halloran, James Boothroyd, Derek B. Thomas, I-Chun Backus, Lisa I. TI Postmarketing Use of Enfuvirtide in Veterans: Provider Compliance with Criteria for Use, Overall Efficacy, and Tolerability SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE compliance; enfuvirtide; HIV; outcome ID HIV-INFECTED PATIENTS; TREATMENT-EXPERIENCED PATIENTS; FUSION INHIBITOR ENFUVIRTIDE; PROTEASE INHIBITORS; RITONAVIR; TRIALS; SAFETY; T-20; THERAPY; WEEK-48 AB BACKGROUND: Most enfuvirtide outcomes data come from controlled trials of limited duration rather than from routine experience. Because of its uniqueness, the Veterans Health Administration (VHA) implemented specific enfuvirtide prescribing and follow-up criteria (criteria for use; CFU) and then assessed providers' compliance with these criteria and outcomes. OBJECTIVE: To report routine medical care experience with the prescribing, efficacy, and tolerability of enfuvirtide in a nonselective group of treatment-experienced, older, HIV-infected veterans. METHODS: Veterans receiving at least one outpatient prescription for enfuvirtide between April 2003 and July 2005 were identified from the VHA's HIV Clinical Case Registry (CCR:HIV). Targeted retrospective chart extraction was completed to address inclusion/exclusion criteria and to evaluate patients' continued use, adherence, and tolerance. CCR:HIV data were used for determination of demographics, prescription records, and laboratory results. The final cohort was used to assess providers' compliance with VHA's CFU for enfuvirtide. RESULTS: Of 275 evaluable subjects, between 52% and 93% who were prescribed enfuvirtide met each VHA CFU. Median change in CD4 cells and viral load from baseline to 6 months was +39 cells/mm(3) and -0.79 log(10) (p<0.001) and at 2 years was +72 cells/mm(3) and -1.57 log(10) (p<0.001); 41% and 55% of veterans achieved viral load less than 400 copies/mL at 6 months and 2 years, respectively. Seventy percent of veterans experienced injection site reactions (11 % were treatment-limiting). New or worsening adverse effects occurred in 56% of veterans: 32% gastrointestinal, 19% musculoskeletal, and 10% respiratory. Seventy percent of veterans discontinued enfuvirtide within 2 years; the largest portion (12%) stopped treatment within the first month. Documented reasons for discontinuation included patient request (42%), suboptimal response/progression (24%), toxicity (18%), death (13%), and transfer of care outside of the VHA (3%). CONCLUSIONS: In this treatment-experienced veteran cohort, providers prescribed enfuvirtide in accordance with most CFU, and favorable treatment responses were sustained in patients able to remain on therapy. Challenges that providers and patients face include ongoing education and support for successful long-term use. C1 [Mole, Larry A.; Halloran, James; Boothroyd, Derek B.; Thomas, I-Chun; Backus, Lisa I.] Ctr Qual Management Publ Hlth, Dept Vet Affairs, Palo Alto, CA USA. [Belperio, Pamela S.] Dept Vet Affairs, Los Angeles, CA USA. RP Belperio, PS (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM pamela.belperio@va.gov NR 19 TC 2 Z9 2 U1 0 U2 1 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD NOV PY 2008 VL 42 IS 11 BP 1573 EP 1580 DI 10.1345/aph.1L265 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 369HG UT WOS:000260684600004 PM 18940919 ER PT J AU Ford, RL Mains, IM Hilton, EJ Reeves, ST Stroud, RE Crawford, FA Ikonomidis, JS Spinale, FG AF Ford, Rachael L. Mains, Ira M. Hilton, Ebony J. Reeves, Scott T. Stroud, Robert E. Crawford, Fred A., Jr. Ikonomidis, John S. Spinale, Francis G. TI Endothelin-A Receptor Inhibition After Cardiopulmonary Bypass: Cytokines and Receptor Activation SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 54th Annual Meeting of the Southern-Thoracic-Surgical-Association CY NOV 07-10, 2007 CL Bonita Springs, FL SP SE Thorac Surg Assoc ID TUMOR-NECROSIS-FACTOR; PULMONARY ARTERIAL-HYPERTENSION; FACTOR-ALPHA GENE; CARDIAC-SURGERY; POSTOPERATIVE RECOVERY; INFLAMMATORY RESPONSE; SIGNAL-TRANSDUCTION; MESSENGER-RNA; ANTAGONIST; BOSENTAN AB Background. Basic studies have suggested that crosstalk exists between the endothelin-A receptor (ET-AR) and tumor necrosis factor signaling pathway. This study tested the hypothesis that administration of an ET-AR antagonist at the separation from cardiopulmonary bypass would alter the tumor necrosis factor activation in the early postoperative period. Methods. Patients (n = 44) were randomly allocated to receive bolus infusion of vehicle, 0.1, 0.5, 1, or 2 mg/kg of the ET-AR antagonist (sitaxsentan), at the separation from cardiopulmonary bypass (n = 9, 9, 9, 9, and 8, respectively). Plasma levels of tumor necrosis factor-alpha and soluble tumor necrosis factor receptor 1 and 2 were measured. Results. Compared with the vehicle group at 24 hours, plasma levels of tumor necrosis factor-alpha and tumor necrosis factor receptor 2 (indicative of receptor activation) were reduced in the 1 mg/kg ET-AR antagonist group (by approximately 13 pg/mL and approximately 0.5 ng/mL, respectively; p < 0.05). Plasma tumor necrosis factor receptor I levels also decreased (by approximately 1 ng/mL) after infusion of the higher doses of the ET-AR antagonist and remained lower (by approximately 3 ng/mL) at 24 hours after infusion (p < 0.05). In addition, a dose effect was observed between the ET-AR antagonist and these indices of tumor necrosis factor activation (p < 0.01). Conclusions. This study demonstrated a mechanistic relationship between the ET-AR and tumor necrosis factor receptor activation in the post-cardiac surgery period. Thus, in addition to the potential cardiovascular effects, a selective ET-AR antagonist can modify other biological processes relevant to the post-cardiac surgery setting. C1 [Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg & Anesthesia, Charleston, SC 29403 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg & Anesthesia, Strom Thurmond Res Bldg,114 Doughty St,Room 625, Charleston, SC 29403 USA. EM wilburnm@musc.edu FU NHLBI NIH HHS [R01 HL075488-04, R01 HL056603, HL075488, HL056603, HL057952, R01 HL057952, R01 HL075488, R01 HL057952-09, R01 HL056603-08] NR 38 TC 13 Z9 13 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD NOV PY 2008 VL 86 IS 5 BP 1576 EP 1583 DI 10.1016/j.athoracsur.2008.06.076 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 361RS UT WOS:000260145400026 PM 19049753 ER PT J AU Kohen, R Cain, KC Mitchell, PH Becker, K Buzaitis, A Millard, SP Navaja, GP Teri, L Tirschwell, D Veith, R AF Kohen, Ruth Cain, Kevin C. Mitchell, Pamela H. Becker, Kyra Buzaitis, Ann Millard, Steven P. Navaja, Grace P. Teri, Linda Tirschwell, David Veith, Richard TI Association of Serotonin Transporter Gene Polymorphisms With Poststroke Depression SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID AFFECTIVE-DISORDERS; PROMOTER POLYMORPHISM; SUICIDAL-BEHAVIOR; LIFETIME RISK; STROKE; METAANALYSIS; SYMPTOMS; 5-HTTLPR; REGION; PREDICTORS AB Context: Polymorphisms of the serotonin transporter gene (SERT) have been associated with mental illness. In people with long-term medical conditions, variants of the 5-HTTLPR and STin2 VNTR polymorphisms of SERT have been shown to confer a heightened vulnerability to comorbid depression. Objective: To determine whether the 5-HTTLPR, STin2 VNTR, and rs25531 polymorphisms of SERT are associated with poststroke depression (PSD) in stroke survivors. Design: A case-control study in which stroke survivors were screened for depressive symptoms and assigned to either a depressed group or a nondepressed group. Setting: Outpatient clinic. Participants: Seventy-five stroke survivors with PSD and 75 nondepressed stroke survivors. Interventions: Blood or saliva samples were collected from each participant for DNA extraction and genotyping. Main Outcome Measures: The associations between the 5-HTTLPR, STin2 VNTR, and rs25531 polymorphisms and PSD. Results: Individuals with the 5-HTTLPR s/s genotype had 3-fold higher odds of PSD compared with l/l or l/xl genotype carriers (odds ratio, 3.1; 95% confidence interval, 1.2-8.3). Participants with the STin2 9/12 or 12/12 genotype had 4-fold higher odds of PSD compared with STin2 10/10 genotype carriers (odds ratio, 4.1; 95% confidence interval, 1.2-13.6). An association of rs25531 with PSD was not shown. Conclusions: The 5-HTTLPR and the STin2 VNTR, but not the rs25531, polymorphisms of SERT are associated with PSD in stroke survivors. This gives further evidence of a role of SERT polymorphisms in mediating resilience to biopsychosocial stress. C1 [Kohen, Ruth; Navaja, Grace P.; Veith, Richard] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Cain, Kevin C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Mitchell, Pamela H.; Buzaitis, Ann] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Becker, Kyra; Tirschwell, David] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Teri, Linda] Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA. [Cain, Kevin C.] Univ Washington, Off Nursing Res, Seattle, WA 98195 USA. [Kohen, Ruth; Millard, Steven P.; Navaja, Grace P.] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Kohen, R (reprint author), Vet Affairs Puget Sound Hlth Care Syst, GRECC S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM ruko@u.washington.edu FU NIA NIH HHS [P50 AG005136, P50 AG005136-25]; NINR NIH HHS [R01 NR007755-04S2, R01 NR007755, R01NR007755] NR 43 TC 53 Z9 57 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD NOV PY 2008 VL 65 IS 11 BP 1296 EP 1302 DI 10.1001/archpsyc.65.11.1296 PG 7 WC Psychiatry SC Psychiatry GA 368DA UT WOS:000260600300007 PM 18981341 ER PT J AU Brose, SW Boninger, ML Fullerton, B McCann, T Collinger, JL Impink, BG Dyson-Hudson, TA AF Brose, Steven W. Boninger, Michael L. Fullerton, Bradley McCann, Thane Collinger, Jennifer L. Impink, Bradley G. Dyson-Hudson, Trevor A. TI Shoulder Ultrasound Abnormalities, Physical Examination Findings, and Pain in Manual Wheelchair Users With Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Rehabilitation; Shoulder; Spinal cord injuries; Ultrasonography; Wheelchairs ID ROTATOR CUFF TEARS; IMPINGEMENT SYNDROME; SUBACROMIAL BURSA; UPPER EXTREMITY; LABRAL TEARS; TENDON TEARS; INDEX WUSPI; DIAGNOSIS; ULTRASONOGRAPHY; INDIVIDUALS AB Objectives: To investigate the presence of ultrasound (US) abnormalities in manual wheelchair users with spinal cord injury (SCI) using a quantitative Ultrasound Shoulder Pathology Rating Scale (USPRS). To investigate physical examination (PE) findings using a quantitative Physical Examination of the Shoulder Scale (PESS), and to obtain data about pain and other subject characteristics such as age, years with SCI, and weight. Design: Case series. Setting: National Veterans' Wheelchair Games 2005 and 2006. Participants: Volunteer sample of manual wheelchair users with SCI participating in the National Veterans' Wheelchair Games. Interventions: Not applicable. Main Outcome Measures: Presence of relationships between US findings, PE findings, pain, and subject characteristics. Results: The USPRS correlated with age, duration of SCI, and weight (all P <.01), and showed a positive trend with the total Wheelchair User's Shoulder Pain Index (WUSPI) score (r=.258, P=.073). Several US findings related to presence of PE findings for specific structures. The PESS score correlated with the WUSPI (r=.679, P <.001) and duration of SCI (P <.05). The presence of untreated shoulder pain that curtailed activity was noted in 24.5% of subjects, and this was related to increased WUSPI scores (P=.002). Conclusions: PE and US abnormalities are common in manual wheelchair users with SCL The USPRS and PESS demonstrated evidence for external validity and hold promise as research tools. Untreated shoulder pain is common in manual wheelchair users with SCI, and further investigation of this pain is indicated. C1 [Brose, Steven W.; Boninger, Michael L.; Collinger, Jennifer L.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. [Boninger, Michael L.; Collinger, Jennifer L.; Impink, Bradley G.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Fullerton, Bradley] Patient Phys Partnership, Austin, TX USA. [Fullerton, Bradley] Childrens Hosp Austin, Austin, TX USA. [McCann, Thane] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA. [McCann, Thane] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Dyson-Hudson, Trevor A.] Kessler Med Rehabil Res & Educ Ctr, W Orange, NJ USA. [Dyson-Hudson, Trevor A.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Sch Med, Newark, NJ 07103 USA. RP Brose, SW (reprint author), Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, 3471 5th Ave,Ste 201, Pittsburgh, PA 15213 USA. EM brosesw@upmc.edu OI Boninger, Michael/0000-0001-6966-919X FU Veterans Affairs Center of Excellence for Wheelchairs; Associated Rehabilitation [B3142C]; National Science Foundation [DGE0333420]; National Institute on Disability and Rehabilitation [H133N000019]; Paralyzed Veterans of America FX Supported by the Veterans Affairs Center of Excellence for Wheelchairs and Associated Rehabilitation (grant no. B3142C), the National Science Foundation (grant no. DGE0333420), the National Institute on Disability and Rehabilitation (grant no. H133N000019), and the Paralyzed Veterans of America. NR 44 TC 29 Z9 30 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2008 VL 89 IS 11 BP 2086 EP 2093 DI 10.1016/j.apmr.2008.05.015 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 373PY UT WOS:000260985600006 PM 18996236 ER PT J AU Friedly, J Nishio, I AF Friedly, Janna Nishio, Isuta TI The Study on the Relationship of Opioid Use and Repeated Epidural Steroid Injections and Lumbar Surgery Respond SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Letter C1 [Friedly, Janna] Univ Washington, Dept Rehabil Med, Ctr Comparat Effectiveness Cost & Outcomes Res, Seattle, WA 98195 USA. [Nishio, Isuta] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Friedly, J (reprint author), Univ Washington, Dept Rehabil Med, Ctr Comparat Effectiveness Cost & Outcomes Res, Seattle, WA 98195 USA. NR 6 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2008 VL 89 IS 11 BP 2220 EP 2221 DI 10.1016/j.apmr.2008.08.208 PG 2 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 373PY UT WOS:000260985600026 ER PT J AU Friedly, J Nishio, I AF Friedly, Janna Nishio, Isuta TI The Relationship Between Repeated Epidural Steroid Injections and Subsequent Opioid Use and Lumbar Surgery Respond SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Letter ID BACK C1 [Friedly, Janna] Univ Washington, Dept Rehabil Med, Ctr Comparat Effectiveness Cost & Outcomes Res, Seattle, WA 98195 USA. [Nishio, Isuta] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Friedly, J (reprint author), Univ Washington, Dept Rehabil Med, Ctr Comparat Effectiveness Cost & Outcomes Res, Seattle, WA 98195 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD NOV PY 2008 VL 89 IS 11 BP 2222 EP 2223 DI 10.1016/j.apmr.2008.08.209 PG 2 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 373PY UT WOS:000260985600028 ER PT J AU Kozora, E Hanly, JG Lapteva, L Filley, CM AF Kozora, Elizabeth Hanly, John G. Lapteva, Larissa Filley, Christopher M. TI Cognitive Dysfunction in Systemic Lupus Erythematosus Past, Present, and Future SO ARTHRITIS AND RHEUMATISM LA English DT Review ID CENTRAL-NERVOUS-SYSTEM; MAGNETIC-RESONANCE-SPECTROSCOPY; CEREBRAL-BLOOD-FLOW; GLUTAMATE-RECEPTOR ANTIBODIES; POSITRON-EMISSION-TOMOGRAPHY; CORTICOTROPIN-RELEASING-FACTOR; FAMILY-BASED ASSOCIATION; P-PROTEIN ANTIBODIES; KINASE M-ZETA; NEUROPSYCHIATRIC LUPUS C1 [Kozora, Elizabeth] Natl Jewish Med & Res Ctr, Denver, CO 80206 USA. [Kozora, Elizabeth; Filley, Christopher M.] Univ Colorado, Denver Sch Med, Boulder, CO 80309 USA. [Kozora, Elizabeth] Hosp Special Surg, New York, NY 10021 USA. [Hanly, John G.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. [Hanly, John G.] Dalhousie Univ, Halifax, NS, Canada. [Lapteva, Larissa] US FDA, Bethesda, MD 20014 USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Kozora, E (reprint author), Natl Jewish Med & Res Ctr, 1400 Jackson St,B106, Denver, CO 80206 USA. EM kozorae@njc.org NR 186 TC 40 Z9 42 U1 3 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD NOV PY 2008 VL 58 IS 11 BP 3286 EP 3298 DI 10.1002/art.23991 PG 13 WC Rheumatology SC Rheumatology GA 374JO UT WOS:000261039800003 PM 18975345 ER PT J AU Allen, D Herbert, DC McMahan, CA Rotrekl, V Sobol, RW Wilson, SH Walter, CA AF Allen, Diwi Herbert, Damon C. McMahan, C. Alex Rotrekl, Vladimir Sobol, Robert W. Wilson, Samuel H. Walter, Christi A. TI Mutagenesis Is Elevated in Male Germ Cells Obtained from DNA Polymerase-beta Heterozygous Mice SO BIOLOGY OF REPRODUCTION LA English DT Article DE base excision repair; DNA repair; gamete biology; gametogenesis; lacl; mutagenesis; POLB; spermatogenesis; spermatogenic cells ID BASE EXCISION-REPAIR; LIGASE-III; NUCLEAR EXTRACTS; MAMMALIAN-CELLS; POLY(ADP-RIBOSE) POLYMERASE; MEIOTIC RECOMBINATION; SPERMATOGENIC CELLS; MUTATION FREQUENCY; BINDING ACTIVITY; TRANSGENIC MICE AB Gametes carry the DNA that will direct the development of the next generation. By compromising genetic integrity, DNA damage and mutagenesis threaten the ability of gametes to fulfill their biological function. DNA repair pathways function in germ cells and serve to ameliorate much DNA damage and prevent mutagenesis. High base excision repair (BER) activity is documented for spermatogenic cells. DNA polymerase-beta (POLB) is required for the short-patch BER pathway. Because mice homozygous null for the Polb gene die soon after birth, mice heterozygous for Polb were used to examine the extent to which POLB contributes to maintaining spermatogenic genomic integrity in vivo. POLB protein levels were reduced only in mixed spermatogenic cells. In vitro short-patch BER activity assays revealed that spermatogenic cell nuclear extracts obtained from Polb heterozygous mice had one third the BER activity of age-matched control mice. Polb heterozygosity had no effect on the BER activities of somatic tissues tested. The Polb heterozygous mouse line was crossed with the lacl transgenic Big Blue mouse line to assess mutant frequency. The spontaneous mutant frequency for mixed spermatogenic cells prepared from Polb heterozygous mice was 2-fold greater than that of wild-type controls, but no significant effect was found among the somatic tissues tested. These results demonstrate that normal POLB abundance is necessary for normal BER activity, which is critical in maintaining a low germline mutant frequency. Notably, spermatogenic cells respond differently than somatic cells to Polb haploinsufficiency. C1 [Allen, Diwi; Herbert, Damon C.; Rotrekl, Vladimir; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA. [Sobol, Robert W.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA. [Sobol, Robert W.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA. [Wilson, Samuel H.] NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA. [Walter, Christi A.] Audie Murphy Mem Vet Affairs Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Mail Code 7762, San Antonio, TX 78229 USA. EM walter@uthscsa.edu RI Sobol, Robert/E-4125-2013 OI Sobol, Robert/0000-0001-7385-3563 FU Elsa U. Pardee Foundation [P20 CA103730]; National Institutes of Health [1 R01 AG24364-01, AG21163]; National Institute of Environmental Health Sciences FX Supported by grant P20 CA103730 from the Elsa U. Pardee Foundation and the National Institutes of Health to R.W.S. and by grants 1 R01 AG24364-01 and AG21163 from the National Institutes of Health to C.A.W. This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences. The contents are solely the responsibility of the authors and do not necessarily reflect the views of the funding agencies. NR 73 TC 15 Z9 17 U1 0 U2 8 PU SOC STUDY REPRODUCTION PI MADISON PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA SN 0006-3363 EI 1529-7268 J9 BIOL REPROD JI Biol. Reprod. PD NOV PY 2008 VL 79 IS 5 BP 824 EP 831 DI 10.1095/biolreprod.108.069104 PG 8 WC Reproductive Biology SC Reproductive Biology GA 364FJ UT WOS:000260321300005 PM 18650495 ER PT J AU Turley, RS Terris, MK Kane, CJ Aronson, WJ Presti, JC Amling, CL Freedland, SJ AF Turley, Ryan S. Terris, Martha K. Kane, Christopher J. Aronson, William J. Presti, Joseph C., Jr. Amling, Christopher L. Freedland, Stephen J. CA SEARCH Database Study Grp TI The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database SO BJU INTERNATIONAL LA English DT Article DE prostate cancer; prostate weight; upgrading; biopsy cores; risk ID RADICAL RETROPUBIC PROSTATECTOMY; SEARCH DATABASE; NEEDLE-BIOPSY; RISK-FACTORS; VOLUME; SPECIMENS; GRADE; HYPERPLASIA; ACCURACY; PROGRESSION AB OBJECTIVE To test the hypothesis that the association between prostate size and risk of Gleason grade upgrading varies as a function of sampling. PATIENTS AND METHODS We examined the association between pathological prostate weight, prostate biopsy scheme and Gleason upgrading (Gleason >= 7 at radical prostatectomy, RP) among 646 men with biopsy Gleason 2-6 disease treated with RP between 1995 and 2007 within the Shared Equal Access Regional Cancer Hospital Database using logistic regression. In all, 204 and 442 men had a sextant (six or seven cores) or extended-core biopsy (eight or more cores), respectively. Analyses were adjusted for centre, age, surgery, preoperative prostate-specific antigen level, clinical stage, body mass index, race, and percentage of cores positive for cancer. RESULTS In all, 281 men (44%) were upgraded; a smaller prostate was positively associated with the risk of upgrading in men who had an extended-core biopsy (P < 0.001), but not among men who had a sextant biopsy (P = 0.22). The interaction between biopsy scheme and prostate size was significant (P interaction = 0.01). CONCLUSIONS These data support the hypothesis that the risk of upgrading is a function of two opposing contributions: (i) a more aggressive phenotype in smaller prostates and thus increased risk of upgrading; and (ii) more thorough sampling in smaller prostates and thus decreased risk of upgrading. When sampled more thoroughly, the phenotype association dominates and smaller prostates are linked with an increased risk of upgrading. In less thoroughly sampled prostates, these opposing factors nullify, resulting in no association between prostate size and risk of upgrading. These findings help to explain previously published disparate results of the importance of prostate size as a predictor of Gleason upgrading. C1 [Turley, Ryan S.; Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol Surg, Duke Prostate Ctr, Durham, NC 27710 USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Vet Affairs Med Ctr, Augusta, GA 30912 USA. [Kane, Christopher J.] Univ Calif San Francisco, San Francisco Sch Med, Dept Urol, San Francisco, CA 94143 USA. [Kane, Christopher J.] Univ Calif San Francisco, Urol Sect, Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Urol Sect, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA. [Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA. [Amling, Christopher L.] Univ Alabama, Div Urol, Birmingham, AL USA. [Freedland, Stephen J.] Duke Univ, Sch Med, Urol Sect, Vet Affairs Med Ctr, Durham, NC 27710 USA. [Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA. RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Div Urol Surg, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU Department of Veterans Affairs, the Georgia Cancer Coalition (MKT),; NIH [R01CA100938, P50 CA92131-01A1]; Department of Defense Prostate Cancer Research Program; American Urological Association Foundation/Astellas Rising Star in Urology Award FX Source of funding: the Department of Veterans Affairs, the Georgia Cancer Coalition (MKT), NIH grant R01CA100938 (WJA), NIH P50 CA92131-01A1 (WJA), the Department of Defense Prostate Cancer Research Program (SJF), and the American Urological Association Foundation/Astellas Rising Star in Urology Award (SJF). NR 29 TC 21 Z9 21 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1464-4096 J9 BJU INT JI BJU Int. PD NOV PY 2008 VL 102 IS 9 BP 1074 EP 1079 DI 10.1111/j.1464-410X.2008.08015.x PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 358TL UT WOS:000259940300007 PM 18778348 ER PT J AU Xiang, N Zhao, R Song, GQ Zhong, WX AF Xiang, Nong Zhao, Rui Song, Guoqing Zhong, Weixiong TI Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells SO CARCINOGENESIS LA English DT Article ID CYTOSINE METHYLATION; PROTECTIVE ROLE; LIVER-CANCER; METHYLTRANSFERASE; PREVENTION; HYPERMETHYLATION; EXPRESSION; PROGNOSIS; DIAGNOSIS; BIOPSIES AB DNA hypermethylation is a common epigenetic alteration in human prostate cancer and is considered to contribute to development of this disease. Accumulating data suggest that dietary factors may alter cancer risk by modifications of epigenetic processes in the cell. The present study was designed to investigate whether selenium (Se) would alter epigenetic events to regulate methylation-silenced genes in human prostate cancer cells. DNA methylation, histone modifications and gene expression were studied in LNCaP cells after selenite treatment using polymerase chain reaction, western blot analysis, chromatin immunoprecipitation assay and enzymatic activity assay. Our study shows that selenite treatment caused partial promoter DNA demethylation and reexpression of the pi-class glutathione-S-transferase (GSTP1) in LNCaP cells in a dose- and time-dependent manner. Selenite treatment decreased messenger RNA levels of DNA methyltransferases (DNMTs) 1 and 3A and protein levels of DNMT1. Selenite also decreased histone deacetylase activity and increased levels of acetylated lysine 9 on histone H3 (H3-Lys 9), but decreased levels of methylated H3-Lys 9. Selenite treatment reduced levels of DNMT1 and methylated H3-Lys 9 associated with the GSTP1 promoter, but increased levels of acetylated H3-Lys 9 associated with this promoter. Additionally, selenite treatment decreased general DNA methylation and caused partial promoter demethylation and reexpression of the tumor suppressor adenomatous polyposis coli and cellular stress response 1, a gene involving tumor growth and metastasis. Our study demonstrates that Se can epigenetically modulate DNA and histones to activate methylation-silenced genes. These epigenetic modifications may contribute to cancer prevention by Se. C1 [Xiang, Nong; Zhao, Rui; Song, Guoqing; Zhong, Weixiong] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA. [Zhong, Weixiong] William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Zhong, WX (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53792 USA. EM wzhong3@wisc.edu FU National Cancer Institute [CA114281]; Office of Research and Development; Biomedical Laboratory Research and Development Service; Department of Veterans Affairs FX National Cancer Institute (CA114281); Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs. NR 37 TC 73 Z9 75 U1 0 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD NOV PY 2008 VL 29 IS 11 BP 2175 EP 2181 DI 10.1093/carcin/bgn179 PG 7 WC Oncology SC Oncology GA 373NE UT WOS:000260977900018 PM 18676679 ER PT J AU Hussein, MR Abu-Dief, EE Kamel, E Abou El-Ghait, AT Abdulwahed, SR Ahmad, MH AF Hussein, Mahmoud R. Abu-Dief, Eman E. Kamel, Esam Abou El-Ghait, Amal T. Abdulwahed, Saad Rezk Ahmad, Mohamed H. TI Melatonin and roentgen irradiation-induced acute radiation enteritis in Albino rats: An animal model SO CELL BIOLOGY INTERNATIONAL LA English DT Article DE Intestine; X-ray irradiation; Melatonin ID X-RAY-IRRADIATION; DAMAGE; GLUTAMINE; TESTIS; CELLS; ORGAN AB Background: Roentgen irradiation can affect normal cells, especially the rapidly growing ones such as the mucosal epithelial cells of the small intestine. The small intestine is the most radiosensitive gastrointestinal organ and patients receiving radiotherapy directed to the abdomen or pelvis may develop radiation enteritis. Although roentgen rays are widely used for both imaging and therapeutic purposes, our knowledge about the morphological changes associated with radiation enteritis is lacking. Hypothesis: This study tries to tests the hypothesis that "the intake of melatonin can minimize the morphological features of cell damage associated with radiation enteritis". Objectives and methods: We performed this investigation to test our hypothesis and to examine the possible radioprotective effects of melatonin in acute radiation enteritis. To achieve these goals, an animal model consisting of 60 Albino rats was established. The animals were divided into five groups: Group 1, non-irradiated; Group 2, X-ray irradiated (X-ray irradiation, 8 Grays); Group 3, X-ray irradiated-pretreated with solvent (ethanol and phosphate buffered saline); Group 4, non-irradiated-group treated with melatonin, and Group 5, X-ray irradiated-pretreated with melatonin. The small intestines were evaluated for gross (macroscopic), histological, morphometric (light microscopy), and ultrastructural changes (transmission electron microscopy). Results: We found morphological variations among the non-irradiated-group, X-ray irradiated-group and X-ray irradiated-intestines of the animals pretreated with melatonin. The development of acute radiation enteritis in X-ray irradiated-group (Groups 2 and 3) was associated with symptoms of enteritis (diarrhea and abdominal distention) and histological features of mucosal injury (mucosal ulceration, necrosis of the epithelial cells). There was a significant reduction of the morphometric parameters (villous count, villous height, crypt height and villous/crypt height ratio). Moreover, the ultrastructural features of cell damage were evident including: apoptosis, lack of parallel arrangement of the microvilli, loss of the covering glycocalyx, desquamation of the microvilli, vacuolation of the apical parts of the cells, dilatation of the rough endoplasmic reticulum, and damage of the mitochondrial cristae. In the non-irradiated-group and in X-ray irradiated-intestines of the animals pretreated with melatonin (Group 5), these changes were absent and the intestinal mucosal structure was preserved. Conclusion: Administration of melatonin prior to irradiation can protect the intestine against X-rays destructive effects, i.e. radiation enteritis. The clinical applications of these observations await further studies. (C) 2008 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved. C1 [Hussein, Mahmoud R.] Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt. [Abu-Dief, Eman E.; Abou El-Ghait, Amal T.; Ahmad, Mohamed H.] Assiut Univ, Fac Med, Dept Histol, Assiut, Egypt. [Abdulwahed, Saad Rezk] Al Azhar Univ, Fac Med, Dept Radiol, Assiut, Egypt. [Hussein, Mahmoud R.] Univ Wisconsin, Sch Med, Madison, WI 53705 USA. [Hussein, Mahmoud R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Hussein, MR (reprint author), Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt. EM mrh17@gawab.com NR 23 TC 11 Z9 16 U1 0 U2 1 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 1065-6995 J9 CELL BIOL INT JI Cell Biol. Int. PD NOV PY 2008 VL 32 IS 11 BP 1353 EP 1361 DI 10.1016/j.cellbi.2008.08.001 PG 9 WC Cell Biology SC Cell Biology GA 369CU UT WOS:000260671900003 PM 18762261 ER PT J AU Tobin, MJ AF Tobin, Martin J. TI The Chaos of War Response SO CHEST LA English DT Letter ID EVIDENCE-BASED MEDICINE; SOUND SCIENTIFIC BASE C1 [Tobin, Martin J.] Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA. [Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Tobin, MJ (reprint author), Edward Hines Vet Adm Med Ctr, 5th Ave & Roosevelt Rd, Hines, IL 60141 USA. EM mtobin2@lumc.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2008 VL 134 IS 5 BP 1108 EP 1108 DI 10.1378/chest.08-1837 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 372RF UT WOS:000260918500038 ER PT J AU Go, AS Magid, DJ Wells, B Sung, SH Cassidy-Bushrow, AE Greenlee, RT Langer, RD Lieu, TA Margolis, KL Masoudi, FA McNeal, CJ Murata, GH Newton, KM Novotny, R Reynolds, K Roblin, DW Smith, DH Vupputuri, S White, RE Olson, J Rumsfeld, JS Gurwitz, JH AF Go, Alan S. Magid, David J. Wells, Barbara Sung, Sue Hee Cassidy-Bushrow, Andrea E. Greenlee, Robert T. Langer, Robert D. Lieu, Tracy A. Margolis, Karen L. Masoudi, Frederick A. McNeal, Catherine J. Murata, Glen H. Newton, Katherine M. Novotny, Rachel Reynolds, Kristi Roblin, Douglas W. Smith, David H. Vupputuri, Suma White, Robert E. Olson, Jean Rumsfeld, John S. Gurwitz, Jerry H. TI The Cardiovascular Research Network A New Paradigm for Cardiovascular Quality and Outcomes Research SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE cardiovascular disease; risk factors; outcomes; epidemiology; quality of care ID ACUTE MYOCARDIAL-INFARCTION; BARE-METAL STENTS; SIROLIMUS-ELUTING STENTS; ACUTE CORONARY SYNDROMES; CLINICAL-DATA STANDARDS; ASSOCIATION TASK-FORCE; HMO-RESEARCH-NETWORK; KEY DATA ELEMENTS; NATIONAL REGISTRY; HEART-FAILURE AB Background-A clear need exists for a more systematic understanding of the epidemiology, diagnosis, and management of cardiovascular diseases. More robust data are also needed on how well clinical trials are translated into contemporary community practice and the associated resource use, costs, and outcomes. Methods and Results-The National Heart, Lung, and Blood Institute recently established the Cardiovascular Research Network, which represents a new paradigm to evaluate the epidemiology, quality of care, and outcomes of cardiovascular disease and to conduct future clinical trials using a community-based model. The network includes 15 geographically distributed health plans with dedicated research centers, National Heart, Lung, and Blood Institute representatives, and an external collaboration and advisory committee. Cardiovascular research network sites bring complementary content and methodological expertise and a diverse population of approximate to 11 million individuals treated through various health care delivery models. Each site's rich electronic databases (eg, sociodemographic characteristics, inpatient and outpatient diagnoses and procedures, pharmacy, laboratory, and cost data) are being mapped to create a standardized virtual data warehouse to facilitate rapid and efficient large-scale research studies. Initial projects focus on (1) hypertension recognition and management, (2) quality and outcomes of warfarin therapy, and (3) use, outcomes, and costs of implantable cardioverter defibrillators. Conclusions-The Cardiovascular Research Network represents a new paradigm in the approach to cardiovascular quality of care and outcomes research among community-based populations. Its unique ability to characterize longitudinally large, diverse populations will yield novel insights into contemporary disease and risk factor surveillance, management, outcomes, and costs. The Cardiovascular Research Network aims to become the national research partner of choice for efforts to improve the prevention, diagnosis, treatment, and outcomes of cardiovascular diseases. (Circ Cardiovasc Qual Outcomes. 2008;1:138-147.) C1 [Go, Alan S.; Sung, Sue Hee] Univ Calif San Francisco, Kaiser Permanente No Calif, San Francisco, CA 94143 USA. [Magid, David J.] Univ Colorado, Kaiser Permanente Colorado, Denver, CO 80202 USA. [Wells, Barbara; Olson, Jean] NHLBI, Bethesda, MD 20892 USA. [Cassidy-Bushrow, Andrea E.] Henry Ford Hlth Syst, Detroit, MI USA. [Greenlee, Robert T.] Univ Wisconsin, Marshfield Clin Fdn Med Res & Educ, Madison, WI USA. [Langer, Robert D.] Geisinger Hlth Syst, Danville, PA USA. [Lieu, Tracy A.] Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA. [Lieu, Tracy A.] Harvard Univ, Sch Med, Boston, MA USA. [Margolis, Karen L.] Univ Minnesota, HealthPartners Res Fdn, Minneapolis, MN USA. [Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA. [McNeal, Catherine J.] Scott & White Mem Hosp & Clin, Temple, TX USA. [McNeal, Catherine J.] Texas A&M Univ, Texas A&M Hlth Sci Ctr, College Stn, TX USA. [Murata, Glen H.; White, Robert E.] Univ New Mexico, Albuquerque, NM 87131 USA. [Murata, Glen H.] New Mexico VA Hlth Care Syst, Albuquerque, NM USA. [Newton, Katherine M.] Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. [Newton, Katherine M.; Smith, David H.] Univ Washington, Seattle, WA 98195 USA. [Novotny, Rachel] Univ Hawaii, Kaiser Permanente Ctr Hlth Res Hawaii, Honolulu, HI 96822 USA. [Reynolds, Kristi] Kaiser Permanente So Calif, Pasadena, CA USA. [Roblin, Douglas W.; Vupputuri, Suma] Kaiser Permanente Georgia, Atlanta, GA USA. [Roblin, Douglas W.] Emory Univ, Atlanta, GA 30322 USA. [Smith, David H.] Kaiser Permanente NW, Portland, OR USA. [Smith, David H.] Oregon State Univ, Corvallis, OR 97331 USA. [White, Robert E.] Lovelace Clin Fdn, Albuquerque, NM USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Gurwitz, Jerry H.] Meyers Primary Care Inst & Fallon Community Hlth, Worcester, MA USA. [Gurwitz, Jerry H.] Univ Massachusetts, Amherst, MA 01003 USA. RP Go, AS (reprint author), Kaiser Permanente No Calif, Div Res, 2000 Broadway St,3rd Floor, Oakland, CA 94612 USA. EM Alan.S.Go@kp.org OI Cassidy-Bushrow, Andrea/0000-0001-8272-4448 FU National Heart, Lung, and Blood Institute [U19 HL91179-01] FX This work was supported by National Heart, Lung, and Blood Institute cooperative agreement U19 HL91179-01. NR 44 TC 49 Z9 49 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2008 VL 1 IS 2 BP 138 EP 147 DI 10.1161/CIRCOUTCOMES.108.801654 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA V11AL UT WOS:000207504400012 PM 20031802 ER PT J AU Spiegel, BMR Melmed, G Robbins, S Esrailiant, E AF Spiegel, Breman M. R. Melmed, Gil Robbins, Sean Esrailiant, Eric TI Biomarkers and Health-Related Quality of Life in End-Stage Renal Disease: A Systematic Review SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID CHRONIC KIDNEY-DISEASE; INCIDENT HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS PATIENTS; PRACTICE PATTERNS; ANEMIA MANAGEMENT; PHYSICAL-ACTIVITY; EMPLOYMENT STATUS; MENTAL-HEALTH; MORTALITY; OUTCOMES AB Background and objectives: Health-related quality of life (HRQOL) predicts mortality in ESRD, yet adoption of HRQOL monitoring is not widespread, and regulatory authorities remain predominantly concerned with monitoring traditional biologic parameters. To assist with future efforts to adopt HRQOL monitoring while acknowledging the importance of biomarkers, this study sought to establish which domains of HRQOL are most affected by ESRD and to measure the strength of evidence linking common biomarkers to HRQOL in ESRD. Design, setting, participants, & measurements: A systematic review was performed to identify studies that measured HRQOL in ESRD. Data were abstracted according to a conceptual model regarding the measurement of HRQOL differences, and HRQOL data were converted to weighted mean effect sizes and correlation coefficients. Results: The impact of ESRD was largest in the Short Form 36 domains of physical functioning (e.g., role-physical, vitality) and smallest in mental functioning (e.g., mental health, role-emotional). Dialysis adequacy, as measured by Kt/V, was a poor correlate for Short Form 36 scores. Similarly, mineral metabolism (e.g., calcium X phosphorous, parathyroid hormone) and inflammatory (e.g., C-reactive protein, TNF) biomarkers had small effect sizes and correlations with HRQOL. In contrast, hematocrit demonstrated small to moderate relationships with mental and physical HRQOL, and nutritional biomarkers (e.g., albumin, creatinine, body mass index) demonstrated moderate to large relationships. Conclusions: HRQOL in ESRD is most affected in the physical domains, and nutritional biomarkers are most closely associated with these domains. In contrast, Kt/V, mineral metabolism indices, and inflammatory markers are poor HRQOL correlates. C1 [Spiegel, Breman M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med,VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA 90073 USA. [Melmed, Gil; Esrailiant, Eric] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90073 USA. [Robbins, Sean] Amgen Inc, Global Hlth Econ, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med,VA Ctr Outcomes Res & Educ CORE, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU VA HSR&D Research Career Development [RCD 03 to 179-2]; CURE Research Center [NIH 2P30 DK 041301-17] FX B.M.R.S. is Supported by VA HSR&D Research Career Development Award RCD 03 to 179-2 and by the CURE Research Center (NIH 2P30 DK 041301-17). Additional support for this study was provided by an investigator-initiated research grant from Amgen, Inc. NR 88 TC 51 Z9 54 U1 0 U2 7 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2008 VL 3 IS 6 BP 1759 EP 1768 DI 10.2215/CJN.00820208 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 366TE UT WOS:000260505500025 PM 18832106 ER PT J AU Watnick, S AF Watnick, Suzanne TI Academic Etiquette for the Nephrologist SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID PHYSICIANS; UNAWARE AB Academic etiquette is an underexplored and underemphasized topic. Yet, a collegial atmosphere is essential to accomplish the missions of an academic medical center. Appropriate social, personal, and cultural behaviors are not only desirable, but they are also necessary to practice and emulate. As faculty in an academic center, one may want to share these thoughts with peers, students, and other healthcare providers. As a trainee, one may want dedicated lectures on this topic and to observe the behaviors modeled by mentors. This article attempts to outline principles of appropriate etiquette in the academic workplace. These include issues of loyalty, collegiality, and collaboration in daily activities from research to clinical care. Approaching personal interactions with grace and integrity can be ail essential tool in the pursuit of academic excellence and success. C1 Portland VA Med Ctr, Portland, OR 97239 USA. RP Watnick, S (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,P3NEPH, Portland, OR 97239 USA. EM watnicks@ohsu.edu NR 11 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV PY 2008 VL 3 IS 6 BP 1884 EP 1886 DI 10.2215/CJN.01750408 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 366TE UT WOS:000260505500043 PM 18715991 ER PT J AU Smetana, GW Conde, MV AF Smetana, Gerald W. Conde, Michelle V. TI Preoperative Pulmonary Update SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Preoperative care; Intraoperative care; Intraoperative complications; Postoperative complications; Pulmonary; Respiratory; Perioperative complications; Elderly; Management ID RANDOMIZED CLINICAL-TRIAL; OBSTRUCTIVE SLEEP-APNEA; PERIOPERATIVE CARDIOVASCULAR EVALUATION; MAJOR NONCARDIAC SURGERY; COLLEGE-OF-PHYSICIANS; POSTOPERATIVE RESPIRATORY-FAILURE; PRACTICE GUIDELINES COMMITTEE; MULTIFACTORIAL RISK INDEX; ASSOCIATION TASK-FORCE; PATIENTS AGED 80 AB Postoperative pulmonary complications are an important source of surgical morbidity. In this paper, the authors review recent studies that shed light on emerging risk factors, a multifactorial index for respiratory failure, and the value of specific risk reduction strategies. Novel risk factors include advanced age, congestive heart failure, pulmonary hypertension, and obstructive sleep apnea. Important risk reduction strategies include postoperative lung expansion maneuvers, the selective use of nasogastric tubes, epidural analgesia, and inspiratory muscle training. C1 [Smetana, Gerald W.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Conde, Michelle V.] Univ Texas Hlth Sci Ctr San Antonio, Div Gen Med, San Antonio, TX 78229 USA. [Conde, Michelle V.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. RP Smetana, GW (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave, Boston, MA 02215 USA. EM gsmetana@bidmc.harvard.edu NR 75 TC 7 Z9 7 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD NOV PY 2008 VL 24 IS 4 BP 607 EP + DI 10.1016/j.cger.2008.06.004 PG 19 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 375YA UT WOS:000261148500004 PM 18984376 ER PT J AU Kahn, JM Branas, CC Schwab, CW Asch, DA AF Kahn, Jeremy M. Branas, Charles C. Schwab, C. William Asch, David A. TI Regionalization of medical critical care: What can we learn from the trauma experience? SO CRITICAL CARE MEDICINE LA English DT Review DE intensive care; patient transport; triage ID INTENSIVE-CARE; UNITED-STATES; MAJOR TRAUMA; MECHANICAL VENTILATION; SYSTEM-DEVELOPMENT; OUTCOMES; MORTALITY; VOLUME; ILL; ORGANIZATION AB Objective: To review the rationale for the regionalization of adult critical care and discuss how lessons from the trauma experience may be relevant to this debate. Design: Narrative review and opinion. Results. Variation in the quality of critical care among hospitals has prompted calls for regionalization of care for critically ill patients. Because of similarities between trauma and critical care, trauma is often cited as a model for the regionalization of critical care services. In reality, there are both important similarities and differences between trauma and critical care. In addition, many lessons from the trauma experience directly apply to future efforts to regionalize critical care services. In this article, we review the analogy between the regionalization of trauma and critical care and discuss how the trauma experience both supports and limits the argument for creation of a formal regionalized system of care for the critically ill. If regionalization efforts in critical care are to proceed, the lessons of the trauma experience can inform policy decisions and provide insight into the design and implementation of an effective regionalized system. (Crit Care Med 2008; 36:3085-3088) C1 [Kahn, Jeremy M.] Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. [Branas, Charles C.; Schwab, C. William] Univ Penn, Sch Med, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA. [Kahn, Jeremy M.; Branas, Charles C.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Kahn, Jeremy M.; Branas, Charles C.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Kahn, JM (reprint author), Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. EM jmkahn@mail.med.upenn.edu OI Asch, David/0000-0002-7970-286X NR 41 TC 43 Z9 43 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD NOV PY 2008 VL 36 IS 11 BP 3085 EP 3088 DI 10.1097/CCM.0b013e31818c37b2 PG 4 WC Critical Care Medicine SC General & Internal Medicine GA 369KU UT WOS:000260694200020 PM 18824900 ER PT J AU Ham, M Kaunitz, JD AF Ham, Maggie Kaunitz, Jonathan D. TI Gastroduodenal mucosal defense SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Article DE bicarbonate; cyclooxygenase inhibitors; duodenum; leptin; matrix metalloproteinase; orexins; stomach; survivin ID NITRIC-OXIDE SYNTHASE; DUODENAL BICARBONATE SECRETION; INDUCED GASTRIC INJURY; HELICOBACTER-PYLORI; GASTROINTESTINAL COMPLICATIONS; HCO3-SECRETION; EXPRESSION; ULCER; RAT; PROTECTION AB Purpose of review The gastrointestinal tract has developed multi le mechanisms of protection intrinsic and extrinsic sources of injury, including but not limited to drugs, ischemic/reperfusion injuries, and infections such as Helicobacter pylori. We review recent developments in host defense against Helicobacter pylori, duodenal bicarbonate secretion, protection from nonsteroidal anti-inflammatory drug induced gastrointestinal injury, and apoptosis, as well as newer therapies. Recent findings Leptin and survivin confer protection against ethanol and indomethacin induced injury. Mucin-1, a cell surface mucin, is an important barrier to gastrointestinal infection. Prostaglandin E-2, Escherichia coli heat-stable enterotoxin, orexins, and carbonated beverages stimulate duodenal bicarbonate secretion. Summary Gastroduodenal mucosal defense is a dynamic process, and further insights into these defense mechanisms have and will lead to safer and more effective treatments. C1 [Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Ham, Maggie; Kaunitz, Jonathan D.] Sch Med, Dept Med, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU NIDDK NIH HHS [R01 DK054221] NR 50 TC 15 Z9 15 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2008 VL 24 IS 6 BP 665 EP 673 DI 10.1097/MOG.0b013e328311cd93 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 374AE UT WOS:000261013800003 PM 19122513 ER PT J AU El-Zimaity, H AF El-Zimaity, Hala TI Gastritis and gastric atrophy SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Article DE atrophy; gastritis; staging ID HELICOBACTER-PYLORI GASTRITIS; DUODENAL-ULCER PATIENTS; INTESTINAL METAPLASIA; PEPTIC-ULCER; PERNICIOUS-ANEMIA; MAJOR AUTOANTIGEN; CORPUS GASTRITIS; HIGH PREVALENCE; SYDNEY SYSTEM; PEPSINOGEN-I AB Purpose of review The majority of problems in interpreting gastritis remain Helicobacter related, but their nature has changed. The present review covers gastritis historically through cancer risk staging systems. Recent findings Key points to remember are: Helicobacter is associated with several forms of gastritis; in the present review, I am focusing on the two ends of the disease, Helicobacter pylori infection', that starts with antral predominant gastritis but can continue to oxyntic predominant disease with atrophy; the role Helicobacter pylori plays in autoimmune gastritis with pernicious anemia remains unresolved; gastritis staging systems for cancer risk, namely Baylor and Operative Link on Gastritis Assessment, are currently available. Summary As most gastric carcinomas arise on a background of atrophic gastritis, and the risk increases with the extent of atrophy, an index of atrophy location and extent could be useful in predicting patients at greatest risk for carcinoma. It is now possible to stage patients for cancer risk. Nonetheless, in a field such as gastritis in which many issues remain unresolved, a classification or staging system that is more descriptive will likely prove more useful. C1 [El-Zimaity, Hala] McMaster Univ, Dept Pathol, Hamilton, ON, Canada. [El-Zimaity, Hala] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP El-Zimaity, H (reprint author), McMaster Div, 1200 Main St W,RM 2N31, Hamilton, ON L8S 3Z5, Canada. EM zimaity@mcmaster.ca NR 50 TC 16 Z9 16 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2008 VL 24 IS 6 BP 682 EP 686 DI 10.1097/MOG.0b013e328311d1cc PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 374AE UT WOS:000261013800005 PM 19122515 ER PT J AU Kahn, SE Carr, DB Faulenbach, MV Utzschneider, KM AF Kahn, S. E. Carr, D. B. Faulenbach, M. V. Utzschneider, K. M. TI An examination of P-cell function measures and their potential use for estimating beta-cell mass SO DIABETES OBESITY & METABOLISM LA English DT Article DE arginine. C-peptide; diabetes mellitus; glucose potentiation; impaired glucose tolerance; insulin; intravenous glucose; obesity; OGTT ID DEPENDENT DIABETES-MELLITUS; INDUCED INSULIN-RESISTANCE; DISPROPORTIONATELY ELEVATED PROINSULIN; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; STREPTOZOCIN-TREATED BABOONS; IMPAIRED GLUCOSE-TOLERANCE; POLYCYSTIC-OVARY-SYNDROME; LIFE-STYLE INTERVENTION; PANCREATIC B-CELL; SECRETORY CAPACITY AB A characteristic and dominant feature of type 2 diabetes is a reduction in P-cell function that is associated with a decrease in P-Cell volume. A decline in the first-phase insulin response following intravenous glucose administration can be demonstrated as the fasting glucose concentration increases. This response is completely absent before the glucose threshold that defines diabetes has been reached and at a time when P-cells are clearly still present, implying that a functional beta-cell lesion has to exist independent of beta-cell loss. Surgical or chemical reductions of tip to 65% of beta-cell volume demonstrate that functional adaptation of the normal P-cell prevents a rise in fasting glucose or reduction in first-phase insulin response. However, the ability Of glucose to potentiate the beta-cell's response to non-glucose secretagogues is reduced and is more closely associated with the reduction in beta-cell volume. The future, in terms of prevention and treatment of type 2 diabetes, lies in the ability to prevent and revert both beta-cell loss and dysfunction. However, until beta-cell volume can be quantified reliably and non-invasively, we will need to rely on the ability of glucose, to potentiate insulin release as the best Surrogate estimate of the number of beta-cells. C1 [Kahn, S. E.; Faulenbach, M. V.; Utzschneider, K. M.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Carr, D. B.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 151 1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU Department of Veterans Affairs; American Diabetes Association Distinguished Clinical Scientist Award; Swiss National Foundation FX This study was supported in part by the, Department of Veterans Affairs. S. E. K. is the recipient of an American Diabetes Association Distinguished Clinical Scientist Award. M. V. F. is supported by Foods from the Swiss National Foundation. NR 81 TC 25 Z9 26 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-8902 EI 1463-1326 J9 DIABETES OBES METAB JI Diabetes Obes. Metab. PD NOV PY 2008 VL 10 SU 4 BP 63 EP 76 DI 10.1111/j.1463-1326.2008.00945.x PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 398IR UT WOS:000262726300008 PM 18834434 ER PT J AU Cowley, MS Boyko, EJ Shofer, JB Ahroni, JH Ledoux, WR AF Cowley, Matthew S. Boyko, Edward J. Shofer, Jane B. Ahroni, Jessie H. Ledoux, William R. TI Foot ulcer risk and location in relation to prospective clinical assessment of foot shape and mobility among persons with diabetes SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Diabetic foot ulcer; Foot deformity; Foot structure; Neuropathy ID LOWER-EXTREMITY ULCERS; PLANTAR PRESSURES; TOE DEFORMITY; NEUROPATHY; PREDICTORS; MELLITUS; WALKING AB Aims: We assessed baseline clinical foot shape for 2939 feet of diabetic subjects who were monitored prospectively for foot ulceration. Methods: Assessments included hammer/claw toes, hallux valgus, hallux limitus, prominent metatarsal heads, bony prominences, Charcot deformity, plantar callus, foot type, muscle atrophy, ankle and hallux mobility, and neuropathy. Risk factors were linked to ulcer occurrence and location via a Cox proportional hazards model. Results: Hammer/claw toes (hazard ratio [HR] (95% confidence interval [CI]) = 1.43 (1.06, 1.94) p = 0.02), marked hammer/claw toes (HR = 1.77 (1.18, 2.66) p = 0.006), bony prominences (HR = 1.38 (1.02, 1.88), p = 0.04), and foot type (Charcot or drop foot vs. neutrally aligned) (HR = 2.34 (1.33, 4.10), p = 0.003) were significant risk factors for ulceration adjusting for age, body mass index, insulin medication, ulcer history and amputation history. With adjustment for neuropathy only hammer/claw toes (HR = 1.40 (1.03, 1.90), p = 0.03) and foot type (HR = 1.76 (1.04, 3.04), p = 0.05) were significantly related to ulceration. However, there was no relationship between ulcer location and foot deformity. Conclusions: Certain foot deformities were predictive of ulceration, although there was no relationship between clinical foot deformity and ulcer location. Published by Elsevier Ireland Ltd. C1 [Cowley, Matthew S.; Shofer, Jane B.; Ledoux, William R.] VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Dept Vet Affairs, Seattle, WA 98108 USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Boyko, Edward J.] Univ Washington, Dept Gen Internal Med, Seattle, WA 98195 USA. [Ahroni, Jessie H.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Ahroni, Jessie H.] NW Weight Loss Surg, Everett, WA 98208 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, Ms 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714; Boyko, Edward/0000-0002-3695-192X FU Department of Veterans Affairs (VA) Rehabilitation Research and Development [A2661C, A318-5RC]; Seattle VA Epidemiologic Research and Information Center (ERIC) [EPC 97-010]; The University of Washington DERC (NIH NIDDK) [P30 DK-17047] FX This research was supported by the Department of Veterans Affairs (VA) Rehabilitation Research and Development grants A2661C and A318-5RC, the Seattle VA Epidemiologic Research and Information Center (ERIC) EPC 97-010 and The University of Washington DERC (NIH NIDDK grant P30 DK-17047). NR 24 TC 23 Z9 23 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD NOV PY 2008 VL 82 IS 2 BP 226 EP 232 DI 10.1016/j.diabres.2008.07.025 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 382HU UT WOS:000261597600012 PM 18829126 ER PT J AU Leung, FW AF Leung, Felix W. TI Water-Related Techniques for Performance of Colonoscopy SO DIGESTIVE DISEASES AND SCIENCES LA English DT Review DE Colonoscopy; Water infusion AB Background Passage through difficult colonic segments, cecal intubation rate, time to reach the cecum, procedure-related discomfort, and medication requirement are important outcome measures of a colonoscopic examination. Several techniques of water infusion to aid insertion have been described. Raising awareness of these simple inexpensive methods may help to enhance colonoscopists' performance. Aim To review water-related methods that facilitated colonoscope insertion. Method A literature search (Medline, PubMed) was conducted using the following terms: sigmoidoscopy, colonoscopy, and water infusion, irrigation, or loading. The effects of water infusion in sedated and unsedated patients are tabulated and discussed. Results Five reports described the use of water infusion in conjunction with usual air insufflation. Enhanced cecal intubation, decreased time to reach the cecum, and attenuated abdominal discomfort were reported. Dose of medication used for sedation was not reduced. The sixth report described a novel method of water infusion in lieu of air insufflation during insertion. When patients accepted sedation on demand, the novel method permitted 52% to complete colonoscopy without sedation. Conclusion Warm water infusion as an adjunct to usual air insufflation enhances colonoscopy outcome. Randomized controlled trials comparing the novel method with usual air insufflation deserve to be considered. C1 [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gastroenterol, Los Angeles, CA 90024 USA. [Leung, Felix W.] VA Greater Los Angels Healthcare Syst, Sepulveda Ambulatory Care Ctr, Res & Med Serv, Div Gastroenterol, North Hills, CA 91343 USA. RP Leung, FW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gastroenterol, Los Angeles, CA 90024 USA. EM felix.leung@va.gov FU Affairs Medical Research Funds; American Society of Gastrointestinal Endoscopy FX This study was supported in part by Veterans Affairs Medical Research Funds and in part by the American Society of Gastrointestinal Endoscopy Career Development Award ( F. W. L., 1985). NR 6 TC 24 Z9 26 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD NOV PY 2008 VL 53 IS 11 BP 2847 EP 2850 DI 10.1007/s10620-008-0259-1 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 363EG UT WOS:000260250000002 PM 18461455 ER PT J AU Leung, FW AF Leung, Felix W. TI Promoting Informed Choice of Unsedated Colonoscopy: Patient-Centered Care for a Subgroup of U. S. Veterans SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Informed choice; Unsedated colonoscopy; Patient-centered care; US veterans ID SCREENING COLONOSCOPY; FLEXIBLE SIGMOIDOSCOPY; ASSISTED COLONOSCOPY; SEDATION; ENDOSCOPY; COMPLICATIONS; OPTIONS; CANCER; TRIAL AB Background In the United States, colonoscopy is usually performed under sedation. In practice, 2.3-7% actually requested unsedated colonoscopy and 1.4% received it because of no escorts. Efforts to increase usage would likely require increased patient counseling and education. Aim We tested the hypothesis that knowledge conveyed by education-a key attribute of patient-centered care-is associated with acceptance of the "non-usual" option. Methods After patients underwent discussions and expressed acceptance of sedated colonoscopy, the pros and cons of and local experience with unsedated colonoscopy were added. The patients who changed from accepting sedated to unsedated colonoscopy and outcomes of their examinations were recorded. Results From January to November 2006, 49 of 176 consecutive patients (28%) changed their choice from sedated to unsedated colonoscopy after being informed of the latter. Forty-eight had satisfactory bowel preparation. Cecal intubation rate was 93.7% (45 of 48). Thirty-six reported good experience and 43, likely to repeat. Cecal intubation, withdrawal, and discharge times were 23.0 +/- 1.4 min, 15.0 +/- 1.0 min, and 5.0 +/- 0.5 min, respectively (n = 45). Ability to communicate with the colonoscopist during and after the examination was the most frequently ranked reason for choosing unsedated colonoscopy. Conclusion Our uncontrolled, non-randomized, single-site observational data revealed that for selected veterans, acceptance of unsedated colonoscopy coincides with knowledge of the option dispensed by patient counseling and education. C1 [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Res & Med Serv, Div Gastroenterol, North Hills, CA 91343 USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gastroenterol, Los Angeles, CA 90024 USA. RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Res & Med Serv, Div Gastroenterol, 111G,16111 Plummer St, North Hills, CA 91343 USA. EM felix.leung@va.gov FU Veterans Affairs Medical Research; ASGE FX This work was supported in part by Veterans Affairs Medical Research Funds and in part by ASGE Career Development Award (FWL 1985). NR 34 TC 9 Z9 11 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD NOV PY 2008 VL 53 IS 11 BP 2955 EP 2959 DI 10.1007/s10620-008-0253-7 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 363EG UT WOS:000260250000017 PM 18461456 ER PT J AU Mu, Y Klamerus, MM Miller, TM Rohan, LC Graham, SH Poloyac, SM AF Mu, Ying Klamerus, Megan M. Miller, Tricia M. Rohan, Lisa C. Graham, Steven H. Poloyac, Samuel M. TI Intravenous Formulation of N-Hydroxy-N '-(4-n-butyl-2-methylphenyl) formamidine (HET0016) for Inhibition of Rat Brain 20-Hydroxyeicosatetraenoic Acid Formation SO DRUG METABOLISM AND DISPOSITION LA English DT Article ID ARACHIDONIC-ACID; SELECTIVE INHIBITOR; 20-HETE; CYTOCHROME-P450; EXPRESSION; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; DERIVATIVES; ISCHEMIA; SYNTHASE; INJURY AB N-Hydroxy-N'-(4-n-butyl-2-methylphenyl)formamidine (HET0016) is a potent inhibitor of 20-hydroxyeicosatetraenoic acid (20-HETE) formation by specific cytochrome P450 isoforms. Previous studies have demonstrated that administration of HET0016 inhibits brain formation of 20-HETE and reduces brain damage in a rat model of thromboembolic stroke. Delineation of the dose, concentration, and neuroprotective effect relationship of HET0016 has been hampered by the relative insolubility of HET0016 in aqueous solutions and the lack of information concerning the mechanism and duration of HET0016 inhibition of brain 20-HETE formation. Therefore, it was the purpose of this study to develop a water-soluble formulation of HET0016 suitable for intravenous (i.v.) administration and to determine the time course and mechanism of brain 20-HETE inhibition after in vivo dosing. In this study we report that HET0016 is a noncompetitive inhibitor of rat brain 20-HETE formation, which demonstrates a tissue concentration range for brain inhibition. In addition, we demonstrate that complexation of HET0016 with hydroxypropyl-beta-cyclodextrin results in increased aqueous solubility of HET0016 from 34.2 +/- 31.2 to 452.7 +/- 63.3 mu g/ml. Administration of the complex as a single HET0016 i.v. dose (1 mg/kg) rapidly reduced rat brain 20-HETE concentrations from 289 to 91 pmol/g. Collectively, these data demonstrate that the i. v. formulation of HET0016 rapidly penetrates the rat brain and significantly inhibits 20-HETE tissue concentrations. These results will enable future studies to determine biopharmaceutics of HET0016 for inhibition of 20-HETE after cerebral ischemia. C1 [Mu, Ying; Klamerus, Megan M.; Miller, Tricia M.; Rohan, Lisa C.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Rohan, Lisa C.] Magee Womens Res Inst, Pittsburgh, PA USA. [Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Graham, Steven H.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Poloyac, SM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, 807 Salk Hall, Pittsburgh, PA 15261 USA. EM poloyac@pitt.edu FU National Institutes of Health [NINDS R01NS052315, NCRR S10RR023461]; NCRR FX We acknowledge National Institutes of Health NINDS R01NS052315 (S. M. P.) and NCRR S10RR023461 (S. M. P.) for support of this work. We also acknowledge the Pharsight Academic License granted for use in the pharmacokinetic analyses. Y.M. and M. M. K. contributed equally to this work. NR 25 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0090-9556 EI 1521-009X J9 DRUG METAB DISPOS JI Drug Metab. Dispos. PD NOV PY 2008 VL 36 IS 11 BP 2324 EP 2330 DI 10.1124/dmd.108.023150 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 361MP UT WOS:000260132100022 PM 18725506 ER PT J AU Zhao, WD Pan, JP Wang, XL Wu, Y Bauman, WA Cardozo, CP AF Zhao, Weidong Pan, Jiangping Wang, Xiaolei Wu, Yong Bauman, William A. Cardozo, Christopher P. TI Expression of the Muscle Atrophy Factor Muscle Atrophy F-Box Is Suppressed by Testosterone SO ENDOCRINOLOGY LA English DT Article ID DEPENDENT PROTEOLYTIC SYSTEM; FOXO TRANSCRIPTION FACTORS; STEROID-HORMONE RECEPTORS; ANDROGEN RECEPTOR; SKELETAL-MUSCLE; UBIQUITIN LIGASES; DNA-BINDING; DENERVATION ATROPHY; GENE-EXPRESSION; DEGRADATION AB The ubiquitin ligase muscle atrophy F-box (MAFbx; also called atrogin-1) is thought to play important roles in muscle loss. Conversely, testosterone reduces atrophy from glucocorticoids or denervation associated with repression of MAFbx. To characterize mechanisms of such repression, the effects of testosterone on MAFbx expression in C2C12 cells were tested. Testosterone reduced MAFbx mRNA levels as well as expression of a reporter gene under the control of 3.1 kb of the human MAFbx promoter. Repression required the androgen receptor (AR) as well as sequences within the first 208 bases upstream of the first codon of the MAFbx gene. This sequence is downstream of known forkhead transcription factor binding sites and testosterone did not alter Forkhead box O 3A phosphorylation. The AR associated with sequences conferring repression in a manner that was stimulated by testosterone and was independent of DNA binding. In gel shift studies, octamer binding transcription factor (Oct)-1 bound two predicted Oct-1 sites within these sequences. Deletion of Oct-1 sites from reporter genes prevented repression by testosterone. Gene knockdown of Oct-1 blocked repression of MAFbx reporter gene activity by testosterone and binding of AR to sequences conferring repression. In conclusion, testosterone represses MAFbx expression via interactions of the AR with Oct-1 that are associated with sequences within the 5 ' untranslated region of the MAFbx promotor located just upstream of the first codon. This action of testosterone may contribute to beneficial actions of testosterone on muscle. (Endocrinology 149: 5449-5460, 2008) C1 [Zhao, Weidong; Pan, Jiangping; Wang, Xiaolei; Wu, Yong; Bauman, William A.; Cardozo, Christopher P.] James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences, SCI, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. RP Cardozo, CP (reprint author), James J Peters Vet Affairs Med Ctr, Ctr Excellence Med Consequences, SCI, Room 1E-02, Bronx, NY 10468 USA. EM chris.cardozo@mssm.edu FU Department of Veterans Affairs Rehabilitation Research and Development Service [B4162C, B3347K, B4616R] FX This work was supported by Grants B4162C, B3347K, and B4616R from the Department of Veterans Affairs Rehabilitation Research and Development Service. NR 44 TC 27 Z9 27 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD NOV PY 2008 VL 149 IS 11 BP 5449 EP 5460 DI 10.1210/en.2008-0664 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 362JM UT WOS:000260194000016 PM 18599544 ER PT J AU Tzermiadianos, MN Renner, SM Phillips, FM Hadjipavlou, AG Zindrick, MR Havey, RM Voronov, M Patwardhan, AG AF Tzermiadianos, Michael N. Renner, Susan M. Phillips, Frank M. Hadjipavlou, Alexander G. Zindrick, Michael R. Havey, Robert M. Voronov, Michael Patwardhan, Avinash G. TI Altered disc pressure profile after an osteoporotic vertebral fracture is a risk factor for adjacent vertebral body fracture SO EUROPEAN SPINE JOURNAL LA English DT Article DE Osteoporosis; Compression fractures; Adjacent fractures; Cement augmentation; Biomechanics; Intervertebral disc ID VIVO BIOMECHANICAL EVALUATION; COMPRESSIVE FOLLOWER PRELOAD; FLEXION-EXTENSION RESPONSE; PERCUTANEOUS VERTEBROPLASTY; LUMBAR SPINE; SUBSEQUENT FRACTURES; INTERVERTEBRAL DISC; FINITE-ELEMENT; SURFACE STRAIN; KYPHOPLASTY AB This study investigated the effect of endplate deformity after an osteoporotic vertebral fracture in increasing the risk for adjacent vertebral fractures. Eight human lower thoracic or thoracolumbar specimens, each consisting of five vertebrae were used. To selectively fracture one of the endplates of the middle VB of each specimen a void was created under the target endplate and the specimen was flexed and compressed until failure. The fractured vertebra was subjected to spinal extension under 150 N preload that restored the anterior wall height and vertebral kyphosis, while the fractured endplate remained significantly depressed. The VB was filled with cement to stabilize the fracture, after complete evacuation of its trabecular content to ensure similar cement distribution under both the endplates. Specimens were tested in flexion-extension under 400 N preload while pressure in the discs and strain at the anterior wall of the adjacent vertebrae were recorded. Disc pressure in the intact specimens increased during flexion by 26 +/- 14%. After cementation, disc pressure increased during flexion by 15 +/- 11% in the discs with un-fractured endplates, while decreased by 19 +/- 26.7% in the discs with the fractured endplates. During flexion, the compressive strain at the anterior wall of the vertebra next to the fractured endplate increased by 94 +/- 23% compared to intact status (p < 0.05), while it did not significantly change at the vertebra next to the unfractured endplate (18.2 +/- 7.1%, p > 0.05). Subsequent flexion with compression to failure resulted in adjacent fracture close to the fractured endplate in six specimens and in a non-adjacent fracture in one specimen, while one specimen had no adjacent fractures. Depression of the fractured endplate alters the pressure profile of the damaged disc resulting in increased compressive loading of the anterior wall of adjacent vertebra that predisposes it to wedge fracture. This data suggests that correction of endplate deformity may play a role in reducing the risk of adjacent fractures. C1 [Tzermiadianos, Michael N.; Havey, Robert M.; Patwardhan, Avinash G.] Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA. [Tzermiadianos, Michael N.; Hadjipavlou, Alexander G.] Univ Hosp Crete, Iraklion, Crete, Greece. [Renner, Susan M.; Havey, Robert M.; Voronov, Michael; Patwardhan, Avinash G.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Phillips, Frank M.] Rush Univ, Chicago, IL 60612 USA. [Zindrick, Michael R.] Hinsdale Orthopaed Associates, Hinsdale, IL USA. RP Patwardhan, AG (reprint author), Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, 2160 S 1st Ave, Maywood, IL 60153 USA. EM apatwar@lumc.edu FU Department of Veterans Affairs, Washington, DC; Kyphon Inc., Sunnyvale, CA FX Institutional research support provided by the Department of Veterans Affairs, Washington, DC, and Kyphon Inc., Sunnyvale, CA. NR 52 TC 13 Z9 20 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0940-6719 J9 EUR SPINE J JI Eur. Spine J. PD NOV PY 2008 VL 17 IS 11 BP 1522 EP 1530 DI 10.1007/s00586-008-0775-x PG 9 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 373DI UT WOS:000260950800017 PM 18795344 ER PT J AU Roodman, GD AF Roodman, G. David TI Novel targets for myeloma bone disease SO EXPERT OPINION ON THERAPEUTIC TARGETS LA English DT Review DE bone disease; myeloma; novel treatments; osteoblast; osteoclast ID MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; MALIGNANT PLASMA-CELLS; MULTIPLE-MYELOMA; IN-VIVO; OSTEOLYTIC LESIONS; RECEPTOR ACTIVATOR; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST FORMATION; MARROW MICROENVIRONMENT; PROTEASOME INHIBITION AB Background: Multiple myeloma (MM) is a plasma cell malignancy in which osteolytic bone lesions develop in over 80% of patients. The increased bone destruction results from increased osteoclast formation and activity, which occurs adjacent to marrow sites involved with MM cells. This is accompanied by suppressed or absent osteoblast differentiation and activity, resulting in severely impaired bone formation and development of purely osteolytic lesions. Objective: The pathophysiology underlying this bone remodeling is reviewed, and potential new strategies to treat MM bone disease are discussed. Results: Recent advances in our understanding of factors involved in pathogenesis of MM bone disease have identified novel therapeutic targets. Several of these are or will be in clinical trials soon. Conclusion: Agents which target the tumor and bone-destructive process, such as the immunomodulatory drugs (IMiDs) or bortezomib, in combination with novel anti-resorptives should be effective. These combinations should be in clinical trials in the next few years. It is unclear if these treatments will be able to 'heal' bone lesions in MM patients. C1 Univ Pittsburgh, Sch Med, Dept Med Hematol Oncol, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Roodman, GD (reprint author), Univ Pittsburgh, Sch Med, Dept Med Hematol Oncol, Vet Affairs Pittsburgh Healthcare Syst, Univ Dr C,Res & Dev 151-U,Room 2E113, Pittsburgh, PA 15240 USA. EM Roodmangd@upmc.edu NR 85 TC 19 Z9 19 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1472-8222 J9 EXPERT OPIN THER TAR JI Expert Opin. Ther. Targets PD NOV PY 2008 VL 12 IS 11 BP 1377 EP 1387 DI 10.1517/14728220802447489 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 368JT UT WOS:000260618100006 PM 18851694 ER PT J AU Hall, DE Koenig, HG Meador, KG AF Hall, Daniel E. Koenig, Harold G. Meador, Keith G. TI HITTING THE TARGET: WHY EXISTING MEASURES OF "RELIGIOUSNESS" ARE REALLY REVERSE-SCORED MEASURES OF "SECULARISM" SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING LA English DT Article DE Religion; spirituality; measurement; precision; health ID HEALTH RESEARCH; SPIRITUALITY; MORTALITY; RELIGIOSITY; PROTESTANTS; ATTENDANCE; SERVICES; SUPPORT; JEWS AB Over 100 measures of religiousness and spirituality are used in research investigating the associations between religion and health. These measures are often used to assess "religiousness in general," but this approach lumps together widely divergent worldviews in ways that can distort religion beyond recognition. The authors suggest that the existing measures of religiousness are perhaps better understood as reverse-coded measures of "secularism." This argument suggests that the existing data regarding religiousness and health might be best interpreted as demonstrating a small, robust health liability associated with a deliberately secular worldview. If true, this conclusion might change the direction of future research, and it would imply that meaningful inferences about the health associations of religious practice will depend on developing tools that measure specific religions in their particularity. C1 [Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equities Res & Promot, Pittsburgh, PA USA. [Hall, Daniel E.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA. [Koenig, Harold G.; Meador, Keith G.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. [Meador, Keith G.] Duke Divin Sch, Dept Pastoral Theol, Durham, NC USA. RP Hall, DE (reprint author), Suite F 1206 Presbyterian,200 Lothrop St, Pittsburgh, PA 15213 USA. EM hallde@upmc.edu RI Koenig, Harold/F-7379-2011; Hall, Daniel/H-4843-2013 OI Hall, Daniel/0000-0001-6382-0522 NR 33 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-8307 J9 EXPLORE-NY JI Explore-J Sci. Heal. PD NOV-DEC PY 2008 VL 4 IS 6 BP 368 EP 373 DI 10.1016/j.explore.2008.08.002 PG 6 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 373SD UT WOS:000260991900005 PM 18984548 ER PT J AU Matthews, AM AF Matthews, Annette M. TI Editorial on "Guideline-concordant hepatitis C virus testing and notification among patients with and without mental disorders" SO GENERAL HOSPITAL PSYCHIATRY LA English DT Editorial Material C1 [Matthews, Annette M.] Portland VA Med Ctr, Portland, OR 97207 USA. [Matthews, Annette M.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Matthews, AM (reprint author), Portland VA Med Ctr, POB 1035, Portland, OR 97207 USA. EM annette.matthews@med.va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2008 VL 30 IS 6 BP 493 EP 494 DI 10.1016/j.genhosppsych.2008.06.011 PG 2 WC Psychiatry SC Psychiatry GA 374EI UT WOS:000261025300001 PM 19061673 ER PT J AU Kilbourne, AM McCarthy, JF Himelhoch, S Welsh, D Hauser, P Blow, FC AF Kilbourne, Amy M. McCarthy, John F. Himelhoch, Seth Welsh, Deborah Hauser, Peter Blow, Frederic C. TI Guideline-concordant hepatitis C virus testing and notification among patients with and without mental disorders SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Mental disorders; Hepatitis C; Guideline-concordant care ID INFECTION; VETERANS; USERS AB Objective: We compared screening for hepatitis C virus (HCV), positive HCV test rates and test result notification among Veterans Affairs (VA) patients diagnosed with psychosis (e.g., schizophrenia, bipolar disorder) or depression or those with no Psychiatric diagnosis. Method: We identified all patients in the VA's External Peer Review Program national random sample of chart reviews regarding HCV care in fiscal year 2004. We then identified individuals diagnosed with psychosis or depression using data from the VA's National Psychosis and Depression registries. Using multivariable logistic regression and generalized estimating equation analyses, we evaluated associations between mental disorder diagnosis and receipt of HCV screening and notification of results. Results: Out of 19,397 patients, 94% received HCV tests. Of those tested, 6.9% were HCV positive, and of those who were positive, 48.2% were notified of their result within 60 days. After adjusting for demographic and clinical factors (including illicit drug use and comorbidities), individuals with psychosis or depression were no less likely to have a positive test or be notified of their result :! 60 days compared to nonpsychiatric groups. Those with drug use disorder diagnoses (OR=4.64; P <.001) and Blacks (OR=1.96; P <.001) were more likely to have a positive test. Conclusions: Study limitations included inability to fully control for sociodemographic Confounders (e.g., homelessness, incarceration), Nevertheless, we found that although the vast majority of patients were tested, only half were notified of test results. VA HCV prevention and follow-up strategies focus on enhanced notification overall and tailoring HCV risk reduction programs to minorities and those with drug use disorders. Published by Elsevier Inc. C1 [Kilbourne, Amy M.; McCarthy, John F.; Blow, Frederic C.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48105 USA. [Kilbourne, Amy M.; McCarthy, John F.; Welsh, Deborah; Blow, Frederic C.] VA Serious Mental Illness Treatment Res & Evaluat, Ann Arbor, MI 48105 USA. [Himelhoch, Seth] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Hauser, Peter] Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Portland, OR 97239 USA. RP Kilbourne, AM (reprint author), Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48105 USA. EM amykilbo@umich.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [02-283, 07-115]; National Institute oil Drug Abuse [K23DA019820]; EPRP [05-024] FX This research was Supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (02-283, 07-115, Dr. Kilbourne) and the National Institute oil Drug Abuse (K23DA019820; Dr. Himelhoch). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. We would like to acknowledge the VA Office Of Quality and Performance for providing access to EPRP data (DUA #05-024). NR 12 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2008 VL 30 IS 6 BP 495 EP 500 DI 10.1016/j.genhosppsych.2008.06.002 PG 6 WC Psychiatry SC Psychiatry GA 374EI UT WOS:000261025300002 PM 19061674 ER PT J AU Richardson, LK Egede, LE Mueller, M Echols, CL Gebregziabher, M AF Richardson, Lisa K. Egede, Leonard E. Mueller, Martina Echols, Carrae L. Gebregziabher, Mulugeta TI Longitudinal effects of depression on glycemic control in veterans with Type 2 diabetes SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Longitudinal effects; Depression; Glycemic control; Veterans; Type 2 diabetes ID BLOOD-GLUCOSE CONTROL; COMORBID DEPRESSION; HEART-DISEASE; COMPLICATIONS; MELLITUS; ADULTS; CARE; METAANALYSIS; INDIVIDUALS; ASSOCIATION AB Objectives: To examine the longitudinal effects of depression on glycermic control in veterans with Type 2 diabetes. Methods: Data on 11.25 veterans with Type 2 diabetes were analyzed. A person-period dataset for each subject to cover 3-month intervals (36 time intervals) from April 1997 to March 2006 was created. Subjects were classified as depressed based on ICD-9 codes for depression. General linear mixed model regression was used to examine changes over time in HbA(1c) levels and whether the changes from baseline were different in depressed and nondepressed diabetic veterans, sequentially adjusting for baseline age, demographic variables and comorbidities (coronary heart disease. stroke and hypertension). Pooled t-tests were used to compare unadjusted mean HbA(1c) at each time point across the depressed and nondepressed groups. SAS was used for statistical analysis. Results: Ninety-seven percent were men. 48% were white, 27% were blacks and 25% were other. Mean age was 66 years and mean follow-up period was 4.1 years. Six percent (696/11,525) of the sample had diagnosed depression. Unadjusted mean HbA(1c), values were significantly J higher in depressed vs. nondepressed subjects at all time points. The adjusted mean HbA(1c) values over time in the final mixed model were significantly higher in depressed vs. nondepressed subjects (mean difference of 0.13; 95% CI [0.03; 0.22]; P=.008). In all adjusted models, differences in mean HbA(1c) Values were significantly higher in depressed vs. nondepressed Subjects with Type 2 diabetes. Conclusion: This study of veterans with Type 2 diabetes demonstrates that there is a significant longitudinal relationship between depression and glycemic control as measured by HbA(1c) and that depression is associated with persistently higher HbA(1c) levels over time. (c) 2008 Elsevier Inc. All rights reserved. C1 [Mueller, Martina] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Richardson, Lisa K.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Richardson, Lisa K.] Murdoch Univ, Sch Psychol, Murdoch, WA 6150, Australia. [Richardson, Lisa K.; Egede, Leonard E.; Mueller, Martina; Echols, Carrae L.; Gebregziabher, Mulugeta] Ralph H Johnson VAMC, Charleston VA TREP, Charleston, SC 29401 USA. [Mueller, Martina; Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU NIDDK NIH HHS [R01 DK081121, R01 DK081121-01A1, R01 DK081121-02, R01 DK081121-03] NR 21 TC 67 Z9 69 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD NOV-DEC PY 2008 VL 30 IS 6 BP 509 EP 514 DI 10.1016/j.genhosppsych.2008.07.001 PG 6 WC Psychiatry SC Psychiatry GA 374EI UT WOS:000261025300004 PM 19061676 ER PT J AU Nguyen, VT Love, AR Kunik, ME AF Nguyen, Vi T. Love, Almer Ray Kunik, Mark E. TI Preventing aggression in persons with dementia SO GERIATRICS LA English DT Article DE aggression; dementia; geriatric assessment; pain; depression; caregiver; psychotherapy ID RATING DEPRESSION SCALE; ALZHEIMERS-DISEASE; SELF; PREVALENCE; DISORDERS AB Persons with dementia often present with non-cognitive clinical symptoms, such as aggression, which can be distressing and dangerous to both caregiver and patient. Depression, pain, caregiver burden, and the quality of the caregiver-patient relationship can contribute to the onset of aggression. Given the risks involved with medication, there is a strong need for preventive and nonpharmacological interventions before such behaviors occur. This article gives practical recommendations for primary care physicians on how to prevent aggression in dementia patients by screening for and treating predictive factors. Clinically useful assessment instruments and treatment options are discussed, in addition to referral sources. C1 [Nguyen, Vi T.] Texas A&M Univ, Coll Med, Texas A&M Hlth Sci Ctr, College Stn, TX 77843 USA. [Love, Almer Ray] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Love, Almer Ray] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kunik, Mark E.] Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Kunik, Mark E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Nguyen, VT (reprint author), Texas A&M Univ, Coll Med, Texas A&M Hlth Sci Ctr, College Stn, TX 77843 USA. NR 26 TC 10 Z9 10 U1 0 U2 3 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 USA SN 0016-867X J9 GERIATRICS JI Geriatrics PD NOV PY 2008 VL 63 IS 11 BP 21 EP 26 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 373QE UT WOS:000260986200006 PM 18998764 ER PT J AU Rodriguez, KL Appelt, CJ Switzer, GE Sonel, AF Arnold, RM AF Rodriguez, Keri L. Appelt, Cathleen J. Switzer, Galen E. Sonel, Ali F. Arnold, Robert M. TI Veterans' decision-making preferences and perceived involvement in care, for chronic heart failure SO HEART & LUNG LA English DT Article ID PATIENT COMMUNICATION; MEDICAL ENCOUNTER; ELDERLY-PATIENTS; PATIENTS DESIRE; CANCER-PATIENTS; CHRONIC ILLNESS; INFORMATION; OUTCOMES; PARTICIPATION; SATISFACTION AB BACKGROUND: Patients with heart failure require a great deal of information about their disease, but it is also important to know about their preferences for involvement in medical decision making and about factors that may influence their preferences so that patients' needs, values, and preferences can be met by clinicians. OBJECTIVES: We assessed patients' preferred role and perceived level of involvement in medical decision making and tested the effects of patients' age and role preference on perceived involvement in medical decision making. METHODS: We conducted a telephone survey of 90 adults being treated for heart failure by a Veterans Affairs primary care provider or cardiologist. Patients' preferred role in treatment decisions was assessed using the Control Preferences Scale. Perceptions about their involvement in decision making during the most recent clinic visit was measured using a subscale of the Perceived Involvement in Care Scale. Descriptive, correlational, and generalized linear regression analyses were conducted. RESULTS: Most patients were elderly (mean = 70.1 years), male (94.4%), and white (85.6%), and had New York Heart Association class 11 disease (55.6%). Forty-three patients (47.8%) preferred a passive role in decision making, 19 patients (21.1%) preferred an active role, and 28 patients (31.1%) preferred a collaborative role. Most patients believed that their decision-making involvement was relatively passive, as indicated by a mean score of .96 (range, 0-4) on the Perceived Involvement in Care Scale decision-making subscale. Older age was associated with passive role preference (r =.263; P <.05) and less perceived involvement in decision making (r = -.279; P <.01). In addition, less perceived involvement in decision making during the last clinic visit was associated with a preference for a more passive decision-making role (r = p.355; P <.01). Generalized linear regression analysis indicated that when patients' perceived decision-making involvement was regressed on age and patients' role preferences, age was no longer significantly associated with involvement (beta = -.196; P =.061), but that control preferences Continued to exhibit an independent effect on perceived involvement in medical decision making (beta -.341; P =.003). CONCLUSION: The results Suggest that the preferences of patients with heart failure for a more passive role in decision making may be a stronger independent predictor of patients' perceived involvement in decision making than patients' age. (Heart Lung (R) 2008,37:440-448.) C1 [Rodriguez, Keri L.; Switzer, Galen E.; Sonel, Ali F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Rodriguez, Keri L.; Switzer, Galen E.; Arnold, Robert M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Appelt, Cathleen J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Edcu & Clin Ctr, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Sonel, Ali F.] VA Pittsburgh Healthcare Syst, Div Cardiol, Pittsburgh, PA USA. [Sonel, Ali F.] Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA 15260 USA. [Arnold, Robert M.] Univ Pittsburgh, Sect Palliat Care & Med Eth, Pittsburgh, PA 15260 USA. [Arnold, Robert M.] Univ Pittsburgh, Inst Enhance Palliat Care, Pittsburgh, PA USA. RP Rodriguez, KL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Bldg 2,Room 4083E 151C-H, Pittsburgh, PA 15206 USA. NR 55 TC 14 Z9 14 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 J9 HEART LUNG JI Heart Lung PD NOV-DEC PY 2008 VL 37 IS 6 BP 440 EP 448 DI 10.1016/j.hrtlng.2008.02.003 PG 9 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA 372QP UT WOS:000260916700005 PM 18992627 ER PT J AU Esteban, A Frutos-Vivar, F Anzueto, A AF Esteban, Andres Frutos-Vivar, Fernando Anzueto, Antonio TI Impact of body weight on critically ill patients: a heavy load!! SO INTENSIVE CARE MEDICINE LA English DT Editorial Material ID OBESITY C1 [Esteban, Andres; Frutos-Vivar, Fernando] Hosp Univ Getafe, Inst Salud Carlos III, Serv Cuidados Intens, CIBER Enfermedades Resp, Madrid 28905, Spain. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem VA Hosp, San Antonio, TX 78229 USA. [Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Esteban, A (reprint author), Hosp Univ Getafe, Inst Salud Carlos III, Serv Cuidados Intens, CIBER Enfermedades Resp, Carretera Toledo Km 12,500, Madrid 28905, Spain. EM aesteban@ucigetafe.com OI Frutos-Vivar, Fernando/0000-0002-4648-9636 NR 10 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 J9 INTENS CARE MED JI Intensive Care Med. PD NOV PY 2008 VL 34 IS 11 BP 1964 EP 1965 DI 10.1007/s00134-008-1244-z PG 2 WC Critical Care Medicine SC General & Internal Medicine GA 364AN UT WOS:000260308700006 PM 18670755 ER PT J AU Mendez, MF Licht, EA Saul, RE AF Mendez, Mario F. Licht, Eliot A. Saul, Ronald E. TI The Frontal Systems Behavior Scale in the evaluation of dementia SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID FRONTOTEMPORAL DEMENTIA C1 [Mendez, Mario F.; Licht, Eliot A.; Saul, Ronald E.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare, Neurobehav Unit 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu NR 5 TC 6 Z9 6 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD NOV PY 2008 VL 23 IS 11 BP 1203 EP 1204 DI 10.1002/gps.2019 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 371OS UT WOS:000260841300016 PM 18395885 ER PT J AU Goldman, S McCarren, M Morkin, E Ladenson, P Edson, R Warren, S Ohm, J Thai, H Churby, L Barnhill, J O'Brien, T Anand, I Warner, A Dunlap, M Hattle, B Erikson, J Shih, MC Lavori, P AF Goldman, Steven McCarren, Madeline Morkin, Eugene Ladenson, Paul Edson, Robert Warren, Stuart Ohm, Janet Thai, Hoang Churby, Lori Barnhill, Jamie O'Brien, Terrence Anand, Inder Warner, Alberta Dunlap, Mark Hattle, Brack Erikson, John Shih, Mei-Chung Lavori, Phil TI DITPA, a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial VA Cooperative Study SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 12th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 21-24, 2008 CL Toronto, CANADA SP Heart Failure Soc Amer C1 [Goldman, Steven; Ohm, Janet; Thai, Hoang] So Arizona VA Hlth Care Syst, Tucson, AZ USA. [McCarren, Madeline] VA Ctr Medicat Safety, Hines, IL USA. [Morkin, Eugene] Univ Arizona Hlth Sci, Tucson, AZ USA. [Ladenson, Paul] Johns Hopkins Univ, Baltimore, MD USA. [Edson, Robert; Shih, Mei-Chung; Lavori, Phil] Palo Alto CSP Coordinating Ctr, Palo Alto, CA USA. [Warren, Stuart; Barnhill, Jamie] CSP Clin Res Pharm Coordinat Ctr, Albuquerque, NM USA. [O'Brien, Terrence] VA Med Ctr, Charleston, SC USA. [Anand, Inder] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Warner, Alberta] Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dunlap, Mark] Louis Stokes VA Healthcare Syst, Cleveland, OH USA. [Hattle, Brack] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Erikson, John] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD NOV PY 2008 VL 14 IS 9 BP 796 EP 796 DI 10.1016/j.cardfail.2008.10.008 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 377SB UT WOS:000261269800013 ER PT J AU Samii, A Carleton, BC Etminan, M AF Samii, Ali Carleton, Bruce C. Etminan, Mahyar TI Statin use and the risk of Parkinson disease: a nested case control study SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Coenzyme Q10; Inflammation; Neuroprotection; Parkinson disease; Statin ID CHOLESTEROL LEVELS; COENZYME Q(10) AB Using the British Columbia Linked Health Databases, we explored the association between the use of statin drugs and the risk of developind Parkinson disease (PD). We followed a cohort of older adults in the Province of British Columbia from 1997 to 2003. Using a study design of nested case control (case-control study within a cohort), the relative risk of developing PD for statin users was 0.94 (0.82-1.09). Our study did not show a statistically significant effect on the risk of PD with statin use. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Samii, Ali] Univ Washington, Dept Neurol, Seattle VA Parkinson Dis Res Educ & Clin Ctr PADR, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Carleton, Bruce C.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada. [Etminan, Mahyar] Vancouver Hosp, Ctr Clin Epidemiol & Eraluat, Vancouver, BC, Canada. RP Samii, A (reprint author), Univ Washington, Dept Neurol, Seattle VA Parkinson Dis Res Educ & Clin Ctr PADR, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,MS-127, Seattle, WA 98108 USA. EM asamii@u.washington.edu OI /0000-0002-4485-4054 FU American Parkinson Disease Association; William N. and Myriam Pennington Foundation FX This study was funded by the Washington State Chapter of the American Parkinson Disease Association and the William N. and Myriam Pennington Foundation. NR 8 TC 22 Z9 23 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD NOV PY 2008 VL 15 IS 11 BP 1272 EP 1273 DI 10.1016/j.jocn.2008.01.016 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 367NR UT WOS:000260559200015 PM 18823780 ER PT J AU Sonnenberg, A AF Sonnenberg, A. TI Environmental influence in ulcerative colitis starts in early childhood SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Article ID CROHNS-DISEASE; TIME TRENDS; PEPTIC-ULCER; MORTALITY; COHORT; PERIOD AB Aims: The present analysis served to address the question at what age environmental factors start to exert their influence on the occurrence of ulcerative colitis. Methods: Mortality data from 21 different countries were accumulated between 1941 and 2004 to analyse the variation of age-specific death rates during consecutive time periods and among different countries. Results: Between 1941 and 2004 the trends of mortality from ulcerative colitis among different age groups formed a fan-like pattern with a progressively steeper decline of mortality among increasingly younger age groups. This general pattern included mortality in all age groups older than 5 years, but was absent in the youngest age group, 0-4 years. In countries with frequent occurrence of ulcerative colitis, high mortality from ulcerative colitis affected different age groups alike. This pattern was reflected by a set of statistically significant correlations between the mortality of each two consecutive age groups from different countries. The progression of significant correlations among consecutive age groups broke off only when the geographic variations of the age groups 0-4 and 5-9 years were compared. Conclusions: The analysis suggests that environmental factors responsible for the temporal and geographic variations of ulcerative colitis start to exert their influence during early childhood. C1 Portland VA Med Ctr, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 11 TC 7 Z9 7 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD NOV PY 2008 VL 62 IS 11 BP 992 EP 994 DI 10.1136/jech.2007.067256 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 359VV UT WOS:000260017100012 PM 18854504 ER PT J AU Bilimoria, KY Bentrem, DJ Merkow, RP Nelson, H Wang, E Ko, CY Soper, NJ AF Bilimoria, Karl Y. Bentrem, David J. Merkow, Ryan P. Nelson, Heidi Wang, Edward Ko, Clifford Y. Soper, Nathaniel J. TI Laparoscopic-assisted vs. Open Colectomy for Cancer: Comparison of Short-term Outcomes from 121 Hospitals SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article; Proceedings Paper CT 49th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract/Digestive Disease Week CY MAY 17-21, 2008 CL San Diego, CA SP Soc Surg Alimentary Tract DE Colon cancer; Colectomy; Laparoscopy; Cancer; Surgery; National Surgical Quality Improvement Program ID RANDOMIZED CONTROLLED-TRIAL; SEGMENTAL COLON RESECTION; COLORECTAL-CANCER; PATIENT OUTCOMES; SURGERY; CERTIFICATION; METAANALYSIS; EXPERIENCE; CARCINOMA AB Background Overall postoperative morbidity and mortality after laparoscopic-assisted colectomy (LAC) and open colectomy (OC) have been shown to be generally comparable; however, differences in the occurrence of specific complications are unknown. The objective of this study was to determine whether certain complications occurred more frequently after LAC vs. OC for colon cancer. Methods Using the American College of Surgeons-National Surgical Quality Improvement Project's (ACS-NSQIP) participant-use file, patients were identified who underwent colectomy for cancer at 121 participating hospitals in 2005-2006. Multiple logistic regression models including propensity scores were developed to assess the risk-adjusted association between surgical approach (LAC vs. OC) and 30-day outcomes. Patients were excluded if they underwent emergent procedures, were ASA class 5, or had metastatic disease. Results Of the 3,059 patients who underwent elective colectomy for cancer, 837 (27.4%) underwent LAC and 2,222 (72.6%) underwent OC. There were no significant differences in age, comorbidities, ASA class, or body mass index (BMI) between patients undergoing LAC vs. OC. Patients undergoing LAC had a lower likelihood of developing any adverse event compared to OC (14.6% vs. 21.7%; OR 0.64, 95% CI 0.51-0.81, P<0.0001), specifically surgical site infections, urinary tract infections, and pneumonias. Mean length of stay was significantly shorter after LAC vs. OC (6.2 vs. 8.7 days, P<0.0001). There were no differences between LAC and OC in the reoperation rate (5.5% vs. 5.8%, P=0.79) or 30-day mortality (1.4% vs. 1.8%, P=0.53). Conclusions Laparoscopic-assisted colectomy was associated with lower morbidity compared to OC in select patients, specifically for infectious complications. C1 [Bilimoria, Karl Y.; Bentrem, David J.; Wang, Edward; Soper, Nathaniel J.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Merkow, Ryan P.] Univ Colorado, Sch Med, Dept Surg, Denver, CO 80202 USA. [Nelson, Heidi] Mayo Clin, Dept Surg, Rochester, MN USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Northwestern Univ, Dept Surg, Feinberg Sch Med, 251 E Huron St,Galter 3-150, Chicago, IL 60611 USA. EM k-bilimoria@northwestern.edu NR 33 TC 68 Z9 71 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD NOV PY 2008 VL 12 IS 11 BP 2001 EP 2009 DI 10.1007/s11605-008-0568-x PG 9 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 363QQ UT WOS:000260282200032 PM 18575941 ER PT J AU Werner, RM Chang, VW AF Werner, Rachel M. Chang, Virginia W. TI The Relationship Between Measured Performance and Satisfaction with Care Among Clinically Complex Patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE measured performance; patient satisfaction; clinically complex patients ID QUALITY-OF-CARE; MENTAL-HEALTH-CARE; TECHNICAL QUALITY; UNINTENDED CONSEQUENCES; PSYCHOMETRIC PROPERTIES; MEDICAL-CARE; GUIDELINES; SERVICES; OUTCOMES; RISK AB BACKGROUND: Recent work has shown that clinically complex patients are more likely to receive recommended care, but it is unknown whether higher achievement on individual performance goals results in improved care for complex patients or detracts from other important but unmeasured aspects of care, resulting in unmet needs and lower satisfaction with care. OBJECTIVE: To examine the relationship between measured performance and satisfaction with care among clinically complex patients DESIGN AND PARTICIPANTS: An observational analysis of a national sample of 35,927 veterans included in the External Peer Review Program in fiscal years 2003 and 2004. MEASUREMENTS: First, compliance with individual performance measures (breast cancer screening with mammography, colorectal cancer screening, influenza vaccination, pneumococcal vaccination, lipid monitoring, use of ACE inhibitor in heart failure, and diabetic eye examination), as well as overall receipt of recommended care, was estimated as a function of each patient's clinical complexity. Second, global satisfaction with care was estimated as a function of clinical complexity and compliance with performance measures. MAIN RESULTS: Higher clinical complexity was predictive of slightly higher overall performance (OR 1.13, 95% CI 1.09 to 1.18) and higher performance on most individual performance measures, an effect that was mediated by increased visit frequency. High measured performance was associated with higher satisfaction with care among patients with high clinical complexity. In fact, as complexity increased, the effect of achieving high performance on the odds of being satisfied with care also increased CONCLUSIONS: Not only was measured performance higher in clinically complex patients, but satisfaction with care was also higher among clinically complex patients with high measured performance, suggesting that compliance with performance measures in clinically complex patients does not crowd out unmeasured care. C1 [Werner, Rachel M.; Chang, Virginia W.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Werner, Rachel M.; Chang, Virginia W.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.; Chang, Virginia W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Chang, Virginia W.] Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@mail.med.upenn.edu FU Center for Health Equity Research and Promotion, Philadelphia VA; Atlantic Philanthropies, SGIM/ACGIM; John A. Hartford Foundation; VA HSR&D Career Development Award. Virginia Chang; NIH/NICHD [K12-HD043459] FX Funding for the study was provided by the Center for Health Equity Research and Promotion, Philadelphia VA and by the Atlantic Philanthropies, SGIM/ACGIM, the John A. Hartford Foundation, and ASP. Rachel Werner is supported in part by a VA HSR&D Career Development Award. Virginia Chang is supported in part by grant K12-HD043459 from the NIH/NICHD. NR 43 TC 13 Z9 13 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2008 VL 23 IS 11 BP 1729 EP 1735 DI 10.1007/s11606-008-0734-6 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 379VI UT WOS:000261423900001 PM 18649107 ER PT J AU Schane, RE Woodruff, PG Dinno, A Covinsky, KE Walter, LC AF Schane, Rebecca E. Woodruff, Prescott G. Dinno, Alexis Covinsky, Ken E. Walter, Louise C. TI Prevalence and Risk Factors for Depressive Symptoms in Persons with Chronic Obstructive Pulmonary Disease SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE chronic obstructive pulmonary disease (COPD); depressive symptoms; risk factors ID QUALITY-OF-LIFE; ACUTE EXACERBATION; HEALTH-STATUS; OLDER WOMEN; SELF-REPORT; COPD; MORTALITY; ANXIETY; IMPACT; ASSOCIATION AB BACKGROUND: Although depression is a risk factor for adverse outcomes in chronic illness, little is known about the prevalence or risk factors for depressive symptoms in chronic obstructive pulmonary disease (COPD). OBJECTIVE: To determine the prevalence of depressive symptoms in COPD as compared to other chronic illnesses and to identify risk factors for depressive symptoms in COPD. DESIGN AND PATIENTS: Cross-sectional study of 18,588 persons (1,736 subjects with self-reported COPD), representing a sample of the US population aged >= 50 years who participated in the 2004 Health and Retirement Survey. MEASUREMENTS: Presence of COPD and other chronic conditions was defined by self-report. Presence of depressive symptoms was assessed using the CES-D8 scale. Participants with a score >= 3 on CES-D8 were classified as having clinically significant depressive symptoms. MAIN RESULTS: Of 1,736 participants with COPD, 40% had >= 3 depressive symptoms. Depressive symptoms were more common in COPD than in coronary heart disease, stroke, diabetes, arthritis, hypertension, and cancer. Risk factors for >= 3 depressive symptoms in COPD: younger age (OR 1.02/per year younger, 95% CI[1.02-1.03]), female gender (1.2[1.1-1.3]), current smoking (1.5[1.3-1.7]), marital status[divorced/separated (1.8[1.6-2.1]), widowed (1.8[1.6-2]), never married (1.4[1.1-1.8]), <= high school degree (1.6[1.5-1.8]), dyspnea (2.3[2.1-2.6]), difficulty walking (2.8[2.5-3.2]), and co-morbid diabetes (1.2[1.1-1.4]), arthritis (1.3[1.2-1.5]) or cancer (1.2[1.1-1.4]). CONCLUSIONS: Depressive symptoms are common in COPD and are more likely to occur in COPD than in other common chronic illnesses. The risk factors identified may be used for targeted depression screening in COPD patients. C1 [Schane, Rebecca E.; Woodruff, Prescott G.] Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Covinsky, Ken E.; Walter, Louise C.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Schane, Rebecca E.; Dinno, Alexis] Univ Calif San Francisco, Dept Med, Ctr Tobacco Control Res & Educ, Cardiovasc Res Inst, San Francisco, CA 94143 USA. RP Schane, RE (reprint author), Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Med, Cardiovasc Res Inst, 530 Parnassus Ave,Suite 366, San Francisco, CA 94143 USA. EM rschane@medsfgh.ucsf.edu FU NIH [T32 HL007185, HL074431, 1 R25 CA113710-02]; National Institute on Aging [R01AG023626] FX Dr. Dinno is a recipient of an NIH Training Grant 1 R25 CA113710-02. NR 45 TC 54 Z9 58 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2008 VL 23 IS 11 BP 1757 EP 1762 DI 10.1007/s11606-008-0749-z PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 379VI UT WOS:000261423900005 PM 18690488 ER PT J AU Sudore, RL Landefeld, CS Pantilat, SZ Noyes, KM Schillinger, D AF Sudore, Rebecca L. Landefeld, C. Seth Pantilat, Steven Z. Noyes, Kathryn M. Schillinger, Dean TI Reach and Impact of a Mass Media Event Among Vulnerable Patients: The Terri Schiavo Story SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE mass media; public health; advance care planning; health literacy; vulnerable populations ID HEALTH-CARE; NEWS MEDIA; LITERACY; LIFE; COMMUNICATION; COVERAGE; CANCER; ADULTS; TRIAL; END AB BACKGROUND: It is unknown whether health-related media stories reach diverse older adults and influence advance care planning (ACP). OBJECTIVE: To determine exposure to media coverage of Terri Schiavo (TS) and its impact on ACP. DESIGN AND PARTICIPANTS: Descriptive study of 117 English/Spanish-speakers, aged >= 50 years (mean 61 years) from a county hospital, interviewed six months after enrollment into an advance directive study. MEASUREMENTS: We assessed whether participants had heard of TS and subject characteristics associated with exposure. We also asked whether, because of TS, subjects engaged in ACP. MAIN RESULTS: Ninety-two percent reported hearing of TS. Participants with adequate literacy were more likely than those with limited literacy to report hearing of TS (100% vs. 79%, P<.001), as were participants with >= a high school vs. < high school education (97% vs. 82%, P=.004), and English vs. Spanish-speakers (96% vs. 85%, P=.04). Because of TS, many reported clarifying their own goals of care (61%), talking to their family/friends about ACP (66%), and wanting to complete an advance directive (37%). CONCLUSIONS: Most diverse older adults had heard of TS and reported that her story activated them to engage in ACP. Media stories may provide a powerful opportunity to engage patients in ACP and develop public health campaigns. C1 [Sudore, Rebecca L.; Landefeld, C. Seth; Noyes, Kathryn M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sudore, Rebecca L.; Landefeld, C. Seth; Noyes, Kathryn M.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Sudore, Rebecca L.; Landefeld, C. Seth; Pantilat, Steven Z.; Schillinger, Dean] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Schillinger, Dean] San Francisco Gen Hosp, UCSF Ctr Vulnerable Populat, San Francisco, CA 94110 USA. RP Sudore, RL (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM rsucsf@yahoo.com FU NCRR NIH HHS [UL1 RR024131]; NIA NIH HHS [5R01AG023626-02, K-23 AG030344-01, AG000212, K07 AG000912, K23 AG030344, R01 AG023626, T32 AG000212] NR 19 TC 10 Z9 11 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD NOV PY 2008 VL 23 IS 11 BP 1854 EP 1857 DI 10.1007/s11606-008-0733-7 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 379VI UT WOS:000261423900020 PM 18716849 ER PT J AU Meeran, SM Punathil, T Katiyar, SK AF Meeran, Syed M. Punathil, Thejass Katiyar, Santosh K. TI IL-12 Deficiency Exacerbates Inflammatory Responses in UV-Irradiated Skin and Skin Tumors SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID NECROSIS-FACTOR-ALPHA; IFN-GAMMA PRODUCTION; GREEN TEA; INTERLEUKIN-12-DEFICIENT MICE; ULTRAVIOLET-RADIATION; COX-2 EXPRESSION; DNA-REPAIR; T-CELL; INHIBITION; CANCER AB IL-12 deficiency has been shown to promote photocarcinogenesis in mice. As UVB-induced inflammation is an important tumor-promoting event in the development of skin tumors, we determined the effects of IL-12-deficiency on UVB-induced inflammatory responses in mice. For this purpose, IL-12-knockout (IL-12 KO) and their wild-type counterparts were subjected to a photocarcinogenesis protocol; skin and tumor samples were collected at the termination of the experiment, and analyzed for biomarkers of inflammation and their mediators. We found that the levels of infiltrating leukocytes, myeloperoxidase, proliferating cell-nuclear antigen (PCNA), COX-2, PGE(2), and the proinflammatory cytokines IL-1 beta, TNF-alpha, and IL-6 were higher in the UVB-exposed skin of IL-12 KO than in that of wild-type mice. In a short-term experiment, pretreatment of IL-12 KO mice with rIL-12 (50 ng per mouse) before each exposure to UVB increased the repair rate of UVB-induced cyclobutane pyrimidine dimers, while inhibiting UVB-induced increases in myeloperoxidase, COX-2, PGE2, PCNA, TNF-alpha, and IL-1 beta in the skin as compared with non-rIL-12-treated IL-12 KO mice. Similarly, tumors of IL-12 KO mice expressed higher levels of inflammatory responses than those of wild-type mice. Together, our data suggest that IL-12 KO mice are more susceptible to both UVB-induced inflammation and photocarcinogenesis because of the deficiency in the repair of UVB-induced DNA damage. C1 [Meeran, Syed M.; Punathil, Thejass; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Center for Complementary and Alternative Medicine, NCCAM/NIH [1 RO1 AT002536]; Veterans Affairs Merit Review Award FX This work was supported by funds from the National Center for Complementary and Alternative Medicine, NCCAM/NIH (1 RO1 AT002536; SKK), and Veterans Affairs Merit Review Award (SKK). NR 36 TC 36 Z9 39 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD NOV PY 2008 VL 128 IS 11 BP 2716 EP 2727 DI 10.1038/jid.2008.140 PG 12 WC Dermatology SC Dermatology GA 364XL UT WOS:000260368800019 PM 18509359 ER PT J AU Fitten, LJ Ortiz, F Fairbanks, L Rosenthal, M Cole, GN Nourhashemi, F Sanchez, MA AF Fitten, L. J. Ortiz, F. Fairbanks, L. Rosenthal, M. Cole, G. N. Nourhashemi, F. Sanchez, M. A. TI DEPRESSION, DIABETES AND METABOLIC-NUTRITIONAL FACTORS IN ELDERLY HISPANICS SO JOURNAL OF NUTRITION HEALTH & AGING LA English DT Article DE Depression; metabolic-nutritional factors; elderly hispanics; sea fish ID 3RD NATIONAL-HEALTH; POLYUNSATURATED FATTY-ACIDS; OLDER MEXICAN-AMERICANS; COGNITIVE IMPAIRMENT; BIPOLAR DEPRESSION; US ADULTS; SYMPTOMS; RISK; OMEGA-3-FATTY-ACIDS; POPULATION AB Objective: To examine the relationship of depression to metabolic and nutritional risk factors in older Hispanics. Design: Crossectional study. Setting: Subjects were part of a community-based, cognitive evaluation project that examined 301 subjects in the Eastern San Fernando Valley of Southern California. Participants: Two elderly Hispanic groups: 53 clinically depressed, with memory complaints but not demented subjects, and 33 generally healthy, cognitively asymptomatic subjects. Measurements: The results of functional and nutritional questionnaires, a medical and neurological examination, 12-hour fasting clinical laboratory tests, MRI or CT scans, and neuropsychological testing. Results: Both groups were nearly identical along socio-demographic variables. However, the depressed group differed significantly from the general healthy group not only in percent of diabetics (38% vs. 18%), but in the amount of poorly controlled diabetes, and the depressed group consumed about half the amount of fish that the generally healthy group did. Conclusions: This study suggests that factors such as poorly controlled diabetes combined with low consumption of foods high in omega-3 fatty acid content Such as sea fish may be associated with an increased risk of developing depression in late life. These factors may be socio-economically and culturally influenced and are therefore amenable to modification. C1 [Fitten, L. J.; Rosenthal, M.; Cole, G. N.] Greater Los Angeles VA Healthcare Syst, Ctr Clin, Los Angeles, CA 91343 USA. [Fitten, L. J.; Ortiz, F.; Fairbanks, L.; Cole, G. N.; Sanchez, M. A.] Univ Calif Los Angeles, David Geffen Sch Med, Alzheimers Dis Res Ctr, Los Angeles, CA 90095 USA. [Fitten, L. J.; Ortiz, F.] Univ Calif Los Angeles, Med Ctr, Dept Psychiat Olive View, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Sch Med, Los Angeles, CA 90024 USA. [Fitten, L. J.; Ortiz, F.; Fairbanks, L.; Cole, G. N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Nourhashemi, F.] Purpan Univ Hosp, Fac Med, Toulouse, France. RP Fitten, LJ (reprint author), Greater Los Angeles VA Healthcare Syst, Ctr Clin, Sepulveda Campus,16111 Plummer St,116A-9, Los Angeles, CA 91343 USA. EM jfitten@ucla.edu; freddyo@ucla.edu FU NIA NIH HHS [P50 AG016570, P50 AG16570] NR 48 TC 6 Z9 6 U1 3 U2 8 PU SERDI EDITION PI PARIS PA 320 RUE SAINT-HONORE, PARIS, 75001, FRANCE SN 1279-7707 J9 J NUTR HEALTH AGING JI J. Nutr. Health Aging PD NOV PY 2008 VL 12 IS 9 BP 634 EP 640 PG 7 WC Geriatrics & Gerontology; Nutrition & Dietetics SC Geriatrics & Gerontology; Nutrition & Dietetics GA 373IW UT WOS:000260966300005 PM 18953461 ER PT J AU Harber, P Wynn, BO Lim, YW Mattke, S Asch, SM Nuckols, TK AF Harber, Philip Wynn, Barbara O. Lim, Yee-Wei Mattke, Soeren Asch, Steven M. Nuckols, Teryl K. TI Selection of Workers' Compensation Treatment Guidelines: California Experience SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CLINICAL-PRACTICE GUIDELINES; PHYSICIAN AWARENESS; QUALITY; MANAGEMENT; ADHERENCE AB Objective: Workers' compensation systems increasingly use mandatory treatment guidelines to guide clinicians and for utilization management This article describes steps for selecting such guidelines. Methods: On the basis of experience with the RAND/University of California, Los Angeles project to help California select guidelines, we identified the necessary choices and process for guideline selection and evaluation. Results: Major steps in guideline selection include: 1) define propose; 2) assign decision-making authority; 3) decide whether to use existing guidelines or develop new ones; 4) choose whether to use one or multiple existing guidelines; 5) specify clinical topics that guidelines should address; 6) identify and screen guidelines; 7) evaluate guidelines; 8) consider implications of results; 9) select guideline(s); 10) disseminate selection; and 11) assess long-term effectiveness. Conclusions: Given the many choices required, selecting mandatory workers' compensation guidelines should involve careful planning and a transparent, well-defined process. (J Occup Environ Med. 2008;50:1282-1292) C1 [Harber, Philip] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Div Occupat & Environm Med, Los Angeles, CA 90095 USA. [Harber, Philip] Univ Calif Los Angeles, Sch Publ Hlth, UCLA Ctr Occupat & Environm Hlth, Los Angeles, CA 90024 USA. [Wynn, Barbara O.; Lim, Yee-Wei; Mattke, Soeren; Asch, Steven M.; Nuckols, Teryl K.] RAND Corp, Santa Monica, CA USA. [Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, Steven M.; Nuckols, Teryl K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Asch, Steven M.; Nuckols, Teryl K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Hlth Serv Res, Los Angeles, CA 90095 USA. RP Harber, P (reprint author), 10880 Wilshire Blvd,Suite 1800, Los Angeles, CA 90024 USA. EM pharber@mednet.ucla.edu FU California Department of Industrial Relations; Southern California Education and Research Center (CDC/NIOSH) FX Christine Baker. Executive Officer; Lachlan Taylor, Administrative Law Judge: and Irina Nemirovsky, Research Program Specialist It: of the California Commission oil Health and Safety and Workers' Compensation: and Anne Searcy, Medical Director. of the California Division of Workers' Compensation participated in study conception and design.; Sponsored in part by the California Department of Industrial Relations (Division of Workers' Compensation and the California Commission on Health and Safety and Workers' Compensation) and the Southern California Education and Research Center (CDC/NIOSH). NR 36 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD NOV PY 2008 VL 50 IS 11 BP 1282 EP 1292 DI 10.1097/JOM.0b013e3181841fb4 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 372DC UT WOS:000260880800009 PM 19001954 ER PT J AU Wilson, B Kutner, JS Levy, C AF Wilson, Barbara Kutner, Jean S. Levy, Cari TI Do Health Insurance Plans Perpetuate Ambiguity About Palliative Care? SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Letter C1 [Levy, Cari] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. [Wilson, Barbara; Kutner, Jean S.; Levy, Cari] Univ Colorado Denver & Hlth Sci Ctr, Denver, CO 80220 USA. RP Levy, C (reprint author), Denver Vet Affairs Med Ctr, 6646 E 17th Ave, Denver, CO 80220 USA. EM Cari.Levy@uchsc.edu NR 3 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV PY 2008 VL 11 IS 9 BP 1182 EP 1182 DI 10.1089/jpm.2008.0122 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 378AL UT WOS:000261293400006 PM 19021474 ER PT J AU Dupreez, AE Smith, MA Liou, JI Frytak, JR Finch, MD Cleary, JF Kind, AJH AF duPreez, Amanda E. Smith, Maureen A. Liou, Jinn-Ing Frytak, Jennifer R. Finch, Michael D. Cleary, James F. Kind, Amy J. H. TI Predictors of Hospice Utilization among Acute Stroke Patients who Died within Thirty Days SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; NURSING-HOMES; OF-LIFE; INTERNATIONAL-CLASSIFICATION; GEOGRAPHIC-VARIATION; CEREBRAL INFARCTION; ADMINISTRATIVE DATA; DECISION-MAKING; UNITED-STATES; MANAGED CARE AB Background: Hospice is considered to be underutilized, particularly among patients with noncancer diagnoses such as stroke. The highest mortality among stroke patients occurs within the first 30 days; however, we know little about the hospice enrollment decision for this population during this critical time frame. Objectives: To determine hospice enrollment rates and to describe sociodemographic and clinical predictors of hospice utilization among patients who die within 30 days of their stroke. Design: Retrospective analysis of administrative data. Subjects: Medicare beneficiaries 65 years and older discharged with ischemic stroke from 422 hospitals and 11 metropolitan regions during the year 2000 who died within 30 days of their stroke. Measures: Hospice utilization within 30 days. Results: The overall hospice enrollment rate in our study was 23%. Using multivariable logistic regression, factors predicting increased hospice enrollment included older age, female gender, health management organization (HMO) membership, length of stay more than 3 days, and dementia. Factors predicting decreased enrollment included African American race, mechanical ventilation, gastrostomy tube placement, uncomplicated diabetes mellitus, and valvular disease. When in-hospital deaths were excluded, overall enrollment increased to 44%, and mechanical ventilation and dementia ceased to predict enrollment. Conclusions: Hospice enrollment rates among patients who die within the first 30 days of their stroke, particularly among those who survive to discharge, are much higher than prior estimates suggest. Although overall enrollment rates were higher than anticipated, there remain important sociodemographic and clinical characteristics unique to this population that predict low hospice utilization that should serve as targets for further research and intervention. C1 [duPreez, Amanda E.; Smith, Maureen A.; Liou, Jinn-Ing; Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA. [duPreez, Amanda E.] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Womens Hlth Res, Madison, WI 53726 USA. [duPreez, Amanda E.] Meriter Hosp, Madison, WI USA. [duPreez, Amanda E.; Kind, Amy J. H.] William S Middleton Hosp, US Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Finch, Michael D.] Finch & King Inc, Minneapolis, MN USA. [Frytak, Jennifer R.] Ingenix, Eden Prairie, MN USA. [Cleary, James F.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Oncol Sect, Madison, WI 53726 USA. [Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Geriatr Sect, Madison, WI 53726 USA. RP Smith, MA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA. EM maureensmith@wisc.edu FU National Institute of Aging [R01-AG19747] FX This study was supported by a grant (R01-AG19747) from the National Institute of Aging. NR 42 TC 7 Z9 7 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV PY 2008 VL 11 IS 9 BP 1249 EP 1257 DI 10.1089/jpm.2008.0124 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 378AL UT WOS:000261293400021 PM 19021489 ER PT J AU Carlson, MDA Morrison, RS AF Carlson, Melissa D. A. Morrison, R. Sean TI User's Guide to Research in Palliative Care: Why Is a New Series Needed? SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HOSPITALIZED-PATIENTS; ADVANCED DEMENTIA; CONSULTATIONS; ETHICS C1 [Carlson, Melissa D. A.; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr, Hertzberg Palliat Care Inst, New York, NY 10029 USA. [Carlson, Melissa D. A.; Morrison, R. Sean] Natl Palliat Care Res Ctr, New York, NY USA. [Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Carlson, MDA (reprint author), Mt Sinai Sch Med, Brookdale Dept Geriatr, Hertzberg Palliat Care Inst, Box 1070, New York, NY 10029 USA. EM melissa.carlson@mssm.edu FU National Institute for Nursing Research [K99NR10495]; National Institute on Aging [K24AG022345] FX Dr. Carlson is a Brookdale National Fellow, and Olive Branch Scholar of the National Palliative Care Research Center, and the recipient of a Pathway to Independence Award (K99NR10495) from the National Institute for Nursing Research.; Dr. Morrison is the recipient of a Mid-Career Investigator Award in Patient Oriented Research from the National Institute on Aging (K24AG022345). NR 15 TC 9 Z9 9 U1 2 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV PY 2008 VL 11 IS 9 BP 1258 EP 1261 DI 10.1089/jpm.2008.9831 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 378AL UT WOS:000261293400022 PM 19021490 ER PT J AU Yang, CC AF Yang, Claire C. TI The Neurourological Examination in Women SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Physical Examination; Female; Neurourology AB The review provides a description of a physical examination protocol to rule out significant neurologic disease as a cause for a woman's sexual complaints, or to confirm a neurologic cause for the sexual dysfunction, particularly in women with known neurologic disease. Yang CC. The neurourological examination in women. J Sex Med 2008;5:2498-2501. C1 [Yang, Claire C.] Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Yang, Claire C.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Yang, Claire C.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. RP Yang, CC (reprint author), VA Puget Sound Hlth Care Syst, S112-UR,1660 S Columbian Way, Seattle, WA 98108 USA. EM cyang@u.washington.edu NR 7 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1743-6095 J9 J SEX MED JI J. Sex. Med. PD NOV PY 2008 VL 5 IS 11 BP 2498 EP 2501 DI 10.1111/j.1743-6109.2008.01022.x PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 374UB UT WOS:000261068100005 PM 19006496 ER PT J AU Ricketts, T Johnson, E Federman, J AF Ricketts, Todd Johnson, Earl Federman, Jeremy TI Individual Differences within and across Feedback Suppression Hearing Aids SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Article DE Feedback suppression; hearing aid; individual differences ID ACOUSTIC FEEDBACK; CANCELLATION; GAIN; ALGORITHMS; SYSTEMS AB Background: New and improved methods of feedback suppression are routinely introduced in hearing aids; however, comparisons of additional gain before feedback (AGBF) values across instruments are complicated by potential variability across subjects and measurement methods. Purpose: To examine the variability in AGBF values across individual listeners and an acoustic manikin. Research Design: A descriptive study of the reliability and variability of the AGBF measured within six commercially available feedback suppression (FS) algorithms using probe microphone techniques. Study Sample: Sixteen participants and an acoustic manikin. Results: The range of AGBF across the six FS algorithms was 0 to 15 dB, consistent with other recent studies. However, measures made in the participants ears and on the acoustic manikin within the same instrument suggest that across instrument comparisons of AGBF measured using acoustic manikin techniques may be misleading, especially when differences between hearing aids are small (i.e., less than 6 dB). Individual subject results also revealed considerable variability within the same FS algorithms. The range of AGBF values was as small as 7 dB and as large as 16 dB depending on the specific FS algorithm, suggesting that some models are much more robust than others. Conclusions: These results suggest caution when selecting FS algorithms clinically since different models can demonstrate similar AGBF when averaging across ears, but result in quite different AGBF values in a single individual ear. C1 [Ricketts, Todd; Federman, Jeremy] Vanderbilt Bill Wilkerson Ctr, Dept Speech & Hearing Sci, Mountain Home, TN USA. [Johnson, Earl] US Dept Vet Affairs, James H Quillen Med Ctr, Mountain Home, TN USA. RP Ricketts, T (reprint author), Dan Maddox Hearing Aid Res Lab, Med Ctr E, 1215 21st Ave S,Room 8310,South Tower, Nashville, TN 37232 USA. EM todd.a.ricketts@vanderbilt.edu FU Siemens Hearing Instruments, Inc FX This study was funded in part by a grant from Siemens Hearing Instruments, Inc. NR 28 TC 4 Z9 4 U1 1 U2 6 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD NOV-DEC PY 2008 VL 19 IS 10 BP 748 EP 757 DI 10.3766/jaaa.19.10.3 PG 10 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 424IY UT WOS:000264561600003 PM 19358455 ER PT J AU Parchman, ML AF Parchman, Michael L. TI The Gordian Knot of Chronic Illness Care SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Editorial Material ID DIABETES CARE; UNITED-STATES; HEALTH; MANAGEMENT; QUALITY; ADULTS C1 [Parchman, Michael L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Parchman, Michael L.] S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Program, San Antonio, TX USA. RP Parchman, ML (reprint author), S Texas Vet Hlth Care, 7400 Merton Mentor Blvd 11C6, San Antonio, TX 78229 USA. EM parchman@uthscsa.edu OI Parchman, Michael/0000-0001-7129-2889 FU NIDDK NIH HHS [R18 DK075692] NR 18 TC 3 Z9 3 U1 0 U2 0 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD NOV-DEC PY 2008 VL 21 IS 6 BP 487 EP 489 DI 10.3122/jabfm.2008.06.080180 PG 3 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 369VH UT WOS:000260721500003 PM 18988714 ER PT J AU Freel, AC Shiloach, M Weigelt, JA Beilman, GJ Mayberry, JC Nirula, R Stafford, RE Tominaga, GT Ko, CY AF Freel, Andrew C. Shiloach, Mira Weigelt, John A. Beilman, Gregory J. Mayberry, John C. Nirula, Rarninder Stafford, Renae E. Tominaga, Gail T. Ko, Clifford Y. TI American College of Surgeons Guidelines Program: A Process for Using Existing Guidelines to Generate Best Practice Recommendations for Central Venous Access SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID CLINICAL-PRACTICE GUIDELINES; MANAGEMENT; APPRAISAL; QUALITY; INSTRUMENT; INSERTION; DEVICES; ADULTS; PAIN AB BACKGROUND: Many professional organizations help their members identify and use quality guidelines. Some of these efforts involve developing new guidelines, and others assess existing guidelines for their clinical usefulness. The American College of Surgeons Guidelines Program attempts to recognize useful surgical guidelines and develop research questions to help clarify existing clinical guidelines. We used existing guidelines about central venous access to develop a set of summary recommendations that could be used by practitioners to establish local best practices. STUDY DESIGN: A comprehensive literature search identified existing clinical guidelines for short-term central venous access. Two reviewers independently rated the guidelines using the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument. Highly scored guidelines were analyzed for content, and their recommendations were compiled into a summary table. The summary table was reviewed by an independent panel of experts for clinical utility. RESULTS: Thirty-two guidelines were identified, and 23 met inclusion criteria. The AGREE rating resulted in four guidelines that were strongly recommended and five that were recommended with alterations. Three comprehensive tables of recommendations were produced: procedural, maintenance, and infectious assessment. A panel of experts came to consensus agreement on the final format of the best practice recommendations, which included 30 summary recommendations. CONCLUSIONS: Our process combined assessing existing guidelines methodology with expert opinion to produce a best practice list of guidelines that could be fashioned into local care routines by practicing physicians. The American College of Surgeons guidelines program believes this process will help validate the clinical utility of existing guidelines and identify areas needing further investigation to determine practical validity. (J Am Coll Surg 2008;207:676-682. (C) 2008 by the American College of Surgeons) C1 [Freel, Andrew C.; Shiloach, Mira; Weigelt, John A.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Freel, Andrew C.] Louisiana State Univ, Hlth Sci Ctr, Dept Surg, New Orleans, LA USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Los Angeles, CA USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Beilman, Gregory J.] Univ Minnesota, Minneapolis, MN USA. [Mayberry, John C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Nirula, Rarninder] Univ Utah, Salt Lake City, UT USA. [Weigelt, John A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Stafford, Renae E.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Tominaga, Gail T.] Scripps Mem Hosp La Jolla, La Jolla, CA USA. RP Shiloach, M (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St, Chicago, IL 60611 USA. OI Beilman, Gregory/0000-0001-5036-3027 FU American College of Surgeons Foundation FX Andrew C Freel participated in the American College of Surgeons Clinical Scholar-in-Residence program from 2006 to 2007. The American College of Surgeons received funding for its Scholars-in-Residence Program from the American College of Surgeons Foundation through a grant from Cook, Inc. NR 28 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD NOV PY 2008 VL 207 IS 5 BP 676 EP 682 DI 10.1016/j.jamcollsurg.2008.06.340 PG 7 WC Surgery SC Surgery GA 372SI UT WOS:000260921700008 PM 18954779 ER PT J AU Chodosh, J Edelen, MO Buchanan, JL Yosef, JA Ouslander, JG Berlowitz, DR Streim, JE Saliba, D AF Chodosh, Joshua Edelen, Maria Orlando Buchanan, Joan L. Yosef, Julia Ann Ouslander, Joseph G. Berlowitz, Dan R. Streim, Joel E. Saliba, Debra TI Nursing Home Assessment of Cognitive Impairment: Development and Testing of a Brief Instrument of Mental Status SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE nursing home; mental status; cognitive assessment; dementia ID MINIMUM DATA SET; DEMENTIA; CARE; RECOGNITION; 3MS; PREVALENCE; RESIDENTS; VALIDITY; SCREEN; OLDER AB To test the accuracy of a brief cognitive assessment of nursing home (NH) residents and to determine whether facility nurses can reliably perform this assessment. Cross-sectional, independent cognitive screening tests with NH residents. Six Department of Veteran Affairs nursing facilities. Three hundred seventy-four residents from six regionally distributed Veteran Affairs NHs. Three cognitive assessment instruments: the Brief Interview of Mental Status (BIMS), created for this study; the Minimum Data Set (MDS) 2.0 Cognitive Performance Scale (CPS), and the Modified Mini-Mental State Examination (3MS) as the criterion standard. The 15-point BIMS tests memory and orientation and includes free and cued recall items. Research assistants administered the 3MS and BIMS to all subjects. Facility nurses administered the same BIMS to a subsample. Three hundred seventy-four of 417 (89.7%) residents approached completed the 3MS and research assistant-administered BIMS (BIMS-R); 212 residents also received a facility nurse-administered BIMS (BIMS-N). The BIMS-R was more highly correlated with the 3MS than was the CPS (Pearson correlation coefficient (r)=0.79 vs 0.62; P <.01 for difference). For the subset who received facility assessments, the BIMS-N was also more highly correlated with the 3MS (Pearson r=0.74 vs 0.65; P <.01 for difference). For any impairment (3MS < 78), the area under the receiver operator characteristic curve (AUC) was 0.86 for the BIMS, versus 0.77 for the CPS. For severe impairment (3MS < 48) the AUC was 0.94, versus 0.85 for the CPS. In this population, a brief cognitive test is a more accurate approach to cognitive assessment than the current observational methods employed using the MDS 2.0. C1 [Chodosh, Joshua; Saliba, Debra] Dept Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. [Chodosh, Joshua; Yosef, Julia Ann; Saliba, Debra] Dept Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv Ctr Excellence, Sepulveda, CA USA. [Chodosh, Joshua; Saliba, Debra] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med,Multicampus Program Geriatr Med & Geront, Los Angeles, CA 90095 USA. [Edelen, Maria Orlando; Saliba, Debra] Rand Hlth, Santa Monica, CA USA. [Buchanan, Joan L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Ouslander, Joseph G.] Atlanta Dept Vet Affairs Med Ctr, Atlanta, GA USA. [Ouslander, Joseph G.] Emory Univ, Wesley Woods Geriatr Hosp, Atlanta, GA 30322 USA. [Berlowitz, Dan R.] Vet Affairs Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Berlowitz, Dan R.] Boston Univ, Sch Publ Hlth, Dept Internal Med, Boston, MA USA. [Berlowitz, Dan R.] Boston Univ, Sch Med, Dept Internal Med, Boston, MA 02118 USA. [Streim, Joel E.] Philadelphia Dept Vet Affairs Med Ctr, Mental Illness Res Ctr, Philadelphia, PA USA. [Streim, Joel E.] Philadelphia Dept Vet Affairs Med Ctr, Educ Ctr, Philadelphia, PA USA. [Streim, Joel E.] Philadelphia Dept Vet Affairs Med Ctr, Clin Care Ctr, Philadelphia, PA USA. [Streim, Joel E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Chodosh, J (reprint author), 11301 Wilshire Blvd GRECC,11G, Los Angeles, CA 90073 USA. EM JChodosh@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU Department of Veterans Affairs, Veterans Health Administration Health Services Research and Development Service [SDR 03-217]; Georgia Medical Care Foundation; Pfizer; Novartis; Amgen; Sepracor FX The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this manuscript. This research was supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service (SDR 03-217). J. Ouslander has a contract with the Georgia Medical Care Foundation, the Medicare Q10 for Georgia; has received grants or funds from Pfizer, Novartis, Amgen, and Sepracor; has been on the speaker forum for Pfizer, Novartis, and Watson; is a consultant to Pfizer, Esprit, and Amgen; and is on the Pfizer Advisory Board. NR 24 TC 36 Z9 37 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2008 VL 56 IS 11 BP 2069 EP 2075 DI 10.1111/j.1532-5415.2008.01944.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 374SS UT WOS:000261064600012 PM 19016941 ER PT J AU Lin, JC Weintraub, N Aragaki, DR AF Lin, James C. Weintraub, Nancy Aragaki, Dixie R. TI Nonsurgical Treatment for Rotator Cuff Injury in the Elderly SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Review DE Shoulder pain; rotator cuff disease; elderly ID SUBACROMIAL IMPINGEMENT SYNDROME; SHOCK-WAVE THERAPY; CONTROLLED CLINICAL-TRIAL; SHOULDER PAIN; COMMUNITY SURVEY; SUPRASPINATUS TENDINOPATHY; MUSCULOSKELETAL DISORDERS; CORTICOSTEROID INJECTION; NATURAL-HISTORY; TEARS AB Shoulder pain is a common musculoskeletal complaint in the general population. The elderly population is often afflicted, and rotator cuff problems are among the most common causes of shoulder pain seen in primary care practices. The prevalence of shoulder pain in the elderly has been estimated to range from 21% to 27%, and the prevalence of rotator cuff tear increases with advanced age. The etiology of rotator cuff disease is likely multifactorial, including both extrinsic and intrinsic factors. Rotator cuff dysfunction encompasses a spectrum of pathological changes, ranging from impingement syndrome to rotator cuff tendonitis to rotator cuff tendon tear. In the elderly population, the clinical manifestations from rotator cuff dysfunction can translate into significant morbidity and disabilities, interfering with ability for self care and functional independence. The goals of managing rotator cuff disease are to regain normal shoulder function and biomechanics, and to improve functional abilities in elderly patients. Treatment can consist of various conservative therapies (including ice, simple exercises, medications), and progress to more intensive physical therapy and/or corticosteroid injections. Rotator cuff dysfunction is a common musculoskeletal disorder in elderly patients and is often underdiagnosed and undertreated. Physicians should be aware of the prevalence of rotator cuff disease in this population and provide early diagnosis and treatment to help preserve the functional ability and independence of older patients. (J Am Med Dir Assoc 2008; 9: 626-632) C1 [Lin, James C.; Weintraub, Nancy; Aragaki, Dixie R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Aragaki, Dixie R.] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA. [Weintraub, Nancy] VA Greater Los Angeles Healthcare Syst, Dept Internal Med, Los Angeles, CA USA. RP Weintraub, N (reprint author), Univ Calif Los Angeles, Greater Los Angeles VA, GRECC, 16111 Pkummer St 11E, Sepulveda, CA 91343 USA. EM nancy.weintraub@va.gov NR 58 TC 16 Z9 19 U1 2 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD NOV PY 2008 VL 9 IS 9 BP 626 EP 632 DI 10.1016/j.jamda.2008.05.003 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 376ZO UT WOS:000261221700004 PM 18992694 ER PT J AU Saha, S Beach, MC Cooper, LA AF Saha, Somnath Beach, Mary Catherine Cooper, Lisa A. TI Patient Centeredness, Cultural Competence and Healthcare Quality SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE cultural competence; patient-physician relationship; quality of care ID PHYSICIAN RELATIONSHIP; INTERNAL-MEDICINE; FRAMEWORK; RACE AB Cultural competence and patient centeredness are approaches to improving healthcare quality that have been promoted extensively in recent years. In this paper, we explore the historical evolution of both cultural competence and patient centeredness. In doing so, we demonstrate that early conceptual models of cultural competence and patient centeredness focused on how healthcare providers and patients might interact at the interpersonal level and that later conceptual models were expanded to consider how patients might be treated by the healthcare system as a whole. We then compare conceptual models for both cultural competence and patient centeredness at both the interpersonal and healthcare system levels to demonstrate similarities and differences. We conclude that, although the concepts have had different histories and foci, many of the core features of cultural competence and patient centeredness are the same. Each approach holds promise for improving the quality of healthcare for individual patients, communities and populations. C1 [Saha, Somnath] Portland VA Med Ctr, Portland, OR 97239 USA. [Saha, Somnath] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Beach, Mary Catherine; Cooper, Lisa A.] Johns Hopkins Sch Med, Baltimore, MD USA. [Beach, Mary Catherine; Cooper, Lisa A.] Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Saha, S (reprint author), Portland VA Med Ctr, P3MED,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sahas@ohsu.edu FU Commonwealth Fund, a New York; Health Services Research and Development Service of the Department of Veterans Affairs; Robert Wood Johnson Foundation; National Heart Lung and Blood Institute [K24HL083113] FX This study was supported by The Commonwealth Fund, a New York City-based private, independent foundation. Dr. Soho was supported by an Advanced Research Career Development Award from the Health Services Research and Development Service of the Department of Veterans Affairs. Drs. Saha and Beach were supported by Generalist Physician Faculty Scholar Awards from the Robert Wood Johnson Foundation. Dr. Cooper was supported by the National Heart Lung and Blood Institute (grant #K24HL083113). The views expressed in this paper are those of the authors and not necessarily those of The Commonwealth Fund, the Department of Veterans Affairs, the National Institutes of Health or the Robert Wood Johnson Foundation. NR 35 TC 122 Z9 123 U1 2 U2 22 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD NOV PY 2008 VL 100 IS 11 BP 1275 EP 1285 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 374KQ UT WOS:000261042600002 PM 19024223 ER PT J AU Zhou, XH Lin, HZ Johnson, E AF Zhou, Xiao-Hua Lin, Huazhen Johnson, Eric TI Non-parametric heteroscedastic transformation regression models for skewed data with an application to health care costs SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY LA English DT Article DE Health care costs; Heteroscedasticity; Non-parametrics; Skewness; Transformation regression models ID 2-PART MODEL; RETRANSFORMATION; LINK; ADO AB We develop a new non-parametric heteroscedastic transformation regression model for predicting the expected value of the outcome of a patient with given patient's covariates when the distribution of the outcome is highly skewed with a heteroscedastic variance. In our model, we allow both the transformation function and the error distribution function to be unknown. We show that under some regularity conditions the estimators for regression parameters, the expected value of the original outcome and the transformation function converge to their true values at the rate n(-1/2). In our simulation studies, we demonstrate that our proposed non-parametric method is robust with little loss of efficiency. Finally, we apply our model to a study on health care costs. C1 [Zhou, Xiao-Hua] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. [Zhou, Xiao-Hua; Johnson, Eric] Univ Washington, Seattle, WA 98195 USA. [Lin, Huazhen] Sichuan Univ, Chengdu 610064, Peoples R China. RP Zhou, XH (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. EM azhou@u.washington.edu FU Agency for Healthcare Research and Quality [R01HSO 13105]; US Department of Veterans Affairs; Veterans Affairs Health Administration; Health Services Research Development [ECI-03-206]; Fund of National Natural Science [10771148] FX Zhou's work was supported in part by Agency for Healthcare Research and Quality grant R01HSO 13105 and US Department of Veterans Affairs, Veterans Affairs Health Administration, Health Services Research & Development grant ECI-03-206. Lin's work was supported in part by the Fund of National Natural Science (grant 10771148) of China. We also thank Dr Jurgen Untitzer for providing us with the data. This paper presents tile findings and conclusions or the authors. It does not necessarily represent those of the Veterans Affairs Health Services Research & Development service. We also express our thanks to the Joint Editor, the Associate Editor and the three referees for many helpful comments and suggestions that led to an improvement in this paper. NR 21 TC 2 Z9 2 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1369-7412 EI 1467-9868 J9 J R STAT SOC B JI J. R. Stat. Soc. Ser. B-Stat. Methodol. PD NOV PY 2008 VL 70 BP 1029 EP 1047 DI 10.1111/j.1467-9868.2008.00669.x PN 5 PG 19 WC Statistics & Probability SC Mathematics GA 400EM UT WOS:000262850800008 ER PT J AU Erickson, TM Koeppe, JR Miller, YE Stuart, RW Camidge, DR AF Erickson, Todd M. Koeppe, John R. Miller, York E. Stuart, Rodney W. Camidge, D. Ross TI Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV A Diagnosis Worth Making SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE HIV; Human immunodeficiency virus; Bronchioloalveolar carcinoma; Bronchoalveolar carcinoma; BAC; Adenocarcinoma; Lung cancer; Lung carcinoma ID ACTIVE ANTIRETROVIRAL THERAPY; LUNG-CANCER; INFECTED PATIENTS; ERA; IMMUNODEFICIENCY; COHORT AB A 52-year-old woman with human immunodeficiency virus (HIV) developed weight loss, cough, and breathing difficulties, accompanied by extensive bilateral Pulmonary infiltrates. A lengthy infectious disease and autoimmune workup failed to reveal the etiology or produce benefit. Expert pathology review raised the possibility Of pure bronchioloalveolar carcinoma. The patient was treated with erlotinib and achieved a dramatic and prolonged response to treatment. After 14 months a solitary lung nodule developed which was excised. This demonstrated all invasive adenocarcinoma with an activating epidermal growth factor receptor mutation (exon 19 deletion). As this nodule had developed in the presence of erlotinib, this deletion is only presumed to reflect the initial driver of erlotinib sensitivity. Known acquired resistance mechanisms were explored, but the lesion was negative for both exon 20 T790M gatekeeper mutations and cMET gene copy number alterations. An as yet unknown mechanism of acquired resistance is therefore assumed to be involved in this case. We discuss the diagnosis and treatment of lung cancer in HIV-positive Populations and review the general and specific characteristics of bronchioloalveolar carcinoma, including response to epidermal growth factor receptor inhibitors, and known mechanisms of acquired resistance. The predilection for lung cancer in HIV-positive patients, the diffuse nature of bronchioloalveolar carcinoma that can mimic infectious etiologies and the potential for dramatic responses to therapy make this an important diagnosis to consider in this setting. C1 [Erickson, Todd M.; Camidge, D. Ross] Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80202 USA. [Koeppe, John R.] Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO 80202 USA. [Miller, York E.] Univ Colorado, Hlth Sci Ctr, Dept Pulm Med, Denver, CO 80202 USA. [Miller, York E.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Stuart, Rodney W.] Univ Colorado, Hlth Sci Ctr, Div Pathol, Denver, CO 80202 USA. RP Camidge, DR (reprint author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Mail Stop F704,POB 6510, Aurora, CO 80045 USA. EM ross.camidge@uchsc.edu NR 10 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2008 VL 3 IS 11 BP 1353 EP 1355 PG 3 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 375KT UT WOS:000261113500020 PM 18978572 ER PT J AU Nieder, AM Porter, MP Soloway, MS AF Nieder, Alan M. Porter, Michael P. Soloway, Mark S. TI Radiation Therapy for Prostate Cancer Increases Subsequent Risk of Bladder and Rectal Cancer: A Population Based Cohort Study SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; urinary bladder neoplasms; rectal neoplasms; radiotherapy; prostatectomy ID RADICAL RETROPUBIC PROSTATECTOMIES; 2ND MALIGNANCIES; RADIOTHERAPY; CARCINOMA; CONTINENCE; SURGERY; POTENCY AB Purpose: Pre-prostate specific antigen era series demonstrated an increased risk of bladder cancer and rectal cancer in men who received radiotherapy for prostate cancer. We estimated the risk of secondary bladder cancer and rectal cancer after prostate radiotherapy using a contemporary population based cohort. Materials and Methods: We identified 243,082 men in the Surveillance, Epidemiology and End Results database who under-went radical prostatectomy or radiotherapy for prostate cancer between 1988 and 2003. We estimated the incidence rate, standardized incidence ratio and age adjusted incidence rate ratio of subsequent bladder cancer and rectal cancer associated with radical prostatectomy, external beam radiotherapy, brachytherapy, and a combination of external beam radiotherapy and brachytherapy. Results: The relative risk of bladder cancer developing after external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy compared to radical prostatectomy was 1.88, 1.52 and 1.85, respectively. Compared to the general United States population the standardized incidence ratio for bladder cancer developing after radical prostatectomy, external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy was 0.99, 1.42, 1.10 and 1.39, respectively. The relative risk of rectal cancer developing after external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy compared to radical prostatectomy was 1.26, 1.08 and 1.21, respectively. The standardized incidence ratio for rectal cancer developing after radical prostatectomy, external beam radiotherapy, brachytherapy and external beam radiotherapy-brachytherapy was 0.91, 0.99, 0.68 and 0.86, respectively. Conclusions: Men who receive radiotherapy for localized prostate cancer have an increased risk of bladder cancer compared to patients undergoing radical prostatectomy and compared to the general population. The risk of rectal cancer is increased in patients who receive external beam radiotherapy compared to radical prostatectomy. Patients should be counseled appropriately regarding these risks. C1 [Nieder, Alan M.; Soloway, Mark S.] Univ Miami, Sch Med, Dept Urol, Miami, FL USA. [Porter, Michael P.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Porter, Michael P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Porter, Michael P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Nieder, AM (reprint author), Columbia Univ, Mt Sinai Med Ctr, Div Urol, 4306 Alton Rd,Suite 3014, Miami Beach, FL 33140 USA. EM alan.nieder@columbia.edu NR 17 TC 69 Z9 71 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD NOV PY 2008 VL 180 IS 5 BP 2005 EP 2009 DI 10.1016/j.juro.2008.07.038 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 361BH UT WOS:000260102000038 PM 18801517 ER PT J AU Chen, JY Tao, ML Tisnado, D Malin, J Ko, C Timmer, M Adams, JL Ganz, PA Kahn, KL AF Chen, Judy Y. Tao, May L. Tisnado, Diana Malin, Jennifer Ko, Clifford Timmer, Martha Adams, John L. Ganz, Patricia A. Kahn, Katherine L. TI Impact of Physician-Patient Discussions on Patient Satisfaction SO MEDICAL CARE LA English DT Article ID QUALITY-OF-LIFE; COMPARING TOTAL MASTECTOMY; EARLY BREAST-CANCER; FOLLOW-UP; SURGICAL-TREATMENT; SURGERY; OUTCOMES; TRIAL; RADIOTHERAPY; IRRADIATION AB Background: When 2 treatment choices (ie, mastectomy vs. breast conserving therapy) show no difference in a primary clinical outcome (ie, survival), patient satisfaction becomes an important marker of the quality of care received. Objectives: To assess the impact of physician-patient discussion of primary surgical treatment outcomes on patients' satisfaction with medical care (MC) among women with incident breast cancer (BC). Method: We used self-report data of a population-based survey of 495 women >= 50 years of age with stage I-II BC in Los Angeles, California in 2000 conducted a mean of 7.5 and 24 months after diagnosis. Using multivariable analyses, we evaluated the impact of physician-patient outcome discussions (ie, BC recurrence, BC Survival, breast appearance, and arm swelling/pain/movement difficulty) on patient satisfaction at baseline and follow-up. Results: Most women were satisfied with their MC (>65%). More than half reported physician-patient discussions of BC recurrence (54%), breast appearance (50%), and ann pain/swelling/movement difficulty (55%). Thirty-one percent discussed BC survival. Women who discussed arm swelling, pain, movement difficulty were significantly more likely to be satisfied at baseline (odds ratio: 1.8, 95% confidence interval: 1.1-3.0, P < 0.05) and follow-up (odds ratio: 1.9, 95% confidence interval: 1.2-3.0, P > 0.01). The more treatment outcomes patients discussed with their physicians., the higher patient satisfaction ratings were at baseline and follow-up. Conclusions: Physician-patient discussions of BC treatment outcomes were highly correlated with patients' satisfaction with overall MC regardless of the procedure received. This Suggests that the quality of BC care should include assessments of physician-patient communication. C1 [Chen, Judy Y.] Hlth Benchmarks Inc, Woodland Hills, CA USA. [Tao, May L.] East Bay Partners Canc Care, Antioch, CA USA. [Malin, Jennifer] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Timmer, Martha; Adams, John L.; Kahn, Katherine L.] RAND Corp, Santa Monica, CA USA. [Kahn, Katherine L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. RP Kahn, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Box 951736,911 Broxton Plaza, Los Angeles, CA 90095 USA. EM kkahn@mednet.ucla.edu FU National Cancer Institute (NCI) [R01 CA8133801A1] FX Supported by the National Cancer Institute (NCI) Grant R01 CA8133801A1. NR 25 TC 26 Z9 26 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD NOV PY 2008 VL 46 IS 11 BP 1157 EP 1162 DI 10.1097/MLR.0b013e31817924bc PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 370EQ UT WOS:000260745900005 PM 18953226 ER PT J AU Warden, SJ Nelson, IR Fuchs, RK Bliziotes, MM Turner, CH AF Warden, Stuart J. Nelson, Ian R. Fuchs, Robyn K. Bliziotes, Michael M. Turner, Charles H. TI Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Article DE Antidepressants; Depression; Neurotransmitter; Osteoporosis; Prozac; Serotonin selective reuptake inhibitor ID MINERAL DENSITY; REUPTAKE INHIBITORS; OLDER WOMEN; MECHANICAL-PROPERTIES; FLUOXETINE TREATMENT; HIP-FRACTURES; ANTIDEPRESSANTS; RISK; DEPRESSION; ASSOCIATION AB Objective: Selective serotonin reuptake inhibitors (SSRIs) treat depression by antagonizing the serotonin (5-hydroxytryptamine) transporter (5-HTT). These drugs may also have skeletal effects given the presence of functional serotonergic pathways in bone and evidence demonstrating detrimental effects of SSRIs on postmenopausal bone changes. This Study aimed to explore the influence of an SSRI (fluoxetine hydrochloride) oil the bone changes associated with estrogen deficiency in adult mice. Design: Adult, female, Swiss-Webster mice underwent ovariectomy (OVX) or sham OVX and were treated daily for 4 weeks with either fluoxetine hydrochloride (5 or 20 mg/kg) or a vehicle solution (control). In vivo assessments of hindlimb areal and tibial volumetric bone mineral density were performed at baseline and after 4 weeks of intervention. Femurs and lumbar vertebrae were subsequently removed and assessed ex vivo for bone mineral density and trabecular bone architecture and turnover. Results: In vivo and ex vivo skeletal measures found no interactions between OVX (estrogen deficiency) and 5-HTT inhibition, indicating that the skeletal effects of these interventions were independent. 5-HTT inhibition had detrimental skeletal effects, with the fluoxetine-treated groups having reduced bone mineral density and altered trabecular architecture. These changes resulted from both a decrease in bone formation and increase in bone resorption. Conclusions: These data indicate that a commonly prescribed SSRI has a negative influence on the adult skeleton, independent of estrogen deficiency. This finding Supports clinical data demonstrating SSRI use to be associated with accelerated bone loss after menopause and highlights a need for further research into the skeletal effects of SSRIs. C1 [Warden, Stuart J.; Nelson, Ian R.; Fuchs, Robyn K.] Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46202 USA. [Warden, Stuart J.; Fuchs, Robyn K.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA. [Bliziotes, Michael M.] Portland VA Med Ctr, Portland, OR USA. [Bliziotes, Michael M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Turner, Charles H.] Indiana Univ Purdue Univ, Purdue Sch Engn & Technol, Dept Biomed Engn, Indianapolis, IN 46202 USA. RP Warden, SJ (reprint author), Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, 1140 W Michigan St,CF-326, Indianapolis, IN 46202 USA. EM stwarden@iupui.edu RI Warden, Stuart/C-5287-2012 OI Warden, Stuart/0000-0002-6415-4936 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR-052018] FX Funding/support: This study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR-052018). NR 44 TC 35 Z9 39 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1072-3714 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD NOV-DEC PY 2008 VL 15 IS 6 BP 1176 EP 1183 DI 10.1097/gme.0b013e318173566b PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 371VA UT WOS:000260858500027 PM 18725867 ER PT J AU Song, LL Alimirah, F Panchanathan, R Xin, H Choubeyt, D AF Song, Lynda Li Alimirah, Fatouma Panchanathan, Ravichandran Xin, Hong Choubeyt, Divaker TI Expression of an IFN-Inducible Cellular Senescence Gene, IFI16, Is Up-Regulated by p53 SO MOLECULAR CANCER RESEARCH LA English DT Article ID HUMAN FIBROBLASTS; POLYMORPHIC VARIANTS; DNA-DAMAGE; CANCER; CELLS; SUPPRESSOR; PATHWAY; PROTEIN; IFI-16; PROGRESSION AB IFN-inducible IFI16 protein (encoded by IFI16 gene at 1q23.1) is the human member of the IFN-inducible structurally related p200 family proteins. Increased expression of the IFI16 protein, a positive modulator of p53-mediated transcription, in normal old human diploid fibroblasts (HDF) is associated with cellular senescence-mediated cell growth arrest. However, the underlying mechanisms that contribute to transcriptional activation of the IFI16 gene in old HDFs remain to be elucidated. Here, we reported that functional activation of p53 in normal young HDFs and p53-null Saos2 cell line resulted in transcriptional activation of the IFI16 gene. We identified a potential p53 DNA-binding site (indicated as IFI16-p53-BS) in the 5'-regulatory region of the IFI16 gene. Importantly, p53 bound to IFI16-p53-BS in a sequence-specific manner in gel-mobility shift assays. Furthermore, p53 associated with the 5'-regulatory region of the IFI16 gene in chromatin immunoprecipitation assays. Interestingly, p53 associated with the regulatory region of the IFI16 gene only on treatment of cells with DNA-damaging agents or in the old, but not in the young, HDFs. Importantly, our promoter-reporter assays, which were coupled with site-directed mutagenesis of IFI16-p53-BS, showed that p53 activates transcription of the IFI16 gene in HDFs through the p53 DNA-binding site. Together, our observations provide support for the idea that up-regulation of IFI16 expression by p53 and functional interactions between IFI16 protein and p53 contribute to cellular senescence. (Mol Cancer Res 2008;6(11):1732-41) C1 [Song, Lynda Li; Panchanathan, Ravichandran; Choubeyt, Divaker] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Alimirah, Fatouma; Choubeyt, Divaker] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Panchanathan, Ravichandran; Xin, Hong; Choubeyt, Divaker] Loyola Univ Chicago, Maywood, IL USA. RP Choubeyt, D (reprint author), Univ Cincinnati, Dept Environm Hlth, 3223 Eden Ave,POB 670056, Cincinnati, OH 45267 USA. EM Divaker.choubeyt@uc.edu RI Panchanathan, Ravichandran/E-1801-2015 FU NIA NIH HHS [AG025036] NR 41 TC 23 Z9 24 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 J9 MOL CANCER RES JI Mol. Cancer Res. PD NOV PY 2008 VL 6 IS 11 BP 1732 EP 1741 DI 10.1158/1541-7786.MCR-08-0208 PG 10 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 375SV UT WOS:000261134500008 PM 18974396 ER PT J AU Dracheva, S Patel, N Woo, DA Marcus, SM Siever, LJ Haroutunian, V AF Dracheva, S. Patel, N. Woo, D. A. Marcus, S. M. Siever, L. J. Haroutunian, V. TI Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide SO MOLECULAR PSYCHIATRY LA English DT Article DE suicide; bipolar disorder; schizophrenia; RNA editing; ADAR; prefrontal cortex ID 5-HT2C RECEPTOR; MENTAL-DISORDERS; GENE FAMILY; BEHAVIOR; TRANSPORTER; EXPRESSION; PROTEIN; NEUROBIOLOGY; ASSOCIATION; MECHANISMS AB Suicide is a major public health problem with similar to 1 million victims each year worldwide. Up to 90% of adults who commit suicide have at least one psychiatric diagnosis such as major depression, bipolar disorder (BPD), schizophrenia (SZ), substance abuse or dependence. A question that has remained unanswered is whether the biological substrates of suicide are distinct from those of the psychiatric disorders in which it occurs. The serotonin 2C receptor (5-HT(2C)R) has been implicated in depression and suicide. We, therefore, compared the frequencies of its mRNA editing variants in postmortem prefrontal cortical specimens from subjects who committed suicide or who died from other causes. All suicides occurred in the context of either SZ or BPD. The non-suicide cases included subjects with either SZ or BPD as well as subjects with no psychiatric diagnosis. We identified 5-HT(2C)R mRNA editing variations that were associated with suicide but not with the comorbid psychiatric diagnoses, and were not influenced by demographic characteristics (age and sex) and alcohol or drug use. These variations consisted of a significant increase in the pool of mRNA variants (ACD and ABCD) that encode one of the most prevalent and highly edited isoforms of 5-HT(2C)R, that is, VSV (Val156-Ser158-Val160). Because the VSV isoform of 5-HT(2C)R exhibits low functional activity, an increase in its expression frequency may significantly influence the serotonergic regulation of the brain. Thus, at least in patients with SZ or BPD, overexpression of the VSV isoform in the prefrontal cortex may represent an additional risk factor for suicidal behavior. C1 [Dracheva, S.; Patel, N.; Woo, D. A.; Marcus, S. M.; Siever, L. J.; Haroutunian, V.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Dracheva, S.; Marcus, S. M.; Siever, L. J.; Haroutunian, V.] James J Peters Vet Affairs Med Ctr, MIRECC, Bronx, NY USA. RP Dracheva, S (reprint author), Bronx VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM stella.dracheva@mssm.edu FU VA Merit; VISN3 Mental Illness Research; Education Clinical Center (MIRECC) FX Postmortem brain tissue was donated by The Stanley Medical Research Institute's array collection courtesy of Drs Michael B Knable, E Fuller Torrey, Maree J Webster and Robert H Yolken. This study was supported by VA Merit award to SD and by the VISN3 Mental Illness Research and Education Clinical Center (MIRECC) (LJS, VH and SD). We thank Dr William M Byne for his help in the preparation of the article. NR 51 TC 43 Z9 44 U1 2 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD NOV PY 2008 VL 13 IS 11 BP 1001 EP 1010 DI 10.1038/sj.mp.4002081 PG 10 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 368OS UT WOS:000260632200003 PM 17848916 ER PT J AU Lundstrom, BN Higgs, MH Spain, WJ Fairhall, AL AF Lundstrom, Brian N. Higgs, Matthew H. Spain, William J. Fairhall, Adrienne L. TI Fractional differentiation by neocortical pyramidal neurons SO NATURE NEUROSCIENCE LA English DT Article ID SPIKE-FREQUENCY ADAPTATION; SENSORY ADAPTATION; NEURAL CODE; CORTICAL-NEURONS; ORDER DYNAMICS; BARREL CORTEX; BRAIN-STEM; POWER-LAW; IN-VITRO; MECHANISMS AB Neural systems adapt to changes in stimulus statistics. However, it is not known how stimuli with complex temporal dynamics drive the dynamics of adaptation and the resulting firing rate. For single neurons, it has often been assumed that adaptation has a single time scale. We found that single rat neocortical pyramidal neurons adapt with a time scale that depends on the time scale of changes in stimulus statistics. This multiple time scale adaptation is consistent with fractional order differentiation, such that the neuron's firing rate is a fractional derivative of slowly varying stimulus parameters. Biophysically, even though neuronal fractional differentiation effectively yields adaptation with many time scales, we found that its implementation required only a few properly balanced known adaptive mechanisms. Fractional differentiation provides single neurons with a fundamental and general computation that can contribute to efficient information processing, stimulus anticipation and frequency-independent phase shifts of oscillatory neuronal firing. C1 [Lundstrom, Brian N.; Higgs, Matthew H.; Spain, William J.; Fairhall, Adrienne L.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Higgs, Matthew H.; Spain, William J.] Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA 98108 USA. RP Fairhall, AL (reprint author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA. EM fairhall@u.washington.edu FU Burroughs-Wellcome Careers at the Scientific Interface grant; McKnight Scholar Award; Sloan Research Fellowship; National Institute of Neurological Disorders and Stroke [F30NS055650]; University of Washington's Medical Scientist Training Program; Achievement Rewards for College Scientists (ARCS) fellowship; Veterans Affairs Merit Review FX We are grateful to B. Aguera y Arcas, W. Bialek, F. Dunn, M. Famulare, M. Giugliano, S. Hong, M. Maravall, P. Murphy, F. Rieke, L. Sorensen and B. Wark for helpful discussions and/or comments on the manuscript. We thank S. Usher for excellent technical assistance. This work was supported by a Burroughs-Wellcome Careers at the Scientific Interface grant, and a McKnight Scholar Award and a Sloan Research Fellowship to A.L.F.B.N.L. was supported by grant number F30NS055650 from the National Institute of Neurological Disorders and Stroke, the University of Washington's Medical Scientist Training Program (supported by the National Institute of General Medical Sciences), and an Achievement Rewards for College Scientists (ARCS) fellowship. M. H. H. and W.J.S. were supported by a Veterans Affairs Merit Review to W.J.S. NR 50 TC 174 Z9 176 U1 3 U2 21 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA SN 1097-6256 J9 NAT NEUROSCI JI Nat. Neurosci. PD NOV PY 2008 VL 11 IS 11 BP 1335 EP 1342 DI 10.1038/nn.2212 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 366HZ UT WOS:000260472700023 PM 18931665 ER PT J AU Rodriguez, M Felsenfeld, AJ AF Rodriguez, Mariano Felsenfeld, Arnold J. TI PTH, FGF-23 and early CKD SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE calcium; CKD; FGF-23; phosphate; PTH ID CHRONIC KIDNEY-DISEASE; SECONDARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; MINERAL METABOLISM; PHOSPHORUS; PHOSPHATE; 1,25-DIHYDROXYVITAMIN-D; ASSOCIATION; CALCIUM C1 [Rodriguez, Mariano] Hosp Univ Reina Sofia, Unidad Invest, Serv Nefrol, Cordoba 14004, Spain. [Felsenfeld, Arnold J.] Univ Calif Los Angeles, Dept Med, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90024 USA. [Felsenfeld, Arnold J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Rodriguez, M (reprint author), Hosp Univ Reina Sofia, Unidad Invest, Serv Nefrol, Avd Menendez Pidal S-N, Cordoba 14004, Spain. EM juanm.rodriguez.sspa@juntadeandalucia.es RI Rodriguez, teresa/H-5452-2011 NR 13 TC 1 Z9 1 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD NOV PY 2008 VL 23 IS 11 DI 10.1093/ndt/gfn438 PG 3 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 361UW UT WOS:000260153600007 ER PT J AU Sas, A Jones, R Tyor, W AF Sas, A. Jones, R. Tyor, W. TI Intra-peritoneal injection of polyclonal anti-interferon alpha antibodies cross the blood brain barrier and neutralize interferon alpha SO NEUROCHEMICAL RESEARCH LA English DT Article DE antibodies; blood brain barrier; interferon alpha ID SINDBIS VIRUS; MICE; PATHOGENESIS AB The central nervous system (CNS) is known to be an immunologically privileged organ in the body largely because the blood brain barrier (BBB) prevents the flow of large molecules, proteins, and cells from crossing into the CNS from the periphery. These restrictive properties of the BBB have made it difficult to treat CNS diseases. In this study, mice were infected intracranially (i.c.) with Sindbis virus (SV) and then treated either i.c. or intraperitoneally (i.p.) with neutralizing antibodies against interferon alpha (IFN alpha). SV infected control mice received i.p. saline. Antibodies against mouse IFN alpha were detected in the brain tissue of mice that received i.p. and i.c. injections of the antibody. ELISA analysis showed that both i.c. and i.p. antibody treated mice had significantly decreased levels of IFN alpha in the brain tissue. Also, mice that received IFN alpha neutralizing antibodies showed decreased presence of protein kinase R (PKR) measured by immunohistochemical densitometry, indicating the antibody successfully inhibited IFN alpha. The data shows that antibodies are capable of crossing the BBB and inhibiting IFN alpha, indicating that it is possible to target molecules of interest in the CNS with peripheral antibody treatment. C1 [Tyor, W.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Sas, A.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Jones, R.; Tyor, W.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Tyor, W (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM william.tyor@va.gov FU MUSC Institute of Neuroscience [NIH F31, NS054592-01A2, NIH C06 RR015455] FX This study was funded by MUSC Institute of Neuroscience Grant, NIH F31 NS054592-01A2 and NIH C06 RR015455. NR 14 TC 7 Z9 8 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-3190 J9 NEUROCHEM RES JI Neurochem. Res. PD NOV PY 2008 VL 33 IS 11 BP 2281 EP 2287 DI 10.1007/s11064-008-9715-8 PG 7 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 352GG UT WOS:000259483300014 PM 18461447 ER PT J AU Simon, JH Kleinschmidt-DeMasters, BK AF Simon, Jack H. Kleinschmidt-DeMasters, B. K. TI Variants of Multiple Sclerosis SO NEUROIMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Devic's Neuromyelitis optica; Balo's concentric sclerosis; Marburg MS; Schilder's disease ID ACUTE DISSEMINATED ENCEPHALOMYELITIS; MYELINOCLASTIC DIFFUSE SCLEROSIS; DEVICS-NEUROMYELITIS-OPTICA; BALOS CONCENTRIC SCLEROSIS; SCHILDERS-DISEASE; MAGNETIZATION-TRANSFER; CLINICAL-COURSE; WATER CHANNEL; MRI FEATURES; SPINAL-CORD AB The classic multiple sclerosis variants including Devic's neuromyelitis optica (NMO), Balo's concentric Sclerosis, Schilder's disease, and Marburg MS are both interesting and instructive from a disease pathophysiology perspective. Although rare, the variants are important as they often arise in the differential diagnosis for severe, acute demyelinating disease, including MS and-acute disseminated encephalomyelitis. In the case of NMO, an originally unsuspected and entirely new pathophysiology based on water channels has been described, only after the recent original description of the more specific diagnostic test for NMO based on serum immunoglobulin. C1 [Simon, Jack H.] Portland VA Med Ctr, Portland, OR 97207 USA. [Simon, Jack H.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97201 USA. [Simon, Jack H.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Kleinschmidt-DeMasters, B. K.] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA. [Kleinschmidt-DeMasters, B. K.] Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. [Kleinschmidt-DeMasters, B. K.] Univ Colorado, Hlth Sci Ctr, Dept Neurosurg, Denver, CO 80262 USA. RP Simon, JH (reprint author), Portland VA Med Ctr, Mail Stop P2IMAG,3710 SW Vet Hosp Rd, Portland, OR 97207 USA. EM jack.simon3@va.gov NR 54 TC 6 Z9 9 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1052-5149 J9 NEUROIMAG CLIN N AM JI Neuroimaging Clin. N. Am. PD NOV PY 2008 VL 18 IS 4 BP 703 EP 716 DI 10.1016/j.nic.2008.06.003 PG 14 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 382ZE UT WOS:000261643100011 PM 19068410 ER PT J AU Khalid, AN Woodworth, BA Prince, A Quraishi, SA Antunes, MB Long, FHA Bolger, WE Chiu, AG Palmer, JN Cohen, NA AF Khalid, Ayesha N. Woodworth, Bradford A. Prince, Anthony Quraishi, Sadeq A. Antunes, Marcelo B. Long, Fenella H. A. Bolger, William E. Chiu, Alexander G. Palmer, James N. Cohen, Noam A. TI Physiologic alterations in the murine model after nasal fungal antigenic exposure SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article ID CILIARY-BEAT FREQUENCY; MAMMALIAN RESPIRATORY-TRACT; CHRONIC RHINOSINUSITIS; EPITHELIAL-CELLS; CULTURE AB OBJECTIVE: To determine whether a recently developed murine model of fungus-induced sinonasal inflammation demonstrated alterations in ciliary activity and expression of inflammatory cytokines. STUDY DESIGN: A prospective randomized controlled study of rhinosinusitis after fungal antigenic sensitization was performed with intraperitoneal aspergillus antigen injection followed by intranasal antigen challenge for 4 weeks. Saline solution was used in a parallel fashion for control animals. SUBJECTS AND METHODS: Six mice were used to validate the model. Additional 15 mice were used for ciliary beat frequency (CBF) analysis and cytokine expression with multiplex technology. Mean values for degree of inflammation, secretory hyperplasia. CBF. and cytokine expression were compared. RESULTS: Histologic analyses demonstrated dense chronic inflammation in aspergillus-challenged animals versus sparse inflammatory cells in controls. Significant differences in mean of aspergillus-challenged versus control animals were observed in degree of inflammation (P < 0.01), secretory hyperplasia (P < 0.01), CBF (P < 0.00002), IL-1 alpha (P < 0.0002), IL-10 (P < 0.0003), IL-4 (P < 0.02) TNF-alpha (P < 0.02). and RANTES (P < 0,01). CONCLUSION: Alteration in baseline CBF accompanied by increased expression of specific inflammatory cytokines was observed in aspergillus-challenged mice. (C) 2008 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved. C1 [Khalid, Ayesha N.] Penn State Coll Med, Div Otolaryngol Head & Neck Surg, Philadelphia, PA USA. [Woodworth, Bradford A.; Prince, Anthony; Antunes, Marcelo B.; Chiu, Alexander G.; Palmer, James N.; Cohen, Noam A.] Univ Penn, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Div Rhinol, Philadelphia, PA 19104 USA. [Woodworth, Bradford A.; Palmer, James N.; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Quraishi, Sadeq A.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Long, Fenella H. A.] Univ Penn, Dept Pathol, Matthew J Ryan Sch Vet Med, Philadelphia, PA 19104 USA. [Bolger, William E.] Suburban ENT Associates, Bethesda, MD USA. RP Cohen, NA (reprint author), Hosp Univ Penn, Div Rhinol, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM cohenn@uphs.upewnn.edu RI Chiu, Alexander/J-1230-2014 OI Chiu, Alexander/0000-0002-7592-6575; Cohen, Noam/0000-0002-9462-3932 FU Research in Otolaryngology and Allergy Development (ROAD) Scholarship (ANK); Young Investigator Award from The Sinus and Allergy Health Partnership (NAC) FX Research was supported by a Research in Otolaryngology and Allergy Development (ROAD) Scholarship (ANK) and a Young Investigator Award from The Sinus and Allergy Health Partnership (NAC). This work was presented at the Annual Meeting of the American Rhinologic Society and the Academy of Otolaryngic Allergy (AAOA), September 2007, in Washington, DC. NR 20 TC 14 Z9 14 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD NOV PY 2008 VL 139 IS 5 BP 695 EP 701 DI 10.1016/j.otohns.2008.07.018 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 369UR UT WOS:000260719900016 PM 18984266 ER PT J AU Undavia, M Goldstein, NE Cohen, P Sinthawanarong, K Singson, M Bhutani, D Munson, T Gomes, JA Fischer, A Mehta, D AF Undavia, Manish Goldstein, Nathan E. Cohen, Pilar Sinthawanarong, Kamoltip Singson, Magdalena Bhutani, Divaya Munson, Tracey Gomes, Joseph Anthony Fischer, Avi Mehta, Davendra TI Impact of Implantable Cardioverter-Defibrillator Recalls on Patients' Anxiety, Depression, and Quality of Life SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article; Proceedings Paper CT 27th Annual Scientific Session of the Heart-Rhythm-Society CY MAY 17-20, 2006 CL Boston, MA SP Heart Rhythm Soc DE ICD recalls; anxiety; depression; quality of life; case-control study ID HOSPITAL ANXIETY; PHYSICIAN COMMUNICATION; ICD RECALL; SCALE; DISEASE; SHOCKS; QUESTIONNAIRE; AMIODARONE; PREVENTION; PACEMAKER AB Background: In the past 2 years, multiple implantable cardioverter-defibrillator ( ICD) manufacturers have issued recalls on ICD models due to the potential for serious malfunction and even patient death. Previous studies examining the relationship between these recalls and patients' psychological well-being have been limited by small sample size and conflicting results. The purpose of this study is to examine the association between ICD recalls and patients' anxiety, depression, and quality of life. Methods: Patients were drawn from an outpatient electrophysiology clinic at a tertiary care hospital in New York City. Patients who had devices subject to a recall ( cases) were identified from lists provided by device manufacturer and controls ( patients with ICDs not subjected to a recall) were drawn from a convenience sample of outpatients. The survey instrument consisted of two validated questionnaires Hospital Anxiety and Depression Score ( HADS) and MacNew heart disease health-related quality of life ( QOL) instrument. In addition, a series of Likert-type scales were designed to elucidate patients' concerns related to the following domains: anger, trust, hope, concerns regarding ICD shock, fear of death ( FOD), and physicians' ability to reduce their concern about the ICD recall. Data were analyzed using simple descriptive statistics and bivariate analyses (x(2) and t-test) as appropriate. Result: Sixty-one cases and 43 control patients were enrolled. Thirty-two patients ( 52%) with devices subject to a recall opted for a generator replacement. There were no significant differences in the mean scores on the HADS scale, or the MacNew QOL scale between these two groups of patients ( cases and controls). Subgroup analysis within the group of patients whose ICDs were recalled ( cases) revealed a reduced QOL among patients with a class I recall ( reasonable probability that the product will cause serious adverse health consequences or death) as compared to those with a class II recall ( product may cause temporary or medically reversible adverse health consequences) ( P = 0.01). Both cases and control patients reported having reduced trust in the health-care system. On the whole, however, patients were satisfied with the way their physicians dealt with the recall. There was no significant change in the overall concern of ICD shocks or FOD between the two groups. Conclusion: In this study of ICD recall, we found no difference in the levels of anxiety, depression, or QOL expressed by patients with an ICD subject to a recall as compared to those without. These findings may be a reflection of good physician-patient communication, which might have reduced any anxiety associated with recalls. ( PACE 2008; 31: 1411 - 1418) C1 [Undavia, Manish; Cohen, Pilar; Sinthawanarong, Kamoltip; Singson, Magdalena; Bhutani, Divaya; Munson, Tracey; Gomes, Joseph Anthony; Fischer, Avi; Mehta, Davendra] Mt Sinai Sch Med, Dept Med, Div Cardiol, New York, NY USA. [Goldstein, Nathan E.] Mt Sinai Sch Med, Dept Geriatr, New York, NY USA. James J Peters VA Med Ctr, Bronx, NY USA. RP Undavia, M (reprint author), Mt Sinai Med Ctr, Dept Cardiol, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM manish.undavia@mssm.edu FU NIA NIH HHS [K23 AG025933-01A1, 1 K23 AG025933-01A1, K23 AG025933, K23 AG025933-03] NR 33 TC 18 Z9 18 U1 1 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD NOV PY 2008 VL 31 IS 11 BP 1411 EP 1418 DI 10.1111/j.1540-8159.2008.01204.x PG 8 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA 391AA UT WOS:000262203600007 PM 18950298 ER PT J AU Rosso, AL Gallagher, RM Luborsky, M Mossey, JM AF Rosso, Andrea L. Gallagher, Rollin M. Luborsky, Mark Mossey, Jana M. TI Depression and Self-Rated Health Are Proximal Predictors of Episodes of Sustained Change in Pain in Independently Living, Community Dwelling Elders SO PAIN MEDICINE LA English DT Article DE Pain; Depression; Self-Rated Health; Aged; Epidemiology; Risk Factor ID OSTEOARTHRITIS PROJECT NORSTOP; OLDER-ADULTS; UNITED-STATES; GENERAL-POPULATION; AFRICAN-AMERICAN; CARE; DISABILITY; SCALE; INTERFERENCE; PREVALENCE AB To identify, in community dwelling elders, the determinants of sustained pain improvement or worsening. A longitudinal study with two baseline and 11 monthly follow-up interviews was conducted. Pain was assessed monthly using the Parmelee adaptation of the McGill Pain Inventory. Subjects included 109 Caucasian and 132 African American, Philadelphia residing Medicare recipients (65-74 years of age). To identify sustained pain change (>= 2 months), the data for each subject were reconfigured to yield 10 overlapping 3-month data segments. Each segment was classified as improved or worsened pain. Other variables included: the Geriatric Depression Scale (GDS), self-rated health (SRH), physical functioning, and number of improved or worsened medical conditions. Pain experienced (over 3-month periods) was typically stable. Sustained improved pain was more likely than worsened pain. Odds ratios obtained through Generalized Estimation Equation analyses showed that a 1-point increase in GDS scores increased the odds of worsened pain by 1.18 (1.11-1.30). Fair/poor SRH, being female, and having medical conditions worsen increased the odds of worsened pain by 4.04 (2.12-7.70), 1.63 (1.11-2.38), and 2.12 (1.42-3.16), respectively. Observed, statistically significant associations between these variables, except gender, and improved pain were in the opposite direction. With a 1-month time lag between predictor variable assessment and follow-up pain measures, the study supports temporal associations between depressive symptoms and SRH and subsequent pain change. Clinicians providing care to community dwelling elders are advised to evaluate and attend to both the depressive symptoms and SRH of their patients. C1 [Rosso, Andrea L.; Mossey, Jana M.] Drexel Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19072 USA. [Gallagher, Rollin M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Gallagher, Rollin M.] Philadelphia VA Med Ctr, Pain Med Serv, Philadelphia, PA USA. [Luborsky, Mark] Wayne State Univ, Inst Gerontol, Detroit, MI 48202 USA. RP Mossey, JM (reprint author), Drexel Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 1501 Race St, Philadelphia, PA 19072 USA. EM jm55@drexel.edu OI Rosso, Andrea/0000-0001-5890-9856 FU NIA NIH HHS [R01 AG015730] NR 57 TC 8 Z9 8 U1 2 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD NOV-DEC PY 2008 VL 9 IS 8 BP 1035 EP 1049 DI 10.1111/j.1526-4637.2008.00533.x PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 375HZ UT WOS:000261106100012 PM 19067830 ER PT J AU Dobscha, SK Corson, K Leibowitz, RQ Sullivan, MD Gerrity, MS AF Dobscha, Steven K. Corson, Kathryn Leibowitz, Ruth Q. Sullivan, Mark D. Gerrity, Martha S. TI Rationale, Design, and Baseline Findings from a Randomized Trial of Collaborative Care for Chronic Musculoskeletal Pain in Primary Care SO PAIN MEDICINE LA English DT Review DE Disease Management; Pain; Chronic Illness; Depression; Narcotics ID MORRIS DISABILITY QUESTIONNAIRE; PHYSICIAN JOB-SATISFACTION; CHRONIC NONMALIGNANT PAIN; CHRONIC NONCANCER PAIN; ABUSE SCREENING-TEST; SPINAL-CORD-INJURY; CHRONIC BACK-PAIN; SELF-REPORT; PATIENT SATISFACTION; MANAGEMENT PROGRAMS AB This article describes the rationale, design, and baseline findings from an ongoing study of collaborative care for chronic musculoskeletal pain and comorbid depression. Cluster randomized clinical trial. Forty-two clinicians and 401 patients from five Veterans Affairs primary care clinics. The intervention was based on the chronic care model, and included patient and provider activation and education, patient assessment, outcomes monitoring, and feedback to providers over 12 months. The intervention team consisted of a full-time psychologist care manager and a part-time physician internist. Approaches included goal setting emphasizing function, patient activation and educating about fear avoidance, and care management. Main outcomes are Roland-Morris Disability Questionnaire (RMDQ) score, depression severity (Patient Health Questionnaire-9), and pain severity (Chronic Pain Grade Severity subscale) at 6 and 12 months. Fifteen percent of primary care patients mailed a study advertisement letter requested screening for the study. The mean age of enrolled patients was 62. Back and neck or joint pain diagnoses were present in 67% and 65% of patients, respectively. Mean pain duration was 15 years, and mean RMDQ score (range 0-24) was 14.7 (standard deviation = 4.4). Sixty-five percent of patients were receiving disability. Eighteen percent of patients met criteria for major depression, 17% for posttraumatic stress disorder, and 9% for alcohol misuse. Thirty-nine percent of patients felt strongly that experiencing pain was a sign of damage, and 60% reported strong avoidance of painful activities. These baseline data support the rationale to develop a multifaceted approach to treat chronic pain in primary care that includes detection and treatment of psychiatric comorbidity. C1 [Gerrity, Martha S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97207 USA. [Dobscha, Steven K.; Corson, Kathryn; Leibowitz, Ruth Q.; Gerrity, Martha S.] Columbia Ctr Study Chron Comorbid Phys & Mental D, Portland, OR 97207 USA. [Dobscha, Steven K.; Corson, Kathryn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Sullivan, Mark D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, Div Hosp & Specialty Med, POB 1034, R&D 66, Portland, OR 97207 USA. EM steven.dobscha@va.gov RI Duncan, Kirsty/H-1911-2011 FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service Projects [PMI 03-195, RCD04129] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Projects PMI 03-195 and RCD04129. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 102 TC 16 Z9 16 U1 5 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PD NOV-DEC PY 2008 VL 9 IS 8 BP 1050 EP 1064 DI 10.1111/j.1526-4637.2008.00457.x PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 375HZ UT WOS:000261106100013 PM 18565008 ER PT J AU Rakonczay, Z Hegyi, P Biczo, G Dosa, S Ivanyi, B Hracsko, Z Varga, IS Gukovsky, I Gukovskaya, AS Pandol, SJ Wittmann, T Takacs, T AF Rakonczay, Z., Jr. Hegyi, P. Biczo, G. Dosa, S. Ivanyi, B. Hracsko, Z. Varga, I. S. Gukovsky, I. Gukovskaya, A. S. Pandol, S. J. Wittmann, T. Takacs, T. TI L-ORNITHINE INDUCES ACUTE NECROTIZING PANCREATITIS IN RATS SO PANCREAS LA English DT Meeting Abstract C1 [Rakonczay, Z., Jr.; Hegyi, P.; Biczo, G.; Wittmann, T.; Takacs, T.] Univ Szeged, Dept Med 1, Szeged, Hungary. [Dosa, S.; Ivanyi, B.] Univ Szeged, Dept Pathol, Szeged, Hungary. [Hracsko, Z.; Varga, I. S.] Univ Szeged, Dept Biochem & Mol Biol, Szeged, Hungary. [Gukovsky, I.; Gukovskaya, A. S.; Pandol, S. J.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD NOV PY 2008 VL 37 IS 4 BP 491 EP 491 DI 10.1097/01.MPA.0000335367.24513.ee PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 365RL UT WOS:000260425400153 ER PT J AU Thrower, E Yuan, J Kelly, M Jones, C Pandol, S Guha, S AF Thrower, E. Yuan, J. Kelly, M. Jones, C. Pandol, S. Guha, S. TI PROTEIN KINASE D: A NOVEL REGULATOR OF ZYMOGEN ACTIVATION AND AMYLASE SECRETION IN ACUTE PANCREATITIS SO PANCREAS LA English DT Meeting Abstract C1 [Thrower, E.; Kelly, M.; Jones, C.] Vet Adm Connecticut Healthcare, Sect Digest Dis, West Haven, CT USA. [Thrower, E.; Kelly, M.; Jones, C.] Yale Univ, Sch Med, New Haven, CT USA. [Yuan, J.; Pandol, S.] VA Greater LA Hlth Care Syst, Los Angeles, CA USA. [Yuan, J.; Pandol, S.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Guha, S.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD NOV PY 2008 VL 37 IS 4 BP 498 EP 498 DI 10.1097/01.MPA.0000335400.62423.be PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 365RL UT WOS:000260425400183 ER PT J AU Whitcomb, DC Muddana, V Langmead, CJ Lamb, J Papachristou, GI AF Whitcomb, D. C. Muddana, V. Langmead, C. J. Lamb, J. Papachristou, G. I. TI ANGIOPOIETIN-2, A REGULATOR OF VASCULAR PERMEABILITY IN INFLAMMATION IS ELEVATED IN SEVERE ACUTE PANCREATITIS AND IS ASSOCIATED WITH SYSTEMIC ORGAN FAILURE SO PANCREAS LA English DT Meeting Abstract C1 [Whitcomb, D. C.; Muddana, V.; Lamb, J.; Papachristou, G. I.] Univ Pittsburgh, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. [Whitcomb, D. C.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA USA. [Whitcomb, D. C.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA USA. [Langmead, C. J.] Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA. [Papachristou, G. I.] Vet Affairs Pittsburgh Hlth Syst, Div Gastroenterol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD NOV PY 2008 VL 37 IS 4 BP 500 EP 501 DI 10.1097/01.MPA.0000335411.31036.03 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 365RL UT WOS:000260425400193 ER PT J AU Haidet, P O'Malley, KJ Sharf, BF Gladney, AP Greisinger, AJ Street, RL AF Haidet, Paul O'Malley, Kimberly J. Sharf, Barbara F. Gladney, Alicia P. Greisinger, Anthony J. Street, Richard L., Jr. TI Characterizing explanatory models of illness in healthcare: Development and validation of the CONNECT instrument SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Physician-patient relations; Cultural diversity; Patient-centered care; Anthropology; Cultural; Patient participation; Psychometrics; Primary health care ID COMMUNICATION; PATIENT; MANAGEMENT; ADHERENCE; COMMUNITY; BELIEFS; LESSONS; DOCTOR; SCALES AB Objective: A growing body of qualitative and quantitative research suggests that individual patients and physicians often have differing perspectives, or 'explanatory models,' regarding the patient's health condition of illness. Discordance between explanatory models may lead to difficulties in communication and poor disease outcomes. However, due to a lack of tools to systematically measure concordance in patient and physician explanatory models, a large-scale study of explanatory models of illness has not been previously possible. The objective of this project was to develop and pilot-test a survey-based tool (the CONNECT Instrument) that measures salient aspects of explanatory models of illness. Methods: We conducted a multi-method survey development project that included qualitative and quantitative item development, refinement, pilot testing, and psychometric evaluation. We evaluated the instrument in two unique, consecutive cohorts of primary care patients in a variety of private and public settings in Houston, TX. We also used the instrument to examine concordance between patient and physician explanatory models in the second cohort. Results: The final version of the CONNECT Instrument contains nineteen items that focus on six dimensions of explanatory models. Cronbach alphas ranged from 0.65 to 0.89 for the six CONNECT dimensions. The instrument demonstrated evidence of criterion-related validity when individual CONNECT dimension scores were compared with scores from previously published instruments, and demonstrated expected differences between patients 'and physicians' explanatory models of illness. Conclusion: The CONNECT instrument is a tool with good psychometric properties that enables researchers to measure important aspects of patients 'and physicians' explanatory models of illness. Our continuing work will focus oil gathering additional validity evidence and evaluating associations between explanatory model concordance and health outcomes. Practice implications: The CONNECT instrument can be used to improve quality in clinical practice and medical education by measuring an important intermediate outcome in the chain of factors leading to patient trust, satisfaction, and adherence. Published by Elsevier Ireland Ltd. C1 [Haidet, Paul] DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Haidet, Paul] Baylor Coll Med, Houston, TX 77030 USA. [O'Malley, Kimberly J.] Pearson Educ Measurement, Austin, TX USA. [Sharf, Barbara F.; Street, Richard L., Jr.] Texas A&M Univ, Dept Speech, College Stn, TX USA. [Gladney, Alicia P.] Harris Cty Dept Educ, Houston, TX USA. [Greisinger, Anthony J.] Kelsey Res Fdn, Houston, TX USA. [Greisinger, Anthony J.] Kelsey Seybold Clin, Houston, TX USA. RP Haidet, P (reprint author), Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM phaidet@bcm.edu FU AHRQ HHS [P01 HS10876] NR 32 TC 18 Z9 18 U1 0 U2 11 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD NOV PY 2008 VL 73 IS 2 BP 232 EP 239 DI 10.1016/j.pec.2008.07.007 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 374DS UT WOS:000261023500012 PM 18760889 ER PT J AU Iosifescu, A Halm, EA McGinn, T Siu, AL Federman, AD AF Iosifescu, Alice Halm, Ethan A. McGinn, Thomas Siu, Albert L. Federman, Alex D. TI Beliefs about generic drugs among elderly adults in hospital-based primary care practices SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Generic drugs; Beliefs; Elderly; Low-income; Access to care ID HEALTH LITERACY; MEDICARE BENEFICIARIES; OLDER-ADULTS; PHYSICIAN COMMUNICATION; POTENTIAL SAVINGS; PATIENTS REQUESTS; MEDICATIONS; SUBSTITUTION; ASSOCIATION; COVERAGE AB Objective: This Study aimed to characterize seniors' belief's about generic drugs, and examine potential correlates of these beliefs, including socioeconomic and health Status variables, health literacy, and physician communication skills. Methods: Older adults (>= 65 years) were interviewed in two primary care practices of an inner-city, tertiary care hospital (n = 311). Beliefs about generics were measured using a scale that compared generic and brand name drugs across four domains. Beliefs were modeled with multivariable linear regression. Results: Negative beliefs about generics were associated with non-white race (p < 0.0001), lower education (p = 0.008) and income (p = 0.001), and having Medicaid coverage (p = 0.001). Individuals with low health literacy and who reported that their physicians had poor communication skills were more likely to hold negative views (p < 0.0001 and p = 0.003, respectively). In multivariable analysis, black race (beta = -2.30. p = 0.006) and inadequate health literacy (beta = -2.17, p = 0.0004) remained strongly associated with negative views about generic drugs. Poor physician communication skills also predicted negative beliefs about generics but the association was not significant for all levels of communication skill. Conclusion: Many low-income seniors mistrust generic medications, especially African-Americans and seniors with low health literacy. Practice implications: Educational efforts to promote generic medications should account for patients' health literacy and Cultural backgrounds. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Halm, Ethan A.; McGinn, Thomas; Federman, Alex D.] Mt Sinai Sch Med, Div Gen Internal Med, New York, NY 10029 USA. [Siu, Albert L.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Siu, Albert L.] Bronx Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Federman, AD (reprint author), Mt Sinai Sch Med, Div Gen Internal Med, 1 Gustave L Levy Pl Box 1087, New York, NY 10029 USA. EM alex.federman@mssm.edu RI Mendoza, Elvia/A-9361-2012 FU Robert Wood Johnson Generalist Physician Faculty Scholars Program Award; National Institute on Aging; American Federation for Aging Research FX Funding: This project was supported by a Robert Wood Johnson Generalist Physician Faculty Scholars Program Award (Dr. Federman). Dr. Federman also receives support from the Paul B. Beeson Career Development Award Program in Aging from the National Institute on Aging and the American Federation for Aging Research. Ms. losifescu's work oil this project was supported by a Medical Student Training in Aging Research (MSTAR) Program award from the American Federation for Aging Research. NR 38 TC 33 Z9 35 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD NOV PY 2008 VL 73 IS 2 BP 377 EP 383 DI 10.1016/j.pec.2008.07.012 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 374DS UT WOS:000261023500033 PM 18706784 ER PT J AU Humbert, IA Robbins, J AF Humbert, Ianessa A. Robbins, JoAnne TI Dysphagia in the Elderly SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Review ID AGE-RELATED-CHANGES; MUSCLE PROTEIN-SYNTHESIS; TRANSCRANIAL MAGNETIC STIMULATION; HUMAN THYROARYTENOID MUSCLE; WHOLE VASTUS LATERALIS; DIFFERENT FIBER TYPES; EVENT-RELATED FMRI; OLDER-ADULTS; MOTOR UNITS; CORTICAL REPRESENTATION AB The capacity to swallow or eat is a basic human need and can be a great pleasure. Older adults look forward to sharing mealtimes and participating in social interactions. The loss of capacity to swallow and dine can have far-reaching implications. With age, the ability to swallow undergoes changes that increase the risk for disordered swallowing, with devastating health implications for older adults. With the growth in the aging population, dysphagia is becoming a national health care burden and concern. Upward of 40% of people in institutionalized settings are dysphagic. There is a need to address dysphagia in ambulatory, acute care, and long-term care settings. C1 [Robbins, JoAnne] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr 11G, Madison, WI 53705 USA. [Humbert, Ianessa A.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21231 USA. [Robbins, JoAnne] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. RP Robbins, J (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr 11G, 2500 Overlook Terrace GRECC 11G, Madison, WI 53705 USA. EM jrobbin2@wisc.edu FU NICHD NIH HHS [K12 HD049112]; NIGMS NIH HHS [R01 GM088477] NR 136 TC 40 Z9 50 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 EI 1558-1381 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD NOV PY 2008 VL 19 IS 4 BP 853 EP + DI 10.1016/j.pmr.2008.06.002 PG 16 WC Rehabilitation SC Rehabilitation GA 437NH UT WOS:000265493700012 PM 18940645 ER PT J AU LeMaster, JW Mueller, MJ Reiber, GE Mehr, DR Madsen, RW Conn, VS AF LeMaster, Joseph W. Mueller, Michael J. Reiber, Gayle E. Mehr, David R. Madsen, Richard W. Conn, Vicki S. TI Effect of Weight-Bearing Activity on Foot Ulcer Incidence in People With Diabetic Peripheral Neuropathy: Feet First Randomized Controlled Trial SO PHYSICAL THERAPY LA English DT Article ID 6-MINUTE WALK TEST; ACTIVITY PROMOTION PROGRAM; INCREASE PHYSICAL-ACTIVITY; OLDER-ADULTS; CARDIOVASCULAR-DISEASE; HIGH-RISK; EXERCISE; METAANALYSIS; RELIABILITY; INTENSITY AB Background. Weight-bearing exercise has been contraindicated among people with diabetic peripheral neuropathy (DM+PN). However, recent cohort studies have suggested that daily weight-bearing activity is associated with lower risk for foot ulceration. Objective. The objective of this study was to determine the effect of a lower-extremity exercise and walking intervention program on weight-bearing activity and foot ulcer incidence in people with DM+PN. Design. This was an observer-blinded, 12-month randomized controlled trial Setting. The settings were physical therapy offices in part I of the intervention and the community in part 2 of the intervention. Participants. The participants were 79 individuals with DM+PN who were randomly assigned either to a control group (n=38) or an intervention group (n=41) group. Intervention. Intervention components included leg strengthening and balance exercises; a graduated, self-monitored walking program (part 1); and motivational telephone calls every 2 weeks (part 2). Both groups received diabetic foot care education, regular foot care, and 8 sessions with a physical therapist. Measurements. Total and exercise bout-related daily steps at baseline and at 3, 6, and 12 months were measured by accelerometers. Foot lesions/ulcers were photographed and classified by an independent panel of dermatologists. Use of adequate footwear was monitored. Results. At 6 months; bout-related daily steps increased 14% from baseline in the intervention group and decreased 6% from baseline in the control group. Although the groups did not differ statistically in the change in total daily steps, at 12 months steps had decreased by 13% in the control group. Foot ulcer rates did not differ significantly between groups. Conclusion. Promoting weight-bearing activity did not lead to significant increases in foot ulcers. Weight-bearing activity can be considered following adequate assessment and counseling of patients with DM+PN. C1 [LeMaster, Joseph W.; Mehr, David R.] Univ Missouri, Sch Med, Dept Family & Community Med, Columbia, MO 65212 USA. [Mueller, Michael J.] Washington Univ, Sch Med, Program Phys Therapy, St Louis, MO USA. [Mueller, Michael J.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv & Epidemiol, Seattle, WA 98195 USA. [Madsen, Richard W.] Univ Missouri, Dept Stat, Columbia, MO 65211 USA. [Conn, Vicki S.] Univ Missouri, Sinclair Sch Nursing, Columbia, MO 65211 USA. [Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP LeMaster, JW (reprint author), Univ Missouri, Sch Med, Dept Family & Community Med, MA306-K Med Sci Bldg,DC032-00, Columbia, MO 65212 USA. EM lemasterj@health.missouri.edu OI Conn, Vicki/0000-0003-2404-6575 FU Robert Wood Johnson Foundation FX This study was funded by the Robert Wood Johnson Foundation Generalist Physician Faculty Scholars program. This material is the result of work supported with resources and the use of facilities at the University of Missouri Health Care System, the Harry S Truman Memorial Veterans' Hospital, and the VA Puget Sound Health Care System. NR 62 TC 46 Z9 49 U1 4 U2 17 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 J9 PHYS THER JI Phys. Ther. PD NOV PY 2008 VL 88 IS 11 BP 1385 EP 1398 DI 10.2522/ptj.20080019 PG 14 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA 369UC UT WOS:000260718400012 PM 18801859 ER PT J AU Cobb, BL Lessard, CJ Harley, JB Moser, KL AF Cobb, Beth L. Lessard, Christopher J. Harley, John B. Moser, Kathy L. TI Genes and Sjogren's Syndrome SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Review DE Sjogren's syndrome; Genetics; HLA; Association ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; SINGLE-NUCLEOTIDE POLYMORPHISM; GENOME-WIDE ASSOCIATION; BINDING LECTIN GENE; LYMPHOID TYROSINE PHOSPHATASE; PROMOTER REGION POLYMORPHISMS; JUVENILE IDIOPATHIC ARTHRITIS; EUROPEAN CONSENSUS GROUP; PTPN22 620W ALLELE; CLASS-II GENES AB The evidence for a strong genetic component conferring susceptibility to primary Sjogren's syndrome (SS) is mounting. Several associations with SS have been reported and provide evidence that the HLA region harbors important susceptibility loci and that multiple genes outside the HLA region play a role. Genetic discovery lags behind success observed in related autoimmune diseases. Identifying genetic factors that cause SS will allow more precise definition of pathogenic mechanisms leading to the overall SS phenotype and clinically heterogeneous subsets of patients. Critical opportunities are certain to follow for translation into improved diagnosis and therapies for SS and its spectrum diseases. C1 [Cobb, Beth L.; Lessard, Christopher J.; Harley, John B.; Moser, Kathy L.] Oklahoma Med Res Fdn, Arthrit & Immunol Program, Oklahoma City, OK 73104 USA. [Lessard, Christopher J.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA. [Harley, John B.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK 73104 USA. RP Moser, KL (reprint author), Oklahoma Med Res Fdn, Arthrit & Immunol Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM moserk@omrf.org FU NIH [DE015223, AR42460, AR12253, AR48940, AR62277, RR020143, AI24717]; Department of Veteran Affairs Merit Award (JBH) [AR050782, AR043274]; Alliance for Lupus Research FX Supported by NIH grants DE015223, AR42460, AR12253, AR48940, AR62277, RR020143, AI24717, a Department of Veteran Affairs Merit Award (JBH), AR050782, and AR043274 (KLM) and the Alliance for Lupus Research. NR 150 TC 21 Z9 21 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD NOV PY 2008 VL 34 IS 4 BP 847 EP + DI 10.1016/j.rdc.2008.08.003 PG 23 WC Rheumatology SC Rheumatology GA 376RD UT WOS:000261199800003 PM 18984408 ER PT J AU Green, MF Penn, DL Bentall, R Carpenter, WT Gaebel, W Gur, RC Kring, AM Park, S Silverstein, SM Heinssen, R AF Green, Michael F. Penn, David L. Bentall, Richard Carpenter, William T. Gaebel, Wolfgang Gur, Ruben C. Kring, Ann M. Park, Sohee Silverstein, Steven M. Heinssen, Robert TI Social Cognition in Schizophrenia: An NIMH Workshop on Definitions, Assessment, and Research Opportunities SO SCHIZOPHRENIA BULLETIN LA English DT Review DE social cognition; schizophrenia; NIMH ID FACIAL-AFFECT RECOGNITION; MEDIAL PREFRONTAL CORTEX; PERSECUTORY DELUSIONS; EMOTION RECOGNITION; SPECTRUM DISORDERS; TRAINING-PROGRAM; MIND DEFICIT; NEURAL BASIS; PERCEPTION; PARANOIA AB Social cognition has become a high priority area for the study of schizophrenia. However, despite developments in this area, progress remains limited by inconsistent terminology and differences in the way social cognition is measured. To address these obstacles, a consensus-building meeting on social cognition in schizophrenia was held at the National Institute of Mental Health in March 2006. Agreement was reached on several points, including definitions of terms, the significance of social cognition for schizophrenia research, and suggestions for future research directions. The importance of translational interdisciplinary research teams was emphasized. The current article presents a summary of these discussions. C1 [Green, Michael F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Penn, David L.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. [Bentall, Richard] Univ Wales, Sch Psychol, Bangor, Gwynedd, Wales. [Carpenter, William T.] Univ Maryland, Sch Med, Dept Psychiat, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA. [Carpenter, William T.] Vet Adm, VISN 5, Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA. [Gaebel, Wolfgang] Univ Dusseldorf, Dept Psychiat, D-4000 Dusseldorf, Germany. [Gur, Ruben C.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kring, Ann M.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Park, Sohee] Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA. [Park, Sohee] Vanderbilt Univ, Dept Psychiat, Nashville, TN 37240 USA. [Silverstein, Steven M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA. [Silverstein, Steven M.] Univ Med & Dent New Jersey, Univ Behav HealthCare, Piscataway, NJ 08854 USA. [Heinssen, Robert] NIMH, Div Adult Translat Res & Treatment Dev, Bethesda, MD 20892 USA. RP Green, MF (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 300 Med Plaza,Room 2263, Los Angeles, CA 90095 USA. EM mgreen@ucla.edu OI Park, Sohee/0000-0003-3797-4776 FU NIMH FX This article presents a summary of the discussion from a workshop supported by the NIMH. The views expressed are those of the authors and do not necessarily reflect the official views of the NIMH, the National Institutes of Health, or any other branch of the US Department of Health and Human Services. NR 101 TC 263 Z9 277 U1 6 U2 30 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD NOV PY 2008 VL 34 IS 6 BP 1211 EP 1220 DI 10.1093/schbul/sbm145 PG 10 WC Psychiatry SC Psychiatry GA 361OI UT WOS:000260136600027 PM 18184635 ER PT J AU Condray, R Yao, JK Steinhauer, SR van Kammen, DP Reddy, RD Morrow, LA AF Condray, Ruth Yao, Jeffrey K. Steinhauer, Stuart R. van Kammen, Daniel P. Reddy, Ravinder D. Morrow, Lisa A. TI Semantic memory in schizophrenia: Association with cell membrane essential fatty acids SO SCHIZOPHRENIA RESEARCH LA English DT Article DE N400; Arachidonic acid; Dopamine; Paranoia; Thought disturbance ID EVENT-RELATED POTENTIALS; SEROTONERGIC RESPONSIVITY; DOPAMINERGIC MODULATION; ORBITOFRONTAL CORTEX; COGNITIVE DYSMETRIA; HUMAN ERYTHROCYTES; DISORDER; LANGUAGE; BRAIN; N400 AB Introduction: Semantic memory and language deficits are associated with schizophrenia. Understanding how these systems operate in this disorder will likely require a multi-factorial model that explains their linkages with cognition and modulation by dopamine. A biological factor that may provide causal convergence for these connections is cell membrane composition and dynamics. Methods: N400 is an electrophysiological measure of semantic memory and language that is sensitive to deficits in schizophrenia. Relationships among N400, cognition, dopamine, and cell membrane polyunsaturated fatty acids (PUFAs) were examined for patients tested under medicated (haloperidol only) and unmedicated (placebo) conditions. Relationships between these factors and clinical symptoms were also evaluated. The sample included 37 male schizophrenia inpatients and 34 male normal controls. The N400 priming effect was measured from visual event-related potentials recorded during a semantic priming-lexical decision task, in which semantic association (related versus unrelated words) and presentation rate (Stimulus Onset Asynchrony/SOAs: 350 and 950 ms) were varied. Results: N400 was associated with cognition (speed, visuoperception, attention) in patients and controls. These relationships were influenced by SOA in both groups, and by pharmacological condition in patients. Levels of total PUFAs and arachidonic acid were associated with N400 in unmedicated patients. Clinical symptoms (paranoia, thought disturbance) were associated with N400, but not with cognition or PUFAs. Conclusions: Results suggest cell membrane fatty acids are associated with semantic memory and language in schizophrenia. Findings also suggest a series of linkages that are modulated by dopamine: cell membrane fatty acids are associated with N400 semantic priming; N400 semantic priming is associated with clinical symptoms. (C) 2008 Published by Elsevier B.V. C1 [Condray, Ruth; Yao, Jeffrey K.; Steinhauer, Stuart R.; Reddy, Ravinder D.; Morrow, Lisa A.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA. [Condray, Ruth; Yao, Jeffrey K.; Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA. [van Kammen, Daniel P.] MRSSI Inc, New York, NY 10016 USA. [van Kammen, Daniel P.] CHDI Inc, Los Angeles, CA 90045 USA. RP Condray, R (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, 3811 OHara St, Pittsburgh, PA 15213 USA. EM condrayr@upmc.edu FU National Institute of Mental Health [MH50631, MH55762, MH44841]; Medical Research Service of the Department of Veterans Affairs; Bataan and Corregidor Medical Fund, Inc.; Veterans Affairs Pittsburgh Healthcare System; Highland Drive Division FX Funding for this work was provided by grants to authors from the National Institute of Mental Health (MH50631, MH55762, MH44841), Medical Research Service of the Department of Veterans Affairs, the Bataan and Corregidor Medical Fund, Inc., and with resources and use of facilities at the Veterans Affairs Pittsburgh Healthcare System, Highland Drive Division. The NIMH and the Medical Research Service of the Department of Veterans Affairs had no further role in the design or conduct of the study, in analyses or interpretation of data, in writing of the reports or in the decision to submit the paper for publication.; This research was supported by the National Institute of Mental Health (ME50631 (RC), MH55762 (SRS), MH44841 (DPvK)), the Medical Research Service of the Department of Veterans Affairs, the Bataan and Corregidor Medical Fund, Inc. (DPvK), and with resources and use of facilities at the Veterans Affairs Pittsburgh Healthcare System, Highland Drive Division. We thank the patients who served as study participants. We are also grateful to a number of individuals who provided valuable contributions to the study, including the clinical and nursing staff of the Veterans Affairs Pittsburgh Healthcare System, Highland Drive Division. The contributions of the anonymous reviewers are also appreciated. NR 82 TC 12 Z9 12 U1 2 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2008 VL 106 IS 1 SI SI BP 13 EP 28 DI 10.1016/j.schres.2008.03.009 PG 16 WC Psychiatry SC Psychiatry GA 377MY UT WOS:000261256500003 PM 18929465 ER PT J AU O'Halloran, JP Kemp, AS Gooch, KN Harvey, PD Palmer, BW Reist, C Schneider, LS AF O'Halloran, James P. Kemp, Aaron S. Gooch, Kirstan N. Harvey, Philip D. Palmer, Barton W. Reist, Christopher Schneider, Lon S. TI Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE CMINDS; Neurocognition; Schizophrenia; Computerized Assessment; Concurrent Validity; Reliability ID SAMPLE-SIZE REQUIREMENTS; CLINICAL-TRIALS; COGNITIVE DEFICITS; INTRACLASS CORRELATION; TEST BATTERY; RELIABILITY; VALIDITY; COEFFICIENT; MEDICATIONS; AGREEMENT AB Neurocognitive assessment is an essential component for clinical trials of candidate "cognitive-enhancing" treatments for schizophrenia. However, manual administration of large, paper-based, neurocognitive batteries is often inefficient, error-prone, and inconsistent across multiple sites. Existing computerized testing systems are also limited both in the assessment instruments available and in the range of impairments that can be accommodated with the subject sitting alone at a single display. Therefore, a dual-display computerized testing system was developed, with funding from the National Institute of Mental Health (NDAH), that integrates (rather than replaces) the examiner for computerized administration of standard neurocognitive assessment batteries. Purpose: To compare standard administration versions (SAVs) of tests selected by the NIMH-sponsored CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) and MATRICS (TM) (Measurement and Treatment Research to Improve Cognition in Schizophrenia) consortia, with structurally- and functionally-equivalent, computerized administration versions (CAVs). Method: 116 outpatients with schizophrenia received both the SAVs and CAVs within one week and again, approximately 30 days later. Results: Intraclass Correlation Coefficient (ICC) comparisons between SAVs and CAVs yielded highly significant measures of absolute agreement for all tests, ranging 0.61-0.95. ICCs for test-retest reliability, ranging 0.56-0.94 for SAVs and 0.59-0.98 for CAVs, were also highly significant for both batteries, though significantly higher for CAVs overall. Conclusions: The CAVs of the neurocognitive assessment instruments selected by the CATIE and MATRICS (TM) consortia are substantially equivalent to antecedent SAVs. Importantly, the increased reliability afforded by computerization highlight the potential for increasing power, thereby decreasing sample size requirements, for clinical evaluations of putative "cognitive-enhancing" treatments. (C) 2007 Elsevier B.V. All rights reserved. C1 [O'Halloran, James P.; Kemp, Aaron S.; Gooch, Kirstan N.] NeuroComp Syst Inc, Irvine, CA 92614 USA. [Kemp, Aaron S.; Reist, Christopher] Univ Calif Irvine, Sch Med, Dept Psychiat & Human Behav, Irvine, CA 92717 USA. [Harvey, Philip D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Harvey, Philip D.] James J Peters Vet Adm VA Med Ctr, Bronx, NY USA. [Palmer, Barton W.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Palmer, Barton W.] Vet Med Res Fdn, San Diego, CA USA. [Reist, Christopher] VA Long Beach Healthcare Syst, Long Beach, CA USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat Neurol & Gerontol, Los Angeles, CA 90033 USA. RP O'Halloran, JP (reprint author), NeuroComp Syst Inc, 1340 Reynolds Ave,Suite 105, Irvine, CA 92614 USA. EM jpo@neurocomp.com OI Kemp, Aaron/0000-0001-6925-5667 FU NIMH Small Business Innovation Research [R43MH068077-01, R44MH068077-02] FX James P. O'Halloran is the founder and president of NeuroComp Systems, Inc. Kirstan N. Gooch is a full-time employee of NeuroComp, Systems, Inc. Aaron S. Kemp is a paid consultant to NeuroComp Systems, Inc. None of the other authors have any previous or on-going financial arrangements with NeuroComp Systems, Inc., aside from receipt of funding from NIMH for participation in this study as subcontract Pls. NR 38 TC 12 Z9 13 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2008 VL 106 IS 1 BP 33 EP 41 DI 10.1016/j.schres.2007.11.015 PG 9 WC Psychiatry SC Psychiatry GA 377MY UT WOS:000261256500005 PM 18160262 ER PT J AU Bowie, CR Reichenberg, A McClure, MM Leung, WL Harvey, PD AF Bowie, Christopher R. Reichenberg, Abraham McClure, Margaret M. Leung, Winnie L. Harvey, Philip D. TI Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: Differential sensitivity of clinical neuropsychological and experimental information processing tests SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Neuropsychology; Cognition; Information processing; Aging ID SCHIZOTYPAL PERSONALITY-DISORDER; PREFRONTAL CORTEX DYSFUNCTION; WORKING-MEMORY; WHITE-MATTER; FOLLOW-UP; MULTIPLE-SCLEROSIS; METABOLIC-RATE; DEFICITS; DECLINE; SYMPTOMS AB Cognitive dysfunction is a common feature of schizophrenia and deficits are present before the onset of psychosis, and are moderate to severe by the time of the first episode. Controversy exists over the course of cognitive dysfunction after the first episode. This study examined age-associated differences in performance on clinical neuropsychological (NP) and information processing tasks in a sample of geriatric community living schizophrenia patients (n = 172). Compared to healthy control subjects (n = 70), people with schizophrenia did not differ on NP tests across age groups but showed evidence for age-associated cognitive worsening on the more complex components of an information-processing test. Age-related changes in cognitive function in schizophrenia may be a function of both the course of illness and the processing demands of the cognitive measure of interest. Tests with fixed difficulty, such as clinical NP tests, may differ in their sensitivity from tests for which parametric difficulty manipulations can be performed. (C) 2007 Elsevier B.V. All rights reserved. C1 [Bowie, Christopher R.; Reichenberg, Abraham; McClure, Margaret M.; Leung, Winnie L.; Harvey, Philip D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Bowie, Christopher R.] James J Peters Bronx VA Med Ctr, Bronx, NY 10468 USA. [Reichenberg, Abraham] Kings Coll London, Inst Psychiat, London SE5 8AF, England. [McClure, Margaret M.; Leung, Winnie L.; Harvey, Philip D.] Bronx VA Med Ctr, VA VISN MIRECC 3, Bronx, NY 10468 USA. [Harvey, Philip D.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. RP Bowie, CR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,4th Floor,Box 1230, New York, NY 10029 USA. EM christopher.bowie@mssm.edu FU NIMH [MH 63116]; Mt. Sinai Silvio Conte Neuroscience Center [MH 36692]; VA VISN 3 MIRECC FX This research was supported by NIMH Grant Number MH 63116 to Dr. Harvey, the Mt. Sinai Silvio Conte Neuroscience Center (NIMH MH 36692; KL Davis PI) and the VA VISN 3 MIRECC. These sponsors had no role in study design, collection of data, data analysis, interpretation of results, or writing of the manuscript. NR 55 TC 23 Z9 24 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD NOV PY 2008 VL 106 IS 1 SI SI BP 50 EP 58 DI 10.1016/j.schres.2007.10.026 PG 9 WC Psychiatry SC Psychiatry GA 377MY UT WOS:000261256500007 PM 18053687 ER PT J AU Sobo, EJ Bowman, C Gifford, AL AF Sobo, Elisa J. Bowman, Candice Gifford, Allen L. TI Behind the scenes in health care improvement: The complex structures and emergent strategies of Implementation Science SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE USA; Implementation science; Structure and agency; Health Services Research; Social construction of knowledge; Institutional ethnography ID CLINICAL REMINDERS; BARRIERS; MEDICINE AB Implementation Science (IS) is a new branch of health services research (HSR) that strives to increase the efficiency and effectiveness of health care quality improvement (QI) efforts. Despite the fact that IS takes a systems approach, building contextual factors into its research designs, the complex systems context of IS itself-and the impact this context has on IS practice-has never been scrutinized. Using individual interviews and participant observation, the research described here characterizes key contextual factors affecting how implementation scientists in one large health care organization approach and conduct their research. Some of the organizational and professional system forces structuring their attitudes and actions were grant-related timelines, administrative burdens, and team turnover. The need for publications also figured highly. While such pressures (and related responses to them) may be rife in most grant-funded health care research settings, IS's particularly marginal position drove these implementation scientists to strategically highlight particular aspects of their work depending on which audience or part of the system they required favor from. Their narratives illuminate the contradictions and contests entailed within and engendered by organizational and professional structures, and the strategies used to negotiate these. They also reveal a great deal about the struggles underwriting disciplinary identity claims in a complex systems context. (c) 2008 Elsevier Ltd. All rights reserved. C1 [Sobo, Elisa J.] San Diego State Univ, Dept Anthropol, San Diego, CA 92182 USA. [Bowman, Candice] Greater Los Angeles VA Healthcare Syst, Ctr Study Healthcare Provider Behav, Sepulveda, CA USA. [Gifford, Allen L.] Boston Univ, Boston, MA 02215 USA. [Gifford, Allen L.] VA New England Healthcare Syst, Ctr Healthcare Qual Outcomes & Econ Res, Bedford, MA USA. RP Sobo, EJ (reprint author), San Diego State Univ, Dept Anthropol, San Diego, CA 92182 USA. EM esobo@mail.sdsu.edu; candybowman@gmail.com; allen.gifford@va.gov NR 33 TC 17 Z9 17 U1 2 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD NOV PY 2008 VL 67 IS 10 BP 1530 EP 1540 DI 10.1016/j.socscimed.2008.06.001 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 370HU UT WOS:000260754100007 PM 18760519 ER PT J AU Yin, W Signore, AP Iwai, M Cao, GD Gao, YQ Chen, J AF Yin, Wei Signore, Armando P. Iwai, Masanori Cao, Guodong Gao, Yanqin Chen, Jun TI Rapidly Increased Neuronal Mitochondrial Biogenesis After Hypoxic-Ischemic Brain Injury SO STROKE LA English DT Article DE neonatal hypoxic ischemia; mitochondria biogenesis; nuclear respiratory factor-1; mitochondrial transcription factor A ID RESPIRATORY FACTOR-I; RAT; PROTEIN; NEURODEGENERATION; INDUCTION; DEATH; CELLS; GAMMA AB Background and Purpose-Mitochondrial biogenesis is regulated through the coordinated actions of both nuclear and mitochondrial genomes to ensure that the organelles are replenished on a regular basis. This highly regulated process has been well defined in skeletal and heart muscle, but its role in neuronal cells, particularly when under stress or injury, is not well understood. In this study, we report for the first time rapidly increased mitochondrial biogenesis in a rat model of neonatal hypoxic/ischemic brain injury (H-I). Methods-Postnatal day 7 rats were subjected to H-I induced by unilateral carotid artery ligation followed by 2.5 hours of hypoxia. The relative amount of brain mitochondrial DNA (mtDNA) was measured semiquantitatively using long fragment PCR at various time points after H-I. HSP60 and COXIV proteins were detected by Western blot. Expression of three genes critical for the transcriptional regulation of mitochondrial biogenesis, peroxisome proliferator-activated receptor coactivator-1 (PGC-1), nuclear respiratory factor-1 (NRF-1), and mitochondrial transcription factor A (TFAM), were examined by Western blot and RT-PCR. Results-Brain mtDNA content was markedly increased 6 hours after H-I, and continued to increase up to 24 hours after H-I. Paralleling the temporal change in mtDNA content, mitochondrial number and proteins HSP60 and COXIV, and citrate synthase activity were increased in neurons in the cortical infarct border zone after H-I. Moreover, cortical expression of NRF-1 and TFAM were increased 6 to 24 hours after H-I, whereas PGC-1 was not changed. Conclusions-Neonatal H-I brain injury rapidly induces mitochondrial biogenesis, which may constitute a novel component of the endogenous repair mechanisms of the brain. (Stroke. 2008; 39: 3057-3063.) C1 [Yin, Wei; Signore, Armando P.; Iwai, Masanori; Cao, Guodong; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Cao, Guodong; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Cao, Guodong; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Signore, Armando P.; Cao, Guodong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507 Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU NIH/NINDS [NS45048, NS36736, NS43802, NS44178]; Geriatric Research, Education and Clinical Center; Veterans Affairs; Pittsburgh Health Care System, Pittsburgh, Pennsylvania FX This project was supported by NIH/NINDS grants NS45048, NS36736, NS43802, and NS44178. J.C. was also supported in part by the Geriatric Research, Education and Clinical Center, Veterans Affairs, Pittsburgh Health Care System, Pittsburgh, Pennsylvania. NR 30 TC 111 Z9 123 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD NOV PY 2008 VL 39 IS 11 BP 3057 EP 3063 DI 10.1161/STROKEAHA.108.520114 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 365SC UT WOS:000260427100024 PM 18723421 ER PT J AU Dransfield, MT Rowe, SM Johnson, J Bailey, W Gerald, L AF Dransfield, M. T. Rowe, S. M. Johnson, J. Bailey, W. Gerald, L. TI Is the coprescription of beta blockers and beta(2) agonists justified in COPD? Response SO THORAX LA English DT Letter ID MYOCARDIAL-INFARCTION; RISK; MORTALITY C1 Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Dransfield, M. T.] Univ Alabama, Birmingham, AL 35294 USA. RP Dransfield, MT (reprint author), Univ Alabama, 215 THT 1900 Univ Blvd, Birmingham, AL 35294 USA. EM mdransfield99@msn.com NR 6 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 J9 THORAX JI Thorax PD NOV PY 2008 VL 63 IS 11 BP 1026 EP 1026 PG 1 WC Respiratory System SC Respiratory System GA 368GY UT WOS:000260610800021 ER PT J AU Dransfield, MT Rowe, SM Johnson, J Bailey, W Gerald, L AF Dransfield, M. T. Rowe, S. M. Johnson, J. Bailey, W. Gerald, L. TI Biases in the observational study of beta blockers in COPD Response SO THORAX LA English DT Letter ID OBSTRUCTIVE PULMONARY-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; THERAPY; RISK C1 Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Dransfield, M. T.] Univ Alabama, Birmingham, AL 35294 USA. RP Dransfield, MT (reprint author), Univ Alabama, 215 THT 1900 Univ Blvd, Birmingham, AL 35294 USA. EM mdransfield99@msn.com NR 5 TC 0 Z9 0 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0040-6376 J9 THORAX JI Thorax PD NOV PY 2008 VL 63 IS 11 BP 1027 EP 1027 PG 1 WC Respiratory System SC Respiratory System GA 368GY UT WOS:000260610800023 ER PT J AU Donze, J Le Gal, G Fine, MJ Roy, PM Sanchez, O Verschuren, F Cornuz, J Meyer, G Perrier, A Righini, M Aujesky, D AF Donze, Jacques Le Gal, Gregoire Fine, Michael J. Roy, Pierre-Marie Sanchez, Olivier Verschuren, Franck Cornuz, Jacques Meyer, Guy Perrier, Arnaud Righini, Marc Aujesky, Drahomir TI Prospective validation of the Pulmonary Embolism Severity Index A clinical prognostic model for pulmonary embolism SO THROMBOSIS AND HAEMOSTASIS LA English DT Article DE Pulmonary embolism; prediction rule; prognosis; risk; validation study ID MOLECULAR-WEIGHT HEPARIN; LOW-RISK PATIENTS; DEEP-VEIN THROMBOSIS; OUTPATIENT TREATMENT; VENOUS THROMBOEMBOLISM; COMPUTED-TOMOGRAPHY; PREDICTION RULE; MANAGEMENT; ULTRASONOGRAPHY; TRIAL AB Practice guidelines recommend outpatient care for selected patients with non-massive pulmonary embolism (PE), but fail to specify how these low-risk patients should be identified. Using data from U.S. patients, we previously derived the Pulmonary Embolism Severity Index (PESI), a prediction rule that risk stratifies patients with PE. We sought to validate the PESI in a European patient cohort. We prospectively validated the PESI in patients with PE diagnosed at six emergency departments in three European countries. We used baseline data for the rule's II prognostic variables to stratify patients into five risk classes (I-V) of increasing probability of mortality. The outcome was overall mortality at 90 days after presentation. To assess the accuracy of the PESI to predict mortality, we estimated the sensitivity, specificity, and predictive values for low- (risk classes I/II) versus higher-risk patients (risk classes III-V), and the discriminatory power using the area under the receiver operating characteristic (ROC) curve. Among 357 patients with PE, overall mortality was 5.9%, ranging from 0% in class I to 17.9% in class V. The 186 (52%) low-risk patients had an overall mortality of 1.1% (95% confidence interval [CI]: 0.1-3.8%) compared to 11.1% (95% CI: 6.8-16.8%) in the 171 (48%) higher-risk patients. The PESI had a high sensitivity (91%, 95% CI: 71-97%) and a negative predictive value (99%,95% CI: 96-100%) for predicting mortality. The area under the ROC curve was 0.78 (95% 0: 0.70-0.86). The PESI reliably identifies patients with PE who are at low risk of death and who are potential candidates for outpatient care. The PESI may help physicians make more rational decisions about hospitalization for patients with PE. C1 [Donze, Jacques; Cornuz, Jacques; Aujesky, Drahomir] Univ Lausanne, Div Gen Internal Med, Lausanne, Switzerland. [Le Gal, Gregoire] Univ Brest, Dept Internal Med & Chest Dis, Brest, France. [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Roy, Pierre-Marie] Univ Angers, Dept Emergency Med, Angers, France. [Sanchez, Olivier; Meyer, Guy] Hop Europeen Georges Pompidou, Dept Resp & Crit Care Med, Paris, France. [Verschuren, Franck] St Luc Univ Hosp, Dept Emergency, Brussels, Belgium. [Perrier, Arnaud] Univ Geneva, Div Gen Internal Med, Geneva, Switzerland. [Righini, Marc] Univ Geneva, Div Angiol & Hemostasis, Geneva, Switzerland. RP Donze, J (reprint author), CHU Vaudois, Serv Med Interne, CH-1011 Lausanne, Switzerland. EM jacques.donze@chuv.ch RI LE GAL, Gregoire/K-1077-2012; Perrier, Arnaud/M-2263-2014 OI LE GAL, Gregoire/0000-0002-9253-248X NR 32 TC 101 Z9 104 U1 0 U2 6 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 0340-6245 J9 THROMB HAEMOSTASIS JI Thromb. Haemost. PD NOV PY 2008 VL 100 IS 5 BP 943 EP 948 DI 10.1160/TH08-05-0285 PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 373GE UT WOS:000260958200036 PM 18989542 ER PT J AU Yin, XM Latif, R Bahn, R Tomer, Y Davies, TF AF Yin, Xiaoming Latif, Rauf Bahn, Rebecca Tomer, Yaron Davies, Terry F. TI Influence of the TSH Receptor Gene on Susceptibility to Graves' Disease and Graves' Ophthalmopathy SO THYROID LA English DT Article ID AUTOIMMUNE THYROID-DISEASE; HUMAN THYROTROPIN RECEPTOR; MOLECULAR-CLONING; ASSOCIATION; POLYMORPHISM; DOMAIN; CTLA-4; LOCI; DISCOVERY; CD28 AB Background: A large gene region, called GD-1, was first described by this laboratory as linked to Graves' disease (GD) and included the gene for the thyroid-stimulating hormone receptor (TSHR). Recent studies have now suggested an association of TSHR intronic polymorphisms with GD. We have taken the opportunity to examine a population of well-characterized patients with autoimmune thyroid disease (AITD) typed for an additional thyroid susceptibility gene, the immunoregulatory gene for cytotoxic T-lymphocyte antigen 4 (CTLA-4), to examine its relationship with the susceptibility to GD endowed by TSHR gene polymorphisms. Methods: We used TSHR-SNP-rs2268458, located in intron 1 of the TSHR gene, measured using standard PCR-RFLP procedures, as our marker for the TSHR gene association. We genotyped 200 patients with GD, 83 patients with Hashimoto's thyroiditis (HT), and 118 healthy controls (all female Caucasians). Results: The allele and genotype frequencies from GD patients, but not HT patients, were significantly different from controls. The frequency of the combined genotype (allele) CC + TC was significantly higher in GD patients versus controls, suggesting that the C-containing genotype increased the risk for GD in a dominant manner (p = 0.018, odds ratio [OR] = 1.8). When compared with CTLA-4 (A/G)(49) single-nucleotide polymorphism (SNP), we were unable to demonstrate additive risk in patients with established AITD. Further, subsetting the patients (n = 120) into those with clinically significant Graves' ophthalmopathy (GO) showed no association with the TSHR SNP. Conclusions: These results demonstrated that the intronic TSHR-SNP-rs2268458 was associated with GD, but not with HT, thus indicating that the TSHR gene has the potential to increase susceptibility to GD. However, we were not able to demonstrate any additive risk with the CTLA-4 (A/G)(49) SNP, which is, therefore, an independent risk factor for AITD. This suggested that, within the limits of the study population, each of these two genes provided a small contribution to GD susceptibility and that neither was essential. In addition, there was no evidence for the TSHR gene association adding to the risk of developing GO. Direct functional analyses are now needed to help explain the mechanisms of this TSHR gene susceptibility to GD. C1 [Yin, Xiaoming; Latif, Rauf; Davies, Terry F.] Mt Sinai Med Ctr, James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY 10029 USA. [Bahn, Rebecca] Mayo Clin, Div Endocrinol, Rochester, MN USA. [Tomer, Yaron] Univ Cincinnati, Div Endocrinol, Cincinnati, OH USA. RP Davies, TF (reprint author), Mt Sinai Med Ctr, James J Peters VA Med Ctr, Thyroid Res Unit, Box 1055 1 Gustave L Levy Pl, New York, NY 10029 USA. EM terry.davies@mssm.edu FU NIH-NIDDKD [DK052464, DK69713] FX This work was supported in part by DK052464 and DK69713 from NIH-NIDDKD, the David Owen Segal Endowment, the James J. Peters VAMC, and the VA Merit Award program. NR 38 TC 29 Z9 32 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD NOV PY 2008 VL 18 IS 11 BP 1201 EP 1206 DI 10.1089/thy.2008.0098 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 373GG UT WOS:000260958400009 PM 18925838 ER PT J AU McCutcheon, SR AF McCutcheon, Stephen R. TI Addressing Problems of Insufficient Competence During the Internship Year SO TRAINING AND EDUCATION IN PROFESSIONAL PSYCHOLOGY LA English DT Article DE predoctoral internship; insufficient competence; competencies; due process; remediation AB Addressing problems of insufficient student competence during the internship year takes on special importance at this penultimate step in the trainee's entry to the profession. The gravity of gate-keeping functions at this late stage of training requires internship faculties to accurately identify the trainees lacking sufficient competence, and to be mindful of errors resulting from assessments of competence that lack adequate sensitivity and specificity. This process occurs within larger systemic and legal contexts described in companion articles contained in this issue. This article serves as an extension of the issues raised in this special section as they apply to the internship year. C1 [McCutcheon, Stephen R.] Puget Sound Healthcare Syst, Vet Affairs, Seattle, WA USA. RP McCutcheon, SR (reprint author), VA Puget Sound, Mental Hlth 116, 1660 South Columbian Way, Seattle, WA 98108 USA. EM stephen.mccutcheon@va.gov NR 15 TC 7 Z9 7 U1 1 U2 2 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1931-3918 J9 TRAIN EDUC PROF PSYC JI Train. Educ. Prof. Psychol. PD NOV PY 2008 VL 2 IS 4 BP 210 EP 214 DI 10.1037/a0013535 PG 5 WC Psychology, Educational SC Psychology GA V29EE UT WOS:000208730900004 ER PT J AU Dasgupta, SK Abdel-Monem, H Guchhait, P Nagata, S Thiagarajan, P AF Dasgupta, Swapan K. Abdel-Monem, Hanan Guchhait, Prasenjit Nagata, Shigekazu Thiagarajan, Perumal TI Role of lactadherin in the clearance of phosphatidylserine-expressing red blood cells SO TRANSFUSION LA English DT Article ID MEMBRANE PHOSPHOLIPID ASYMMETRY; APOPTOTIC CELLS; HUMAN-ERYTHROCYTES; PROLONGED STORAGE; PHAGOCYTOSIS; MACROPHAGES; ENGULFMENT; EXPOSURE; BINDING; ADHESION AB In red blood cells (RBCs) anionic phospholipids, such as phosphatidylserine, are present in the inner leaflet of the membrane bilayer. Exposure of phosphatidylserine occurs during senescence and during long-term storage of RBCs and is considered as the tag for removal from the circulation by macrophages. Lactadherin is a phosphatidylserine-binding glycoprotein secreted by macrophages that promotes the engulfment of phosphatidylserine-expressing apoptotic lymphocytes. This study investigates the role of lactadherin in the phagocytosis of phosphatidylserine-expressing RBCs. Transbilayer movement of phosphatidylserine was induced in RBCs either by storage beyond 30 days or by treatment with calcium ionophore A23187 and N-ethylmaleimide. Phosphatidylserine-expressing RBCs were incubated with phorbol ester-stimulated THP-1, and phagocytosis was determined by measuring the pseudoperoxidase activity of hemoglobin. The in vivo clearance of phosphatidylserine-enriched RBCs was measured in lactadherin-deficient mice and in their littermate controls. Lactadherin promoted phagocytosis of phosphatidylserine-expressing RBCs by macrophages in a concentration-dependent manner. Splenic macrophages from lactadherin-deficient mice had diminished capacity to phagocytose phosphatidylserine-expressing RBCs. The life span of RBCs in lactadherin-deficient mice was similar to wild-type littermate controls in vivo. However, when an excess of phosphatidylserine-expressing RBCs were infused, there was only a mild impairment in the clearance in lactadherin-deficient mice compared to wild-type littermate controls. These results show that clearance of phosphatidylserine-expressing RBCs is not diminished in a significant way in lactadherin-deficient mice under physiologic conditions and suggest the presence of redundant pathways. C1 [Thiagarajan, Perumal] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Osaka Univ, Sch Med, Dept Genet, Osaka, Japan. RP Thiagarajan, P (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Mail Stop 113,2002 Holcombe Blvd, Houston, TX 77030 USA. EM perumalt@bcm.tmc.edu OI Thiagarajan, Perumal/0000-0003-2186-7036 FU Veterans Affairs Research Service and the Gulf Coast Blood Center; American Heart Association FX Supported by grants from the Veterans Affairs Research Service and the Gulf Coast Blood Center (PT) and a Grant in Aid from American Heart Association (PG). NR 39 TC 18 Z9 18 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0041-1132 J9 TRANSFUSION JI Transfusion PD NOV PY 2008 VL 48 IS 11 BP 2370 EP 2376 DI 10.1111/j.1537-2995.2008.01841.x PG 7 WC Hematology SC Hematology GA 375AZ UT WOS:000261086200017 PM 18647368 ER PT J AU Sun, HY Singh, N Cacciarelli, TV Wannstedt, C Wagener, MM Steele, C AF Sun, Hsin-Yun Singh, Nina Cacciarelli, Thomas V. Wannstedt, Cheryl Wagener, Marilyn M. Steele, Chad TI Dysregulated expression of T-helper cell responses and susceptibility to infections in high-risk liver transplant recipients SO TRANSPLANT IMMUNOLOGY LA English DT Article DE Transplants; Cytomegalovirus; Fungal infections; Bacterial infections; T-helper cells; Cytokines ID RENAL REPLACEMENT THERAPY; CYTOMEGALOVIRUS-INFECTION; MONONUCLEAR PHAGOCYTES; HEMODIALYSIS-PATIENTS; ANTIFUNGAL ACTIVITY; PREEMPTIVE THERAPY; CYTOKINE; DIALYSIS; MORTALITY; PROFILES AB Background: Liver transplant recipients requiring dialysis have poor outcomes including higher risk of infection, and allograft rejection. The role of T-helper cell cytokine responses in the pathogenesis of infections in these patients has not been fully defined. Methods: Cases were 11 dialyzed liver transplant recipients. Controls (2 for each case) were patients who were transplanted next to the case but did not require dialysis at any time before or after transplantation. Cytokine responses were assessed in sera collected immediately before transplantation. Data were analyzed for candidate cytokines for pro-inflammatory Th1 (IL-1 beta, IL-12p70, and IFN-gamma), and Th17 (IL-12p40, IL-17), and anti-inflammatory Th2 phenotypes (IL-4, IL-5, IL-10, and IL-13). Results: Cases were more likely to have an increase in any of the Th1 or Th1 and Th17 cytokines than the controls (p = 0.016 and p = 0.04, respectively). Major infections developed in 27% of the study population: these included 46% of the cases and 18%, of the controls (p = 0.09). Patients with infections vs. those without these were more likely to have an increase in any of the Th2 cytokines (p = 0.005). CMV viremia occurred in 30% of the patients and was significantly associated with Th1 responses even when adjusted for CMV recipient/donor serostatus or any major infection (OR 3.2. 95% CI 0.96-10.73, p = 0.05). Conclusions: Requirement of dialysis was characterized by a state of heightened expression of inflammatory responses. However, patients developing infections preferentially expressed Th2 phenotype that may act as a negative regulator of protective inflammatory responses. An enhanced expression of inflammatory mediators may serve to promote CMV infection in liver transplant recipients. (C) 2008 Elsevier B.V. All rights reserved. C1 [Singh, Nina; Cacciarelli, Thomas V.; Wannstedt, Cheryl; Wagener, Marilyn M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei, Taiwan. [Steele, Chad] Univ Alabama, Birmingham, AL USA. RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM nis5@pitt.edu; chadsteele@uab.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 NR 46 TC 10 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0966-3274 J9 TRANSPL IMMUNOL JI Transpl. Immunol. PD NOV PY 2008 VL 20 IS 1-2 BP 68 EP 72 DI 10.1016/j.trim.2008.08.001 PG 5 WC Immunology; Transplantation SC Immunology; Transplantation GA 385TX UT WOS:000261837600013 PM 18761089 ER PT J AU Colli, JL Amling, CL AF Colli, Janet L. Amling, Christopher L. TI Exploring causes for declining prostate cancer mortality rates in the United States SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article DE Ecology; Prostate cancer; Risk factors; United States; Epidemiology ID TRIAL; CELLS AB Objectives: Prostate cancer mortality rates in the U.S.A. increased in the late 1980s and declined from 1993 until 2003. The purpose of this study is to compare declining prostate cancer mortality rates among states with independent variables that may have an association to explore causes for the decline. Methods and materials: Annual rates of prostate cancer mortality for men over 50 were obtained from the National Vital Statistic System public use data file for states for individual years from 1993 to 2003. The annual rate of prostate cancer mortality decline for each state Was Calculated by the Joinpoint Regression Program (Statistical Research and Applications Branch of NCI). Annual rates of prostate cancer decline were cross-correlated to state levels of PSA screening, health insurance coverage, obesity, physical inactivity, diabetes, and high cholesterol for males front 45 to 64. Results: Declining prostate cancer mortality rates for white males correlated with high cholesterol levels (R = -0.42, P = 0.002) and PSA screening levels (R = -0.28. P = 0.05). Declining, prostate cancer mortality rates for black males correlated with health insurance coverage (R = -0.43. P = 0.03). Conclusions: Declining prostate cancer mortality rates are weakly associated with increased PSA screening for White Males but there was no association for black males, possibly because blacks have less access to medical care. The strong inverse correlation between declining prostate cancer mortality rates and levels of white males with high cholesterol levels was unexpected but may be associated with the widespread use of cholesterol reducing medications (statins), which are hypothesized to reduce prostate cancer risk. (c) 2008 Elsevier Inc. All rights reserved. C1 [Colli, Janet L.; Amling, Christopher L.] Univ Alabama, Dept Urol, Birmingham, AL 35294 USA. [Colli, Janet L.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Colli, JL (reprint author), Univ Alabama, Dept Urol, Birmingham, AL 35294 USA. EM jan.colli@ccc.uab.edu NR 9 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD NOV-DEC PY 2008 VL 26 IS 6 BP 627 EP 633 DI 10.1016/j.urolonc.2007.05.016 PG 7 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 377XH UT WOS:000261285100012 PM 18367111 ER PT J AU Gee, J Lee, IL Grossman, HB Sabichi, AL AF Gee, Jason Lee, I-Ling Grossman, H. Barton Sabichi, Anita L. TI Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article DE Transitional cell carcinoma; Cyclooxygenase-2; Prostaglandin E(2) ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; PROSTAGLANDIN E-2; BLADDER-CANCER; CYCLOOXYGENASE-2 INHIBITOR; COLORECTAL-CANCER; URINARY-BLADDER; APOPTOSIS; CELECOXIB; CARCINOMA AB Objectives: Cyclooxygenase 2 (COX-2) is aberrantly expressed in multiple tumor types including bladder cancer is associated with enhanced growth, resistance to apoptosis, invasion, and angiogenesis. To evaluate the mechanisms through which COX-2 expression alters normal urothelium, we transfected the SV-40 immortalized human urothelial cell line SV-HUC with COX-2. Methods: SV-HUC cells were stably transfected with a plasmid containing COX-2 Under a CMV promoter. Following isolation (of monoclonal transfectants, COX-2 expression was determined by Western and Northern analyses. Prostaglandin E(2) (PGE(2)) in the culture supernatant was measured by ELISA. Cell growth was measured by crystal violet assay. Cellular invasion through Matrigel and anchorage-independent growth in 0.4% agarose were assessed. Tumorigenicity was evaluated by subcutaneous injection of cells in nude mice with and without Matrigel. Results: Four of 12 clones stably overexpressing COX-2 at high levels relative to vector-transfected control cells were chosen for further study. Cell growth rates of these 4 clones were higher than vector control cells. PGE(2) production was elevated in 3 of these 4 clones, and PGE(2) levels correlated significantly with invasion through Matrigel. COX-2-transfected cells did not form colonies in soft agarose or tumors in nude mice. Conclusions: Forced COX-2 expression in SV-HUC immortalized urothelial cells contributes to increased PGE(2) production and increased invasion through Matrigel. However, it is insufficient to induce malignant transformation. (c) 2008 Elsevier Inc. All rights reserved. C1 [Gee, Jason] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. [Gee, Jason] Univ Wisconsin, Hosp & Clin, Div Urol, Madison, WI 53705 USA. [Lee, I-Ling; Grossman, H. Barton] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA. [Sabichi, Anita L.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA. RP Gee, J (reprint author), Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. EM gee@surgery.wisc.edu FU NCI NIH HHS [CA91846] NR 28 TC 14 Z9 14 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD NOV-DEC PY 2008 VL 26 IS 6 BP 641 EP 645 DI 10.1016/j.urolonc.2007.05.015 PG 5 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 377XH UT WOS:000261285100014 PM 18367112 ER PT J AU Freedland, SJ Wen, J Wuerstle, M Shah, A Lai, D Moalej, B Atala, C Aronson, WJ AF Freedland, Stephen J. Wen, Joanne Wuerstle, Melanie Shah, Amy Lai, Dominic Moalej, Bita Atala, Christina Aronson, William J. TI Obesity Is a Significant Risk Factor for Prostate Cancer at the Time of Biopsy SO UROLOGY LA English DT Article ID BODY-MASS INDEX; RADICAL PROSTATECTOMY; WEIGHT CHANGE; SERUM-LEVELS; ANTIGEN; MEN; AGE; MORTALITY; PSA; HYPERPLASIA AB OBJECTIVES Studies suggest obesity is associated with decreased prostate cancer risk. We hypothesized obesity is biologically associated with increased risk, although this is obscured owing to hemodilution of prostate-specific antigen (PSA) and larger prostate size. METHODS We retrospectively studied 441 consecutive men undergoing prostate biopsy between 1999 and 2003 at two equal access centers within the Veterans Affairs Greater Los Angeles Healthcare System. We estimated the association between obesity (body mass index >= 30 kg/m(2)) and positive biopsy and Gleason >= 4+3 using logistic regression analysis adjusting for multiple clinical characteristics. RESULTS A total of 123 men (28%) were obese and 149 men (34%) had cancer. Median PSA and age were 5.7 ng/mL and 63.9 years, respectively. Obese men had significantly tower PSA concentrations (P = .02) and larger prostate volumes (P = .04). Obesity was not significantly related to age (P = .19) or race (P = .37). On univariate analysis, obesity was not associated with prostate cancer risk (odds ratio [OR] 1.13, 95% confidence interval [CI] 0.73-1.75, P = .58). However, after adjusting for multiple clinical characteristics, obesity was associated with significantly increased prostate cancer risk (OR 1.98, 95% Cl 1.17-3.32, P = .01). After multivariable adjustment, there was no significant association between obesity and high-grade disease (P = .18). CONCLUSIONS Without adjustment for clinical characteristics, obesity was not significantly associated with prostate cancer risk in this equal-access, clinic-based population. However, after adjusting for the lower PSA levels and the larger prostate size, obesity was associated with a 98% increased prostate cancer risk. These findings support the fact that current prostate cancer screening practices may be biased against obese men. UROLOGY 72: 1102-1105, 2008. (C) 2008 Elsevier Inc. C1 [Freedland, Stephen J.] Duke Univ, Sch Med, DUMC, Div Urol,Duke Prostate Ctr,Dept Surg, Durham, NC 27710 USA. Duke Univ, Sch Med, Dept Pathol, Duke Prostate Ctr, Durham, NC 27710 USA. Duke Univ, Vet Affairs Med Ctr, Urol Sect, Durham, NC 27710 USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, DUMC, Div Urol,Duke Prostate Ctr,Dept Surg, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu FU Department of Defense; Department of Veterans Affairs, National Institute of Health [R01CA100938]; NIH Specialized Programs of Research Excellence [P50 CA92131-01AI]; American Urological Association Foundation/Astellas Rising Star in Urology Award (SJF) FX Supported by the Department of Defense, Prostate Cancer Research Program (SJF); Department of Veterans Affairs, National Institute of Health Grant R01CA100938 (WJA), NIH Specialized Programs of Research Excellence Grant P50 CA92131-01AI (WJA), and the American Urological Association Foundation/Astellas Rising Star in Urology Award (SJF). Views and opinions of, and endorsements by the authors do not reflect those of the US Army or the Department of Defense. NR 24 TC 40 Z9 42 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD NOV PY 2008 VL 72 IS 5 BP 1102 EP 1105 DI 10.1016/j.urology.2008.05.044 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 372OH UT WOS:000260910400043 PM 18722650 ER PT J AU Grubaugh, AL Slagle, DM Long, M Frueh, BC Magruder, KM AF Grubaugh, Anouk L. Slagle, David M. Long, Mary Frueh, B. Christopher Magruder, Kathryn M. TI RACIAL DISPARITIES IN TRAUMA EXPOSURE, PSYCHIATRIC SYMPTOMS, AND SERVICE USE AMONG FEMALE PATIENTS IN VETERANS AFFAIRS PRIMARY CARE CLINICS SO WOMENS HEALTH ISSUES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-SERVICES; VIETNAM VETERANS; NATIONAL SAMPLE; WOMEN VETERANS; SEXUAL ASSAULT; UNITED-STATES; GULF-WAR; PTSD; VA AB Objective. We sought to compare female African-American (n = 84) and Caucasian (n = 99) veterans from primary care clinics at 4 Veterans Affairs Medical Centers (VAMCs) on rates of trauma, posttraumatic stress disorder, other psychiatric diagnoses, functional status, and use of VA services and disability benefits. Methods. Analyses were based on a cross-sectional, epidemiologic design incorporating self-report measures, structured interviews, and chart reviews. Results. With the exception of higher rates of child sexual abuse among Caucasian women and higher rates of physical assault among African-American women, there were no other statistically significant racial differences across analyses. However, some clinically meaningful trends emerged, and the implications of these findings are discussed within the context of our other results. Conclusions. Among female veterans seen in VA primary care clinics, African-Americans and Caucasians do not differ dramatically with regard to the manifestation or severity of psychopathology, or in their use of relevant VA health care services and disability benefits. These data are important because women represent the fastest growing segment of the VA population after aging veterans. Further research is needed to replicate and extend these findings to ensure that female veterans' needs are adequately identified and met by VAMC providers. C1 [Grubaugh, Anouk L.] Med Univ S Carolina, Div Publ Psychiat, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Grubaugh, Anouk L.; Long, Mary; Magruder, Kathryn M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Slagle, David M.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Frueh, B. Christopher] Baylor Coll Med, Menninger Clin, Houston, TX 77030 USA. [Frueh, B. Christopher] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Grubaugh, AL (reprint author), Med Univ S Carolina, Div Publ Psychiat, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. EM grubaugh@musc.edu NR 43 TC 13 Z9 13 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD NOV-DEC PY 2008 VL 18 IS 6 BP 433 EP 441 DI 10.1016/j.whi.2008.08.001 PG 9 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 388BD UT WOS:000261994400002 PM 19041595 ER PT J AU Yu, J Zhu, H Ko, D Kindy, MS AF Yu, Jin Zhu, Hong Ko, Dorothy Kindy, Mark S. TI Motoneuronotrophic factor analog GM6 reduces infarct volume and behavioral deficits following transient ischemia in the mouse SO BRAIN RESEARCH LA English DT Article DE Stroke; Trophic factor; Middle cerebral artery occlusion; Mouse; Neuroprotection ID DEVELOPING NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; SKELETAL-MUSCLE; BRAIN-INJURY; NEUROTROPHIC FACTORS; EXPERIMENTAL STROKE; GLOBAL-ISCHEMIA; CELL-DEATH; NEUROGENESIS; SURVIVAL AB Motoneuronotrophic factor (MNTF) is an endogenous neurotrophin that is highly specific for the human nervous system, and some of the observed effects of MNTF include motoneuron differentiation, maintenance, survival, and reinnervation of target muscles and organs. MNTF is a neuro-signaling molecule that binds to specific receptors. Using In Silico Analysis, one of the active sites of MNTF was identified as an analog of six amino acids (GM6). The effect of chemically synthesized GM6 on ischemic stroke was studied in the middle cerebral artery occlusion (MCAo) mouse model. Mice were subjected to 1 hur of ischemia followed by 24 h of reperfusion. Mice were injected intravenously with a bolus of GM6, at various doses (1 and S mg/kg) immediately after the start of reperfusion and examined for changes in physiological parameters, neurological deficits and infarct volume. GM6 was able to penetrate the blood brain barrier, and at both 1 and S mg/kg showed a significant protection from infarct damage, which translated to improvement of neurological deficits. Administration of GM6 demonstrated no changes in HR, BP, PO2, pCO(2), or pH. A significant increase over the control group in CBF after reperfusion was observed with GM6 administration, which helped to mitigate the ischemic effect caused by the blockage of blood flow. The time window of treatment was assessed at various times following cerebral ischemia with GM6 demonstrating a significant protective effect up to 6-12 h post ischemia. In addition, GM6 increased neurogenesis, and decreased apoptosis and inflammation in the mouse brain following cerebral ischemic injury. These data suggest that GM6 is neuroprotective to the brain following IV injection in the mouse model of MCAo. Published by Elsevier B.V. C1 [Yu, Jin; Zhu, Hong; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Ko, Dorothy] Genervon Biopharmaceut, Montebello, CA USA. [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Kindy, Mark S.] Neurol Testing Serv Inc, Charleston, SC 29425 USA. RP Kindy, MS (reprint author), Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave,BSB 403, Charleston, SC 29425 USA. EM kindyms@musc.edu FU NIA NIH HHS [R01 AG019323-04, R01 AG019323] NR 60 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD OCT 31 PY 2008 VL 1238 BP 143 EP 153 DI 10.1016/j.brainres.2008.08.053 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 371UX UT WOS:000260858100015 PM 18789909 ER PT J AU Sullivan, MD Ciechanowski, PS Russo, JE Spertus, JA Soine, LA Jordan-Keith, K Caldwell, JH AF Sullivan, Mark D. Ciechanowski, Paul S. Russo, Joan E. Spertus, John A. Soine, Laurie A. Jordan-Keith, Kier Caldwell, James H. TI Angina pectoris during daily activities and exercise stress testing: The role of inducible myocardial ischemia and psychological distress SO PAIN LA English DT Article DE Health status; Quality of life; Coronary heart disease; Depression; Anxiety; Somatization; Symptoms; Chest pain; Visceral pain ID CORONARY-ARTERY-DISEASE; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED TRIAL; CHRONIC REFRACTORY ANGINA; COPING STRATEGIES; CHEST-PAIN; INTERVENTION; INVENTORY; MORTALITY; ANXIETY AB Physicians often consider angina pectoris to be synonymous with myocardial ischemia. However, the relationship between angina and myocardial ischemia is highly variable and we have little insight into the Sources of this variability. We investigated the relationship of inducible myocardial ischemia oil SPECT stress perfusion imaging to angina reported with routine daily activities during the previous four weeks (N = 788) and to angina reported during an exercise stress test (N = 371) in individuals with confirmed or Suspected coronary disease referred for clinical testing. We found that angina experienced during daily lire is more strongly and consistently associated with psychological distress and the personal threat associated with angina than with inducible myocardial ischemia. In multivariable models, the presence of any angina during routine activities over the prior month was significantly associated with age, perceived risk of myocardial infarction, and anxiety when compared to those with no reported angina in the past month. Angina during daily life was not significantly associated with inducible myocardial ischemia oil stress perfusion imaging in bivariate or multivariable models. In contrast, angina experienced during exercise stress testing was significantly related to image and ECG ischemia, though it was also significantly associated with anxiety. These results suggest that angina frequency over the previous four weeks is more strongly associated with personal threat and psychosocial distress than with inducible myocardial ischemia. These results lend support to angina treatment strategies that aim to reduce threat and distress as well as to reduce myocardial ischemia. (C) 2008 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Sullivan, Mark D.; Ciechanowski, Paul S.; Russo, Joan E.; Soine, Laurie A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Div Consultat Liaison Psychiat, Seattle, WA 98195 USA. [Spertus, John A.] Univ Missouri, Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Jordan-Keith, Kier; Caldwell, James H.] VA Puget Sound Hlth Care Syst, Dept Cardiol, Seattle, WA USA. [Caldwell, James H.] Univ Washington, Dept Med, Div Cardiol, Seattle, WA 98195 USA. [Caldwell, James H.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. RP Sullivan, MD (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Div Consultat Liaison Psychiat, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA. EM sullimar@u.washington.edu FU American Heart Association [0450094Z] FX Dr. Sullivan thanks the American Heart Association For the grant that supported this research 0450094Z. The authors have no conflicts of interest to report. NR 55 TC 2 Z9 2 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD OCT 31 PY 2008 VL 139 IS 3 BP 551 EP 561 DI 10.1016/j.pain.2008.06.009 PG 11 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 372IG UT WOS:000260894700010 PM 18694624 ER PT J AU Ross, JS Nunez-Smith, M Forsyth, BA Rosenbaum, JR AF Ross, Joseph S. Nunez-Smith, Marcella Forsyth, Beverly A. Rosenbaum, Julie R. TI Racial and ethnic differences in personal cervical cancer screening amongst post-graduate physicians: Results from a cross-sectional survey SO BMC PUBLIC HEALTH LA English DT Article ID UNITED-STATES; HEALTH-SERVICES; NATIONAL-SURVEY; HISPANIC WOMEN; CARE; BEHAVIORS; AMERICAN; BREAST; DISPARITIES; POPULATION AB Background: Racial and ethnic disparities in cervical cancer screening have been attributed to socioeconomic, insurance, and cultural differences. Our objective was to explore racial and ethnic differences in adherence to cervical cancer screening recommendations among female post-graduate physicians. Methods: We conducted a cross-sectional survey at one university hospital among a convenience sample of 204 female post-graduate physicians (52% of all potential participants), examining adherence to United States Preventive Services Task Force cervical cancer screening recommendations, perception of adherence to recommendations, and barriers to obtaining care. Results: Overall, 83% of women were adherent to screening recommendations and 84% accurately perceived adherence or non-adherence. Women who self-identified as Asian were significantly less adherent when compared with women who self-identified as white (69% vs. 87%; Relative Risk [RR] = 0.79, 95% Confidence Interval [CI], 0.64-0.97; P < 0.01). Women who self-identified as East Indian were significantly less likely to accurately perceive adherence or non-adherence when compared to women who self-identified as white (64% vs. 88%; RR = 0.73, 95% CI, 0.49-1.09, P = 0.04). Women who self-identified as Asian were significantly more likely to report any barrier to obtaining care when compared with women who self-identified as white (60% vs. 35%; RR = 1.75, 95% CI, 1.24-2.47; P = 0.001) and there was a nonsignificant tendency toward women who self-identified as East Indian being more likely to report any barrier to obtaining care when compared with women who self-identified as white (60% vs. 34%; RR = 1.74, 95% CI, 1.06-2.83; P = 0.06). Conclusion: Among a small group of insured, highly-educated physicians who have access to health care, we found racial and ethnic differences in adherence to cervical cancer screening recommendations, suggesting that culture may play a role in cervical cancer screening. C1 [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, HSR&D Targeted Res Enhancement Program, Bronx, NY USA. [Nunez-Smith, Marcella] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA. [Forsyth, Beverly A.] Mt Sinai Sch Med, Dept Med, Div Infect Dis, Bronx, NY USA. [Rosenbaum, Julie R.] Yale Univ, Sch Med, Primary Care Internal Med Residency Program, New Haven, CT USA. [Rosenbaum, Julie R.] Waterbury Hosp & Hlth Ctr, Ctr Hlth, Dept Med, New Haven, CT USA. RP Ross, JS (reprint author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Bronx, NY USA. EM joseph.ross@mssm.edu; marcella.nunez-smith@yale.edu; beverly.a.forsyth@mssm.edu; julie.rosenbaum@yale.edu NR 29 TC 6 Z9 6 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD OCT 30 PY 2008 VL 8 AR 378 DI 10.1186/1471-2458-8-378 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 379PP UT WOS:000261409000001 PM 18973674 ER PT J AU Rodrigues, GR Walker, RH Bader, B Danek, A Marques, W Tumas, V AF Rodrigues, Guilherme Riccioppo Walker, Ruth H. Bader, Benedikt Danek, Adrian Marques, Wilson, Jr. Tumas, Vitor TI Chorea-Acanthocytosis: Report of Two Brazilian Cases SO MOVEMENT DISORDERS LA English DT Article DE Chorea-acanthocytosis ID PROTEIN; GENE AB Chorea-acanthocytosis (ChAc) is a neurodegenerative disorder characterized by chorea, neuropsychiatric disturbances and acanthocytosis, caused by mutations of VPS13A. This gene produces the protein chorein which is absent in patients with ChAc on Western blot assay. We report the first two Brazilian patients with ChAc confirmed by chorein detection. Patient I is a 36-year-old man with chorea, epilepsy, myopathy. and suicidal ideation. Patient 2 is a 60-year-old woman with a 30 Year history of psychiatric disturbances, epilepsy, choreic movements, and myopathy. Both patients had acanthocytosis, elevated creatine kinase (CK), and absence (of chorein on Western blot analysis. The presence of chorea and neuropsychiatric disturbances associated with elevated CK levels, epilepsy, hyporeflexia, and acanthocytosis suggests the diagnosis of ChAc. Chorein assay of peripheral blood confirms the diagnosis. (C) 2008 Movement Disorder Society C1 [Rodrigues, Guilherme Riccioppo; Marques, Wilson, Jr.; Tumas, Vitor] Ribeirao Preto Sch Med, Dept Neurol, BR-14049900 Ribeirao Preto, Brazil. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA. [Bader, Benedikt; Danek, Adrian] Univ Munich, Dept Neurol, D-8000 Munich, Germany. RP Tumas, V (reprint author), Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Neurol Psychiat & Med Psychol, Campus Univ, BR-14049900 Ribeirao Preto, Brazil. EM tumasv@rnp.fmrp.usp.br RI Rodrigues, Guilherme/D-3547-2009; Danek, Adrian/G-7339-2011; Marques, Wilson/G-4240-2012; Tumas, Vitor/C-9949-2014 OI Rodrigues, Guilherme/0000-0002-4296-1016; Danek, Adrian/0000-0001-8857-5383; Marques, Wilson/0000-0002-4589-2749; NR 10 TC 6 Z9 6 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD OCT 30 PY 2008 VL 23 IS 14 BP 2090 EP 2093 DI 10.1002/mds.22305 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 374DA UT WOS:000261021500020 PM 18785241 ER PT J AU Palevsky, PM Zhang, JHY O'Connor, TZ AF Palevsky, Paul M. Zhang, Jane Hongyuan O'Connor, Theresa Z. CA VA-NIH Acute Renal Failure Trial N TI Renal support in critically ill patients with acute kidney injury - Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID INTERMITTENT HEMODIALYSIS; FAILURE; DIALYSIS; TRIAL C1 [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Zhang, Jane Hongyuan; O'Connor, Theresa Z.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu NR 5 TC 3 Z9 3 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 30 PY 2008 VL 359 IS 18 BP 1961 EP 1962 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 366BL UT WOS:000260454500020 ER PT J AU Bradley, SM Gabriel, EE Aufderheide, TP Barnes, R Christenson, J Davis, DP Stiell, IG Nichol, G AF Bradley, Steven M. Gabriel, Erin E. Aufderheide, Tom P. Barnes, Roxy Christenson, Jim Davis, Daniel P. Stiell, Ian G. Nichol, Graham CA Resuscitation Outcomes Consortium TI Survival Increases with CPR Before Defibrillation of Out-of-Hospital Ventricular Fibrillation or Ventricular Tachycardia: Observations from the Resuscitation Outcomes Consortium SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Bradley, Steven M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Gabriel, Erin E.; Nichol, Graham] Univ Washington, Seattle, WA 98195 USA. [Aufderheide, Tom P.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Barnes, Roxy] Vancouver Fire Dept, Vancouver, WA USA. [Christenson, Jim] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Davis, Daniel P.] Univ Calif San Diego, San Diego, CA 92103 USA. [Stiell, Ian G.] Univ Ottawa, Ottawa, ON, Canada. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S1445 EP S1445 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104504664 ER PT J AU Dewland, TA Pellegrini, CN Wang, YF Marcus, GM Varosy, PD AF Dewland, Thomas A. Pellegrini, Cara N. Wang, Yongfei Marcus, Gregory M. Varosy, Paul D. TI Dual Chamber ICD Selection is Associated with Racial and Socioeconomic Disparities and Increased Complication Rates Among Patients Enrolled in the NCDR ICD Registry SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Dewland, Thomas A.; Pellegrini, Cara N.; Marcus, Gregory M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wang, Yongfei] Yale Univ, Sch Med, New Haven, CT USA. [Varosy, Paul D.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S834 EP S835 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104503055 ER PT J AU Goebel, JR Doering, LV Shugarman, LR Asch, SM Sherbourne, CD Lanto, AB Evangelista, LS Nyamathi, AM Maliski, SL Lorenz, KA AF Goebel, Joy R. Doering, Lynn V. Shugarman, Lisa R. Asch, Steven M. Sherbourne, Cathy D. Lanto, Andy B. Evangelista, Lorraine S. Nyamathi, Adeline M. Maliski, Sally L. Lorenz, Karl A. TI Heart Failure, the Hidden Problem of Pain SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Goebel, Joy R.] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Doering, Lynn V.; Asch, Steven M.; Evangelista, Lorraine S.; Nyamathi, Adeline M.; Maliski, Sally L.; Lorenz, Karl A.] Univ Calif Los Angeles, Los Angeles, CA USA. [Shugarman, Lisa R.; Sherbourne, Cathy D.] RAND Corp, Santa Monica, CA USA. [Lanto, Andy B.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S823 EP S824 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104503011 ER PT J AU Ho, PM Maddox, TM Wang, L Fihn, SD Jesse, RL Peterson, ED Rumsfeld, JS AF Ho, P. Michael Maddox, Thomas M. Wang, Li Fihn, Stephan D. Jesse, Robert L. Peterson, Eric D. Rumsfeld, John S. TI Proton Pump Inhibitors May Attenuate the Benefits of Clopidogrel among ACS Patients: Empirical Evidence from 3,311 ACS Patients SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.] Denver Va Med Ctr, Denver, CO USA. [Wang, Li; Fihn, Stephan D.] Puget Sound VA Med Cntr, Seattle, WA USA. [Jesse, Robert L.] Richmond VA Med Cntr, Richmond, VA USA. [Peterson, Eric D.] Duke Clin Rsch Inst, Durham, NC USA. NR 0 TC 3 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S1165 EP S1165 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104504623 ER PT J AU Jacobson, AF AF Jacobson, Arnold F. TI Impact of Right Ventricular Function on Long-term Survival of Patients with Left Ventricular Dysfunction SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Jacobson, Arnold F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S953 EP S953 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104503529 ER PT J AU Kolm, P Jiang, XZ Spertus, JA Maron, DJ O'Rourke, R Teo, KK Zhang, W Boden, WE Weintraub, WS AF Kolm, Paul Jiang, Xiaozhang Spertus, John A. Maron, David J. O'Rourke, Robert Teo, Koon K. Zhang, Wei Boden, William E. Weintraub, William S. TI Baseline Physical Limitation is Related to Death and MI in the COURAGE Trial SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Kolm, Paul; Jiang, Xiaozhang; Zhang, Wei; Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Maron, David J.] Vanderbilt Univ Med Cntr, Nashville, TN USA. [O'Rourke, Robert] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Teo, Koon K.] McMaster Univ, Med Ctr, Hamilton, ON, Canada. [Boden, William E.] Buffalo Gen Hosp, Buffalo, NY 14203 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S1162 EP S1162 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104504610 ER PT J AU Mehta, RH Sheng, S O'Brien, SM Gammie, JS Grover, FL Ferguson, TB Peterson, ED AF Mehta, Rajendra H. Sheng, Shubin O'Brien, Sean M. Gammie, James S. Grover, Frederick L. Ferguson, T. Bruce, Jr. Peterson, Eric D. CA Soc Thoracic Surg Natl Cardiac Dat TI Reoperation for Bleeding among 528,279 Patients Undergoing Coronary Artery Bypass Surgery: The Society of Thoracic Surgeons National Database Experience SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Mehta, Rajendra H.; Sheng, Shubin; O'Brien, Sean M.; Peterson, Eric D.] Duke Clin Rsch Inst, Durham, NC USA. [Gammie, James S.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. [Grover, Frederick L.] Denver VA Med Ctr, Denver, CO USA. [Grover, Frederick L.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Ferguson, T. Bruce, Jr.] E Carolina Univ, Brodie Sch Med, Greenville, NC USA. RI O'Brien, Sean/H-6268-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S940 EP S940 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104503477 ER PT J AU Wang, T Peterson, ED Ou, FS Nallamothu, BK Rumsfeld, JS Roe, MT AF Wang, Tracy Peterson, Eric D. Ou, Fang-Shu Nallamothu, Brahmajee K. Rumsfeld, John S. Roe, Matthew T. TI Do Hospitals that Improve "Direct Arrival" Door to Balloon Times for Primary Percutaneous Coronary Intervention Also Improve "Transfer In" Door to Balloon Times? SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Wang, Tracy; Peterson, Eric D.; Ou, Fang-Shu; Roe, Matthew T.] Duke Univ, Durham, NC USA. [Nallamothu, Brahmajee K.] Univ Michigan, Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA. [Rumsfeld, John S.] Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S1108 EP S1108 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104504400 ER PT J AU Zahid, M Good, CB Sonel, AF AF Zahid, Maliha Good, Chester B. Sonel, Ali F. TI Clinical Significance of Borderline Elevated Troponin-1 Levels Across Different Assays SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Zahid, Maliha] Univ Pittsburgh, Pittsburgh, PA USA. [Good, Chester B.; Sonel, Ali F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S636 EP S636 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104502015 ER PT J AU Zhao, XH Cai, JM Underhill, H OiKawa, M Dong, L Ota, H Hatsukami, T Yuan, C AF Zhao, Xihai Cai, Jianming Underhill, Hunter OiKawa, Minako Dong, Li Ota, Hideki Hatsukami, Thomas Yuan, Chun TI Prevalence of Carotid Atherosclerotic Plaque Composition and Surface Disruption for Different Categories of Normalized Wall Index as Measured by Magnetic Resonance Imaging SO CIRCULATION LA English DT Meeting Abstract CT 81st Annual Scientific Session of the American-Heart-Association CY NOV 08-12, 2008 CL New Orleans, LA SP Amer Heart Assoc C1 [Zhao, Xihai; Underhill, Hunter; OiKawa, Minako; Dong, Li; Ota, Hideki; Yuan, Chun] Univ Washington, Seattle, WA 98195 USA. [Cai, Jianming] Peoples Liberat Army Gen Hosp, Beijing, Peoples R China. [Hatsukami, Thomas] VA Puget Sound Healthcare Syst, Seattle, WA USA. RI Ota, Hideki/A-3717-2012 OI Ota, Hideki/0000-0002-7239-3152 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 28 PY 2008 VL 118 IS 18 BP S688 EP S688 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 389ON UT WOS:000262104502220 ER PT J AU Joos, B Fischer, M Kuster, H Pillai, SK Wong, JK Boni, J Hirschel, B Weber, R Trkola, A Gunthard, HF AF Joos, Beda Fischer, Marek Kuster, Herbert Pillai, Satish K. Wong, Joseph K. Boeni, Juerg Hirschel, Bernard Weber, Rainer Trkola, Alexandra Guenthard, Huldrych F. CA Swiss HIV Cohort Study TI HIV rebounds from latently infected cells, rather than from continuing low-level replication SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE HIV-1; latent reservoir; structured treatment interruption; viral diversity; coreceptor usage ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; STRUCTURED TREATMENT INTERRUPTIONS; IN-VIVO; PLASMA VIREMIA; INTRINSIC STABILITY; CELLULAR RESERVOIRS; TYPE-1 REPLICATION; VIRAL CONTROL; T-CELLS AB Rapid rebound of plasma viremia in patients after interruption of long-term combination antiretroviral therapy (cART) suggests persistence of low-level replicating cells or rapid reactivation of latently infected cells. To further characterize rebounding virus, we performed extensive longitudinal clonal evolutionary studies of HIV env C2-V3-C3 regions and exploited the temporal relationships of rebounding plasma viruses with regard to pretreatment sequences in 20 chronically HIV-1-infected patients having undergone multiple 2-week structured treatment interruptions (STI). Rebounding virus during the short STI was homogeneous, suggesting mono- or oligoclonal origin during reactivation. No evidence for a temporal structure of rebounding virus in regard to pretreatment sequences was found. Furthermore, expansion of distinct lineages at different STI cycles emerged. Together, these findings imply stochastic reactivation of different clones from long-lived latently infected cells rather than expansion of viral populations replicating at low levels. After treatment was stopped, diversity increased steadily, but pretreatment diversity was, on average, achieved only >2.5 years after the start of STI when marked divergence from preexisting quasispecies also emerged. In summary, our results argue against persistence of ongoing low-level replication in patients on suppressive cART. Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy. C1 [Joos, Beda; Fischer, Marek; Kuster, Herbert; Weber, Rainer; Trkola, Alexandra; Guenthard, Huldrych F.] Univ Zurich Hosp, Div Infect Dis, Dept Med, CH-8091 Zurich, Switzerland. [Joos, Beda; Fischer, Marek; Kuster, Herbert; Weber, Rainer; Trkola, Alexandra; Guenthard, Huldrych F.] Univ Zurich Hosp, Hosp Epidemiol, CH-8091 Zurich, Switzerland. [Pillai, Satish K.; Wong, Joseph K.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Boeni, Juerg] Univ Zurich, Natl Ctr Retroviruses, CH-8028 Zurich, Switzerland. [Hirschel, Bernard] Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland. RP Joos, B (reprint author), Univ Zurich Hosp, Div Infect Dis, Dept Med, CH-8091 Zurich, Switzerland. EM beda.joos@usz.ch; huldrych.guenthard@usz.ch RI gunthard, huldrych/F-1724-2011; Trkola, Alexandra/K-2115-2012; Joos, Beda/D-5547-2009; Kuster, Herbert/A-3912-2013; Infektiologie, USZ/A-6921-2011; SHCS, all/G-4072-2011; SHCS, ch/G-4077-2011; SHCS, only/G-4080-2011; Weber, Rainer/D-5175-2012; Pantaleo, Giuseppe/K-6163-2016 OI gunthard, huldrych/0000-0002-1142-6723; Trkola, Alexandra/0000-0003-1013-876X; Joos, Beda/0000-0002-3082-8875; FU Swiss National Science Foundation (SNF) [3345-65168, 3100AO-103748/1, PP00B-102647, 320000-116035]; Swiss HIV Cohort Study (SHCS) [290]; SNF [33CSC0-10878]; EMDO Foundation; Elizabeth Glaser Pediatric AIDS Foundation; National Institutes of Health [R01 NS51132] FX We thank the participating patients for their commitment; Christine Schneider, Christina Grube, and Roland Hafner for excellent patient care; Esther Beerli, Friederike Burgener, Christine Leemann, Tuyet Trinh Lu, Barbara Niederost, and Barbel Sauer for laboratory support; and Ingrid Nievergelt and Christine Vogtli for administrative assistance. This work was supported by Swiss National Science Foundation (SNF) Grants 3345-65168 and 3100AO-103748/1 (to H.F.G. and A.T.), PP00B-102647 (to A.T.), and 320000-116035 (to H.F.G.); the Swiss HIV Cohort Study (SHCS) (SNF Grant 33CSC0-10878) SHCS Project No. 290 (to H.F.G.); a grant from the EMDO Foundation (to H.F.G., and a research grant from the Kanton of Zurich. A.T. is the Elizabeth Glaser Scientist supported by the Elizabeth Glaser Pediatric AIDS Foundation. J.K.W. was supported by National Institutes of Health Grant R01 NS51132. NR 62 TC 151 Z9 152 U1 1 U2 5 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD OCT 28 PY 2008 VL 105 IS 43 BP 16725 EP 16730 DI 10.1073/pnas.0804192105 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 372PM UT WOS:000260913500058 PM 18936487 ER PT J AU Ganzini, L Goy, ER Dobscha, SK AF Ganzini, Linda Goy, Elizabeth R. Dobscha, Steven K. TI Prevalence of depression and anxiety in patients requesting physicians' aid in dying: cross sectional survey SO BRITISH MEDICAL JOURNAL LA English DT Article ID MENTAL STATUS QUESTIONNAIRE; REDUCING SUICIDAL IDEATION; TERMINALLY-ILL PATIENTS; PRIMARY-CARE PATIENTS; ASSISTED SUICIDE; HASTENED DEATH; OLDER PATIENTS; CANCER; HOPELESSNESS; DESIRE AB Objective To determine the prevalence of depression and anxiety in terminally ill patients pursuing aid in dying from physicians. Design Cross sectional survey. Setting State of Oregon, USA. Participants 58 Oregonians, most terminally ill with cancer or amyotrophic lateral sclerosis, who had either requested aid in dying from a physician or contacted an aid in dying advocacy organisation. Main outcome measures Diagnosis of depression or anxiety according to the hospital anxiety and depression scale and the structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders. Results 15 study participants met "caseness" criteria for depression, and 13 met criteria for anxiety. 42 patients died by the end of the study; 18 received a prescription fora lethal drug under the Death with Dignity Act, and nine died by lethal ingestion. 15 participants who received a prescription for a lethal drug did not meet criteria for depression; three did. All three depressed participants died by legal ingestion within two months of the research interview. Conclusion Although most terminally ill Oregonians who receive aid in dying do not have depressive disorders, the current practice of the Death with Dignity Act may fail to protect some patients whose choices are influenced by depression from receiving a prescription for a lethal drug. C1 [Ganzini, Linda; Goy, Elizabeth R.; Dobscha, Steven K.] Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Mental & Phys D, Hlth Serv Res & Dev, Portland, OR 97239 USA. [Ganzini, Linda; Goy, Elizabeth R.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Mental & Phys D, Hlth Serv Res & Dev, POB 1034, Portland, OR 97239 USA. EM Linda.Ganzini@va.gov FU Northwest Health Foundation FX Northwest Health Foundation. The funding source had no role in any aspect of the study or this paper. NR 37 TC 50 Z9 50 U1 2 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD OCT 25 PY 2008 VL 337 IS 7676 AR a1682 DI 10.1136/bmj.a1682 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 363WS UT WOS:000260298800034 PM 18842645 ER PT J AU Reyes, CV Jensen, JD AF Reyes, Cesar V. Jensen, Joanne D. TI On-Site Evaluation of Bronchial Brushing cytology SO CANCER CYTOPATHOLOGY LA English DT Meeting Abstract C1 [Reyes, Cesar V.] Morris Hosp, Morris, IL USA. [Reyes, Cesar V.] Vet Affairs Edward Hines Jr Hosp, Morris, IL USA. [Jensen, Joanne D.] Morris Hosp, Hines, IL USA. [Jensen, Joanne D.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD OCT 25 PY 2008 VL 114 IS 5 SU S BP 408 EP 408 PG 1 WC Oncology; Pathology SC Oncology; Pathology GA 361PY UT WOS:000260140800103 ER PT J AU Offner, H AF Offner, Halina TI Immunoregulatory and neuroprotective effect of sex steroids on EAE and MS SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Meeting Abstract C1 [Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Offner, Halina] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD OCT 25 PY 2008 VL 203 IS 2 BP 205 EP 206 PG 2 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 377SJ UT WOS:000261270600220 ER PT J AU Bhattacharya, D Hoover, S Falk, SP Weisblum, B Vestling, M Striker, R AF Bhattacharya, Dipankar Hoover, Spencer Falk, Shaun P. Weisblum, Bernard Vestling, Martha Striker, Rob TI Phosphorylation of yellow fever virus NS5 alters methyltransferase activity SO VIROLOGY LA English DT Article DE Phosphorylation; Methyltransferase; RNA cap; Flavivirus ID RNA CAP; CRYSTAL-STRUCTURE; PROTEINS; SEQUENCE; SUBSTRATE; TRANSCOMPLEMENTATION; HYPERPHOSPHORYLATION; TRANSCRIPTION; METHYLATIONS; REPLICATION AB Serine/threonine phosphorylation of the nonstructural protein 5 (NS5) is conserved feature of flaviviruses, but the kinase(s) responsible and function(s) remain unknown. Mass spectrometry was used to characterize phosphorylated residues of yellow fever virus (YFV) NS5 expressed in mammalian cells. Multiple different phosphopeptides were detected. Mutational and additional mass spectrometry data implicated serine 56 (S56), a conserved residue near the active site in the NS5 methyltransferase domain, as one of the phosphorylation sites. Methyltransferase activity is required to form a methylated RNA cap structure and for translation of the YFV polyprotein. We show the 2'-O methylation reaction requires the hydroxyl side chain of S56, and replacement with a negative charge inhibits enzymatic activity. Furthermore mutational alteration of S56, S56A or S56D, prevents amplification in a viral replicon system. Collectively our data suggest phosphorylation of NS5 S56 may act to shut down capping in the viral life cycle. Published by Elsevier Inc. C1 [Bhattacharya, Dipankar; Hoover, Spencer; Striker, Rob] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Falk, Shaun P.; Weisblum, Bernard] Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA. [Vestling, Martha] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA. [Striker, Rob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Striker, R (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA. EM rtstriker@wisc.edu FU NIH/NIAID Regional Center of Excellence FX This work was sponsored by the NIH/NIAID Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) Program. The authors wish to acknowledge membership within and support from the Region V 'Great Lakes' RCE (NIH award 1-U54-AI-057153). We thank the UW Madison Biotechnology mass spectrometry facility and the Human Proteomics Mass Spectrometry Facility supported by the "The Wisconsin Partnership Fund for a Healthy Future" for technical assistance. We also thank Janet Smith and Richard Kuhn for helpful discussions, and Deane Mosher for comments on drafts of this manuscript. NR 35 TC 19 Z9 19 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT 25 PY 2008 VL 380 IS 2 BP 276 EP 284 DI 10.1016/j.virol.2008.07.013 PG 9 WC Virology SC Virology GA 361SW UT WOS:000260148400013 PM 18757072 ER PT J AU Chudakova, DA Zeidan, YH Wheeler, BW Yu, J Novgorodov, SA Kindy, MS Hannun, YA Gudz, TI AF Chudakova, Daria A. Zeidan, Youssef H. Wheeler, Brian W. Yu, Jin Novgorodov, Sergei A. Kindy, Mark S. Hannun, Yusuf A. Gudz, Tatyana I. TI Integrin-associated Lyn Kinase Promotes Cell Survival by Suppressing Acid Sphingomyelinase Activity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SRC FAMILY KINASES; OLIGODENDROCYTE PROGENITOR MIGRATION; CYTOPLASMIC DOMAIN; CEREBRAL-ISCHEMIA; TYROSINE KINASES; SALVAGE PATHWAY; FACTOR RECEPTOR; BRAIN-INJURY; C-DELTA; CERAMIDE AB Integrins govern cellular adhesion and transmit signals leading to activation of intracellular signaling pathways aimed to prevent apoptosis. Herein we report that attachment of oligodendrocytes (OLs) to fibronectin via alpha(v)beta(3) integrin receptors rendered the cells more resistant to apoptosis than the cells attached to laminin via alpha(6)beta(1) integrins. Investigation of molecular mechanisms involved in alpha(v)beta(3) integrin-mediated cell survival revealed that ligation of the integrin with fibronectin results in higher expression of activated Lyn kinase. Both in OLs and in the mouse brain, Lyn selectively associates with alpha(v)beta(3) integrin, not with alpha(v)beta(5) integrin, leading to suppression of acid sphingomyelinase activity and preventing ceramide-mediated apoptosis. In OLs, knockdown of Lyn with small interfering RNA resulted in OL apoptosis with concomitant accumulation of C-16-ceramide due to activation of acid sphingomyelinase (ASMase) and sphingomyelin hydrolysis. Knocking down ASMase partially protected OLs from apoptosis. In the brain, ischemia/reperfusion (IR) triggered rearrangements in the alpha(v)beta(3) integrin-Lyn kinase complex leading to disruption of Lyn kinase-mediated suppression of ASMase activity. Thus, co-immunoprecipitation studies revealed an increased association of alpha(v)beta(3) integrin-Lyn kinase complex with ionotropic glutamate receptor subunits, GluR2 and GluR4, after cerebral IR. Sphingolipid analysis of the brain demonstrated significant accumulation of ceramide and sphingomyelin hydrolysis. The data suggest a novel mechanism for regulation of ASMase activity during cell adhesion in which Lyn acts as a key upstream kinase that may play a critical role in cerebral IR injury. C1 [Chudakova, Daria A.; Wheeler, Brian W.; Yu, Jin; Kindy, Mark S.; Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.; Gudz, Tatyana I.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Novgorodov, Sergei A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Zeidan, Youssef H.; Novgorodov, Sergei A.; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Gudz, TI (reprint author), Med Univ S Carolina, Dept Neurosci, 114 Doughty St, Charleston, SC 29425 USA. EM gudz@musc.edu FU National Institutes of Health/NCCR COBRE in Lipidomics and Pathobiology [P20 RR 17677-04]; National Institutes of Health [P01-CA97132, AG16583]; National Science Foundation EPSCOR [EPS0132573]; Veterans Affairs Merit Awards FX This work was supported, in whole or in part, by National Institutes of Health/NCCR COBRE in Lipidomics and Pathobiology Grant P20 RR 17677-04 (to T. I. G.) and National Institutes of Health Grant P01-CA97132 (to Y.A.H.). This work was also supported by National Science Foundation EPSCOR Grant EPS0132573 (to M. S. K.), and Veterans Affairs Merit Awards (to T. I. G. and M. S. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.; Supported by National Institutes of Health Grant AG16583. NR 63 TC 23 Z9 24 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD OCT 24 PY 2008 VL 283 IS 43 BP 28806 EP 28816 DI 10.1074/jbc.M803301200 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 362EB UT WOS:000260179900005 PM 18682390 ER PT J AU Pierce, A Mirzaei, H Muller, F De Waal, E Taylor, AB Leonard, S Van Remmen, H Regnier, F Richardson, A Chaudhuri, A AF Pierce, Anson Mirzaei, Hamid Muller, Florian De Waal, Eric Taylor, Alexander B. Leonard, Shanique Van Remmen, Holly Regnier, Fred Richardson, Arlan Chaudhuri, Asish TI GAPDH Is Conformationally and Functionally Altered in Association with Oxidative Stress in Mouse Models of Amyotrophic Lateral Sclerosis SO JOURNAL OF MOLECULAR BIOLOGY LA English DT Article DE protein oxidation; amyotrophic lateral sclerosis; BisANS; protein unfolding; GAPDH ID MOTOR-NEURON DEGENERATION; COPPER-BINDING-SITE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SUPEROXIDE-DISMUTASE; PROTEIN OXIDATION; CREATINE-KINASE; SKELETAL-MUSCLE; TRANSGENIC MICE; SELECTIVE DEGRADATION; HYDROGEN-PEROXIDE AB It is proposed that conformational changes induced in proteins by oxidation can lead to loss of activity or protein aggregation through exposure of hydrophobic residues and alteration in surface hydrophobicity. Because increased oxidative stress and protein aggregation are consistently observed in amyotrophic lateral sclerosis (ALS), we used a 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid (BisANS) photolabeling approach to monitor changes in protein unfolding in vivo in skeletal muscle proteins in ALS mice. We find two major proteins, creatine kinase (CK) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), conformationally affected in the ALS G93A mouse model concordant with a 43% and 41% reduction in enzyme activity, respectively. This correlated with changes in conformation and activity that were detected in CK and GAPDH with in vitro oxidation. Interestingly, we found that GAPDH, but not CK, is conformationally and functionally affected in a longer-lived ALS model (H46R/H48Q), exhibiting a 22%, reduction in enzyme activity. We proposed a reaction mechanism for BisANS with nucleophilic amino acids Such as lysine, serine, threonine, and tyrosine, and BisANS was found to be primarily incorporated to lysine residues in GAPDH. We identified the specific BisANS incorporation sites on GAPDH in nontransgenic (NTg), G93A, and H46R/H48Q mice using liquid chromatography-tandem mass spectrometry analysis. Four BisANS-containing sites (K52, K104, K212, and K248) were found in NTg GAPDH, while three out of four of these sites were lost in either G93A or H46R/H48Q GAPDH. Conversely, eight new sites (K2, K63, K69, K114, K183, K251, S330, and K331) were found on GAPDH for G93A, including one common site (K114) for H46R/H48Q, which is not found on GAPDH from NTg mice. These data show that GAPDH is differentially affected structurally and functionally in vivo in accordance with the degree of oxidative stress associated with these two models of ALS. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Pierce, Anson; Muller, Florian; Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Mirzaei, Hamid; Regnier, Fred] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA. [De Waal, Eric; Taylor, Alexander B.; Chaudhuri, Asish] Univ Texas San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Leonard, Shanique; Van Remmen, Holly; Richardson, Arlan; Chaudhuri, Asish] Univ Texas San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Van Remmen, Holly; Richardson, Arlan; Chaudhuri, Asish] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. [Taylor, Alexander B.] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. RP Chaudhuri, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM Chaudhuria@uthscsa.edu RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 FU Veterans Affairs (VA)-Veterans Integrated Service Network; Amyotrophic Lateral Sclerosis Association; VA Merit; MDA 3879; National Institutes of Health [AG025362, AG23843, R37 AG26557]; Department of VA; VA CDA-2 FX We would like to thank Dr. David Borchelt for kindly providing us with the H46R/H48Q mice for use in this study. We would also like to thank Dr. Susan Weintraub and the Mass Spectrometry Core for access to their facility and tlieir assistance in the identification of proteins by MALDI-TOF MS. This work was supported by Veterans Affairs (VA)-Veterans Integrated Service Network, Amyotrophic Lateral Sclerosis Association, and VA Merit grants (A.C.); VA Merit and MDA 3879 (H.V.R.); National Institutes of Health grant AG025362 (F.R. and H.V.R.); National Institutes of Health grants AG23843 and R37 AG26557 (A.R.); a Research Enhancement Award Program grant from the Department of VA (to A.R., H.V.R., and A.C.); and a VA CDA-2 grant (to A.P.). NR 51 TC 44 Z9 45 U1 1 U2 8 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2836 EI 1089-8638 J9 J MOL BIOL JI J. Mol. Biol. PD OCT 24 PY 2008 VL 382 IS 5 BP 1195 EP 1210 DI 10.1016/j.jmb.2008.07.088 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 363LY UT WOS:000260270000009 PM 18706911 ER PT J AU Gillespie, K Kodani, I Dickinson, DP Ogbureke, KUE Camba, AM Wu, MJ Looney, S Chu, TC Qin, HY Bisch, F Sharawy, M Schuster, GS Hsu, SD AF Gillespie, Kevin Kodani, Isamu Dickinson, Douglas P. Ogbureke, Kalu U. E. Camba, Amy M. Wu, Mengjie Looney, Stephen Chu, Tin-Chun Qin, Haiyan Bisch, Frederick Sharawy, Mohamed Schuster, George S. Hsu, Stephen D. TI Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease SO LIFE SCIENCES LA English DT Article DE Sjogren's syndrome; Green tea; EGCG; Autoimmune disease; Non-obese diabetic mice ID SALIVARY-GLAND; CELLS; PATHOGENESIS; EXPRESSION; THERAPIES AB Significance: Protection of glandular cells from autoimmune-induced damage would be of significant clinical benefit to Sjogren's syndrome (SS) patients. Epigallocatechin-3-gallate (EGCG) possesses anti-apoptotic, anti-inflammatory, and autoantigen-inhibitory properties. Aims: To investigate if EGCG protects against certain autoimmune-induced pathological changes in the salivary glands of the non-obese diabetic (NOD) mouse model for SS. Main methods: Animals were provided with either water or water containing 0.2% EGCG. At the age of 8,16 and 22 weeks, submandibular salivary gland tissue and serum samples were collected for pathological and serological analysis. Key findings: Significant lymphocyte infiltration was observed in the salivary glands of the water-fed group at the age of 16 weeks, while the EGCG group showed reduced lymphocyte infiltration. By 22 weeks of age, water-fed animals demonstrated elevated levels of apoptotic activity within the lymphocytic infiltrates, and high levels of serum total anti-nuclear antibody, compared to EGCG-fed animals. Remarkably, proliferating cell nuclear antigen (PCNA) and Ki-67 levels in the salivary glands of water-fed NOD mice were significantly elevated in comparison to BALB/c control mice; in contrast, PCNA and Ki-67 levels in EGCC-fed NOD animals were similar to BALB/c mice. These results indicate that EGCG protects the NOD mouse submandibular glands from autoimmune-induced inflammation, and reduces serum autoantibody levels. Abnormal proliferation, rather than apoptosis, appears to be a characteristic of the NOD mouse gland that is normalized by EGCG. The evidence suggests that EGCG could be useful in delaying or managing SS-like autoimmune disorders. (C) 2008 Elsevier Inc. All rights reserved. C1 [Dickinson, Douglas P.; Ogbureke, Kalu U. E.; Camba, Amy M.; Looney, Stephen; Qin, Haiyan; Sharawy, Mohamed; Schuster, George S.; Hsu, Stephen D.] Med Coll Georgia, Sch Dent, Dept Oral Biol, Augusta, GA 30912 USA. [Gillespie, Kevin; Bisch, Frederick] USA, Dept Periodontol, Ft Gordon, GA USA. [Kodani, Isamu] Tottori Univ, Fac Med, Tottori Univ Hosp, Dept Oral & Maxillofacial Surg, Yonago, Tottori 683, Japan. [Wu, Mengjie] Zhejiang Univ, Sch Dent, Hosp Stomotol, Hangzhou 310003, Zhejiang, Peoples R China. [Chu, Tin-Chun] Seton Hall Univ, Coll Arts & Sci, Dept Biol Sci, S Orange, NJ USA. [Hsu, Stephen D.] US Dept Vet Affairs, VA Med Ctr, Augusta, GA USA. RP Hsu, SD (reprint author), Med Coll Georgia, Sch Dent, Dept Oral Biol, AD1443, Augusta, GA 30912 USA. EM shsu@mail.mcg.edu RI Dickinson, Douglas/B-9111-2009 OI Chu, Tinchun/0000-0002-6314-1009 FU MCG; US Army Periodontics; Department of Oral Biology; School of Dentistry FX The authors thank Ms. Vera B. Larke for her technical assistance. This study was supported in part by funds from a grant from MCG, a fund from US Army Periodontics, and from Department of Oral Biology, School of Dentistry to S.H. NR 28 TC 34 Z9 37 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-3205 J9 LIFE SCI JI Life Sci. PD OCT 24 PY 2008 VL 83 IS 17-18 BP 581 EP 588 DI 10.1016/j.lfs.2008.08.011 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 365JJ UT WOS:000260401700001 PM 18809413 ER PT J AU Pettigrew, LC Kindy, MS Scheff, S Springer, JE Kryscio, RJ Li, Y Grass, DS AF Pettigrew, L. Creed Kindy, Mark S. Scheff, Stephen Springer, Joe E. Kryscio, Richard J. Li, Yizhao Grass, David S. TI Focal cerebral ischemia in the TNFalpha-transgenic rat SO JOURNAL OF NEUROINFLAMMATION LA English DT Article ID TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; BRAIN-INJURY; PROINFLAMMATORY CYTOKINES; INDUCED APOPTOSIS; ARTERY OCCLUSION; FACTOR RECEPTOR; MICE LACKING; TNF-ALPHA; STROKE AB Background: To determine if chronic elevation of the inflammatory cytokine, tumor necrosis factor-alpha (TNF alpha), will affect infarct volume or cortical perfusion after focal cerebral ischemia. Methods: Transgenic (TNF alpha-Tg) rats overexpressing the murine TNF alpha gene in brain were prepared by injection of mouse DNA into rat oocytes. Brain levels of TNF alpha mRNA and protein were measured and compared between TNF alpha-Tg and non-transgenic (non-Tg) littermates. Mean infarct volume was calculated 24 hours or 7 days after one hour of reversible middle cerebral artery occlusion (MCAO). Cortical perfusion was monitored by laser-Doppler flowmetry (LDF) during MCAO. Cortical vascular density was quantified by stereology. Post-ischemic cell death was assessed by immunohistochemistry and regional measurement of caspase-3 activity or DNA fragmentation. Unpaired t tests or analysis of variance with post hoc tests were used for comparison of group means. Results: In TNF alpha-Tg rat brain, the aggregate mouse and rat TNF alpha mRNA level was fourfold higher than in non-Tg littermates and the corresponding TNF alpha protein level was increased fivefold (p <= 0.01). Infarct volume was greater in TNF alpha-Tg rats than in non-Tg controls at 24 hours (p <= 0.05) and 7 days (p <= 0.01). Within the first 10 minutes of MCAO, cortical perfusion measured by LDF was reduced in TNF alpha-Tg rats (p <= 0.05). However, regional vascular density was equivalent between TNF alpha-Tg and non-Tg animals (p = NS). Neural cellular apoptosis was increased in transgenic animals as shown by elevated caspase-3 activity (p = 0.05) and DNA fragmentation (p <= 0.001) at 24 hours. Conclusion: Chronic elevation of TNF alpha protein in brain increases susceptibility to ischemic injury but has no effect on vascular density. TNF alpha-Tg animals are more susceptible to apoptotic cell death after MCAO than are non-Tg animals. We conclude that the TNF alpha-Tg rat is a valuable new tool for the study of cytokine-mediated ischemic brain injury. C1 [Pettigrew, L. Creed; Scheff, Stephen] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. [Pettigrew, L. Creed] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA. [Pettigrew, L. Creed] Vet Adm Med Ctr, Lexington, KY 40511 USA. [Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Springer, Joe E.] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY 40536 USA. [Kryscio, Richard J.] Univ Kentucky, Dept Stat, Lexington, KY 40536 USA. [Kryscio, Richard J.] Univ Kentucky, Sch Publ Hlth, Lexington, KY 40536 USA. [Li, Yizhao] Jinan Great Wall Hosp, Jinan, Shandong, Peoples R China. [Grass, David S.] Xenogen Biosci, Cranbury, NJ USA. RP Pettigrew, LC (reprint author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. EM cpetti@uky.edu; kindyms@musc.edu; sscheff@email.uky.edu; joe.springer@uky.edu; kryscio@email.uky.edu; swillia@uky.edu; David.Grass@xenogen.com FU NIH/NINDS [R01 NS047395, R01 NS039588]; Shandong University, China FX Financial support was provided by NIH/NINDS grants R01 NS047395 (LCP) and R01 NS039588 (MSK) and by a Visiting Research Scientist Award provided by Shandong University, China (YL) for training at the University of Kentucky in Lexington, Kentucky. Dr. George Kollias prepared the microinjection construct containing the murine TNF alpha gene and its promoter that was used to make the transgenic animal. Mr. Richard Coffee constructed the animal at Xenogen Biosciences in Cranbury, New Jersey. We thank Mary Louise Holtz, Ph. D., Xaio-Hong Song, M. D., Susan D. Craddock, and Ravikumar Rao for technical contributions to this work and Sherry Chandler Williams, ELS, for editing the manuscript and preparing the illustrations. NR 48 TC 33 Z9 33 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD OCT 23 PY 2008 VL 5 AR 47 DI 10.1186/1742-2094-5-47 PG 19 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 371YZ UT WOS:000260869900001 PM 18947406 ER PT J AU Mehta, RH Liang, L Karve, AM Hernandez, AF Rumsfeld, JS Fonarow, GC Peterson, ED AF Mehta, Rajendra H. Liang, Li Karve, Amrita M. Hernandez, Adrian F. Rumsfeld, John S. Fonarow, Gregg C. Peterson, Eric D. TI Association of patient case-mix adjustment, hospital process performance rankings, and eligibility for financial incentives SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ACUTE CORONARY SYNDROMES; COOPERATIVE CARDIOVASCULAR PROJECT; ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; ELDERLY-PATIENTS; UNSTABLE ANGINA; HEALTH-CARE; DISPARITIES; CRUSADE; PREVENTION AB Context While most comparisons of hospital outcomes adjust for patient characteristics, process performance comparisons typically do not. Objective To evaluate the degree to which hospital process performance ratings and eligibility for financial incentives are altered after accounting for hospitals' patient demographics, clinical characteristics, and mix of treatment opportunities. Design, Setting, and Patients Using data from the American Heart Association's Get With the Guidelines program between January 2, 2000, and March 28, 2008, we analyzed hospital process performance based on the Centers for Medicare & Medicaid Services' defined core measures for acute myocardial infarction. Hospitals were initially ranked based on crude composite process performance and then ranked again after accounting for hospitals' patient demographics, clinical characteristics, and eligibility for measures using a hierarchical model. We then compared differences in hospital performance rankings and pay-for-performance financial incentive categories (top 20%, middle 60%, and bottom 20% institutions). Main Outcome Measures Hospital process performance ranking and pay-for-performance financial incentive categories. Results A total of 148 472 acute myocardial infarction patients met the study criteria from 449 centers. Hospitals for which crude composite acute myocardial infarction performance was in the bottom quintile (n=89) were smaller nonacademic institutions that treated a higher percentage of patients from racial or ethnic minority groups and also patients with greater comorbidities than hospitals ranked in the top quintile (n=90). Although there was overall agreement on hospital rankings based on observed vs adjusted composite scores (weighted kappa, 0.74), individual hospital ranking changed with adjustment (median, 22 ranks; range, 0-214; interquartile range, 9-40). Additionally, 16.5% of institutions (n=74) changed pay-for-performance financial status categories after accounting for patient and treatment opportunity mix. Conclusion Our findings suggest that accounting for hospital differences in patient characteristics and treatment opportunities is associated with modest changes in hospital performance rankings and eligibility for financial benefits in pay-for-performance programs for treatment of myocardial infarction. C1 [Mehta, Rajendra H.; Liang, Li; Karve, Amrita M.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC 27715 USA. [Mehta, Rajendra H.; Liang, Li; Karve, Amrita M.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Univ, Med Ctr, Durham, NC USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. RP Mehta, RH (reprint author), Duke Clin Res Inst, Box 17969, Durham, NC 27715 USA. EM mehta007@dcri.duke.edu RI Hernandez, Adrian F./A-7818-2016 OI Hernandez, Adrian F./0000-0003-3387-9616 FU GlaxoSmithKline; Medtronic; Merck; Pfizer; National Institutes of Health; AHA; American Heart Association Pharmaceutical Roundtable [0675060N]; Elliot Corday (Los Angeles, California) Foundation; Ahmanson (Los Angeles, California) Foundation FX Dr Hernandez reports receiving research support from GlaxoSmithKline, Johnson & Johnson (Scios Inc), Medtronic, Novartis, and Roche Diagnostics; and honoraria from AstraZeneca, Novartis, Sanofi-Aventis, and Thoratec Corporation. Dr Peterson reports receiving research support from Schering Plough, BMS/Sanofi; and serving as the principal investigator for the American Heart Association's (AHA's) Get With the Guidelines Analytical Center. Drs Hernandez and Peterson report detailed listings of financial disclosures at http://www.dcri.duke.edu/research/coi.jsp. Dr Rumsfeld reports receiving an honorariun for participating on the scientific research advisory board of United Healthcare. Dr Fonarow reports receiving research grants from GlaxoSmithKline, Medtronic, Merck, Pfizer, and the National Institutes of Health; consulting for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Merck, Novartis, Pfizer, Sanofi-Aventis, and Schering Plough; receiving honoraria from AstraZeneca, Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Merck, Novartis, Pfizer, Sanofi-Aventis, and Schering Plough; and serving as chair of the AHA's Get With the Guidelines Steering Committee. Drs Mehta and Liang and Ms Karve report no disclosures. The Get With the Guidelines program is supported by the AHA in part through an unrestricted education grant from Merck-Schering Plough. Dr Hernandez reports receiving support from an American Heart Association Pharmaceutical Roundtable grant 0675060N. Dr Fonarow reports receiving support from the Elliot Corday (Los Angeles, California) and Ahmanson (Los Angeles, California) Foundations. NR 30 TC 40 Z9 40 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 22 PY 2008 VL 300 IS 16 BP 1897 EP 1903 DI 10.1001/jama.300.16.1897 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 362UR UT WOS:000260223100019 PM 18940976 ER PT J AU Ross, JS Detsky, AS AF Ross, Joseph S. Detsky, Allan S. TI Comparison of the US and Canadian health care systems - A tale of 2 Mount Sinai's SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID UNITED-STATES; COUNTRIES C1 [Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada. [Detsky, Allan S.] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada. [Detsky, Allan S.] Univ Toronto, Dept Med & Hlth Policy, Toronto, ON, Canada. [Detsky, Allan S.] Univ Toronto, Dept Management, Toronto, ON, Canada. [Detsky, Allan S.] Univ Toronto, Dept Evaluat, Toronto, ON, Canada. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Detsky, AS (reprint author), Mt Sinai Hosp, Dept Med, 427-600 Univ Ave, Toronto, ON M5G 1X5, Canada. EM adetsky@mtsinai.on.ca NR 13 TC 6 Z9 6 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 22 PY 2008 VL 300 IS 16 BP 1934 EP 1936 DI 10.1001/jama.300.16.1934 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 362UR UT WOS:000260223100026 PM 18940983 ER PT J AU Hebert, PL Sisk, JE Wang, JJ Tuzzio, L Casabianca, JM Chassin, MR Horowitz, C McLaughlin, MA AF Hebert, Paul L. Sisk, Jane E. Wang, Jason J. Tuzzio, Leah Casabianca, Jodi M. Chassin, Mark R. Horowitz, Carol McLaughlin, Mary Ann TI Cost-Effectiveness of Nurse-Led Disease Management for Heart Failure in an Ethnically Diverse Urban Community SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED-TRIAL; SF-12; CARE; QUALITY; HEALTH; POPULATION; UTILITY; TRENDS; RISK AB Background: Randomized, controlled trials have shown that nurse-led disease management for patients with heart failure can reduce hospitalizations. Less is known about the cost-effectiveness of these interventions. Objective: To estimate the cost-effectiveness of a nurse-led disease management intervention over 12 months, implemented in a randomized, controlled effectiveness trial. Design: Cost-effectiveness analysis conducted alongside a randomized trial. Data Sources: Medical costs from administrative records, and self-reported quality of life and nonmedical costs from patient surveys. Participants: Patients with systolic dysfunction recruited from ambulatory clinics in Harlem, New York. Time Horizon: 12 months. Perspective: Societal and payer. Intervention: 12-month program that involved 1 face-to-face encounter with a nurse and regular telephone follow- up. Outcome Measures: Quality of life as measured by the Health Utilities Index Mark 3 and EuroQol-5D and cost-effectiveness as measured by the incremental cost-effectiveness ratio ( ICER). Results of Base-Case Analysis: Costs and quality of life were higher in the nurse-managed group than the usual care group. The ICERs over 12 months were $17 543 per EuroQol-5D-based quality-adjusted life-year ( QALY) and $15 169 per Health Utilities Index Mark 3-based QALY ( in 2001 U. S. dollars). Results of Sensitivity Analysis: From a payer perspective, the ICER ranged from $3673 to $4495 per QALY. Applying national prices in place of New York City prices yielded a societal ICER of $13 460 to $ 15 556 per QALY. Cost-effectiveness acceptability curves suggest that the intervention was most likely cost-effective for patients with less severe ( New York Heart Association classes I to II) heart failure. Limitation: The trial was conducted in an ethnically diverse, inner-city neighborhood; thus, results may not be generalizable to other communities. Conclusion: Over 12 months, the nurse-led disease management program was a reasonably cost-effective way to reduce the burden of heart failure in this community. C1 Univ Washington, Sch Publ Hlth & Community Med, Vet Adm Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. Mt Sinai Sch Med, New York, NY USA. Fordham Univ, Bronx, NY 10458 USA. Joint Commiss, Oak Brook Terrace, IL USA. RP Hebert, PL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Paul.Hebert2@va.gov FU Agency for Healthcare Research and Quality [R01 HS10402-01] FX Grant Support: Dr. Sisk was supported by a grant from the Agency for Healthcare Research and Quality (R01 HS10402-01). NR 39 TC 48 Z9 50 U1 4 U2 17 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 21 PY 2008 VL 149 IS 8 BP 540 EP W105 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 367XJ UT WOS:000260585600003 PM 18936502 ER PT J AU Bell, BD Giovagnoli, AR AF Bell, Brian D. Giovagnoli, Anna R. TI Memory after temporal lobe epilepsy surgery Risk and reward SO NEUROLOGY LA English DT Editorial Material ID LOBECTOMY C1 [Bell, Brian D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53792 USA. [Bell, Brian D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Giovagnoli, Anna R.] Ist Nazl Neurol Carlo Besta, Dept Clin Neurosci, Neuropsychol Lab, Milan, Italy. RP Bell, BD (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, 600 Highland Ave, Madison, WI 53792 USA. EM bell@neurology.wisc.edu NR 6 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD OCT 21 PY 2008 VL 71 IS 17 BP 1302 EP 1303 DI 10.1212/01.wnl.0000326065.70180.03 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 362IJ UT WOS:000260191100002 PM 18784375 ER PT J AU Sorror, ML Storer, BE Sandmaier, BM Maris, M Shizuru, J Maziarz, R Agura, E Chauncey, TR Pulsipher, MA McSweeney, PA Wade, JC Bruno, B Langston, A Radich, J Niederwieser, D Blume, KG Storb, R Maloney, DG AF Sorror, Mohamed L. Storer, Barry E. Sandmaier, Brenda M. Maris, Michael Shizuru, Judith Maziarz, Richard Agura, Edward Chauncey, Thomas R. Pulsipher, Michael A. McSweeney, Peter A. Wade, James C. Bruno, Benedetto Langston, Amelia Radich, Jerald Niederwieser, Dietger Blume, Karl G. Storb, Rainer Maloney, David G. TI Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT Tandem Bone Marrow Transplantation Meeting CY FEB 16, 2007 CL Keystone, CO SP Amer Soc Bone Marrow Transplant ID VERSUS-HOST-DISEASE; MINIMAL RESIDUAL DISEASE; BONE-MARROW-TRANSPLANTATION; TREATMENT-RELATED MORTALITY; VARIABLE-REGION MUTATIONS; HEAVY-CHAIN GENE; GENOMIC ABERRATIONS; CLINICAL-EFFICACY; ZAP-70 EXPRESSION; CD38 EXPRESSION AB Purpose We reported encouraging early results of allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had advanced chronic lymphocytic leukemia (CLL). Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients. Patients and Methods Eighty-two patients, age 42 to 72 years, who had fludarabine-refractory CLL were conditioned with 2 Gy total-body irradiation alone or combined with fludarabine followed by HCT from related (n = 52) or unrelated (n = 30) donors. Results Complete remission (CR) and partial remission were achieved in 55% and 15% of patients, respectively. Higher CR rates were noted after unrelated HCT (67% v 48%). The 5-year incidences of nonrelapse mortality (NRM), progression/relapse, overall survival, and progression-free survival were 23%, 38%, 50%, and 39%, respectively. Among 25 patients initially reported in CR, 8% relapsed and 8% died as a result of NRM, whereas 84% have remained alive and in CR. Among 14 responding patients who were tested and who had molecular eradication of their disease, two died as a result of NRM, two relapsed, and 10 have remained negative. At 5 years, 76% of living patients were entirely well, whereas 24% continued to receive immunosuppression for chronic graft-versus-host disease; the median performance status in each group was 100% and 90%, respectively. Lymphadenopathy >= 5 cm, but not cytogenetic abnormalities at HCT, predicted relapse. In a risk-stratification model, patients who had lymphadenopathy less than 5 cm and no comorbidities had a 5-year OS of 71%. Conclusion Nonmyeloablative HCT resulted in a median survival of 5 years for patients who had fludarabine-refractory CLL with sustained remissions and in the continued resolution of chronic graft-versus-host disease in surviving patients. C1 [Sorror, Mohamed L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Stanford Univ, Stanford, CA 94305 USA. Univ Leipzig, Leipzig, Germany. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Baylor Univ, Baylor, TX USA. Univ Utah, Salt Lake City, UT USA. Univ Colorado, Boulder, CO 80309 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Univ Turin, Turin, Italy. Emory Univ, Atlanta, GA 30322 USA. RP Sorror, ML (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM msorror@fhcrc.org FU NCI NIH HHS [CA15704, CA18029, CA78902, P01 CA018029, P01 CA078902] NR 51 TC 172 Z9 176 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 20 PY 2008 VL 26 IS 30 BP 4912 EP 4920 DI 10.1200/JCO.2007.15.4757 PG 9 WC Oncology SC Oncology GA 361FT UT WOS:000260113600013 PM 18794548 ER PT J AU New, AS Triebwasser, J Charney, DS AF New, Antonia S. Triebwasser, Joseph Charney, Dennis S. TI The case for shifting borderline personality disorder to Axis I SO BIOLOGICAL PSYCHIATRY LA English DT Review DE Axis I; Axis II; borderline personality disorder; nosology; specificity; validity ID POSITRON-EMISSION-TOMOGRAPHY; CHILDHOOD SEXUAL-ABUSE; IMPULSIVE AGGRESSIVE-BEHAVIOR; DEPRESSED-PATIENTS; PREFRONTAL CORTEX; BIPOLAR DISORDER; RISK-FACTORS; FOLLOW-UP; ANTERIOR CINGULATE; LIFE EVENTS AB Through reviewing what is known about the nature, course, and heritability of borderline personality disorder (BPD), we argue for a reconceptualization of this disorder that would lead to its placement on Axis I. Borderline personality disorder is a prevalent and disabling condition, and yet the empirical research into its nature and treatment has not been commensurate with the seriousness of the illness. We not only review empirical evidence about the etiology, phenomenology, and course of the disorder in BPD but we also address fundamental misconceptions about BPD that we believe have contributed to misunderstanding and stigmatization of the disease. Finally, we suggest future directions for research that might permit the identification of core features of this disorder, with a focus on the importance of naturalistic assessments and of assessments through the course of development. C1 [New, Antonia S.; Triebwasser, Joseph; Charney, Dennis S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [New, Antonia S.; Triebwasser, Joseph] Bronx Vet Affairs Med Ctr, New York, NY USA. RP New, AS (reprint author), Mt Sinai Sch Med, Dept Psychiat, Box 1217, New York, NY 10029 USA. EM antonia.new@mssm.edu FU Veterans Administration (VA) [9001-03-0051] FX Dr. New gratefully acknowledges the support of the Veterans Administration (VA) for ber VA Merit Award (VA Project #: 9001-03-0051). NR 100 TC 33 Z9 34 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD OCT 15 PY 2008 VL 64 IS 8 BP 653 EP 659 DI 10.1016/j.biopsych.2008.04.020 PG 7 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 357TE UT WOS:000259868600003 PM 18550033 ER PT J AU Ford, JM Roach, BJ Hoffman, RS Mathalon, DH AF Ford, Judith M. Roach, Brian J. Hoffman, Ralph S. Mathalon, Daniel H. TI The dependence of P300 amplitude on gamma synchrony breaks down in schizophrenia SO BRAIN RESEARCH LA English DT Article DE Schizophrenia; EEG; Phase synchrony; Power ID SINGLE-TRIAL ANALYSIS; AUDITORY ODDBALL PARADIGM; EVOKED-RESPONSES; WAVELET ANALYSIS; EEG ACTIVITY; METAANALYSIS; VARIABILITY; STIMULI; HUMANS AB Introduction: Auditory P300 amplitude reduction in schizophrenia is canonical and may be explained by poor synchronization or reduced power of the underlying neural activity. We asked if patients have reduced synchrony and power, and whether together with P300 amplitude, they make unique or overlapping contributions to the discrimination between patients and controls. We also asked whether people who have large P300s have higher power and greater synchrony of neural activity, and if the relationships between P300 and power and synchrony are different in patients and healthy controls. Methods: We recorded EEG data from 22 controls and 21 patients with schizophrenia (DSM-IV) while they performed an auditory target detection task. We used wavelet analyses of the single trial data to estimate total power and synchrony of delta, theta, alpha, beta, and gamma activity in a 50ms window around the peak of the P300 to the target. We measured P300 amplitude from the average of the single trials, in a 50ms window around its peak. Results and conclusions: P300 amplitude and delta and theta synchrony were reduced in patients; delta power and synchrony better distinguished between groups than P300 amplitude. In healthy controls, but not patients, gamma synchrony predicted P300 amplitude. In patients, P300 and gamma synchrony are affected by independent factors; the relationship between them is attenuated by an additional pathophysiological process. (c) Published by Elsevier B.V. C1 [Ford, Judith M.; Roach, Brian J.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Ford, Judith M.; Roach, Brian J.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. [Hoffman, Ralph S.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Ford, JM (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM judith.ford@ucsf.edu OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974 FU VA Schizophrenia Biological Research Center; National Institute of Mental Health [MH40052, MH S8262, MH067967]; National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) FX This work was supported by the VA Schizophrenia Biological Research Center and grants from National Institute of Mental Health (MH40052, MH S8262, MH067967), and the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD). NR 33 TC 40 Z9 40 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD OCT 15 PY 2008 VL 1235 SI SI BP 133 EP 142 DI 10.1016/j.brainres.2008.06.048 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 371UZ UT WOS:000260858400014 PM 18621027 ER PT J AU Wang, JH Cai, Y Yu, WD Ren, CX Spencer, DM Ittmann, M AF Wang, Jianghua Cai, Yi Yu, Wendong Ren, Chengxi Spencer, David M. Ittmann, Michael TI Pleiotropic Biological Activities of Alternatively Spliced TMPRSS2/ERG Fusion Gene Transcripts SO CANCER RESEARCH LA English DT Article ID HUMAN PROSTATE-CANCER; TMPRSS2-ERG FUSION; EXPRESSION; ERG; TUMORIGENESIS; ANGIOGENESIS; ABERRATIONS; PROGRESSION; METASTASIS; EPITHELIUM AB TMPRSS2/ERG gene fusions are found in the majority of prostate cancers; however, there is significant heterogeneity in the 5' region of the alternatively spliced fusion gene transcripts. We have found that there is also significant heterogeneity within the coding exons as well. There is variable inclusion of a 72-bp exon and other novel alternatively spliced isoforms. To assess the biological significance of these alternatively spliced transcripts, we expressed various transcripts in primary prostatic epithelial cells (PrEC) and in an immortalized PrEC line, PNT1a. The fusion gene transcripts promoted proliferation, invasion, and motility with variable activities that depended on the structure of the 5' region encoding the TMPRSS2/ERG fusion and the presence of the 72-bp exon. Cotransfection of different isoforms further enhanced biological activity, mimicking the situation in vivo, in which multiple isoforms are expressed. Finally, knockdown of the fusion gene in VCaP cells resulted in inhibition of proliferation in vitro and tumor progression in an in vivo orthotopic mice model. Our results indicate that TMPRSS2/ERG fusion isoforms have variable biological activities promoting tumor initiation and progression and are consistent with our previous clinical observations indicating that certain TMPRSS2/ERG fusion isoforms are significantly correlated with more aggressive disease. [Cancer Res 2008; 68(20):8516-24] C1 [Wang, Jianghua; Cai, Yi; Yu, Wendong; Ren, Chengxi; Ittmann, Michael] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Spencer, David M.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. [Wang, Jianghua; Cai, Yi; Yu, Wendong; Ren, Chengxi; Ittmann, Michael] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu FU Department of Defense Prostate Cancer Research [DAMD W81XWH-08-1-0055]; National Cancer Institute [P50CA058204]; Department of Veterans Affairs; Michael E. DeBakey Veterans Affairs Medical Center FX Grant support: This work was supported by grants from the Department of Defense Prostate Cancer Research program (DAMD W81XWH-08-1-0055), the National Cancer Institute to the Baylor Prostate Cancer Specialized Program of Research Excellence (P50CA058204), and the Department of Veterans Affairs Merit Review program (M. Ittmann) and by the use of the facilities of the Michael E. DeBakey Veterans Affairs Medical Center. NR 35 TC 89 Z9 95 U1 1 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD OCT 15 PY 2008 VL 68 IS 20 BP 8516 EP 8524 DI 10.1158/0008-5472.CAN-08-1147 PG 9 WC Oncology SC Oncology GA 364GE UT WOS:000260323400038 PM 18922926 ER PT J AU Chen, YM Chen, PL Chen, CF Jiang, XZ Riley, DJ AF Chen, Yumay Chen, Phang-Lang Chen, Chi-Fen Jiang, Xianzhi Riley, Daniel J. TI Never-in-mitosis related kinase 1 functions in DNA damage response and checkpoint control SO CELL CYCLE LA English DT Article DE checkpoint control; radiation; S-phase; mitosis; chromosome breaks ID POLYCYSTIC KIDNEY-DISEASE; NIMA-RELATED KINASES; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; FAMILY KINASE; CHROMATIN CONDENSATION; ATAXIA-TELANGIECTASIA; MITOTIC PROGRESSION; MURINE MODELS; NEK2 KINASE AB Nek1, the first mammalian ortholog of the fungal protein kinase never in mitosis A, is involved early in the DNA damage sensing/repair pathway after ionizing radiation. Here we extend this finding by showing that Nek1 localizes to nuclear foci of DNA damage in response to many different types of damage in addition to IR. Untransformed cells established from kat2J/Nek1(-/-) mice fail to arrest properly at G(1)/S and M-phase checkpoints in response to DNA damage. G(1)-S-phase checkpoint control can be rescued by ectopically overexpressing wild-type Nek1. In Nek1(-/-) murine cells and in human cells with Nek1 expression silenced by siRNA, the checkpoint kinases Chk1 and Chk2 fail to be activated properly in response to ionizing or UV radiation. In cells without functional Nek1, DNA is not repaired properly, double-stranded DNA breaks persist long after low dose IR, and excessive numbers of chromosome breaks are observed. These data show that Nek1 is important for efficient DNA damage checkpoint control and for proper DNA damage repair. C1 [Chen, Yumay; Riley, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Chen, Phang-Lang; Chen, Chi-Fen; Jiang, Xianzhi] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA. [Riley, Daniel J.] S Texas Vet Hlth Care Syst, Renal Res Div, Audie L Murphy Div, San Antonio, TX USA. RP Chen, YM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM cheny@uthscsa.edu RI Jiang, Xianzhi/A-5427-2013 OI Jiang, Xianzhi/0000-0002-4645-154X FU PKD foundation; American Society of Nephrology; National Kidney Foundation; NIH [R01-DK067339, P50-DK061597, R01-DK61626]; George M. O'Brien Kidney Research Center; Veterans Administration Renal Research FX This work was supported by grants from the PKD foundation, the American Society of Nephrology, the National Kidney Foundation, and the NIH (R01-DK067339) to Y. C.; a George M. O'Brien Kidney Research Center grant from the NIH to Y. C. (P50-DK061597), Hanna E. Abboud, Program Director); and a grant from the NIH to D. J. R. (R01-DK61626). We thank Huai-Chin Chiang and Sergio Garcia for technical support, and a Veterans Administration Renal Research Excellence Award to the South Texas Veterans Health Care System, Audie L. Murphy Division, for help with core services, equipment, and institutional NR 42 TC 34 Z9 34 U1 0 U2 3 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1538-4101 J9 CELL CYCLE JI Cell Cycle PD OCT 15 PY 2008 VL 7 IS 20 BP 3194 EP 3201 DI 10.4161/cc.7.20.6815 PG 8 WC Cell Biology SC Cell Biology GA 363JI UT WOS:000260263200015 PM 18843199 ER PT J AU Mandell, L Wunderink, R Anzueto, A Bartlett, J Campbell, D Dean, N Dowell, S File, T Musher, D Niederman, M Torres, A Whitney, C Fine, M AF Mandell, Lionel Wunderink, Richard Anzueto, Antonio Bartlett, John Campbell, Douglas Dean, Nathan Dowell, Scott File, Thomas Musher, Daniel Niederman, Michael Torres, Antonio Whitney, Cynthia Fine, Mike CA IDSA ATS Guidelines Comm Community TI Guideline Tyranny: A response to the article by Baum and Kaltsas SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA C1 [Mandell, Lionel] McMaster Univ, Henderson Hosp, Dept Med, Hamilton, ON L8V 1C3, Canada. [Wunderink, Richard] Northwestern Univ, Sch Med, Chicago, IL USA. [Anzueto, Antonio] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Musher, Daniel] Baylor Coll Med, Houston, TX 77030 USA. [Bartlett, John] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Campbell, Douglas] LDS Hosp, Salt Lake City, UT USA. [Dean, Nathan] Univ Utah, Salt Lake City, UT USA. [File, Thomas] Summa Hlth Syst, Akron, OH USA. [Niederman, Michael] SUNY Stony Brook, Stony Brook, NY 11794 USA. [Whitney, Cynthia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Fine, Mike] Univ Pittsburgh, Pittsburgh, PA USA. [Dowell, Scott] Thai MOPH US CDC Collaborat, Nonthaburi, Thailand. [Torres, Antonio] Hosp Clin Barcelona, Barcelona, Spain. RP Mandell, L (reprint author), McMaster Univ, Henderson Hosp, Dept Med, 711 Concess St, Hamilton, ON L8V 1C3, Canada. EM lmandell@mcmaster.ca OI Wunderink, Richard/0000-0002-8527-4195 NR 6 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2008 VL 47 IS 8 BP 1117 EP 1118 DI 10.1086/592385 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 349XA UT WOS:000259315400028 PM 18800941 ER PT J AU Kaunitz, JD Yamaguchi, DT AF Kaunitz, Jonathan D. Yamaguchi, Dean T. TI TNAP, TrAP, Ecto-Purinergic Signaling, and Bone Remodeling SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE OSTEOBLAST: OSTEOCLAST; P2Y RECEPTORS; BONE REMODELING COMPARTMENT; BONE LINING CELLS; BICARBONATE; EXTRACELLULAR pH ID RESISTANT ACID-PHOSPHATASE; OSTEOBLAST-LIKE CELLS; UTERINE BICARBONATE SECRETION; STIMULATED ATPASE ACTIVITY; ALKALINE-PHOSPHATASE; CYSTIC-FIBROSIS; CARBONIC-ANHYDRASES; EPITHELIAL-CELLS; EXTRACELLULAR PH; DEFICIENT MICE AB Bone remodeling is a process of continuous resorption and formation/mineralization carried out by osteoclasts and osteoblasts, which, along with osteocytes, comprise the bone multicellular unit (BMU). A key component of the BMU is the bone remodeling compartment (BRC), isolated from the marrow by a canopy of osteoblast-like lining cells. Although much progress has been made regarding the cytokine-dependent and hormonal regulation of bone remodeling, less attention has been placed on the role of extracellular pH (pH(e)). Osteoclastic bone resorption occurs at acidic pH(e). Furthermore, osteoclasts can be regarded as epithelial-like cells, due to their polarized structure and ability to form a seal against bone, isolating the lacunar space. The major ecto-phosphatases of osteoclasts and osteoblasts, acid and alkaline phosphatases, both have ATPase activity with pH optima several units different from neutrality. Furthermore, osteoclasts and osteoblasts express plasma membrane purinergic P2 receptors that, upon activation by ATP, accelerate bone osteoclast resorption and impair osteoblast mineralization. We hypothesize that these ecto-phosphatases help regulate [ATP](e) and localized pH(e) at the sites of bone resorption and mineralization by pH-dependent ATP hydrolysis coupled with P2Y-dependent regulation of osteoclast and osteoblast function. Furthermore, osteoclast cellular HCO(3)(-), formed as a product of lacunar V-ATPase H(+) secretion, is secreted into the BRC, which could elevate BRC pH(e), in turn affecting osteoblast function. We will review the existing data addressing regulation of BRC pH(e), present a hypothesis regarding its regulation, and discuss the hypothesis in the context of the function of proteins that regulate pH(e). J. Cell. Biochem. 105: 655-662, 2008. (c) 2008 Wiley-Liss, Inc. C1 [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Div Gastroenterol, Dept Med, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.; Yamaguchi, Dean T.] Univ Calif Los Angeles, Sch Med, Greater Los Angeles Vet Affairs Hlth Syst, Res Serv, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.; Yamaguchi, Dean T.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU Medical Service, West Los Angeles Veterans Affairs Medical Center FX We thank Dr. Baruch Frenkel and Dr. Yasutada Akiba for their kind, informed, and helpful advice, the Medical Service, West Los Angeles Veterans Affairs Medical Center for its support, and Jenifer Kugler for her editorial assistance. NR 75 TC 52 Z9 55 U1 1 U2 12 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD OCT 15 PY 2008 VL 105 IS 3 BP 655 EP 662 DI 10.1002/jcb.21885 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 388MH UT WOS:000262023400005 PM 18773425 ER PT J AU Zhang, XY Yu, SB Galson, DL Luo, M Fan, J Zhang, J Guan, YF Xiao, GZ AF Zhang, Xiaoyan Yu, Shibing Galson, Deborah L. Luo, Min Fan, Jie Zhang, Jian Guan, Youfei Xiao, Guozhi TI Activating Transcription Factor 4 Is Critical for Proliferation and Survival in Primary Bone Marrow Stromal Cells and Calvarial Osteoblasts SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE ATF4; OSTEOBLASTS; PROLIFERATION; APOPTOSIS; CELL CYCLE; CYCLIN D1 ID OSTEOCALCIN GENE-EXPRESSION; DNA-BINDING PROTEINS; CYCLIN D1 PROMOTER; RESPONSE ELEMENT; LEUCINE-ZIPPER; TARGETED DISRUPTION; PARATHYROID-HORMONE; ANABOLIC ACTIONS; IN-VITRO; ATF4 AB Activating transcription factor 4 (ATF4) is essential for bone formation. However, the mechanism of its actions in bone is poorly understood. The present study examined the role for ATF4 in the regulation of proliferation and survival of primary mouse bone marrow stromal cells (BMSCs) and osteoblasts. Results showed that Atf4(-/-) cells display a severe proliferative defect as measured by multiple cell proliferation assays. Cell cycle progression of Atf4(-/-) BMSCs was largely delayed with significant G1 arrest. Expression of cyclin D1 was decreased both at the mRNA and protein level. A similar proliferation defect was observed in Atf4(-/-) calvarial periosteal osteoblasts when compared with wt control. Knocking down Atf4 mRNA by small interfering RNA in MC3T3-E1 subclone 4 preosteoblasts markedly reduced expression of cyclin D1 and cell proliferation. In contrast, overexpression of ATF4 increased cyclin D1 expression as well as cell proliferation in AV4(-/-) BMSCs. In addition, apoptosis was significantly increased in Atf4(-/-) BMSCs and calvarial periosteal osteoblasts relative to wt controls. Taken together, these results for the first time demonstrate that ATF4 is a critical regulator of proliferation and survival in BMSCs and osteoblasts in vitro and in vivo. J. Cell. Biochem. 105: 885-895, 2008. (C) 2008 Wiley-Liss, Inc. C1 [Zhang, Xiaoyan; Yu, Shibing; Galson, Deborah L.; Luo, Min; Zhang, Jian; Xiao, Guozhi] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15240 USA. [Zhang, Xiaoyan; Guan, Youfei] Peking Beijing Univ Hlth Sci Ctr, Dept Physiol & Pathophysiol, Beijing 100083, Peoples R China. [Fan, Jie] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15240 USA. RP Xiao, GZ (reprint author), VA Pittsburgh Healthcare Syst, Rm 2E-109,151-U, Pittsburgh, PA 15240 USA. EM xiaog@upmc.edu RI Perez , Claudio Alejandro/F-8310-2010; YU, SHIBING/B-7648-2012; Galson, Deborah/E-9370-2010 OI Perez , Claudio Alejandro/0000-0001-9688-184X; Galson, Deborah/0000-0002-2045-8807 FU NIH [DK072230]; Department of Defense [W81XWH-07-1-0160]; China National Natural Science Foundation [NNSF 30530340, NNSF 30725033] FX Thanks to Diane George and Dr. Scott Kulich ofthe VA Pittsburgh Healthcare System for assistance in bone histology and the Nucleofector electroporation transfection, respectively. This work was supported by an NIH Grant DK072230 and a Department of Defense Grant W81XWH-07-1-0160 (to GX) and two China National Natural Science Foundation grants NNSF 30530340 and NNSF 30725033 (to Y.G). NR 54 TC 16 Z9 17 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD OCT 15 PY 2008 VL 105 IS 3 BP 885 EP 895 DI 10.1002/jcb.21888 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 388MH UT WOS:000262023400028 PM 18729081 ER PT J AU Gelati, M Aplin, AC Fogel, E Smith, KD Nicosia, RF AF Gelati, Maurizio Aplin, Alfred C. Fogel, Eric Smith, Kelly D. Nicosia, Roberto F. TI The angiogenic response of the aorta to injury and inflammatory cytokines requires macrophages SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-ASSOCIATED MACROPHAGES; LIPOSOME-MEDIATED DEPLETION; STIMULATING FACTOR-I; RAT AORTA; GENE-THERAPY; CXCR2; MODEL; VIVO; NEOVASCULARIZATION AB The purpose of this study was to define early events during the angiogenic response of the aortic wall to injury. Rat aortic rings produced neovessels in collagen culture but lost this capacity over time. These quiescent rings responded to vascular endothelial growth factor but not to a mixture of macrophage-stimulatory cytokines and chemokines that was angiogenically active on fresh rings. Analysis of cytokine receptor expression revealed selective loss in quiescent rings of the proangiogenic chemokine receptor CXCR2, which was expressed predominantly in aortic macrophages. Pharmacologic inhibition of CXCR2 impaired angiogenesis from fresh rings but had no effect on vascular endothelial growth factor-induced angiogenesis from quiescent explants. Angiogenesis was also impaired in cultures of aortic rings from CXCR2-deficient mice. Reduced CXCR2 expression in quiescent rat aortic rings correlated with marked macrophage depletion. Pharmacologic ablation of macrophages from aortic explants blocked formation of neovessels in vitro and reduced aortic ring-induced angiogenesis in vivo. The angiogenic response of macrophage-depleted rings was completely restored by adding exogenous macrophages. Moreover, angiogenesis from fresh rings was promoted by macrophage CSF (CSF-1) and inhibited with anti-CSF-1 Ab. Thus, aortic angiogenic sprouting following injury is strongly influenced by conditions that modulate resident macrophage numbers and function. C1 [Gelati, Maurizio] Carlo Besta Inst, Lab Neurobiol & Neuroregenerat Med, Milan, Italy. [Aplin, Alfred C.; Smith, Kelly D.; Nicosia, Roberto F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Fogel, Eric; Nicosia, Roberto F.] Vet Adm Puget Sound Hlth Care Syst, Div Pathol & Lab Med, Seattle, WA 98108 USA. RP Nicosia, RF (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Pathol & Lab Med S Lab 113, 1660 S Columbian Way, Seattle, WA 98108 USA. EM roberto.nicosia@va.gov RI Gelati, Maurizio/H-2110-2016 OI Gelati, Maurizio/0000-0002-4828-9849 FU National Heart, Lung, and Blood Institute [HL52585]; Department of Veterans Affairs Medical Research Service FX Supported by National Heart, Lung, and Blood Institute Grant HL52585 and by a Merit Review Grant from the Department of Veterans Affairs Medical Research Service. NR 48 TC 24 Z9 25 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD OCT 15 PY 2008 VL 181 IS 8 BP 5711 EP 5719 PG 9 WC Immunology SC Immunology GA 359YX UT WOS:000260025300065 PM 18832730 ER PT J AU Ho, PM Peterson, PN Masoudi, FA AF Ho, P. Michael Peterson, Pamela N. Masoudi, Frederick A. TI Evaluating the evidence - Is there a rigid hierarchy? SO CIRCULATION LA English DT Article DE cardiovascular diseases; epidemiology; research design ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; VENTRICULAR SYSTOLIC DYSFUNCTION; TO-BALLOON TIME; ESTROGEN PLUS PROGESTIN; BETA-BLOCKER THERAPY; HEART-FAILURE; CLINICAL-TRIALS; POSTMENOPAUSAL ESTROGEN; CARDIOVASCULAR-DISEASE C1 [Ho, P. Michael] Denver Vet Affairs Med Ctr, Denver, CO 80202 USA. [Ho, P. Michael; Peterson, Pamela N.; Masoudi, Frederick A.] Univ Colorado, Denver, CO 80202 USA. [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA. RP Masoudi, FA (reprint author), MC 0960,777 Bannock St, Denver, CO 80204 USA. EM fred.masoudi@uchsc.edu FU Amgen; Oklahoma Foundation for Medical Quality; Colorado Foundation for Medical Care FX Dr Masoudi has served on advisory boards for Takeda, NA; Amgen; and United Healthcare. Dr Masoudi has also received research support from Amgen, has contracts with the Oklahoma Foundation for Medical Quality and the Colorado Foundation for Medical Care, and is an Associate Editor for Journal Watch Cardiology of the Massachusetts Medical Society. The other authors report no conflicts. NR 75 TC 59 Z9 59 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 14 PY 2008 VL 118 IS 16 BP 1675 EP 1684 DI 10.1161/CIRCULATIONAHA.107.721357 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 359KX UT WOS:000259986700011 PM 18852378 ER PT J AU Alelu-Paz, R Iturrieta-Zuazo, I Byne, W Haroutunian, V Garcia-Villanueva, M Rabano, A Garcia-Amado, M Prensa, L Gimenez-Amaya, JM AF Alelu-Paz, Raul Iturrieta-Zuazo, Ignacio Byne, William Haroutunian, Vahram Garcia-Villanueva, Mercedes Rabano, Alberto Garcia-Amado, Maria Prensa, Lucia Manuel Gimenez-Amaya, Jose TI A New Antigen Retrieval Technique for Human Brain Tissue SO PLOS ONE LA English DT Article AB Immunohistochemical staining of tissues is a powerful tool used to delineate the presence or absence of an antigen. During the last 30 years, antigen visualization in human brain tissue has been significantly limited by the masking effect of fixatives. In the present study, we have used a new method for antigen retrieval in formalin-fixed human brain tissue and examined the effectiveness of this protocol to reveal masked antigens in tissues with both short and long formalin fixation times. This new method, which is based on the use of citraconic acid, has not been previously utilized in brain tissue although it has been employed in various other tissues such as tonsil, ovary, skin, lymph node, stomach, breast, colon, lung and thymus. Thus, we reported here a novel method to carry out immunohistochemical studies in free-floating human brain sections. Since fixation of brain tissue specimens in formaldehyde is a commonly method used in brain banks, this new antigen retrieval method could facilitate immunohistochemical studies of brains with prolonged formalin fixation times. C1 [Alelu-Paz, Raul; Iturrieta-Zuazo, Ignacio; Garcia-Amado, Maria; Prensa, Lucia; Manuel Gimenez-Amaya, Jose] Univ Autonoma Madrid, Fac Med, Dept Anat Histol & Neurociencia, Madrid, Spain. [Iturrieta-Zuazo, Ignacio; Garcia-Amado, Maria] Univ Navarra, Clin Univ, Lab Neuromorfol Funcion, E-31080 Pamplona, Spain. [Byne, William; Haroutunian, Vahram] Mount Sinai Sch Med, Dept Psychiat, New York, NY USA. [Byne, William; Haroutunian, Vahram] Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Garcia-Villanueva, Mercedes] Hosp Ramon & Cajal, Dept Anat Patol, Madrid, Spain. [Rabano, Alberto] Hosp Alcorcon, Lab Neuropatol, Madrid, Spain. RP Alelu-Paz, R (reprint author), Univ Autonoma Madrid, Fac Med, Dept Anat Histol & Neurociencia, Madrid, Spain. EM josemanuel.gimenezamaya@uam.es RI Garcia-Amado, Maria/K-2705-2014 OI Garcia-Amado, Maria/0000-0001-6778-5680 FU Spanish Ministerio de Educacion y Ciencia [BFU2006-01189] FX This study was supported by a grant from the Spanish Ministerio de Educacion y Ciencia (BFU2006-01189). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 8 Z9 9 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 13 PY 2008 VL 3 IS 10 AR e3378 DI 10.1371/journal.pone.0003378 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 432GN UT WOS:000265121600004 PM 18852880 ER PT J AU Azmoon, S Lepor, NE Ebrahimi, R Madyoon, H AF Azmoon, Shah Lepor, Norman E. Ebrahimi, Ramin Madyoon, Hooman TI Interpretation of Symptoms in addition to the predictive Value of Coronary Artery Calcium Scores in Assessing Coronary Obstructive Risk SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Meeting Abstract CT 20th Annual Transcatheter Cardiovascular Therapeutics Conference CY OCT 12-17, 2008 CL Washington, CA SP Cardiovasc Res Fdn C1 [Azmoon, Shah] NYMC, Valhalla, NY USA. [Lepor, Norman E.; Madyoon, Hooman] Westside Med Imaging, Beverly Hills, CA USA. [Ebrahimi, Ramin] W Los Angeles Vet Affairs Hosp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 12 PY 2008 VL 102 IS 8A BP 95I EP 95I PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 360YM UT WOS:000260094700216 ER PT J AU Azmoon, S Madyoon, H Ebrahimi, R Lepor, NE AF Azmoon, Shah Madyoon, Hooman Ebrahimi, Ramin Lepor, Norman E. TI Gender Differences in the Assessment of Coronary Artery Stenosis in Patients with Abnormal Coronary Calcium Scores Undergoing 64 Slice CT Angiography SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Meeting Abstract CT 20th Annual Transcatheter Cardiovascular Therapeutics Conference CY OCT 12-17, 2008 CL Washington, CA SP Cardiovasc Res Fdn C1 [Azmoon, Shah] NYMC, Valhalla, NY USA. [Madyoon, Hooman; Lepor, Norman E.] Westside Med Coll, Beverly Hills, CA USA. [Ebrahimi, Ramin] W Los Angeles Vet Affairs Hosp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 12 PY 2008 VL 102 IS 8A BP 98I EP 98I PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 360YM UT WOS:000260094700227 ER PT J AU Movahed, MR Ebrahimi, R Jamal, MM Hashemzadeh, M AF Movahed, Mohammad Reza Ebrahimi, Ramin Jamal, M. Mazen Hashemzadeh, Mehrtash TI Significant Decline in the Nationwide Trends in the Mortality in Patients undergoing Percutaneous Coronary Intervention SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Meeting Abstract CT 20th Annual Transcatheter Cardiovascular Therapeutics Conference CY OCT 12-17, 2008 CL Washington, CA SP Cardiovasc Res Fdn C1 [Movahed, Mohammad Reza] Univ Arizona, Med Ctr, Tucson, AZ USA. [Movahed, Mohammad Reza] So Arizona VA Hlth Care Syst, Tucson, AZ USA. [Ebrahimi, Ramin] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Jamal, M. Mazen] VA Long Beach Hlth Care Syst, Long Beach, CA USA. [Hashemzadeh, Mehrtash] VA Long Beach Healthcare Syst, Long Beach, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 12 PY 2008 VL 102 IS 8A BP 216I EP 217I PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 360YM UT WOS:000260094700540 ER PT J AU Movahed, MR Hashemzadeh, MH Jamal, MM Ebrahimi, R AF Movahed, Mohammad Reza Hashemzadeh, Mehrtash Hashmezadeh Jamal, M. Mazen Ebrahimi, Ramin TI Significant Decline in the Nationwide Trends in the Mortality in Patients undergoing Multi Vessel Percutaneous Coronary Intervention SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Meeting Abstract CT 20th Annual Transcatheter Cardiovascular Therapeutics Conference CY OCT 12-17, 2008 CL Washington, CA SP Cardiovasc Res Fdn C1 [Movahed, Mohammad Reza] So Arizona VA Hlth Care Syst, Tucson, AZ USA. [Movahed, Mohammad Reza] Univ Arizona, Med Ctr, Tucson, AZ USA. [Hashemzadeh, Mehrtash Hashmezadeh; Jamal, M. Mazen] VA Long Beach Hlth Care Syst, California, CA USA. [Ebrahimi, Ramin] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 12 PY 2008 VL 102 IS 8A BP 217I EP 217I PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 360YM UT WOS:000260094700541 ER PT J AU Shipman, C Gysels, M White, P Worth, A Murray, SA Barclay, S Forrest, S Shepherd, J Dale, J Dewar, S Peters, M White, S Richardson, A Lorenz, K Koffman, J Higginson, IJ AF Shipman, Cathy Gysels, Marjolein White, Patrick Worth, Allison Murray, Scott A. Barclay, Stephen Forrest, Sarah Shepherd, Jonathan Dale, Jeremy Dewar, Steve Peters, Marilyn White, Suzanne Richardson, Alison Lorenz, Karl Koffman, Jonathan Higginson, Irene J. TI Improving generalist end of life care: national consultation with practitioners, commissioners, academics, and service user groups SO BRITISH MEDICAL JOURNAL LA English DT Article ID PRIMARY PALLIATIVE CARE; GOLD-STANDARDS-FRAMEWORK; CANCER; DEATH; COMMUNICATION; COUNTRIES; TRENDS; FAMILY; PLACE; DIE AB Objective To identify major concerns of national and local importance in the provision, commissioning, research, and use of generalist end of life care. Design A national consultation and prioritising exercise using a modified form of the nominal group technique. Participants Healthcare practitioners, commissioners, academics, and representatives of user and voluntary groups. Setting Primary and secondary care, specialist palliative care, and academic and voluntary sectors in England and Scotland. Results 74% of those invited ( 210/ 285) participated. The stage of life to which "end of life care" referred was not understood in a uniform way. Perceptions ranged from a period of more than a year to the last few days of life. Prominent concerns included difficulties in prognosis and the availability of adequate support for patients with advanced non- malignant disease. Generalists in both primary and secondary care were usually caring for only a few patients approaching the end of life at any one time at a point in time. It was therefore challenging to maintain skills and expertise particularly as educational opportunities were often limited. End of life care took place among many other competing and incentivised activities for general practitioners in the community. More needs to be known about models of end of life care and how these can be integrated in a generalist's workload. A greater evidence base is needed about the effectiveness and application of current tools such as the gold standards framework and Liverpool care pathway and about models of palliation in patients with diseases other than cancer. Conclusions Definitions of end of life care need clarification and standardisation. A greater evidence base is needed to define models of good practice together with a commitment to provide education and training and adequate resources for service provision. More needs to be known about the context of provision and the influence of competing priorities and incentives. C1 [Shipman, Cathy; Gysels, Marjolein; Koffman, Jonathan; Higginson, Irene J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Weston Educ Ctr, London SE5 9RJ, England. [Shipman, Cathy; White, Patrick; Peters, Marilyn; White, Suzanne] Kings Coll London, Dept Gen Practice & Primary Care, London SE11 6SP, England. [Worth, Allison; Murray, Scott A.] Univ Edinburgh, Primary Palliat Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland. [Barclay, Stephen; Forrest, Sarah] Univ Cambridge, Gen Practice & Primary Care Res Unit, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England. [Shepherd, Jonathan; Dale, Jeremy] Univ Warwick, Ctr Primary Hlth Care Studies, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England. [Dewar, Steve] Kings Fund, London W1G 0AN, England. [Richardson, Alison] Kings Coll London, Florence Nightingale Sch Nursing & Midwifery, London SE1 8WA, England. [Lorenz, Karl] Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Shipman, C (reprint author), Kings Coll London, Dept Palliat Care Policy & Rehabil, Weston Educ Ctr, London SE5 9RJ, England. EM Catherine.shipman@kcl.ac.uk RI green, sam/C-2608-2008 OI Barclay, Stephen/0000-0002-4505-7743; White, Patrick/0000-0002-2047-8787; Dale, Jeremy/0000-0001-9256-3553 FU National Institute of Health Research Service Development and Organisation research and development programme FX National Institute of Health Research Service Development and Organisation research and development programme. NR 42 TC 68 Z9 68 U1 2 U2 12 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD OCT 11 PY 2008 VL 337 IS 7674 AR a1720 DI 10.1136/bmj.a1720 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 358FU UT WOS:000259903300032 PM 18829640 ER PT J AU Gazzin, S Strazielle, N Schmitt, C Fevre-Montange, M Ostrow, JD Tiribelli, C Ghersi-Egea, JF AF Gazzin, Silvia Strazielle, Nathalie Schmitt, Charlotte Fevre-Montange, Michelle Ostrow, J. Donald Tiribelli, Claudio Ghersi-Egea, Jean-Francois TI Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE blood-brain barrier; choroid plexus; postnatal development; neuroprotection ID P-GLYCOPROTEIN EXPRESSION; CHOROID-PLEXUS; ENDOTHELIAL-CELLS; RAT-BRAIN; POSTNATAL MATURATION; BARRIER; TRANSPORT; MRP1; EFFLUX; DRUGS AB Cerebral homeostasis results from the presence of the protective blood-brain and blood-cerebrospinal fluid barriers located respectively at the brain capillary endothelium and the choroid plexus epithelium. ABCb1. (Pgp) and ABCc1 (Mrp1) transporters are two major proteins of neuroprotection whose localization and functional significance at both barriers remain partly unsettled. We conducted a comparative analysis of their relative protein content between the two blood-brain interfaces. Microvessels and choroid plexuses located in the fourth and lateral ventricles were isolated from developing and adult rat brains, and whole homogenates were submitted to quantitative Western blot analysis by using standard curves generated from one of the samples. In adult, choroid plexus-associated Pgp content was less than 0.5% of the level in microvessels, whereas Mrp1 content in microvessels was 4% of that in the fourth ventricle choroid plexus. Pgp but not Mrp1 was enriched in microvessels over parenchyma. In choroid plexuses, Mrp1 displayed a basolateral epithelial localization, and reached its high adult protein level, early during postnatal development. In postnatal as in adult microvessels, Pgp localization appeared luminal. However, by contrast to Mrp1, the level of this transporter increased 4.6-fold between 9-day-old and adult animals. Western blot analysis of human samples confirmed the mirror image of Pgp and Mrp1. expression between the two barriers. We conclude that there are major differences in the mechanisms by which blood-brain interfaces fulfill their neuroprotective functions. The data also highlight the significance of the neuroprotective function of the choroid plexus during brain maturation, when the microvasculature is still developing. C1 [Gazzin, Silvia; Strazielle, Nathalie; Schmitt, Charlotte; Fevre-Montange, Michelle; Ghersi-Egea, Jean-Francois] Univ Lyon, INSERM, U842, Fac Med Laennec, F-69372 Lyon, France. [Gazzin, Silvia; Tiribelli, Claudio] Univ Trieste, Ctr Fegato, Basovizza & Dept Life Sci, I-34012 Trieste, Italy. [Strazielle, Nathalie] Brain i, F-69008 Lyon, France. [Ostrow, J. Donald] Univ Washington, Sch Med, Div Gastroenterol Hepatol, Seattle, WA 98195 USA. [Ostrow, J. Donald] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98195 USA. RP Ghersi-Egea, JF (reprint author), Univ Lyon, INSERM, U842, Fac Med RTH Laennec, Rue Guillaume Paradin, F-69372 Lyon 08, France. EM jean-francois.ghersi-egea@inserm.fr OI Ghersi-Egea, Jean-Francois/0000-0002-0181-4909 FU ANR [ANR-06-SEST-38-03]; Amelie la vie-ANOCEF; Telethon (Italy) [GGP 05062] FX Grant sponsor ANR; Grant number: ANR-06-SEST-38-03; Grant sponsor: Amelie la vie-ANOCEF; (to J.F.G.E.); Grant sponsor: Telethon (Italy): Grant number: GGP 05062 (to C.T.). NR 47 TC 73 Z9 74 U1 2 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD OCT 10 PY 2008 VL 510 IS 5 BP 497 EP 507 DI 10.1002/cne.21808 PG 11 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA 347ES UT WOS:000259124000004 PM 18680196 ER PT J AU Holschneider, DP Yang, J Sadler, TR Galifianakis, NB Bozorgzadeh, MH Bading, JR Conti, PS Maarek, JMI AF Holschneider, D. P. Yang, J. Sadler, T. R. Galifianakis, N. B. Bozorgzadeh, M. H. Bading, J. R. Conti, P. S. Maarek, J. -M. I. TI Changes in regional brain perfusion during functional brain activation: Comparison of [Cu-64]-PTSM with [C-14]-Iodoantipyrine SO BRAIN RESEARCH LA English DT Article DE Brain mapping; Motor activity; Cerebral blood flow; Copper radioisotope ID CEREBRAL-BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; GLUCOSE-METABOLISM; PET; TRACER; COPPER-62-PTSM; RADIOPHARMACEUTICALS; EXTRACTION; WALKING; MODEL AB A dilemma in behavioral brain mapping is that conventional techniques immobilize the subject, extinguishing all but the simplest behaviors. This is avoided if brain activation is imaged after completion of the behavior and tissue capture of the tracer. A single-pass flow tracer proposed for positron emission tomography (PET) is a radiolabeled copper(II) complex of pyruvaldehyde bis(N-4-methylthiosemicarbazone), [Cu-64]-PTSM. [Cu-64]-PTSM reaches steady-state cerebral distribution more rapidly than the metabolic tracer [F-18]fluorodeoxyglucose, allowing imaging with substantially greater temporal resolution. Using dual-label autoradiography, this study compares the relative regional cerebral blood flow tracer distribution (CBF-TR) of [Cu-64]-PTSM to that of the classic perfusion tracer [C-14]-iodoantipyrine in a rat model during treadmill walking. Rats were exposed to continuous walking on a treadmill and compared to quiescent controls. [Cu-64]-PTSM was bolus injected (iv) after 1 min, followed by a 5-minute uptake and subsequent bolus injection of [C-14]-iodoantipyrine. CBF-TR was quantified by autoradiography and analyzed in the three-dimensionally reconstructed brain by statistical parametric mapping, as well as by region-of-interest analysis. A high homology was found between the [Cu-64] -PTSM and [C-14]-iodoantipyrine patterns of cerebral activation in cortical and subcortical regions. For white matter, however, [Cu-64] -PTSM showed lower perfusion than [Cu-14] -iodoantipyrine. [Cu-64]-PTSM is a useful tracer for functional brain mapping in freely-moving subjects. Its application in conjunction with PET promises to increase our understanding of the neural circuitry of behaviors dependent on locomotion. (c) 2008 Elsevier B.V. All rights reserved. C1 [Holschneider, D. P.] Univ So Calif, Dept Cell & Neurobiol, Keck Sch Med, Los Angeles, CA 90089 USA. [Holschneider, D. P.; Yang, J.] Univ So Calif, Dept Psychiat & Behav Sci, Keck Sch Med, Los Angeles, CA 90089 USA. [Holschneider, D. P.; Galifianakis, N. B.] Univ So Calif, Dept Neurol, Keck Sch Med, Los Angeles, CA 90089 USA. [Sadler, T. R.] Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90089 USA. [Bozorgzadeh, M. H.; Bading, J. R.; Conti, P. S.] Univ So Calif, Dept Radiol, Keck Sch Med, PET Imaging Sci Ctr, Los Angeles, CA 90089 USA. [Holschneider, D. P.; Conti, P. S.; Maarek, J. -M. I.] Univ So Calif, Dept Biomed Engn, Viterbi Sch Engn, Los Angeles, CA 90089 USA. [Holschneider, D. P.; Yang, J.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Holschneider, DP (reprint author), Univ So Calif, Dept Cell & Neurobiol, Keck Sch Med, 1333 San Pablo St,BMT 403,MC 9112, Los Angeles, CA 90089 USA. EM holschne@usc.edu FU Mallinckrodt Institute at Washington University; NCI [5R24CA086307-03]; NIMH [R21 MH073000]; NCRR [S10 RR15703] FX We would like to acknowledge Dr. X. Chen, Michel Tohme and Ryan Park, for their technical help in conducting the dynamic PET study, Pooja Sharma for her help with the selection of the regions of interest, and Dr. Oscar U. Scremin for his comments AA regarding the manuscript. [64CU] was obtained through the Research Resource in Radionuclide Research at the Mallinckrodt Institute at Washington University, St. Louis (NCI grant 5R24CA086307-03). Supported by grants from NIMH #R21 MH073000 (DH) and NCRR S10 RR15703 (PC). NR 35 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD OCT 9 PY 2008 VL 1234 BP 32 EP 43 DI 10.1016/j.brainres.2008.07.038 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 363RZ UT WOS:000260285700005 PM 18687316 ER PT J AU Nandakumar, V Singh, T Katiyar, SK AF Nandakumar, Vijayalakshmi Singh, Tripti Katiyar, Santosh K. TI Multi-targeted prevention and therapy of cancer by proanthocyanidins SO CANCER LETTERS LA English DT Review DE Proanthocyanidins; Cancer prevention; Interleukin; Matrix metalloproteinases; Ultraviolet radiation ID GRAPE SEED PROANTHOCYANIDINS; NF-KAPPA-B; INDUCED OXIDATIVE STRESS; PROSTATE TUMOR-GROWTH; SKH-1 HAIRLESS MICE; IN-VITRO; CARCINOMA-CELLS; INDUCE APOPTOSIS; PHENOLIC-ACIDS; DIETARY AGENTS AB In recent years, a considerable emphasis has been focused on the importance of the naturally available botanicals that can be consumed in an individual's everyday diet and that can also be useful as a chemopreventive or chemotherapeutic agent for certain diseases, including cancers. A wide variety of botanicals, mostly dietary flavonoids or polyphenolic substances, have been reported to possess substantial anti-carcinogenic and antimutagenic activities because of their antioxidant and anti-inflammatory properties. Proanthocyanidins are considered as one of them, and are abundantly available in various parts of the plants, such as fruits, berries, bark and seeds. Their modes of action were evaluated through a number of in vitro and in vivo studies which showed their potential role as anti-carcinogenic agent. We summarize and highlight the latest developments on anti-carcinogenic activities of proanthocyanidins from different sources, specifically from grape seeds, and their molecular targets, such as NF-kappa B, mitogen-activated protein kinases, PI3K/Akt, caspases, cytokines, angiogenesis and cell cycle regulatory proteins and other check points, etc. Although the bioavailability and metabolism data on proanthocyanidins is still largely unavailable, certain reports indicate that at least monomers and smaller oligomeric procyanidins are absorbed in the gut. The modulation of various molecular targets by proanthocyanidins in vitro and in vivo tumor models suggests their importance, contribution and mechanism of action to the prevention of cancers of different organs. (C) 2008 Elsevier Ireland Ltd. All rights reserved. C1 [Nandakumar, Vijayalakshmi; Singh, Tripti; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Cancer Institute/NIH [CA104428]; Veterans Affairs Merit Review Award FX The work reported from the author's laboratory was supported by the funds from National Cancer Institute/NIH (CA104428) and Veterans Affairs Merit Review Award (S.K.K.). The content of this article does not necessarily reflect the views or policies of the funding sources. The authors apologize for not discussing and citing several valuable publications because of the limitations of space and the number of references. NR 58 TC 138 Z9 142 U1 2 U2 33 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3835 J9 CANCER LETT JI Cancer Lett. PD OCT 8 PY 2008 VL 269 IS 2 BP 378 EP 387 DI 10.1016/j.canlet.2008.03.049 PG 10 WC Oncology SC Oncology GA 361QZ UT WOS:000260143500017 PM 18457915 ER PT J AU Werner, RM Goldman, LE Dudley, RA AF Werner, Rachel M. Goldman, L. Elizabeth Dudley, R. Adams TI Comparisons of safety-net and non-safety-net hospitals - Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE C1 [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Goldman, L. Elizabeth] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Dudley, R. Adams] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA. RP Werner, RM (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. EM rwerner@mail.med.upenn.edu NR 5 TC 1 Z9 1 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 8 PY 2008 VL 300 IS 14 BP 1652 EP 1652 DI 10.1001/jama.300.14.1652 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 356YF UT WOS:000259812800022 ER PT J AU Liu, H Shekelle, P Qaseem, A Orwoll, E AF Liu, Hau Shekelle, Paul Qaseem, Amir Orwoll, Eric TI The effects of race, ethnicity, and underlying medical diseases on osteoporosis are still unguided territory for internists - Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Liu, Hau] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA. [Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. [Orwoll, Eric] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Liu, H (reprint author), Santa Clara Valley Med Ctr, San Jose, CA 95128 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD OCT 7 PY 2008 VL 149 IS 7 BP 515 EP 516 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 359QY UT WOS:000260004400014 ER PT J AU Kay, DM Factor, SA Samii, A Higgins, DS Griffith, A Roberts, JW Leis, BC Nutt, JG Montimurro, JS Keefe, RG Atkins, AJ Yearout, D Zabetian, CP Payami, H AF Kay, Denise M. Factor, Stewart A. Samii, Ali Higgins, Donald S. Griffith, Alida Roberts, John W. Leis, Berta C. Nutt, John G. Montimurro, Jennifer S. Keefe, Robert G. Atkins, April J. Yearout, Dora Zabetian, Cyrus P. Payami, Haydeh TI Genetic Association Between alpha-Synuclein and Idiopathic Parkinson's Disease SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE REP1; risk; age at onset; relative predispositional effects; mode of inheritance ID LOCUS TRIPLICATION; ALLELIC VARIATION; NACP-REP1; SUSCEPTIBILITY; SNCA; RELIABILITY; DUPLICATION; ONSET; RISK AB Point mutations and copy number variations in SNCA, the gene encoding a-synuclein, cause familial Parkinson's disease (PD). A dinucleotide polymorphism. (REPI.) in the SNCA promoter may be a risk factor for common forms of PD. We studied 1,802 PD patients and 2,129 controls from the NeuroGenetics Research Consortium, using uniform, standardized protocols for diagnosis, subject recruitment, data collection, genotyping, and data analysis. Three common REP1 alleles (257, 259, and 261 bp, with control frequencies of 0.28, 0.65, and 0.06) and several rare alleles (combined frequency <0.01) were detected. We confirmed association of REP1 with PD risk [odds ratio (OR)=0.86, P=0.006 for 257-carriers; OR=1.25, P=0.022 for 261-carriers]. Using a normalization procedure, we showed that the 257 and 261 alleles are both independently associated with PD risk (for 257, P=0.002 in overall data, 0.003 in non-familial PD, 0.001 in early-onset PD; for 261, P=0.056 in overall data, 0.024 in non-familial PD, 0.052 in early-onset PD). The 257-associated risk was consistent with a dominant model [hazard ratio (HR)=0.99, P=0.91 for 257/257 vs. 257/X where X denotes all other common alleles; HR=1.16, P=0.004 for X/X vs. 257/X]. The 261-associated risk was consistent with a recessive model (HR=1.89, P=0.026 for 261/261 vs. 261/X; HR=0.95, P=0.42 for X/X vs. 261/X). Genotype-specific mean onset ages (+/- SD) ranged from 54.8 +/- 12.1 for 261/261 to 59.4 +/- 11.5 for 257/257, displaying a trend of decreasing onset age with increasing allele size (P=0.055). Genetic variation in SNCA and its regulatory regions play an important role in both familial and sporadic PD. (C) 2008 Wiley-Liss, Inc. C1 [Kay, Denise M.; Montimurro, Jennifer S.; Keefe, Robert G.; Atkins, April J.; Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Div Genet Disorders, Albany, NY 12208 USA. [Factor, Stewart A.; Higgins, Donald S.] Albany Med Ctr, Parkinsons Dis & Movement Disorder Clin, Albany, NY USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Samii, Ali; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Samii, Ali; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Griffith, Alida; Leis, Berta C.] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Yearout, Dora; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Div Genet Disorders, POB 22002, Albany, NY 12208 USA. EM hpayami@wadsworth.org OI Kay, Denise/0000-0002-9928-2698 FU Michael J. Fox Foundation; National Institutes of Health (NIH) [NS R01-36960, K08-NS044138, AG 08017]; VA Merit Award; Mental Health and Geriatric Research Education and Clinical Centers; Genomics Institute of the New York State Department of Health Wadsworth Center FX Grant sponsor: Michael J. Fox Foundation Edmond J. Safra Global Genetics Consortia Grant-Grant sponsor: National Institutes of Health (NIH) National Institute for Neurological Disorders and Stroke grants; Grant numbers: NS R01-36960, K08-NS044138; Grant sponsor: VA Merit Award; Grant sponsor: NIH National Institutes of Aging grant; Grant number: AG 08017; Grant sponsor: Mental Health and Geriatric Research Education and Clinical Centers at the VA Puget Sound Health Care System; Grant sponsor: Genomics Institute of the New York State Department of Health Wadsworth Center. NR 26 TC 36 Z9 37 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD OCT 5 PY 2008 VL 147B IS 7 BP 1222 EP 1230 DI 10.1002/ajmg.b.30758 PG 9 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 359IK UT WOS:000259979500029 PM 18404644 ER PT J AU Turner, EH Moaleji, NJ Arnold, BL AF Turner, Erick H. Moaleji, Norwan J. Arnold, Beth L. TI Closing a loophole in the FDA Amendments Act SO SCIENCE LA English DT Letter ID MYOCARDIAL-INFARCTION; RISK; ROSIGLITAZONE; PUBLICATION; TRIALS C1 [Turner, Erick H.] Portland VA Med Ctr, Portland, OR 97239 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Moaleji, Norwan J.] Loma Linda Vet Affairs Med Ctr, Loma Linda, CA 92357 USA. [Arnold, Beth L.] Fircrest Sch RHC, Shoreline, WA 98155 USA. RP Turner, EH (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. EM turnere@ohsu.edu OI Turner, Erick/0000-0002-3522-3357 NR 6 TC 10 Z9 10 U1 0 U2 1 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD OCT 3 PY 2008 VL 322 IS 5898 BP 44 EP 45 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 355AE UT WOS:000259680200019 PM 18832629 ER PT J AU Goldberger, ZD Weinberger, SE Nicosia, RF Saint, S Young, BA AF Goldberger, Zachary D. Weinberger, Steven E. Nicosia, Roberto F. Saint, Sanjay Young, Bessie A. TI Variations on a theme SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID GLOMERULAR BASEMENT-MEMBRANE; GOODPASTURES-SYNDROME; ALVEOLAR HEMORRHAGE; ANTIBODY DISEASE; GLOMERULONEPHRITIS; EXPOSURE C1 [Goldberger, Zachary D.; Saint, Sanjay] Univ Michigan Hlth Syst, Dept Internal Med, Div Cardiovasc Med, CVC Cardiovasc Med, Ann Arbor, MI 48109 USA. [Saint, Sanjay] Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI 48109 USA. [Saint, Sanjay] Univ Michigan Hlth Syst, Patient Safety Enhancement Program, Ann Arbor, MI 48109 USA. [Goldberger, Zachary D.; Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Nicosia, Roberto F.] Vet Affairs Puget Sound Hlth Care Syst, Pathol Serv, Seattle, WA USA. [Nicosia, Roberto F.] Vet Affairs Puget Sound Hlth Care Syst, Lab Serv, Seattle, WA USA. [Nicosia, Roberto F.] Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA USA. [Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Div Nephrol, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA USA. [Weinberger, Steven E.] Amer Coll Physicians, Philadelphia, PA USA. RP Goldberger, ZD (reprint author), Univ Michigan Hlth Syst, Dept Internal Med, Div Cardiovasc Med, CVC Cardiovasc Med, 1500 E Med Ctr Dr,SPC 5853, Ann Arbor, MI 48109 USA. EM zgoldber@med.umich.edu FU Advanced Career Development Award; Health Services Research and Development Program of the Department of Veterans Affairs; National Institutes of Health [RO1 DK079745-01] FX We thank Drs. David Au, Vijay Reddy, and Heather Davidson for their care of the patient. NR 15 TC 2 Z9 3 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 2 PY 2008 VL 359 IS 14 BP 1502 EP 1507 DI 10.1056/NEJMcps0708762 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 354ID UT WOS:000259631700012 PM 18832249 ER PT J AU Huddle, TS Heudebert, GR AF Huddle, Thomas S. Heudebert, Gustavo R. TI Internal Medicine Training in the 21st Century SO ACADEMIC MEDICINE LA English DT Article ID RECOMMENDATIONS AB Many are calling for changes for internal medicine training, arguing that changes in the practice environment mandate changes in how the internal medicine residency is structured. Residency could be shorter, more conducive to role differentiation among general internists, and more supportive of subspecialization. Training could provide more experience in ambulatory care, multidisciplinary team-based care, chronic disease management, and quality improvement. The authors contend that the claim that internal medicine training ought to mirror internal medicine practice is mistaken. Many changes now proposed would likely damage if not destroy the consultant-generalist ideal of traditional internal medicine training which remains critical to effective medical care in the 21st century. The authors propose a model for training similar in structure but different in spirit from contending models. This model, like others, would involve a core experience in the first two years with tracking in the final year; unlike others, it would provide a conceptually coherent experience based on internal medicine's traditional ideal. Outpatient experience would be subsidiary to a predominantly inpatient experience, and it would be structured in blocks rather than continuity clinics. Twenty-first-century internists will continue to face what has always been the internist's task: the resolution of complex and ill-defined patient problems into proper diagnoses and therapeutic options. Contemporary internal medicine training must fit trainees for that task and must, thus, continue to offer the training experience necessary for the realization of the Oslerian ideal: a substantial apprenticeship taking care of inpatients with a wide range of medical illnesses. C1 [Huddle, Thomas S.] UAB, Sch Med, Div Gen Internal Med, Birmingham, AL 35294 USA. [Huddle, Thomas S.] Birmingham VA Med Ctr, Birmingham, AL USA. [Heudebert, Gustavo R.] Univ Alabama, Sch Med, Dept Med, Birmingham, AL 35294 USA. RP Huddle, TS (reprint author), UAB, Sch Med, Div Gen Internal Med, 1530 3rd Ave S,FOT 720, Birmingham, AL 35294 USA. EM thuddle@uab.edu NR 14 TC 19 Z9 19 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD OCT PY 2008 VL 83 IS 10 BP 910 EP 915 DI 10.1097/ACM.0b013e3181850a92 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 466IJ UT WOS:000267654500006 PM 18820519 ER PT J AU Bagic, A Theodore, WH Boudreau, EA Bonwetsch, R Greenfield, J Elkins, W Sato, S AF Bagic, A. Theodore, W. H. Boudreau, E. A. Bonwetsch, R. Greenfield, J. Elkins, W. Sato, S. TI Towards a non-invasive interictal application of hypothermia for treating seizures: a feasibility and pilot study SO ACTA NEUROLOGICA SCANDINAVICA LA English DT Article DE brain; core temperature; cortical excitability; epilepsy; non-invasive hypothermia; interictal cooling; seizures; treatment ID EXPERIMENTAL NEOCORTICAL SEIZURES; TEMPERATURE-MEASUREMENT; FOCAL SEIZURES; TECHNICAL NOTE; CRITICAL-CARE; EPILEPSY; BRAIN; PLACEBO; CORTEX; TERMINATION AB Objectives - To evaluate the feasibility and safety of head-neck cooling in conscious normal volunteers (10) and patients with medically refractory epilepsy (5) without causing shivering. Patients and methods - We used a non-invasive head-neck cooling system (CoolSystems Inc., Lincoln, CA, USA). The tympanic temperature (TT) and intestinal temperature (IT) were measured as two measurements of 'core temperature' (CT), and multi-site external temperatures, several physiologic variables and EEG were monitored. Seizure counts over 4-week precooling, treatment and follow-up phases were compared. Results - All 15 participants completed all the cooling sessions without significant complaints. At the end of 60 min of cooling, scalp temperature fell on average by 12.2 degrees C (P < 0.001), TT by 1.67 degrees C (P < 0.001), and IT by 0.12 degrees C (P = NS). Average weekly seizure frequency decreased from 2.7 to 1.7 events per patient per week (MANOVA: P < 0.05). Conclusions - Non-invasive head-neck cooling is safe and well-tolerated. Initial pilot data in patients suggest that additional therapeutic studies are warranted. C1 [Bagic, A.] Univ Pittsburgh, Sch Med, CABMSI, Pittsburgh, PA 15213 USA. [Bagic, A.; Bonwetsch, R.; Greenfield, J.; Sato, S.] NINDS, NIH, EEG Sect, Bethesda, MD 20892 USA. [Bagic, A.; Theodore, W. H.] NINDS, NIH, Clin Epilepsy Sect, Bethesda, MD 20892 USA. [Boudreau, E. A.] Portland VA Med Ctr, Portland, OR USA. [Elkins, W.] CoolSyst Inc, Lincoln, CA USA. BioCool Technol, Lincoln, CA USA. RP Bagic, A (reprint author), Univ Pittsburgh, Sch Med, CABMSI, Suite 811,Kaufmann Med Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA. EM bagica@upmc.edu FU Intramural NIH HHS [Z01 NS002236-33] NR 38 TC 9 Z9 9 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0001-6314 J9 ACTA NEUROL SCAND JI Acta Neurol. Scand. PD OCT PY 2008 VL 118 IS 4 BP 240 EP 244 DI 10.1111/j.1600-0404.2008.01008.x PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 345BC UT WOS:000258970000005 PM 18355392 ER PT J AU Casserly, IP AF Casserly, Ivan P. TI Interventional Management of Critical Limb Ischemia in Renal Patients SO ADVANCES IN CHRONIC KIDNEY DISEASE LA English DT Article DE Kidney insufficiency; End-stage renal disease; Critical limb ischemia; Revascularization; Endovascular therapy; Limb salvage ID PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL-DISEASE; SURGICAL REVASCULARIZATION; BYPASS-SURGERY; INSUFFICIENCY; MORTALITY; FIBROSIS; DIALYSIS; OUTCOMES; SALVAGE AB Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral arterial disease (PAD), defined as the presence of chronic ischemic rest pain, ulcers, or gangrene attributable to objectively proven arterial occlusive disease. The occurrence of CLI in patients with kidney insufficiency portends a strikingly high rate of subsequent morbidity and mortality. Generally, the primary therapy for CLI is revascularization of the affected limb. However, patients with CLI and kidney insufficiency represent a unique and challenging patient subset, and data from surgical series suggest reduced rates of limb salvage and higher medium and long-term mortality rates for patients with kidney insufficiency compared with those with normal kidney function. In contemporary practice, endovascular techniques are fast replacing surgical bypass as the first-line revascularization strategy for CLI, based on high technical success rates and low rates of procedure-related morbidity and mortality. However, a large series on endovascular outcomes for the treatment of CLI in patients with kidney insufficiency is lacking. Based on the severely reduced long-term survival rates of patients with CLI and kidney insufficiency, future efforts should focus on early detection of PAD in patients with kidney insufficiency and institution of aggressive medical therapy to prevent progression in the global burden of atherosclerosis in this patient population. Published by Elsevier Inc. C1 Denver VA Med Ctr, Denver, CO USA. Univ Colorado Hlth Sci Aurora, Aurora, CO USA. RP Casserly, IP (reprint author), Univ Colorado Hosp, Cardiac & Vasc Ctr, Mail Stop B-132,Anschutz Med Campus,Leprino Bldg,, Aurora, CO 80045 USA. EM ivan.casserly@uchsc.edu NR 27 TC 13 Z9 14 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1548-5595 J9 ADV CHRONIC KIDNEY D JI Adv. Chronic Kidney Dis. PD OCT PY 2008 VL 15 IS 4 BP 384 EP 395 DI 10.1053/j.ackd.2008.07.008 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA 360YH UT WOS:000260094200009 PM 18805385 ER PT J AU Strong, R Miller, RA Astle, CM Floyd, RA Flurkey, K Hensley, KL Javors, MA Leeuwenburgh, C Nelson, JF Ongini, E Nadon, NL Warner, HR Harrison, DE AF Strong, Randy Miller, Richard A. Astle, Clinton M. Floyd, Robert A. Flurkey, Kevin Hensley, Kenneth L. Javors, Martin A. Leeuwenburgh, Christiaan Nelson, James F. Ongini, Ennio Nadon, Nancy L. Warner, Huber R. Harrison, David E. TI Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice SO AGING CELL LA English DT Article DE aging; aspirin; longevity; mice; nordihydroguaiaretic acid ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TERT-BUTYL NITRONE; COLORECTAL-CANCER; BREAST-CANCER; RATS; 5-LIPOXYGENASE; ACTIVATION; GROWTH; CELLS; MODEL AB The National Institute on Aging's Interventions Testing Program was established to evaluate agents that are purported to increase lifespan and delay the appearance of age-related disease in genetically heterogeneous mice. Up to five compounds are added to the study each year and each compound is tested at three test sites (The Jackson Laboratory, University of Michigan, and University of Texas Health Science Center at San Antonio). Mice in the first cohort were exposed to one of four agents: aspirin, nitroflurbiprofen, 4-OH-alpha-phenyl-N-tert-butyl nitrone, or nordihydroguaiaretic acid (NDGA). Sample size was sufficient to detect a 10% difference in lifespan in either sex, with 80% power, using data from two of the three sites. Pooling data from all three sites, a log-rank test showed that both NDGA (p = 0.0006) and aspirin (p = 0.01) led to increased lifespan of male mice. Comparison of the proportion of live mice at the age of 90% mortality was used as a surrogate for measurement of maximum lifespan; neither NDGA (p = 0.12) nor aspirin (p = 0.16) had a significant effect in this test. Measures of blood levels of NDGA or aspirin and its salicylic acid metabolite suggest that the observed lack of effects of NDGA or aspirin on lifespan in females could be related to gender differences in drug disposition or metabolism. Further studies are warranted to find whether NDGA or aspirin, over a range of doses, might prove to postpone death and various age-related outcomes reproducibly in mice. C1 [Strong, Randy] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Strong, Randy] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA. [Miller, Richard A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA. [Miller, Richard A.] Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA. [Astle, Clinton M.; Flurkey, Kevin; Harrison, David E.] Jackson Lab, Bar Harbor, ME 04609 USA. [Floyd, Robert A.; Hensley, Kenneth L.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. [Floyd, Robert A.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA. [Javors, Martin A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Leeuwenburgh, Christiaan] Univ Florida, Dept Aging & Geriatr, Gainesville, FL 32610 USA. [Nelson, James F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Nelson, James F.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Ongini, Ennio] Nicox Res Inst, Milan, Italy. [Nadon, Nancy L.] NIA, Biol Aging Program, Bethesda, MD 20892 USA. [Warner, Huber R.] Univ Minnesota, Coll Biol Sci, St Paul, MN 55108 USA. RP Strong, R (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM strong@uthscsa.edu FU National Institute on Aging [AG022303, AG025707, AG022308, AG022307, AG13319]; Department of Veterans Affairs FX This work was supported by National Institute on Aging grants AG022303 (R.A.M.), AG025707 and AG022308 (D.E.H.), and AG022307 and AG13319 (R.S.), and the Department of Veterans Affairs (R.M. and R.S.). We wish to thank Vivian Diaz, Elizabeth Fernandez, Greg Friesenhahn, Melissa Han, Patricia Harrison, Roni Kobrosly, Bill Kohler, Pam Krason, Jessica Sewald, and Maggie Lauderdale for technical support. We thank Scott Pletcher and Andrzej Galecki for assistance in power analysis and study design. NR 51 TC 103 Z9 106 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1474-9718 J9 AGING CELL JI Aging Cell PD OCT PY 2008 VL 7 IS 5 BP 641 EP 650 DI 10.1111/j.1474-9726.2008.00414.x PG 10 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 349TU UT WOS:000259307000005 PM 18631321 ER PT J AU Sands, LP Xu, H Craig, BA Eng, C Covinsky, KE AF Sands, Laura P. Xu, Huiping Craig, Bruce A. Eng, Catherine Covinsky, Kenneth E. TI Predicting change in functional status over quarterly intervals for older adults enrolled in the PACE community-based long-term care program SO AGING CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE ADL status; change in functioning; long-term care ID PHYSICAL PERFORMANCE; UNITED-STATES; RISK-FACTORS; HOME HEALTH; UNMET NEED; DISABILITY; DEPENDENCE; DECLINE; SERVICES; RECOVERY AB Background and aims: Many frail older adults experience multiple changes in activities of daily living (ADL) functioning over the course of a year. Accurate predictions of ADL status over quarterly intervals may improve the precision of care planning for older adults who seek long-term care in the community. The study sought to develop and validate a model that predicts older adults' ADL status over quarterly intervals. Methods: The study included 3127 enrollees from 11 Program of All Inclusive Care for the Elderly (PACE) sites. Nurses assessed ADL status quarterly. Potential predictors included baseline assessment of age, sex, race, and living situation and quarterly assessments of prior functioning, co-morbidities, prior hospitalizations, and mental status. Results: Change in level of functioning occurred for 30% of quarterly observations. Predictors of functioning at the end of a quarter were prior ADL change, prior hospitalization, living with others, impaired mental status., cancer, dementia, coronary artery disease, congestive heart failure and chronic obstructive pulmonary disease. When the model was applied to the validation observations, 93% of predictions were within one level and 72% of the predictions were the same level of ADL functioning observed at the end of the quarter. Conclusions: In a sample of community-living ADL-disabled older adults, changes in functional status over a quarter were common and associated with functional and health status at the beginning of the quarter. Further validation of the model may result in an index that helps clinicians better predict future ADL needs of community-living older adults who need long-term care. (Aging Clin Exp Res 2008; 20: 419-427) (c) 2008, Editrice Kurtis. C1 [Sands, Laura P.] Purdue Univ, Sch Nursing, W Lafayette, IN 47907 USA. [Sands, Laura P.; Craig, Bruce A.] Purdue Univ, Ctr Aging & Life Course, W Lafayette, IN 47907 USA. [Eng, Catherine] OnLok Senior Hlth Serv, San Francisco, CA USA. [Eng, Catherine; Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.] Univ Calif San Francisco, MT Z Ctr Aging, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Sands, LP (reprint author), Purdue Univ, Sch Nursing, 502 N Univ St, W Lafayette, IN 47907 USA. EM lsands@nursing.purdue.edu RI Craig, Bruce/D-5797-2017; Sands, Laura/E-8919-2015 OI Craig, Bruce/0000-0001-9346-467X; Sands, Laura/0000-0003-2446-4486 FU NIH [R01AG-022090, R01AG023626] FX This work was supported by NIH grants R01AG-022090 and R01AGO23626 to L. Sands and K. Covinsky, respectively. A portion of this paper was presented at the 58th Annual Scientific meeting of the Gerontological Society of America, Washington DC. NR 36 TC 5 Z9 5 U1 1 U2 5 PU EDITRICE KURTIS S R L PI MILAN PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY SN 1594-0667 J9 AGING CLIN EXP RES JI Aging Clin. Exp. Res. PD OCT PY 2008 VL 20 IS 5 BP 419 EP 427 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 381BR UT WOS:000261510300006 PM 19039283 ER PT J AU Pyne, JM Asch, SM Lincourt, K Kilbourne, AM Bowman, C Atkinson, H Gifford, A AF Pyne, Jeffrey M. Asch, Steven M. Lincourt, Katherine Kilbourne, Amy M. Bowman, Candice Atkinson, Hamp Gifford, Allen TI Quality indicators for depression care in HIV patients SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE depression; expert panel; HIV; quality of care ID MULTICENTER AIDS COHORT; ANTIRETROVIRAL THERAPY; HEALTH-CARE; PSYCHIATRIC COMORBIDITY; INFECTED PATIENTS; RISK-FACTORS; DRUG-USERS; ADHERENCE; SYMPTOMS; DISORDERS AB HIV patients are at increased risk for depression. However, a comprehensive set of quality of care indicators for depression in the context of HIV does not exist. We report the results of a recent expert panel convened to develop a comprehensive set of HIV depression quality indicators. We systematically reviewed the depression and HIV depression literature to provide the evidence for the quality indicators. The HIV depression quality indicators were divided into six chapters: general, bereavement, substance abuse, viral hepatitis, cognitive impairment and drug interactions. A modified Delphi expert panel method was used to evaluate the validity and feasibility of the candidate quality indicators. The expert panel included HIV physicians, psychiatrists and a pharmacist, all with experience with HIV depression. The in-person eleven-member panel rated 80 candidate HIV-depression quality indicators. Indicators were evaluated using main and sensitivity analysis criteria for validity and feasibility. Seventy-four percent (59/80) of the quality indicators met a priori main analysis criteria for validity and feasibility and 61% met sensitivity analysis criteria. Approved indicators that are more specific to HIV depression include: depression screening frequency; depression screening and treatment in the context of hepatitis C optimizing depression and HIV treatment in the context of cognitive impairment;, and starting antidepressants at lower doses but advancing to doses typical for the general population. Most adverse medication interaction indicators did not meet main analysis validity criteria. The quality indicators identified in this study provide a useful tool for measuring and informing the quality of HIV-depression care. C1 [Pyne, Jeffrey M.; Lincourt, Katherine] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. [Asch, Steven M.] GLAHS, Dept Vet Affairs, Los Angeles, CA USA. [Kilbourne, Amy M.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kilbourne, Amy M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Kilbourne, Amy M.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Bowman, Candice] VA San Diego Healthcare Syst, QUERI HIV, Hlth Serv Res & Dev, San Diego, CA USA. [Atkinson, Hamp] San Diego Vet Healthcare Syst, Psychiat Serv, San Diego, CA USA. [Atkinson, Hamp] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Gifford, Allen] VA Bedford Ctr Hlth Qual, Ctr Hlth Qual Outcomes & Econ Res, Boston, MA USA. EM jmpyne@uams.edu NR 44 TC 9 Z9 9 U1 5 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD OCT PY 2008 VL 20 IS 9 BP 1075 EP 1083 DI 10.1080/09540120701796884 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 363WN UT WOS:000260298300007 PM 18825515 ER PT J AU Al-Khatib, SM Sanders, GD Carlson, M Cicic, A Curtis, A Fonarow, GC Groeneveld, PW Hayes, D Heidenreich, P Mark, D Peterson, E Prystowsky, EN Sager, P Salive, ME Thomas, K Yancy, CW Zareba, W Zipes, D AF Al-Khatib, Sana M. Sanders, Gillian D. Carlson, Mark Cicic, Aida Curtis, Anne Fonarow, Gregg C. Groeneveld, Peter W. Hayes, David Heidenreich, Paul Mark, Daniel Peterson, Eric Prystowsky, Eric N. Sager, Philip Salive, Marcel E. Thomas, Kevin Yancy, Clyde W. Zareba, Wojciech Zipes, Douglas TI Preventing tomorrow's sudden cardiac death today: Dissemination of effective therapies for sudden cardiac death prevention SO AMERICAN HEART JOURNAL LA English DT Editorial Material ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; INITIATE LIFESAVING TREATMENT; LEFT-VENTRICULAR DYSFUNCTION; QUALITY-OF-CARE; TRIAL SCD-HEFT; COST-EFFECTIVENESS; RACIAL DISPARITY; ELDERLY-PATIENTS AB Because the burden of sudden cardiac death (SCD) is substantial, it is important to use all guideline-driven therapies to prevent SCD. Among those therapies is the implantable cardioverter defibrillator (ICD). When indicated, ICD use is beneficial and cost-effective. Unfortunately, studies suggest that most patients who have indications for this therapy for primary or secondary prevention of SCD ore not receiving it. To explore potential reasons for this underuse and to propose potential facilitators for ICD dissemination, the Duke Center for the Prevention of SCD at the Duke Clinical Research Institute (Durham, NC) organized a think tank meeting of experts on this issue. The meeting took place on December 12 and 13, 2007, and it included representatives of clinical cardiology, cardiac electrophysiology, general internal medicine, economics, health policy, the US Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Agency for Health care Research and Quality, and the device and pharmaceutical industry. Although the meeting was funded by industry participants, this article summarizing the presentations and discussions that occurred of the meeting presents the expert opinion of the authors. C1 [Al-Khatib, Sana M.; Sanders, Gillian D.; Mark, Daniel; Peterson, Eric; Thomas, Kevin] Duke Clin Res Inst, Durham, NC 27715 USA. [Carlson, Mark] St Jude Med, Sylmar, CA USA. [Cicic, Aida] Medtronic Inc, Mounds View, MN USA. [Curtis, Anne] Univ S Florida, Tampa, FL USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Groeneveld, Peter W.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Hayes, David] Mayo Clin, Rochester, MN USA. [Heidenreich, Paul] Palo Alto Vet Affairs Hlth Care Syst, Palo Alto, CA USA. [Prystowsky, Eric N.] St Vincents Hosp, Indianapolis, IN USA. [Sager, Philip] CardioDx Inc, Palo Alto, CA USA. [Salive, Marcel E.] Ctr Medicare, Baltimore, MD USA. [Salive, Marcel E.] Ctr Medicaid Serv, Baltimore, MD USA. [Yancy, Clyde W.] Baylor Univ, Med Ctr, Dallas, TX USA. [Zareba, Wojciech] Univ Rochester, Rochester, NY USA. [Zipes, Douglas] Indiana Univ, Indianapolis, IN 46204 USA. RP Al-Khatib, SM (reprint author), Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA. EM alkha001@mc.duke.edu OI Mark, Daniel/0000-0001-6340-8087; Zipes, Douglas/0000-0001-7141-6829; Heidenreich, Paul/0000-0001-7730-8490 NR 60 TC 30 Z9 32 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD OCT PY 2008 VL 156 IS 4 BP 613 EP 622 DI 10.1016/j.ahj.2008.05.027 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 359CH UT WOS:000259963300001 PM 18926144 ER PT J AU Maddox, TM Ross, C Ho, PM Masoudi, FA Magid, D Daugherty, SL Peterson, P Rumsfeld, JS AF Maddox, Thomas M. Ross, Colleen Ho, P. Michael Masoudi, Frederick A. Magid, David Daugherty, Stacie L. Peterson, Pam Rumsfeld, John S. TI Imaging and diagnostic testing - The prognostic importance of abnormal heart rate recovery and chronotropic response among exercise treadmill test patients SO AMERICAN HEART JOURNAL LA English DT Article ID CORONARY-ARTERY DISEASE; BAROREFLEX SENSITIVITY; MYOCARDIAL-INFARCTION; RATE-VARIABILITY; MORTALITY; PREDICTOR; SCORE; INCOMPETENCE; ELECTROCARDIOGRAM; FAILURE AB Background Heart rate recovery (HRR) and chronotropic response to exercise (CR) each have prognostic value among patients undergoing exercise treadmill testing (ETT). However, little is known about their prognostic use in combination and in addition to the Duke Treadmill Score (DTS). Methods We studied 9,519 outpatients undergoing ETT between 2001 and 2004. Patients were categorized by HRR and CR. The primary outcome was all-cause mortality or nonfatal myocardial infarction (MI). Cox proportional hazards modeling was used to control for demographics, clinical history, and DTS. Results After multivariable adjustment for DTS and other demographic and clinical variables, patients with abnormal HRR and CR had higher rates of all-cause mortality or nonfatal MI, as compared to patients with normal HRR and CR (hazard ratio [HR] = 1.90, 95% CI 1.35-2.69). Addition of the HRR and CR to the DTS improved outcome prediction (c-statistic improved from 0.61 to 0.68). Low-risk DTS patients with abnormal HRR and CR had significantly higher rates of all-cause mortality or nonfatal MI (HR 2.59, 95% CI 1.55-4.32), compared to low-risk DTS patients with normal HRR and CR. Conclusions Abnormal HRR and CR identified ETT patients with higher rates of all-cause mortality or nonfatal MI and provided additional risk stratification among low-risk DTS patients. These results support the routine incorporation of HRR and CR in ETT reporting and suggest the need to evaluate whether further testing and/or more intensive treatment of these higher risk patients can improve outcomes. C1 [Maddox, Thomas M.; Ho, P. Michael; Rumsfeld, John S.] Univ Colorado, Denver VAMC, Cardiol Sect 111B, Denver, CO 80209 USA. [Ross, Colleen; Magid, David] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Masoudi, Frederick A.; Peterson, Pam] Univ Colorado, Denver Hlth, Denver, CO 80209 USA. RP Maddox, TM (reprint author), Univ Colorado, Denver VAMC, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80209 USA. EM thomas.maddox@va.gov NR 29 TC 26 Z9 28 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD OCT PY 2008 VL 156 IS 4 BP 736 EP 744 DI 10.1016/j.ahj.2008.05.025 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 359CH UT WOS:000259963300016 PM 18926155 ER PT J AU Garcia, S Moritz, TE Ward, HB Pierpont, G Goldman, S Larsen, GC Littooy, F Krupski, W Thottapurathu, L Reda, DJ McFalls, EO AF Garcia, Santiago Moritz, Thomas E. Ward, Herbert B. Pierpont, Gordon Goldman, Steve Larsen, Greg C. Littooy, Fred Krupski, William Thottapurathu, Lizy Reda, Domenic J. McFalls, Edward O. TI Usefulness of revascularization of patients with multivessel coronary artery disease before elective vascular surgery for abdominal aortic and peripheral occlusive disease SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID LONG-TERM SURVIVAL; NONCARDIAC SURGERY; CARDIAC RISK; CARP TRIAL; MORTALITY; OUTCOMES AB The Coronary Artery Revascularization Prophylaxis (CARP) study showed no survival benefit with preoperative coronary artery revascularization before elective vascular surgery. The generalizability of the trial results to all patients with multivessel. coronary artery disease (CAD) has been questioned. The objective of this study was to determine the impact of prophylactic coronary revascularization on long-term survival in patients with multivessel CAD. Over a 4-year period, 1,048 patients underwent coronary angiography before vascular surgery during screening into the CARP trial. The cohort was composed of registry (n = 586) and randomized (n = 462) patients, and their survival was determined at 2.5 years after vascular surgery. High-risk coronary anatomy without previous bypass surgery included 2-vessel disease (n = 204 [19.5%]), 3-vessel disease (n = 130 [12.4%]), and left main coronary artery stenosis >= 50% (n = 48 [4.6%]). By log-rank test, preoperative revascularization was associated with improved survival in patients with a left main coronary artery stenoses (0.84 vs 0.52, p <0.01) but not those with either 2-vessel (0.80 vs 0.79, p = 0.83) or 3-vessel (0.79 vs 0.71, p = 0.15) disease. In conclusion, unprotected left main coronary artery disease was present in 4.6% of patients who underwent coronary angiography before vascular surgery, and this was the only subset of patients showing a benefit with preoperative coronary artery revascularization. (C) 2008 Elsevier Inc. All rights reserved. C1 [Garcia, Santiago; Ward, Herbert B.; Pierpont, Gordon; McFalls, Edward O.] Univ Minnesota, Vet Affairs Med Ctr, Cardiol Sect, Minneapolis, MN 55455 USA. [Littooy, Fred] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Goldman, Steve] Univ Arizona, So Arizona Vet Affairs Hlth Care Ctr, Tucson, AZ USA. [Larsen, Greg C.] Portland VA Med Ctr, Portland, OR USA. [Larsen, Greg C.] Oregon Hlth & Sci Univ, Portland, OR USA. [Krupski, William] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80202 USA. RP McFalls, EO (reprint author), Univ Minnesota, Vet Affairs Med Ctr, Cardiol Sect, Minneapolis, MN 55455 USA. EM mcfal001@umn.edu FU United States Department of Veterans Affairs, Office of Research and Development, Washington, District of Columbia FX This study was supported by the Cooperative Studies Program of the United States Department of Veterans Affairs, Office of Research and Development, Washington, District of Columbia. NR 16 TC 31 Z9 31 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD OCT 1 PY 2008 VL 102 IS 7 BP 809 EP 813 DI 10.1016/j.amjcard.2008.05.022 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 354CI UT WOS:000259616100003 PM 18805102 ER PT J AU Spiegel, B Strickland, A Naliboff, BD Mayer, EA Chang, L AF Spiegel, Brennan Strickland, Amy Naliboff, Bruce D. Mayer, Emeran A. Chang, Lin TI Predictors of Patient-Assessed Illness Severity in Irritable Bowel Syndrome SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID QUALITY-OF-LIFE; FUNCTIONAL GASTROINTESTINAL DISORDERS; EDUCATIONAL-NEEDS; REPORTED OUTCOMES; SYMPTOM SEVERITY; IMPACT; PAIN; IBS; QUESTIONNAIRE; FIBROMYALGIA AB BACKGROUND: Conceptual models suggest that "irritable bowel syndrome (IBS) severity" is a multidimensional outcome that is related to, yet distinct from, health-related quality of life (HRQOL). Existing severity questionnaires are largely based on physician rather than patient-based ratings. Since severity is a patient-centered outcome, it is essential that future instruments are based on patients' self-perceptions of severity. We measured patient-derived predictors of severity in a large cohort of IBS patients. METHODS: We performed a cross-sectional analysis in 755 IBS patients recruited at a university-based center. Subjects completed a bowel symptom questionnaire, SCL-90, and SF-36. The main outcome was patient-assessed "overall severity of gastrointestinal symptoms," as measured on a 0-20 scale (20 = most severe). We first developed a conceptual model of IBS, and then performed bivariate analyses to identify biopsychosocial predictors of severity. We then entered significant predictors into a multivariable model to measure the independent association of each predictor with severity. RESULTS: Six factors predicted severity: (a) abdominal pain rating (P < 0.001); (b) belief that "something serious is wrong with body" (P < 0.001); (c) straining with defecation (P = 0.001); (d) myalglas (P 0.02); (e) urgency with defecation (P = 0.03); and (f) bloating (P = 0.05). Severity correlated highly with HRQOL in bivariate, but not multivariate, analysis. CONCLUSION: Patient-derived severity in IBS is related to, yet distinct from, generic HRQOL. IBS severity is predicted by abdominal pain, bloating, straining, urgency, myalgias, and disease-related concern. These symptoms fall along both poles of the "brain-gut axis," indicating that a full assessment of patient severity must include a balanced biopsychosocial history. C1 [Spiegel, Brennan; Naliboff, Bruce D.; Mayer, Emeran A.; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90073 USA. [Spiegel, Brennan; Naliboff, Bruce D.; Chang, Lin] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CORE, Los Angeles, CA 90073 USA. [Strickland, Amy] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90073 USA. RP Chang, L (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Ctr Neurovisceral Sci & Womens Hlth, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. FU NCCIH NIH HHS [1 R24AT002681, R24 AT002681, R24 AT002681-01]; NIDDK NIH HHS [P50 DK064539, 2P30DK041301-17, P50 DK64539, P50 DK064539-019001, P30 DK041301] NR 57 TC 57 Z9 58 U1 1 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2008 VL 103 IS 10 BP 2536 EP 2543 DI 10.1111/j.1572-0241.2008.01997.x PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 362DM UT WOS:000260178400018 PM 18637089 ER PT J AU Baruch, L Gupta, B Lieberman-Blum, SS Agarwal, S Eng, C AF Baruch, Lawrence Gupta, Bhanu Lieberman-Blum, Sharon S. Agarwal, Sanjay Eng, Calvin TI Ezetimibe 5 and 10 mg for Lowering LDL-C: Potential Billion-Dollar Savings With Improved Tolerability SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CHOLESTEROL ABSORPTION INHIBITOR; DENSITY-LIPOPROTEIN-CHOLESTEROL; CORONARY-HEART-DISEASE; PRIMARY HYPERCHOLESTEROLEMIA; HIGH-RISK; SIMVASTATIN; TRIAL; MORBIDITY; MORTALITY; THERAPY AB Objective:To compare the clinical efficacy of ezetimibe 5 mg (prescribed as a 10-mg tablet split in half) with a whole 10-mg tablet. Study Design: From January 2003 through July 2005, all Bronx Veterans Administration ezetimibe prescriptions were for 10 mg. In August 2005, it was mandated that all new ezetimibe prescriptions be 5 mg, prescribed as a 10-mg tablet split in half. Methods:The impact of the 2 ezetimibe dosing strategies on percent lowering of low-density lipoprotein cholesterol (LDL-C) and achievement of National Cholesterol Education Program Adult Treatment Panel III (ATP 111) goals was assessed in all patients prescribed ezetimibe 5 or 10 mg. Results: A total of 272 patients were prescribed ezetimibe; 86 received 5 mg and 186 received 10 mg. Of those 272 patients, 197 had evaluable baseline and posttreatment LDL-C (55 taking the 5-mg dose and 142 taking the 10-mg dose). The effects of ezetimibe 5 and 10 mg on all lipid parameters were similar. Ezetimibe 10 mg reduced LDL-C by 26.1%, whereas 5 mg reduced LDL-C by 25.8%. The percentages of patients achieving goal LDL-C were similar: 61.8% (5 mg) and 60.5% (10 mg). Conclusion: These data strongly suggest that ezetimibe 5 mg and ezetimibe 10 mg are clinically equivalent with respect to LDL-C reduction and achievement of ATP III LDL-C goals. Widespread adoption of this low-dose strategy could result in a potential cost savings of more than a billion dollars annually, with a potential reduction in hepatotoxicity. (Am J Manag Care. 2008;14(10):637-641) C1 [Baruch, Lawrence; Gupta, Bhanu; Lieberman-Blum, Sharon S.; Agarwal, Sanjay; Eng, Calvin] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Baruch, Lawrence; Gupta, Bhanu; Agarwal, Sanjay; Eng, Calvin] Mt Sinai Sch Med, New York, NY USA. RP Baruch, L (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM lawrence.baruch@va.gov NR 27 TC 3 Z9 4 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD OCT PY 2008 VL 14 IS 10 BP 637 EP 641 PG 5 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 357VQ UT WOS:000259875700001 PM 18837641 ER PT J AU Mallya, G Pollack, CE Polsky, D AF Mallya, Giridhar Pollack, Craig Evan Polsky, Daniel TI Are Primary Care Physicians Ready to Practice in a Consumer-Driven Environment? SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID DIRECTED HEALTH PLANS; OF-POCKET COSTS; QUALITY AB Objective:To evaluate physicians' readiness to care for patients enrolled in consumer-directed health plans (CDHPs), which change the nature of cost sharing and medical decision making in primary care. Study Design: Mailed cross-sectional survey of 1500 nationally representative primary care physicians. Methods: Physicians' knowledge of CDHP benefit design, readiness to advise patients about financial issues, and views regarding the role of quality-of-care information in patient decision making were assessed. Results were analyzed using descriptive statistics and multivariate models. Results: Five hundred twenty-eight of 1076 eligible physicians (49%) responded to the survey. Forty percent of physicians had CDHP enrollees in their practices. Forty-three percent of physicians reported low knowledge of CDHP cost sharing, and approximately one-third reported low knowledge of how medical savings accounts function. Overall, physicians with CDHP enrollees in their practices had higher knowledge than physicians without these patients; however, 1 in 4 of these providers reported low knowledge of CDHP cost sharing. More than two-thirds of all physicians were ready to advise patients on the costs of office visits, medications, and laboratory tests; approximately half or less were ready to advise on the costs of radiologic studies, specialist visits, and hospitalizations, Forty-eight percent were ready to discuss medical budgets with patients. Twenty-one percent of physicians thought that patients could trust quality-of-care information from government Web sites, and 8% thought that patients could trust quality-of-care information from insurance Web sites. Conclusion: Many primary care physicians report low knowledge of CDHPs, limited readiness to advise patients on issues of cost and medical budgeting, and minimal trust in quality-of-care information. (Am J Manag Care. 2008;14(10):667-668) C1 [Mallya, Giridhar; Pollack, Craig Evan] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Mallya, Giridhar; Pollack, Craig Evan; Polsky, Daniel] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Polsky, Daniel] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Polsky, Daniel] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Polsky, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Mallya, G (reprint author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 423 Guardian Dr,1303A Blockley Hall, Philadelphia, PA 19104 USA. EM gmallya@mail.med.upenn.edu FU Robert Wood Johnson Clinical Scholars Program FX This Study was supported by the Robert Wood Johnson Clinical Scholars Program. The funder had no role in the design or conduct of the Study; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript. NR 25 TC 10 Z9 10 U1 0 U2 4 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD OCT PY 2008 VL 14 IS 10 BP 661 EP 668 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 357VQ UT WOS:000259875700004 PM 18837644 ER PT J AU Forooghian, F Macdonald, IM Heckenlively, JR Heon, E Gordon, LK Hooks, JJ Detrick, B Nussenblatt, RB AF Forooghian, Farzin Macdonald, Ian M. Heckenlively, John R. Heon, Elise Gordon, Lynn K. Hooks, John J. Detrick, Barbara Nussenblatt, Robert B. TI The need for standardization of antiretinal antibody detection and measurement SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID CANCER-ASSOCIATED RETINOPATHY; ALPHA-ENOLASE AUTOANTIBODIES; PARANEOPLASTIC RETINOPATHY; AUTOIMMUNE RETINOPATHY; RETINAL AUTOANTIBODIES; RECOVERIN ANTIBODIES; PHOTORECEPTOR DEGENERATION; RETINITIS-PIGMENTOSA; ENDOMETRIAL CANCER; APOPTOTIC DEATH AB PURPOSE: To review the current literature on the detection and measurement of antiretinal antibodies. DESIGN: Collaborative essay. METHODS: Literature review and interpretation. RESULTS: There is strong evidence to suggest a role for antiretinal antibodies, particularly those targeting recoverin and alpha-enolase, in the pathogenesis of autoimmune retinopathy (AIR). Additionally, numerous other autoantibodies have been described as putative mediators of retinal degeneration and more remain to be discovered. However, assay methods described in the literature by many laboratories for the detection of circulating antiretinal antibodies have been varied and diverse, making it difficult to interpret and compare their results. CONCLUSIONS: There is currently little standardization of laboratory methods used to detect and monitor antiretinal antibodies. To measure and monitor levels of circulating antiretinal antibodies optimally in patients with AIR, development of standardized assays with stringent internal controls is required. A multicenter collaborative and validation effort is encouraged to reach a consensus on this issue. C1 [Hooks, John J.; Nussenblatt, Robert B.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA. [Forooghian, Farzin] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA. [Macdonald, Ian M.] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA. [Heckenlively, John R.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA. [Heon, Elise] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada. [Heon, Elise] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Gordon, Lynn K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Jules Stein Eye Inst,Ocular Inflammatory Dis Ctr, Los Angeles, CA 90095 USA. [Gordon, Lynn K.] Greater Los Angeles Vet Affairs Healthcare Serv, Los Angeles, CA USA. [Nussenblatt, Robert B.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. RP Nussenblatt, RB (reprint author), NEI, Immunol Lab, NIH, Bldg 10,Rm 10N112,10 Ctr Dr, Bethesda, MD 20892 USA. EM drbob@nei.nih.gov OI MacDonald, Ian/0000-0001-7472-8385 FU NATIONAL EYE INSTITUTE INTRAMURAL RESEARCH PROGRAM, NATIONAL INSTITUTES of Health, Bethesda, Maryland FX THIS STUDY WAS SUPPORTED BY THE NATIONAL EYE INSTITUTE INTRAMURAL RESEARCH PROGRAM, NATIONAL INSTITUTES of Health, Bethesda, Maryland. The authors indicate no financial conflict of interest. Involved in design and conduct of study (F.F., I.M.M., J.R.H., E.H., L.K.G., J.H.J., B.D., R.B.N.); collection, management, analysis, and interpretation of the data (F.F., I.M.M., J.R.H., E.H., L.K.G., J.H.J., B.D., R.B.N.); and preparation, review, and approval of the manuscript (F.F., I.M.M., J.R.H., E.H., L.K.G., J.H.J., B.D., R.B.N.). The authors thank Dr Robert Fariss, National Eye Institute, Bethesda, Maryland for his technical advice on immunohistochemical detection of antiretinal antibodies. NR 62 TC 25 Z9 26 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD OCT PY 2008 VL 146 IS 4 BP 489 EP 495 DI 10.1016/j.ajo.2008.05.046 PG 7 WC Ophthalmology SC Ophthalmology GA 355XH UT WOS:000259742200003 PM 18672221 ER PT J AU Ding, D Souza, A Cooper, RA Fitzgerald, SG Cooper, R Kelleher, A Boninger, ML AF Ding, Dan Souza, Ana Cooper, Rory A. Fitzgerald, Shirley G. Cooper, Rosemarie Kelleher, Annmarie Boninger, Michael L. TI A preliminary study on the impact of pushrim-activated power-assist wheelchairs among individuals with tetraplegia. SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE wheelchairs; spinal cord injury; community participation; assistive technology ID MANUAL WHEELCHAIR; STROKE FREQUENCY; NERVE FUNCTION; PROPULSION; MOTION; PERFORMANCE; EFFICIENCY; RANGE; PAIN AB Objectives: This preliminary study was to evaluate the impact of pushrim-activated power-assist wheelchairs (PAPAWs) on mobility, community participation, satisfaction, and psychosocial impact among individuals with tetraplegia. Design: Fifteen manual wheelchair users with tetraplegia completed a 4-wk protocol including a 2-wk trial where they used their personal wheelchairs for mobility and a 2-wk trial where they were provided with a PAPAW and could choose either wheelchair for mobility. The mobility levels with both wheelchair's were recorded by a datarlogger. Participants completed daily questionnaires regarding community participation and their satisfaction with the wheelchair used. The Psychosocial Impact of Assistive Devices Scale was used to compare the psychosocial impact of PAPAWs with their personal wheelchairs. Results: Participants chose to use PAPAWs and their personal wheelchairs at a similar frequency in the PAPAW trial. The distances traveled with both wheelchairs were not statistically different (P = 0.09). Participants traveled significantly faster with PAPAWs (P = 0.03). PAPAWs did not result in significantly greater community participation, satisfaction, and psychosocial impacts than the personal wheelchairs. Conclusions: PAPAWs could be a viable mobility option for individuals with tetraplegia, which can provide independent mobility especially for outdoor activities. A user's preference, life sty le, physical conditions, transportation issues, and environmental factors should be considered in prescribing such a device. C1 [Ding, Dan; Souza, Ana; Cooper, Rory A.; Kelleher, Annmarie; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Ding, Dan; Souza, Ana; Cooper, Rory A.; Cooper, Rosemarie; Kelleher, Annmarie; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Fitzgerald, Shirley G.] James A Haley Tampa VA, Patient Safety Ctr, Tampa, FL USA. RP Ding, D (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,Bldg 4,2nd Floor E,151R1-H, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X NR 23 TC 16 Z9 16 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD OCT PY 2008 VL 87 IS 10 BP 821 EP 829 DI 10.1097/PHM.0b013e318186bd1a PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 355AJ UT WOS:000259680700006 PM 18806509 ER PT J AU Zavadzkas, JA Plyler, RA Bouges, S Koval, CN Rivers, WT Beck, CU Chang, EI Stroud, RE Mukherjee, R Spinale, FG AF Zavadzkas, Juozas A. Plyler, Rebecca A. Bouges, Shenikqua Koval, Christine N. Rivers, William T. Beck, Christy U. Chang, Eileen I. Stroud, Robert E. Mukherjee, Rupak Spinale, Francis G. TI Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE ventricular function ID HEART-FAILURE; IN-VITRO; IMMUNOGLOBULIN SUPERFAMILY; COLLAGEN-SYNTHESIS; TARGETED DELETION; CYCLOPHILIN-A; EMMPRIN CD147; CANCER CELLS; MEMBRANE; FIBROBLASTS AB The matrix metalloproteinases ( MMPs) play a pivotal role in adverse left ventricular (LV) myocardial remodeling. The transmembrane protein extracellular MMP inducer ( EMMPRIN) causes increased MMP expression in vitro, and elevated levels occur in patients with LV failure. However, the direct consequences of a prolonged increase in the myocardial expression of EMMPRIN in vivo remained unexplored. Cardiac-restricted EMMPRIN expression (EMMPRINexp) was constructed in mice using the full-length human EMMPRIN gene ligated to the myosin heavy chain promoter, which yielded approximately a twofold increase in EMMPRIN compared with that of the age/strain-matched wild-type (WT) mice; EMMPRINexp (n = 27) and WT (n = 33) mice were examined at 3.2 +/- 0.1 or at 13.3 +/- 0.5 mo of age (n = 43 and 26, respectively). LV end-diastolic volume (EDV) was similar in young EMMPRINexp and WT mice (54 +/- 2 vs. 57 +/- 3 mu l), but LV ejection fraction (EF) was reduced (51 +/- 1 vs. 57 +/- 1%; P < 0.05). In old EMMPRINexp mice, LV EDV was increased compared with WT mice values (76 +/- 3 vs. 58 +/- 3 mu l; P < 0.05) and LV EF was significantly reduced (45 +/- 1 vs. 57 +/- 2%; P < 0.05). In EMMPRINexp old mice, myocardial MMP-2 and membrane type-1 MMP levels were increased by > 50% from WT values (P < 0.05) and were accompanied by a twofold higher collagen content (P < 0.05). Persistent myocardial EMMPRINexp in aging mice caused increased levels of both soluble and membrane type MMPs, fibrosis, and was associated with adverse LV remodeling. These findings suggest that EMMPRIN is an upstream signaling pathway that can play a mechanistic role in adverse remodeling within the myocardium. C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Rm 625,770 MUSC Complex,114 Doughty St, Charleston, SC 29425 USA. EM wilburnm@musc.edu OI Chang, Eileen/0000-0002-3444-7260 FU Veterans Affairs Health Administration FX This study was supported by a merit award from the Veterans Affairs Health Administration (to F. G. Spinale). NR 53 TC 23 Z9 27 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD OCT PY 2008 VL 295 IS 4 BP H1394 EP H1402 DI 10.1152/ajpheart.00346.2008 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 357PB UT WOS:000259857500006 PM 18689500 ER PT J AU Chang, DW Hayashi, S Gharib, SA Vaisar, T King, ST Tsuchiya, M Ruzinski, JT Park, DR Matute-Bello, G Wurfel, MM Bumgarner, R Heinecke, JW Martin, TR AF Chang, Dong W. Hayashi, Shinichi Gharib, Sina A. Vaisar, Tomas King, S. Trevor Tsuchiya, Mitsuhiro Ruzinski, John T. Park, David R. Matute-Bello, Gustavo Wurfel, Mark M. Bumgarner, Roger Heinecke, Jay W. Martin, Thomas R. TI Proteomic and computational analysis of bronchoalveolar proteins during the course of the acute respiratory distress syndrome SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE acute respiratory distress syndrome; acute lung injury; proteomic analysis; bronchoalveolar lavage; 2D gel electrophoresis ID ACUTE LUNG INJURY; POSTTRAUMATIC CYTOKINE RELEASE; STIMULATED WHOLE-BLOOD; GENDER-DIFFERENCES; TRAUMA-HEMORRHAGE; SEX-DIFFERENCES; SEVERE SEPSIS; EDEMA FLUID; P38 MAPK; ARDS AB Rationale: Acute lung injury causes complex changes in protein expression in the lungs. Whereas most prior studies focused on single proteins, newer methods allowing the simultaneous study of many proteins could lead to a better understanding of pathogenesis and new targets for treatment. Objectives: The purpose of this study was to examine the changes in protein expression in the bronchoalveolar lavage fluid (BALF) of patients during the course of the acute respiratory distress syndrome (ARDS). Methods: Using two-dimensional difference gel electrophoresis (DIGE), the expression of proteins in the BALF from patients on Days 1 (n = 7), 3 (n = 8), and 7 (n = 5) of ARDS were compared with findings in normal volunteers (n = 9). The patterns of protein expression were analyzed using principal component analysis (PCA). Biological processes that were enriched in the BALF proteins of patients with ARDS were identified using Gene Ontology (GO) analysis. Protein networks that model the protein interactions in the BALF were generated using Ingenuity Pathway Analysis. Measurements and Main Results: An average of 991 protein spots were detected using DIGE. Of these, 80 protein spots, representing 37 unique proteins in all of the fluids, were identified using mass spectrometry. PCA confirmed important differences between the proteins in the ARDS and normal samples. GO analysis showed that these differences are due to the enrichment of proteins involved in inflammation, infection, and injury. The protein network analysis showed that the protein interactions in ARDS are complex and redundant, and revealed unexpected central components in the protein networks. Conclusions: Proteomics and protein network analysis reveals the complex nature of lung protein interactions in ARDS. The results provide new insights about protein networks in injured lungs, and identify novel mediators that are likely to be involved in the pathogenesis and progression of acute lung injury. C1 [Martin, Thomas R.] VA Puget Sound Hlth Care Syst, Pulm Res Labs, Med Res Serv, Seattle, WA 98108 USA. [Chang, Dong W.; Hayashi, Shinichi; Gharib, Sina A.; Ruzinski, John T.; Park, David R.; Matute-Bello, Gustavo; Wurfel, Mark M.; Martin, Thomas R.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Vaisar, Tomas; Heinecke, Jay W.] Univ Washington, Div Endocrinol & Metab, Dept Med, Seattle, WA 98195 USA. [King, S. Trevor; Tsuchiya, Mitsuhiro; Bumgarner, Roger] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. [Gharib, Sina A.] Univ Washington, Ctr Lung Biol, Seattle, WA 98195 USA. [Gharib, Sina A.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. RP Martin, TR (reprint author), VA Puget Sound Hlth Care Syst, Pulm Res Labs, Med Res Serv, 1660 S Columbian Way,151L, Seattle, WA 98108 USA. EM trmartin@u.washington.edu RI Bumgarner, Roger/K-3531-2015 OI Bumgarner, Roger/0000-0002-8168-6985 FU NIH/NHLBI [HL073996, HL090298] FX Funding: NIH/NHLBI HL073996, NIH/NHBLI HL090298. NR 35 TC 41 Z9 41 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 1 PY 2008 VL 178 IS 7 BP 701 EP 709 DI 10.1164/rccm.200712-1895OC PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 353RJ UT WOS:000259585600010 PM 18658106 ER PT J AU Cooke, CR Frank, D Frank, R AF Cooke, Colin R. Frank, Danielle Frank, Reanne TI The relative importance of unmeasured covariates in racial/ethnic disparities research SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID RACE; HEALTH C1 [Cooke, Colin R.] Univ Washington, Seattle, WA 98195 USA. [Frank, Danielle] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Frank, Reanne] Ohio State Univ, Columbus, OH 43210 USA. RP Cooke, CR (reprint author), Univ Washington, Seattle, WA 98195 USA. FU NHLBI NIH HHS [F32 HL090220] NR 6 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD OCT 1 PY 2008 VL 178 IS 7 BP 774 EP 774 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 353RJ UT WOS:000259585600018 PM 18796653 ER PT J AU Reese, PP Feldman, HI McBride, MA Anderson, K Asch, DA Bloom, RD AF Reese, P. P. Feldman, H. I. McBride, M. A. Anderson, K. Asch, D. A. Bloom, R. D. TI Substantial variation in the acceptance of medically complex live kidney donors across US renal transplant centers SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE kidney transplantation; live donor; outcomes research ID HYPERTENSIVE LIVING DONORS; GLOMERULAR-FILTRATION-RATE; BODY-MASS INDEX; BLOOD-PRESSURE; FOLLOW-UP; ORGAN PROCUREMENT; DONATION; DISEASE; RISK; ASSOCIATION AB Concern exists about accepting live kidney donation from 'medically complex donors'-those with risk factors for future kidney disease. This study's aim was to examine variation in complex kidney donor use across US transplant centers. We conducted a retrospective cohort study of live kidney donors using organ procurement and transplantation network data. Donors with hypertension, obesity or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m(2) were considered medically complex. Among 9319 donors, 2254 (24.2%) were complex: 1194 (12.8%) were obese, 956 (10.3%) hypertensive and 392 (4.2%) had low eGFR. The mean proportion of medically complex donors at a center was 24% (range 0-65%). In multivariate analysis, donor characteristics associated with medical complexity included spousal relationship to the recipient (OR 1.29, CI 1.06-1.56, p < 0.01), low education (OR 1.19, CI 1.04-1.37, p = 0.01), older age (OR 1.01 per year, CI 1.01-1.02, p < 0.01) and non-US citizenship (OR 0.70, CI 0.51-0.97, p = 0.03). Renal transplant centers with the highest transplant volume (OR 1.26, CI 1.02-1.57, p = 0.03), and with a higher proportion of (living donation)/(all kidney transplants) (OR 1.97, CI 1.23-3.16, p < 0.01) were more likely to use medically complex donors. Though controversial, the use of medically complex donors is widespread and varies widely across centers. C1 [Reese, P. P.; Feldman, H. I.; Bloom, R. D.] Univ Penn, Dept Med, Div Renal, Philadelphia, PA 19104 USA. [McBride, M. A.; Anderson, K.] United Network Organ Sharing, Richmond, VA USA. [Asch, D. A.] Univ Penn, Dept Med, Leonard Davis Inst, Philadelphia, PA 19104 USA. [Asch, D. A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Reese, PP (reprint author), Univ Penn, Dept Med, Div Renal, Philadelphia, PA 19104 USA. EM peter.reese@uphs.upenn.edu OI Asch, David/0000-0002-7970-286X FU NIH [K23 DK078688-01] FX Dr. Reese is supported by NIH Career Development Award, K23 DK078688-01. NR 50 TC 78 Z9 78 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2008 VL 8 IS 10 BP 2062 EP 2070 DI 10.1111/j.1600-6143.2008.02361.x PG 9 WC Surgery; Transplantation SC Surgery; Transplantation GA 349GS UT WOS:000259269900014 PM 18727695 ER PT J AU Esch, RE Bush, RK Peden, D Lockey, RF AF Esch, Robert E. Bush, Robert K. Peden, David Lockey, Richard F. TI Sublingual-oral administration of standardized allergenic extracts: Phase I safety and dosing results - Response SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Letter C1 [Esch, Robert E.] Greer Labs, Res & Dev, Lenoir, NC USA. [Bush, Robert K.] Univ Wisconsin, Dept Med, William S Middleton Mem Vet Hosp, Sect Allergy Immunol Pulm, Madison, WI USA. [Peden, David] Univ N Carolina, Sch Med, Divis Pediat Immunol & Infect Dis, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA. [Lockey, Richard F.] Univ S Florida, Coll Med, Dept Internal Med, James A Haley Vet Hosp,Div Allergy & Immunol, Tampa, FL 33612 USA. RP Esch, RE (reprint author), Greer Labs, Res & Dev, Lenoir, NC USA. EM esch@greerlabs.com NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD OCT PY 2008 VL 101 IS 4 BP 445 EP 446 PG 2 WC Allergy; Immunology SC Allergy; Immunology GA 359II UT WOS:000259979300020 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Birth-Cohort Patterns of Mortality From Ulcerative Colitis and Peptic Ulcer SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Birth Cohorts; Duodenal Ulcer; Enteric Infections; Etiology of Ulcerative Colitis; Gastric Ulcer; Mortality; Time Trends ID INFLAMMATORY-BOWEL-DISEASE; HELICOBACTER-PYLORI INFECTION; TIME TRENDS; CROHNS-DISEASE; RISK-FACTORS; PREVALENCE; EPIDEMIOLOGY; ENGLAND; COUNTY; PERIOD AB PURPOSE: The aim was to follow the time trends of mortality from ulcerative colitis and compare them with those of gastric and duodenal ulcer. METHODS: Mortality data from 21' different countries between 1941 and 2004 were analyzed. The age-specific death rates of each individual country, as well as the average age-specific rates of all countries, were plotted against the periods of birth and death. RESULTS: The average trends of mortality from ulcerative colitis, gastric and duodenal ulcer reveal distinctive and unique birth-cohort patterns of all three diseases. Similar to both types of peptic ulcer, the risk of developing ulcerative colitis started to rise in successive generations born during the second half of the 19(th) century. It peaked shortly before the turn of the century and has continued to decline since then. The rise and fall in the occurrence of ulcerative colitis preceded those of both ulcer types. CONCLUSION: The birth-cohort pattern indicates that exposure to the relevant risk factors of ulcerative colitis occurs during early life. As the model of H. pylori and its associated birth-cohort patterns of gastric and duodenal ulcer suggest, an enteric infection provides a possible explanation for such temporal trends of ulcerative colitis as well. Ann Epidemiol 2008;18:813-819. (C) 2008 Elsevier Inc. All rights reserved. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-G1,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 18 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD OCT PY 2008 VL 18 IS 10 BP 813 EP 819 DI 10.1016/j.annepidem.2008.07.006 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 359XS UT WOS:000260022200010 PM 18922397 ER PT J AU Esnaola, NF Hall, BL Hosokawa, PW Ayanian, JZ Henderson, WG Khuri, SE Zinner, MJ Rogers, SO AF Esnaola, Nestor F. Hall, Bruce L. Hosokawa, Patrick W. Ayanian, John Z. Henderson, William G. Khuri, Shukri E. Zinner, Michael J. Rogers, Selwyn O., Jr. TI Race and Surgical Outcomes It Is Not All Black and White SO ANNALS OF SURGERY LA English DT Article ID QUALITY IMPROVEMENT PROGRAM; 30-DAY POSTOPERATIVE MORTALITY; UNIVERSITY MEDICAL-CENTERS; VETERANS-AFFAIRS HOSPITALS; CLINICAL COMORBIDITY INDEX; HIGH-VOLUME HOSPITALS; 8 COMMON OPERATIONS; RISK-ADJUSTMENT; RACIAL-DIFFERENCES; COLORECTAL-CANCER AB Background: Studies using Medicare data have suggested that African American race is an independent predictor of death after major surgery. We hypothesized that the apparent adverse effect of race on surgical outcomes is due to confounding by comorbidity, not race itself Methods: We identified all non-Hispanic white and African American general surgery, private sector patients included in the National Surgery Quality Improvement Program (NSQIP) Patient Safety in Surgery Study (2001-2004). Patient characteristics, comorbidities, and postoperative outcomes were collected/analyzed using NSQIP methodology. Characteristics between races were compared using Student t and chi(2) tests. Odds ratios (OR) for 30-day morbidity and mortality were calculated using multivariable logistic regression. Results: We identified 34,141 white and 5068 African American patients. African Americans were younger but more likely to undergo emergency surgery and present with hypertension, dyspnea, diabetes, renal failure, open wounds/infection, or advanced American Society of Anesthesiology class (all P < 0.001). African Americans underwent less complex procedures but had higher unadjusted 30-day morbidity (14.33% vs. 12.35%; P < 0.001) and mortality (2.09% vs. 1.65%; P = 0.02). After controlling for comorbidity, African American race had no independent effect on mortality (OR 0.95, (0.74-1.23)) but was associated with a higher risk of postoperative cardiac arrest (OR 2.49, (1.80-3.45)) and renal insufficiency/failure (OR 1.70 (1.32-2.18)). Conclusion: African American race is associated with greater comorbidity and cardiac/renal complications but is not an independent predictor of perioperative mortality after general surgery. Efforts to improve postoperative outcomes in African Americans should focus on reducing the need for emergency surgery and improving perioperative management of comorbid conditions. C1 [Esnaola, Nestor F.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Esnaola, Nestor F.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Barnes Jewish Hosp, Dept Surg, Sch Med, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO 63130 USA. [Hosokawa, Patrick W.; Henderson, William G.] Colorado Hlth Outcomes Program, Aurora, CO USA. [Ayanian, John Z.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Ayanian, John Z.; Zinner, Michael J.; Rogers, Selwyn O., Jr.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Ayanian, John Z.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Khuri, Shukri E.] Vet Adm Med Ctr, Dept Surg, W Roxbury, MA USA. [Zinner, Michael J.; Rogers, Selwyn O., Jr.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. RP Esnaola, NF (reprint author), Med Univ S Carolina, Dept Surg, 25 Courtenay Dr Suite 7018 MSC 295, Charleston, SC 29425 USA. EM esnaolan@musc.edu FU Agency for Healthcare Research and Quality [1U18HS11913-03] FX Supported by Agency for Healthcare Research and Quality grant 1U18HS11913-03. NR 53 TC 24 Z9 24 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD OCT PY 2008 VL 248 IS 4 BP 647 EP 654 DI 10.1097/SLA.0b013e31818a159a PG 8 WC Surgery SC Surgery GA 366LT UT WOS:000260483700029 PM 18936578 ER PT J AU Chu, D Bakaeen, FG Wang, XL Dao, TK LeMaire, SA Coselli, JS Huh, J AF Chu, Danny Bakaeen, Faisal G. Wang, Xing Li Dao, Tam K. LeMaire, Scott A. Coselli, Joseph S. Huh, Joseph TI The impact of peripheral vascular disease on long-term survival after coronary artery bypass graft surgery SO ANNALS OF THORACIC SURGERY LA English DT Article ID INTERMITTENT CLAUDICATION; CARDIAC-SURGERY; RISK-FACTORS; MORTALITY; REVASCULARIZATION; MORBIDITY; MODEL AB Background. Although peripheral vascular disease is known to negatively affect overall survival, its effects on survival after surgical myocardial revascularization have not been well described. The objective of this study was to examine the impact of peripheral vascular disease on long-term survival after coronary artery bypass grafting. Methods. We reviewed records of 1,164 consecutive patients (370 with peripheral vascular disease and 794 without it) who underwent primary isolated coronary artery bypass graft surgery between 1997 and 2007. Univariate and multivariate logistic regression methods were used to analyze variables associated with early outcomes. We assessed long-term survival by using Kaplan-Meier curves generated by log-rank tests, adjusting for confounding factors with Cox proportional hazards regression analysis. Results. Patients with peripheral vascular disease were generally sicker and had more comorbidities than patients without peripheral vascular disease. The presence of peripheral vascular disease does not predict increased rates of 30- day mortality or major adverse cardiac events. However, after controlling for potential confounding factors, patients with peripheral vascular disease had a significantly worse 9- year survival rate than patients without peripheral vascular disease (72.9% +/- 4.1% versus 82.8% +/- 2.4%; adjusted hazard ratio, 1.7; 95% confidence interval: 1.2 to 2.4; p = 0.004). Conclusions. Although peripheral vascular disease does not affect early outcomes in coronary artery bypass operations, it is an independent predictor of poor long-term survival among patients undergoing coronary artery bypass graft surgery. Identifying the mechanism that underlies this difference is important for improving survival in patients with peripheral vascular disease who undergo surgical myocardial revascularization. C1 [Chu, Danny] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiac Surg, Houston, TX USA. RP Chu, D (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM dchumd@gmail.com NR 19 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD OCT PY 2008 VL 86 IS 4 BP 1175 EP 1180 DI 10.1016/j.athoracsur.2008.06.024 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 357LT UT WOS:000259848000018 PM 18805156 ER PT J AU Craig, WA Andes, DR AF Craig, W. A. Andes, D. R. TI In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID METHICILLIN-RESISTANT STAPHYLOCOCCI; PARENTERAL CEPHALOSPORIN; SPECTRUM CEPHALOSPORIN; BAL9141; PHARMACOKINETICS; VITRO; ANTIBIOTICS; PNEUMONIA; EFFICACY; BAL5788 AB Ceftobiprole medocaril is the parenteral prodrug of ceftobiprole, a novel pyrrolidinone broad-spectrum cephalosporin with in vitro and in vivo bactericidal activities against methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP). We have used murine thigh and lung infection models in neutropenic and normal mice to characterize the in vivo pharmacokinetic (PK)-pharmacodynamic (PD) activities of ceftobiprole against multiple strains of S. aureus (including MRSA), S. pneumoniae (including PRSP), and gram-negative bacilli. Serum levels of ceftobiprole following the administration of multiple doses were determined by a microbiological assay. In vivo bactericidal activities and postantibiotic effects (PAEs) of ceftobiprole against MRSA and PRSP strains were determined from serial CFU/thigh values following single doses of ceftobiprole (40 and 160 mg/kg of body weight). Dose fractionation studies were used to determine which PK-PD index correlated best with activity. Magnitudes of the PK-PD indices were calculated from MICs and PK parameters. A sigmoid dose-response model was used to estimate the dose (mg/kg/24 h) required to achieve a static and 2-log(10) kill effects over 24 h. PK results showed area under the concentration-time curve/dose values of 1.8 to 2.8 and half-lives of 0.29 to 0.51 h. MICs ranged from 0.015 to 2 mu g/ml. Ceftobiprole demonstrated time-dependent killing; its in vivo PAEs varied from 3.8 h to 4.8 h for MRSA and from 0 to 0.8 h for PRSP. The time above MIC (T > MIC) correlated best with efficacy for both MRSA and PRSP. The T > MIC values required for the static doses were significantly longer (P < 0.001) for Enterobacteriaceae (36 to 45%) than for S. aureus (14 to 28%) and S. pneumoniae (15 to 22%). The drug showed activities in the lung model similar to those in the thigh model. The presence of neutrophils significantly enhanced the activity of ceftobiprole against S. pneumoniae but only slightly against Klebsiella pneumoniae. Based on its PD profile, ceftobiprole is a promising new beta-lactam agent with activity against gram-negative and gram-positive organisms including MRSA and PRSP. C1 [Craig, W. A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Craig, W. A.; Andes, D. R.] Univ Wisconsin, Dept Med, Infect Dis Sect, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Craig, WA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM wac@medicine.wisc.edu NR 25 TC 46 Z9 47 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD OCT PY 2008 VL 52 IS 10 BP 3492 EP 3496 DI 10.1128/AAC.01273-07 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 352FJ UT WOS:000259480800004 PM 18676887 ER PT J AU Forrest, GN Roghmann, MC Toombs, LS Johnson, JK Weekes, E Lincalis, DP Venezia, RA AF Forrest, Graeme N. Roghmann, Mary-Claire Toombs, Latoya S. Johnson, Jennifer K. Weekes, Elizabeth Lincalis, Durry P. Venezia, Richard A. TI Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: Delivering earlier effective antimicrobial therapy SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID VANCOMYCIN-RESISTANT ENTEROCOCCUS; BLOOD-STREAM INFECTIONS; STEM-CELL TRANSPLANT; RISK-FACTORS; FAECIUM BACTEREMIA; STAPHYLOCOCCUS-AUREUS; CANDIDA-ALBICANS; RAPID DETECTION; MORTALITY; IDENTIFICATION AB Hospital-acquired vancomycin-resistant enterococcal bacteremia has been associated with increased hospital costs, length of stay, and mortality. The peptide nucleic acid fluorescent in situ hybridization (PNA FISH) test for Enterococcus faecalis and other enterococci (EFOE) is a multicolor probe that differentiates E. faecalis from other enterococcal species within 3 h directly from blood cultures demonstrating gram-positive cocci in pairs and chains (GPCPC). A quasiexperimental study was performed over two consecutive years beginning in 2005 that identified GPCPC by conventional microbiological methods, and in 2006 PNA FISH was added with a treatment algorithm developed by the antimicrobial team (AMT). The primary outcome assessed was the time from blood culture draw to the implementation of effective antimicrobial therapy before and after PNA FISH. The severity of illness, patient location, and empirical antimicrobial therapy were measured. A total of 224 patients with hospital-acquired enterococcal bacteremia were evaluated, with 129 in the preintervention period and 95 in the PNA FISH period. PNA FISH identified E. faecalis 3 days earlier than conventional cultures (1.1 versus 4.1 days; P < 0.001). PNA FISH identified Enterococcus faecium a median 2.3 days earlier (1.1 versus 3.4 days; P < 0.001) and was associated with statistically significant reductions in the time to initiating effective therapy (1.3 versus 3.1 days; P < 0.001) and decreased 30-day mortality (26% versus 45%; P = 0.04). The EFOE PNA FISH test in conjunction with an AMT treatment algorithm resulted in earlier initiation of appropriate empirical antimicrobial therapy for patients with hospital-acquired E. faecium bacteremia. C1 [Forrest, Graeme N.] Univ Maryland, Sch Med, Div Infect Dis, Baltimore, MD 21201 USA. [Roghmann, Mary-Claire] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Toombs, Latoya S.; Weekes, Elizabeth] Univ Maryland, Dept Pharm, Med Ctr, Baltimore, MD 21201 USA. [Johnson, Jennifer K.; Lincalis, Durry P.; Venezia, Richard A.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, 3701 SW US Vet Hosp Rd,P31D, Portland, OR 97239 USA. EM forrestg@ohsu.edu OI Roghmann, Mary-Claire/0000-0003-1063-9257 FU AdvanDx; Cubist Pharmaceuticals, Inc.; Pfizer Inc; 3M FX Potential conflicts of interest: G.N.F. has received research funding and speaking honoraria from AdvanDx, Cubist Pharmaceuticals, Inc., and Pfizer Inc. M.-C.R. has received research funding from 3M and Merck. R.A.V. and J.K.J. have received speaking honoraria from AdvanDx. NR 40 TC 81 Z9 83 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD OCT PY 2008 VL 52 IS 10 BP 3558 EP 3563 DI 10.1128/AAC.00283-08 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 352FJ UT WOS:000259480800013 PM 18663022 ER PT J AU Pagulayan, KF Hoffman, JM Temkin, NR Machamer, JE Dikmen, SS AF Pagulayan, Kathleen Farrell Hoffman, Jeanne M. Temkin, Nancy R. Machamer, Joan E. Dikmen, Sureyya S. TI Functional Limitations and Depression After Traumatic Brain Injury: Examination of the Temporal Relationship SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Brain injuries; Depression; Longitudinal studies; Rehabilitation; Sickness Impact Profile ID MAJOR DEPRESSION; RANDOMIZED-TRIAL; PRIMARY-CARE; CHRONIC PAIN; HEAD-INJURY; SCALE; RELIABILITY; DISORDER; VALIDITY; PREVALENCE AB Objective: To examine the temporal relationship between self-reported injury-related functional limitations and depressive symptomatology after traumatic brain injury (TBI). Design: A longitudinal cohort study with 3 evaluation points. Setting: A level I trauma center. Participants: Adolescents and adults (N=135) with complicated mild to severe TBI (72% had complicated mild injuries) who were recruited within 24 hours of injury and then completed the measure at all 3 time points. Interventions: Not applicable. Main Outcome Measures: Sickness Impact Profile and Center for Epidemiological Studies-Depression Scale. Results: Individuals who reported more depressive symptomatology consistently endorsed more injury-related difficulties, showing the strong relationship between depression and perceived psychosocial functioning. Examination of these relationships over time revealed that increased depressive symptomatology follows higher levels of perceived injury-related changes but that reports of injury-related changes are not associated with earlier depression. These findings suggest a unidirectional temporal relationship between these variables. Conclusions: Perceived changes in daily functioning appear to influence emotional well-being over time after TBI. However, depressive symptoms do not appear to negatively impact individuals' perception of later functioning. These results further our understanding of the complicated relationship between these variables and may have important implications for treatment of depression after TBI. C1 [Pagulayan, Kathleen Farrell; Hoffman, Jeanne M.; Temkin, Nancy R.; Machamer, Joan E.; Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Pagulayan, KF (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116 MHC, Seattle, WA 98108 USA. EM farkat@u.washington.edu FU National Institute of Neurological Disorders and Stroke; National Institutes of Health [RO1 NS19643, F32 HD048030]; National Center for Medical Rehabilitation Research FX Supported by the National Institute of Neurological Disorders and Stroke, National Institutes of Health (grant no. RO1 NS19643) and the National Center for Medical Rehabilitation Research, National Institutes of Health (grant no. F32 HD048030). NR 56 TC 46 Z9 46 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2008 VL 89 IS 10 BP 1887 EP 1892 DI 10.1016/j.apmr.2008.03.019 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 366LY UT WOS:000260484200006 PM 18929017 ER PT J AU Kaafarani, HMA Atluri, PV Thornby, J Itani, KMF AF Kaafarani, Haytham M. A. Atluri, Prasad V. Thornby, John Itani, Kamal M. F. TI beta-Blockade in Noncardiac Surgery Outcome at All Levels of Cardiac Risk SO ARCHIVES OF SURGERY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; VASCULAR-SURGERY; MYOCARDIAL-INFARCTION; MORTALITY; METOPROLOL; ISCHEMIA AB Hypothesis: We hypothesized that the relationship among beta-blocker use, heart rate control, and perioperative cardiovascular outcome would be similar in patients at all levels of cardiac risk. Design: Retrospective cohort study. Setting: Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. Patients: Among all patients who underwent various noncardiac surgical procedures in 2000, those who received perioperative beta-blockers were matched and compared with a control group from the same patient population. Main Outcome Measures: Thirty-day stroke, cardiac arrest, myocardial infarction, and mortality, as well as mortality at 1 year. Results: Patients at all levels of cardiac risk who received beta-blockers had lower preoperative and intraoperative heart rates. The beta-blocker group had higher rates of 30-day myocardial infarction (2.94% vs 0.74%, P=.03) and 30-day mortality (2.52% vs 0.25%, P=.007) compared with the control group. In the beta-blocker group, patients who died perioperatively had significantly higher preoperative heart rate (86 vs 70 beats/min, P=.03). None of the deaths occurred among the patients at high cardiac risk. Conclusion: Among patients at all levels of cardiac risk undergoing noncardiac surgery, administration of beta-blockers should achieve adequate heart rate control and should be carefully monitored in patients who are not at high cardiac risk. C1 [Kaafarani, Haytham M. A.] Univ S Florida, Dept Surg, Tampa, FL 33620 USA. [Kaafarani, Haytham M. A.; Itani, Kamal M. F.] Vet Affairs Boston Hlth Care Syst, W Roxbury, MA USA. [Kaafarani, Haytham M. A.; Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA. [Kaafarani, Haytham M. A.; Itani, Kamal M. F.] Boston Univ, Boston, MA 02215 USA. [Atluri, Prasad V.] Baylor Coll Med, Dept Anesthesia, Houston, TX 77030 USA. [Thornby, John] Michael E DeBakey Vet Affairs Med Ctr, Biostat Lab, Houston, TX USA. RP Itani, KMF (reprint author), Vet Affairs Boston Healthcare Syst 112, Dept Surg, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM kitani@med.va.gov NR 14 TC 18 Z9 19 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD OCT PY 2008 VL 143 IS 10 BP 940 EP 944 DI 10.1001/archsurg.143.10.940 PG 5 WC Surgery SC Surgery GA 360GG UT WOS:000260045400005 PM 18936371 ER PT J AU Swanlund, JM Kregel, KC Oberley, TD AF Swanlund, Jamie M. Kregel, Kevin C. Oberley, Terry D. TI Autophagy following heat stress - The role of aging and protein nitration SO AUTOPHAGY LA English DT Article DE mitochondria; 3-nitrotyrosine; autophagy; heat stress; oxidative stress; nitric oxide ID OXIDATIVE STRESS; RAT HEPATOCYTES; CELLS; PEROXYNITRITE; SECTIONS AB Stress can originate from a variety of sources (e.g., physical, chemical, etc.,) and cause protein denaturation, DNA damage and possibly death. In an effort to prevent such deleterious consequences, most organisms possess one or more ways to counteract or even prevent the harmful effect(s) from a given stressor. Such compensation by an organism is known as a stress response; this involves inhibition of housekeeping genes and subsequent activation of genes associated with the stress response.(1) One of the most widely studied groups of stress response genes Is a family of molecular chaperones known as heat shock proteins (HSPs). Work from our laboratory agrees with many other studies showing an age-related decline in stress-induced synthesis of HSPs.(2) A decline in the availability and/or function of HSPs with age can lead to accumulation of damaged proteins, which in turn damages cells. Recently, our laboratory found a significant increase in mitochondrial damage as well as evidence of increased autophagy in rat hepatocytes following heat stress.(3) These results, along with findings of increased protein nitration with age, suggest a major role for reactive nitrogen species (RNS) in both the decline in HSP induction and increased hepatocyte pathology observed in old rats following heat stress. C1 [Swanlund, Jamie M.; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Madison, WI 53705 USA. [Oberley, Terry D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. [Kregel, Kevin C.] Univ Iowa, Dept Radiat Oncol, Dept Integrat Physiol, Iowa City, IA USA. [Kregel, Kevin C.] Univ Iowa, Dept Radiat Oncol, Free Radical & Radiat Biol Program, Iowa City, IA USA. RP Oberley, TD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Pathol & Lab Med, Room A-35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@wisc.edu FU NIA NIH HHS [R01 AG012350-09A1] NR 25 TC 19 Z9 19 U1 0 U2 0 PU LANDES BIOSCIENCE PI AUSTIN PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD OCT 1 PY 2008 VL 4 IS 7 BP 936 EP 939 PG 4 WC Cell Biology SC Cell Biology GA 357ES UT WOS:000259829700016 PM 18758235 ER PT J AU Guichard, C Moreau, R Pessayre, D Epperson, TK Krause, KH AF Guichard, Cecile Moreau, Richard Pessayre, Dominique Epperson, Terry Kay Krause, Karl-Heinz TI NOX family NADPH oxidases in liver and in pancreatic islets: a role in the metabolic syndrome and diabetes? SO BIOCHEMICAL SOCIETY TRANSACTIONS LA English DT Article; Proceedings Paper CT 3rd Intracellular Proteolysis Meeting CY MAR 05-07, 2008 CL Canary Isl, SPAIN SP Joint Biochem Soc, INPROTEOLYS Network DE diabetes; liver; metabolic Syndrome; NADPH oxidase; NOX family; pancreatic islet ID HEPATIC STELLATE CELLS; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ENZYME GENE-EXPRESSION; OXIDATIVE STRESS; BETA-CELL; NAD(P)H OXIDASE; INSULIN-RESISTANCE; MITOCHONDRIAL DYSFUNCTION; HEPATOCYTE APOPTOSIS AB The incidence of obesity and non-esterified ('free') fatty acid-associated metabolic disorders such as the metabolic syndrome and diabetes is increasing dramatically in most countries. Although the pathogenesis of these metabolic disorders is complex, there is emerging evidence that ROS (reactive oxygen species) are critically involved in the aberrant signalling and tissue damage observed in this context. indeed, it is now widely accepted that ROS not only play an important role in physiology, but also contribute to cell and tissue dysfunction. inappropriate ROS generation may contribute to tissue dysfunction in two ways: (i) dysregulation of redox-sensitive signalling pathways, and (ii) oxidative damage to biological structures (DNA, proteins, lipids, etc.). An important source of ROS is the NOX family of NADPH oxidases. Several NOX isoforms are expressed in the liver and pancreatic beta-cells. There is now evidence that inappropriate activation of NOX enzymes may damage the liver and pancreatic beta-cells. in the context of the metabolic syndrome, the emerging epidemic of non-alcoholic steatohepatitis is thought to be NOX/ROS-dependent and of particular medical relevance. NOX/ROS-dependent beta-cell damage is thought to be involved in glucolipotoxicity and thereby leads to progression from the metabolic syndrome to Type 2 diabetes. Thus understanding the role of NOX enzymes in liver and beta-cell damage should lead to an increased understanding of pathomechanisms in the metabolic syndrome and diabetes and may identify useful targets for novel therapeutic strategies. C1 [Guichard, Cecile; Pessayre, Dominique; Krause, Karl-Heinz] Geneva Med Fac, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland. [Guichard, Cecile; Pessayre, Dominique; Krause, Karl-Heinz] Univ Hosp Geneva, CH-1211 Geneva, Switzerland. [Guichard, Cecile; Pessayre, Dominique; Krause, Karl-Heinz] Geneva Med Fac, Dept Genet, CH-1211 Geneva 4, Switzerland. [Guichard, Cecile; Pessayre, Dominique; Krause, Karl-Heinz] Geneva Med Fac, Lab Med, CH-1211 Geneva 4, Switzerland. [Guichard, Cecile; Moreau, Richard] Ctr Rech Biomed Bichat Beaujon CRB3, U773, INSERM, F-75870 Paris, France. [Pessayre, Dominique] Univ Beaujon, Grp Hosp, Serv Hepatol, F-92110 Clichy, France. [Epperson, Terry Kay] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Epperson, Terry Kay] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. RP Krause, KH (reprint author), Geneva Med Fac, Dept Pathol & Immunol, CH-1211 Geneva 4, Switzerland. EM Karl-Heinz.Krause@medecine.unige.ch RI Krause, Karl-Heinz/E-8030-2011 OI Moreau, Richard /0000-0003-0862-403X NR 86 TC 61 Z9 64 U1 0 U2 4 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0300-5127 J9 BIOCHEM SOC T JI Biochem. Soc. Trans. PD OCT PY 2008 VL 36 BP 920 EP 929 DI 10.1042/BST0360920 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 360RW UT WOS:000260076300027 PM 18793162 ER PT J AU Miller, DD Caroff, SN Davis, SM Rosenheck, RA McEvoy, JP Saltz, BL Riggio, S Chakos, MH Swartz, MS Keefe, RSE Stroup, TS Lieberman, JA AF Miller, Del D. Caroff, Stanley N. Davis, Sonia M. Rosenheck, Robert A. McEvoy, Joseph P. Saltz, Bruce L. Riggio, Silvana Chakos, Miranda H. Swartz, Marvin S. Keefe, Richard S. E. Stroup, T. Scott Lieberman, Jeffrey A. CA CATIE Investigators TI Extrapyramidal side-effects of antipsychotics in a randomised trial SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID TARDIVE-DYSKINESIA; CHRONIC-SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTICS; 2ND-GENERATION ANTIPSYCHOTICS; SCHIZOAFFECTIVE DISORDER; ACUTE EXACERBATION; CLINICAL-TRIAL; RISPERIDONE; HALOPERIDOL; OLANZAPINE AB Background There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. Aims To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia. Method Incidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. mixed model analyses of change in rating scales from baseline were also conducted. Results There were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing second-generation antipsychotics with perphenazine or comparing between second-generation antipsychotics. Secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine. Conclusions The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia. C1 [Miller, Del D.] Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA. [Caroff, Stanley N.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Caroff, Stanley N.] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Davis, Sonia M.] Quintiles Inc, Morrisville, NC USA. [Rosenheck, Robert A.] Yale Univ, Sch Med, West Haven, CT 06516 USA. [McEvoy, Joseph P.; Swartz, Marvin S.] Duke Univ, Med Ctr, Durham, NC USA. [Saltz, Bruce L.] Mental Hlth Advocates Inc, Boca Raton, FL USA. [Riggio, Silvana] Mt Sinai Sch Med James J Peter VAMC, Bronx, NY USA. [Chakos, Miranda H.] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA. [Stroup, T. Scott] Neurosci Hosp, N Carolina Sch Med, Chapel Hill, NC USA. [Lieberman, Jeffrey A.] Columbia Univ, Coll Phys & Surg, New York, NY USA. RP Miller, DD (reprint author), Univ Iowa, Carver Coll Med, 2-105 MEB,500 Newton Rd, Iowa City, IA 52242 USA. EM del-miller@uiowa.edu RI ; Stroup, Thomas/F-9188-2014 OI Adler, Lawrence/0000-0002-6619-2493; Stroup, Thomas/0000-0002-3123-0672 FU NIMH NIH HHS [N01MH90001, N01 MH90001] NR 51 TC 103 Z9 106 U1 2 U2 9 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND SN 0007-1250 EI 1472-1465 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD OCT PY 2008 VL 193 IS 4 BP 279 EP 288 DI 10.1192/bjp.bp.108.050088 PG 10 WC Psychiatry SC Psychiatry GA 363RS UT WOS:000260285000004 PM 18827289 ER PT J AU Nemenoff, R Meyer, AM Hudish, TM Mozer, AB Snee, A Narumiya, S Stearman, RS Winn, RA Weiser-Evans, M Geraci, MW Keith, RL AF Nemenoff, Raphael Meyer, Amy M. Hudish, Tyler M. Mozer, Anthony B. Snee, Amy Narumiya, Shuh Stearman, Robert S. Winn, Robert A. Weiser-Evans, Mary Geraci, Mark W. Keith, Robert L. TI Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator-Activated Receptor gamma SO CANCER PREVENTION RESEARCH LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PULMONARY PROSTACYCLIN; SYNTHASE OVEREXPRESSION; PROSTANOID RECEPTORS; TRANSGENIC MICE; A/J MICE; CELL; INHIBITION; TUMORIGENESIS; EXPRESSION AB Overexpression of prostacyclin synthase (PGIS) decreases lung tumor multiplicity in chemical- and cigarette-smoke-induced murine lung cancer models. Prostacyclin signals through a single G-protein-coupled receptor (IP), which signals through cyclic AMP. To determine the role of this receptor in lung cancer chemoprevention by prostacyclin, PGIS-overexpressing mice were crossed to mice that lack the IP receptor [IP(-/-)]. Carcinogen-induced lung tumor incidence was similar in IP(+/+), IP(+/-), and IP(-/-) mice, and overexpression of PGIS gave equal protection in all three groups, indicating that the protective effects of prostacyclin are not mediated through activation of IP. Because prostacyclin can activate members of the peroxisomal proliferator-activated receptor (PPAR) family of nuclear receptors, we examined the role of PPAR. in the protection of prostacyclin against lung tumorigenesis. Iloprost, a stable prostacyclin analogue, activated PPAR. in nontransformed bronchial epithelial cells and in a subset of human non-small-cell lung cancer cell lines. Iloprost-impregnated chow fed to wild-type mice resulted in elevated lung macrophages and decreased lung tumor formation. Transgenic animals with lung-specific PPAR. overexpression also developed fewer lung tumors. This reduction was not enhanced by administration of supplemental iloprost. These studies indicate that PPAR. is a critical target for prostacyclin-mediated lung cancer chemoprevention and may also have therapeutic activity. C1 [Hudish, Tyler M.; Mozer, Anthony B.; Keith, Robert L.] Denver VA Med Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80220 USA. [Nemenoff, Raphael; Meyer, Amy M.; Snee, Amy; Weiser-Evans, Mary] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA. [Stearman, Robert S.; Winn, Robert A.; Geraci, Mark W.; Keith, Robert L.] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA. [Narumiya, Shuh] Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 606, Japan. [Narumiya, Shuh] Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Kyoto 606, Japan. RP Keith, RL (reprint author), Denver VA Med Ctr, Dept Med, Div Pulm Sci & Crit Care Med, 1055 Clermont St,Box 111A, Denver, CO 80220 USA. EM Robert.Keith@UCHSC.edu FU NIH [CA103618, CA108610, CA58187]; Department of Veterans Affairs FX Grant support: NIH grants CA103618, CA108610, and CA58187. R.L. Keith was supported by VA Advanced Career Development and Merit Review Awards from the Department of Veterans Affairs. NR 42 TC 37 Z9 37 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 J9 CANCER PREV RES JI Cancer Prev. Res. PD OCT PY 2008 VL 1 IS 5 BP 349 EP 356 DI 10.1158/1940-6207.CAPR-08-0145 PG 8 WC Oncology SC Oncology GA 420MK UT WOS:000264293700007 PM 19138979 ER PT J AU Aqel, R Zoghbi, GJ Hage, F Dell'Italia, L Iskandrian, AE AF Aqel, Raed Zoghbi, Gilbert J. Hage, Fadi Dell'Italia, Louis Iskandrian, Ami E. TI Hemodynamic Evaluation of Coronary Artery Bypass Graft Lesions Using Fractional Flow Reserve SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE bypass grafts; coronary; coronary flow; hemodynamics; quantitative coronary angiography ID EMISSION COMPUTED-TOMOGRAPHY; MYOCARDIAL-PERFUSION; PRESSURE MEASUREMENT; BLOOD-FLOW; FOLLOW-UP; ANGIOGRAPHY; STENOSIS; VELOCITY; DISEASE; PREDICT AB Background: Coronary angiography is limited by its inability to assess the hemodynamic significance of a coronary artery stenosis. The assessment of the physiological significance of saphenous vein graft (SVG) lesions with a pressure wire to determine the fractional flow reserve (FFR) is lacking. Methods: FFR was determined in 10 SVG lesions of 10 males who had stress myocardial perfusion imaging (MPI) prior to referral for percutaneous coronary intervention for clinical indications. Results: All SVGs had a diameter stenosis (DS) >50% and 30% had a DS >= 70%. A significant FFR was present in 30% of patients. Ischemia along the territory of the SVG was present in 20% of patients. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FFR <0.75 for the detection of ischemia on stress MPI were 50, 75, 33, 85, and 70%, respectively. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FFR <0.75 for detecting >= 70% DS on angiography were 33, 71, 33, 71, and 60%, respectively. There was no significant correlation between FFR and % DS (R(2) = 0.1, P = 0.35). Conclusion: The use of FFR to assess the physiological significance of SVG lesions is feasible and provides an acceptable specificity and negative predictive value compared to stress MPI. (C) 2008 Wiley-Liss, Inc. C1 [Aqel, Raed; Zoghbi, Gilbert J.; Hage, Fadi; Dell'Italia, Louis] Birmingham VA Med Ctr, Birmingham, VA USA. [Aqel, Raed; Zoghbi, Gilbert J.; Hage, Fadi; Dell'Italia, Louis; Iskandrian, Ami E.] Univ Alabama, Birmingham, VA USA. RP Aqel, R (reprint author), 1808 7th Ave S,BDB 383, Birmingham, AL 35294 USA. EM raed.aqel@va.gov OI Hage, Fadi/0000-0002-1397-4942 FU Radi Medical Systems, Inc FX Dr. Aqel received a grant from Radi Medical Systems, Inc. NR 19 TC 18 Z9 18 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1522-1946 J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD OCT 1 PY 2008 VL 72 IS 4 BP 479 EP 485 DI 10.1002/ccd.21675 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 379JM UT WOS:000261392500008 PM 18814221 ER PT J AU Adly, MA Assaf, HA Hussein, MRA AF Adly, Mohamed A. Assaf, Hanan A. Hussein, Mahmoud Rezk A. TI Heat shock protein 27 expression in the human testis showing normal and abnormal spermatogenesis SO CELL BIOLOGY INTERNATIONAL LA English DT Article DE Testis; HSP27; Spermatogenesis ID CUTANEOUS MALIGNANT MELANOMAS; MALE GERM-CELLS; IMMUNE-RESPONSE; MICROSATELLITE INSTABILITY; TRANSCRIPTION FACTOR-1; DECREASED EXPRESSION; MOLECULAR CHAPERONES; SERTOLI-CELLS; TUMOR-CELLS; HEAT-SHOCK-PROTEIN-70 AB Heat shock proteins (HSPs) are molecular chaperones involved in protein folding, assembly and transport, and which play critical roles in the regulation of cell growth, survival and differentiation. We set out to test the hypothesis that HSP27 protein is expressed in the human testes and its expression varies with the state of spermatogenesis. HSP27 expression was examined in 30 human testicular biopsy specimens (normal spermatogenesis, maturation arrest and Sertoli cell only syndrome, 10 cases each) using immunofluorescent methods. The biopsies were obtained from patients undergoing investigations for infertility. The seminiferous epithelium of the human testes showing normal spermatogenesis had a cell type-specific expression of HSP27. HSP27 expression was strong in the cytoplasm of the Sertoli cells, spermatogonia, and Leydig cells. Alternatively, the expression was moderate in the spermatocytes, weak in the spermatids and absent in the spermatozoa. In testes showing maturation arrest, HSP27 expression was strong in the Sertoli cells, weak in the spermatogonia, and spermatocytes. It was absent in the spermatids and Leydig cells. In Sertoli cell only syndrome, HSP27 expression was strong in the Sertoli cells and absent in the Leydig cells. We report for the first time the expression patterns of HSP27 in the human testes and show differential expression during normal spermatogenesis, indicating a possible role in this process. The altered expression of this protein in testes showing abnormal spermatogenesis may be related to the pathogenesis of male infertility. (c) 2008 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved. C1 [Hussein, Mahmoud Rezk A.] Assuit Univ Hosp, Fac Med, Dept Pathol, Assiut, Egypt. [Adly, Mohamed A.] S Valley Univ, Sohag Fac Sci, Dept Zool, Kena, Egypt. [Adly, Mohamed A.] King Khalid Univ, Fac Sci, Dept Life Sci, Abha, Saudi Arabia. [Assaf, Hanan A.] S Valley Univ, Sohag Fac Med, Dept Dermatol & Venerol, Kena, Egypt. [Hussein, Mahmoud Rezk A.] KKU, Assir Cent Hosp, Dept Pathol, Abha, Saudi Arabia. [Hussein, Mahmoud Rezk A.] Univ Wisconsin, Sch Med, Madison, WI 53705 USA. [Hussein, Mahmoud Rezk A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Hussein, MRA (reprint author), Assuit Univ Hosp, Fac Med, Dept Pathol, Assiut, Egypt. EM mrh17@gawab.com NR 54 TC 13 Z9 14 U1 0 U2 1 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1065-6995 J9 CELL BIOL INT JI Cell Biol. Int. PD OCT PY 2008 VL 32 IS 10 BP 1247 EP 1255 DI 10.1016/j.cellbi.2008.07.009 PG 9 WC Cell Biology SC Cell Biology GA 369CT UT WOS:000260671800009 PM 18692580 ER PT J AU Feng, P Yee, KK Rawson, NE Feldman, LM Feldman, RS Breslin, PAS AF Feng, Pu Yee, Karen K. Rawson, Nancy E. Feldman, Lauren M. Feldman, Roy S. Breslin, Paul A. S. TI Immune Cell Populations in Healthy Human Fungiform Papillae SO CHEMICAL SENSES LA English DT Meeting Abstract CT 15th International Symposium on Olfaction and Taste CY JUL 21-26, 2008 CL San Francisco, CA C1 [Feng, Pu; Yee, Karen K.; Rawson, Nancy E.; Feldman, Roy S.; Breslin, Paul A. S.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. [Feldman, Lauren M.] Barnard Coll, New York, NY USA. [Feldman, Roy S.] Philadelphia Vet Affairs Med Ctr, Dent Serv, Philadelphia, PA USA. [Feldman, Lauren M.] Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0379-864X J9 CHEM SENSES JI Chem. Senses PD OCT PY 2008 VL 33 IS 8 BP S73 EP S73 PG 1 WC Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology SC Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology GA 359GE UT WOS:000259973600289 ER PT J AU Maurer, J Rebbapragada, V Borson, S Goldstein, R Kunik, ME Yohannes, AM Hanania, NA AF Maurer, Janet Rebbapragada, Venkata Borson, Soo Goldstein, Roger Kunik, Mark E. Yohannes, Abebaw M. Hanania, Nicola A. CA ACCP Workshop Panel Anxiety Depr TI Anxiety and Depression in COPD Current Understanding, Unanswered Questions, and Research Needs SO CHEST LA English DT Review DE anxiety; comorbidities; COPD; depression; mood disorders ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; CHRONIC BREATHING DISORDERS; AIR-FLOW LIMITATION; HEALTH-STATUS; PRIMARY-CARE; MYOCARDIAL-INFARCTION; COLLABORATIVE CARE AB Background: Approximately 60 million people in the United States live with one of four chronic conditions: heart disease, diabetes, chronic respiratory disease, anti major depression. Anxiety and depression are very common comorbidities in COPD and have significant impact on patients, their families, society, and the course of the disease. Methods: We report the proceedings of a multidisciplinary, workshop on anxiety and depression in COPD that aimed to shed light on the current understanding of these comorbidities, and outline unanswered questions and areas of future research needs. Results: Estimates of prevalence of anxiety and depression in COPD vary widely but are generally higher than those reported in sonic other advanced chronic diseases. Untreated and undetected anxiety and depressive symptoms may increase physical disability, morbidity, and health-care utilization. Several patient, physician, and system barriers contribute to the underdiagnosis of these disorders in patients with COPD. While few published studies demonstrate that these disorders associated with COPD respond well to appropriate pharmacologic and nonpharmacologic therapy, only a small proportion of COPD patients with these disorders receive effective treatment. Conclusion: Future research is needed to address the impact, early detection, and management of anxiety and depression in COPD. (CHEST 2008; 134:43S-56S) C1 [Rebbapragada, Venkata; Hanania, Nicola A.] Baylor Coll Med, Pulm & Crit Care Med Sect, Houston, TX 77030 USA. [Maurer, Janet] Hlth Dialog Inc, Phoenix, AZ USA. [Borson, Soo] Univ Washington, Sch Med, Seattle, WA USA. [Goldstein, Roger] Univ Toronto, Toronto, ON, Canada. [Kunik, Mark E.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Yohannes, Abebaw M.] Manchester Metropolitan Univ, Manchester M15 6BH, Lancs, England. RP Hanania, NA (reprint author), Baylor Coll Med, Pulm & Crit Care Med Sect, 1504 Taub Loop, Houston, TX 77030 USA. EM Hanania@bcm.edu FU National Institute of Mental Health and the Alpha-1 Foundation [R13-MH07322S-01A1] FX This workshop was supported by grant R13-MH07322S-01A1 from the National Institute of Mental Health and the Alpha-1 Foundation. NR 105 TC 184 Z9 188 U1 5 U2 29 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD OCT PY 2008 VL 134 IS 4 SU S BP 43S EP 56S DI 10.1378/chest.08-0342 PG 14 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 360ZQ UT WOS:000260097700001 PM 18842932 ER PT J AU Sonnenberg, A Rodriguez, SA Faigel, DO AF Sonnenberg, Amnon Rodriguez, Sarah A. Faigel, Douglas O. TI Diagnostic Ascertainment of Suspicious Pancreatic Mass: A Threshold Analysis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID FINE-NEEDLE-ASPIRATION; QUALITY-OF-LIFE; ENDOSCOPIC ULTRASOUND; COST-EFFECTIVENESS; AUTOIMMUNE PANCREATITIS; COMPUTED-TOMOGRAPHY; CYSTIC NEOPLASMS; CANCER; PANCREATICODUODENECTOMY; EUS AB Background & Aims: it is frequently difficult to differentiate between a benign and malignant pancreatic mass. The aim of this study was to assess the parameters that affect the decision to perform surgery on a suspicious pancreatic head lesion. Methods : A cost-benefit analysis, using decision tree and threshold analysis, accumulates costs and quality-adjusted life years in patients undergoing pancreaticoduodenectomy or expectant management. The threshold value is defined as the diagnostic probability for pancreatic cancer when the cost-benefit relationships of pancreaticoduodenectomy or expectant management are equal. Results: For a localized pancreatic head lesion, the threshold probability of cancer is 43%. Any higher probability of pancreatic cancer makes pancreaticoduodenectomy the preferred treatment option. Within a range of $20,000 to $80,000 spent on surgery, the threshold in favor of Whipple procedure remains relatively low at 40% to 65%. A reduced quality of life after surgery weighs against surgery and raises its threshold. Varying quality of life between 100% and 80% changes the threshold between 31% and 67%. The threshold also is increased in younger patients because of the potentially more dire consequences of unnecessary surgery in instances of long life expectancy. Conclusion : Even if diagnostic certainty cannot be achieved, it frequently is beneficial to perform surgery despite the risk of subjecting the occasional patient with benign pancreatic head lesion to an unnecessary pancreaticoduodenectomy. C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 36 TC 4 Z9 7 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD OCT PY 2008 VL 6 IS 10 BP 1162 EP 1166 DI 10.1016/j.cgh.2008.05.015 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 360VS UT WOS:000260086900020 PM 18928941 ER PT J AU Bradshaw, S Zheng, WJ Tsoi, LC Gilkeson, G Zhang, XK AF Bradshaw, Sarah Zheng, W. Jim Tsoi, Lam C. Gilkeson, Gary Zhang, Xian K. TI A role for Fli-1 in B cell proliferation: Implications for SLE pathogenesis SO CLINICAL IMMUNOLOGY LA English DT Article DE B cell; BCR; Fli-1; IL12; NFAT; proliferation; SLE; TNF beta; TLR ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRIMARY SJOGRENS-SYNDROME; BLOOD MONONUCLEAR-CELLS; MRL/MP-LPR/LPR MICE; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTOR; ETS FAMILY; PERIPHERAL-BLOOD; RENAL-DISEASE; SOLUBLE CD23 AB Transgenic overexpression of Fli-1 in normal mice leads to SLE-like disease and increased expression was reported in SLE-affected human and murine lymphocytes. Reducing Fli-1 expression in MRL/lpr mice decreased antibody production, proteinuria, renal pathology, and mortality. Compared to those with wild-type expression of Fli-1, we report here that proliferative responses of Fli-1-deficient naive B cells to several mitogens were reduced in lupus-prone and control mice. Expression of mitogen receptors, including BCR, TLR4, and TLR9, was not significantly impacted in Fli-1-deficient naive B cells. IL12a transcripts were upregulated and NFAT transcripts were downregulated in Fli-1-deficient MRL/lpr B cells. These results demonstrate that Fli-1 deficiency affects B cell proliferative responses to mitogens, independent of BCR and TLR expression. IL12a and NFAT, known to influence proliferation, were identified as potential mediators of this effect. This may be a mechanism by which overexpression of Fli-1 contributes to B cell hyperactivity and subsequent SLE pathogenesis. (C) 2008 Elsevier Inc. All rights reserved. C1 [Bradshaw, Sarah; Gilkeson, Gary; Zhang, Xian K.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Zheng, W. Jim; Tsoi, Lam C.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Gilkeson, Gary] Ralph H Johnson Vet Adm Med Ctr, Med Res Serv, Charleston, SC USA. RP Bradshaw, S (reprint author), 96 Jonathan Lucas St,Suite 912,MSC 637, Charleston, SC 29425 USA. EM gallant@musc.edu OI Tsoi, Lam Cheung/0000-0003-1627-5722 FU NIAMS NIH HHS [R03 AR054546, K01 AR051385, K01 AR051385-01A1, R03 AR054546-01] NR 86 TC 16 Z9 17 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 EI 1521-7035 J9 CLIN IMMUNOL JI Clin. Immunol. PD OCT PY 2008 VL 129 IS 1 BP 19 EP 30 DI 10.1016/j.clim.2008.05.010 PG 12 WC Immunology SC Immunology GA 351XM UT WOS:000259459200004 PM 18692443 ER PT J AU Musher, DM AF Musher, Daniel M. TI Neurosyphilis: Diagnosis and response to treatment SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID HUMAN-IMMUNODEFICIENCY-VIRUS; CEREBROSPINAL-FLUID; SYPHILIS; PENICILLIN C1 [Musher, Daniel M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd,Rm 4B-370, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 16 TC 3 Z9 5 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2008 VL 47 IS 7 BP 900 EP 902 DI 10.1086/591535 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 345ZO UT WOS:000259038400006 PM 18715158 ER PT J AU Sano, M AF Sano, Mary TI NON-AMYLOID APPROACHES TO NEUROPROTECTION SO CNS SPECTRUMS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; MODERATE ALZHEIMERS-DISEASE; MILD COGNITIVE IMPAIRMENT; GLOBAL FUNCTION; DOUBLE-BLIND; PLACEBO; ROFECOXIB; ATORVASTATIN; INDIVIDUALS; DONEPEZIL C1 [Sano, Mary] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Sano, Mary] James J Peters VAMC, Bronx, NY USA. [Sano, Mary] Bristol Myers Squibb Co, New York, NY 10154 USA. Eisai & Co Ltd, Teaneck, NJ 07666 USA. [Sano, Mary] GlaxoSmithKline Inc, Res Triangle Pk, NC 27709 USA. [Sano, Mary] Pfizer, New York, NY USA. RP Sano, M (reprint author), Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY 10029 USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU M B L COMMUNICATIONS, INC PI NEW YORK PA 333 HUDSON ST, 7TH FLOOR, NEW YORK, NY 10013 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD OCT PY 2008 VL 13 IS 10 SU 16 BP 42 EP 44 PG 3 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 364ZF UT WOS:000260373900013 PM 18955963 ER PT J AU Linden, M Golier, J AF Linden, Maria Golier, Julia TI Challenges in the Implementation of Manualized Psychotherapy in Combat-related PTSD SO CNS SPECTRUMS LA English DT Article C1 [Linden, Maria; Golier, Julia] Mt Sinai Sch Med, New York, NY 10029 USA. [Golier, Julia] Bronx Vet Adm Med Ctr, PTSD Clin, Dept Psychiat, New York, NY USA. RP Linden, M (reprint author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM maria.linden@mssm.edu NR 4 TC 2 Z9 2 U1 0 U2 0 PU M B L COMMUNICATIONS, INC PI NEW YORK PA 333 HUDSON ST, 7TH FLOOR, NEW YORK, NY 10013 USA SN 1092-8529 J9 CNS SPECTRUMS JI CNS Spectr. PD OCT PY 2008 VL 13 IS 10 BP 872 EP 877 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 363KT UT WOS:000260266900008 PM 18955942 ER PT J AU Liu, YL Chacko, BK Ricksecker, A Shingarev, R Andrews, E Patel, RP Lang, JD AF Liu, Yuliang Chacko, Balu K. Ricksecker, Ana Shingarev, Roman Andrews, Eric Patel, Rakesh P. Lang, John D., Jr. TI Modulatory effects of hypercapnia on in vitro and in vivo pulmonary endothelial-neutrophil adhesive responses during inflammation SO CYTOKINE LA English DT Article DE Hypercapnia; Neutrophil; Endothelium; Adhesion molecule; Lung injury ID RESPIRATORY-DISTRESS-SYNDROME; INDUCED LUNG INJURY; FACTOR-KAPPA-B; MECHANICAL VENTILATION; ESCHERICHIA-COLI; GENE-EXPRESSION; CELL-ADHESION; INTERLEUKIN-8; ACTIVATION; CYTOKINE AB Reducing tidal volume as a part of a protective ventilation strategy may result in hypercapnia. In this study, we focused on the influence of hypercapnia on endothelial-neutrophil responses in models of inflammatory-stimulated human pulmonary microvascular endothelial cells (HMVEC) and in an animal model of lipopolysaccharide (LPS)-induced acute lung injury. Neutrophil adhesion and adhesion molecules expression and nuclear factor-kappa B (NF-kappa B) were analyzed in TNF-alpha and LPS-treated HMVEC exposed to either eucapnia or hypercapnia. In the in vivo limb, bronchoalveolar lavage fluid cell counts and differentials, adhesion molecule and chemokine expression were assessed in LPS-treated rabbits ventilated with either low tidal volume ventilation and eucapnia or hypercapnia. In both the in vitro and in vivo models, hypercapnia significantly increased neutrophil adhesion and adhesion molecule expression compared to eucapnia. Activity of NF-kappa B was significantly enhanced by hypercapnia in the in vitro experiments. IL-8 expression was greatest both in vitro and in vivo under conditions of hypercapnia and concomitant inflammation. CD11a expression was greatest in isolated human neutrophils exposed to hypercapnia + LPS. Our results demonstrate that endothelial-neutrophil responses per measurement of fundamental molecules of adhesion are significantly increased during hypercapnia and that hypercapnia mimics conditions of eucapnia + inflammation. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Liu, Yuliang; Lang, John D., Jr.] Univ Washington, Sch Med, Dept Anesthesiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Ricksecker, Ana] Univ Alabama, Dept Anesthesiol, Birmingham, AL 35294 USA. [Chacko, Balu K.; Patel, Rakesh P.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Shingarev, Roman; Andrews, Eric] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. RP Liu, YL (reprint author), Univ Washington, Sch Med, Dept Anesthesiol, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM yuliang6@u.washington.edu OI Patel, Rakesh/0000-0002-1526-4303 FU National Institutes of Health [HL067982] FX This work was supported by a National Institutes of Health Grant, #HL067982 to John D. Lang, Jr., M.D. NR 41 TC 14 Z9 16 U1 0 U2 0 PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD OCT PY 2008 VL 44 IS 1 BP 108 EP 117 DI 10.1016/j.cyto.2008.06.016 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 369NG UT WOS:000260700600018 PM 18713668 ER PT J AU Simone, S Gorin, Y Velagapudi, C Abboud, HE Habib, SL AF Simone, Simona Gorin, Yves Velagapudi, Chakradhar Abboud, Hanna E. Habib, Samy L. TI Mechanism of oxidative DNA damage in diabetes - tuberin inactivation and downregulation of DNA repair enzyme 8-oxo-7,8-dihydro-2'-deoxyguanosine-DNA glycosylase SO DIABETES LA English DT Article ID RENAL EPITHELIAL-CELLS; AKT/PROTEIN KINASE-B; HIGH GLUCOSE; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; SIGNALING PATHWAYS; MITOCHONDRIAL-DNA; NAD(P)H OXIDASE; SKELETAL-MUSCLE; MESANGIAL CELLS AB OBJECTIVE-To investigate potential mechanisms of oxidative DNA damage in a rat model of type 1 diabetes and in murine proximal tubular epithelial cells and primary culture of rat proximal tubular epithelial cells. RESEARCH DESIGN AND METHODS-Phosphorylation of Akt and tuberin, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) levels, and 8-oxoG-DNA glycosylase (OGG1) expression were measured in kidney cortical tissue of control and type 1 diabetic animals and in proximal tubular cells incubated with normal or high glucose. RESULTS-In the renal cortex of diabetic rats, the increase in Akt phosphorylation is associated with enhanced phosphorylation of tuberin, decreased OGG1 protein expression, and 8-oxodG accumulation. Exposure of proximal tubular epithelial cells to high glucose causes a rapid increase in reactive oxygen species (ROS) generation that correlates with the increase in Akt and tuberin phosphorylation. High glucose also resulted in downregulation of OGG1 protein expression, paralleling its effect on Akt and tuberin. Inhibition of phosphatidylinositol 3-kinase/Akt significantly reduced high glucose-induced tuberin phosphorylation and restored OGG1 expression. Hydrogen peroxide stimulates Akt and tuberin phosphorylation and decreases OGG1 protein expression. The antioxidant N-acetylcysteine significantly inhibited ROS generation, Akt/protein kinase B, and tuberin phosphorylation and resulted in deceased 8-oxodG accumulation and upregulation of OGG1 protein expression. CONCLUSIONS-Hyperglycemia in type 1 diabetes and treatment of proximal tubular epithelial cells with high glucose leads to phosphorylation/inactivation of tuberin and downregulation of OGG1 via a redox-dependent activation of Akt in renal tubular epithelial cells. This signaling cascade provides a mechanism of oxidative stress-mediated DNA damage in diabetes. C1 [Simone, Simona; Gorin, Yves; Velagapudi, Chakradhar; Abboud, Hanna E.; Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78284 USA. [Simone, Simona] Univ Bari, Dept Emergency & Transplantat, Bari, Italy. [Abboud, Hanna E.; Habib, Samy L.] S Texas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78284 USA. EM habib@uthscsa.edu RI Velagapudi, Chakradhar/F-9750-2015 OI Gorin, Yves/0000-0003-4048-6925 FU NIDDK NIH HHS [R37 DK033665, R37-DK-33665] NR 49 TC 44 Z9 45 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD OCT PY 2008 VL 57 IS 10 BP 2626 EP 2636 DI 10.2337/db07-1579 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 360FT UT WOS:000260043800012 PM 18599524 ER PT J AU Lopes-Virella, MF Carter, RE Gilbert, GE Klein, RL Jaffa, M Jenkins, AJ Lyons, TJ Garvey, WT Virella, G AF Lopes-Virella, Maria F. Carter, Rickey E. Gilbert, Gregory E. Klein, Richard L. Jaffa, Miran Jenkins, Alicia J. Lyons, Timothy J. Garvey, W. Timothy Virella, Gabriel CA DCCT EDIC Cohort Study Grp TI Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular Complications SO DIABETES CARE LA English DT Article ID TYPE-1 DIABETIC-PATIENTS; INTIMA-MEDIA THICKNESS; C-REACTIVE PROTEIN; LOW-GRADE INFLAMMATION; ADHESION MOLECULE-1; CLINICAL-EVIDENCE; PLASMA MARKERS; MELLITUS; ASSOCIATION; PROGRESSION AB OBJECTIVE - Because endothelial cell dysfunction and inflammation are key contributors to the development of complications in type 1 diabetes, we studied risk factors related to endothelial dysfunction and inflammation (C-reactive protein and fibrinogen, soluble vascular cell adhesion molecule-1, intracellular adhesion molecule-1 , and E-selectin, and fibrinolytic markers) in a subgroup) Of patients from the Diabetes Control and Complications Trial (DCCT)/Epidemiology, of Diabetes Intervention and Complications (EDIC) Study cohort. RESEARCH DESIGN AND METHODS - We determined which of these risk factors or clusters thereof -,ire associated with the presence of and Subsequent development of nephropathy and macrovascular complications (reflected by carotid intima-media thickness [IMT]). RESULTS - After adjustment for conventional risk factors (age, sex, DCCT treatment group, diabetes duration, A1C, systolic blood pressure, waist-to-hip ratio, total and HDL cholesterol,a nd smoking status), fibrinogen remained strongly associated with progression of internal and common carotid IMT (P < 0.01) and soluble E-selectin had a strong association with nephropathy (P < 0.01). CONCLUSIONS - The best predictor for IMT progression in the DCCT/EDIC cohort was plasma fibrinogen, and the levels of soluble E-selectin discriminate patients with albuminuria better than conventional risk factors. C1 [Lopes-Virella, Maria F.; Klein, Richard L.; Jenkins, Alicia J.; Lyons, Timothy J.; Garvey, W. Timothy] Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.; Klein, Richard L.; Jenkins, Alicia J.; Lyons, Timothy J.; Garvey, W. Timothy] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Carter, Rickey E.; Gilbert, Gregory E.; Jaffa, Miran] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Jenkins, Alicia J.; Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Endocrinol Sect, Oklahoma City, OK USA. [Garvey, W. Timothy] Univ Alabama, Dept Nutr, Birmingham, AL USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA. EM virellam@musc.edu RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496 FU Merit Review Program of the Department of Veterans Affairs; National Institutes of Health and Juvenile Diabetes Research Foundation [PO1 HL55782]; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health FX This research was supported by funding of the Merit Review Program of the Department of Veterans Affairs and by joint funding of the National Institutes of Health and Juvenile Diabetes Research Foundation (PO1 HL55782). The DCCT/EDIC Research Group is sponsored through research contracts from the National Institute of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institutes of Health.; The technical assistance of Charlyne Chassereau, Andrea Semler, and Karma Moller and efforts of stud), coordinators jenny Smith, Leslie Nicholson, Marlene Brabham, and Erica Hood are gratefully acknowledged. Finally, the authors are grateful to the patients in the DCCT/EDIC cohort for their long-term participation in this important trial. NR 25 TC 53 Z9 55 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2008 VL 31 IS 10 BP 2006 EP 2012 DI 10.2337/dc08-0659 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 360FR UT WOS:000260043600017 PM 18628568 ER PT J AU Baddley, JW Sankara, IR Rodriquez, JM Pappas, PG Many, WJ AF Baddley, John W. Sankara, Ishwara R. Rodriquez, J. Martin Pappas, Peter G. Many, Wickliffe J., Jr. TI Histoplasmosis in HIV-infected patients in a Southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Histoplasma capsulatum; HIV; histoplasmosis; mortality ID HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; DIAGNOSIS; BRAZIL AB Histoplasmosis is an important opportunistic infection among HIV-infected patients in endemic areas, and clinical outcomes are often poor. Additional data on factors associated with outcomes are needed to better identify patients who may require aggressive care. Using a cohort of 46 HIV-infected patients with histoplasmosis from an underserved city endemic for histoplasmosis, we explored epidemiology, outcomes, and prognostic factors. Histoplasmosis was the 1st recognized manifestation of HIV Infection in 12 (26.1%) of 46 patients. Death occurred in IS (39%) patients within 3 months of diagnosis of histoplasmosis. Fungemia (odds ratio [OR], 12. 1; 95% confidence interval [0], 1.9-76; P = 0.008), renal insufficiency (OR, 11.3; 95% Cl, 1.7-77.2; P = 0.01), and age (OR, 0.9; 95% CI, 0.8-0.98; P = 0.02) were independent predictors of poor prognosis. Histoplasmosis in HIV patients is associated with poor outcomes. Identification of prognostic factors may be helpful in identifying patients who require more aggressive care. Published by Elsevier Inc. C1 [Baddley, John W.; Pappas, Peter G.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35322 USA. [Sankara, Ishwara R.; Rodriquez, J. Martin; Many, Wickliffe J., Jr.] UAB Hlth Ctr Montgomery, Dept Med, Montgomery, AL 36116 USA. RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. EM jbaddley@uab.edu NR 13 TC 24 Z9 30 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD OCT PY 2008 VL 62 IS 2 BP 151 EP 156 DI 10.1016/j.diagmicrobio.2008.05.006 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 356SG UT WOS:000259797300005 PM 18597967 ER PT J AU Leung, FW AF Leung, Felix W. TI Risk factors for gastrointestinal complications in aspirin users: Review of clinical and experimental data SO DIGESTIVE DISEASES AND SCIENCES LA English DT Review DE aspirin; stomach; NSAID; smoking; alcohol; nitric oxide; nitroglycerin ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LOW-DOSE ASPIRIN; PROTON PUMP INHIBITORS; INDUCED GASTRIC-ULCERS; NITRIC-OXIDE-DONORS; MUCOSAL BLOOD-FLOW; FIBROBLAST-GROWTH-FACTOR; TOBACCO CIGARETTE-SMOKE; ACETIC-ACID ULCERS; PEPTIC-ULCER AB This paper reviews recent clinical evidence that suggests that aspirin prophylaxis against cardiac and cerebral vascular ischemia is associated with significant gastrointestinal complications. The clinical and experimental evidence to confirm the role of risk factors of concomitant use of nonsteroidal anti-inflammatory drugs (NSAID), tobacco cigarette smoking, and alcohol consumption are discussed. The limitations of long-term acid suppression treatment for the prevention of these complications are considered. Future experimental studies to guide the clinical approach to develop novel and potentially cost-effective management strategies are discussed. C1 [Leung, Felix W.] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Div Gastroenterol Res & Med Serv, Sepulveda, CA 91343 USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Leung, FW (reprint author), VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, Div Gastroenterol Res & Med Serv, 111G,16111 Plummer St, Sepulveda, CA 91343 USA. EM felix.leung@va.gov FU VA Medical Research Funds FX This work was supported in part by VA Medical Research Funds. NR 102 TC 4 Z9 6 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD OCT PY 2008 VL 53 IS 10 BP 2604 EP 2615 DI 10.1007/s10620-007-0178-6 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 343DV UT WOS:000258833800003 PM 18306040 ER PT J AU Rosman, AS Chaparala, G Monga, A Spungen, AM Bauman, WA Korsten, MA AF Rosman, Alan S. Chaparala, Geeta Monga, Amit Spungen, Ann M. Bauman, William A. Korsten, Mark A. TI Intramuscular neostigmine and glycopyrrolate safely accelerated bowel evacuation in patients with spinal cord injury and defecatory disorders SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE bowel care; difficulty with evacuation; glycopyrrolate; neostigmine; spinal cord injury ID ACUTE COLONIC PSEUDOOBSTRUCTION; INTRANASAL NEOSTIGMINE; MYASTHENIA-GRAVIS; ATROPINE; CARE AB Difficulty with evacuation after spinal cord injury (SCI) may be due to a lack of parasympathetic stimulation of the colon. Prior studies in persons with spinal cord injury have suggested that intravenous administration of neostigmine stimulates colonic motility while glycopyrrolate attenuates some of the cholinergic side effects of neostigmine. We thus performed a double-blind, cross-over study to evaluate the effect of neostigmine/glycopyrrolate injections in patients with SCI and defecatory difficulties. Seven subjects received active treatment (neostigmine 2 mg and glycopyrrolate 0.4 mg intramuscularly) during three consecutive bowel evacuation sessions and were crossed-over to placebo injections for three consecutive sessions. Compared with placebo, neostigmine/glycopyrrolate reduced the total bowel evacuation time from 98.1 +/- 7.2 to 74.8 min +/- 5.8 (p < 0.05). The lowest heart rate or blood pressure was not significantly different between the treatment and placebo groups. In conclusion, neostigmine/glycopyrrolate may improve bowel evacuation in patients with SCI-related defecatory disorders. C1 [Rosman, Alan S.; Korsten, Mark A.] James J Peters VA Med Ctr, Gastroenterol Practice & Spinal Cord Ctr Excellen, Bronx, NY 10468 USA. [Chaparala, Geeta; Monga, Amit; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Spinal Cord Ctr Excellence, Bronx, NY 10468 USA. [Rosman, Alan S.; Chaparala, Geeta; Monga, Amit; Spungen, Ann M.; Bauman, William A.; Korsten, Mark A.] NYU, Mt Sinai Sch Med, New York, NY USA. RP Korsten, MA (reprint author), James J Peters VA Med Ctr, Gastroenterol Practice & Spinal Cord Ctr Excellen, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Mark.Korsten@VA.gov NR 18 TC 17 Z9 18 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD OCT PY 2008 VL 53 IS 10 BP 2710 EP 2713 DI 10.1007/s10620-008-0216-z PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 343DV UT WOS:000258833800018 PM 18338263 ER PT J AU Leung, FW AF Leung, Felix W. TI Unsedated colonoscopy introduced to ensure access is acceptable to a subgroup of veterans SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE unsedated colonoscopy; access; trainee; nursing shortage ID FLEXIBLE SIGMOIDOSCOPY; SEDATION; ENDOSCOPY; INTUBATION; SKILLS AB Background Nurses for monitoring and recovery are required for sedated colonoscopy. A nursing shortage necessitated discontinuation of sedated colonoscopy at a VA academic training program. Aim Elements of a case series that documented acceptance of unsedated colonoscopy are reviewed to raise awareness of the feasibility of this option. Method The pros and cons of sedation and no sedation were summarized. After discussion, patients who chose the unsedated option were scheduled for examination locally while those who desired sedation were scheduled at another VA site. Colonoscopy was performed by supervised trainees. Results From September 2002 to June 2005 scheduled unsedated colonoscopy was accepted by 145 of 483 veterans. Cecal intubation was achieved in 81%. Thus, of the cohort 30% had local access to and 24% completed unsedated colonoscopy. Implementation of unsedated colonoscopy obviated the need for two registered nurses previously required for sedated colonoscopy. Conclusion Unsedated colonoscopy offered as an option to ensure access was acceptable to a subgroup of our veteran patients. Implementation required less nursing resources. Techniques to enhance the cecal intubation rate of unsedated colonoscopy performed by supervised trainees deserves to be assessed in future studies. C1 [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, VAGLAHS, Sepulveda Ambulatory Care Ctr,Div Gastroenterol, Sepulveda, CA 91343 USA. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Vet Affairs Med Ctr, Sepulveda Ambulatory Care Ctr, Res & Med Serv, Los Angeles, CA USA. RP Leung, FW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VAGLAHS, Sepulveda Ambulatory Care Ctr,Div Gastroenterol, 111G,16111 Plummer St, Sepulveda, CA 91343 USA. EM Felix.leung@va.gov FU Veterans Affairs Medical Research Funds; ASGE Endoscopic Career Development Award FX This work was supported in part by the Veterans Affairs Medical Research Funds and ASGE Endoscopic Career Development Award (FWL 1985). The author has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The author has no conflict of interest to declare. NR 25 TC 8 Z9 8 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD OCT PY 2008 VL 53 IS 10 BP 2719 EP 2722 DI 10.1007/s10620-007-0192-8 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 343DV UT WOS:000258833800020 PM 18274901 ER PT J AU Adla, M Downey, KK Ahmad, J AF Adla, Mahathi Downey, Kathy K. Ahmad, Jawad TI Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: Case report and review of literature SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article ID OF-THE-LITERATURE; VIRUS-INFECTION; RIBAVIRIN THERAPY; PLUS RIBAVIRIN C1 [Adla, Mahathi; Ahmad, Jawad] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. [Downey, Kathy K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Ahmad, J (reprint author), Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. EM ahmadj@msx.upmc.edu NR 17 TC 11 Z9 11 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD OCT PY 2008 VL 53 IS 10 BP 2810 EP 2812 DI 10.1007/s10620-008-0209-y PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 343DV UT WOS:000258833800035 PM 18320314 ER PT J AU Gallun, F Souza, P AF Gallun, Frederick Souza, Pamela TI Exploring the role of the modulation spectrum in phoneme recognition SO EAR AND HEARING LA English DT Article ID AMPLITUDE-MODULATION; FREQUENCY-SELECTIVITY; TEMPORAL INFORMATION; RELATIVE IMPORTANCE; SPEECH RECOGNITION; INTELLIGIBILITY; RECEPTION; MASKING; CUES AB Objectives: The ability of human listeners to identify consonants (presented as nonsense syllables) on the basis of primarily temporal information was compared with the predictions of a simple model based on the amplitude modulation spectra of the stimuli calculated for six octave-spaced carrier frequencies (250 to 8000 Hz) and six octave-spaced amplitude modulation frequencies (1 to 32 Hz). Design: The listeners and the model were presented with 16 phonemes each spoken by four different talkers processed so that one, two, four, or eight bands of spectral information remained. The average modulation spectrum of each of the processed phonemes was extracted and similarity across phonemes was calculated by the use of a spectral correlation index (SCI). Results: The similarity of the modulation spectra across phonemes as assessed by the spectral correlation index was a strong predictor of the confusions made by human listeners. Conclusions: This result suggests that a sparse set of time-averaged patterns of modulation energy can capture a meaningful aspect of the information listeners use to distinguish among speech signals. C1 [Gallun, Frederick] Portland VA Med Ctr, VA RR&D Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Souza, Pamela] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA. RP Gallun, F (reprint author), VA NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Frederick.Gallun@va.gov OI Gallun, Frederick/0000-0002-4145-2199 FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [DC006014]; National Institute for Deaffness and Communication Disorders [DC04661]; Bloedel Hearing Research Center FX The research was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (to F. G.), grants DC006014 and DC04661 from the National Institute for Deaffness and Communication Disorders (to P. S.), and by the Bloedel Hearing Research Center (to P. S.). NR 39 TC 25 Z9 25 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD OCT PY 2008 VL 29 IS 5 BP 800 EP 813 DI 10.1097/AUD.0b013e31817e73ef PG 14 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 350FS UT WOS:000259338700012 PM 18596640 ER PT J AU Lin, D Bucci, MK Eisele, DW Wang, SJ AF Lin, Doris Bucci, M. Kara Eisele, David W. Wang, Steven J. TI Squamous cell carcinoma of the buccal mucosa: A retrospective analysis of 22 cases SO ENT-EAR NOSE & THROAT JOURNAL LA English DT Article AB We examined our institution's experience with 22 cases of previously untreated buccal squamous cell carcinoma via a retrospective chart review. Eleven of these patients had been treated with a combination of surgical excision and postoperative radiation therapy, 8 patients with surgical excision alone, and 3 patients with radiation therapy alone. The overall 3-year locoregional recurrence rate was 32% (n = 7). The 3-year survival rates were 82% after surgery plus radiation (9 of 11 patients), 63% after surgery alone (5 of 8), and 33% after radiation alone (1 of 3). Three-year T-category-specific survival rates were 100% for category T1 tumors (3 of 3 patients), 73% for T2 (8 of 11), 50% for T3 (3 of 6), and 50% for T4 (1 of 2). Although the small size of our study precluded any statistically significant conclusions, we believe that locoregional control and survival rates may be greater with surgical excision plus postoperative radiation than with treatment with either modality alone. C1 [Lin, Doris; Eisele, David W.; Wang, Steven J.] Univ Calif San Francisco, Sch Med, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA. [Bucci, M. Kara] Univ Calif San Francisco, Sch Med, Dept Radiat Oncol, San Francisco, CA 94143 USA. RP Wang, SJ (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111B, San Francisco, CA 94121 USA. EM swang@ohns.ucsf.edu NR 15 TC 3 Z9 3 U1 0 U2 0 PU VENDOME GROUP LLC PI NEW YORK PA 149 FIFTH AVE, 10TH FLOOR, NEW YORK, NY 10010 USA SN 0145-5613 J9 ENT-EAR NOSE THROAT JI ENT-Ear Nose Throat J. PD OCT PY 2008 VL 87 IS 10 BP 582 EP 586 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA V10PD UT WOS:000207475000012 PM 18833538 ER PT J AU Zdychova, J Kazdova, L Pelikanova, T Lindsley, JN Anderson, S Komers, R AF Zdychova, Jana Kazdova, Ludmila Pelikanova, Terezie Lindsley, Jessie N. Anderson, Sharon Komers, Radko TI Renal activity of Akt kinase in obese Zucker rats SO EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article DE Akt kinase; phosphatidylinositol 3-kinase; Zucker rat; mammalian target of rapamycin; mTOR; endothelial nitric oxide synthase ID MESSENGER-RNA TRANSLATION; DIABETIC KIDNEY-DISEASE; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; EPITHELIAL-CELLS; HIGH GLUCOSE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; MAMMALIAN TARGET; SKELETAL-MUSCLE AB Insulin resistance (IR) and consequent hyperinsulinemia are hallmarks of Type 2 diabetes (DM2). Akt kinase (Akt) is an important molecule in insulin signaling, implicated in regulation of glucose uptake, cell growth, cell survival, protein synthesis, and endothelial nitric oxide (NO) production. Impaired Akt activation in insulin-sensitive tissues contributes to IR. However, Akt activity in other tissues, particularly those affected by complications of DM2, has been less studied. We hypothesized that hyperinsulinemia could have an impact on activity of Akt and its effectors involved in regulation of renal morphology and function in DM2. To address this issue, renal cortical Akt was determined in obese Zucker rats (ZO), a model of DM2, and lean controls (ZL). We also studied expression and phosphorylation of the mammalian target of rapamycin (mTOR) and endothelial NO synthase (eNOS), molecules downstream of Akt in the insulin signaling cascade, and documented modulators of renal injury. Akt activity was measured by a kinase assay with GSK-3 as a substrate. Expression of phosphorylated (active) and total proteins was measured by immunoblotting and immunohistochemistry. Renal Akt activity was increased in ZO as compared to ZL rats, in parallel with progressive hyperinsulinemia. No differences in Akt were observed in the skeletal muscle. Corresponding to increases in Akt activity, ZO rats demonstrated enhanced phosphorylation of renal mTOR. Acute PI3K inhibition with wortmannin (100 mu g/kg) attenuated renal Akt and mTOR activities in ZO, but not in ZL rats. In contrast to mTOR, eNOS phosphorylation was similar in ZO and ZL rats, despite higher total eNOS expression. In conclusion, ZO rats demonstrated increases in renal Akt and mTOR activity and expression. However, eNOS phosphorylation did not follow this pattern. These data suggest that DM2 is associated with selective IR in the kidney, allowing pro-growth signaling via mTOR, whereas potentially protective effects mediated by eNOS are blunted. C1 [Lindsley, Jessie N.; Anderson, Sharon; Komers, Radko] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, Portland, OR 97239 USA. [Zdychova, Jana; Kazdova, Ludmila; Pelikanova, Terezie; Komers, Radko] Inst Clin & Expt Med, Ctr Diabet, Prague, Czech Republic. [Anderson, Sharon] Portland VA Med Ctr, Portland, OR 97329 USA. RP Komers, R (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM komersr@ohsu.edu FU Czech Ministry of Health Care [MZO 00023001]; NIH [DK 63231] FX These studies were supported by the institutional Grant # MZO 00023001 of the Czech Ministry of Health Care (RK), and by DK 63231 from the NIH (SA). NR 50 TC 14 Z9 17 U1 0 U2 2 PU SOC EXPERIMENTAL BIOLOGY MEDICINE PI MAYWOOD PA 195 WEST SPRING VALLEY AVE, MAYWOOD, NJ 07607-1727 USA SN 1535-3702 J9 EXP BIOL MED JI Exp. Biol. Med. PD OCT PY 2008 VL 233 IS 10 BP 1231 EP 1241 DI 10.3181/0801-RM-29 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 355SU UT WOS:000259729500005 PM 18641049 ER PT J AU Venkatesan, B Ghosh-Choudhury, N Das, F Mahimainathan, L Kamat, A Kasinath, BS Abboud, HE Choudhury, GG AF Venkatesan, Balachandar Ghosh-Choudhury, Nandini Das, Falguni Mahimainathan, Lenin Kamat, Amrita Kasinath, Balakuntalam S. Abboud, Hanna E. Choudhury, Goutam Ghosh TI Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B SO FASEB JOURNAL LA English DT Article DE SIRT1; Akt kinase; CDK2 ID PROTEIN-TYROSINE PHOSPHATASE-1B; INDUCED DNA-SYNTHESIS; CARCINOMA A431 CELLS; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; INSULIN SENSITIVITY; SIRT1 DEACETYLASE; IN-VIVO; C-FOS; PROLIFERATIVE GLOMERULONEPHRITIS AB Mesangioproliferative glomerulonephritis is associated with overactive PDGF receptor signal transduction. We show that the phytoalexin resveratrol dose dependently inhibits PDGF-induced DNA synthesis in mesangial cells with an IC50 of 10 mu M without inducing apoptosis. Remarkably, the increased SIRT1 deacetylase activity induced by resveratrol was not necessary for this inhibitory effect. Resveratrol significantly blocked PDGF-stimulated c-Src and Akt kinase activation, resulting in reduced cyclin D1 expression and attenuated pRb phosphorylation and cyclin-dependent kinase-2 (CDK2) activity. Furthermore, resveratrol inhibited PDGFR phosphorylation at the PI 3 kinase and Grb-2 binding sites tyrosine-751 and tyrosine-716, respectively. This deficiency in PDGFR phosphorylation resulted in significant inhibition of PI 3 kinase and Erk1/2 MAPK activity. Interestingly, resveratrol increased the activity of protein tyrosine phosphatase PTP1B, which dephosphorylates PDGF-stimulated phosphorylation at tyrosine-751 and tyrosine-716 on PDGFR with concomitant reduction in Akt and Erk1/2 kinase activity. PTP1B significantly inhibited PDGF-induced DNA synthesis without inducing apoptosis. These results for the first time provide evidence that the stilbene resveratrol targets PTP1B to inhibit PDGFR mitogenic signaling. C1 [Venkatesan, Balachandar; Das, Falguni; Mahimainathan, Lenin; Kamat, Amrita; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, OBrien Kidney Res Ctr, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, OBrien Kidney Res Ctr, Dept Pathol, San Antonio, TX 78229 USA. [Kamat, Amrita; Choudhury, Goutam Ghosh] Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78284 USA. [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, OBrien Kidney Res Ctr, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu OI /0000-0001-5077-3552 FU National Institutes of Health (NIH) [RO1 DK 50190]; Juvenile Diabetes Research Foundation; NIH [RO1 AR52425, RO1 DK 33665]; VA Merit Review and Morrison Trust; VA VISN; American Diabetes Association [077295]; VA Research Service Merit FX We thank Dr. Brent Wagner for critically reading the manuscript. This work was supported by National Institutes of Health (NIH) grant RO1 DK 50190, the Juvenile Diabetes Research Foundation, and a VA Merit Review grant to G.G.C., who is a research career scientist in the Department of Veterans Affairs. N.G.C. is supported by NIH RO1 AR52425 and VA Merit Review and Morrison Trust grants. A.K. is a recipient of a VA VISN grant. B.S.K. is supported by grants from the NIH O'Brien Kidney Center, NIH RO1 DK 077295, the American Diabetes Association, and a VA Research Service Merit. Review grant. H.E.A. is supported by NIH RO1 DK 33665 and VA Merit Review grants. NR 95 TC 26 Z9 26 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD OCT PY 2008 VL 22 IS 10 BP 3469 EP 3482 DI 10.1096/fj.08-109488 PG 14 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 354MB UT WOS:000259642600009 PM 18567737 ER PT J AU Grady, WM Carethers, JM AF Grady, William M. Carethers, John M. TI Genomic and epigenetic instability in colorectal cancer pathogenesis SO GASTROENTEROLOGY LA English DT Review ID DNA MISMATCH REPAIR; ISLAND METHYLATOR PHENOTYPE; NONPOLYPOSIS COLON-CANCER; TUMOR MICROSATELLITE-INSTABILITY; HMLH1 PROMOTER HYPERMETHYLATION; CAUSE CHROMOSOMAL INSTABILITY; REPLICATION PROTEIN-A; BASE-EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; ABERRANT CRYPT FOCI AB Colorectal cancer arises as a consequence of the accumulation of genetic alterations (gene mutations, gene amplification, and so on) and epigenetic alterations (aberrant DNA methylation, chromatin modifications, and so on) that transform colonic epithelial cells into colon adenocarcinoma cells. The loss of genomic stability and resulting gene alterations are key molecular pathogenic steps that occur early in tumorigenesis; they permit the acquisition of a sufficient number of alterations in tumor suppressor genes and oncogenes that transform cells and promote tumor progression. Two predominant forms of genomic instability that have been identified in colon cancer are microsatellite instability and chromosome instability. Substantial progress has been made to identify causes of chromosomal instability in colorectal cells and to determine the effects of the different forms of genomic instability on the biological and clinical behavior of colon tumors. In addition to genomic instability, epigenetic instability results in the aberrant methylation of tumor suppressor genes. Determining the causes and roles of genomic and epigenomic instability in colon tumor formation has the potential to yield more effective prevention strategies and therapeutics for patients with colorectal cancer. C1 [Carethers, John M.] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA. [Carethers, John M.] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, La Jolla, CA 92093 USA. [Carethers, John M.] VA San Diego Healthcare Syst, San Diego, CA USA. [Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Grady, William M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Grady, William M.] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Carethers, JM (reprint author), Univ Calif San Diego, Dept Med, Div Gastroenterol, UC303,MC 0063,9500 Gilman Dr, La Jolla, CA 92093 USA. EM jcarethers@ucsd.edu FU US Public Health Service [CA11518, DK067287, DK080506]; VA Research Service FX Supported by the US Public Health Service (CA11518 to W.M.G. and DK067287 and DK080506 to J.M.C.) and the VA Research Service (W.M.G. and J.M.C.). NR 215 TC 347 Z9 359 U1 5 U2 32 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2008 VL 135 IS 4 BP 1079 EP 1099 DI 10.1053/j.gastro.2008.07.076 PG 21 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 359JM UT WOS:000259982800015 PM 18773902 ER PT J AU Lieberman, D Moravec, M Holub, J Michaels, L Eisen, G AF Lieberman, David Moravec, Matthew Holub, Jennifer Michaels, Leann Eisen, Glenn TI Polyp size and advanced histology in patients undergoing colonoscopy screening: Implications for CT colonography SO GASTROENTEROLOGY LA English DT Article ID AMERICAN-CANCER-SOCIETY; COLORECTAL-CANCER; ASYMPTOMATIC ADULTS; ADVANCED NEOPLASIA; TASK-FORCE; SURVEILLANCE; ADENOMAS; POLYPECTOMY; GUIDELINES; UPDATE AB Background & Aims: Colorectal cancer screening with diagnostic imaging can detect polyps. The management of patients whose largest polyp is less than 10 mm is uncertain. The primary aim of this study was to determine rates of advanced histology in patients undergoing colorectal cancer screening whose largest polyp is 9 mm or less. Methods: Subjects include all asymptomatic adults receiving colonoscopy for screening during 2005 from 17 practice sites, which provide both colonoscopy and pathology reports to the Clinical Outcomes Research Initiative repository. Patients were classified by size of largest polyp. Advanced histology was defined as an adenoma. with villous or serrated histology, highgrade dysplasia, or an invasive cancer. Risk factors for advanced histology were determined using Pearson X-2 and Fisher exact tests. Results: Among 13,992 asymptomatic patients who had screening colonoscopy, 6360 patients (45%) had polyps, with complete histology available in 5977 (94%) patients. The proportion with advanced histology was 1.7% in the 1- to 5-mm group, 6.6% in the 6- to 9-mm group, 30.6% in the greater than 10-mm group, and 72.1% in the tumor group. Distal location was associated with advanced histology in the 6- to 9-mm group (P = .04) and in the greater than 10-mm group (P = .002). Conclusions: One in 15 asymptomatic patients whose largest polyp is 6 to 9 nun will have advanced histology and would undergo surveillance at 3 years based on current guidelines. Because histology is necessary for this decision, most of these patients should be offered colonoscopy. Further study should determine whether patients whose largest polyp is 1-5 mm. can be safely followed without polypectomy. C1 [Lieberman, David; Moravec, Matthew; Holub, Jennifer; Michaels, Leann; Eisen, Glenn] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97239 USA. RP Lieberman, D (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, P3-GI,1037 SW Vet Hosp Rd, Portland, OR 97239 USA. EM lieberma@ohsu.edu FU NIDDK [U01 DK57132, R33-DK6177801]; AstraZeneca; Bard International; Pentax USA; ProVation; Endosoft; GIVEN Imaging; Ethicon; federal and industry sources FX Supported with funding from NIDDK U01 DK57132 and R33-DK6177801, and, in addition, the practice network (Clinical Outcomes Research Ini tiative) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon; however, the commercial entities had no involvement in this research.; Financial disclosure and conflicts of interest: Dr Lieberman is the executive director of the Clinical Outcomes Research Initiative (CORI), a nonprofit organization that receives funding from federal and industry sources. The CORI database is used in this study. This relationship has been reviewed and managed by the OHSU and Portland VAMC Conflict of Interest in Research Committee. NR 21 TC 199 Z9 204 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2008 VL 135 IS 4 BP 1100 EP 1105 DI 10.1053/j.gastro.2008.06.083 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 359JM UT WOS:000259982800016 PM 18691580 ER PT J AU Hawes, C Kimbell, A AF Hawes, C. Kimbell, A. TI ELDER ABUSE IN ASSISTED LIVING AND RESIDENTIAL CARE: EXAMINING THE PERFORMANCE OF LICENSURE AGENCIES, LTC OMBUDSMEN AND APS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hawes, C.] Texas A&M Hlth Sci Ctr, Sch Rural Publ Hlth, College Stn, TX USA. [Kimbell, A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 153 EP 153 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810600529 ER PT J AU Williams, BR Woodby, L Bailey, A Ritchie, C Durham, R Burgio, K AF Williams, B. R. Woodby, L. Bailey, A. Ritchie, C. Durham, R. Burgio, K. TI PALLIATIVE CARE AT THE VA:ADAPTING TO THE CHANGING FACE OF AGING SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Williams, B. R.; Woodby, L.; Bailey, A.; Ritchie, C.; Burgio, K.] Birmingham Atlanta GRECC BVAMC, Birmingham, AL USA. [Williams, B. R.; Woodby, L.; Bailey, A.; Ritchie, C.; Burgio, K.] UAB Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Durham, R.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 258 EP 258 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810600904 ER PT J AU Bolkan, C Coehlo, D Hooker, K AF Bolkan, C. Coehlo, D. Hooker, K. TI MARITAL STATUS, HEALTH GOALS, AND SOCIAL NETWORKS OF OLDER WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bolkan, C.] Univ Washington, Seattle, WA USA. [Bolkan, C.] VA Puget Sound, Seattle, WA USA. [Coehlo, D.] Oregon State Univ Cascades, Bend, OR USA. [Hooker, K.] Oregon State Univ, Corvallis, OR 97331 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 346 EP 346 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810601255 ER PT J AU Kvale, E Ekundayo, O Ritchie, C Ahmed, A AF Kvale, E. Ekundayo, O. Ritchie, C. Ahmed, A. TI PREDICTORS OF MORTALITY AMONG COMMUNITY-DWELLING OLDER ADULTS WITH A HISTORY OF CANCER IN A PROSPECTIVE POPULATION-BASED STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kvale, E.; Ekundayo, O.; Ritchie, C.; Ahmed, A.] Univ Alabama, Birmingham, AL USA. [Kvale, E.; Ritchie, C.; Ahmed, A.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 414 EP 414 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810601484 ER PT J AU Phillips, LL Skinner-Falco, J Paukert, A Balsis, S Cully, J AF Phillips, L. L. Skinner-Falco, J. Paukert, A. Balsis, S. Cully, J. TI EFFECTS OF A BRIEF SKILLS-BASED INTERVENTION ON QUALITY OF LIFE AND NEGATIVE AFFECT AMONG OLDER CHRONICALLY ILL VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Phillips, L. L.; Skinner-Falco, J.; Balsis, S.; Cully, J.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Paukert, A.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 519 EP 519 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602060 ER PT J AU Brown, CJ Ekundayo, O Ritchie, C Sims, R Ahmed, A AF Brown, C. J. Ekundayo, O. Ritchie, C. Sims, R. Ahmed, A. TI HISTORY OF FREQUENT FALLS AND MORTALITY IN COMMUNITY-DWELLING OLDER ADULTS: A PROPENSITY-MATCHED PROSPECTIVE POPULATION-BASED STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Brown, C. J.; Ekundayo, O.; Ritchie, C.; Ahmed, A.] Univ Alabama, Birmingham, AL USA. [Sims, R.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 536 EP 536 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602121 ER PT J AU Keyes, C Fry, P Ong, A Sawyer, P Allman, R Martin, P MacDonald, M Margrett, J Poon, L AF Keyes, C. Fry, P. Ong, A. Sawyer, P. Allman, R. Martin, P. MacDonald, M. Margrett, J. Poon, L. TI PSYCHOSOCIAL FRONTIERS OF RESILIENCE IN LATER LIFE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Keyes, C.] Emory Univ, Atlanta, GA 30322 USA. [Fry, P.] Trinity Western Univ, Langley, BC, Canada. [Ong, A.] Cornell Univ, Ithaca, NY USA. [Sawyer, P.] UAB, Sch Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Allman, R.] Univ Alabama, Div Gerontol & Geriatr Med, Birmingham, AL USA. [Allman, R.] Birmingham VAMC, Birmingham, AL USA. [Martin, P.; MacDonald, M.; Margrett, J.] Iowa State Univ, Ames, IA USA. [Poon, L.] Univ Georgia, Inst Gerontol, Athens, GA 30602 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 566 EP 566 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602229 ER PT J AU Nelson, MM Smith, MA Martinson, BC Kind, A Luepker, RV AF Nelson, Melissa M. Smith, Maureen A. Martinson, Brian C. Kind, Amy Luepker, Russell V. TI Declining Patient Functioning and Caregiver Burden/Health: The Minnesota Stroke Survey-Quality of Life After Stroke Study SO GERONTOLOGIST LA English DT Article DE Burden; Competence; Functional decline; Proxies; Social exchange ID CANADIAN NEUROLOGICAL SCALE; SOCIAL-EXCHANGE; MEDICAL RECORD; OLDER-ADULTS; OF-LIFE; BURDEN; HEALTH; COMORBIDITY; DISABILITY; IMPACT AB Purpose: Caregivers of stroke patients may adapt to changes in patient functioning over time. If adaptation occurs, then caregiver burden and health may be influenced more by worsening in patient functioning than by static levels of functioning. This study examines the relationship between patients' baseline and changes in functioning and caregivers' subjective and objective burden as well as their health. Design and Methods: Only stroke patients who had caregivers were included in this analysis (N = 356). Stroke patients In = 281) or their proxies (n = 75) were interviewed within 4 months of hospital discharge and patients' medical records were abstracted. The primary caregiver also was interviewed at approximately the same time as the patient or proxy (N = 356). In all but one of the 75 proxy cases, the proxy was the. patient's caregiver. Binomial and ordinal logistic regression models were used. Results: Declining patient neurological functioning predicted greater objective burden and subjective burden relating to consequences for caregivers' personal lives, but it did not predict caregiver health. Implications: The impact a patient's stroke has on a caregiver's personal life and the number of hours spent caring for the patient appear to be a function of the changes of the patient's status over time rather than a function of a "snapshot" of their functioning at baseline. If these results are confirmed, interventions to protect caregivers may be indicated for stroke patients who continue to decline after hospital discharge. C1 [Nelson, Melissa M.] Univ Minnesota, Div Hlth Policy & Management, Minneapolis, MN USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Martinson, Brian C.] HealthPartners Res Fdn, Minneapolis, MN USA. [Kind, Amy] US Dept Vet Affairs, William S Middleton Hosp, Madison, WI USA. [Kind, Amy] Univ Wisconsin, Dept Med, Geriatr Sect, Madison, WI 53706 USA. [Luepker, Russell V.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. RP Nelson, MM (reprint author), Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 30 Coll Ave, New Brunswick, NJ 08901 USA. EM mnelson@ifh.rutgers.edu RI Garrido, Melissa/F-2885-2010 OI Garrido, Melissa/0000-0002-8986-3536 FU AHRQ HHS [T32 HS-000036, T32 HS000036]; NINDS NIH HHS [R01-NS39028-01A1, R01 NS039028, R01 NS039028-01A1] NR 41 TC 12 Z9 13 U1 6 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 IS 5 BP 573 EP 583 PG 11 WC Gerontology SC Geriatrics & Gerontology GA 372RQ UT WOS:000260919700002 PM 18981274 ER PT J AU Mavandadi, S Klaus, J Oslin, D AF Mavandadi, S. Klaus, J. Oslin, D. TI THE BEHAVIORAL HEALTH LABORATORY: APPLICATION AND EVALUATION OF A CLINICAL SERVICE FOR BEHAVIORAL HEALTH IN PRIMARY CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mavandadi, S.; Klaus, J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Oslin, D.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 585 EP 585 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602287 ER PT J AU Kimbell, K Kimbell, A AF Kimbell, K. Kimbell, A. TI END-OF-LIFE PREPARATIONS MADE BY PRE- AND EARLY-RETIREES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kimbell, K.] Univ Texas Austin, Sch Social Work, Austin, TX 78712 USA. [Kimbell, A.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 604 EP 604 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602355 ER PT J AU Williams, BR Ekundayo, J Ritchie, C Ahmed, A AF Williams, B. R. Ekundayo, J. Ritchie, C. Ahmed, A. TI WIDOWHOOD AND MORTALITY IN COMMUNITY DWELLING OLDER ADULTS: A PROPENSITY-MATCHED PROSPECTIVE POPULATION-BASED STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Williams, B. R.; Ritchie, C.] Birmingham Atlanta VA GRECC, Birmingham, AL USA. [Williams, B. R.] UAB, Dept Med, Birmingham, AL USA. [Ritchie, C.] UAB, Ctr Aging, Birmingham, AL USA. [Ahmed, A.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 617 EP 618 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602401 ER PT J AU Phillips, L AF Phillips, L. TI PREDICTING QUALITY OF LIFE AND TRUST IN HEALTHCARE AMONG OLDER MALE INMATES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Phillips, L.] Michael DeBakey Vet Affairs Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 677 EP 677 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602605 ER PT J AU Kono, A Fujita, T Kondo, T Tsumura, C Kushiyama, K Rubenstein, L AF Kono, A. Fujita, T. Kondo, T. Tsumura, C. Kushiyama, K. Rubenstein, L. TI A PREVENTIVE HOME VISIT PROGRAM TARGETED TO SPECIFIC CARE-NEEDS OF AMBULATORY FRAIL ELDERS: PILOT RESULTS FROM A RANDOMIZED CONTROLLED TRIAL (RCT) SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Kondo, T.] Osaka City Univ, Sch Nursing, Osaka, CA 558, Japan. [Tsumura, C.] Izumiotsu Community Based Comprehens Care Ctr, Izumiotsu, CA, Japan. [Tsumura, C.] Konan Womens Univ, Sch Nursing & Rehabil, Kobe, CA, Japan. [Kushiyama, K.] Misaki Town Goverment Off, Dept Hlth & Welf, Osaka, CA, Japan. [Rubenstein, L.] GRECC & UCLA, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 726 EP 726 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602778 ER PT J AU Bolkan, C Coehlo, D Hooker, K AF Bolkan, C. Coehlo, D. Hooker, K. TI SELF-REGULATORY FOCUS AND HEALTH-RELATED POSSIBLE SELVES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bolkan, C.] VA Puget Sound, Seattle, WA USA. [Bolkan, C.] Univ Washington, Seattle, WA 98195 USA. [Coehlo, D.] Oregon State Univ Cascades, Bend, OR USA. [Hooker, K.] Oregon State Univ, Coll Hlth & Human Sci, Corvallis, OR 97331 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 751 EP 751 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602862 ER PT J AU Gleason, C AF Gleason, C. TI CLINICAL SCREENING AND EVALUATION OF DRIVING IN PATIENTS WITH DEMENTIA SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Gleason, C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD OCT PY 2008 VL 48 SI 3 BP 754 EP 754 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 399PA UT WOS:000262810602875 ER PT J AU Hausmann, LRM Levine, JM Higgins, ET AF Hausmann, Leslie R. M. Levine, John M. Higgins, E. Tory TI Communication and group perception: Extending the 'saying is believing' effect SO GROUP PROCESSES & INTERGROUP RELATIONS LA English DT Article DE communication; group perception; saying is believing; shared reality; stereotype development ID MESSAGE MODIFICATION; SOCIAL STEREOTYPES; GROUP DECISION; MEMORY; CONSENSUS; CONSEQUENCES; IMPRESSIONS; FRAMEWORK; AUDIENCE; INFORMATION AB The saying-is-believing (SIB) effect occurs when tailoring a message to suit an audience influences a communicator's subsequent memories and impressions about the communication topic. Previous studies were restricted to one-person audiences and individuals as the communication topic. The present studies explored the SIB effect with multiple-person audiences and groups as the communication topic. In Study 1, the SIB effect occurred with a 1-person, but not a 3-person, audience. In Study 2, the SIB effect occurred with a 3-person audience when the audience explicitly validated communicators' messages. These findings demonstrate the generalizability of the SIB effect to group contexts, provide further evidence for a shared reality interpretation of this effect, and suggest a potentially important mechanism underlying stereotype development. C1 [Hausmann, Leslie R. M.] Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. [Levine, John M.] Univ Pittsburgh, Ctr Learning Res & Dev, Pittsburgh, PA 15260 USA. [Higgins, E. Tory] Columbia Univ, New York, NY 10027 USA. RP Hausmann, LRM (reprint author), Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA. EM leslie.hausmann@gmail.com NR 59 TC 15 Z9 16 U1 1 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1368-4302 J9 GROUP PROCESS INTERG JI Group Process Intergroup Relat. PD OCT PY 2008 VL 11 IS 4 BP 539 EP 554 DI 10.1177/1368430208095405 PG 16 WC Psychology, Social SC Psychology GA 351QT UT WOS:000259440100009 ER PT J AU Werner, RM Bradlow, ET Asch, DA AF Werner, Rachel M. Bradlow, Eric T. Asch, David A. TI Does hospital performance on process measures directly measure high quality care or is it a marker of unmeasured care? SO HEALTH SERVICES RESEARCH LA English DT Article DE quality of care; quality improvement; performance measurement; process measures ID ACUTE MYOCARDIAL-INFARCTION; COMMUNITY-ACQUIRED PNEUMONIA; PRACTICE GUIDELINES COMMITTEE; LEFT-VENTRICULAR DYSFUNCTION; ASSOCIATION TASK-FORCE; HEART-FAILURE; AMERICAN-COLLEGE; MORTALITY-RATES; ACC/AHA GUIDELINES; RANDOMIZED-TRIAL AB Objective. Quality measures may be associated with improved outcomes for two reasons. First, measured activities may directly improve care. Second, success on these measures may be a marker for other unmeasured aspects of high quality care. Our objective is to test the contribution of both possible effects. Data Sources. 2004 Medicare data on hospital performance from Hospital Compare and risk-adjusted mortality rates from Medicare Part A claims. Study Design. We studied 3,657 acute care U.S. hospitals and compared observed differences in condition-specific hospital mortality rates based on hospital performance with expected differences in mortality from the clinical studies underlying the measures. Principal Findings. Differences in observed mortality rates across U.S. hospitals are larger than what would be expected if these differences were due only to the direct effects of delivering measured care. Conclusions. Performance measures reflect care processes that both improve care directly and are also markers of elements of health care quality that are otherwise unmeasured. This finding suggests that process measures capture important information about care that is not directly measured, and that these unmeasured effects are in general larger than the measured effects. C1 [Werner, Rachel M.; Asch, David A.] Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Werner, Rachel M.; Asch, David A.] Univ Penn, VA Div Gen Internal Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.; Bradlow, Eric T.; Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Bradlow, Eric T.] Univ Penn, Dept Marketing, Philadelphia, PA 19104 USA. [Bradlow, Eric T.] Univ Penn, Dept Stat, Philadelphia, PA 19104 USA. [Bradlow, Eric T.] Univ Penn, Dept Educ, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. NR 55 TC 27 Z9 27 U1 3 U2 12 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2008 VL 43 IS 5 BP 1464 EP 1484 DI 10.1111/j.1475-6773.2007.00817.x PN 1 PG 21 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 350HR UT WOS:000259343800002 PM 22568614 ER PT J AU Yano, EM Rubenstein, LV Farmer, MM Chernof, BA Mittman, BS Lanto, AB Simon, BF Lee, ML Sherman, SE AF Yano, Elizabeth M. Rubenstein, Lisa V. Farmer, Melissa M. Chernof, Bruce A. Mittman, Brian S. Lanto, Andrew B. Simon, Barbara F. Lee, Martin L. Sherman, Scott E. TI Targeting primary care referrals to smoking cessation clinics does not improve quit rates: Implementing evidence-based interventions into practice SO HEALTH SERVICES RESEARCH LA English DT Article DE smoking cessation; quality of health care; veterans ID QUALITY IMPROVEMENT; TOBACCO CESSATION; PRACTICE GUIDELINE; RANDOMIZED-TRIAL; AHCPR GUIDELINE; HEALTH; DEPRESSION; SMOKERS; RECOMMENDATIONS; COLLABORATIVES AB Objective. To evaluate the impact of a locally adapted evidence-based quality improvement (EBQI) approach to implementation of smoking cessation guidelines into routine practice. Data Sources/Study Setting. We used patient questionnaires, practice surveys, and administrative data in Veterans Health Administration (VA) primary care practices across five southwestern states. Study Design. In a group-randomized trial of 18 VA facilities, matched on size and academic affiliation, we evaluated intervention practices' abilities to implement evidence-based smoking cessation care following structured evidence review, local priority setting, quality improvement plan development, practice facilitation, expert feedback, and monitoring. Control practices received mailed guidelines and VA audit-feedback reports as usual care. Data Collection. To represent the population of primary care-based smokers, we randomly sampled and screened 36,445 patients to identify and enroll eligible smokers at baseline (n=1,941) and follow-up at 12 months (n=1,080). We used computer-assisted telephone interviewing to collect smoking behavior, nicotine dependence, readiness to change, health status, and patient sociodemographics. We used practice surveys to measure structure and process changes, and administrative data to assess population utilization patterns. Principal Findings. Intervention practices adopted multifaceted EBQI plans, but had difficulty implementing them, ultimately focusing on smoking cessation clinic referral strategies. While attendance rates increased (p <.0001), we found no intervention effect on smoking cessation. Conclusions. EBQI stimulated practices to increase smoking cessation clinic referrals and try other less evidence-based interventions that did not translate into improved quit rates at a population level. C1 [Yano, Elizabeth M.] Sepulveda VA Ambulatory Care Ctr 152, VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA 91343 USA. [Rubenstein, Lisa V.] VA Greater Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Rubenstein, Lisa V.] RAND Hlth, Santa Monica, CA USA. [Yano, Elizabeth M.; Farmer, Melissa M.; Mittman, Brian S.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Chernof, Bruce A.] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. [Lee, Martin L.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. RP Yano, EM (reprint author), Sepulveda VA Ambulatory Care Ctr 152, VA Greater Los Angeles HSR&D Ctr Excellence, 16111 Plummer St, Sepulveda, CA 91343 USA. EM elizabeth.yano@va.gov OI Mittman, Brian/0000-0003-3589-9178; Sherman, Scott/0000-0003-1752-7303 FU the VA HSRD Service [CPG 97-012]; VA HSRD [MRP 04-221, RCS 05-195]; the VA Greater Los Angeles HSR& D Center of Excellence [HFP 94-028] FX This study was funded by the VA HSR&D Service (Project #CPG 97-012). The trial was registered through ClinicalTrials.gov (Registry No. NCT00012987). Dr. Farmer was supported ;by a VA HSR&D career development award (Project # MRP 04-221). Dr. Yano was supported by the original grant, and subsequently by the VA Greater Los Angeles HSR& D Center of Excellence (Project #HFP 94-028) and a VA HSR& D Research Career Scientist Award (Project #RCS 05-195). We acknowledge the support of our site principal investigators: Timothy Carmody, Ph. D., Carol Chavez, N. P., Linda Ferry, M. D., Michael Gould, M. D., Betty Hedrick, N. P., Linda Hill, R. N., James Howard, M. D., Susan Blair Knepper, F. N. P., Charles McCreary, M. D., Matthew Meyer, Ph. D., Celia Michael, Ph. D., Nicole Miller, Ph. D., Sharon Rapp, Ph. D., Mitch Rice, R. N., M. N., Robert Smyer, M. D., David Webb, M. D., Brian Yee, M. D., and Sheila Young, Ph. D. We also acknowledge MingMing Wang, M. P. H., for administrative data acquisition and analysis, Ismelda Canelo, M. P. A., for administrative support, and the many interviewers and staff at California Survey Research Services Inc. (CSRS) in Van Nuys, CA. We would also like to thank the editors and reviewers for their extremely helpful, substantive input leading to improved reporting of these trial results. NR 68 TC 14 Z9 14 U1 3 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD OCT PY 2008 VL 43 IS 5 BP 1637 EP 1661 DI 10.1111/j.1475-6773.2008.00865.x PN 1 PG 25 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 350HR UT WOS:000259343800011 PM 18522670 ER PT J AU Ferreira, AC Isomoto, H Moriyama, M Fujioka, T Machado, JC Yamaoka, Y AF Ferreira, Antonio Carlos Isomoto, Hajime Moriyama, Masatsugu Fujioka, Toshio Machado, Jose Carlos Yamaoka, Yoshio TI Helicobacter and gastric malignancies SO HELICOBACTER LA English DT Article DE Helicobacter pylori; gastric cancer; MALT lymphoma ID LYMPHOID-TISSUE LYMPHOMAS; IN-SITU HYBRIDIZATION; BETA-CATENIN SIGNAL; MALT LYMPHOMA; PYLORI ERADICATION; PROMOTER HYPERMETHYLATION; E-CADHERIN; ATROPHIC GASTRITIS; PEPTIC-ULCERATION; EPITHELIAL-CELLS AB Individuals infected with Helicobacter pylori, a stomach colonizing bacteria, have an increased risk of developing gastric malignancies. The risk for developing cancer relates to the physiologic and histologic changes that H. pylori infection induces in the stomach. In the last year numerous studies have been conducted in order to characterize the association between H. pylori infection and gastric cancer. These studies range from epidemiologic approaches aiming at the identification of environmental, host genetic, and bacterial factors associated with risk of gastric cancer, to molecular and cell biology approaches aiming at understanding the interaction between H. pylori and the transforming epithelial cell. In this review an account of the last year's research activity on the relationship between H. pylori and gastric cancer will be given. C1 [Ferreira, Antonio Carlos; Machado, Jose Carlos] Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, Fac Med, P-4100 Oporto, Portugal. [Isomoto, Hajime] Nagasaki Univ, Sch Med, Dept Endoscopy, Nagasaki 852, Japan. [Moriyama, Masatsugu] Oita Univ, Dept Mol Pathol, Yufu City, Oita 8795593, Japan. [Fujioka, Toshio] Oita Univ, Fac Med, Dept Gastroenterol, Yufu City, Oita 8795593, Japan. [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. RP Machado, JC (reprint author), IPATIMUP, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal. EM josem@ipatimup.pt RI Machado, Jose Carlos/C-5907-2009 OI Machado, Jose Carlos/0000-0003-4741-8415 FU NIDDK NIH HHS [R01 DK062813, R01 DK062813-05, R0I DK 62813] NR 51 TC 32 Z9 41 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD OCT PY 2008 VL 13 SU 1 BP 28 EP 34 DI 10.1111/j.1523-5378.2008.00633.x PG 7 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 335AL UT WOS:000258263100006 PM 18783519 ER PT J AU Graham, DY Kwon, DH AF Graham, D. Y. Kwon, D. H. TI Genome-scale transcriptional modulation in response to metronidazole stress in metronidazole resistant and susceptible H-pylori SO HELICOBACTER LA English DT Meeting Abstract CT 21st International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer CY SEP 18-20, 2008 CL Riga, LATVIA C1 [Graham, D. Y.; Kwon, D. H.] Baylor Coll Med, Houston, TX 77030 USA. [Graham, D. Y.; Kwon, D. H.] VA Med Ctr, Houston, TX USA. [Kwon, D. H.] Long Isl Univ, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD OCT PY 2008 VL 13 IS 5 BP 409 EP 409 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 336ZF UT WOS:000258404600057 ER PT J AU Ohno, T Backstrom, A Arnqvist, A Rugge, M Ota, H Graham, DY Yamaoka, Y AF Ohno, T. Backstrom, A. Arnqvist, A. Rugge, M. Ota, H. Graham, D. Y. Yamaoka, Y. TI Changes in H-pylori adherence properties during long-term Mongolian gerbil infection SO HELICOBACTER LA English DT Meeting Abstract CT 21st International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer CY SEP 18-20, 2008 CL Riga, LATVIA C1 [Ohno, T.; Graham, D. Y.; Yamaoka, Y.] ME DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Ohno, T.; Graham, D. Y.; Yamaoka, Y.] Baylor Coll Med, Houston, TX 77030 USA. [Backstrom, A.] Umea Univ, Dept Odontol Oral Microbiol, Umea, Sweden. [Backstrom, A.; Arnqvist, A.] Umea Univ, Dept Med Biochem & Biophys, Umea, Sweden. [Rugge, M.] Univ Padua, Dept Diagnost Sci & Special Therapies, Pathol Unit, Padua, Italy. [Ota, H.] Shinshu Univ, Sch Med, Sch Hlth Sci, Dept Biomed Lab Sci, Matsumoto, Nagano 390, Japan. RI Rugge, Massimo/K-7525-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD OCT PY 2008 VL 13 IS 5 BP 410 EP 410 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 336ZF UT WOS:000258404600061 ER PT J AU Sugimoto, M Sakai, K Kita, M Imanishi, J Yamaoka, Y AF Sugimoto, M. Sakai, K. Kita, M. Imanishi, J. Yamaoka, Y. TI Prevalence of H-pylori infection in patients receiving long-term Hemodialysis SO HELICOBACTER LA English DT Meeting Abstract CT 21st International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer CY SEP 18-20, 2008 CL Riga, LATVIA C1 [Sugimoto, M.; Yamaoka, Y.] Baylor Coll Med, Houston, TX 77030 USA. [Sugimoto, M.; Yamaoka, Y.] ME DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Sakai, K.] Nara City Hosp, Dept Gastroenterol & Hepatol, Nara, Japan. [Kita, M.; Imanishi, J.] Kyoto Prefectural Univ Med, Dept Microbiol, Kyoto 602, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD OCT PY 2008 VL 13 IS 5 BP 439 EP 439 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 336ZF UT WOS:000258404600142 ER PT J AU Imamura, S Yamaoka, Y Sumida, Y Kanemasa, K AF Imamura, S. Yamaoka, Y. Sumida, Y. Kanemasa, K. TI H-pylori infection protects against allergic diseases SO HELICOBACTER LA English DT Meeting Abstract CT 21st International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer CY SEP 18-20, 2008 CL Riga, LATVIA C1 [Imamura, S.] Aiseikai Yamashina Hosp, Kyoto, Japan. [Yamaoka, Y.] Baylor Coll Med, Houston, TX 77030 USA. [Yamaoka, Y.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. [Sumida, Y.; Kanemasa, K.] Nara City Hosp, Nara, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD OCT PY 2008 VL 13 IS 5 BP 441 EP 441 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 336ZF UT WOS:000258404600147 ER PT J AU Weisbord, SD Bossola, M Fried, LF Giungi, S Tazza, L Palevsky, PM Arnold, RM Luciani, G Kimmel, PL AF Weisbord, Steven D. Bossola, Maurizio Fried, Linda F. Giungi, Stefania Tazza, Luigi Palevsky, Paul M. Arnold, Robert M. Luciani, Giovanna Kimmel, Paul L. TI Cultural comparison of symptoms in patients on maintenance hemodialysis SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE cross-cultural; hemodialysis; symptoms; quality of life ID QUALITY-OF-LIFE; STAGE RENAL-DISEASE; ERECTILE DYSFUNCTION; DIALYSIS PATIENTS; PSYCHOSOCIAL FACTORS; SEXUAL DYSFUNCTION; ASSESSMENT SYSTEM; KIDNEY-DISEASE; MINI-COG; DEPRESSION AB Although symptoms are common and frequently severe in patients on maintenance hemodialysis, little is known about the relationship between cultural background and symptom burden. The aim of this study was to explore differences in the prevalence and severity of symptoms between American and Italian hemodialysis patients. We administered the 30-item Dialysis Symptom Index to American and Italian patients receiving maintenance hemodialysis during routine dialysis sessions. The prevalence and severity of individual symptoms were compared between patient populations, adjusting for multiple comparisons. Multivariable logistic regression and ordinal logistic regression were used to assess the independent associations of cultural background with the prevalence and severity of symptoms, respectively. We enrolled 75 American and 61 Italian patients. American patients were more likely to be black (36% vs. 0%, P < 0.001) and diabetic (53% vs. 13%, P < 0.001). Italian patients were more likely to report decreased interest in sex, decreased sexual arousal, feeling nervous, feeling irritable, and worrying (P < 0.001, respectively). Adjustment for demographic and clinical variables had no impact on these cultural differences in symptom prevalence. The median severity of 11 symptoms including muscle soreness, muscle cramps, and itching was greater among Americans (P < 0.001, respectively), although nearly all of these differences were rendered nonstatistically significant with adjustment for race, diabetes, and/or Kt/V. Italian patients receiving chronic hemodialysis report a greater burden of symptoms than American patients, particularly those related to sexual dysfunction and psychosocial distress. These findings suggest that cultural background may affect adaptation to chronic hemodialysis therapy. C1 [Weisbord, Steven D.; Fried, Linda F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Fried, Linda F.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.; Fried, Linda F.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Bossola, Maurizio; Giungi, Stefania; Tazza, Luigi; Luciani, Giovanna] Catholic Univ, Dept Surg, Dialysis Unit, Rome, Italy. [Arnold, Robert M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Arnold, Robert M.] Univ Pittsburgh, Inst Enhance Palliat Care, Pittsburgh, PA USA. [Kimmel, Paul L.] George Washington Univ, Sch Med, Div Renal Dis & Hypertens, Washington, DC USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu FU Institute to Enhance Palliative Care at the University of Pittsburgh; VA Health Services Research and Development Career Development Award [RCD 03-176] FX Dr Weisbord was supported by a grant from the Institute to Enhance Palliative Care at the University of Pittsburgh and a VA Health Services Research and Development Career Development Award (RCD 03-176). Although some of the data in the 3 tables has been published previously in the Clinical Journal of the American Society of Nephrology, the content and results specific to this study have not been published previously. NR 34 TC 9 Z9 9 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD OCT PY 2008 VL 12 IS 4 BP 434 EP 440 DI 10.1111/j.1542-4758.2008.00307.x PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 357RN UT WOS:000259864000006 PM 19090866 ER PT J AU Kanwal, F Asch, S Schnitzler, MS Bacon, BR AF Kanwal, Fasiha Asch, Steven Schnitzler, Mark S. Bacon, Bruce R. TI PREDICTORS OF QUALITY CARE AMONG PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION SO HEPATOLOGY LA English DT Meeting Abstract CT 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 31-NOV 04, 2008 CL San Francisco, CA SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr C1 [Kanwal, Fasiha] St Louis VA Med Ctr, St Louis, MO USA. [Kanwal, Fasiha; Schnitzler, Mark S.] St Louis Univ, Sch Med, St Louis, MO USA. [Asch, Steven] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asch, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2008 VL 48 IS 4 SU S MA 118 BP 358A EP 358A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 356CX UT WOS:000259757400109 ER PT J AU Rongey, C Kanwal, F Hoang, T Gifford, A Asch, S AF Rongey, Catherine Kanwal, Fasiha Hoang, Tuyen Gifford, Allen Asch, Steven TI PREDICTORS OF VIRAL RNA TESTING IN HEPATITIS C ANTIBODY POSITIVE VETERANS SO HEPATOLOGY LA English DT Meeting Abstract CT 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 31-NOV 04, 2008 CL San Francisco, CA SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr C1 [Rongey, Catherine] LACUSC, Los Angeles, CA USA. [Rongey, Catherine] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Kanwal, Fasiha] St Louis Univ, Ctr Outcomes Res, St Louis, MO 63103 USA. [Hoang, Tuyen] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gifford, Allen] Boston Univ, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2008 VL 48 IS 4 SU S MA 119 BP 358A EP 358A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 356CX UT WOS:000259757400110 ER PT J AU Kramer, JR Kanwal, F Giordano, TP Richardson, P Petersen, L El-Serag, HB AF Kramer, Jennifer R. Kanwal, Fasiha Giordano, Thomas P. Richardson, Peter Petersen, Laura El-Serag, Hashem B. TI PATIENT, PROVIDER, AND FACILITY CHARACTERISTICS OF HCV ANTIVIRAL TREATMENT AMONG US VETERANS WITH HCV-HIV COINFECTION SO HEPATOLOGY LA English DT Meeting Abstract CT 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 31-NOV 04, 2008 CL San Francisco, CA SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr C1 [Kramer, Jennifer R.; Giordano, Thomas P.; Richardson, Peter; Petersen, Laura; El-Serag, Hashem B.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Kanwal, Fasiha] St Louis Univ, Sch Med, St Louis, MO USA. [Kanwal, Fasiha] St Louis Univ, John Cochran Vet Affairs Med Ctr, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2008 VL 48 IS 4 SU S MA 121 BP 359A EP 359A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 356CX UT WOS:000259757400112 ER PT J AU Lo Re, V Amorosa, V Localio, AR O'Flynn, RM Teal, V Dorey-Stein, Z Kostman, J Gross, R AF Lo Re, Vincent Amorosa, Valerianna Localio, A. Russell O'Flynn, Rose M. Teal, Valerie Dorey-Stein, Zachariah Kostman, Jay Gross, Robert TI DIFFERENCES IN ADHERENCE TO PEG-INTERFERON AND RIBAVIRIN AMONG SUBGROUPS PERCEIVED TO BE AT-RISK FOR NON-ADHERENCE SO HEPATOLOGY LA English DT Meeting Abstract CT 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 31-NOV 04, 2008 CL San Francisco, CA SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr C1 [Lo Re, Vincent; Amorosa, Valerianna; Dorey-Stein, Zachariah; Kostman, Jay; Gross, Robert] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Localio, A. Russell; Teal, Valerie] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Localio, A. Russell; Teal, Valerie] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lo Re, Vincent; Localio, A. Russell; Gross, Robert] Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. [Amorosa, Valerianna; O'Flynn, Rose M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RI Lo Re, Vincent/N-7817-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2008 VL 48 IS 4 SU S MA 1317 BP 896A EP 897A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 356CX UT WOS:000259757401696 ER PT J AU Lai, KK Lohia, N Booth, GC Shang, SF Campbell, JS Beretta, L AF Lai, Keane K. Lohia, Neha Booth, Garrett C. Shang, Sufen Campbell, Jean S. Beretta, Laura TI PROTEOME CHANGES ASSOCIATED WITH DISEASE PROGRESSION IN THE PDGF-C TRANSGENIC MOUSE MODEL OF HEPATIC FIBROSIS AND HEPATOCELLULAR CARCINOMA SO HEPATOLOGY LA English DT Meeting Abstract CT 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 31-NOV 04, 2008 CL San Francisco, CA SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr C1 [Lohia, Neha; Booth, Garrett C.; Shang, Sufen; Beretta, Laura] Fred Hutchinson Canc Res Ctr, Mol Diagnost Program, Seattle, WA 98104 USA. [Lai, Keane K.] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA. [Campbell, Jean S.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Lai, Keane K.] Fred Hutchinson Canc Res Ctr, Mol Diagnost Program, Div Gastroenterol, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2008 VL 48 IS 4 SU S MA 1502 BP 974A EP 975A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 356CX UT WOS:000259757402174 ER PT J AU Xu, YH Li, H Gao, RL Kaplan, DE AF Xu, Yanhui Li, Hong Gao, Rui Lin Kaplan, David E. TI SUPPRESSED TUMOR ANTIGEN SPECIFIC T-CELL RESPONSES IN HUMAN HEPATOCELLULAR CARCINOMA SO HEPATOLOGY LA English DT Meeting Abstract CT 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY OCT 31-NOV 04, 2008 CL San Francisco, CA SP Amer Assoc Study Liver Dis, Moscone West Convent Ctr C1 [Gao, Rui Lin; Kaplan, David E.] Res Philadelphia VA Med Ctr, Philadelphia, PA USA. [Xu, Yanhui; Li, Hong; Kaplan, David E.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2008 VL 48 IS 4 SU S MA 1523 BP 984A EP 984A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 356CX UT WOS:000259757402194 ER PT J AU Peralta, CA Shlipak, MG AF Peralta, Carmen A. Shlipak, Michael G. TI Hypertension in children with chronic kidney disease - A call to action SO HYPERTENSION LA English DT Editorial Material ID BLOOD-PRESSURE; PROGRESSION; ADOLESCENTS C1 [Peralta, Carmen A.] San Francisco VA Med Ctr, Div Nephrol, San Francisco, CA USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Shlipak, MG (reprint author), VA Med Ctr 111A1, Gen Internal Med Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM Michael.shlipak@ucsf.edu NR 10 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X J9 HYPERTENSION JI Hypertension PD OCT PY 2008 VL 52 IS 4 BP 610 EP 612 DI 10.1161/HYPERTENSIONAHA.108.117242 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 349KF UT WOS:000259279000004 PM 18725582 ER PT J AU Fisher, LE Miller, ME Bailey, SN Davis, JA Anderson, JS Rhode, L Tyler, DJ Triolo, RJ AF Fisher, Lee E. Miller, Michael E. Bailey, Stephanie N. Davis, John A., Jr. Anderson, James S. Rhode, Lori Tyler, Dustin J. Triolo, Ronald J. TI Standing After Spinal Cord Injury With Four-Contact Nerve-Cuff Electrodes for Quadriceps Stimulation SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE Functional neuromuscular stimulation; implantable electrodes; paraplegia; rehabilitation ID FUNCTIONAL ELECTRICAL-STIMULATION; RESTORATION; INDIVIDUALS; PATIENT AB This paper describes the performance of a 16-channel implanted neuroprosthesis for standing and transfers after spinal cord injury including four-contact nerve-cuff electrodes stimulating the femoral nerve for knee extension. Responses of the nerve-cuffs were stable and standing times increased by 600% over time-matched values with a similar eight-channel neuroprosthesis utilizing muscle-based electrodes on vastus lateralis for knee extension. C1 [Fisher, Lee E.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA. [Miller, Michael E.; Bailey, Stephanie N.] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Cleveland, OH 44106 USA. [Davis, John A., Jr.] Tulane Univ, Med Ctr, Dept Orthopaed, New Orleans, LA 70112 USA. [Anderson, James S.] Case Western Reserve Univ, Dept Surg, Metrohlth Med Ctr, Cleveland, OH 44106 USA. [Rhode, Lori] Univ Hosp, Case Med Ctr, Cleveland, OH 44106 USA. [Tyler, Dustin J.; Triolo, Ronald J.] US Dept Vet Affairs, Rehabil Res & Dev Serv, Cleveland, OH 44106 USA. RP Fisher, LE (reprint author), Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA. EM lee.e.fisher@case.edu; mem9@po.cwru.edu; dustin.tyler@case.edu; ronald.triolo@case.edu RI Fisher, Lee/A-3947-2011; Tyler, Dustin/C-7995-2015 OI Tyler, Dustin/0000-0002-2298-8510; Fisher, Lee/0000-0002-9072-3119 FU NCRR NIH HHS [UL1 RR024989, UL1-RR024989]; NIBIB NIH HHS [R01 EB001889-01, 5-R01-EB001889, R01 EB001889, R01 EB001889-02, R01 EB001889-03, R01 EB001889-04, R01 EB001889-05, R01 EB001889-06, R01 EB001889-07, T32 EB004314, T32-EB04314-08] NR 19 TC 30 Z9 30 U1 1 U2 4 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 1534-4320 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD OCT PY 2008 VL 16 IS 5 BP 473 EP 478 DI 10.1109/TNSRE.2008.2003390 PG 6 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA 373FN UT WOS:000260956500005 PM 18990650 ER PT J AU Buxbaum, LU AF Buxbaum, Laurence U. TI A detrimental role for IgG and FcgammaR in Leishmania mexicana infection SO IMMUNOLOGIC RESEARCH LA English DT Article DE Immunoglobulin G; Protozoan parasite; Leishmania; FcgammaR; IL-10; IL-12; Macrophage; Immune complex ID REGULATORY T-CELLS; WORLD CUTANEOUS LEISHMANIASIS; INNATE IMMUNE-RESPONSE; NITRIC-OXIDE SYNTHASE; GAMMA-RIII CD16; INTERFERON-GAMMA; INTERLEUKIN-10-DEFICIENT MICE; VISCERAL LEISHMANIASIS; DEFICIENT MICE; IN-VIVO AB The intracellular protozoan parasite Leishmania causes leishmaniasis, which is the second biggest killer worldwide among parasitic diseases, after malaria. As drug therapy for leishmaniasis is toxic and resistance is growing, a vaccine is an important weapon against this disease. Unfortunately, no effective vaccine exists for any human parasitic infection. Worse yet, nearly all effective vaccines whose mechanisms are known work through the induction of protective antibodies. Leishmania mexicana causes primarily chronic cutaneous disease. Not only are antibodies not effective at killing Leishmania, as it hides inside the parasitophorous vacuole of the host cell, but new research indicates that IgG antibodies may be crucial in suppressing the host immune response by generating an immunosuppressive interleukin-10 response. IL-10 is able to decrease the needed Th1-generated IFN-gamma and downregulates production of nitric oxide, a required effector mechanism of parasite killing. We have been studying the pathways that the host uses to partially control L. mexicana infection, which include STAT4, IFN-gamma, and inducible nitric oxide synthase, but found that the IL-12 pathway is suppressed by IL-10. We are now studying the mechanisms by which IgG, bound to parasites, can induce IL-10 through Fc gamma R ligation and how this suppresses a healing immune response. We are examining which IgG isotypes bind to which Fc gamma Rs and whether macrophages are the necessary source of IL-10 for chronic disease. Elucidation of these mechanisms may help us to design vaccines that will not induce antibody-mediated immunosuppressive IL-10 responses. C1 [Buxbaum, Laurence U.] Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Buxbaum, Laurence U.] Univ Penn, Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA. RP Buxbaum, LU (reprint author), Vet Affairs Med Ctr, 3900 Woodland Ave,Res 151, Philadelphia, PA 19104 USA. EM buxbaum@mail.med.upenn.edu FU University of Pennsylvania; NIH [K08-AI01805]; Department of Veterans Affairs FX The work was begun by the author in the lab of Dr. Phillip Scott and continued by Dr. Buxbaum in his own independent lab. We would like to thank Dr. Bolaji Thomas for his in vitro work on macrophages, and Andrea Rosso and Dr. Niansheng Chu for technical help with other aspects of the research. This work was supported by the University of Pennsylvania, by NIH (K08-AI01805), and by a Merit Review Award from the Department of Veterans Affairs. NR 55 TC 14 Z9 14 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0257-277X J9 IMMUNOL RES JI Immunol. Res. PD OCT PY 2008 VL 42 IS 1-3 BP 197 EP 209 DI 10.1007/s12026-008-8074-5 PG 13 WC Immunology SC Immunology GA 387KW UT WOS:000261952100017 PM 19002608 ER PT J AU Morandi, A Pandharipande, P Trabucchi, M Rozzini, R Mistraletti, G Trompeo, AC Gregoretti, C Gattinoni, L Ranieri, MV Brochard, L Annane, D Putensen, C Guenther, U Fuentes, P Tobar, E Anzueto, AR Esteban, A Skrobik, Y Salluh, JIF Soares, M Granja, C Stubhaug, A de Rooij, SE Ely, EW AF Morandi, A. Pandharipande, P. Trabucchi, M. Rozzini, R. Mistraletti, G. Trompeo, A. C. Gregoretti, C. Gattinoni, L. Ranieri, M. V. Brochard, L. Annane, D. Putensen, C. Guenther, U. Fuentes, P. Tobar, E. Anzueto, A. R. Esteban, A. Skrobik, Y. Salluh, J. I. F. Soares, M. Granja, C. Stubhaug, A. de Rooij, S. E. Ely, E. Wesley TI Understanding international differences in terminology for delirium and other types of acute brain dysfunction in critically ill patients SO INTENSIVE CARE MEDICINE LA English DT Editorial Material DE delirium; delirio; delire; delier; delir; delire; confusion; confusione; coma; acute brain dysfunction; psychosis; delirium tremens; Durchgangs-Syndrom; acute verwardheid ID INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; SUBSYNDROMAL DELIRIUM; PROGNOSTIC-SIGNIFICANCE; HOSPITAL PATIENTS; MOTORIC SUBTYPES; MEDICAL PATIENTS; SYMPTOMS; OUTCOMES AB Background: Delirium (acute brain dysfunction) is a potentially life threatening disturbance in brain function that frequently occurs in critically ill patients. While this area of brain dysfunction in critical care is rapidly advancing, striking limitations in use of terminology related to delirium internationally are hindering cross-talk and collaborative research. In the English literature, synonyms of delirium such as the Intensive Care Unit syndrome, acute brain dysfunction, acute brain failure, psychosis, confusion, and encephalopathy are widely used. This often leads to scientific "confusion" regarding published data and methodology within studies, which is further exacerbated by organizational, cultural and language barriers. We undertook this multinational effort to identify conflicts in terminology and phenomenology of delirium to facilitate communication across medical disciplines and languages. Methods: The evaluation of the terminology used for acute brain dysfunction was determined conducting communications with 24 authors from academic communities throughout countries/regions that speak the 13 variants of the Romanic languages included into this manuscript. Results: In the 13 languages utilizing Romanic characters, included in this report, we identified the following terms used to define major types of acute brain dysfunction: coma, delirium, delirio, delirium tremens, delire, confusion mentale, delir, delier, Durchgangs-Syndrom, acute verwardheid, intensiv-psykose, IVA-psykos, IVA-syndrom, akutt konfusion/forvirring. Interestingly two terms are very consistent: 100 % of the selected languages use the term coma or koma to describe patients unresponsive to verbal and/or physical stimuli, and 100% use delirium tremens to define delirium due to alcohol withdrawal. Conversely, only 54% use the term delirium to indicate the disorder as defined by the DSM-IV as an acute change in mental status, inattention, disorganized thinking and altered level of consciousness. Conclusions. Attempts towards standardization in terminology, or at least awareness of differences across languages and specialties, will help cross-talk among clinicians and researchers. C1 [Ely, E. Wesley] Vanderbilt Univ Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37203 USA. [Morandi, A.; Ely, E. Wesley] Ctr Hlth Serv Res, Nashville, TN 37232 USA. [Morandi, A.; Rozzini, R.] Poliambulanza Hosp, Dept Internal Med & Geriatr, Brescia, Italy. [Morandi, A.; Trabucchi, M.; Rozzini, R.] Geriatr Res Grp, Brescia, Italy. [Pandharipande, P.] Vanderbilt Univ Sch Med, Dept Anesthesiol, Div Crit Care Med, Nashville, TN USA. [Mistraletti, G.] Univ Milan, Ist Anestesiol & Rianimaz, UO Anestesia & Rianimaz, Azienda Osped San Paolo,Polo Univ, Milan, Italy. [Trompeo, A. C.; Ranieri, M. V.] Univ Turin, Molinette Mauriziano Hosp, Intens Care Unit, Turin, Italy. [Gregoretti, C.] Azienda Osped CTO CRF ICORMA, Intens Care Unit, Turin, Italy. [Gattinoni, L.] Univ Milan, Ist Anestesiol & Rianimaz,Osped Maggiore Policlin, UO Anestesia & Rianimaz,Fdn IRCCS, Dipartimento Anestesia Rianimaz Intens & Subinten, Milan, Italy. [Brochard, L.] Univ Paris 12, Ctr Hosp Albert Chenevier, AP HP, Creteil, France. [Annane, D.] Univ Versailles, Hop Raymond Poincare, AP HP, Serv Reanimat, Garches, France. [Putensen, C.; Guenther, U.] Univ Hosp Sigmund Freud, Dept Anesthesiol & Intens Care Med, Bonn, Germany. [Fuentes, P.] Univ Chile, Clin Hosp, Dept Med, Geriatr Sect, Santiago, Chile. [Anzueto, A. R.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Esteban, A.] Hosp Univ Getafe, Intens Care Unit, CIBER Enfermedades Resp, Madrid, Spain. [Skrobik, Y.] Univ Montreal, Hosp Maisonnevue Rosemont, Intens Care Unit, Montreal, PQ, Canada. [Salluh, J. I. F.; Soares, M.] INCA, Inst Nacl Canc, Ctr Tratamento Intens, Intens Care Unit, Rio De Janeiro, Brazil. [Granja, C.] Hosp Pedro Hispano, Med Intens Care Unit, Matosinhos, Portugal. [Stubhaug, A.] Aker Univ Hosp, Rikshosp, Dept Anesthesiol & Intens Care, Oslo, Norway. [de Rooij, S. E.] Univ Amsterdam, Acad Med Ctr, Dept Geriatr, NL-1105 AZ Amsterdam, Netherlands. [Ely, E. Wesley] VA Tennessee Valley Geriatr Res Educ & Clin Ctr, Nashville, TN USA. RP Ely, EW (reprint author), Vanderbilt Univ Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37203 USA. EM wes.ely@vanderbilt.edu RI Salluh, Jorge/F-6779-2012; Soares, Marcio/B-3083-2013; Granja, Cristina/H-8146-2013; Skrobik, Yoanna/K-8165-2014; Tobar, Eduardo/D-4555-2016; FMUP, CINTESIS/C-6631-2014 OI Soares, Marcio/0000-0003-2503-6088; Skrobik, Yoanna/0000-0002-5315-6020; Tobar, Eduardo/0000-0003-2123-6082; FMUP, CINTESIS/0000-0001-7248-2086; Granja, Cristina/0000-0002-5503-051X; Salluh, Jorge/0000-0002-8164-1453 NR 45 TC 50 Z9 62 U1 13 U2 29 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 J9 INTENS CARE MED JI Intensive Care Med. PD OCT PY 2008 VL 34 IS 10 BP 1907 EP 1915 DI 10.1007/s00134-008-1177-6 PG 9 WC Critical Care Medicine SC General & Internal Medicine GA 353LT UT WOS:000259570100026 PM 18563387 ER PT J AU Graber, CJ Jacobson, MA Perdreau-Remington, F Chambers, HF Diep, BA AF Graber, Christopher J. Jacobson, Mark A. Perdreau-Remington, Francoise Chambers, Henry F. Diep, Binh An TI Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID UNITED-STATES; RISK-FACTORS; USA300; CLONE; MEN; SEX C1 [Graber, Christopher J.; Jacobson, Mark A.; Perdreau-Remington, Francoise; Chambers, Henry F.; Diep, Binh An] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA. RP Graber, CJ (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. FU NIAID NIH HHS [5T32 AI 060530-02] NR 8 TC 20 Z9 20 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD OCT 1 PY 2008 VL 49 IS 2 BP 231 EP 233 DI 10.1097/QAI.0b013e318183a947 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 353SB UT WOS:000259587400019 PM 18820536 ER PT J AU Griffith, JM Hasley, JP Liu, H Severn, DG Conner, LH Adler, LE AF Griffith, Jay M. Hasley, Joseph P. Liu, Hong Severn, Daniel G. Conner, Latoya H. Adler, Lawrence E. TI Qigong Stress Reduction in Hospital Staff SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; TAI-CHI; ESSENTIAL-HYPERTENSION; PERCEIVED STRESS; BLOOD-PRESSURE; EXERCISE; ANXIETY; HEALTH; MANAGEMENT; DISORDERS AB Objective: The aim of this study was to investigate the effectiveness of a qigong training program in reducing stress in hospital staff. Methods: Subjects were randomly assigned to a 6-week intervention of either qigong practice (n = 16) or a waiting list (n = 21). The primary measure of stress was the Perceived Stress Scale. Secondary measures included the Short Form 36 (SF-36) quality-of-life measure and a 100-mm analog pain scale. Results: The qigong group demonstrated a statistically significant reduction of perceived stress compared to the control group (p = 0.02). On the Social Interaction subscale of the SF-36, the qigong group demonstrated greater improvement compared to controls (p = 0.04). Within-groups analyses demonstrated that the qigong group (p = 0.03), but not the control group, experienced a significant reduction of pain intensity. A regression analysis demonstrated an association between higher baseline stress levels and greater improvement within the qigong group (R-2 = 0.34; p = 0.02). Conclusions: These results suggest that short-term exposure to qigong was effective in reducing stress in hospital staff. Further studies are needed to evaluate the possible effectiveness of qigong in reducing pain and in improving quality of life. C1 [Griffith, Jay M.; Adler, Lawrence E.] VISN 19 MIRECC, Dept Psychiat, Denver, CO USA. [Griffith, Jay M.; Severn, Daniel G.; Adler, Lawrence E.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA. [Hasley, Joseph P.; Conner, Latoya H.] Denver Vet Affairs Med Ctr, VISN MIRECC 19, Denver, CO USA. [Liu, Hong] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA. RP Griffith, JM (reprint author), 7904 E 9th Ave, Denver, CO 80230 USA. EM jaymgriffithmd@aol.com FU Department of Veterans Affairs VISN 19 MIRECC; National Institutes of Mental Health [5RO1 MH050787-10]; Department of Defense DAMD [17-01-1-0760] FX The authors wish to acknowledge Pamela Staves, C. N. S., N. P. for her assistance with study logistics. This research was supported by the Department of Veterans Affairs VISN 19 MIRECC and by the following grants to Dr. Adler: National Institutes of Mental Health 5RO1 MH050787-10 and Department of Defense DAMD 17-01-1-0760. There are no conflicts of interest to report. NR 29 TC 19 Z9 18 U1 2 U2 9 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD OCT PY 2008 VL 14 IS 8 BP 939 EP 945 DI 10.1089/acm.2007.0814 PG 7 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 374FN UT WOS:000261028700011 PM 18823261 ER PT J AU Brenes, GA Knudson, M McCall, WV Williamson, JD Miller, ME Stanley, MA AF Brenes, Gretchen A. Knudson, Mark McCall, W. Vaughn Williamson, Jeff D. Miller, Michael E. Stanley, Melinda A. TI Age and racial differences in the presentation and treatment of Generalized Anxiety Disorder in primary care SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE age differences; anxiety; elderly; Generalized Anxiety Disorder; racial differences ID STATE WORRY QUESTIONNAIRE; OLDER-ADULTS; UNITED-STATES; PANIC DISORDER; PSYCHOMETRIC PROPERTIES; ETHNIC-DIFFERENCES; AFRICAN-AMERICANS; MENTAL-DISORDERS; BODY-COMPOSITION; NEGATIVE AFFECT AB Despite the prevalence and impact of Generalized Anxiety Disorder (GAD) in the primary care setting, little is known about its presentation in this setting. The purpose of this study is to examine age and racial differences in the presentation and treatment of GAD in medical patients. Participants were recruited from one family medicine clinic and one internal medicine clinic. The prevalence of GAD was lowest for older adults. Age differences were found in the presentation of GAD, with young adults reporting greater cognitive symptoms of anxiety, negative affect, and depressive symptoms. African-Americans with GAD reported more positive affect and lower rates of treatment. The lower levels of negative affect and depressive symptoms reported among older adults may affect the recognition of GAD by primary care physicians. Further research is needed to better understand the causes of racial differences in treatment. (C) 2007 Elsevier Ltd. All rights reserved. C1 [Brenes, Gretchen A.; McCall, W. Vaughn] Wake Forest Univ, Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC 27157 USA. [Knudson, Mark] Wake Forest Univ, Sch Med, Dept Family & Community Med, Winston Salem, NC 27157 USA. [Williamson, Jeff D.] Wake Forest Univ, Sch Med, Dept Internal Med, Sect Geriatr, Winston Salem, NC 27157 USA. [Williamson, Jeff D.] Wake Forest Univ, Sch Med, Sticht Ctr Aging, Winston Salem, NC 27157 USA. [Miller, Michael E.] Wake Forest Univ, Sch Med, Dept Biostat Sci, Winston Salem, NC 27157 USA. [Stanley, Melinda A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Stanley, Melinda A.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. RP Brenes, GA (reprint author), Wake Forest Univ, Sch Med, Dept Psychiat & Behav Med, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM gbrenes@wfubmc.edu FU NIA NIH HHS [P30 AG021332]; NIMH NIH HHS [MH 65281, K23 MH065281, K23 MH065281-01A2] NR 55 TC 19 Z9 20 U1 2 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD OCT PY 2008 VL 22 IS 7 BP 1128 EP 1136 DI 10.1016/j.janxdis.2007.11.011 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 347AJ UT WOS:000259110700004 PM 18182275 ER PT J AU Long, ME Elhai, JD Schweinle, A Gray, MJ Grubaugh, AL Frueh, BC AF Long, Mary E. Elhai, Jon D. Schweinle, Amy Gray, Matt J. Grubaugh, Anouk L. Frueh, B. Christopher TI Differences in posttraumatic stress disorder diagnostic rates and symptom severity between Criterion A1 and non-Criterion A1 stressors SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE posttraumatic stress disorder; Criterion A1; psychological assessment; emotional trauma; diagnosis ID LIFE EVENTS; TRAUMATIC STRESS; DSM-V; PTSD; DISTRESS; CATEGORY; EXPOSURE; VIOLENCE; VICTIMS; SCALES AB This study addresses the ongoing controversy regarding the definition of DSM-IV posttraumatic stress disorder's (PTSD) traumatic stressor criterion (A 1). A sample of 119 college students completed the PTSD Symptom Scale separately in relation to both Criterion A1 and non-Criterion A1 stressful events, using a mixed between-groups (administration order) and within-subjects (stressor type) design. Contrary to what was expected, analyses revealed that non-Criterion A1 events were associated with greater likelihood of "probable" PTSD diagnoses and a greater PTSD symptom frequency than Criterion A1 events. Symptom frequency relationships, however, were moderated by the order in which the measures were administered. The non-Criterion A1 PTSD scores were only higher when non-Criterion A1 measures were presented first in the administration order. Similar patterns of differences in PTSD scores between stressor types were also found across the three PTSD symptom criteria. Implications are discussed as to the ongoing controversy of the PTSD construct. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Long, Mary E.; Elhai, Jon D.] Univ S Dakota, Disaster Mental Hlth Inst, Dept Psychol, Vermillion, SD 57069 USA. [Schweinle, Amy] Univ S Dakota, Sch Educ, Div Counseling & Psychol, Vermillion, SD 57069 USA. [Gray, Matt J.] Univ Wyoming, Dept Psychol, Laramie, WY 82071 USA. [Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Grubaugh, Anouk L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. RP Elhai, JD (reprint author), Univ S Dakota, Disaster Mental Hlth Inst, Dept Psychol, Vermillion, SD 57069 USA. EM jon.elhai@usd.edu OI Schweinle, Amy/0000-0002-5813-2423 NR 40 TC 39 Z9 39 U1 4 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD OCT PY 2008 VL 22 IS 7 BP 1255 EP 1263 DI 10.1016/j.janxdis.2008.01.006 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 347AJ UT WOS:000259110700015 PM 18281192 ER PT J AU Gaynes, BI Torczynski, E Varro, Z Grostern, R Perlman, J AF Gaynes, Bruce Ira Torczynski, Elise Varro, Zoltan Grostern, Richard Perlman, Jay TI Retinal toxicity of chloroquine hydrochloride administered by intraperitoneal injection SO JOURNAL OF APPLIED TOXICOLOGY LA English DT Article DE chloroquine; intraperitoneal; bioavailability; toxicity; retina ID DRUG; RETINOPATHY; LIVER AB Chloroquine is quinolone derivative known to exert dose-related retinal toxicity, albeit in a variable manner. It is thought that variability in the presentation of chloroquine retinopathy may be the result of perturbations in drug bioavailability subsequent to oral ingestion. In order to better understand the ramifications of bioavailability on the development of retinal injury subsequent to chloroquine use, this study investigated the relationship between retinal injury and chloroquine administration via intraperitoneal rather than oral administration. Four-week-old C57/6J mice underwent daily intraperitoneal injection of 10 mg kg(-1) chloroquine hydrochloride for a total of 62 days. Following treatment, tissue was fixed in preparation for analysis by light and transmission electron microscopy. Treated animals demonstrated marked abnormality of the outer retinal layers described as complete loss of the outer plexiform layer as well as photo-receptors and photoreceptor nuclei. The retinal pigmented epithelium demonstrated focal atrophy, loss of nuclei and pigment irregularity. Findings in the inner retina were notable for the loss of Muller cells and the presence of membranous cytoplasmic bodies. Retinae of control animals were entirely normal. In contrast to previous studies in the murine model examining chloroquine retinopathy subsequent to oral administration, this study suggests that intraperitoneal chloroquine administration facilitates retinal toxicity, presumably, due to heightened drug absorption and bioavailability. It is posited that an increased rate of drug accumulation within the retina leads to an enhanced lysosomotrophic drug effect due to inability of the lysosome to compensate for chloroquine-induced elevation in pH through re-acidification of the intra-lysosomal content. Copyright (C) 2008 John Wiley & Sons, Ltd. C1 [Gaynes, Bruce Ira; Torczynski, Elise; Varro, Zoltan; Grostern, Richard] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Perlman, Jay] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Gaynes, BI (reprint author), Rush Univ, Med Ctr, 1725 W Harrison,Suite 931, Chicago, IL 60612 USA. EM bgaynes@rush.edu NR 20 TC 6 Z9 8 U1 0 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0260-437X J9 J APPL TOXICOL JI J. Appl. Toxicol. PD OCT PY 2008 VL 28 IS 7 BP 895 EP 900 DI 10.1002/jat.1353 PG 6 WC Toxicology SC Toxicology GA 360QR UT WOS:000260072900009 PM 18484088 ER PT J AU Song, MK Baik, YH Li, CJ Pei, CZ Gao, Y AF Song, Moon Ki Baik, Young Ho Li, Chang Jun Pei, Chang Zhuo Gao, Yuan TI Cyclo (his-pro) plus zinc treatment significantly ameliorated diabetes in humans SO JOURNAL OF BIOTECHNOLOGY LA English DT Meeting Abstract C1 [Song, Moon Ki] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. [Song, Moon Ki] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Baik, Young Ho; Li, Chang Jun; Pei, Chang Zhuo; Gao, Yuan] Yanbian Hanmi Med Ctr, Yanji, Jilin, Peoples R China. EM mksong@erathlink.net NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1656 EI 1873-4863 J9 J BIOTECHNOL JI J. Biotechnol. PD OCT PY 2008 VL 136 SU S MA I1-O-080 BP S25 EP S25 DI 10.1016/j.jbiotec.2008.07.045 PG 1 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA V32VT UT WOS:000208979400053 ER PT J AU Cotter, G Dittrich, HC Weatherley, BD Bloomfield, DM O'Connor, CM Metra, M Massie, BM AF Cotter, Gad Dittrich, Howard C. Weatherley, Beth Davison Bloomfield, Daniel M. O'Connor, Christopher M. Metra, Marco Massie, Barry M. CA Protect Steering Comm TI The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A(1) Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Adenosine receptor antagonists; chronic kidney disease; heart failure; renal function; rolofylline ID SYSTOLIC DYSFUNCTION; CLINICAL-TRIALS; KIDNEY-FUNCTION; BG9719 CVT-124; END-POINT; OUTCOMES; METAANALYSIS; RATIONALE; MORTALITY; EPILEPSY AB Background: Rolofylline, an adenosine A(1) receptor antagonist, facilitates diuresis and preserves renal function in patients with acute heart failure (AHF) with renal impairment. Although not powered around any specific hypothesis, this pilot study was designed to identify an efficacious dose while refining inclusion criteria and end points. Methods: A total of 301 patients hospitalized for AHF with an estimated creatinine clearance of 20 to 80 mL/min and elevated natriuretic peptide levels were enrolled within 24 hours of presentation to placebo or rolofylline 10, 20, or 30 mg administered as 4-hour infusions for 3 days in addition to intravenously administered loop diuretics. Post hoc analyses for end points chosen for subsequent Phase III studies were performed. Results: Compared with placebo, rolofylline produced trends toward greater proportions of patients with marked or moderately improved dyspnea and fewer patients with worsening heart failure or renal function. Serum creatinine increased in patients receiving placebo and remained stable or tended to decrease in those receiving rolofylline. On day 14 the absolute differences between placebo and rolofylline for change in creatinine increased with increasing rolofylline dose, reflecting the lesser increase in creatinine in rolofylline-treated patients (r = -0.12, P = .030). Treatment with 30 mg, the dose selected for the pivotal trials, was associated with a trend toward reduced 60-day mortality or readmission for cardiovascular or renal cause (hazard ratio, 0.55; 95% confidence interval, 0.28-1.04). Conclusion: These results demonstrate that adenosine A, receptor blockade with rolofylline can prevent renal impairment in patients with AHF and may positively affect acute symptoms and 60-day outcome. A 2000-patient trial of this agent is now under way. (J Cardiac Fail 2008;14:631-640) C1 [Massie, Barry M.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Cardiol, San Francisco, CA 94121 USA. [Cotter, Gad; Weatherley, Beth Davison] Momentum Res Inc, Durham, NC USA. [Dittrich, Howard C.] Nova Cardia Inc, San Diego, CA USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Metra, Marco] Univ Brescia, Brescia, Italy. RP Massie, BM (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA. RI Zateyshchikov, Dmitry/D-6575-2012; Zadionchenko, Vladimir/A-7445-2016; Ponikowski, Piotr/O-6454-2015 OI Zateyshchikov, Dmitry/0000-0001-7065-2045; Zadionchenko, Vladimir/0000-0003-2377-5266; Ponikowski, Piotr/0000-0002-3391-7064; Davison, Beth/0000-0003-2374-6449; Metra, Marco/0000-0001-6691-8568 FU PROTECT [NCT00328692 (PROTECT-1), NCT00354458 (PROTECT-2)] FX The PROTECT study is registered on www.clinicaltrials.gov as NCT00328692 (PROTECT-1) and NCT00354458 (PROTECT-2). NR 30 TC 100 Z9 105 U1 0 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD OCT PY 2008 VL 14 IS 8 BP 631 EP 640 DI 10.1016/j.cardfail.2008.08.010 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 361NF UT WOS:000260133700001 PM 18926433 ER PT J AU Singh, BN AF Singh, Bramah N. TI Amiodarone as Paradigm for Developing New Drugs for Atrial Fibrillation SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Review DE amiodarone; atrial fibrillation; amiodarone congeners; dronedarone ID ANTI-ANGINAL DRUG; VENTRICULAR-FIBRILLATION; ANTIARRHYTHMIC-DRUGS; CARDIAC MUSCLE; SINUS RHYTHM; DRONEDARONE; PROFILE; AGENT; MECHANISMS; PREVENTION AB Introduced as an anti-anginal compound in 1962, amiodarone emerged in the 1970s as a uniquely effective antiarrhythmic and antifibrillatory drug with a multiplicity of properties, the most striking being the lengthening of the repolarization in the atria and ventricles associated with bradycardia but without a significant propensity for inducing torsade de pointes. Amiodarone is now the most frequently used agent for maintaining sinus rhythm in patients with AF. Its effectiveness for maintaining sinus rhythm remains unrivalled. Although the drug has few absolute contraindications to its use as an antiarrhythmic agent, limiting side effects such as thyroid dysfunction, pulmonary fibrosis, dermatological changes, and myriad lesser adverse effects often limit the use of the drug long-term in a proportion of patients. Thus, the idea has arisen that amiodarone might serve as a model for the synthesis and development of newer and novel antiarrhythmic agents devoid of organ toxicity. Amiodarone is an iodinated compound, and the possibility that its molecule may be modified with or without elimination of the iodine is being tested. The deletion of the iodine radical, substituting ethyl with butyl in the side chain of the aromatic ring, and adding a methylsulphonyl radical to the benzofuran component of the molecule leads to the loss of thyroid and pulmonary effects. The resulting compound, dronedarone, is in advanced clinical development. It is likely the first amiodarone congener that will be used in the control of atrial fibrillation. Others are in earlier phases of development. C1 [Singh, Bramah N.] VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA 90073 USA. [Singh, Bramah N.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Singh, BN (reprint author), VA Greater Los Angeles Healthcare Syst, Div Cardiol, 11301 Wils Blvd, Los Angeles, CA 90073 USA. EM bsingh@ucla.edu NR 38 TC 31 Z9 33 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD OCT PY 2008 VL 52 IS 4 BP 300 EP 305 DI 10.1097/FJC.0b013e31818914b6 PG 6 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 367ZB UT WOS:000260590000002 PM 18841075 ER PT J AU Ulu, A Davis, BB Tsai, HJ Kim, IH Morisseau, C Inceoglu, B Fiehn, O Hammock, BD Weiss, RH AF Ulu, Arzu Davis, Benjamin B. Tsai, Hsing-Ju Kim, In-Hae Morisseau, Christophe Inceoglu, Bora Fiehn, Oliver Hammock, Bruce D. Weiss, Robert H. TI Soluble Epoxide Hydrolase Inhibitors Reduce the Development of Atherosclerosis in Apolipoprotein E-Knockout Mouse Model SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE soluble epoxide hydrolase; 1-adamantan-3-(5-(2-(2-ethylethoxy)ethoxy)pentyl)urea; atherosclerosis; Apo E knockout mice; epoxycicosatrienoic acid ID II-INDUCED HYPERTENSION; LEUKOTOXIN 9,10-EPOXY-12-OCTADECENOATE; BLOOD-PRESSURE; MICE; DISEASE; RISK; INFLAMMATION; METABOLISM; TARGET; KIDNEY AB To determine whether sEH inhibitors influence atherosclerotic lesion formation, we used an established murine model of accelerated atherogenesis, ApoE knockout (-/-) mice. The sEH inhibitor, 1-adamantan-3-(5-(2-(2-ethylethoxy)ethoxy)pentyl)urea (AEPU) was delivered in drinking water. All animals were fed an atherogenic dict while simultaneously inflused with angiotensin II by osmotic minipump to induce atherosclerosis. In AEPU-treated animals, there was a 53% reduction in atherosclerotic lesions in the descending aortae as compared to control aortae. AEPU and its major metabolites were detected in the plasma of animals which received it. As expected from the inhibition of sEH, a significant increase in linoleic and arachidonic acid epoxides, as well as an increase in individual 11,12-EET/DHET ratios, were observed. The reduction in atherosclerotic lesion area was inversely correlated with 11,12- and 14,15- EET/DHET ratios, suggesting that the reduction corresponds to the inhibition of sEH. Our data suggest that orally-available sEH inhibitors may be useful in the treatment of patients with atherosclerotic cardiovascular disease. C1 [Weiss, Robert H.] Univ Calif Davis, Div Nephrol, Dept Internal Med, Canc Res Ctr, Davis, CA 95616 USA. [Ulu, Arzu; Tsai, Hsing-Ju; Kim, In-Hae; Morisseau, Christophe; Inceoglu, Bora; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA. [Davis, Benjamin B.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA. [Fiehn, Oliver] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA. [Fiehn, Oliver] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA. [Weiss, Robert H.] US Dept Vet Affairs, Med Ctr, Sacramento, CA USA. RP Weiss, RH (reprint author), Univ Calif Davis, Div Nephrol, Dept Internal Med, Canc Res Ctr, Genome & Biomed Sci Bldg,Room 6312, Davis, CA 95616 USA. EM rhweiss@ucdavis.edu OI Inceoglu, Bora/0000-0002-8473-6036 FU National Cancer Institute [IR21CA 91259-01AI]; U.S. Department of Veterans' Affairs; Phillip Morris Extramural Research [NIH ES011634, EPA R832414]; NIEHS [R37 ES02710, P42 ES004699, P01 ES11269]; NIH [HL85727]; NCRR-NIH [ULI RR024146]; Howard Hughes Medical Institute fellowship FX Supported by grant IR21CA 91259-01AI and the Early Detection Research Network from the National Cancer Institute; U.S. Department of Veterans' Affairs (RHW); the Phillip Morris Extramural Research Program; NIH ES011634 and EPA R832414 (BBD) and NIEHS grants R37 ES02710, P42 ES004699, and P01 ES11269, NIH HL85727 (BDH), UCD CTSC predoctoral clinical research training program fellowship NCRR-NIH ULI RR024146 (AU) and Howard Hughes Medical Institute fellowship (HJT). NR 36 TC 73 Z9 83 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD OCT PY 2008 VL 52 IS 4 BP 314 EP 323 DI 10.1097/FJC.0b013e318185fa3c PG 10 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 367ZB UT WOS:000260590000004 PM 18791465 ER PT J AU Sabbal, MJ Looper, JM Zavadzkas, JA Stroud, RE Ford, RL Rivers, WT Koval, CN McEvoy, MD Reeves, ST Spinale, FG AF Sabbal, Michel J. Looper, J. Michael Zavadzkas, Juozas A. Stroud, Robert E. Ford, Rachael L. Rivers, William T. Koval, Christine N. McEvoy, Matthew D. Reeves, Scott T. Spinale, Francis G. TI Aprotinin Exacerbates Left Ventricular Dysfunction After Ischemia/Reperfusion in Mice Lacking Tumor Necrosis Factor Receptor I SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE serine protease inhibitor; tumor necrosis factor; ischemia-reperfusion ID SYSTEMIC INFLAMMATORY RESPONSE; CARDIOPULMONARY BYPASS; CARDIAC-SURGERY; CUTTING EDGE; TNF-ALPHA; ECHOCARDIOGRAPHY; METAANALYSIS; INHIBITION; PERFUSION; MODELS AB Aprotinin is a serine protease inhibitor with diverse biological effects: until recently, it was utilized in the context of ischemia reperfusion (I/R). It has been hypothesized that a signaling pathway modulated by aprotinin in the context of I/R is the tumor necrosis factor-alpha receptor (TNFR) path-way. An intact Mouse model of I/R (30 min ischemia and 60 min reperfusion) was used and left ventricular (LV) peak + maximal rate of left ventricular (LV) peak pressure (dP/dt) was measured in wild-type mice (WT, C57BL/6; n = 10), WT mice with aprotinin (4 mL/kg; n = 10), transgenic mice devoid of the TNFRI (TNFRI-null; n = 10), and TNFRI-null with aprotinin (n=10). Following I/R, LV peak + dP/dt decreased in both WT groups, but remained similar to baseline values in the TNFRI-null group. In contrast, aprotinin caused a marked reduction in LV peak + dP/dt in the TNFRI-null group following I/R. Soluble plasma TNF levels increased in the WT and TNFRI-null mice with I/R and was reduced with aprotinin. Soluble TNFRI and TNFRII levels, indicative of TNF activation, increased in the WT mice following I/R and remained elevated with aprotinin. Soluble TNFRII levels were increased in the TNFRI-null mice following I/R and remained elevated with aprotinin. The new and unique findings of this study were twofold. First, aprotinin failed to improve LV function after I/R despite a reduction in circulating TNF levels. Second. genetic ablation of TNFRI uncovered a negative inotropic effect of aprotinin. These findings demonstrate that complex biological pathways and interactions are affected with broad spectrum serine protease inhibition, which are relevant to myocardial function in the context of I/R. C1 [Spinale, Francis G.] Med Univ S Carolina, Div Cardiothorac Surg, Dept Cardiothorac Surg, Charleston, SC 29403 USA. [Sabbal, Michel J.; Looper, J. Michael; McEvoy, Matthew D.; Reeves, Scott T.] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29403 USA. [Spinale, Francis G.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Dept Cardiothorac Surg, 114 Doughty St,Room 625, Charleston, SC 29403 USA. EM wilburnm@musc.edu FU National Heart. Lung, and Blood Institute [POI-HL-48788, ROI-HL-59165]; Research Service of the Department of Veterans Affairs; Bayer Pharmaceuticals; Foundation for Anesthesia Education and Research FX Supported by the National Heart. Lung, and Blood Institute (POI-HL-48788 and ROI-HL-59165 to F.G.S.), Research Service of the Department of Veterans Affairs (to F.G.S.). Research Fellowships from Bayer Pharmaceuticals (to M.D.M..), and the Foundation for Anesthesia Education and Research (to M.D.M.). NR 36 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-2446 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD OCT PY 2008 VL 52 IS 4 BP 355 EP 362 DI 10.1097/FJC.0b013e3181893659 PG 8 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 367ZB UT WOS:000260590000009 PM 18841074 ER PT J AU Meng, Z Jackson, NL Choi, H King, PH Emanuel, PD Blume, SW AF Meng, Zheng Jackson, Nateka L. Choi, Hyoungsoo King, Peter H. Emanuel, Peter D. Blume, Scott W. TI Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID GROWTH-FACTOR-I; INTERNAL RIBOSOME ENTRY; NUCLEAR RIBONUCLEOPROTEIN-C; 5' UNTRANSLATED REGION; OPEN READING FRAMES; MESSENGER-RNA; RECEPTOR GENE; 5'-UNTRANSLATED REGION; MEDIATED TRANSLATION; MULTIPLE-MYELOMA AB The type 1 insulin-like growth factor receptor (IGF-IR) is integrally involved in the control of cellular proliferation and survival. An internal ribosomal entry site (IRES) within the 1,038 nucleoticle 5'-untranslated region of the human IGF-IR mRNA helps to provide the tight control of IGF-IR expression necessary for maintenance of normal cellular and tissue homeostasis. The IRES maps to a discrete sequence of 85 nucleotides positioned just upstream of the IGF-IR initiation codon, allowing the ribosome to bypass the highly structured regions of the 5'-UTR as well as the upstream open reading frame. The authenticity of the IGF-IR IRES has been confirmed by its sensitivity to deletion of the promoter from a bicistronic reporter construct, and its resistance in a monocistronic reporter construct to co-expression of a viral 2A protease. We previously characterized HuR as a potent repressor of IGF-IR translation. Here we demonstrate that hnRNP C competes with HuR for binding the IGF-IR 5'-UTR and enhances IRES-mediated translation initiation in a concentration-dependent manner. We observed changes in binding of hnRNP C versus HuR to the IGF-IR 5'-UTR in response to physiological alterations in cellular environment or proliferative status. Furthermore, we have found distinct alterations in the pattern of protein binding to the IGF-IR 5'-UTR in human breast tumor cells in which IGF-IR IRES activity and relative translational efficiency are aberrantly increased. These results suggest that dysregulation of the IGF-IR IRES through changes in the activities of RNA-binding translation-regulatory proteins could be responsible for IGF-IR overexpression in a proportion of human breast tumors. C1 [Meng, Zheng; Emanuel, Peter D.; Blume, Scott W.] Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA. [Jackson, Nateka L.; Choi, Hyoungsoo; Emanuel, Peter D.; Blume, Scott W.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [King, Peter H.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. [King, Peter H.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Emanuel, Peter D.; Blume, Scott W.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. RP Blume, SW (reprint author), Univ Alabama, Dept Biochem & Mol Genet, 1824 6th Ave S,WT1 508, Birmingham, AL 35294 USA. EM scott.blume@ccc.uab.edu OI Emanuel, Peter/0000-0002-9764-2434 FU National Cancer Institute [CA1 08886]; Breast Cancer Research Program DAMD [17-03-1-0207]; UAB SPORE FX The authors would like to thank Cornell Badorff for generously providing the coxsackie virus B3 2A protease expression plasmid, and Gideon Dreyfuss for generously providing the hnRNP C expression vector and 4F4 antibody. This work was supported by Public Health Service Grant CA1 08886 from the National Cancer Institute, the Breast Cancer Research Program DAMD 17-03-1-0207 from the Department of Defense, and the UAB SPORE in Ovarian Cancer. NR 49 TC 31 Z9 31 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD OCT PY 2008 VL 217 IS 1 BP 172 EP 183 DI 10.1002/jcp.21486 PG 12 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 344BJ UT WOS:000258899900019 PM 18452152 ER PT J AU Kahn, SE Cefalu, WT AF Kahn, Steven E. Cefalu, William T. TI Glucose control, macro- and microvascular disease, and the food and drug administration: Let's keep our eye on the ball SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Editorial Material ID CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK; ROSIGLITAZONE; COMPLICATIONS; SULFONYLUREAS; METFORMIN; DEATH C1 [Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98108 USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98108 USA. [Cefalu, William T.] Pennington Biomed Res Ctr, Div Nutr & Chron Dis, Baton Rouge, LA 70808 USA. RP Kahn, SE (reprint author), Vet Affairds Puger Sound Hlth Care Syst 151,1660, Seattle, WA 98108 USA. EM skahn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 NR 12 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2008 VL 93 IS 10 BP 3727 EP 3729 DI 10.1210/jc.2008-1799 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 358FY UT WOS:000259903700009 PM 18765506 ER PT J AU Butt, AA Khan, UA Skanderson, M AF Butt, Adeel A. Khan, Uzma A. Skanderson, Melissa TI Comorbidities and their impact on mortality in HCV and HCV-HIV-coinfected persons on dialysis SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE HIV; dialysis; USRDS; survival ID HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC HEPATITIS-C; STAGE LIVER-DISEASE; HEMODIALYSIS-PATIENTS; PEGINTERFERON ALPHA-2A; PLUS RIBAVIRIN; UNITED-STATES; INFECTION; VETERANS; SURVIVAL AB Aim: To determine the rates of non-human immunodeficiency virus (HIV)-related comorbidities and their impact on survival in hepatitis C virus (HCV) and HCV-HIV coinfected persons oil dialysis. Methods: We identified HCV-infected subjects and diagnoses of medical and psychiatric comorbidities in the United States Renal Data System using ICD-9 codes. Logistic regression was used to determine the odds of comorbidities and predictors of mortality. Results: We identified 5310 HCV-infected and 427 HCV-HIV-coinfected subjects. The latter were younger, more likely to be male, black race, and had a lower body mass index. After adjusting for age, race and sex we found that coronary artery disease (CAD), diabetes mellitus (DM) as primary cause of renal failure and cirrhosis were less frequently diagnosed in the HCV- HIV-coinfected subjects, whereas hepatitis B, washing, drug and alcohol abuse, and dependence were more frequently diagnosed. Increasing age. CAD, stroke, DM. cirrhosis, wasting, cancer, and drug abuse and dependence were associated with higher odds of death in the HCV monoinfected subjects, whereas cirrhosis, wasting, and smoking were the only such factors in the HCV-HIV-coinfected subjects. Conclusions: The frequency and patterns of comorbidities and predictors of death differ in HCV-monoinfected and HCV- HIV-coinfected persons on dialysis. These differences should be taken into account when designing future interventions. C1 [Butt, Adeel A.] Univ Pittsburgh, Med Ctr, Div Infect Dis, Pittsburgh, PA 15213 USA. [Butt, Adeel A.; Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Khan, Uzma A.] Albany Med Ctr, Albany, NY USA. RP Butt, AA (reprint author), Univ Pittsburgh, Med Ctr, Div Infect Dis, MS 3601 5th Ave,Suite 3A,Falk Med Bldg, Pittsburgh, PA 15213 USA. EM butta@dom.pitt.edu NR 37 TC 6 Z9 6 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD OCT PY 2008 VL 42 IS 9 BP 1054 EP 1059 DI 10.1097/MCG.0b013e3181574d58 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 354RK UT WOS:000259656500015 PM 19013829 ER PT J AU Cushman, WC Ford, CE Einhorn, PT Wright, JT Preston, RA Davis, BR Basile, JN Whelton, PK Weiss, RJ Bastien, A Courtney, DL Hamilton, BP Kirchner, K Louis, GT Retta, TM Vidt, DG AF Cushman, William C. Ford, Charles E. Einhorn, Paula T. Wright, Jackson T., Jr. Preston, Richard A. Davis, Barry R. Basile, Jan N. Whelton, Paul K. Weiss, Robert J. Bastien, Arnaud Courtney, Donald L. Hamilton, Bruce P. Kirchner, Kent Louis, Gail T. Retta, Tamrat M. Vidt, Donald G. CA ALLHAT Collaborat Res Grp TI Blood Pressure Control by Drug Group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID JOINT NATIONAL COMMITTEE; HYPERTENSION; OUTCOMES; CHLORTHALIDONE; MANAGEMENT; RECRUITMENT; POPULATION; CARDIOLOGY; ADULTS AB Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9 years) by randomized groups: chlorthalidone, 12.5-25 mg/d (n=15,255), amlodipine 2.5-10 mg/d (n=9048), or lisinopril 10-40 mg/d (n=9054) in a randomized double-blind hypertension trial. Participants were hypertensives aged 55 or older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents from other classes were added as needed to achieve BP control. BP was reduced from 145/83 mm Hg (27% control) to 134/76 mm Hg (chlorthalidone, 68% control), 135/75 mm Hg (amlodipine, 66% control), and 136176 mm Hg (lisinopril, 61% control) by 5 years; the mean number of drugs prescribed was 1.9, 2.0, and 2.1, respectively. Only 28% (chlorthalidone), 24% (amlodipine), and 24% (lisinopril) were controlled on monotherapy. BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP < 140/90 mm Hg in a majority of patients. J Clin Hypertens (Greenwich). 2008;1.0:751-760. (c) 2008 Le Jacq C1 [Ford, Charles E.; Davis, Barry R.] Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77030 USA. [Cushman, William C.] Vet Affairs Med Ctr, Memphis, TN USA. [Einhorn, Paula T.] NHLBI, Bethesda, MD 20892 USA. [Wright, Jackson T., Jr.] Univ Hosp Cleveland, Gen Clin Res Ctr, Cleveland, OH 44106 USA. [Preston, Richard A.] Vet Affairs Med Ctr, Miami, FL 33125 USA. [Basile, Jan N.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Whelton, Paul K.] Loyola Univ, Hlth Syst & Med Ctr, Maywood, IL 60153 USA. [Weiss, Robert J.] Androscoggin Cardiol Associates, Auburn, ME USA. [Bastien, Arnaud] Bristol Myers Squibb Co, Princeton, NJ USA. [Courtney, Donald L.] DD Eisenhower Vet Affairs Med Ctr, Leavenworth, KS USA. [Hamilton, Bruce P.] Vet Affairs Med Ctr, Baltimore, MD USA. [Kirchner, Kent] Vet Affairs Med Ctr, Jackson, MS USA. [Louis, Gail T.] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. [Retta, Tamrat M.] Howard Univ, Hypertens & Lipid Clin, Washington, DC 20059 USA. [Vidt, Donald G.] Cleveland Clin Fdn, Cleveland, OH 44195 USA. RP Ford, CE (reprint author), Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, 1200 Hermann Pressler, Houston, TX 77030 USA. EM charles.e.ford@uth.tmc.edu FU National Heart, Lung, and Blood Institute [N0.1-HC-35130]; National Institutes of Health, US Department of Health and Human Services, Bethesda, MD; AstraZeneca; GlaxoSmithKline; Novartis FX This research was supported by Health and Human Services contract number N0.1-HC-35130 from the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD. The ALLHAT investigators acknowledge contributions of study medications supplied by Pfizer, Inc (amlodipine), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support provided by Pfizer, Inc. JNB has consulted for Novartis and Sankyo and has received honoraria from AstraZeneca and Pfizer. WCC has consulted for Calpis, King, Myogen, Novartis, Pfizer, Roche, Sankyo, Sanofi Aventis and Takeda and has received honoraria from AstraZeneca, Boehringer Ingelheini, Forest Pharmaceuticals, Novartis, and Sankyo. He has also received research grants from Abbott 14 Laboratories and Novartis. BRD has consulted for BioMarin, GlaxoSmithKline, Proctor and Gamble, and Takeda. CEF has consulted for BioMarin. RAP has received researched grants from Berlex, Bristol-Myers Squibb, Ferring, Novartis, Schering Plough, Takeda, and Wyeth and has received honoraria from is Berlex, Ferring, and Pfizer. DGV has consulted for AstraZeneca, received honoraria from AstraZeneca and Merck, and has received a research grant from Boehringer Ingelheim. JTW has consulted for GlaxoSmithKline, Novartis, PfiZer, and Sanofi-Synthelabo; has received honoraria from GlaxoSmithKline; and has received research grants from GlaxoSmithKline and Novartis. The rest of the authors have no financial interests to disclose. NR 31 TC 43 Z9 45 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD OCT PY 2008 VL 10 IS 10 BP 751 EP 760 DI 10.1111/j.1751-7176.2008.00015.x PG 10 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 381XN UT WOS:000261569300003 PM 19090876 ER PT J AU Furmaga, EM Cunningham, FE Cushman, WC Dong, D Jiang, R Basile, J Katz, LA Rutan, GH Berlowitz, DR Papademetriou, V Glassman, PA AF Furmaga, Elaine M. Cunningham, Francesca E. Cushman, William C. Dong, Diane Jiang, Rang Basile, Jan Katz, Lois A. Rutan, Gale H. Berlowitz, Dan R. Papademetriou, Vasilios Glassman, Peter A. TI National Utilization of Antihypertensive Medications From 2000 to 2006 in the Veterans Health Administration: Focus on Thiazide Diuretics SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID LIPID-LOWERING TREATMENT; ATTACK TRIAL ALLHAT; MAJOR CARDIOVASCULAR EVENTS; HIGH BLOOD-PRESSURE; UNITED-STATES; HYPERTENSION; METAANALYSIS; OUTCOMES; ADULTS; PREVENTION AB The authors sought to determine the prescribing practices of clinicians treating veterans with hypertension. A descriptive analysis was performed using a national pharmacy database of patients with a diagnosis of hypertension receiving antihypertensive medication in the fiscal years 2000 to 2006. Angiotensin-converting enzyme inhibitors were the most frequently prescribed antihypertensive class, with utilization increasing from 56.0% in fiscal year 2000 to 63.2% of patients in 2006. Utilization of thiazide-type diuretics increased from 31.9% of patients in fiscal year 2000 to 42.0% in 2006. When patient comorbidities were taken into consideration, 48.1% of patients defined as having uncomplicated hypertension bad at least one prescription for a thiazide-type diuretic in fiscal year 2006. Utilization by monotherapy and combination therapy were also evaluated. The trends in utilization allowed for identification of areas in which a change in prescribing practices may improve blood pressure control and health outcomes in the Veterans Health Administration. J Clin Hypertens (Greenwich). 2008;10:770-778. (c) 2008 Le Jacq C1 [Furmaga, Elaine M.; Cunningham, Francesca E.] Vet Hlth Adm, Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL 60141 USA. [Cunningham, Francesca E.; Dong, Diane; Jiang, Rang] PBM Pharmacoepidemiol Outcomes Res, Hines, IL USA. [Cunningham, Francesca E.; Dong, Diane; Jiang, Rang; Glassman, Peter A.] Natl Ctr Medicat Safety, Hines, IL USA. [Cushman, William C.] Memphis VAMC, Prevent Med, Memphis, TN USA. [Basile, Jan] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC USA. [Katz, Lois A.] VA NY Harbor Healthcare Syst, Special Emphasis Programs & Qual Management, New York, NY USA. [Rutan, Gale H.] DC VAMC, Washington, DC USA. [Berlowitz, Dan R.] Bedford VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Berlowitz, Dan R.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Papademetriou, Vasilios] Vet Adm, Washington, DC USA. [Papademetriou, Vasilios] Georgetown Univ, Med Ctr, Washington, DC 20007 USA. [Glassman, Peter A.] VHA PBM Med Advisory Panel, Hines, IL USA. [Glassman, Peter A.] Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Glassman, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Furmaga, EM (reprint author), Vet Hlth Adm, Dept Vet Affairs, Pharm Benefits Management Serv, 119D,POB 126, Hines, IL 60141 USA. EM elaine.furmaga@va.gov OI Papademetriou, Vasilios/0000-0002-2882-2757 FU Novartis Pharmaceuticals; Abbott Laboratories; AstraZeneca FX We would like to acknowledge the contributions of Sandra M. Walsh, NM, VAMC Memphis, Hypertension/Lipids Research Section, and Roxane Ruscb, RN, BSN, MPA, clinical specialist for policy analysis and forecasting and VHA Office of the Assistant Deputy Under Secretary for Health for Policy and Planning, for their involvement on the Hypertension Field Advisory Committee. William C. Cushman, MD, has received grantl research support from Novartis Pharmaceuticals and Abbott Laboratories and is a consultant for and/or has received honoraria from AstraZeneca, Sanofi Aventis, Bristol-Myers Squibb, Novartis Pharmaceuticals, Pfizer Inc, Daiichi Sankyo, Forest Laboratories, King Pharmaceuticals, Boehringer Ingetheim, Roche Pharmaceuticals, Calpis Company Ltd, Myogen, Inc, and Takeda Pharmaceutical Company Ltd. Jan Basile, MD, has received grant/research support from Boehringer Ingelheim and Novartis Pharmaceuticals and is on the speaker's bureau for AstraZeneca, Boehringer Ingetheim, Daiichi Sankyo, Forest Laboratories, Merck, and Novartis Pharmaceuticals. Lois A. Katz, MD, has received grantl research support from Boehringer Ingetheim, Abbott Laboratories, and Kos Pharmaceuticals and honoraria from Novartis Pharmaceuticals. Dan R. Berlowitz, MD, has received grant/research support from Bristol-Myers Squibb and Sanofi Aventis and honoraria from Bristol-Myers Squibb. Vasilios Papademetriou, MD, has received grant/research support from AstraZeneca and honoraria from AstraZeneca and Novartis Pharmaceuticals. NR 32 TC 9 Z9 9 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD OCT PY 2008 VL 10 IS 10 BP 770 EP 778 DI 10.1111/j.1751-7176.2008.00019.x PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 381XN UT WOS:000261569300005 PM 19090878 ER PT J AU Bilimoria, KY Bentrem, DJ Feinglass, JM Stewart, AK Winchester, DP Talamonti, MS Ko, CY AF Bilimoria, Karl Y. Bentrem, David J. Feinglass, Joseph M. Stewart, Andrew K. Winchester, David P. Talamonti, Mark S. Ko, Clifford Y. TI Directing surgical quality improvement initiatives: Comparison of perioperative mortality and long-term survival for cancer surgery SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 61st Annual Cancer Symposium of the Society-of-Surgical-Oncology CY MAR 13-16, 2008 CL Chicago, IL SP Soc Surg Oncol ID SEGMENTAL COLON RESECTION; HIGH-RISK SURGERY; HOSPITAL VOLUME; OPERATIVE MORTALITY; PATIENT OUTCOMES; UNITED-STATES; CAROTID-ENDARTERECTOMY; CLINICAL PATHWAY; DATA-BASE; CARE AB Purpose Quality-improvement initiatives are being developed to decrease volume-based variability in surgical outcomes. Resources for national and hospital quality-improvement initiatives are limited. It is unclear whether quality initiatives in surgical oncology should focus on factors affecting perioperative mortality or long-term survival. Our objective was to determine whether differences in hospital surgical volume have a larger effect on perioperative mortality or long-term survival using two methods. Patients and Methods From the National Cancer Data Base, 243,103 patients who underwent surgery for nonmetastatic colon, esophageal, gastric, liver, lung, pancreatic, or rectal cancer were identified. Multivariable modeling was used to evaluate 60-day mortality and 5-year conditional survival (excluding perioperative deaths) across hospital volume strata. The number of potentially avoidable perioperative and long-term deaths were calculated if outcomes at low-volume hospitals were improved to those of the highest-volume hospitals. Results Risk-adjusted perioperative mortality and long-term conditional survival worsened as hospital surgical volume decreased for all cancer sites, except for liver resections where there was no difference in survival. When comparing low-with high-volume hospitals, the hazard ratios for perioperative mortality were substantially larger than for long-term survival. However, the number of potentially avoidable deaths each year in the United States, if outcomes at low-volume hospitals were improved to the level of highest-volume centers, was significantly larger for long-term survival. Conclusion Although the magnitude of the hazard ratios implies that quality-improvement efforts should focus on perioperative mortality, a larger number of deaths could be avoided by focusing quality initiatives on factors associated with long-term survival. C1 Northwestern Univ, Dept Surg, Div Gen Internal Med, Feinberg Sch Med, Evanston, IL 60208 USA. [Bilimoria, Karl Y.] Amer Coll Surg, Canc Programs, Chicago, IL 60611 USA. Evanston NW Healthcare, Dept Surg, Evanston, IL USA. Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Canc Programs, 633 N St Clair St,25th Floor, Chicago, IL 60611 USA. EM k-bilimoria@northwestern.edu NR 60 TC 78 Z9 79 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 1 PY 2008 VL 26 IS 28 BP 4626 EP 4633 DI 10.1200/JCO.2007.15.6356 PG 8 WC Oncology SC Oncology GA 354OG UT WOS:000259648300019 PM 18574159 ER PT J AU Raymond, E Brandes, AA Dittrich, C Fumoleau, P Coudert, B Clement, PMJ Frenay, M Rampling, R Stupp, R Kros, JM Heinrich, MC Gorlia, T Lacombe, D van den Bent, MJ AF Raymond, Eric Brandes, Alba A. Dittrich, Christian Fumoleau, Pierre Coudert, Bruno Clement, Paul M. J. Frenay, Marc Rampling, Roy Stupp, Roger Kros, Johan M. Heinrich, Michael C. Gorlia, Thierry Lacombe, Denis van den Bent, Martin J. TI Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID GROWTH-FACTOR; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMAS; TYROSINE KINASE; PROGENITOR-CELL; RECEPTOR EXPRESSION; CLINICAL-TRIALS; OLIGODENDROGLIOMAS; ASSOCIATION; PHARMACOKINETICS AB Purpose To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. Patients and Methods This was a single-arm, phase II study. Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging. Three different histologic groups were studied: glioblastomas (GBM), pure/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A). Imatinib was started at a dose of 600 mg/d with dose escalation to 800 mg in case of no toxicity; during the trial this dose was increased to 800 mg/d with escalation to 1,000 mg/d. Trial design was one-stage Fleming; both an objective response and 6 months of progression-free survival (PFS) were considered a successful outcome to treatment. Results A total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was 2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16% (95% CI, 8.0% to 34.0%) in GBM, 4.0% (95% CI, 0.3% to 15.0%) in OD, and 9% (95% CI, 2.0% to 25.0%) in A. The exposure to imatinib was significantly lower in patients using enzyme-inducing antiepileptic drugs. The presence of ABCG2 point mutations were not correlated with pharmacokinetic findings. No somatic activating mutations of KIT or platelet-derived growth factor receptor -A or -B were found. Conclusion In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas. C1 Beaujon Univ Hosp, Serv Inter Hosp Cancerol, Clichy, France. Ctr Georges Francois Leclerc, Dijon, France. Ctr Antoine Lacassagne, F-06054 Nice, France. Bellaria & Maggiore Hosp, Azienda Unita Sanitaria Locale Bologna, Bologna, Italy. Kaiser Franz Josef Spital, Ludwig Boltzmann Inst Appl Canc Res, Vienna, Austria. Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium. European Org Res & Treatment Canc Data Ctr, Brussels, Belgium. Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland. Univ Hosp, Multidisciplinary Oncol Ctr, Lausanne, Switzerland. Univ Lausanne, Lausanne, Switzerland. [van den Bent, Martin J.] Erasmus Univ Hosp, Dr Daniel Den Hoed Canc Ctr, Neurooncol Unit, NL-3008 AE Rotterdam, Netherlands. Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR 97201 USA. RP van den Bent, MJ (reprint author), Erasmus Univ Hosp, Dr Daniel Den Hoed Canc Ctr, Neurooncol Unit, POB 5201, NL-3008 AE Rotterdam, Netherlands. EM m.vandenbent@erasmusmc.nl OI Brandes, Alba/0000-0002-2503-9089 FU European Organisation for Research and Treatment of Cancer Charitable Trust [5U10 CA11488-32]; National Cancer Institute (Bethesda, MD) [5U10 CA11488-34] FX Supported by the European Organisation for Research and Treatment of Cancer Charitable Trust and Grants No. 5U10 CA11488-32 through 5U10 CA11488-34 from the National Cancer Institute (Bethesda, MD). Additional funding was provided by Novartis Pharma AG and a Veterans Affairs Merit Review Grant (M. C. H.). The imatinib used in this study was provided free of charge by Novartis Pharma AG. NR 32 TC 126 Z9 126 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 1 PY 2008 VL 26 IS 28 BP 4659 EP 4665 DI 10.1200/JCO.2008.16.9235 PG 7 WC Oncology SC Oncology GA 354OG UT WOS:000259648300024 PM 18824712 ER PT J AU Bartlett, BL Tyring, SK Fife, K Gnann, JW Hadala, JT Kianifard, F Berber, E AF Bartlett, Brenda L. Tyring, Stephen K. Fife, Kenneth Gnann, John W., Jr. Hadala, Joseph T. Kianifard, Farid Berber, Erhan TI Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Famciclovir; Genital herpes; Recurrent; Herpes simplex virus ID PLACEBO-CONTROLLED TRIAL; SIMPLEX-VIRUS-INFECTION; DAILY ORAL FAMCICLOVIR; DOUBLE-BLIND; THERAPY; SUPPRESSION; PREVENTION; ACYCLOVIR; VALACYCLOVIR; MULTICENTER AB Background: Recurrent genital HSV outbreaks are common among those suffering from the disease. Antiviral medications taken as suppressive therapy can reduce the frequency of these recurrences and reduce viral shedding occurring in between recurrences. Objectives: To investigate the efficacy and safety of oral famciclovir as episodic (125 mg twice daily for 5 days) and suppressive (250 mg twice daily) treatment of recurrent genital herpes (RGH). Study design: This was a randomized, multicenter, 6-month, open-label study. Efficacy variables were time to first recurrence of RGH symptoms, and change in total score of the Recurrent Genital Herpes Quality of Life (RGHQoL) questionnaire. Subject satisfaction questions were summarized. Results: 384 subjects were randomized. There was a highly statistically significant difference between treatments in time to first recurrence of symptoms in favor of suppressive treatment (p < 0.0001). There was no significant difference between treatments in total score of the RGHQoL or in subject satisfaction with treatment. Conclusions: This study demonstrated that, compared to episodic treatment, suppressive treatment with oral famciclovir may extend the time to symptomatic outbreaks in patients with frequent recurrences of genital herpes. (C) 2008 Elsevier B.V. All rights reserved. C1 [Bartlett, Brenda L.; Tyring, Stephen K.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA. [Fife, Kenneth] Indiana Univ, Sch Med, Indianapolis, IN USA. [Gnann, John W., Jr.] Univ Alabama, Birmingham, AL USA. [Gnann, John W., Jr.] Birmingham VA Med Ctr, Birmingham, AL USA. [Hadala, Joseph T.; Kianifard, Farid; Berber, Erhan] Novartis Pharmaceut Corp, E Hanover, NJ 07936 USA. RP Tyring, SK (reprint author), Ctr Clin Studies, 2060 Space Pk Dr, Houston, TX 77058 USA. EM bbartlett@ccstexas.com; styring@ccstexas.com; kfife@iupui.edu; jgnann@uab.edu; joseph.hadala@novartis.com; farid.kianifard@novartis.com; erhan.berber@novartis.com FU Novartis; Antigenics, Astellas, GlaxoSmithKline, Merck, and Novartis; Astellas, Merck, and Novartis FX Liptak and Mark J. Fedele of Novartis Pharmaceuticals Corporation for writing and editorial assistance. ST has received research grants from Novartis and has participated in Novartis' advisory boards and speakers' bureau. KF has received research grants from Antigenics, Astellas, GlaxoSmithKline, Merck, and Novartis, has consulted for GlaxoSmithKline, and received speaking fees from Merck. GWG has received research funding from Astellas, Merck, and Novartis, has consulted for Merck and ViroPharma and has received speaking fees from GlaxoSmithKline and Merck. JTH, KF, and EB are employees of Novartis Pharmaceuticals Corporation and are eligible for Novartis stock and stock options. NR 28 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD OCT PY 2008 VL 43 IS 2 BP 190 EP 195 DI 10.1016/j.jcv.2008.06.004 PG 6 WC Virology SC Virology GA 360QF UT WOS:000260071700011 PM 18621575 ER PT J AU Metlay, JP Hennessy, S Localio, AR Han, XY Yang, W Cohen, A Leonard, CE Haynes, K Kimmel, SE Feldman, HI Strom, BL AF Metlay, Joshua P. Hennessy, Sean Localio, A. Russell Han, Xiaoyan Yang, Wei Cohen, Abigail Leonard, Charles E. Haynes, Kevin Kimmel, Stephen E. Feldman, Harold I. Strom, Brian L. TI Patient reported receipt of medication instructions for warfarin is associated with reduced risk of serious bleeding events SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 30th Annual Meeting of the Society-of-General-Internal-Medicine CY APR 25-28, 2007 CL Toronto, CANADA SP Soc Gen Internal Med DE anticoagulation; patient communication; medication safety ID ADVERSE DRUG EVENTS; ANTICOAGULATION-CONTROL; INDEX; CARE; COMPLICATIONS; THERAPY; HEALTH; IMPACT AB BACKGROUND: Adverse drug events are an important cause of preventable hospitalizations. OBJECTIVE: To identify whether patient report of receipt of medication instructions and markers of complex care (multiple physicians, recent hospitalization) predict the risk of serious bleeding for older adults on warfarin. DESIGN: Prospective cohort study of older adults. PARTICIPANTS: Subjects filled new or refill prescriptions for warfarin at the time of enrollment. MEASUREMENTS: Hospitalizations were identified through a state-wide registry. Discharge summaries of hospitalizations for possible warfarin related bleeding events were reviewed by trained abstractors and clinical experts. Incidence rate ratios (IRR) were estimated based on person-months of exposure using Poisson regression models. RESULTS: From March 2002 through May 2003, we enrolled a total of 2346 adults on warfarin. Over a two-year follow-up period, there were 126 hospitalizations due to warfarin-related bleeding (4.6 hospitalizations per 100 person-years of exposure). Patients who reported receiving medication instructions from either a physician or nurse plus a pharmacist had a 60% reduced rate of subsequently experiencing a serious bleeding event over the next 2 years (adjusted IRR 0.40, 95% CI 0.24-0.68). Having >= 4 physicians providing medication prescriptions over the last 3 months and filling prescriptions at > 1 pharmacy over the last 3 months were independently associated with increased bleeding rates (adjusted IRRs 2.37, 95% CI 1.22-4.57 and 1.61, 95% CI 0.97-2.67, respectively). CONCLUSIONS: The rate of warfarin-related hospitalization for bleeding is substantially lower for patients who report receiving medication instructions from a physician or nurse and a pharmacist. C1 [Metlay, Joshua P.; Hennessy, Sean; Localio, A. Russell; Han, Xiaoyan; Yang, Wei; Cohen, Abigail; Leonard, Charles E.; Haynes, Kevin; Kimmel, Stephen E.; Feldman, Harold I.; Strom, Brian L.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.; Hennessy, Sean; Han, Xiaoyan; Yang, Wei; Cohen, Abigail; Leonard, Charles E.; Kimmel, Stephen E.; Feldman, Harold I.; Strom, Brian L.] Univ Penn, PRIME, Philadelphia, PA 19104 USA. [Metlay, Joshua P.; Hennessy, Sean; Localio, A. Russell; Cohen, Abigail; Leonard, Charles E.; Haynes, Kevin; Kimmel, Stephen E.; Feldman, Harold I.; Strom, Brian L.] Univ Penn, CERTs, Philadelphia, PA 19104 USA. [Metlay, Joshua P.; Kimmel, Stephen E.; Feldman, Harold I.; Strom, Brian L.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Metlay, JP (reprint author), 712 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jmetlay@mail.med.upenn.edu RI Leonard, Charles/K-3447-2012; Yang, Wei/A-9223-2009; Cohen, Abigail/K-9180-2013 OI Yang, Wei/0000-0001-8984-4389; Cohen, Abigail/0000-0002-7425-7218 FU AHRQ HHS [P01 HS011530, P01-HS11530]; NHLBI NIH HHS [R01 HL076697, K24 HL070936, R01 HL066176]; NIA NIH HHS [F32 AG026180, R01 AG025152]; NIDDK NIH HHS [K24 DK002651] NR 23 TC 20 Z9 23 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2008 VL 23 IS 10 BP 1589 EP 1594 DI 10.1007/s11606-008-0708-8 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 347LD UT WOS:000259142200008 PM 18618191 ER PT J AU Pollack, CE Mallya, G Polsky, D AF Pollack, Craig Evan Mallya, Giridhar Polsky, Daniel TI The impact of consumer-directed health plans and patient socioeconomic status on physician recommendations for colorectal cancer screening SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE consumer-directed health plans; patient socioeconomic status; physician decision-making; colorectal cancer screening ID OF-POCKET COSTS; FECAL OCCULT BLOOD; PREVENTIVE SERVICES; NATIONAL-SURVEY; CARE; PARTICIPATION; COMMUNICATION; COLONOSCOPY; PERSPECTIVE; INSURANCE AB BACKGROUND: Consumer-directed health plans are increasingly common, yet little is known about their impact on physician decision-making and preventive service use. OBJECTIVE: To determine how patients' deductible levels and socioeconomic status may affect primary care physicians' recommendations for colorectal cancer screening. DESIGN, SETTING AND PARTICIPANTS: Screening recommendations were elicited using hypothetical vignettes from a national sample of 1,500 primary care physicians. Physicians were randomized to one of four vignettes describing a patient with either low or high socioeconomic status (SES) and either low- or high-deductible plan. Bivariate and multivariate analyses were used to examine how recommendations varied as a function of SES and deductible. OUTCOME MEASURES: Rates of recommendation for home fecal occult blood testing, sigmoidoscopy, colonoscopy, and inappropriate screening, defined as no screening or office-based fecal occult blood testing. RESULTS: A total of 528 (49%) eligible physicians responded. Overall, 7.2% of physicians recommended inappropriate screening; 3.2% of patients with high SES in low-deductible plans received inappropriate screening recommendations and 11.4% of patients with low SES in high-deductible plans for an adjusted odds ratio of 0.22 (0.05-0.89). The odds of a colonoscopy recommendation were over ten times higher (AOR 11.46, 5.26-24.94) for patients with high SES in low-deductible plans compared to patients with low SES in high-deductible plans. Funds in medical savings accounts eliminated differences in inappropriate screening recommendations. CONCLUSIONS: Patient SES and deductible-level affect physician recommendations for preventive care. Coverage of preventive services and funds in medical savings accounts may help to mitigate the impact of high-deductibles and SES on inappropriate recommendations. C1 [Pollack, Craig Evan; Mallya, Giridhar] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Pollack, Craig Evan; Mallya, Giridhar; Polsky, Daniel] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Pollack, Craig Evan] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Polsky, Daniel] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Polsky, Daniel] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. RP Pollack, CE (reprint author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 1303B Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM craige@mail.med.upenn.edu FU Robert Wood Johnson Clinical Scholars Program at the University of Pennsylvania FX The authors wish to thank the following individuals for their helpful suggestions and advice: David Asch M. D., Judy Shea Ph. D., Katrina Armstrong M. D., and Josh Metlay M. D. Ph. D. at the University of Pennsylvania and Caleb Alexander M. D. at the University of Chicago. No compensation was received for their contributions.; Funding for the study was provided by the Robert Wood Johnson Clinical Scholars Program at the University of Pennsylvania. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and the preparation, review or approval of the manuscript. Drs. Pollack and Mallya had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. This work has been presented at the annual meetings of the Robert Wood Johnson Clinical Scholars Program (Fort Lauderdale, November 2007) and the North American Primary Care Research Group (Vancouver, October 2007); Funding for the study was provided by the Robert Wood Johnson Clinical Scholars Program at the University of Pennsylvania. NR 47 TC 7 Z9 7 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2008 VL 23 IS 10 BP 1595 EP 1601 DI 10.1007/s11606-008-0714-x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 347LD UT WOS:000259142200009 PM 18629590 ER PT J AU Lagu, T Kaufman, EJ Asch, DA Armstrong, K AF Lagu, Tara Kaufman, Elinore J. Asch, David A. Armstrong, Katrina TI Content of weblogs written by health professionals SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE weblog; professionalism; Internet ID MEDICINE; TOOL AB BACKGROUND: Medical weblogs ("blogs") have emerged as a new connection between health professionals and the public. OBJECTIVE: To examine the scope and content of medical blogs and approximate how often blog authors commented about patients, violated patient privacy, or displayed a lack of professionalism. DESIGN: We defined medical blogs as those that contain some medical content and were apparently written by physicians or nurses. We used the Google search term "medical blog" to begin a modified snowball sampling method to identify sites posting entries from 1/1/06 through 12/14/06. We reviewed five entries per blog, categorizing content and characteristics. RESULTS: We identified 271 medical blogs. Over half (56.8%) of blog authors provided sufficient information in text or image to reveal their identities. Individual patients were described in 114 (42.1%) blogs. Patients were portrayed positively in 43 blogs (15.9%) and negatively in 48 blogs (17.7%). Of blogs that described interactions with individual patients, 45 (16.6%) included sufficient information for patients to identify their doctors or themselves. Three blogs showed recognizable photographic images of patients. Healthcare products were promoted, either by images or descriptions, in 31 (11.4%) blogs. CONCLUSIONS: Blogs are a growing part of the public face of the health professions. They offer physicians and nurses the opportunity to share their narratives. They also risk revealing confidential information or, in their tone or content, risk reflecting poorly on the blog authors and their professions. The health professions should assume some responsibility for helping authors and readers negotiate these challenges. C1 [Lagu, Tara; Kaufman, Elinore J.; Armstrong, Katrina] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. [Lagu, Tara; Asch, David A.; Armstrong, Katrina] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Lagu, T (reprint author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 423 Guardian Dr,13th Floor Blockley, Philadelphia, PA 19104 USA. EM lagutc@gmail.com RI Roundtree, Aimee/B-8838-2012 OI Asch, David/0000-0002-7970-286X; Kaufman, Elinore/0000-0001-7550-0024 FU The Robert Wood Johnson Foundation Clinical Scholars Program FX Funding: Supported in part by The Robert Wood Johnson Foundation Clinical Scholars Program. NR 28 TC 88 Z9 89 U1 2 U2 21 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2008 VL 23 IS 10 BP 1642 EP 1646 DI 10.1007/s11606-008-0726-6 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 347LD UT WOS:000259142200016 PM 18649110 ER PT J AU Hausmann, LRM Jeong, K Bost, JE Ibrahim, SA AF Hausmann, Leslie R. M. Jeong, Kwonho Bost, James E. Ibrahim, Said A. TI Perceived discrimination in health care and use of preventive health services SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE perceived discrimination; preventive health; behavioral risk factor surveillance system; centers for disease control and prevention ID RACISM; EXPERIENCES; POPULATION; COMMUNITY AB OBJECTIVE: To examine the relationship between perceived discrimination and preventive health care utilization. DESIGN AND PARTICIPANTS: Cross-sectional analysis using the 2004 Behavioral Risk Factor Surveillance System "Reactions to Race" module (N = 28,839). MEASUREMENTS: Outcomes were self-reported utilization of seven preventive health services. Predictors included perceived negative and positive racial discrimination ( vs. none) while seeking health care in the past year. Multivariable models adjusted for additional patient characteristics. MAIN RESULTS: In unadjusted models, negative discrimination was significantly associated with less utilization of mammogram, pap test, PSA test, blood stool test, and sigmoidoscopy/colonoscopy (ORs = 0.53-0.73, p <.05), but not flu or pneumococcal vaccines (ORs = 0.76 and 0.84). Positive discrimination was significantly associated with more utilization of all services (ORs = 1.29-1.58, p <.05) except pap test (OR = 0.94). In adjusted models, neither negative nor positive discrimination was predictive of utilization, except for PSA test (positive discrimination OR = 1.33, p <.05). CONCLUSIONS: Perceived racial discrimination in health care does not independently predict preventive health care utilization. C1 [Hausmann, Leslie R. M.; Ibrahim, Said A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA. [Jeong, Kwonho] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Bost, James E.] Univ Pittsburgh, Ctr Data, Ctr Res Hlth Care, Pittsburgh, PA USA. [Ibrahim, Said A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM leslie.hausmann@gmail.com FU NCRR NIH HHS [UL1 RR024153]; NIAMS NIH HHS [K24 AR055259, 1K24AR055259-01] NR 15 TC 30 Z9 30 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2008 VL 23 IS 10 BP 1679 EP 1684 DI 10.1007/s11606-008-0730-x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 347LD UT WOS:000259142200022 PM 18649109 ER PT J AU Musher, DM Rueda, AM Nahm, MH Graviss, EA Rodriguez-Barradas, MC AF Musher, Daniel M. Rueda, Adriana M. Nahm, Moon H. Graviss, Edward A. Rodriguez-Barradas, Maria C. TI Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 44th Annual Meeting of the Infectious-Diseases-Society-of-America CY OCT 12-15, 2006 CL Toronto, CANADA SP Infect Dis Soc Amer ID HIV-INFECTED ADULTS; STREPTOCOCCUS-PNEUMONIAE; ANTIBODY-RESPONSES; RANDOMIZED-TRIAL; OLDER-ADULTS; T-CELLS; B-CELLS; IMMUNOGENICITY; IMMUNIZATION; EFFICACY AB Background. Controversy persists over the benefits of pneumococcal polysaccharide vaccine (PPV) for adults at high risk for pneumococcal disease. We studied PPV, protein-conjugate pneumococcal vaccine (PCV), and immunologic "priming" with PCV followed by "boosting" with PPV in adults who had recovered from pneumococcal pneumonia. Methods. Subjects received PPV followed by PCV 6 months later, or vice versa. The levels of IgG to capsular polysaccharide and opsonophagocytic killing activity (OPK) were studied at baseline and at 4-8 weeks and 6 months after each vaccination. Results. PPV and PCV stimulated similar IgG levels and OPK at 4-8 weeks after vaccination. Six months after receipt of PPV, the antibody levels declined to baseline but remained modestly elevated after receipt of PCV. PCV administered 6 months after PPV stimulated modest increases in IgG level that failed to reach the peaks observed after receipt of PPV. In contrast, PPV administered 6 months after PCV caused dramatic increases in the levels of IgG and OPK for all polysaccharides at 4-8 weeks, consistent with a booster effect. Six months after receipt of the second vaccination, however, levels of IgG and OPK fell precipitously in all patients, approaching baseline levels. Conclusions. In these high-risk subjects who have recovered after treatment for pneumonia, the effect of PPV is short-lived; PCV stimulates a more prolonged response. The use of PPV as a booster following PCV causes early increases in antibody levels, but the level of IgG declines rapidly thereafter, consistent with induction of suppressor cells or tolerance. Protein vaccines may be needed for high-risk adults. C1 [Musher, Daniel M.; Rueda, Adriana M.; Rodriguez-Barradas, Maria C.] Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Serv, Houston, TX 77030 USA. [Musher, Daniel M.; Rueda, Adriana M.; Graviss, Edward A.; Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Graviss, Edward A.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Nahm, Moon H.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Med Serv, Room 4B-370,2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@med.va.gov OI Nahm, Moon/0000-0002-6922-1042 FU NIAID NIH HHS [AI-69695, R01 AI069509, R01 AI069509-02] NR 45 TC 52 Z9 52 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2008 VL 198 IS 7 BP 1019 EP 1027 DI 10.1086/591629 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 345EO UT WOS:000258979100011 PM 18710324 ER PT J AU Garcia, S McFalls, EO Goldman, S Larsen, GC Littooy, F Moritz, TE Reda, DJ Ward, HB Shunk, K Hattler, B AF Garcia, Santiago McFalls, Edward O. Goldman, Steven Larsen, Greg C. Littooy, Fred Moritz, Thomas E. Reda, Domenic J. Ward, Herbert B. Shunk, Kendrick Hattler, Brack TI Diagnostic coronary angiography in patients with peripheral arterial disease: A sub-study of the Coronary Artery Revascularization Prophylaxis trial SO JOURNAL OF INTERVENTIONAL CARDIOLOGY LA English DT Article ID MAJOR VASCULAR-SURGERY; PERIOPERATIVE CARDIOVASCULAR EVALUATION; CARDIAC-CATHETERIZATION; NONCARDIAC SURGERY; COMPLICATIONS; RISK; ARTERIOGRAPHY; INTERVENTIONS; GUIDELINES; SOCIETY AB Background: Although patients in need of elective vascular surgery are often considered candidates for diagnostic coronary angiography, the safety of this invasive study has not been systematically studied in a large cohort of patients scheduled for an elective vascular operation. The goal of this sub-study of the Coronary Artery Revascularization Prophylaxis (CARP) trial was to assess the safety of coronary angiography in patients with peripheral vascular disease. Methods: The CARP trial tested the long-term benefit of coronary artery revascularization prior to elective vascular operations. Among those patients who underwent diagnostic coronary angiography during screening for the trial, the associated complications were determined at 24 hours following the diagnostic procedure. Results: Over 5,000 patients were screened during a 4-year recruitment period at 18 major VA medical centers and the present cohort consists of 1,298 patients who underwent preoperative coronary angiography. Surgical indications for vascular surgery included an expanding aortic aneurysm (AAA) (n = 446; 34.4%) or arterial occlusive disease with either claudication (n = 457; 35.2%) or rest pain (n = 395; 30.4%). A total of 39 patients had a confirmed complication with a major complication identified in 17 patients (1.3%). Complication rates were higher in patients with arterial occlusive symptoms compared with expanding aneurysms (1.8% vs. 0.5%; P = 0.07) and were not dissimilar with femoral (2.8%) versus nonfemoral (4.7%) access sites (P = 0.42). Conclusions: Coronary angiography is safe in patients with peripheral arterial disease undergoing preoperative coronary angiography. The complication rate is higher in patients with symptoms of arterial occlusive disease. C1 [Garcia, Santiago; McFalls, Edward O.; Ward, Herbert B.] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA. [Garcia, Santiago; McFalls, Edward O.; Ward, Herbert B.] Univ Minnesota, Minneapolis, MN USA. [Goldman, Steven] Univ Arizona, Sarver Heart Ctr, Tucson, AZ USA. [Goldman, Steven] So Arizona VA Hlth Care Syst, Tucson, AZ USA. [Larsen, Greg C.] Oregon Hlth & Sci Univ, Portland, OR USA. [Larsen, Greg C.] Oregon VA Med Ctr, Portland, OR USA. [Littooy, Fred; Moritz, Thomas E.; Reda, Domenic J.] Hines VA Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL USA. [Shunk, Kendrick] San Francisco VA Med Ctr, San Francisco, CA USA. [Shunk, Kendrick] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hattler, Brack] Denver VA Med Ctr, Denver, CO USA. RP McFalls, EO (reprint author), VA Med Ctr, Div Cardiol 111C, 1 Vet Dr, Minneapolis, MN 55417 USA. EM mcfal001@umn.edu FU Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development FX The CARP trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development. NR 18 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0896-4327 J9 J INTERV CARDIOL JI J. Interv. Cardiol. PD OCT PY 2008 VL 21 IS 5 BP 369 EP 374 DI 10.1111/j.1540-8183.2008.00391.x PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 357IK UT WOS:000259839300001 PM 18761563 ER PT J AU Bird, KG Meyer, L Dellavalle, RP AF Bird, K. G. Meyer, L. Dellavalle, R. P. TI Reduced incidence of melanoma in a VA population using statins: a case-control study SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Congress of the International-Dermato-Epidemiology-Association CY SEP 07-11, 2008 CL Nottingham, ENGLAND SP Int Dermato Epidemiol Assoc C1 [Bird, K. G.] Univ Colorado, Denver AMC, Denver, CO 80262 USA. [Meyer, L.] VA Salt Lake City HCS, Salt Lake City, UT 84148 USA. [Dellavalle, R. P.] Denver VA Med Ctr, Denver, CO 80220 USA. NR 1 TC 0 Z9 0 U1 3 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD OCT PY 2008 VL 128 IS 10 MA 21 BP 2553 EP 2553 PG 1 WC Dermatology SC Dermatology GA 348RW UT WOS:000259228600051 ER PT J AU Dellavalle, RP AF Dellavalle, R. P. TI Benchmarking US department of veterans affairs dermatologic mission fulfillment SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Congress of the International-Dermato-Epidemiology-Association CY SEP 07-11, 2008 CL Nottingham, ENGLAND SP Int Dermato Epidemiol Assoc C1 [Dellavalle, R. P.] Univ Colorado, Denver AMC, Denver, CO 80262 USA. [Dellavalle, R. P.] Denver VA Med Ctr, Denver, CO 80220 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD OCT PY 2008 VL 128 IS 10 MA 23 BP 2553 EP 2553 PG 1 WC Dermatology SC Dermatology GA 348RW UT WOS:000259228600052 ER EF